assays_ss_d,assays_td,assays_ss_ctgr,assays_ss_tst_tp,assays_cnfdnc_scr,assays_ss_strn,assays_rltnshp_tp,assays_ss_sbclllr_frctn,assays_ss_tss,assays_ss_cll_tp,assays_crtd_b,assays_dscrptn,assays_ss_tp,assays_src_d,assays_vrnt_d,assays_dc_d,assays_chmbl_d,assays_cll_d,assays_b_frmt,assays_tss_d
1,12052,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,1,,11087,CHEMBL615117,,BAO_0000019,
2,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,1,,684,CHEMBL615118,,BAO_0000219,
3,22226,,,0,,U,,,,Autocuration,,B,1,,15453,CHEMBL615119,,BAO_0000019,
4,104729,,,4,,H,,,,Autocuration,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,1,,17841,CHEMBL615120,,BAO_0000249,
5,80001,,,1,,N,,,143B,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,1,,17430,CHEMBL615121,163.0,BAO_0000219,
6,80001,,,1,,N,,,143B,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,1,,17430,CHEMBL615122,163.0,BAO_0000219,
7,80001,,,1,,N,,,143B,Intermediate,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,1,,13799,CHEMBL615123,163.0,BAO_0000219,
8,80001,,,1,,N,,,143B,Expert,In vitro cell cytotoxicity was determined against 143B cell line,F,1,,17774,CHEMBL615124,163.0,BAO_0000219,
9,80001,,,1,,N,,,143B,Intermediate,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,1,,3801,CHEMBL615125,163.0,BAO_0000219,
10,80001,,,1,,N,,,143B,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,1,,17430,CHEMBL615126,163.0,BAO_0000219,
11,80001,,,1,,N,,,143B,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,1,,17430,CHEMBL615127,163.0,BAO_0000219,
12,80001,,,1,,N,,,143B,Expert,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,1,,17774,CHEMBL615128,163.0,BAO_0000219,
13,50185,,,1,,N,,,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1,,11324,CHEMBL857900,,BAO_0000218,
14,50185,,,1,,N,,,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1,,11324,CHEMBL615129,,BAO_0000218,
15,50185,,,1,,N,,,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1,,11324,CHEMBL615130,,BAO_0000218,
16,50185,,,1,,N,,,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1,,11324,CHEMBL615131,,BAO_0000218,
17,100122,,,9,,D,,,,Expert,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,1,,11347,CHEMBL884521,,BAO_0000357,
18,12054,,,8,,H,,,,Autocuration,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,1,,16474,CHEMBL615132,,BAO_0000357,
19,12054,,,8,,H,,,,Autocuration,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,1,,10091,CHEMBL615133,,BAO_0000019,
20,12054,,,8,,H,,,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,1,,16474,CHEMBL615134,,BAO_0000357,
21,12054,,,8,,H,,,,Autocuration,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,1,,16474,CHEMBL615135,,BAO_0000357,
22,12054,,,8,,H,,,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,1,,16474,CHEMBL615136,,BAO_0000357,
23,12054,,,8,,H,,,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,1,,16474,CHEMBL615137,,BAO_0000357,
24,12054,,,8,,H,,,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,1,,16474,CHEMBL615138,,BAO_0000357,
25,22226,,,0,,U,,,,Autocuration,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,1,,14352,CHEMBL836324,,BAO_0000219,
26,12054,,,8,,H,,,,Autocuration,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,1,,5646,CHEMBL615139,,BAO_0000357,
27,12054,,,8,,H,,,,Autocuration,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,1,,5646,CHEMBL615140,,BAO_0000357,
28,12426,,,8,,H,,,,Autocuration,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,1,,10997,CHEMBL615141,,BAO_0000219,
29,12054,,,8,,H,,,,Autocuration,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,1,,6309,CHEMBL615142,,BAO_0000357,
30,12054,,,8,,H,,,,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,1,,167,CHEMBL615143,,BAO_0000357,
31,12054,,,8,,H,,,,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,1,,167,CHEMBL615144,,BAO_0000357,
32,12054,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,1,,11087,CHEMBL872867,,BAO_0000357,
33,12054,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,1,,11087,CHEMBL615145,,BAO_0000357,
34,12054,,,8,,H,,,,Autocuration,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,1,,13622,CHEMBL615146,,BAO_0000357,
35,12054,,,8,,H,,,,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,1,,13622,CHEMBL615147,,BAO_0000357,
36,22226,,,0,,U,,,,Autocuration,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,1,,11347,CHEMBL615148,,BAO_0000019,
37,22226,,,0,,U,,,,Autocuration,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,1,,5926,CHEMBL615149,,BAO_0000019,
38,22226,,,0,,U,,,,Autocuration,Dissociation constant with dimeric 16S rRNA RNA construct B,B,1,,4567,CHEMBL615150,,BAO_0000019,
39,22222,,,3,,M,,,,Intermediate,Dissociation constant towards 16S rRNA construct A,B,1,,3782,CHEMBL615151,,BAO_0000225,
40,22222,,,3,,M,,,,Intermediate,Dissociation constant towards 16S rRNA construct B,B,1,,3782,CHEMBL615152,,BAO_0000225,
41,100263,,,3,,M,,,,Expert,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,1,,4466,CHEMBL615153,,BAO_0000225,
42,100263,,,3,,M,,,,Expert,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,1,,6592,CHEMBL615154,,BAO_0000225,
43,13053,,,8,,H,,,,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,1,,898,CHEMBL615155,,BAO_0000019,
44,13053,,,8,,H,,,,Autocuration,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,1,,898,CHEMBL615156,,BAO_0000019,
45,20001,,,8,,H,,,,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,1,,13163,CHEMBL615157,,BAO_0000019,
46,20001,,,8,,H,,,,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,1,,13163,CHEMBL615158,,BAO_0000019,
47,12971,,,9,,D,,,,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,1,,10691,CHEMBL615159,,BAO_0000019,
48,12971,,,9,,D,,,,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,1,,10691,CHEMBL615172,,BAO_0000019,
49,12971,,,9,,D,,,,Expert,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,1,,10691,CHEMBL615173,,BAO_0000019,
50,12971,,,9,,D,,,,Expert,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,1,,10691,CHEMBL615174,,BAO_0000019,
51,13053,,,8,,H,,,,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,1,,898,CHEMBL884518,,BAO_0000019,
52,11512,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,1,,912,CHEMBL615175,,BAO_0000357,
53,11512,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,1,,912,CHEMBL615176,,BAO_0000357,
54,11512,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,1,,912,CHEMBL615177,,BAO_0000357,
55,104740,,,5,,D,Membranes,,,Autocuration,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,1,,15103,CHEMBL615178,,BAO_0000249,
56,80002,,,1,,N,,,1A9,Intermediate,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,1,,5116,CHEMBL615179,506.0,BAO_0000219,
57,104835,,,7,,D,,,Oocytes,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,1,,14578,CHEMBL615180,,BAO_0000219,
58,104821,,,7,,D,,,Oocytes,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,1,,14578,CHEMBL615181,,BAO_0000219,
59,104848,,,7,,D,,,Oocytes,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,1,,14578,CHEMBL615182,,BAO_0000219,
60,80002,,,1,,N,,,1A9,Expert,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,1,,4787,CHEMBL615183,506.0,BAO_0000219,
61,80002,,,1,,N,,,1A9,Intermediate,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,1,,4787,CHEMBL615184,506.0,BAO_0000219,
62,80002,,,1,,N,,,1A9,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,1,,3547,CHEMBL615185,506.0,BAO_0000219,
63,80002,,,1,,N,,,1A9,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,1,,3547,CHEMBL615186,506.0,BAO_0000219,
64,80002,,,1,,N,,,1A9,Intermediate,Effective dose of compound against replication of 1A9 cell line was evaluated,F,1,,6726,CHEMBL615187,506.0,BAO_0000219,
65,80002,,,1,,N,,,1A9,Expert,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,1,,3455,CHEMBL885343,506.0,BAO_0000219,
66,80002,,,1,,N,,,1A9,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,1,,5726,CHEMBL615188,506.0,BAO_0000219,
67,80002,,,1,,N,,,1A9,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,1,,5726,CHEMBL615189,506.0,BAO_0000219,
68,80002,,,1,,N,,,1A9,Intermediate,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,1,,5726,CHEMBL615190,506.0,BAO_0000219,
69,80002,,,1,,N,,,1A9,Intermediate,Inhibitory activity against Taxol resistant 1A9 cell lines,F,1,,3395,CHEMBL615191,506.0,BAO_0000219,
70,80002,,,1,,N,,,1A9,Expert,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,1,,3415,CHEMBL615192,506.0,BAO_0000219,
71,80002,,,1,,N,,,1A9,Expert,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,1,,3415,CHEMBL827083,506.0,BAO_0000219,
72,80002,,,1,,N,,,1A9,Expert,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,1,,17099,CHEMBL615193,506.0,BAO_0000219,
73,80002,,,1,,N,,,1A9,Intermediate,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,1,,17099,CHEMBL615194,506.0,BAO_0000219,
74,80002,,,1,,N,,,1A9,Intermediate,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,1,,17099,CHEMBL615195,506.0,BAO_0000219,
75,80002,,,1,,N,,,1A9,Intermediate,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,1,,17099,CHEMBL615196,506.0,BAO_0000219,
76,81072,,,1,,N,,,Jurkat,Intermediate,Inhibitory concentration against Jurkat cells,F,1,,17721,CHEMBL615197,503.0,BAO_0000219,
77,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,1,,1229,CHEMBL615198,,BAO_0000019,
78,100121,,,9,,D,,,,Expert,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,1,,11347,CHEMBL615199,,BAO_0000357,
79,11231,,,8,,H,,,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,1,,17117,CHEMBL615200,,BAO_0000357,
80,11231,,,8,,H,,,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,1,,17117,CHEMBL615201,,BAO_0000357,
81,11231,,,8,,H,,,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,1,,17117,CHEMBL615202,,BAO_0000357,
82,11231,,,8,,H,Microsomes,,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,1,,11375,CHEMBL615203,,BAO_0000251,
83,11231,,,8,,H,Microsomes,,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,1,,11375,CHEMBL615204,,BAO_0000251,
84,11231,,,8,,H,Microsomes,,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,1,,11375,CHEMBL615205,,BAO_0000251,
85,11231,,,8,,H,Microsomes,,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,1,,11375,CHEMBL615206,,BAO_0000251,
86,12083,,,8,,H,Microsomes,Liver,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,1,,11375,CHEMBL615207,,BAO_0000251,2107.0
87,11231,,,8,,H,,,,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,1,,791,CHEMBL827084,,BAO_0000019,
88,11231,,,8,,H,,,,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,1,,791,CHEMBL615208,,BAO_0000019,
89,11231,,,8,,H,,,,Autocuration,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,1,,791,CHEMBL615209,,BAO_0000019,
90,12083,,,9,,D,Microsomes,Liver,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,1,,11375,CHEMBL615210,,BAO_0000251,2107.0
91,12083,,,9,,D,Microsomes,Liver,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,1,,11375,CHEMBL615211,,BAO_0000251,2107.0
92,12083,,,9,,D,Microsomes,Liver,,Autocuration,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,1,,153,CHEMBL615212,,BAO_0000251,2107.0
93,11377,,,8,,H,,,,Expert,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,1,,8269,CHEMBL615213,,BAO_0000357,
94,11377,,,8,,H,,,,Expert,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,1,,8269,CHEMBL615273,,BAO_0000357,
95,81020,,,1,,N,,,HepG2,Expert,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,1,,17653,CHEMBL615274,726.0,BAO_0000219,
96,81020,,,1,,N,,,HepG2,Intermediate,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,1,,14277,CHEMBL615275,726.0,BAO_0000219,
97,81020,,,1,,N,,,HepG2,Intermediate,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,1,,1717,CHEMBL615276,726.0,BAO_0000219,
98,81020,,,1,,N,,,HepG2,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,1,,14091,CHEMBL615277,726.0,BAO_0000219,
99,81020,,,1,,N,,,HepG2,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,1,,14091,CHEMBL615326,726.0,BAO_0000219,
100,50606,,,1,,N,,,,Expert,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,1,,17653,CHEMBL883130,,BAO_0000218,
101,81020,,,1,,N,,,HepG2,Intermediate,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,1,,13105,CHEMBL884519,726.0,BAO_0000219,
102,81020,,,1,,N,,,HepG2,Intermediate,Concentration required to inhibit 50% of 2.2.15 cell line,F,1,,1717,CHEMBL615327,726.0,BAO_0000219,
103,81020,,,1,,N,,,HepG2,Intermediate,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,1,,13105,CHEMBL615328,726.0,BAO_0000219,
104,50587,,,1,,N,,,2.2.15,Intermediate,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,1,,13600,CHEMBL615329,,BAO_0000218,
105,50587,,,1,,N,,,2.2.15,Intermediate,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,1,,13467,CHEMBL615330,,BAO_0000218,
106,50606,,,1,,N,,,2.2.15,Expert,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,1,,17477,CHEMBL615331,,BAO_0000218,
107,50587,,,1,,N,,,2.2.15,Intermediate,In vitro anti-HBV activity in 2.2.15 cells,F,1,,1593,CHEMBL615332,,BAO_0000218,
108,50587,,,1,,N,,,2.2.15,Intermediate,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,1,,1593,CHEMBL615333,,BAO_0000218,
109,50587,,,1,,N,,,2.2.15,Intermediate,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,1,,15089,CHEMBL615334,,BAO_0000218,
110,50587,,,1,,N,,,2.2.15,Intermediate,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,1,,15089,CHEMBL615335,,BAO_0000218,
111,50587,,,1,,N,,,2.2.15,Intermediate,Cytotoxicity in 2.2.15 cells,F,1,,1593,CHEMBL615336,,BAO_0000218,
112,50587,,,1,,N,,,2.2.15,Intermediate,Cytotoxicity in 2.2.15 cells; Not determined,F,1,,1593,CHEMBL615337,,BAO_0000218,
113,50587,,,1,,N,,,2.2.15,Intermediate,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,1,,13600,CHEMBL615338,,BAO_0000218,
114,50587,,,1,,N,,,2.2.15,Intermediate,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,1,,13467,CHEMBL615339,,BAO_0000218,
115,50587,,,1,,N,,,2.2.15,Intermediate,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,1,,13467,CHEMBL615340,,BAO_0000218,
116,81020,,,1,,N,,,HepG2,Intermediate,Antiviral activity against HBV was determined in 2.215 cell line,F,1,,14764,CHEMBL615341,726.0,BAO_0000219,
117,22226,,,0,,U,Microsomes,,,Autocuration,Inhibition of 20-HETE synthesis in human renal microsomes,B,1,,6531,CHEMBL615342,,BAO_0000251,
118,22226,,,0,,U,,,,Autocuration,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,1,,17322,CHEMBL615343,,BAO_0000019,
119,80612,,,1,,N,,,2008,Intermediate,Inhibitory concentration against 2008 (ovarian) cells,F,1,,17072,CHEMBL615344,388.0,BAO_0000219,
120,80612,,,1,,N,,,2008,Intermediate,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,1,,16936,CHEMBL615345,388.0,BAO_0000219,
121,80612,,,1,,N,,,2008,Intermediate,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,1,,16936,CHEMBL615346,388.0,BAO_0000219,
122,80612,,,1,,N,,,2008,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,1,,17146,CHEMBL615347,388.0,BAO_0000219,
123,80612,,,1,,N,,,2008,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,1,,17146,CHEMBL615348,388.0,BAO_0000219,
124,80613,,,1,,N,,,2008/R,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line,F,1,,10797,CHEMBL827085,561.0,BAO_0000219,
125,80613,,,1,,N,,,2008/R,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,1,,10797,CHEMBL615349,561.0,BAO_0000219,
126,80614,,,1,,N,,,2008/S,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line,F,1,,10797,CHEMBL615350,389.0,BAO_0000219,
127,80614,,,1,,N,,,2008/S,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,1,,10797,CHEMBL615351,389.0,BAO_0000219,
128,100256,,,2,,S,,,,Expert,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,1,,4823,CHEMBL615352,,BAO_0000220,
129,100256,,,2,,S,,,,Intermediate,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,1,,12912,CHEMBL615353,,BAO_0000220,
130,100256,,,2,,S,,,,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome,B,1,,2957,CHEMBL615354,,BAO_0000220,
131,100256,,,2,,S,,,,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,1,,2957,CHEMBL615355,,BAO_0000220,
132,100256,,,2,,S,,,,Intermediate,Inhibitory activity against 20S proteosome,B,1,,3260,CHEMBL615356,,BAO_0000220,
133,22226,,,0,,U,,,,Autocuration,Compound was tested for inhibitory activity against tryptase,B,1,,3451,CHEMBL615357,,BAO_0000019,
134,81020,,,1,,N,,,HepG2,Intermediate,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,1,,13885,CHEMBL615358,726.0,BAO_0000219,
135,81020,,,1,,N,,,HepG2,Intermediate,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,1,,13885,CHEMBL827086,726.0,BAO_0000219,
136,22226,,,0,,U,,,,Autocuration,Compound was tested for the inhibition of Alpha-glucosidase,B,1,,3676,CHEMBL615359,,BAO_0000019,
137,235,,,8,,H,,,,Autocuration,Inhibitory concentration against human neutrophil elastase (HNE),B,1,,6043,CHEMBL615360,,BAO_0000357,
138,22226,,,0,,U,,Heart,,Autocuration,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,1,,11140,CHEMBL615361,,BAO_0000218,948.0
139,19640,,,8,,H,,,,Autocuration,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,1,,10543,CHEMBL615362,,BAO_0000019,
140,19640,,,8,,H,,,,Expert,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,1,,10543,CHEMBL615363,,BAO_0000019,
141,19640,,,8,,H,,,,Autocuration,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,1,,10543,CHEMBL615364,,BAO_0000357,
142,19640,,,8,,H,,,,Expert,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,1,,10543,CHEMBL615365,,BAO_0000019,
143,80360,,,1,,N,,,P338,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,1,,11365,CHEMBL615366,524.0,BAO_0000219,
144,80360,,,1,,N,,,P338,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,1,,11365,CHEMBL615367,524.0,BAO_0000219,
145,80384,,,1,,N,,,PBL,Intermediate,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,1,,11803,CHEMBL615368,554.0,BAO_0000219,
146,22226,,,0,,U,,,,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,1,,11803,CHEMBL615369,,BAO_0000019,
147,22226,,,0,,U,,,,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,1,,11803,CHEMBL615370,,BAO_0000019,
148,191,,,8,,H,,,,Autocuration,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,1,,12278,CHEMBL615673,,BAO_0000357,
149,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,1,,8249,CHEMBL615674,,BAO_0000019,
150,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,1,,8249,CHEMBL615675,,BAO_0000019,
151,22226,,,0,,U,,,CCRF-CEM,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,1,,8249,CHEMBL615676,635.0,BAO_0000219,
152,22226,,,0,,U,,,CCRF-CEM,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,1,,8249,CHEMBL615677,635.0,BAO_0000219,
153,22226,,,0,,U,,,CCRF-CEM,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,1,,8249,CHEMBL615678,635.0,BAO_0000219,
154,22226,,,0,,U,,,CCRF-CEM,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,1,,8249,CHEMBL615679,635.0,BAO_0000219,
155,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,1,,8249,CHEMBL615680,,BAO_0000019,
156,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,1,,8249,CHEMBL615681,,BAO_0000019,
157,104290,,,6,,H,,,,Autocuration,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,1,,16992,CHEMBL857972,,BAO_0000249,
158,50264,,,1,,N,,,,Intermediate,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,1,,10543,CHEMBL857899,,BAO_0000218,
159,50527,,,1,,N,,,,Intermediate,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,1,,17833,CHEMBL615371,,BAO_0000218,
160,50527,,,1,,N,,,HEL,Expert,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,1,,17290,CHEMBL615372,468.0,BAO_0000218,
161,50527,,,1,,N,,,,Intermediate,Antiviral activity against 07/1 strain of VZV; ND: No data,F,1,,17290,CHEMBL615373,,BAO_0000218,
162,50527,,,1,,N,,,,Intermediate,Antiviral activity against 07/1 strain of VZV; ND=No data,F,1,,17290,CHEMBL615374,,BAO_0000218,
163,50145,,,1,,N,,,,Intermediate,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,1,,10932,CHEMBL615375,,BAO_0000218,
164,22226,,,0,,U,,,,Autocuration,Ratio of Ki at A2 to Ki at A1 receptors,B,1,,9707,CHEMBL615376,,BAO_0000019,
165,11143,,,8,,H,,,,Expert,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,1,,2346,CHEMBL615377,,BAO_0000249,
166,18077,,,8,,H,,,,Expert,"Inhibition of 1,3-beta-glucan synthase",B,1,,2205,CHEMBL615378,,BAO_0000357,
167,80609,,,1,,N,,,1-87 tumor cell line,Intermediate,Inhibition of growth of 1-87 human tumor cell line,F,1,,11900,CHEMBL615379,832.0,BAO_0000219,
168,12166,,,9,,D,,,,Expert,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,1,,14864,CHEMBL615380,,BAO_0000219,
169,100171,,,9,,D,,,,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,1,,16474,CHEMBL615381,,BAO_0000357,
170,100171,,,9,,D,,,,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,1,,16474,CHEMBL615382,,BAO_0000357,
171,100171,,,9,,D,,,,Autocuration,% inhibition against soybean 1-lipoxygenase (SLO),B,1,,16474,CHEMBL615383,,BAO_0000357,
172,100171,,,9,,D,,,,Autocuration,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,1,,16474,CHEMBL615384,,BAO_0000357,
173,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,1,,3094,CHEMBL615385,,BAO_0000357,
174,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,1,,3094,CHEMBL615386,,BAO_0000357,
175,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,1,,3094,CHEMBL615387,,BAO_0000357,
176,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,1,,3094,CHEMBL615388,,BAO_0000357,
177,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,1,,3094,CHEMBL615214,,BAO_0000357,
178,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,1,,3094,CHEMBL827087,,BAO_0000357,
179,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,1,,3094,CHEMBL615215,,BAO_0000357,
180,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,1,,3094,CHEMBL615216,,BAO_0000357,
181,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,1,,3094,CHEMBL615217,,BAO_0000357,
182,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,1,,3094,CHEMBL615218,,BAO_0000357,
183,100171,,,9,,D,,,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,1,,3094,CHEMBL615219,,BAO_0000357,
184,22226,,,0,,U,,,,Autocuration,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,1,,10413,CHEMBL615220,,BAO_0000019,
185,80049,,,1,,N,,,C3H 10T1/2,Intermediate,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,1,,16929,CHEMBL615221,294.0,BAO_0000219,
186,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,1,,1229,CHEMBL615222,,BAO_0000019,
187,11489,,,8,,H,,,,Autocuration,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,1,,16587,CHEMBL615223,,BAO_0000357,
188,11862,,,8,,H,,,,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,1,,16587,CHEMBL615224,,BAO_0000357,
189,11862,,,8,,H,,,,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,1,,16587,CHEMBL615225,,BAO_0000357,
190,11489,,,8,,H,,,,Autocuration,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,1,,16587,CHEMBL615226,,BAO_0000357,
191,11862,,,8,,H,,,,Autocuration,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,1,,16587,CHEMBL615227,,BAO_0000357,
192,12347,,,9,,D,,,,Expert,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,1,,8058,CHEMBL615228,,BAO_0000019,
193,100120,,,9,,D,,,,Expert,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,1,,9065,CHEMBL615229,,BAO_0000357,
194,100120,,,9,,D,,Adrenal gland,,Expert,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,1,,8865,CHEMBL615230,,BAO_0000357,2369.0
195,100120,,,9,,D,,,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,B,1,,9066,CHEMBL615231,,BAO_0000357,
196,100120,,,9,,D,,,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,B,1,,8394,CHEMBL884520,,BAO_0000357,
197,100120,,,9,,D,,,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,1,,8394,CHEMBL615232,,BAO_0000357,
198,10328,,,8,,H,,,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,1,,6431,CHEMBL615233,,BAO_0000019,
199,11490,,,8,,H,,,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,1,,6431,CHEMBL827088,,BAO_0000357,
200,11490,,,8,,H,,,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,1,,6431,CHEMBL615234,,BAO_0000357,
201,11134,,,8,,H,,,,Autocuration,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,1,,9295,CHEMBL615235,,BAO_0000019,
202,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,1,,10193,CHEMBL615236,,BAO_0000019,
203,11134,,,8,,H,,,,Autocuration,Compound was tested in vitro for inhibition of 12-LO human platelet,B,1,,13622,CHEMBL615237,,BAO_0000019,
204,11134,,,8,,H,,,,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,F,1,,12079,CHEMBL615238,,BAO_0000019,
205,11134,,,8,,H,,,,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,1,,13622,CHEMBL615239,,BAO_0000019,
206,11134,,,9,,D,,,,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,F,1,,12079,CHEMBL615240,,BAO_0000019,
207,11835,,,8,,H,,,,Expert,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,1,,13500,CHEMBL615241,,BAO_0000019,
208,11601,,,8,,H,,,,Expert,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,1,,13723,CHEMBL615242,,BAO_0000357,
209,11134,,,8,,H,,,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,1,,16474,CHEMBL615243,,BAO_0000019,
210,11134,,,8,,H,,,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase,B,1,,1630,CHEMBL615244,,BAO_0000019,
211,11134,,,8,,H,,,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,1,,167,CHEMBL615245,,BAO_0000019,
212,11134,,,8,,H,,,,Autocuration,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,1,,16474,CHEMBL615246,,BAO_0000019,
213,11134,,,8,,H,,,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,1,,167,CHEMBL615247,,BAO_0000019,
214,11134,,,8,,H,,,,Autocuration,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,1,,16474,CHEMBL615248,,BAO_0000019,
215,11601,,,8,,H,,,,Autocuration,Inhibitory activity towards porcine 12-lipoxygenase,B,1,,10091,CHEMBL615249,,BAO_0000357,
216,11601,,,8,,H,,,,Autocuration,Tested for inhibition against porcine 12-LO,B,1,,11966,CHEMBL615250,,BAO_0000357,
217,12052,,,8,,H,,,,Autocuration,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,1,,951,CHEMBL615251,,BAO_0000019,
218,12052,,,8,,H,,,,Autocuration,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,1,,10997,CHEMBL615252,,BAO_0000019,
219,12052,,,8,,H,,,,Expert,In vitro inhibition of rat platelet 12-lipoxygenase,B,1,,10193,CHEMBL828340,,BAO_0000019,
220,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,1,,10193,CHEMBL615253,,BAO_0000019,
221,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,1,,10193,CHEMBL615254,,BAO_0000019,
222,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,1,,10193,CHEMBL615255,,BAO_0000019,
223,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,1,,10193,CHEMBL615256,,BAO_0000019,
224,12052,,,8,,H,,,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,1,,10193,CHEMBL615257,,BAO_0000019,
225,12052,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,1,,11087,CHEMBL615258,,BAO_0000019,
226,80007,,,1,,N,,,41M,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,1,,15569,CHEMBL615259,621.0,BAO_0000219,
227,80007,,,1,,N,,,41M,Expert,In vitro antitumor activity against 41M cell line.,F,1,,12989,CHEMBL615260,621.0,BAO_0000219,
228,80007,,,1,,N,,,41M,Intermediate,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,1,,16745,CHEMBL615261,621.0,BAO_0000219,
229,80007,,,1,,N,,,41M,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,1,,15569,CHEMBL615262,621.0,BAO_0000219,
230,80007,,,1,,N,,,41M,Expert,In vitro antitumor activity against 41McisR cell line.,F,1,,12989,CHEMBL615263,621.0,BAO_0000219,
231,80007,,,1,,N,,,41M,Expert,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,1,,12989,CHEMBL838393,621.0,BAO_0000219,
232,80007,,,1,,N,,,41M,Intermediate,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,1,,16745,CHEMBL615264,621.0,BAO_0000219,
233,84,,,9,,D,,,,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,1,,6210,CHEMBL615265,,BAO_0000357,
234,68,,,9,,D,,,,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,1,,6210,CHEMBL615266,,BAO_0000357,
235,68,,,8,,H,,,,Expert,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,1,,6226,CHEMBL615267,,BAO_0000357,
236,10201,,,8,,H,,,,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,1,,17855,CHEMBL615268,,BAO_0000357,
237,10201,,,8,,H,,,,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,1,,17855,CHEMBL615269,,BAO_0000357,
238,10201,,,8,,H,,,,Expert,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,1,,17855,CHEMBL615270,,BAO_0000357,
239,12220,,,8,,H,,,,Autocuration,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,1,,10413,CHEMBL615271,,BAO_0000357,
240,11303,,,8,,H,,,,Autocuration,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,1,,10413,CHEMBL615272,,BAO_0000357,
241,11303,,,8,,H,,,,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,1,,10413,CHEMBL615103,,BAO_0000357,
242,11303,,,8,,H,,,,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,1,,10413,CHEMBL615104,,BAO_0000357,
243,12220,,,8,,H,,,,Autocuration,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,1,,10413,CHEMBL615105,,BAO_0000357,
244,12220,,,8,,H,,,,Autocuration,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,1,,10413,CHEMBL872866,,BAO_0000357,
245,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,1,,7587,CHEMBL615106,,BAO_0000357,
246,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,1,,7587,CHEMBL615107,,BAO_0000019,
247,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,1,,7587,CHEMBL615108,,BAO_0000357,
248,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,1,,7587,CHEMBL615109,,BAO_0000357,
249,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,1,,7587,CHEMBL615110,,BAO_0000357,
250,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,1,,7587,CHEMBL840105,,BAO_0000019,
251,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,1,,7587,CHEMBL615111,,BAO_0000019,
252,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,1,,7587,CHEMBL615112,,BAO_0000019,
253,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,1,,7587,CHEMBL615113,,BAO_0000019,
254,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,1,,7587,CHEMBL615114,,BAO_0000019,
255,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,1,,7587,CHEMBL615115,,BAO_0000357,
256,11303,,,8,,H,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,1,,7587,CHEMBL615116,,BAO_0000019,
257,11303,,,8,,H,,,,Autocuration,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,1,,7323,CHEMBL615698,,BAO_0000357,
258,22226,,,0,,U,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,1,,7587,CHEMBL615699,,BAO_0000019,
259,22226,,,0,,U,,,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,1,,7587,CHEMBL615700,,BAO_0000019,
260,100249,,,8,,H,,,,Expert,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,1,,13750,CHEMBL615701,,BAO_0000357,
261,22226,,,0,,U,,,,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,1,,7662,CHEMBL615702,,BAO_0000019,
262,22226,,,0,,U,,,,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,1,,7662,CHEMBL615703,,BAO_0000019,
263,22226,,,0,,U,,,,Autocuration,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,1,,7662,CHEMBL615704,,BAO_0000019,
264,104698,,,6,,H,,,,Autocuration,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,1,,12211,CHEMBL615705,,BAO_0000019,
265,104698,,,6,,H,,,,Autocuration,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,1,,12211,CHEMBL615706,,BAO_0000019,
266,20033,,,9,,D,,Ileum,,Intermediate,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,1,,12211,CHEMBL615707,,BAO_0000221,2116.0
267,10623,,,8,,H,,,,Expert,Stimulatory activity of intragastric pressure was tested in the rat,F,1,,12211,CHEMBL615708,,BAO_0000019,
268,121,,,8,,H,,,,Autocuration,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,1,,15453,CHEMBL615709,,BAO_0000357,
269,22226,,,0,,U,,,,Autocuration,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,1,,11884,CHEMBL615710,,BAO_0000218,
270,12688,,,8,,H,,,,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,1,,7185,CHEMBL615711,,BAO_0000019,
271,121,,,9,,D,,,,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,1,,6876,CHEMBL615712,,BAO_0000357,
272,121,,,9,,D,,,,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,1,,6876,CHEMBL836325,,BAO_0000357,
273,12198,,,8,,H,,,,Autocuration,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,1,,11863,CHEMBL615713,,BAO_0000019,
274,12198,,,8,,H,,,,Autocuration,Inhibition constant of high-affinity 5-HT uptake,B,1,,11863,CHEMBL615714,,BAO_0000357,
275,12198,,,8,,H,,,,Autocuration,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,1,,11863,CHEMBL615715,,BAO_0000019,
276,12198,,,8,,H,,,,Autocuration,Maximum rate was determined for high affinity transport of 5-HT,F,1,,11863,CHEMBL615716,,BAO_0000019,
277,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-HT uptake,F,1,,4639,CHEMBL615717,,BAO_0000019,
278,10577,,,8,,H,,,,Expert,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,1,,15796,CHEMBL881818,,BAO_0000019,
279,105,,,8,,H,,,,Expert,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,1,,15796,CHEMBL884540,,BAO_0000357,
280,104744,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,1,,12801,CHEMBL615718,,BAO_0000224,
281,104744,,,4,,H,,,,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,1,,12801,CHEMBL615719,,BAO_0000224,
282,104744,,,4,,H,Membranes,,,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,1,,12120,CHEMBL615720,,BAO_0000249,
283,104744,,,4,,H,Membranes,,,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,1,,12120,CHEMBL615721,,BAO_0000249,
284,104744,,,4,,H,,,,Autocuration,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,1,,11963,CHEMBL615722,,BAO_0000019,
285,51,,,8,,H,,,,Autocuration,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,1,,11701,CHEMBL615723,,BAO_0000019,
286,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615724,,BAO_0000221,10000000.0
287,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615725,,BAO_0000221,10000000.0
288,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615726,,BAO_0000221,10000000.0
289,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,1,,16394,CHEMBL615727,,BAO_0000218,
290,105570,,,9,,D,,,,Intermediate,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,1,,11574,CHEMBL615728,,BAO_0000019,
291,279,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL857971,449.0,BAO_0000219,
292,107,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,1,,15363,CHEMBL615729,,BAO_0000357,
293,12687,,,9,,D,,,,Expert,Efficacy against 5-hydroxytryptamine 2A receptor,F,1,,15363,CHEMBL615730,,BAO_0000019,
294,12687,,,8,,H,,,,Expert,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,1,,15329,CHEMBL615731,,BAO_0000019,
295,12687,,,8,,H,,,,Expert,Relative potency towards 5-HT2A receptor of rat tail artery,F,1,,15329,CHEMBL615732,,BAO_0000019,
296,12687,,,8,,H,,,,Expert,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,1,,15329,CHEMBL615733,,BAO_0000019,
297,12687,,,8,,H,,,,Expert,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,1,,15329,CHEMBL615734,,BAO_0000019,
298,12687,,,8,,H,,,,Autocuration,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,1,,15329,CHEMBL615735,,BAO_0000019,
299,12687,,,8,,H,,,,Expert,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,1,,15329,CHEMBL615736,,BAO_0000019,
300,20033,,,9,,D,,Ileum,,Intermediate,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,1,,273,CHEMBL615737,,BAO_0000221,2116.0
301,20033,,,9,,D,,Ileum,,Intermediate,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,1,,273,CHEMBL615738,,BAO_0000221,2116.0
302,20033,,,9,,D,,Ileum,,Intermediate,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,1,,273,CHEMBL615739,,BAO_0000221,2116.0
303,10623,,,8,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,1,,12092,CHEMBL615278,,BAO_0000357,
304,10623,,,9,,D,,,,Expert,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,1,,1317,CHEMBL615279,,BAO_0000019,
305,168,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,B,1,,12409,CHEMBL615280,,BAO_0000357,
306,22226,,,0,,U,,,,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,1,,11126,CHEMBL615281,,BAO_0000019,
307,22226,,,0,,U,,,,Autocuration,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,1,,11126,CHEMBL615282,,BAO_0000019,
308,22226,,,0,,U,,,,Autocuration,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,1,,11126,CHEMBL615283,,BAO_0000019,
309,80156,,,1,,N,,,HL-60,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,1,,11126,CHEMBL615284,649.0,BAO_0000219,
310,22226,,,0,,U,,,,Autocuration,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,1,,11126,CHEMBL615285,,BAO_0000019,
311,22226,,,0,,U,,,,Autocuration,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,1,,11126,CHEMBL615286,,BAO_0000019,
312,104703,,,7,,D,,,Oocytes,Autocuration,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,1,,17807,CHEMBL615287,,BAO_0000219,
313,100256,,,2,,S,,,,Intermediate,Chymotryptic inhibitory activity against 26S proteasome,F,1,,16575,CHEMBL615288,,BAO_0000220,
314,100256,,,2,,S,,,,Intermediate,Inhibitory activity against 26S proteasome degradation of IkB,B,1,,15407,CHEMBL615289,,BAO_0000220,
315,81034,,,1,,N,,,A2780,Intermediate,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,1,,10797,CHEMBL615290,478.0,BAO_0000219,
316,81034,,,1,,N,,,A2780,Intermediate,In vitro inhibition of 2780/S ovarian cancer cell line,F,1,,10797,CHEMBL884522,478.0,BAO_0000219,
317,22226,,,0,,U,,,,Autocuration,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,1,,3469,CHEMBL615291,,BAO_0000019,
318,22222,,,3,,M,,,,Intermediate,Association constant for binding to AATT 28-mer AATT hairpin,B,1,,16037,CHEMBL615292,,BAO_0000225,
319,22222,,,3,,M,,,,Intermediate,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,1,,16037,CHEMBL615293,,BAO_0000225,
320,22222,,,3,,M,,,,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,B,1,,16037,CHEMBL615294,,BAO_0000225,
321,22222,,,3,,M,,,,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,B,1,,16037,CHEMBL615295,,BAO_0000225,
322,22226,,,0,,U,,,,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,1,,16524,CHEMBL825021,,BAO_0000019,
323,22226,,,0,,U,,,,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,1,,16524,CHEMBL615296,,BAO_0000019,
324,22226,,,0,,U,,,,Autocuration,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,1,,16524,CHEMBL615297,,BAO_0000019,
325,22226,,,0,,U,,,,Autocuration,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,1,,16758,CHEMBL615298,,BAO_0000019,
326,22226,,,0,,U,,,,Autocuration,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,1,,16758,CHEMBL615299,,BAO_0000019,
327,22226,,,0,,U,,,,Autocuration,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,1,,16758,CHEMBL615300,,BAO_0000019,
328,241,,,8,,H,,,,Autocuration,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,1,,14360,CHEMBL615301,,BAO_0000357,
329,241,,,9,,D,,,,Expert,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,1,,14360,CHEMBL615302,,BAO_0000357,
330,22226,,,0,,U,,,,Autocuration,Selectivity ratio of ID50 in liver and heart,B,1,,9964,CHEMBL615303,,BAO_0000019,
331,12132,,,8,,H,,,,Autocuration,"Selectivity, ratio of relative ID50 in liver and heart",B,1,,9964,CHEMBL615304,,BAO_0000019,
332,12132,,,8,,H,,,,Autocuration,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,1,,9964,CHEMBL615305,,BAO_0000019,
333,12132,,,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615306,,BAO_0000218,
334,12132,,,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615307,,BAO_0000218,
335,12132,,In vivo,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615308,,BAO_0000218,
336,12132,,In vivo,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,1,,9964,CHEMBL615309,,BAO_0000218,
337,22226,,,0,,U,,,,Autocuration,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,1,,9964,CHEMBL615310,,BAO_0000019,
338,12132,,,8,,H,,,,Autocuration,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,1,,9964,CHEMBL615311,,BAO_0000019,
339,22226,,,0,,U,,,,Autocuration,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,1,,9964,CHEMBL615312,,BAO_0000019,
340,12132,,,8,,H,,,,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,1,,9964,CHEMBL615313,,BAO_0000019,
341,12132,,,8,,H,,,,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,1,,9964,CHEMBL615314,,BAO_0000019,
342,12132,,,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615315,,BAO_0000019,
343,22226,,,0,,U,,,,Autocuration,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,1,,9964,CHEMBL615316,,BAO_0000218,
344,12132,,In vivo,8,,H,,,,Autocuration,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,1,,9964,CHEMBL615317,,BAO_0000218,
345,12132,,,8,,H,,,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615318,,BAO_0000218,
346,22226,,,0,,U,,,,Autocuration,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,1,,9964,CHEMBL615319,,BAO_0000218,
347,12132,,,8,,H,,,,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,1,,9964,CHEMBL615320,,BAO_0000019,
348,12132,,,8,,H,,,,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,1,,9964,CHEMBL615321,,BAO_0000019,
349,22226,,,0,,U,,,,Autocuration,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,1,,3796,CHEMBL615322,,BAO_0000019,
350,19690,,,8,,H,,,,Autocuration,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,1,,4251,CHEMBL615323,,BAO_0000357,
351,19690,,,8,,H,,,,Autocuration,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,1,,4251,CHEMBL615407,,BAO_0000357,
352,19690,,,8,,H,,,,Autocuration,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,1,,4251,CHEMBL857267,,BAO_0000357,
353,19690,,,8,,H,,,,Autocuration,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,1,,4251,CHEMBL615408,,BAO_0000357,
354,19690,,,8,,H,,,,Autocuration,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,1,,166,CHEMBL615409,,BAO_0000357,
355,19690,,,8,,H,,,,Autocuration,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,1,,17861,CHEMBL615410,,BAO_0000357,
356,19690,,,8,,H,,,,Autocuration,Inhibition constant against 3-dehydroquinate synthase,B,1,,166,CHEMBL615411,,BAO_0000357,
357,19690,,,8,,H,,,,Autocuration,Association rate constant against 3-dehydroquinate synthase,B,1,,166,CHEMBL615412,,BAO_0000357,
358,19690,,,8,,H,,,,Autocuration,Rate constant against 3-dehydroquinate synthase,B,1,,166,CHEMBL615413,,BAO_0000357,
359,22226,,,0,,U,,,,Autocuration,Inhibitory activity against fuc-TVII,B,1,,3548,CHEMBL615414,,BAO_0000019,
360,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,1,,9877,CHEMBL615415,,BAO_0000251,2107.0
361,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,1,,9877,CHEMBL615416,,BAO_0000251,2107.0
362,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,1,,9877,CHEMBL615417,,BAO_0000251,2107.0
363,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,1,,9877,CHEMBL615418,,BAO_0000251,2107.0
364,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,1,,9877,CHEMBL615419,,BAO_0000251,2107.0
365,12236,,,9,,D,Microsomes,Liver,,Autocuration,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,1,,9877,CHEMBL615420,,BAO_0000251,2107.0
366,12236,,,9,,D,Microsomes,Liver,,Autocuration,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,1,,9877,CHEMBL615421,,BAO_0000251,2107.0
367,12236,,,9,,D,Microsomes,Liver,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,1,,9877,CHEMBL615422,,BAO_0000251,2107.0
368,12236,,,9,,D,Microsomes,Liver,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,1,,9877,CHEMBL615423,,BAO_0000251,2107.0
369,12236,,,9,,D,Microsomes,Liver,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,1,,9877,CHEMBL872868,,BAO_0000251,2107.0
370,12236,,,9,,D,Microsomes,Liver,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,1,,9877,CHEMBL615424,,BAO_0000251,2107.0
371,104832,,,4,,H,,,,Autocuration,Inhibitory activity against 3-phosphoglycerate kinase.,B,1,,3003,CHEMBL825022,,BAO_0000224,
372,104832,,,4,,H,,,,Autocuration,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,1,,3003,CHEMBL615425,,BAO_0000224,
373,104832,,,4,,H,,,,Autocuration,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,1,,3003,CHEMBL615426,,BAO_0000224,
374,10612,,,9,,D,,,,Expert,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,1,,17185,CHEMBL615427,,BAO_0000357,
375,80616,,,1,,N,,,3677 melanoma cell line,Intermediate,Cytotoxicity on 3677 melanoma cells,F,1,,6072,CHEMBL615428,844.0,BAO_0000219,
376,80616,,,1,,N,,,3677 melanoma cell line,Intermediate,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,1,,6072,CHEMBL615429,844.0,BAO_0000219,
377,80617,,,1,,N,,,MC-38,Intermediate,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,1,,5018,CHEMBL615430,700.0,BAO_0000219,
378,22226,,,0,,U,,,,Intermediate,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,1,,2852,CHEMBL615431,,BAO_0000019,
379,22226,,,0,,U,,,B16,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,1,,8663,CHEMBL615432,798.0,BAO_0000218,
380,22226,,,0,,U,,,B16,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,1,,8663,CHEMBL615433,798.0,BAO_0000218,
381,12464,,,9,,D,,,,Expert,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,1,,3245,CHEMBL615434,,BAO_0000019,
382,50085,,,1,,N,,,,Intermediate,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,1,,3245,CHEMBL615435,,BAO_0000218,
383,50679,,,1,,N,,,,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,1,,3877,CHEMBL615436,,BAO_0000218,
384,50679,,,1,,N,,,,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,1,,3877,CHEMBL615437,,BAO_0000218,
385,12464,,,9,,D,,,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,1,,5861,CHEMBL615438,,BAO_0000019,
386,12464,,,9,,D,,,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,1,,5861,CHEMBL615439,,BAO_0000019,
387,12464,,,9,,D,,,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,1,,5861,CHEMBL615440,,BAO_0000019,
388,12464,,,9,,D,,,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,1,,5861,CHEMBL615441,,BAO_0000019,
389,50665,,,1,,N,,,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,1,,13748,CHEMBL615641,,BAO_0000218,
390,50665,,,1,,N,,,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,1,,13748,CHEMBL872065,,BAO_0000218,
391,50665,,,1,,N,,,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,1,,13748,CHEMBL825023,,BAO_0000218,
392,50665,,,1,,N,,,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,1,,13748,CHEMBL615642,,BAO_0000218,
393,12464,,,8,,H,,,,Expert,Inhibition of human rhinovirus 3C protease,B,1,,13748,CHEMBL615643,,BAO_0000357,
394,22226,,,0,,U,,,,Autocuration,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,1,,17699,CHEMBL615644,,BAO_0000019,
395,80619,,,1,,N,,,3EM 37,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,1,,7145,CHEMBL615645,833.0,BAO_0000218,
396,80619,,,1,,N,,,3EM 37,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,1,,7145,CHEMBL615646,833.0,BAO_0000218,
397,80619,,,1,,N,,,3EM 37,Intermediate,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,1,,7145,CHEMBL615647,833.0,BAO_0000218,
398,80619,,,1,,N,,,3EM 37,Intermediate,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,1,,7145,CHEMBL615648,833.0,BAO_0000218,
399,80619,,,1,,N,,,3EM 37,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,1,,7145,CHEMBL615649,833.0,BAO_0000218,
400,80619,,,1,,N,,,3EM 37,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,1,,7145,CHEMBL615650,833.0,BAO_0000218,
401,80620,,,1,,N,,,3LL cell line,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,1,,5325,CHEMBL615651,847.0,BAO_0000218,
402,80620,,,1,,N,,,3LL cell line,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,1,,5325,CHEMBL615652,847.0,BAO_0000218,
403,80620,,,1,,N,,,3LL cell line,Expert,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,1,,5325,CHEMBL615653,847.0,BAO_0000218,
404,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,1,,16169,CHEMBL615654,847.0,BAO_0000219,
405,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,1,,16169,CHEMBL615655,847.0,BAO_0000219,
406,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,1,,16169,CHEMBL825024,847.0,BAO_0000219,
407,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,1,,16169,CHEMBL615656,847.0,BAO_0000219,
408,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,1,,16169,CHEMBL615657,847.0,BAO_0000219,
409,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,1,,16169,CHEMBL615658,847.0,BAO_0000219,
410,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,1,,16169,CHEMBL615659,847.0,BAO_0000219,
411,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,1,,16169,CHEMBL615660,847.0,BAO_0000219,
412,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,1,,16169,CHEMBL615661,847.0,BAO_0000219,
413,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,1,,16169,CHEMBL615662,847.0,BAO_0000219,
414,80620,,,1,,N,,,3LL cell line,Intermediate,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,1,,16169,CHEMBL615663,847.0,BAO_0000219,
415,80620,,,1,,N,,,3LL cell line,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,1,,16169,CHEMBL615664,847.0,BAO_0000219,
416,80620,,,1,,N,,,3LL cell line,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,1,,16169,CHEMBL615665,847.0,BAO_0000219,
417,80620,,,1,,N,,,3LL cell line,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,1,,16169,CHEMBL615666,847.0,BAO_0000219,
418,80620,,,1,,N,,,3LL cell line,Intermediate,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,1,,16169,CHEMBL615667,847.0,BAO_0000219,
419,80620,,,1,,N,,,3LL cell line,Intermediate,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,1,,16169,CHEMBL615668,847.0,BAO_0000219,
420,80620,,,1,,N,,,3LL cell line,Intermediate,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,1,,16169,CHEMBL615669,847.0,BAO_0000219,
421,80620,,,1,,N,,,3LL cell line,Intermediate,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,1,,16169,CHEMBL615670,847.0,BAO_0000219,
422,80620,,,1,,N,,,3LL cell line,Intermediate,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,1,,16169,CHEMBL836739,847.0,BAO_0000219,
423,80620,,,1,,N,,,3LL cell line,Intermediate,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,1,,16169,CHEMBL615671,847.0,BAO_0000219,
424,80620,,,1,,N,,,3LL cell line,Intermediate,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,1,,16169,CHEMBL615672,847.0,BAO_0000219,
425,80620,,,1,,N,,,3LL cell line,Intermediate,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,1,,16169,CHEMBL615791,847.0,BAO_0000219,
426,80620,,,1,,N,,,3LL cell line,Intermediate,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,1,,16169,CHEMBL615792,847.0,BAO_0000219,
427,80620,,,1,,N,,,3LL cell line,Intermediate,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,1,,16169,CHEMBL615793,847.0,BAO_0000219,
428,80620,,,1,,N,,,3LL cell line,Intermediate,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,1,,16169,CHEMBL615794,847.0,BAO_0000219,
429,80620,,,1,,N,,,3LL cell line,Intermediate,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,1,,16169,CHEMBL615795,847.0,BAO_0000219,
430,80621,,,1,,N,,,3LLD122,Intermediate,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,1,,15547,CHEMBL615590,971.0,BAO_0000219,
431,22226,,,0,,U,,,,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,1,,8663,CHEMBL615591,,BAO_0000218,
432,22226,,,0,,U,,,,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,1,,8663,CHEMBL615592,,BAO_0000218,
433,22226,,,0,,U,,,,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,1,,8663,CHEMBL615593,,BAO_0000218,
434,22226,,,0,,U,,,,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,1,,8663,CHEMBL615594,,BAO_0000218,
435,80951,,,1,,N,,,NIH3T3,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,1,,4504,CHEMBL615595,723.0,BAO_0000219,
436,80951,,,1,,N,,,NIH3T3,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,1,,4504,CHEMBL615596,723.0,BAO_0000219,
437,11169,,,8,,H,,,NIH3T3,Expert,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,1,,12695,CHEMBL615597,723.0,BAO_0000219,
438,80951,,,1,,N,,,NIH3T3,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,1,,12695,CHEMBL615598,723.0,BAO_0000219,
439,80951,,,1,,N,,,NIH3T3,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,1,,12695,CHEMBL615599,723.0,BAO_0000219,
440,80951,,,1,,N,,,NIH3T3,Expert,Effective dose against murine 3T3 fibroblasts cells,F,1,,17642,CHEMBL615600,723.0,BAO_0000219,
441,80951,,,1,,N,,,NIH3T3,Expert,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,1,,17642,CHEMBL615601,723.0,BAO_0000219,
442,80951,,,1,,N,,,NIH3T3,Expert,Cytotoxic effect on 3T3 cells,F,1,,12340,CHEMBL615602,723.0,BAO_0000219,
443,80951,,,1,,N,,,NIH3T3,Expert,Cytotoxic effect on 3T3 cells,F,1,,12340,CHEMBL615603,723.0,BAO_0000219,
444,80951,,,1,,N,,,NIH3T3,Intermediate,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,1,,12716,CHEMBL615604,723.0,BAO_0000219,
445,80951,,,1,,N,,,NIH3T3,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,1,,6277,CHEMBL615605,723.0,BAO_0000219,
446,80951,,,1,,N,,,NIH3T3,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,1,,6277,CHEMBL615606,723.0,BAO_0000219,
447,80951,,,1,,N,,,NIH3T3,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,1,,6277,CHEMBL884526,723.0,BAO_0000219,
448,80951,,,1,,N,,,NIH3T3,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,1,,6277,CHEMBL615607,723.0,BAO_0000219,
449,80951,,,1,,N,,,NIH3T3,Intermediate,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,1,,6277,CHEMBL615608,723.0,BAO_0000219,
450,80951,,,1,,N,,,NIH3T3,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,1,,6277,CHEMBL615609,723.0,BAO_0000219,
451,80951,,,1,,N,,,NIH3T3,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,1,,6277,CHEMBL615682,723.0,BAO_0000219,
452,80951,,,1,,N,,,NIH3T3,Intermediate,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,1,,6277,CHEMBL615683,723.0,BAO_0000219,
453,80951,,,1,,N,,,NIH3T3,Expert,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,1,,17780,CHEMBL615684,723.0,BAO_0000218,
454,104860,,,7,,D,,,,Autocuration,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,1,,12751,CHEMBL615685,,BAO_0000219,
455,80951,,,1,,N,,,NIH3T3,Expert,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,1,,12380,CHEMBL615686,723.0,BAO_0000219,
456,80951,,,1,,N,,,NIH3T3,Intermediate,Inhibitory activity against 3T3 cell line,F,1,,14892,CHEMBL615687,723.0,BAO_0000219,
457,80951,,,1,,N,,,NIH3T3,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,1,,12695,CHEMBL884523,723.0,BAO_0000219,
458,11169,,,8,,H,,,,Expert,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,1,,12695,CHEMBL615688,,BAO_0000019,
459,80951,,,1,,N,,,NIH3T3,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,1,,12695,CHEMBL615689,723.0,BAO_0000219,
460,80951,,,1,,N,,,NIH3T3,Intermediate,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,1,,12695,CHEMBL615690,723.0,BAO_0000219,
461,11169,,,8,,H,,,,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,1,,12695,CHEMBL615691,,BAO_0000019,
462,11169,,,8,,H,,,,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,1,,12695,CHEMBL615692,,BAO_0000019,
463,80951,,,1,,N,,,NIH3T3,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,1,,6277,CHEMBL615693,723.0,BAO_0000219,
464,80951,,,1,,N,,,NIH3T3,Expert,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,1,,6277,CHEMBL615324,723.0,BAO_0000219,
465,9,,,9,,D,,,NIH3T3,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,1,,4959,CHEMBL615325,723.0,BAO_0000219,
466,9,,,9,,D,,,NIH3T3,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,1,,4959,CHEMBL615490,723.0,BAO_0000219,
467,188,,,9,,D,,,NIH3T3,Expert,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,1,,4959,CHEMBL615491,723.0,BAO_0000219,
468,188,,,9,,D,,,NIH3T3,Expert,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,1,,4959,CHEMBL615492,723.0,BAO_0000219,
469,80951,,,1,,N,,,NIH3T3,Intermediate,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,1,,12082,CHEMBL615493,723.0,BAO_0000219,
470,80951,,,1,,N,,,NIH3T3,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,1,,12082,CHEMBL615494,723.0,BAO_0000219,
471,80951,,,1,,N,,,NIH3T3,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,1,,12082,CHEMBL615495,723.0,BAO_0000219,
472,80951,,,1,,N,,,NIH3T3,Intermediate,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,1,,12082,CHEMBL615496,723.0,BAO_0000219,
473,80951,,,1,,N,,,NIH3T3,Intermediate,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,1,,2643,CHEMBL615497,723.0,BAO_0000219,
474,80951,,,1,,N,,,NIH3T3,Expert,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,1,,11926,CHEMBL615498,723.0,BAO_0000219,
475,80951,,,1,,N,,,NIH3T3,Intermediate,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,1,,15204,CHEMBL615499,723.0,BAO_0000219,
476,80951,,,1,,N,,,NIH3T3,Expert,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,1,,15992,CHEMBL835522,723.0,BAO_0000219,
477,80951,,,1,,N,,,NIH3T3,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,1,,16279,CHEMBL615500,723.0,BAO_0000219,
478,80951,,,1,,N,,,NIH3T3,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,1,,16279,CHEMBL615501,723.0,BAO_0000219,
479,80951,,,1,,N,,,NIH3T3,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,1,,16279,CHEMBL615502,723.0,BAO_0000219,
480,80951,,,1,,N,,,NIH3T3,Intermediate,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,1,,16279,CHEMBL615503,723.0,BAO_0000219,
481,80951,,,1,,N,,,NIH3T3,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,1,,16279,CHEMBL615504,723.0,BAO_0000219,
482,80951,,,1,,N,,,NIH3T3,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,1,,16279,CHEMBL615505,723.0,BAO_0000219,
483,80951,,,1,,N,,,NIH3T3,Expert,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,1,,12831,CHEMBL615506,723.0,BAO_0000219,
484,80951,,,1,,N,,,NIH3T3,Intermediate,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,1,,13497,CHEMBL615507,723.0,BAO_0000219,
485,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,1,,13715,CHEMBL615508,620.0,BAO_0000218,
486,80006,,,1,,N,,,3T3-L1,Intermediate,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,1,,13618,CHEMBL615509,620.0,BAO_0000219,
487,80006,,,1,,N,,,3T3-L1,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,1,,11902,CHEMBL615510,620.0,BAO_0000219,
488,80006,,,1,,N,,,3T3-L1,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,1,,11902,CHEMBL615511,620.0,BAO_0000219,
489,80006,,,1,,N,,,3T3-L1,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,1,,11902,CHEMBL615512,620.0,BAO_0000219,
490,80006,,,1,,N,,,3T3-L1,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,1,,14840,CHEMBL615513,620.0,BAO_0000218,
491,80006,,,1,,N,,,3T3-L1,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,1,,14840,CHEMBL615514,620.0,BAO_0000218,
492,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,1,,13715,CHEMBL615515,620.0,BAO_0000219,
493,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,1,,13715,CHEMBL615516,620.0,BAO_0000219,
494,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,1,,13715,CHEMBL615517,620.0,BAO_0000219,
495,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,1,,13715,CHEMBL615518,620.0,BAO_0000219,
496,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,1,,13715,CHEMBL615519,620.0,BAO_0000219,
497,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,1,,13715,CHEMBL615520,620.0,BAO_0000218,
498,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,1,,13715,CHEMBL615521,620.0,BAO_0000218,
499,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,1,,13715,CHEMBL615522,620.0,BAO_0000218,
500,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,1,,13715,CHEMBL615523,620.0,BAO_0000218,
501,80006,,,1,,N,,,3T3-L1,Expert,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,1,,13715,CHEMBL615524,620.0,BAO_0000218,
502,80006,,,1,,N,,,3T3-L1,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,1,,13715,CHEMBL615525,620.0,BAO_0000218,
503,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,1,,13715,CHEMBL615526,620.0,BAO_0000218,
504,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,1,,13715,CHEMBL615527,620.0,BAO_0000218,
505,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,1,,13715,CHEMBL615528,620.0,BAO_0000218,
506,80006,,,1,,N,,,3T3-L1,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,1,,13715,CHEMBL615529,620.0,BAO_0000218,
507,80006,,,1,,N,,,3T3-L1,Expert,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,1,,13715,CHEMBL615530,620.0,BAO_0000218,
508,80006,,,1,,N,,,3T3-L1,Expert,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,1,,13715,CHEMBL615531,620.0,BAO_0000218,
509,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,1,,13715,CHEMBL615532,620.0,BAO_0000219,
510,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,1,,13715,CHEMBL615533,620.0,BAO_0000219,
511,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,1,,13715,CHEMBL615534,620.0,BAO_0000219,
512,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,1,,13715,CHEMBL615535,620.0,BAO_0000218,
513,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,1,,13715,CHEMBL615536,620.0,BAO_0000218,
514,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,1,,13715,CHEMBL615537,620.0,BAO_0000218,
515,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,1,,13715,CHEMBL615538,620.0,BAO_0000218,
516,80006,,,1,,N,,,3T3-L1,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,1,,13715,CHEMBL836166,620.0,BAO_0000218,
517,11214,,,8,,H,,,3T3-L1,Expert,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,1,,6411,CHEMBL615539,620.0,BAO_0000219,
518,80006,,,1,,N,,,3T3-L1,Intermediate,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,1,,6411,CHEMBL615540,620.0,BAO_0000219,
519,11214,,,8,,H,,,3T3-L1,Expert,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,1,,6411,CHEMBL615541,620.0,BAO_0000219,
520,80006,,,1,,N,,,3T3-L1,Expert,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,1,,3966,CHEMBL615542,620.0,BAO_0000219,
521,80006,,,1,,N,,,3T3-L1,Intermediate,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,1,,3966,CHEMBL615543,620.0,BAO_0000219,
522,80006,,,1,,N,,,3T3-L1,Expert,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,1,,15556,CHEMBL615544,620.0,BAO_0000219,
523,80006,,,1,,N,,,3T3-L1,Expert,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,1,,5845,CHEMBL615545,620.0,BAO_0000219,
524,80006,,,1,,N,,,3T3-L1,Expert,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,1,,14422,CHEMBL615546,620.0,BAO_0000219,
525,80006,,,1,,N,,,3T3-L1,Expert,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,1,,5845,CHEMBL615547,620.0,BAO_0000219,
526,80006,,,1,,N,,,3T3-L1,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,1,,14508,CHEMBL615548,620.0,BAO_0000219,
527,80006,,,1,,N,,,3T3-L1,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,1,,14508,CHEMBL615549,620.0,BAO_0000219,
528,80006,,,1,,N,,,3T3-L1,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,1,,14508,CHEMBL615550,620.0,BAO_0000219,
529,80622,,,1,,N,,,3Y1 cell line,Intermediate,Inhibitory activity against rat fibroblast (3Y1) cell line,F,1,,6349,CHEMBL615551,1118.0,BAO_0000219,
530,80622,,,1,,N,,,3Y1 cell line,Expert,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,1,,15899,CHEMBL615552,1118.0,BAO_0000219,
531,80622,,,1,,N,,,3Y1 cell line,Expert,Cytotoxicity in 3Y1 cells.,F,1,,15899,CHEMBL615553,1118.0,BAO_0000219,
532,80622,,,1,,N,,,3Y1 cell line,Expert,Cytostatic effect in 3Y1 cells.,F,1,,15899,CHEMBL615554,1118.0,BAO_0000219,
533,80622,,,1,,N,,,3Y1 cell line,Intermediate,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,1,,15899,CHEMBL615555,1118.0,BAO_0000219,
534,80622,,,1,,N,,,3Y1 cell line,Expert,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,1,,17038,CHEMBL615556,1118.0,BAO_0000219,
535,22226,,,0,,U,,,,Autocuration,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,1,,12421,CHEMBL615557,,BAO_0000019,
536,22226,,,0,,U,,,,Autocuration,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,1,,12947,CHEMBL615558,,BAO_0000019,
537,22226,,,0,,U,,,,Autocuration,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,1,,12947,CHEMBL872066,,BAO_0000019,
538,11607,,,9,,D,,,,Expert,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,1,,4896,CHEMBL615559,,BAO_0000019,
539,11607,,,8,,H,,,,Autocuration,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,1,,6148,CHEMBL615560,,BAO_0000019,
540,11607,,,8,,H,,,,Autocuration,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,1,,16432,CHEMBL615561,,BAO_0000019,
541,11607,,,8,,H,,,,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,1,,4978,CHEMBL857062,,BAO_0000019,
542,11607,,,8,,H,,,,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,1,,4978,CHEMBL615562,,BAO_0000019,
543,11607,,,8,,H,,,,Autocuration,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,1,,3723,CHEMBL615563,,BAO_0000019,
544,11607,,,8,,H,,,,Autocuration,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,1,,3518,CHEMBL615564,,BAO_0000357,
545,11607,,,8,,H,,,,Autocuration,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,1,,4164,CHEMBL615565,,BAO_0000019,
546,11607,,,8,,H,,,,Autocuration,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,1,,3518,CHEMBL615566,,BAO_0000019,
547,11607,,,9,,D,,,,Expert,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,1,,4164,CHEMBL615567,,BAO_0000019,
548,11607,,,8,,H,,,,Autocuration,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,1,,3518,CHEMBL615568,,BAO_0000019,
549,11607,,,8,,H,,,,Autocuration,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,1,,3518,CHEMBL615569,,BAO_0000357,
550,11607,,,8,,H,,,,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,1,,4978,CHEMBL615570,,BAO_0000019,
551,11607,,,8,,H,,,,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,1,,4978,CHEMBL615571,,BAO_0000019,
552,104733,,,4,,H,,,,Autocuration,Binding affinity against melatonin (MT1) receptor (pC1),B,1,,6455,CHEMBL615572,,BAO_0000224,
553,22226,,,0,,U,,,,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,1,,2222,CHEMBL615573,,BAO_0000019,
554,22226,,,0,,U,,,,Autocuration,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,1,,13020,CHEMBL615574,,BAO_0000019,
555,22226,,,0,,U,,,,Autocuration,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,1,,13021,CHEMBL615575,,BAO_0000019,
556,10619,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,1,,14532,CHEMBL615576,,BAO_0000357,
557,10619,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,1,,14118,CHEMBL615577,,BAO_0000357,
558,51,,,8,,H,,Hippocampus,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,1,,11884,CHEMBL615578,,BAO_0000221,10000000.0
559,51,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,1,,13969,CHEMBL615579,,BAO_0000357,
560,51,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,B,1,,13392,CHEMBL615580,,BAO_0000357,
561,51,,,8,,H,,,,Expert,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,1,,14430,CHEMBL615581,,BAO_0000019,
562,51,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,1,,12248,CHEMBL615582,,BAO_0000221,10000000.0
563,51,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,1,,12249,CHEMBL615583,,BAO_0000221,10000000.0
564,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615584,,BAO_0000221,10000000.0
565,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL833691,,BAO_0000221,10000000.0
566,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615585,,BAO_0000221,10000000.0
567,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615586,,BAO_0000221,10000000.0
568,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL884524,,BAO_0000221,10000000.0
569,51,,,8,,H,,Hippocampus,,Autocuration,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,1,,12249,CHEMBL615587,,BAO_0000221,10000000.0
570,51,,,8,,H,,Hippocampus,,Autocuration,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,1,,11799,CHEMBL615588,,BAO_0000221,10000000.0
571,10576,,,9,,D,Membranes,,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,1,,14331,CHEMBL615589,,BAO_0000249,
572,51,,,8,,H,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,1,,11884,CHEMBL615442,,BAO_0000221,10000000.0
573,51,,,8,,H,,Hippocampus,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,1,,14331,CHEMBL615443,,BAO_0000221,10000000.0
574,51,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,1,,11701,CHEMBL615444,,BAO_0000221,10000000.0
575,51,,,8,,H,,Hippocampus,,Expert,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,1,,11701,CHEMBL615445,,BAO_0000221,10000000.0
576,51,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,1,,12248,CHEMBL615446,,BAO_0000221,10000000.0
577,51,,,8,,H,,,CHO,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,1,,12248,CHEMBL615447,449.0,BAO_0000219,
578,51,,,8,,H,,Hippocampus,,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,1,,12248,CHEMBL615448,,BAO_0000221,10000000.0
579,51,,,8,,H,,Hippocampus,,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,1,,12249,CHEMBL615449,,BAO_0000221,10000000.0
580,51,,,8,,H,,,CHO,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,1,,12248,CHEMBL615450,449.0,BAO_0000219,
581,51,,,8,,H,,Hippocampus,,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,1,,11799,CHEMBL615451,,BAO_0000221,10000000.0
582,51,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,1,,634,CHEMBL615452,,BAO_0000357,
583,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615453,,BAO_0000221,10000000.0
584,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615454,,BAO_0000221,10000000.0
585,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615455,,BAO_0000221,10000000.0
586,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615456,,BAO_0000221,10000000.0
587,51,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,1,,9995,CHEMBL615457,,BAO_0000221,10000000.0
588,51,,,8,,H,,Hippocampus,,Expert,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,1,,12210,CHEMBL615458,,BAO_0000218,10000000.0
589,51,,,8,,H,,Hippocampus,,Expert,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,13311,CHEMBL615459,,BAO_0000221,10000000.0
590,51,,,9,,D,,,CHO,Expert,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,1,,2331,CHEMBL615460,449.0,BAO_0000219,
591,51,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,1,,1375,CHEMBL615461,,BAO_0000019,
592,51,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,1,,1375,CHEMBL615462,,BAO_0000019,
593,51,,,8,,H,,Hippocampus,,Autocuration,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,1,,11574,CHEMBL615463,,BAO_0000221,10000000.0
594,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,1,,12867,CHEMBL615464,,BAO_0000221,2116.0
595,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,1,,12867,CHEMBL615465,,BAO_0000221,2116.0
596,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,1,,12867,CHEMBL615466,,BAO_0000221,2116.0
597,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,1,,12867,CHEMBL615467,,BAO_0000221,2116.0
598,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,1,,12867,CHEMBL615468,,BAO_0000221,2116.0
599,51,,,8,,H,,Ileum,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,1,,12867,CHEMBL615469,,BAO_0000221,2116.0
600,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,11574,CHEMBL615470,,BAO_0000357,
601,51,,,8,,H,,,,Autocuration,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,13114,CHEMBL615471,,BAO_0000357,
602,51,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,1,,13181,CHEMBL615472,,BAO_0000357,
603,106,,,8,,H,,Hippocampus,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,1,,10639,CHEMBL883242,,BAO_0000221,10000000.0
604,106,,,8,,H,,Hippocampus,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,1,,10639,CHEMBL615473,,BAO_0000221,10000000.0
605,11863,,,8,,H,,,CHO,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,1,,11883,CHEMBL615474,449.0,BAO_0000218,
606,51,,,8,,H,,,,Autocuration,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,1,,17785,CHEMBL615475,,BAO_0000357,
607,51,,,8,,H,,,HeLa,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,1,,1558,CHEMBL615476,308.0,BAO_0000219,
608,51,,,8,,H,,,HeLa,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,1,,1558,CHEMBL615477,308.0,BAO_0000219,
609,51,,,8,,H,,,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,1,,15740,CHEMBL615478,,BAO_0000019,
610,51,,,8,,H,,,CHO,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,1,,17624,CHEMBL615160,449.0,BAO_0000219,
611,51,,,8,,H,,,CHO,Expert,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,1,,17624,CHEMBL615161,449.0,BAO_0000219,
612,51,,,8,,H,,,CHO,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,1,,17624,CHEMBL615162,449.0,BAO_0000219,
613,51,,,8,,H,,,CHO,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,1,,17624,CHEMBL615163,449.0,BAO_0000219,
614,51,,,8,,H,,,CHO,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL615164,449.0,BAO_0000219,
615,51,,,8,,H,,,CHO,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL615165,449.0,BAO_0000219,
616,51,,,8,,H,,,CHO,Autocuration,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,1,,17624,CHEMBL615166,449.0,BAO_0000219,
617,51,,,8,,H,,,,Autocuration,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,1,,14256,CHEMBL615167,,BAO_0000219,
618,51,,,9,,D,,,HeLa,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,1,,3445,CHEMBL615168,308.0,BAO_0000219,
619,51,,,9,,D,,,HeLa,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,1,,3445,CHEMBL615169,308.0,BAO_0000219,
620,51,,,9,,D,,,CHO,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,1,,17200,CHEMBL615170,449.0,BAO_0000219,
621,51,,,9,,D,,,CHO,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,1,,17200,CHEMBL615171,449.0,BAO_0000219,
622,51,,,8,,H,,,,Autocuration,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,1,,15180,CHEMBL615694,,BAO_0000019,
623,51,,,8,,H,,,,Autocuration,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,1,,15180,CHEMBL615695,,BAO_0000019,
624,51,,,8,,H,,,,Autocuration,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,1,,16026,CHEMBL615696,,BAO_0000019,
625,51,,,8,,H,,,CHO,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,1,,2759,CHEMBL615697,449.0,BAO_0000219,
626,51,,,9,,D,,,CHO,Expert,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,1,,2759,CHEMBL859410,449.0,BAO_0000219,
627,51,,,8,,H,,,CHO,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,1,,2759,CHEMBL615841,449.0,BAO_0000219,
628,51,,,9,,D,,,CHO,Expert,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,1,,2759,CHEMBL615842,449.0,BAO_0000219,
629,51,,,8,,H,,,CHO,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,1,,2759,CHEMBL835003,449.0,BAO_0000219,
630,51,,,8,,H,,,CHO,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,1,,2759,CHEMBL615843,449.0,BAO_0000219,
631,51,,,9,,D,,,CHO,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,1,,2759,CHEMBL615979,449.0,BAO_0000219,
632,51,,,8,,H,,,CHO,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,1,,2759,CHEMBL615980,449.0,BAO_0000219,
633,51,,,9,,D,,,CHO,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,1,,2759,CHEMBL615981,449.0,BAO_0000219,
634,51,,,9,,D,,,,Expert,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,1,,3445,CHEMBL615982,,BAO_0000019,
635,51,,,9,,D,,,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,1,,5272,CHEMBL615983,,BAO_0000019,
636,51,,,9,,D,,,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,1,,5272,CHEMBL615984,,BAO_0000019,
637,51,,,9,,D,,,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,1,,5272,CHEMBL615985,,BAO_0000019,
638,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,1,,17624,CHEMBL615986,449.0,BAO_0000219,
639,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,1,,17624,CHEMBL615987,449.0,BAO_0000219,
640,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,1,,17624,CHEMBL615988,449.0,BAO_0000219,
641,51,,,8,,H,,,CHO,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,1,,17624,CHEMBL615989,449.0,BAO_0000219,
642,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,1,,17624,CHEMBL615990,449.0,BAO_0000219,
643,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,1,,17624,CHEMBL615991,449.0,BAO_0000219,
644,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,1,,17624,CHEMBL615992,449.0,BAO_0000219,
645,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,1,,17624,CHEMBL615993,449.0,BAO_0000219,
646,51,,,8,,H,,,CHO,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,1,,17624,CHEMBL615994,449.0,BAO_0000219,
647,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,1,,17624,CHEMBL615995,449.0,BAO_0000219,
648,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,1,,17624,CHEMBL615996,449.0,BAO_0000219,
649,51,,,8,,H,,,CHO,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,1,,17624,CHEMBL615997,449.0,BAO_0000219,
650,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,1,,6563,CHEMBL615998,,BAO_0000019,
651,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,1,,6563,CHEMBL615999,,BAO_0000019,
652,51,,,8,,H,,,,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,1,,6563,CHEMBL616000,,BAO_0000019,
653,51,,,8,,H,,,HEK293,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,1,,17296,CHEMBL616001,722.0,BAO_0000219,
654,51,,,9,,D,,,,Expert,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,1,,6876,CHEMBL616002,,BAO_0000019,
655,51,,,8,,H,,,,Expert,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,1,,6876,CHEMBL616003,,BAO_0000019,
656,51,,,9,,D,,,,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,1,,5272,CHEMBL616004,,BAO_0000019,
657,51,,,9,,D,,,,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,1,,5272,CHEMBL616005,,BAO_0000019,
658,51,,,8,,H,,,,Autocuration,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,1,,5548,CHEMBL616006,,BAO_0000019,
659,51,,,8,,H,,,,Expert,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,1,,5548,CHEMBL616007,,BAO_0000019,
660,51,,,8,,H,,,,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,1,,5548,CHEMBL616008,,BAO_0000019,
661,51,,,8,,H,,,,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,1,,5548,CHEMBL616009,,BAO_0000019,
662,51,,,8,,H,,,,Expert,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,1,,5929,CHEMBL616010,,BAO_0000019,
663,51,,,9,,D,,,,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,1,,5929,CHEMBL616011,,BAO_0000019,
664,51,,,9,,D,,,,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,1,,5929,CHEMBL615740,,BAO_0000019,
665,51,,,8,,H,,,,Autocuration,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,1,,16245,CHEMBL615741,,BAO_0000019,
666,51,,,8,,H,,,,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,1,,5640,CHEMBL615742,,BAO_0000019,
667,51,,,8,,H,,,,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,1,,5640,CHEMBL615743,,BAO_0000019,
668,51,,,8,,H,,,CHO,Autocuration,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,1,,14509,CHEMBL615744,449.0,BAO_0000219,
669,51,,,8,,H,,,CHO,Expert,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,1,,14509,CHEMBL615745,449.0,BAO_0000219,
670,51,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL615746,,BAO_0000357,
671,51,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL615747,,BAO_0000357,
672,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,1,,6563,CHEMBL615748,,BAO_0000019,
673,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,1,,6563,CHEMBL615749,,BAO_0000019,
674,51,,,8,,H,,,,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,1,,6563,CHEMBL615750,,BAO_0000019,
675,51,,,9,,D,,,,Expert,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,1,,6563,CHEMBL616259,,BAO_0000019,
676,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,1,,6563,CHEMBL616260,,BAO_0000019,
677,51,,,9,,D,,,,Expert,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,1,,5272,CHEMBL616261,,BAO_0000019,
678,51,,,9,,D,,,,Expert,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,1,,5272,CHEMBL616262,,BAO_0000019,
679,51,,,9,,D,,,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,1,,5272,CHEMBL616263,,BAO_0000019,
680,51,,,9,,D,,,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,1,,5272,CHEMBL616264,,BAO_0000019,
681,51,,,9,,D,,,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,1,,5272,CHEMBL616265,,BAO_0000019,
682,51,,,9,,D,,,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,1,,5272,CHEMBL616266,,BAO_0000019,
683,51,,,9,,D,,,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,1,,5272,CHEMBL616267,,BAO_0000019,
684,51,,,9,,D,,,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,1,,5272,CHEMBL616268,,BAO_0000019,
685,51,,,9,,D,,,,Expert,Inhibition of human 5-hydroxytryptamine 1A receptor,B,1,,16146,CHEMBL616269,,BAO_0000357,
686,51,,,8,,H,,,CHO,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL884528,449.0,BAO_0000219,
687,105,,,9,,D,,,HEK293,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,1,,13706,CHEMBL616270,722.0,BAO_0000219,
688,51,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,1,,15250,CHEMBL616271,449.0,BAO_0000219,
689,51,,,8,,H,,,CHO,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,1,,17624,CHEMBL616272,449.0,BAO_0000219,
690,51,,,8,,H,,,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,1,,6861,CHEMBL616273,,BAO_0000357,
691,51,,,9,,D,,,,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,1,,17200,CHEMBL616274,,BAO_0000357,
692,51,,,8,,H,,,CHO,Autocuration,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL616275,449.0,BAO_0000219,
693,51,,,8,,H,,,CHO,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL616276,449.0,BAO_0000219,
694,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,1,,12058,CHEMBL616277,,BAO_0000218,
695,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,1,,12058,CHEMBL616278,,BAO_0000218,
696,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,1,,12058,CHEMBL616279,,BAO_0000218,
697,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,1,,12058,CHEMBL616280,,BAO_0000218,
698,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,1,,12058,CHEMBL616281,,BAO_0000218,
699,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,1,,12058,CHEMBL616282,,BAO_0000218,
700,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,1,,12058,CHEMBL616283,,BAO_0000218,
701,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,1,,12058,CHEMBL616284,,BAO_0000218,
702,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,1,,12058,CHEMBL616285,,BAO_0000218,
703,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,1,,12058,CHEMBL616286,,BAO_0000218,
704,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,1,,12058,CHEMBL616287,,BAO_0000218,
705,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,1,,12058,CHEMBL616288,,BAO_0000218,
706,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,1,,12058,CHEMBL616289,,BAO_0000218,
707,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,1,,12058,CHEMBL615610,,BAO_0000218,
708,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,1,,12058,CHEMBL615611,,BAO_0000218,
709,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,1,,12058,CHEMBL615612,,BAO_0000218,
710,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,1,,12058,CHEMBL615613,,BAO_0000218,
711,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,1,,12058,CHEMBL615614,,BAO_0000218,
712,22226,,In vivo,0,,U,,,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,1,,12058,CHEMBL615615,,BAO_0000218,
713,105093,,,4,,H,,,,Autocuration,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,1,,11440,CHEMBL615616,,BAO_0000019,
714,11923,,,8,,H,,Hypothalamus,,Autocuration,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,1,,6238,CHEMBL615617,,BAO_0000249,1898.0
715,10577,,,8,,H,,,,Autocuration,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,1,,10046,CHEMBL615618,,BAO_0000019,
716,10577,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,1,,10046,CHEMBL615619,,BAO_0000019,
717,10577,,,8,,H,,,,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,1,,10046,CHEMBL615620,,BAO_0000019,
718,55,,,8,,H,,,,Autocuration,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,1,,167,CHEMBL615621,,BAO_0000357,
719,55,,,8,,H,,,,Autocuration,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,1,,167,CHEMBL615622,,BAO_0000357,
720,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,1,,11520,CHEMBL615623,,BAO_0000019,
721,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,1,,11520,CHEMBL615624,,BAO_0000019,
722,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,1,,11520,CHEMBL615625,,BAO_0000019,
723,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,1,,11520,CHEMBL767045,,BAO_0000019,
724,55,,,8,,H,,,,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,1,,135,CHEMBL615626,,BAO_0000019,
725,55,,,8,,H,,,,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,1,,135,CHEMBL615627,,BAO_0000019,
726,55,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,1,,11311,CHEMBL615628,,BAO_0000019,
727,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,1,,10193,CHEMBL615629,,BAO_0000357,
728,55,,,9,,D,,,,Expert,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,1,,12281,CHEMBL615630,,BAO_0000357,
729,55,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL615631,,BAO_0000219,
730,17087,,,8,,H,,,,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,1,,12576,CHEMBL615632,,BAO_0000218,
731,17087,,,8,,H,,,,Autocuration,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,1,,12281,CHEMBL615633,,BAO_0000357,
732,17087,,,8,,H,,,,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,1,,12576,CHEMBL615634,,BAO_0000218,
733,55,,,8,,H,,,,Expert,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,1,,11089,CHEMBL615635,,BAO_0000019,
734,12166,,,8,,H,,,,Expert,In vitro inhibition of rat 5-Lipoxygenase,B,1,,11006,CHEMBL615636,,BAO_0000357,
735,12166,,,9,,D,,,,Expert,Inhibitory activity against 5-Lipoxygenase,B,1,,11481,CHEMBL615637,,BAO_0000357,
736,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,1,,10864,CHEMBL615638,702.0,BAO_0000219,
737,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,1,,3595,CHEMBL615639,702.0,BAO_0000219,
738,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,1,,11311,CHEMBL615640,702.0,BAO_0000219,
739,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,1,,11311,CHEMBL615796,,BAO_0000019,
740,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL615845,,BAO_0000219,
741,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,1,,11006,CHEMBL615846,,BAO_0000357,
742,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,1,,3595,CHEMBL615847,702.0,BAO_0000219,
743,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,1,,11311,CHEMBL615848,,BAO_0000357,
744,22226,,,0,,U,,,,Autocuration,Ratio of IC50 against 5-LO and COX,B,1,,11481,CHEMBL615849,,BAO_0000019,
745,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,1,,11006,CHEMBL615850,,BAO_0000357,
746,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,1,,11006,CHEMBL615851,,BAO_0000357,
747,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,1,,11311,CHEMBL615852,,BAO_0000219,
748,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,1,,11006,CHEMBL615853,,BAO_0000019,
749,120,,,8,,H,,Prostate gland,,Autocuration,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,1,,4288,CHEMBL884527,,BAO_0000357,2367.0
750,22226,,,0,,U,,,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,1,,7587,CHEMBL872871,,BAO_0000019,
751,22226,,,0,,U,,,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,1,,7587,CHEMBL615854,,BAO_0000019,
752,22226,,,0,,U,,,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,1,,7587,CHEMBL767046,,BAO_0000019,
753,10732,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,1,,11249,CHEMBL615855,,BAO_0000357,
754,12198,,,9,,D,,,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,1,,8003,CHEMBL615856,,BAO_0000019,
755,12198,,,9,,D,,,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,1,,8003,CHEMBL615857,,BAO_0000019,
756,12198,,,9,,D,,,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,1,,8003,CHEMBL615858,,BAO_0000019,
757,10576,,,8,,H,,Hippocampus,,Expert,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,1,,12416,CHEMBL615859,,BAO_0000221,10000000.0
758,51,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,1,,16293,CHEMBL615860,,BAO_0000357,
759,22226,,,0,,U,,,,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL615861,,BAO_0000019,
760,22226,,,0,,U,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL615862,,BAO_0000019,
761,22226,,,0,,U,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL615863,,BAO_0000019,
762,22226,,,0,,U,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL615864,,BAO_0000019,
763,104744,,,4,,H,,Hippocampus,,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,1,,10085,CHEMBL615865,,BAO_0000221,10000000.0
764,104744,,,4,,H,,Hippocampus,,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,1,,10085,CHEMBL615866,,BAO_0000221,10000000.0
765,104744,,,4,,H,,Hippocampus,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,1,,10085,CHEMBL615867,,BAO_0000221,10000000.0
766,104744,,,4,,H,Membranes,,,Autocuration,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,1,,9841,CHEMBL615868,,BAO_0000249,
767,104744,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,1,,8822,CHEMBL615869,,BAO_0000249,
768,104744,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,1,,9806,CHEMBL615870,,BAO_0000019,
769,104744,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,1,,9806,CHEMBL615871,,BAO_0000019,
770,104744,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,1,,8868,CHEMBL615872,,BAO_0000224,
771,104744,,,4,,H,,Hippocampus,,Autocuration,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,1,,9036,CHEMBL833492,,BAO_0000221,10000000.0
772,104744,,,4,,H,,Hippocampus,,Autocuration,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,1,,11374,CHEMBL615873,,BAO_0000221,10000000.0
773,104744,,,4,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,1,,10881,CHEMBL615479,,BAO_0000224,
774,104744,,,4,,H,,,,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,1,,8822,CHEMBL615480,,BAO_0000019,
775,104744,,,5,,D,,,,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,1,,9806,CHEMBL615481,,BAO_0000249,
776,104744,,,4,,H,,,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,1,,15463,CHEMBL872869,,BAO_0000019,
777,104744,,,4,,H,,,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,1,,15463,CHEMBL615482,,BAO_0000019,
778,104744,,,4,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,1,,14542,CHEMBL615483,,BAO_0000221,955.0
779,104744,,,4,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,1,,14542,CHEMBL615484,,BAO_0000221,955.0
780,104744,,,4,,H,,,,Autocuration,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,1,,8569,CHEMBL615485,,BAO_0000019,
781,104744,,,5,,D,,,,Autocuration,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,1,,10062,CHEMBL615486,,BAO_0000224,
782,104744,,,4,,H,,,,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,1,,4771,CHEMBL615487,,BAO_0000224,
783,104744,,,4,,H,,,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,1,,10062,CHEMBL615488,,BAO_0000224,
784,104744,,,4,,H,,,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,1,,10062,CHEMBL615489,,BAO_0000224,
785,104744,,,4,,H,,,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,1,,10062,CHEMBL615389,,BAO_0000224,
786,104744,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,1,,15463,CHEMBL615390,,BAO_0000019,
787,104744,,,4,,H,,,,Autocuration,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,1,,15463,CHEMBL615391,,BAO_0000019,
788,104744,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,1,,9098,CHEMBL615392,,BAO_0000224,
789,22226,,,0,,U,,,,Autocuration,Affinity for 5-hydroxytryptamine 1 receptor,B,1,,3070,CHEMBL615393,,BAO_0000019,
790,104744,,,4,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,1,,14542,CHEMBL615394,,BAO_0000221,955.0
791,104744,,,4,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,1,,14542,CHEMBL615395,,BAO_0000221,955.0
792,104744,,,4,,H,,,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,1,,6398,CHEMBL615396,,BAO_0000224,
793,104744,,,4,,H,,Brain,,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,1,,1344,CHEMBL615397,,BAO_0000221,955.0
794,104744,,,4,,H,,,,Autocuration,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,1,,11963,CHEMBL615398,,BAO_0000019,
795,22226,,,0,,U,,,,Autocuration,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,1,,8908,CHEMBL615399,,BAO_0000019,
796,104744,,,4,,H,,,,Autocuration,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,1,,9098,CHEMBL615400,,BAO_0000019,
797,104744,,,5,,D,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,1,,8841,CHEMBL615401,,BAO_0000019,
798,22226,,,0,,U,,,,Autocuration,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,1,,8814,CHEMBL615402,,BAO_0000019,
799,104744,,,4,,H,,,,Autocuration,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,1,,11752,CHEMBL615403,,BAO_0000019,
800,104744,,,4,,H,,Brain,,Autocuration,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,1,,11642,CHEMBL615404,,BAO_0000221,955.0
801,104744,,,4,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,1,,11642,CHEMBL615781,,BAO_0000019,
802,104744,,,4,,H,,Brain,,Autocuration,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,1,,9231,CHEMBL615782,,BAO_0000220,955.0
803,104744,,,4,,H,,Brain,,Autocuration,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,1,,11351,CHEMBL615783,,BAO_0000221,955.0
804,22226,,,0,,U,,,,Autocuration,Compound was tested for binding affinity against 5-HT1 receptor,B,1,,4639,CHEMBL873481,,BAO_0000019,
805,22226,,,0,,U,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,1,,1205,CHEMBL615784,,BAO_0000019,
806,10576,,,8,,H,,,,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,1,,10025,CHEMBL615785,,BAO_0000357,
807,10576,,,8,,H,,,,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,1,,13241,CHEMBL615786,,BAO_0000249,
808,10576,,In vivo,8,,H,,,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,1,,16245,CHEMBL615787,,BAO_0000218,
809,10576,,In vivo,8,,H,,,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,1,,16245,CHEMBL615788,,BAO_0000218,
810,10576,,,8,,H,,,,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,1,,12438,CHEMBL767044,,BAO_0000019,
811,10576,,In vivo,8,,H,,,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,1,,16245,CHEMBL615789,,BAO_0000218,
812,10576,,In vivo,8,,H,,,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,1,,16245,CHEMBL615790,,BAO_0000218,
813,10576,,,8,,H,,,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,1,,15740,CHEMBL615813,,BAO_0000019,
814,10576,,,8,,H,,,,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,1,,15535,CHEMBL615814,,BAO_0000219,
815,51,,,8,,H,,,,Expert,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,1,,15535,CHEMBL615815,,BAO_0000219,
816,10576,,,8,,H,,,,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,1,,15535,CHEMBL615816,,BAO_0000219,
817,10576,,,8,,H,,,,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,1,,9888,CHEMBL615817,,BAO_0000249,
818,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,1,,10085,CHEMBL615818,,BAO_0000221,10000000.0
819,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,1,,10085,CHEMBL615819,,BAO_0000221,10000000.0
820,10576,,,8,,H,Membranes,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,1,,17331,CHEMBL615820,,BAO_0000249,
821,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,1,,10845,CHEMBL615821,,BAO_0000221,10000000.0
822,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,1,,10845,CHEMBL615822,,BAO_0000221,10000000.0
823,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,1,,10845,CHEMBL615823,,BAO_0000221,10000000.0
824,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,1,,10845,CHEMBL615824,,BAO_0000221,10000000.0
825,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,1,,10845,CHEMBL615825,,BAO_0000221,10000000.0
826,10576,,,8,,H,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,1,,13730,CHEMBL615826,,BAO_0000357,
827,10576,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,1,,13508,CHEMBL615827,,BAO_0000249,
828,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,1,,13508,CHEMBL615828,,BAO_0000249,10000000.0
829,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,12073,CHEMBL615829,,BAO_0000221,10000000.0
830,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,1,,4671,CHEMBL615830,,BAO_0000221,10000000.0
831,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,1,,13631,CHEMBL615831,,BAO_0000221,10000000.0
832,10576,,,8,,H,,,,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,1,,12438,CHEMBL615832,,BAO_0000357,
833,10576,,,8,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,1,,10483,CHEMBL615833,,BAO_0000019,
834,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,1,,10483,CHEMBL615834,,BAO_0000221,10000000.0
835,10576,,,8,,H,,,,Intermediate,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,1,,12352,CHEMBL615835,,BAO_0000249,
836,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,1,,14732,CHEMBL615836,,BAO_0000249,10000000.0
837,10576,,,9,,D,,,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,1,,11049,CHEMBL615837,,BAO_0000019,
838,10576,,,9,,D,,,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,1,,11049,CHEMBL615838,,BAO_0000019,
839,10576,,,8,,H,,,,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,1,,13657,CHEMBL615839,,BAO_0000249,
840,10576,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,1,,11473,CHEMBL884525,,BAO_0000019,
841,10576,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,1,,2014,CHEMBL615840,,BAO_0000249,
842,10576,,,8,,H,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,3086,CHEMBL615405,,BAO_0000221,10000000.0
843,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,1,,15854,CHEMBL615406,,BAO_0000019,
844,10576,,,8,,H,,Hippocampus,,Expert,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,1,,10922,CHEMBL615900,,BAO_0000221,10000000.0
845,10576,,,8,,H,,Hippocampus,,Expert,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,1,,13346,CHEMBL615901,,BAO_0000221,10000000.0
846,10576,,,8,,H,,,,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,1,,15311,CHEMBL615902,,BAO_0000357,
847,10576,,,8,,H,,Hippocampus,,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,1,,10922,CHEMBL615903,,BAO_0000221,10000000.0
848,10576,,,8,,H,,,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,1,,10025,CHEMBL615904,,BAO_0000357,
849,10576,,,8,,H,,,,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,1,,10025,CHEMBL615905,,BAO_0000357,
850,10576,,,8,,H,,,,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,1,,9742,CHEMBL615906,,BAO_0000019,
851,10576,,,8,,H,,,,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,1,,9742,CHEMBL615907,,BAO_0000019,
852,10576,,,8,,H,,,,Expert,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,1,,12304,CHEMBL615908,,BAO_0000019,
853,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,1,,15789,CHEMBL615909,,BAO_0000221,10000000.0
854,10576,,,8,,H,,,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,1,,9912,CHEMBL615910,,BAO_0000019,
855,10576,,,8,,H,,,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,1,,9912,CHEMBL615911,,BAO_0000019,
856,10576,,,8,,H,,,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,1,,9912,CHEMBL615912,,BAO_0000019,
857,10576,,,8,,H,,,,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,1,,16693,CHEMBL615913,,BAO_0000019,
858,10576,,,8,,H,,,,Expert,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,1,,13276,CHEMBL615914,,BAO_0000357,
859,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,1,,12678,CHEMBL615915,,BAO_0000221,10000000.0
860,10576,,,8,,H,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,1,,11825,CHEMBL615916,,BAO_0000357,
861,10576,,,8,,H,,,,Expert,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,1,,12443,CHEMBL615917,,BAO_0000357,
862,10576,,,8,,H,,,,Expert,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,1,,13830,CHEMBL615918,,BAO_0000357,
863,10576,,,8,,H,,Hippocampus,,Expert,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,1,,14286,CHEMBL615919,,BAO_0000249,10000000.0
864,10576,,,9,,D,,Hippocampus,,Expert,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,1,,14356,CHEMBL615920,,BAO_0000221,10000000.0
865,10576,,,8,,H,,,,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,1,,15306,CHEMBL615921,,BAO_0000357,
866,10576,,,8,,H,,,,Expert,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,1,,15306,CHEMBL615922,,BAO_0000357,
867,10576,,,9,,D,,,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,1,,16616,CHEMBL881290,,BAO_0000249,
868,10576,,,8,,H,,Hippocampus,,Autocuration,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,1,,3651,CHEMBL615923,,BAO_0000221,10000000.0
869,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,1,,14331,CHEMBL615924,,BAO_0000221,10000000.0
870,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,1,,14331,CHEMBL615925,,BAO_0000221,10000000.0
871,10576,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,1,,14178,CHEMBL615926,,BAO_0000357,
872,10576,,,9,,D,,,,Expert,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,1,,10639,CHEMBL615927,,BAO_0000019,
873,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,1,,12306,CHEMBL615928,,BAO_0000221,10000000.0
874,10576,,,9,,D,,,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,1,,1348,CHEMBL615929,,BAO_0000357,
875,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,1,,13605,CHEMBL615930,,BAO_0000221,10000000.0
876,51,,,8,,H,,,CHO,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,1,,17624,CHEMBL615931,449.0,BAO_0000219,
877,51,,,8,,H,,,CHO,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,1,,17624,CHEMBL615932,449.0,BAO_0000219,
878,51,,,8,,H,,,CHO,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,1,,17624,CHEMBL615933,449.0,BAO_0000219,
879,51,,,8,,H,,,,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,1,,15267,CHEMBL615934,,BAO_0000357,
880,51,,,8,,H,,,,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,1,,16532,CHEMBL615935,,BAO_0000357,
881,51,,,8,,H,,,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,1,,6563,CHEMBL615936,,BAO_0000019,
882,51,,,8,,H,,,CHO,Autocuration,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,1,,4751,CHEMBL615937,449.0,BAO_0000219,
883,51,,,8,,H,,,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,1,,15463,CHEMBL615938,,BAO_0000357,
884,51,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL615797,,BAO_0000357,
885,51,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,5640,CHEMBL615798,,BAO_0000357,
886,51,,,8,,H,,,,Autocuration,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,1,,6563,CHEMBL872870,,BAO_0000357,
887,51,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,1,,5548,CHEMBL615799,,BAO_0000357,
888,51,,,8,,H,,,,Autocuration,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,6347,CHEMBL615800,,BAO_0000357,
889,51,,,8,,H,,,HEK293,Autocuration,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,1,,17296,CHEMBL615801,722.0,BAO_0000219,
890,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,1,,13047,CHEMBL615802,,BAO_0000019,
891,51,,,8,,H,,,,Autocuration,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,1,,15740,CHEMBL615803,,BAO_0000357,
892,51,,,8,,H,,,,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,1,,5640,CHEMBL835002,,BAO_0000019,
893,51,,,8,,H,,,,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,1,,5640,CHEMBL615804,,BAO_0000019,
894,51,,,8,,H,,,HeLa,Expert,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,1,,17211,CHEMBL615805,308.0,BAO_0000219,
895,51,,,8,,H,,,CHO,Autocuration,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,1,,4751,CHEMBL615806,449.0,BAO_0000219,
896,51,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,1,,6491,CHEMBL615807,,BAO_0000357,
897,51,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,1,,4707,CHEMBL615808,,BAO_0000357,
898,51,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,13910,CHEMBL615809,,BAO_0000357,
899,51,,,8,,H,,,HeLa,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,1,,16190,CHEMBL615810,308.0,BAO_0000219,
900,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,16633,CHEMBL615811,,BAO_0000357,
901,51,,,8,,H,,,CHO,Autocuration,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,1,,11898,CHEMBL615812,449.0,BAO_0000219,
902,51,,,8,,H,,,CHO,Autocuration,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,1,,11898,CHEMBL615751,449.0,BAO_0000219,
903,51,,,8,,H,,,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,1,,14331,CHEMBL615752,,BAO_0000357,
904,51,,,8,,H,,,CHO,Expert,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,1,,17624,CHEMBL615753,449.0,BAO_0000219,
905,51,,,8,,H,,,CHO,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,1,,17624,CHEMBL615754,449.0,BAO_0000219,
906,51,,,8,,H,,,,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,1,,3307,CHEMBL615755,,BAO_0000357,
907,51,,,9,,D,,,CHO,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,1,,6563,CHEMBL615756,449.0,BAO_0000219,
908,51,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,1,,14165,CHEMBL615757,,BAO_0000019,
909,51,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,1,,5732,CHEMBL615758,,BAO_0000357,
910,51,,,8,,H,,,,Expert,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,1,,13366,CHEMBL615759,,BAO_0000357,
911,51,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,1,,17626,CHEMBL615760,,BAO_0000357,
912,51,,,8,,H,,,HeLa,Expert,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,1,,6588,CHEMBL615761,308.0,BAO_0000219,
913,51,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,1,,16209,CHEMBL872104,,BAO_0000357,
914,51,,,8,,H,,,,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,1,,15463,CHEMBL615762,,BAO_0000357,
915,51,,,8,,H,,,,Autocuration,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,1,,15463,CHEMBL615763,,BAO_0000357,
916,51,,,8,,H,,,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,1,,14770,CHEMBL615764,,BAO_0000357,
917,51,,,8,,H,,,Cell line,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,1,,16245,CHEMBL615765,1167.0,BAO_0000219,
918,51,,,8,,H,,,,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,1,,16245,CHEMBL615766,,BAO_0000019,
919,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,5548,CHEMBL615767,,BAO_0000357,
920,51,,,8,,H,,,,Expert,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,5548,CHEMBL615768,,BAO_0000357,
921,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,5548,CHEMBL615769,,BAO_0000357,
922,51,,,8,,H,,,,Expert,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,1,,6876,CHEMBL615770,,BAO_0000357,
923,51,,,8,,H,,,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,2598,CHEMBL615771,,BAO_0000357,
924,51,,,8,,H,,,,Expert,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,1,,17785,CHEMBL615772,,BAO_0000357,
925,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,6013,CHEMBL615773,,BAO_0000357,
926,51,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,1,,5929,CHEMBL615774,,BAO_0000357,
927,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,16633,CHEMBL615775,,BAO_0000357,
928,51,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,1,,1558,CHEMBL615776,,BAO_0000357,
929,51,,,8,,H,,,,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,16026,CHEMBL615777,,BAO_0000357,
930,51,,,8,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,1,,12469,CHEMBL615778,,BAO_0000219,
931,51,,,9,,D,,,,Expert,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,1,,15874,CHEMBL615779,,BAO_0000357,
932,51,,,8,,H,,,,Autocuration,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,1,,15874,CHEMBL615780,,BAO_0000357,
933,51,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,1,,3935,CHEMBL616298,,BAO_0000357,
934,51,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,1,,15818,CHEMBL616299,,BAO_0000357,
935,51,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,1,,13706,CHEMBL616300,485.0,BAO_0000219,
936,51,,,8,,H,,,CHO-K1,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,1,,13729,CHEMBL616301,485.0,BAO_0000219,
937,51,,,8,,H,,,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,1,,15413,CHEMBL616302,,BAO_0000019,
938,51,,,8,,H,,,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,1,,15413,CHEMBL616117,,BAO_0000019,
939,51,,,8,,H,,,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,1,,15413,CHEMBL616118,,BAO_0000019,
940,51,,,8,,H,,,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,1,,15413,CHEMBL616119,,BAO_0000019,
941,51,,,9,,D,,,HeLa,Expert,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,1,,3445,CHEMBL616120,308.0,BAO_0000219,
942,51,,,8,,H,,,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,1,,15740,CHEMBL616121,,BAO_0000357,
943,51,,,8,,H,,,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,1,,15740,CHEMBL616122,,BAO_0000357,
944,51,,,8,,H,,,,Autocuration,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,1,,17626,CHEMBL616123,,BAO_0000357,
945,51,,,9,,D,,,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,1,,4234,CHEMBL616124,,BAO_0000357,
946,51,,,8,,H,,,,Expert,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,1,,5640,CHEMBL616125,,BAO_0000357,
947,51,,,8,,H,,,,Expert,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,1,,5272,CHEMBL616126,,BAO_0000357,
948,51,,,8,,H,,,CHO,Autocuration,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,1,,4622,CHEMBL616127,449.0,BAO_0000219,
949,51,,,8,,H,,,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,1,,17085,CHEMBL616128,,BAO_0000019,
950,51,,,8,,H,,,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,1,,3025,CHEMBL616129,,BAO_0000357,
951,51,,,8,,H,,,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,1,,15315,CHEMBL616130,,BAO_0000357,
952,51,,,8,,H,,,,Autocuration,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,1,,15267,CHEMBL616131,,BAO_0000357,
953,51,,,8,,H,,,HeLa,Autocuration,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,1,,17158,CHEMBL616132,308.0,BAO_0000219,
954,51,,,9,,D,,,HeLa,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,1,,14214,CHEMBL616133,308.0,BAO_0000219,
955,51,,,8,,H,,,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,17133,CHEMBL616134,,BAO_0000357,
956,51,,,8,,H,,,,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,1,,16532,CHEMBL616135,,BAO_0000357,
957,51,,,9,,D,,,,Expert,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,1,,2391,CHEMBL616136,,BAO_0000357,
958,51,,,8,,H,,,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,1,,14447,CHEMBL616137,,BAO_0000019,
959,51,,,8,,H,,,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,1,,14447,CHEMBL872105,,BAO_0000019,
960,51,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,1,,15086,CHEMBL616138,,BAO_0000357,
961,51,,,9,,D,,,,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,1,,13051,CHEMBL616139,,BAO_0000357,
962,51,,,8,,H,,,,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,1,,16026,CHEMBL616140,,BAO_0000019,
963,51,,,8,,H,,,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,1,,17085,CHEMBL616141,,BAO_0000019,
964,51,,,8,,H,,,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,17133,CHEMBL616142,,BAO_0000357,
965,51,,,8,,H,,,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,1,,17133,CHEMBL616143,,BAO_0000357,
966,51,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,1,,17211,CHEMBL616144,308.0,BAO_0000219,
967,51,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,1,,17211,CHEMBL616145,308.0,BAO_0000219,
968,51,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,1,,17211,CHEMBL616012,308.0,BAO_0000219,
969,51,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,1,,17211,CHEMBL616013,308.0,BAO_0000219,
970,51,,,8,,H,,,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,1,,16394,CHEMBL616014,,BAO_0000019,
971,51,,,8,,H,,,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,1,,16394,CHEMBL616015,,BAO_0000019,
972,51,,,8,,H,,,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,1,,16394,CHEMBL616016,,BAO_0000019,
973,51,,In vivo,8,,H,,,,Autocuration,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,1,,16394,CHEMBL616017,,BAO_0000218,
974,51,,,8,,H,,,,Autocuration,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,1,,16394,CHEMBL616018,,BAO_0000019,
975,51,,,8,,H,,,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,1,,15740,CHEMBL616019,,BAO_0000019,
976,51,,,8,,H,,,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,1,,15740,CHEMBL616020,,BAO_0000019,
977,51,,,8,,H,,,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,1,,15740,CHEMBL858018,,BAO_0000357,
978,51,,,8,,H,,,HEK293,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,1,,17296,CHEMBL616021,722.0,BAO_0000219,
979,51,,,8,,H,,,,Expert,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,1,,5640,CHEMBL616022,,BAO_0000019,
980,51,,,8,,H,,,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,1,,5640,CHEMBL616023,,BAO_0000019,
981,51,,,8,,H,,,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,1,,5640,CHEMBL616024,,BAO_0000019,
982,51,,,8,,H,,,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,1,,5640,CHEMBL616025,,BAO_0000019,
983,51,,,8,,H,,,CHO,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,1,,2759,CHEMBL616026,449.0,BAO_0000219,
984,51,,,8,,H,,,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,1,,16394,CHEMBL616027,,BAO_0000019,
985,51,,,9,,D,,,,Expert,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,1,,16394,CHEMBL616028,,BAO_0000019,
986,51,,,9,,D,,,,Expert,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,1,,3445,CHEMBL616029,,BAO_0000019,
987,51,,,8,,H,,,CHO,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,1,,4316,CHEMBL616030,449.0,BAO_0000219,
988,51,,,8,,H,,,,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,1,,4316,CHEMBL616031,,BAO_0000019,
989,51,,,9,,D,,,,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,1,,15180,CHEMBL616032,,BAO_0000019,
990,51,,,9,,D,,,,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,1,,15180,CHEMBL616033,,BAO_0000019,
991,51,,,8,,H,,,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,1,,15042,CHEMBL616034,,BAO_0000019,
992,51,,,8,,H,,,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,1,,15042,CHEMBL616035,,BAO_0000019,
993,51,,,8,,H,,,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,1,,15042,CHEMBL616036,,BAO_0000019,
994,51,,,8,,H,,,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,1,,15042,CHEMBL616037,,BAO_0000019,
995,51,,,8,,H,,,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,1,,15042,CHEMBL616038,,BAO_0000019,
996,51,,,8,,H,,,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,1,,15042,CHEMBL616039,,BAO_0000019,
997,51,,,8,,H,,,,Autocuration,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,1,,15042,CHEMBL616040,,BAO_0000019,
998,51,,,9,,D,,,HeLa,Expert,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,1,,15180,CHEMBL616041,308.0,BAO_0000219,
999,51,,,9,,D,,,HeLa,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,1,,15180,CHEMBL616042,308.0,BAO_0000219,
1000,51,,,9,,D,,,HeLa,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,1,,15180,CHEMBL616043,308.0,BAO_0000219,
1001,51,,,8,,H,,,,Autocuration,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,1,,16245,CHEMBL616044,,BAO_0000019,
1002,51,,,8,,H,,,,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,1,,16026,CHEMBL616045,,BAO_0000019,
1003,51,,,8,,H,,,HEK293,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,1,,17296,CHEMBL616046,722.0,BAO_0000219,
1004,51,,,8,,H,,,CHO,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,1,,2759,CHEMBL616047,449.0,BAO_0000219,
1005,51,,,8,,H,,,CHO,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,1,,2759,CHEMBL616048,449.0,BAO_0000219,
1006,51,,,9,,D,,,CHO,Expert,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,1,,2759,CHEMBL616049,449.0,BAO_0000219,
1007,51,,,8,,H,,,CHO,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,1,,2759,CHEMBL616050,449.0,BAO_0000219,
1008,51,,,8,,H,,,,Expert,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,1,,15419,CHEMBL616051,,BAO_0000219,
1009,51,,,8,,H,,,,Autocuration,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,1,,15419,CHEMBL616212,,BAO_0000219,
1010,51,,,8,,H,,,,Autocuration,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,1,,16026,CHEMBL616213,,BAO_0000019,
1011,51,,In vitro,8,,H,,,,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,1,,1414,CHEMBL616214,,BAO_0000219,
1012,51,,In vitro,8,,H,,,,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,1,,1414,CHEMBL616215,,BAO_0000219,
1013,51,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL616216,,BAO_0000357,
1014,51,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,1,,12861,CHEMBL616217,,BAO_0000019,
1015,51,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,1,,5104,CHEMBL616218,,BAO_0000357,
1016,51,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,1,,5105,CHEMBL616219,,BAO_0000357,
1017,51,,,8,,H,,,,Autocuration,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,1,,16312,CHEMBL616220,,BAO_0000357,
1018,51,,,9,,D,,,,Expert,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,1,,15180,CHEMBL833493,,BAO_0000357,
1019,51,,,8,,H,,,,Autocuration,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,1,,5033,CHEMBL616221,,BAO_0000357,
1020,51,,,9,,D,,,CHO,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,1,,16909,CHEMBL616222,449.0,BAO_0000219,
1021,51,,,8,,H,,,,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,1,,2590,CHEMBL616223,,BAO_0000019,
1022,51,,,8,,H,,,,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,1,,2590,CHEMBL616224,,BAO_0000019,
1023,51,,,8,,H,,,,Expert,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,1,,16394,CHEMBL616225,,BAO_0000019,
1024,51,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,1,,4540,CHEMBL616226,722.0,BAO_0000219,
1025,51,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,1,,17296,CHEMBL616227,722.0,BAO_0000219,
1026,51,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,1,,17296,CHEMBL616228,722.0,BAO_0000219,
1027,51,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,1,,15779,CHEMBL616229,722.0,BAO_0000219,
1028,51,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,1,,15779,CHEMBL616230,722.0,BAO_0000219,
1029,51,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,1,,15779,CHEMBL616231,722.0,BAO_0000219,
1030,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,1,,6166,CHEMBL616232,,BAO_0000357,
1031,51,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,1,,15779,CHEMBL616233,722.0,BAO_0000219,
1032,51,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,1,,4199,CHEMBL857973,722.0,BAO_0000219,
1033,51,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,1,,15316,CHEMBL616234,,BAO_0000219,
1034,51,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,1,,14875,CHEMBL616235,,BAO_0000357,
1035,51,,,8,,H,,,HeLa,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,1,,14727,CHEMBL616236,308.0,BAO_0000219,
1036,51,,,8,,H,,,,Expert,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,1,,14727,CHEMBL616237,,BAO_0000019,
1037,51,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,1,,15146,CHEMBL616238,722.0,BAO_0000219,
1038,51,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,1,,5213,CHEMBL616239,722.0,BAO_0000219,
1039,51,,,8,,H,,,,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,1,,16429,CHEMBL616240,,BAO_0000219,
1040,51,,,9,,D,,,HeLa,Expert,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,1,,15042,CHEMBL616241,308.0,BAO_0000219,
1041,51,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,1,,14818,CHEMBL616242,722.0,BAO_0000219,
1042,51,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,1,,4829,CHEMBL616243,722.0,BAO_0000219,
1043,51,,,9,,D,,,,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,1,,17200,CHEMBL616244,,BAO_0000357,
1044,51,,,9,,D,,,,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,1,,13051,CHEMBL616245,,BAO_0000357,
1045,106,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,1,,5486,CHEMBL616246,,BAO_0000357,
1046,105,,,8,,H,,,,Autocuration,Binding affinity against 5-HT1D receptor,B,1,,5254,CHEMBL616247,,BAO_0000357,
1047,105,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,5254,CHEMBL616248,,BAO_0000357,
1048,107,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL616249,,BAO_0000357,
1049,10576,,,8,,H,,,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,1,,13506,CHEMBL616250,,BAO_0000357,
1050,51,,,8,,H,,,,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,1,,15267,CHEMBL616251,,BAO_0000357,
1051,11863,,In vivo,8,,H,,,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,1,,16616,CHEMBL616252,,BAO_0000218,
1052,11863,,In vivo,8,,H,,,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,1,,16616,CHEMBL616253,,BAO_0000218,
1053,11863,,In vivo,8,,H,,,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,1,,16616,CHEMBL616254,,BAO_0000218,
1054,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,1,,16616,CHEMBL616255,,BAO_0000218,
1055,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,1,,16616,CHEMBL832872,,BAO_0000218,
1056,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,1,,16616,CHEMBL616256,,BAO_0000218,
1057,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,1,,16616,CHEMBL616257,,BAO_0000218,
1058,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,1,,16616,CHEMBL616258,,BAO_0000218,
1059,11863,,,9,,D,,,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,1,,16616,CHEMBL616384,,BAO_0000218,
1060,11863,,,8,,H,,Hippocampus,,Autocuration,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,1,,10297,CHEMBL616385,,BAO_0000221,10000000.0
1061,11863,,,8,,H,,,,Expert,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,1,,13704,CHEMBL616386,,BAO_0000357,
1062,11863,,,9,,D,,Hippocampus,,Expert,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,1,,10297,CHEMBL616387,,BAO_0000221,10000000.0
1063,11863,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,1,,10297,CHEMBL616388,,BAO_0000221,10000000.0
1064,11863,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,1,,10297,CHEMBL616389,,BAO_0000221,10000000.0
1065,11863,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,1,,10297,CHEMBL616390,,BAO_0000221,10000000.0
1066,11863,,,8,,H,,,,Autocuration,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,1,,217,CHEMBL616391,,BAO_0000357,
1067,11863,,,9,,D,,Hippocampus,,Expert,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,1,,10297,CHEMBL616392,,BAO_0000221,10000000.0
1068,51,,,8,,H,,,,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,1,,4921,CHEMBL616393,,BAO_0000357,
1069,51,,,8,,H,,,,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,1,,4921,CHEMBL616394,,BAO_0000357,
1070,51,,,8,,H,,,,Autocuration,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,1,,4996,CHEMBL616395,,BAO_0000019,
1071,51,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,1,,12918,CHEMBL616396,,BAO_0000357,
1072,51,,,8,,H,,,,Autocuration,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,1,,5333,CHEMBL872907,,BAO_0000019,
1073,51,,,8,,H,,,,Autocuration,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,1,,4437,CHEMBL616397,,BAO_0000019,
1074,51,,,8,,H,,,,Autocuration,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,1,,1742,CHEMBL616398,,BAO_0000019,
1075,51,,,8,,H,,,,Expert,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,1,,16688,CHEMBL616399,,BAO_0000357,
1076,51,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL857065,,BAO_0000357,
1077,51,,,8,,H,,,,Expert,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,1,,12861,CHEMBL616400,,BAO_0000019,
1078,51,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,1,,12861,CHEMBL616401,,BAO_0000019,
1079,10624,,,8,,H,,,,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,1,,12490,CHEMBL616402,,BAO_0000019,
1080,51,,,8,,H,,,,Expert,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,1,,11828,CHEMBL616403,,BAO_0000019,
1081,51,,,8,,H,,Hippocampus,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,1,,11866,CHEMBL616404,,BAO_0000221,10000000.0
1082,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,1,,12827,CHEMBL616405,,BAO_0000249,
1083,51,,,8,,H,,,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,1,,12918,CHEMBL616406,,BAO_0000019,
1084,51,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,1,,12919,CHEMBL616407,,BAO_0000019,
1085,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,1,,13047,CHEMBL616408,,BAO_0000019,
1086,10576,,,9,,D,,,,Expert,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,1,,15796,CHEMBL616409,,BAO_0000249,
1087,10576,,,9,,D,,Hippocampus,,Expert,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,1,,3651,CHEMBL616410,,BAO_0000221,10000000.0
1088,10576,,,8,,H,,,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,1,,188,CHEMBL616411,,BAO_0000357,
1089,10576,,,9,,D,Membranes,,,Expert,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,1,,16616,CHEMBL616412,,BAO_0000249,
1090,10576,,,9,,D,Membranes,Hippocampus,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,1,,16616,CHEMBL616413,,BAO_0000249,10000000.0
1091,10576,,,8,,H,,Hippocampus,,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,1,,12306,CHEMBL616414,,BAO_0000221,10000000.0
1092,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,1,,17167,CHEMBL616415,,BAO_0000221,10000000.0
1093,10576,,,8,,H,,,,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,1,,14776,CHEMBL616416,,BAO_0000019,
1094,10576,,,8,,H,,,,Expert,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,1,,12158,CHEMBL616417,,BAO_0000357,
1095,10576,,,8,,H,,,,Autocuration,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,1,,13481,CHEMBL616418,,BAO_0000357,
1096,10576,,In vitro,8,,H,,,,Autocuration,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,1,,13427,CHEMBL616419,,BAO_0000219,
1097,10576,,,8,,H,,,,Autocuration,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,1,,10210,CHEMBL616420,,BAO_0000357,
1098,10576,,,8,,H,Membranes,,,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,1,,10205,CHEMBL616421,,BAO_0000249,
1099,10576,,,8,,H,Membranes,,,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,1,,10205,CHEMBL616422,,BAO_0000249,
1100,10576,,,8,,H,Membranes,,,Expert,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,1,,10205,CHEMBL616423,,BAO_0000249,
1101,10576,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,1,,12280,CHEMBL616424,,BAO_0000357,
1102,10576,,,8,,H,,,,Expert,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,1,,17386,CHEMBL616425,,BAO_0000357,
1103,10576,,,8,,H,,,,Expert,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,1,,13654,CHEMBL616426,,BAO_0000357,
1104,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,1,,14423,CHEMBL616427,,BAO_0000221,10000000.0
1105,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,1,,15412,CHEMBL616428,,BAO_0000221,10000000.0
1106,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,12073,CHEMBL616290,,BAO_0000221,10000000.0
1107,10576,,,9,,D,,,,Expert,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,1,,4101,CHEMBL616052,,BAO_0000357,
1108,10576,,,8,,H,,,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,1,,10062,CHEMBL616053,,BAO_0000357,
1109,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,1,,6238,CHEMBL616054,,BAO_0000249,
1110,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,16273,CHEMBL616055,,BAO_0000357,
1111,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,1,,11139,CHEMBL616056,,BAO_0000357,
1112,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,1,,16796,CHEMBL616057,,BAO_0000019,
1113,10576,,,9,,D,,Brain,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,1,,9548,CHEMBL616058,,BAO_0000221,955.0
1114,10576,,,8,,H,,Brain,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,1,,10381,CHEMBL616059,,BAO_0000221,955.0
1115,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,1,,13408,CHEMBL616060,,BAO_0000249,
1116,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,1,,13825,CHEMBL616061,,BAO_0000221,10000000.0
1117,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,1,,11147,CHEMBL616062,,BAO_0000221,10000000.0
1118,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,1,,10552,CHEMBL616063,,BAO_0000249,
1119,10576,,,8,,H,,Striatum,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,1,,10552,CHEMBL616064,,BAO_0000249,2435.0
1120,10576,,,9,,D,Membranes,,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,1,,17136,CHEMBL616065,,BAO_0000249,
1121,10576,,,9,,D,Membranes,,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,1,,5778,CHEMBL616066,,BAO_0000249,
1122,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,13481,CHEMBL616067,,BAO_0000221,10000000.0
1123,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,1,,13481,CHEMBL616068,,BAO_0000221,10000000.0
1124,10576,,,8,,H,,Hippocampus,,Intermediate,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,1,,13630,CHEMBL616069,,BAO_0000221,10000000.0
1125,10576,,,8,,H,,,,Expert,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,1,,16245,CHEMBL616070,,BAO_0000249,
1126,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,1,,14509,CHEMBL616071,,BAO_0000221,10000000.0
1127,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,1,,14509,CHEMBL616072,,BAO_0000221,10000000.0
1128,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,1,,14509,CHEMBL616073,,BAO_0000221,10000000.0
1129,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,1,,14509,CHEMBL616074,,BAO_0000221,10000000.0
1130,10576,,,8,,H,,,,Expert,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,1,,14256,CHEMBL616075,,BAO_0000019,
1131,10576,,,8,,H,,,,Autocuration,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,1,,11139,CHEMBL616076,,BAO_0000357,
1132,10576,,,9,,D,,,,Expert,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,1,,11047,CHEMBL616077,,BAO_0000019,
1133,10576,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,1,,11047,CHEMBL616078,,BAO_0000019,
1134,10576,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,1,,11047,CHEMBL616079,,BAO_0000019,
1135,10576,,,9,,D,,,CHO-K1,Expert,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,1,,2395,CHEMBL616080,485.0,BAO_0000219,
1136,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,9699,CHEMBL616081,,BAO_0000357,
1137,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,1,,12028,CHEMBL616082,,BAO_0000221,10000000.0
1138,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,1,,12028,CHEMBL616083,,BAO_0000221,10000000.0
1139,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,1,,5815,CHEMBL616084,,BAO_0000019,
1140,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,1,,16616,CHEMBL616085,,BAO_0000019,
1141,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,1,,5815,CHEMBL616086,,BAO_0000019,
1142,10576,,,8,,H,,Hippocampus,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,1,,2761,CHEMBL616087,,BAO_0000221,10000000.0
1143,10576,,,8,,H,,,,Expert,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,1,,13133,CHEMBL616088,,BAO_0000357,
1144,10576,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,1,,10444,CHEMBL616089,,BAO_0000019,
1145,10576,,,9,,D,,,,Expert,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,1,,13278,CHEMBL616090,,BAO_0000357,
1146,10576,,,8,,H,,,,Autocuration,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,1,,15874,CHEMBL616091,,BAO_0000357,
1147,10576,,,8,,H,Membranes,Striatum,,Autocuration,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,1,,10552,CHEMBL616092,,BAO_0000249,2435.0
1148,10576,,,8,,H,,,,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,1,,11130,CHEMBL616093,,BAO_0000357,
1149,10576,,In vivo,8,,H,,,,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,1,,11130,CHEMBL616094,,BAO_0000218,
1150,10576,,,8,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,1,,14542,CHEMBL616095,,BAO_0000221,955.0
1151,10576,,,9,,D,,,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,1,,13670,CHEMBL616096,,BAO_0000357,
1152,10576,,,8,,H,,,,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,1,,9888,CHEMBL616097,,BAO_0000249,
1153,10576,,,9,,D,Membranes,,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,1,,3678,CHEMBL616098,,BAO_0000249,
1154,10576,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,1,,11332,CHEMBL616099,,BAO_0000221,10000000.0
1155,10576,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,1,,11332,CHEMBL616100,,BAO_0000221,10000000.0
1156,10576,,,8,,H,,,,Expert,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,1,,1185,CHEMBL616101,,BAO_0000357,
1157,10576,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,1,,2014,CHEMBL616102,,BAO_0000249,
1158,10576,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,1,,1185,CHEMBL616103,,BAO_0000357,
1159,10576,,,8,,H,,,,Expert,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,1,,14429,CHEMBL616104,,BAO_0000019,
1160,10576,,,8,,H,,,,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,1,,16288,CHEMBL616105,,BAO_0000019,
1161,10576,,,9,,D,,,,Expert,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,1,,5432,CHEMBL616106,,BAO_0000019,
1162,10576,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,1,,14429,CHEMBL616107,,BAO_0000019,
1163,10576,,,8,,H,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,1,,13672,CHEMBL616108,,BAO_0000357,
1164,10576,,,8,,H,,Hippocampus,,Expert,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,1,,11296,CHEMBL616109,,BAO_0000221,10000000.0
1165,10576,,,8,,H,,,,Autocuration,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,1,,11296,CHEMBL616110,,BAO_0000357,
1166,10576,,,8,,H,,,CHO,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,1,,14749,CHEMBL616111,449.0,BAO_0000219,
1167,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,1,,15086,CHEMBL616112,,BAO_0000019,
1168,10576,,,8,,H,,Hippocampus,,Autocuration,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,1,,13462,CHEMBL616113,,BAO_0000221,10000000.0
1169,10576,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,1,,15363,CHEMBL616114,,BAO_0000019,
1170,10576,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,1,,15363,CHEMBL616115,,BAO_0000019,
1171,10576,,,8,,H,,,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,1,,10796,CHEMBL616116,,BAO_0000357,
1172,10576,,,8,,H,,Brain,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,1,,12816,CHEMBL615844,,BAO_0000221,955.0
1173,10576,,,8,,H,,Hippocampus,,Expert,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,1,,13542,CHEMBL615939,,BAO_0000221,10000000.0
1174,10576,,,8,,H,,,,Expert,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,1,,13308,CHEMBL615940,,BAO_0000019,
1175,10576,,,8,,H,,Hippocampus,,Expert,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,1,,13541,CHEMBL615941,,BAO_0000221,10000000.0
1176,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,1,,10058,CHEMBL615942,,BAO_0000221,10000000.0
1177,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,1,,10058,CHEMBL615943,,BAO_0000221,10000000.0
1178,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,1,,10058,CHEMBL615944,,BAO_0000221,10000000.0
1179,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,1,,10058,CHEMBL615945,,BAO_0000221,10000000.0
1180,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,1,,10058,CHEMBL615946,,BAO_0000221,10000000.0
1181,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,1,,10058,CHEMBL615947,,BAO_0000221,10000000.0
1182,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,1,,10058,CHEMBL615948,,BAO_0000221,10000000.0
1183,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,1,,10058,CHEMBL615949,,BAO_0000221,10000000.0
1184,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,1,,10058,CHEMBL615950,,BAO_0000221,10000000.0
1185,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,1,,10058,CHEMBL615951,,BAO_0000221,10000000.0
1186,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,1,,10058,CHEMBL615952,,BAO_0000221,10000000.0
1187,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,1,,10058,CHEMBL615953,,BAO_0000221,10000000.0
1188,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,1,,10058,CHEMBL615954,,BAO_0000221,10000000.0
1189,10576,,,9,,D,,Hippocampus,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,1,,10058,CHEMBL615955,,BAO_0000221,10000000.0
1190,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,1,,10058,CHEMBL615956,,BAO_0000221,10000000.0
1191,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,1,,10058,CHEMBL615957,,BAO_0000221,10000000.0
1192,10576,,,8,,H,,,,Expert,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,1,,12879,CHEMBL615958,,BAO_0000019,
1193,10576,,,8,,H,,,,Expert,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,1,,11964,CHEMBL615959,,BAO_0000019,
1194,10576,,,8,,H,,,,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,1,,11964,CHEMBL615960,,BAO_0000019,
1195,10576,,,8,,H,,,,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,1,,11964,CHEMBL615961,,BAO_0000019,
1196,10576,,,8,,H,,Brain,,Expert,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,1,,9548,CHEMBL615962,,BAO_0000221,955.0
1197,10576,,,8,,H,,,,Expert,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,1,,9098,CHEMBL615963,,BAO_0000019,
1198,10576,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,1,,9098,CHEMBL615964,,BAO_0000019,
1199,10576,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,1,,9098,CHEMBL615965,,BAO_0000019,
1200,10576,,,8,,H,,,CHO,Expert,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,1,,13248,CHEMBL615966,449.0,BAO_0000219,
1201,10576,,,8,,H,,,,Expert,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,1,,3147,CHEMBL615967,,BAO_0000249,
1202,10576,,,8,,H,,,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,1,,13949,CHEMBL615968,,BAO_0000019,
1203,10576,,,8,,H,,,CHO,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,1,,11883,CHEMBL615969,449.0,BAO_0000218,
1204,10576,,,8,,H,,,,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,1,,11883,CHEMBL615970,,BAO_0000218,
1205,10576,,,9,,D,,,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,1,,11883,CHEMBL615971,,BAO_0000357,
1206,10576,,,8,,H,Membranes,,,Expert,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,1,,15535,CHEMBL615972,,BAO_0000249,
1207,10576,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,1,,15535,CHEMBL615973,,BAO_0000249,
1208,10576,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,1,,15535,CHEMBL615974,,BAO_0000249,
1209,51,,,9,,D,,,CHO,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,1,,16372,CHEMBL615975,449.0,BAO_0000219,
1210,10576,,,8,,H,,,,Expert,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,1,,14608,CHEMBL615976,,BAO_0000249,
1211,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,1,,4795,CHEMBL872106,,BAO_0000221,10000000.0
1212,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,1,,13863,CHEMBL615977,,BAO_0000357,
1213,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,1,,13863,CHEMBL615978,,BAO_0000357,
1214,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,1,,13863,CHEMBL616166,,BAO_0000357,
1215,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,1,,13863,CHEMBL616167,,BAO_0000357,
1216,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,1,,13863,CHEMBL616168,,BAO_0000357,
1217,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,1,,13863,CHEMBL616169,,BAO_0000357,
1218,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,1,,13863,CHEMBL616170,,BAO_0000357,
1219,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,1,,13863,CHEMBL616171,,BAO_0000357,
1220,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,1,,13863,CHEMBL616172,,BAO_0000357,
1221,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,1,,13863,CHEMBL616173,,BAO_0000357,
1222,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,1,,13863,CHEMBL616174,,BAO_0000357,
1223,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,1,,13863,CHEMBL616175,,BAO_0000357,
1224,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,1,,13863,CHEMBL616176,,BAO_0000357,
1225,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,1,,13863,CHEMBL616177,,BAO_0000357,
1226,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,1,,13863,CHEMBL616178,,BAO_0000357,
1227,10576,,,8,,H,,,,Autocuration,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,1,,9742,CHEMBL616179,,BAO_0000019,
1228,10576,,,8,,H,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,1,,12073,CHEMBL616180,,BAO_0000357,
1229,10576,,,8,,H,,,,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,1,,4101,CHEMBL616181,,BAO_0000357,
1230,10576,,,8,,H,,,,Autocuration,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,1,,15360,CHEMBL616182,,BAO_0000019,
1231,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,1,,11576,CHEMBL616183,,BAO_0000221,10000000.0
1232,10576,,,8,,H,,,,Expert,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,1,,5834,CHEMBL615874,,BAO_0000019,
1233,10576,,,9,,D,,,CHO-K1,Expert,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,1,,2395,CHEMBL615875,485.0,BAO_0000219,
1234,10576,,,8,,H,,,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,1,,1375,CHEMBL615876,,BAO_0000019,
1235,10576,,,8,,H,,,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,1,,1375,CHEMBL615877,,BAO_0000019,
1236,10576,,,8,,H,,,,Autocuration,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,1,,3967,CHEMBL615878,,BAO_0000357,
1237,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,1,,12884,CHEMBL615879,,BAO_0000357,
1238,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,1,,2343,CHEMBL615880,,BAO_0000357,
1239,10576,,,8,,H,,,,Autocuration,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,1,,11511,CHEMBL615881,,BAO_0000019,
1240,10576,,,9,,D,,,,Expert,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,1,,11511,CHEMBL615882,,BAO_0000019,
1241,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,1,,16394,CHEMBL615883,,BAO_0000218,
1242,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,1,,16394,CHEMBL615884,,BAO_0000218,
1243,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,1,,16394,CHEMBL615885,,BAO_0000218,
1244,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,1,,16394,CHEMBL615886,,BAO_0000218,
1245,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,1,,16394,CHEMBL615887,,BAO_0000218,
1246,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,1,,16394,CHEMBL615888,,BAO_0000218,
1247,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,1,,16394,CHEMBL615889,,BAO_0000218,
1248,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,1,,16394,CHEMBL615890,,BAO_0000218,
1249,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,1,,16394,CHEMBL615891,,BAO_0000218,
1250,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,1,,16394,CHEMBL615892,,BAO_0000218,
1251,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,1,,16394,CHEMBL615893,,BAO_0000218,
1252,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,1,,16394,CHEMBL615894,,BAO_0000218,
1253,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,1,,16394,CHEMBL615895,,BAO_0000218,
1254,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,1,,16394,CHEMBL615896,,BAO_0000218,
1255,10576,,In vivo,8,,H,,,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,1,,16394,CHEMBL615897,,BAO_0000218,
1256,10576,,,9,,D,Membranes,,,Expert,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,1,,16616,CHEMBL615898,,BAO_0000249,
1257,10576,,,8,,H,,,,Autocuration,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,1,,16796,CHEMBL615899,,BAO_0000019,
1258,10576,,,8,,H,,,,Autocuration,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,1,,16796,CHEMBL616291,,BAO_0000019,
1259,10576,,,8,,H,,,,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,1,,15629,CHEMBL616292,,BAO_0000357,
1260,10576,,,8,,H,,,,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,1,,13241,CHEMBL616293,,BAO_0000249,
1261,10576,,,8,,H,,Hippocampus,,Expert,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,12073,CHEMBL616294,,BAO_0000221,10000000.0
1262,10576,,,8,,H,,Hippocampus,,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,1,,14286,CHEMBL616295,,BAO_0000249,10000000.0
1263,10576,,,8,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,1,,14542,CHEMBL616296,,BAO_0000221,955.0
1264,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,1,,13630,CHEMBL616297,,BAO_0000019,
1265,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,1,,13630,CHEMBL616605,,BAO_0000019,
1266,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,1,,13630,CHEMBL616606,,BAO_0000019,
1267,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,1,,13630,CHEMBL616607,,BAO_0000019,
1268,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,1,,13630,CHEMBL616608,,BAO_0000019,
1269,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,1,,13630,CHEMBL616609,,BAO_0000019,
1270,10576,,,9,,D,,,,Expert,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,1,,13630,CHEMBL616610,,BAO_0000019,
1271,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,1,,13630,CHEMBL616611,,BAO_0000019,
1272,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,1,,13630,CHEMBL616612,,BAO_0000019,
1273,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,1,,13630,CHEMBL616613,,BAO_0000019,
1274,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,1,,13630,CHEMBL616614,,BAO_0000019,
1275,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,1,,13630,CHEMBL616615,,BAO_0000019,
1276,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,1,,13630,CHEMBL616616,,BAO_0000019,
1277,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,1,,13630,CHEMBL616617,,BAO_0000019,
1278,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,1,,13630,CHEMBL616618,,BAO_0000019,
1279,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,1,,13630,CHEMBL616619,,BAO_0000019,
1280,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,1,,13630,CHEMBL616620,,BAO_0000019,
1281,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,1,,13630,CHEMBL616621,,BAO_0000019,
1282,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,1,,13630,CHEMBL616622,,BAO_0000019,
1283,10576,,,8,,H,,,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,1,,13630,CHEMBL616146,,BAO_0000019,
1284,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,1,,13630,CHEMBL832873,,BAO_0000019,
1285,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,1,,13630,CHEMBL616147,,BAO_0000019,
1286,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,1,,13630,CHEMBL872872,,BAO_0000019,
1287,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,1,,13630,CHEMBL616148,,BAO_0000019,
1288,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,1,,9783,CHEMBL616149,,BAO_0000221,10000000.0
1289,10576,,,8,,H,,Hippocampus,,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,1,,9783,CHEMBL616150,,BAO_0000221,10000000.0
1290,10576,,,9,,D,Membranes,,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,1,,14331,CHEMBL616151,,BAO_0000249,
1291,10576,,,8,,H,,Hippocampus,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,1,,15260,CHEMBL872873,,BAO_0000221,10000000.0
1292,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,1,,15260,CHEMBL616670,,BAO_0000221,10000000.0
1293,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,1,,15260,CHEMBL616671,,BAO_0000221,10000000.0
1294,10576,,,9,,D,,,,Expert,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,1,,16616,CHEMBL884861,,BAO_0000249,
1295,10576,,,8,,H,,,,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,1,,15629,CHEMBL616672,,BAO_0000357,
1296,10576,,,8,,H,,,,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,1,,15086,CHEMBL616673,,BAO_0000019,
1297,10576,,,8,,H,,,,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,1,,5717,CHEMBL616674,,BAO_0000019,
1298,10576,,,8,,H,,,,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,1,,12652,CHEMBL616675,,BAO_0000357,
1299,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,1,,14608,CHEMBL616676,,BAO_0000221,10000000.0
1300,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,1,,12306,CHEMBL616677,,BAO_0000221,10000000.0
1301,10576,,,8,,H,,Hippocampus,,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,1,,12306,CHEMBL616678,,BAO_0000221,10000000.0
1302,10576,,,9,,D,,,,Expert,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,1,,15247,CHEMBL616679,,BAO_0000357,
1303,10576,,,8,,H,,Hippocampus,,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,1,,17529,CHEMBL616680,,BAO_0000221,10000000.0
1304,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,14826,CHEMBL616681,,BAO_0000221,10000000.0
1305,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,14826,CHEMBL616682,,BAO_0000221,10000000.0
1306,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,1,,13241,CHEMBL616683,,BAO_0000221,10000000.0
1307,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,1,,14093,CHEMBL616684,,BAO_0000221,10000000.0
1308,10576,,,8,,H,,Hippocampus,,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,1,,14093,CHEMBL616685,,BAO_0000221,10000000.0
1309,10576,,,8,,H,,Brain,,Autocuration,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,1,,14442,CHEMBL616686,,BAO_0000221,955.0
1310,10576,,,8,,H,,,,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,B,1,,9919,CHEMBL616687,,BAO_0000357,
1311,10576,,,8,,H,,,,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,B,1,,9919,CHEMBL616688,,BAO_0000357,
1312,10576,,,8,,H,,Hippocampus,,Autocuration,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,1,,11440,CHEMBL616689,,BAO_0000221,10000000.0
1313,10576,,,8,,H,,,,Autocuration,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,1,,11257,CHEMBL616690,,BAO_0000357,
1314,10576,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,1,,10330,CHEMBL616691,,BAO_0000357,
1315,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,1,,17331,CHEMBL616692,,BAO_0000221,10000000.0
1316,10576,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,1,,16567,CHEMBL616693,,BAO_0000249,
1317,10576,,,9,,D,,,,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,1,,12058,CHEMBL616694,,BAO_0000019,
1318,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,1,,9699,CHEMBL616695,,BAO_0000221,10000000.0
1319,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,1,,9547,CHEMBL616696,,BAO_0000357,
1320,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,1,,10330,CHEMBL616697,,BAO_0000357,
1321,10576,,,8,,H,,,,Autocuration,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,1,,14331,CHEMBL616698,,BAO_0000357,
1322,10576,,,9,,D,,,,Expert,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,1,,14060,CHEMBL616949,,BAO_0000019,
1323,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,1,,14744,CHEMBL616950,,BAO_0000221,10000000.0
1324,10576,,,8,,H,,,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,1,,13506,CHEMBL832875,,BAO_0000357,
1325,10576,,,8,,H,,Brain,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,1,,10862,CHEMBL616951,,BAO_0000221,955.0
1326,10576,,,8,,H,,Brain,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,1,,10862,CHEMBL616952,,BAO_0000221,955.0
1327,10576,,,8,,H,,,,Expert,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,1,,10062,CHEMBL616953,,BAO_0000357,
1328,10576,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,1,,12073,CHEMBL616954,,BAO_0000357,
1329,106,,,8,,H,,,,Autocuration,GTPgammaS radioligand binding assay,B,1,,14875,CHEMBL616955,,BAO_0000357,
1330,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,1,,2391,CHEMBL616956,,BAO_0000357,
1331,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,1,,2391,CHEMBL616957,,BAO_0000019,
1332,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,1,,2391,CHEMBL616958,,BAO_0000019,
1333,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,1,,2391,CHEMBL616959,,BAO_0000357,
1334,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,1,,2391,CHEMBL616960,,BAO_0000357,
1335,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,1,,2391,CHEMBL616961,,BAO_0000019,
1336,106,,,8,,H,,,HeLa,Expert,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,1,,17211,CHEMBL616962,308.0,BAO_0000219,
1337,106,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,1,,17211,CHEMBL616963,308.0,BAO_0000219,
1338,106,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,1,,6491,CHEMBL616524,,BAO_0000357,
1339,106,,,8,,H,,,CHO,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,1,,16190,CHEMBL616525,449.0,BAO_0000219,
1340,106,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,1,,14165,CHEMBL872908,,BAO_0000019,
1341,106,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,1,,14165,CHEMBL616526,,BAO_0000019,
1342,106,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,1,,4234,CHEMBL616527,,BAO_0000357,
1343,106,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,1,,6328,CHEMBL616528,,BAO_0000219,
1344,106,,,8,,H,,,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,1,,14770,CHEMBL616529,,BAO_0000357,
1345,106,,,8,,H,,,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,1,,2598,CHEMBL616530,,BAO_0000357,
1346,106,,,8,,H,,,,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,1,,6897,CHEMBL616531,,BAO_0000357,
1347,106,,,8,,H,,,,Autocuration,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,1,,6897,CHEMBL616532,,BAO_0000357,
1348,106,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,1,,6013,CHEMBL616533,,BAO_0000357,
1349,106,,,8,,H,,,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,1,,5843,CHEMBL616534,,BAO_0000357,
1350,106,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,1,,14454,CHEMBL616535,,BAO_0000357,
1351,106,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,1,,16209,CHEMBL616536,,BAO_0000357,
1352,106,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,1,,3935,CHEMBL616537,,BAO_0000357,
1353,106,,,8,,H,,,CHO-K1,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,1,,13729,CHEMBL616538,485.0,BAO_0000219,
1354,106,,,8,,H,,,,Expert,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,1,,14251,CHEMBL616539,,BAO_0000019,
1355,106,,,8,,H,,,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,1,,17085,CHEMBL616540,,BAO_0000019,
1356,106,,,8,,H,,,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,1,,3025,CHEMBL616429,,BAO_0000357,
1357,106,,,8,,H,,,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,1,,15315,CHEMBL616430,,BAO_0000357,
1358,106,,,9,,D,,,,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,1,,14214,CHEMBL616431,,BAO_0000219,
1359,106,,,9,,D,,,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,1,,3804,CHEMBL616432,,BAO_0000357,
1360,106,,,9,,D,,,,Expert,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,1,,2391,CHEMBL616433,,BAO_0000357,
1361,106,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,1,,4175,CHEMBL616434,,BAO_0000357,
1362,106,,,8,,H,,,CHO,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,1,,17296,CHEMBL616435,449.0,BAO_0000219,
1363,106,,,8,,H,,,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,1,,17085,CHEMBL616436,,BAO_0000019,
1364,106,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,1,,17211,CHEMBL616437,308.0,BAO_0000219,
1365,106,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,1,,17211,CHEMBL616438,308.0,BAO_0000219,
1366,106,,,8,,H,,,HeLa,Autocuration,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,1,,17211,CHEMBL616439,308.0,BAO_0000219,
1367,106,,,9,,D,,,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,1,,15926,CHEMBL616440,,BAO_0000357,
1368,106,,,8,,H,,,CHO-K1,Autocuration,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,1,,16312,CHEMBL616441,485.0,BAO_0000219,
1369,106,,,8,,H,,,,Expert,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,1,,5843,CHEMBL616442,,BAO_0000357,
1370,106,,,8,,H,,,,Autocuration,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,1,,5843,CHEMBL616443,,BAO_0000357,
1371,106,,,8,,H,,,CHO-K1,Expert,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,1,,16312,CHEMBL616444,485.0,BAO_0000219,
1372,106,,,9,,D,,,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,B,1,,15926,CHEMBL616445,,BAO_0000357,
1373,106,,,9,,D,,,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,B,1,,15926,CHEMBL616446,,BAO_0000357,
1374,106,,,9,,D,,,CHO,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,1,,4540,CHEMBL616447,449.0,BAO_0000219,
1375,106,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,1,,6166,CHEMBL616448,,BAO_0000357,
1376,106,,,8,,H,,,CHO,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,1,,17296,CHEMBL616449,449.0,BAO_0000219,
1377,106,,,8,,H,,,CHO,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,1,,17296,CHEMBL616450,449.0,BAO_0000219,
1378,106,,,8,,H,,,CHO,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,1,,17296,CHEMBL857974,449.0,BAO_0000219,
1379,106,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,1,,15779,CHEMBL616451,449.0,BAO_0000219,
1380,106,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,1,,15779,CHEMBL616452,449.0,BAO_0000219,
1381,106,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,1,,15779,CHEMBL616453,449.0,BAO_0000219,
1382,106,,,8,,H,,,CHO,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,1,,4199,CHEMBL616454,449.0,BAO_0000219,
1383,106,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,1,,14875,CHEMBL616455,,BAO_0000357,
1384,106,,,8,,H,,,CHO,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,1,,15146,CHEMBL616456,449.0,BAO_0000219,
1385,106,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,1,,5213,CHEMBL616457,,BAO_0000357,
1386,106,,,8,,H,,,CHO,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,1,,14818,CHEMBL616458,449.0,BAO_0000219,
1387,106,,,8,,H,,,CHO,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL616459,449.0,BAO_0000219,
1388,106,,,8,,H,,,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,1,,14454,CHEMBL616460,,BAO_0000019,
1389,106,,,8,,H,,,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,1,,14454,CHEMBL616461,,BAO_0000019,
1390,106,,,8,,H,,,CHO,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,1,,14875,CHEMBL616462,449.0,BAO_0000219,
1391,106,,,8,,H,,,CHO,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,1,,14875,CHEMBL616463,449.0,BAO_0000219,
1392,105,,,8,,H,,,,Autocuration,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,1,,15250,CHEMBL616464,,BAO_0000019,
1393,105,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,1,,15250,CHEMBL616465,449.0,BAO_0000219,
1394,17105,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,1,,15086,CHEMBL832874,,BAO_0000357,
1395,106,,,8,,H,,,,Autocuration,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,1,,3025,CHEMBL616184,,BAO_0000019,
1396,106,,,8,,H,,,,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,1,,14998,CHEMBL616185,,BAO_0000019,
1397,106,,,8,,H,,,,Intermediate,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,1,,14998,CHEMBL616186,,BAO_0000019,
1398,106,,,8,,H,,,,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,1,,14998,CHEMBL616187,,BAO_0000019,
1399,10577,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,1,,13969,CHEMBL616188,,BAO_0000357,
1400,10577,,,9,,D,,,,Intermediate,Binding affinity for 5-hydroxytryptamine 1B receptor,B,1,,13392,CHEMBL873475,,BAO_0000357,
1401,10577,,,9,,D,,Striatum,,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,1,,3651,CHEMBL616189,,BAO_0000019,2435.0
1402,10577,,,8,,H,,,,Expert,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,1,,10025,CHEMBL616190,,BAO_0000357,
1403,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,1,,13863,CHEMBL616191,,BAO_0000357,
1404,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,1,,13863,CHEMBL616192,,BAO_0000357,
1405,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,1,,13863,CHEMBL616193,,BAO_0000357,
1406,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,1,,13863,CHEMBL616194,,BAO_0000357,
1407,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,1,,13863,CHEMBL616195,,BAO_0000357,
1408,10576,,,8,,H,,,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,1,,13863,CHEMBL616196,,BAO_0000357,
1409,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,1,,4622,CHEMBL616197,,BAO_0000249,10000000.0
1410,10576,,,8,,H,,,,Intermediate,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,1,,14911,CHEMBL616198,,BAO_0000019,
1411,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,1,,12678,CHEMBL616199,,BAO_0000221,10000000.0
1412,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,1,,12678,CHEMBL616200,,BAO_0000221,10000000.0
1413,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,1,,14235,CHEMBL616201,,BAO_0000221,10000000.0
1414,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,1,,14949,CHEMBL616202,,BAO_0000221,10000000.0
1415,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,1,,14949,CHEMBL616203,,BAO_0000221,10000000.0
1416,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,1,,14949,CHEMBL616204,,BAO_0000221,10000000.0
1417,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,1,,14949,CHEMBL616205,,BAO_0000221,10000000.0
1418,10576,,,8,,H,,Hippocampus,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,1,,14949,CHEMBL616206,,BAO_0000221,10000000.0
1419,10576,,,8,,H,,,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,1,,16118,CHEMBL616207,,BAO_0000249,
1420,10576,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,1,,3268,CHEMBL616208,,BAO_0000249,
1421,10576,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,1,,3268,CHEMBL616209,,BAO_0000249,
1422,10576,,,8,,H,,,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,1,,16117,CHEMBL616210,,BAO_0000357,
1423,10576,,,8,,H,,Hippocampus,,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,1,,9783,CHEMBL616211,,BAO_0000221,10000000.0
1424,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,1,,9783,CHEMBL616504,,BAO_0000221,10000000.0
1425,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,1,,14356,CHEMBL616505,,BAO_0000221,10000000.0
1426,10576,,,8,,H,,,,Autocuration,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,1,,15740,CHEMBL616506,,BAO_0000019,
1427,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,1,,12306,CHEMBL872107,,BAO_0000221,10000000.0
1428,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,1,,13348,CHEMBL616507,,BAO_0000221,10000000.0
1429,10576,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,1,,10394,CHEMBL616303,,BAO_0000249,
1430,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,1,,15260,CHEMBL616304,,BAO_0000221,10000000.0
1431,10576,,,8,,H,,Hippocampus,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,1,,10046,CHEMBL616305,,BAO_0000221,10000000.0
1432,10576,,,8,,H,,Hippocampus,,Intermediate,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,1,,15260,CHEMBL616306,,BAO_0000221,10000000.0
1433,10576,,,8,,H,,,,Autocuration,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,1,,12851,CHEMBL616307,,BAO_0000357,
1434,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,1,,2148,CHEMBL881829,,BAO_0000221,10000000.0
1435,10576,,,8,,H,,,,Expert,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,1,,13134,CHEMBL616308,,BAO_0000357,
1436,10576,,,8,,H,,,,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,1,,12462,CHEMBL616309,,BAO_0000019,
1437,10576,,,8,,H,,,,Expert,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,1,,12462,CHEMBL616310,,BAO_0000019,
1438,10576,,,8,,H,,,CHO,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,1,,12462,CHEMBL616311,449.0,BAO_0000219,
1439,10576,,,8,,H,,,,Expert,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,1,,11933,CHEMBL616312,,BAO_0000357,
1440,10576,,,8,,H,,,,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,1,,11933,CHEMBL616313,,BAO_0000357,
1441,10576,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,1,,403,CHEMBL616314,,BAO_0000221,10000000.0
1442,10576,,,8,,H,,Hippocampus,,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,15538,CHEMBL616315,,BAO_0000221,10000000.0
1443,10576,,,8,,H,,Hippocampus,,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,1,,15538,CHEMBL616567,,BAO_0000221,10000000.0
1444,10576,,,8,,H,,Hippocampus,,Autocuration,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,1,,15538,CHEMBL616568,,BAO_0000221,10000000.0
1445,10576,,,8,,H,,,,Intermediate,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,1,,12464,CHEMBL616569,,BAO_0000019,
1446,10576,,,8,,H,,,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,1,,1455,CHEMBL616570,,BAO_0000357,
1447,10576,,,8,,H,,,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,1,,12652,CHEMBL616571,,BAO_0000357,
1448,10576,,,8,,H,,Hippocampus,,Autocuration,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,1,,12639,CHEMBL616572,,BAO_0000221,10000000.0
1449,10576,,,8,,H,,,,Expert,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,1,,13949,CHEMBL616573,,BAO_0000249,
1450,10576,,,9,,D,,,,Expert,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,1,,12463,CHEMBL616574,,BAO_0000357,
1451,10576,,,8,,H,,Hippocampus,,Expert,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,1,,14829,CHEMBL616575,,BAO_0000221,10000000.0
1452,10576,,,8,,H,,Hippocampus,,Autocuration,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,1,,14829,CHEMBL872108,,BAO_0000221,10000000.0
1453,10576,,,8,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,1,,12092,CHEMBL616576,,BAO_0000357,
1454,10576,,,8,,H,,,,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,1,,403,CHEMBL616577,,BAO_0000249,
1455,10576,,,8,,H,,,,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,1,,403,CHEMBL616578,,BAO_0000249,
1456,10576,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,1,,3967,CHEMBL616579,,BAO_0000357,
1457,10576,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,1,,12771,CHEMBL616580,,BAO_0000019,
1458,10576,,,8,,H,,,,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,1,,15086,CHEMBL616581,,BAO_0000019,
1459,10576,,,8,,H,,Hippocampus,,Autocuration,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,14909,CHEMBL616582,,BAO_0000221,10000000.0
1460,10576,,,8,,H,,Hippocampus,,Expert,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,1,,14949,CHEMBL616583,,BAO_0000221,10000000.0
1461,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,1,,2309,CHEMBL616584,,BAO_0000221,10000000.0
1462,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,4170,CHEMBL616585,,BAO_0000357,
1463,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,1,,11642,CHEMBL616586,,BAO_0000221,10000000.0
1464,10576,,,8,,H,,Hippocampus,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,1,,11642,CHEMBL616587,,BAO_0000221,10000000.0
1465,10576,,,8,,H,,Hippocampus,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,1,,12953,CHEMBL616588,,BAO_0000221,10000000.0
1466,10576,,,8,,H,,Hippocampus,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,1,,12953,CHEMBL616589,,BAO_0000221,10000000.0
1467,10576,,,8,,H,,Hippocampus,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,1,,12953,CHEMBL616590,,BAO_0000221,10000000.0
1468,10576,,,8,,H,,,CHO,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,1,,12903,CHEMBL616591,449.0,BAO_0000219,
1469,10576,,,8,,H,,,,Expert,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,1,,12536,CHEMBL616592,,BAO_0000357,
1470,10576,,,8,,H,,,,Autocuration,The inhibition activity of 5-HT1A at 1 uM,B,1,,10058,CHEMBL616593,,BAO_0000357,
1471,10576,,,8,,H,,,CHO-K1,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,1,,12902,CHEMBL616594,485.0,BAO_0000219,
1472,10576,,,8,,H,,,,Expert,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,1,,14057,CHEMBL616595,,BAO_0000249,
1473,10576,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,1,,11296,CHEMBL616596,,BAO_0000357,
1474,10576,,,8,,H,,Hippocampus,,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,1,,11296,CHEMBL616597,,BAO_0000221,10000000.0
1475,10576,,,8,,H,,Hippocampus,,Expert,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,1,,11296,CHEMBL616598,,BAO_0000221,10000000.0
1476,10576,,,9,,D,Membranes,,,Expert,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,1,,16616,CHEMBL616599,,BAO_0000249,
1477,10576,,,9,,D,Membranes,Hippocampus,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,1,,16616,CHEMBL616600,,BAO_0000249,10000000.0
1478,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,1,,16567,CHEMBL616601,,BAO_0000019,
1479,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,1,,16567,CHEMBL616602,,BAO_0000019,
1480,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,1,,16567,CHEMBL616603,,BAO_0000019,
1481,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,1,,16567,CHEMBL616604,,BAO_0000019,
1482,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,1,,17136,CHEMBL616316,,BAO_0000249,
1483,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,1,,17136,CHEMBL616317,,BAO_0000249,
1484,10576,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,1,,16616,CHEMBL616318,,BAO_0000019,
1485,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,1,,17331,CHEMBL616319,,BAO_0000221,10000000.0
1486,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,1,,17331,CHEMBL616320,,BAO_0000221,10000000.0
1487,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,1,,17167,CHEMBL616321,,BAO_0000221,10000000.0
1488,10576,,,8,,H,,,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,1,,15740,CHEMBL616322,,BAO_0000019,
1489,10576,,,8,,H,,,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,1,,15740,CHEMBL616323,,BAO_0000019,
1490,10576,,,8,,H,,,,Autocuration,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,1,,4671,CHEMBL616324,,BAO_0000357,
1491,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,1,,10058,CHEMBL616325,,BAO_0000221,10000000.0
1492,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,1,,10058,CHEMBL616326,,BAO_0000221,10000000.0
1493,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,1,,10058,CHEMBL616327,,BAO_0000221,10000000.0
1494,10576,,,8,,H,,,,Autocuration,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,1,,12073,CHEMBL616328,,BAO_0000357,
1495,10576,,,8,,H,,,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,1,,2759,CHEMBL858110,,BAO_0000249,
1496,10576,,,8,,H,,,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,1,,2759,CHEMBL616329,,BAO_0000249,
1497,10576,,,8,,H,,,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,1,,2759,CHEMBL616330,,BAO_0000249,
1498,10576,,,8,,H,,,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,1,,2759,CHEMBL616331,,BAO_0000249,
1499,10576,,,8,,H,,,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,1,,2759,CHEMBL616332,,BAO_0000249,
1500,10576,,,8,,H,,Brain,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,1,,9737,CHEMBL857063,,BAO_0000249,955.0
1501,10576,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,1,,9737,CHEMBL616333,,BAO_0000019,
1502,10576,,,8,,H,,,,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,1,,5717,CHEMBL616334,,BAO_0000019,
1503,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,1,,12253,CHEMBL616335,,BAO_0000221,10000000.0
1504,10576,,,8,,H,,,,Autocuration,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,1,,14025,CHEMBL616336,,BAO_0000019,
1505,10576,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,1,,10425,CHEMBL616337,,BAO_0000249,
1506,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,1,,14998,CHEMBL616338,,BAO_0000019,
1507,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,1,,13694,CHEMBL616339,,BAO_0000221,10000000.0
1508,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,1,,13694,CHEMBL616340,,BAO_0000221,10000000.0
1509,10576,,,8,,H,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,1,,4342,CHEMBL616341,,BAO_0000357,
1510,10576,,,9,,D,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,1,,12936,CHEMBL616342,,BAO_0000357,
1511,10576,,,9,,D,,,,Expert,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,1,,13144,CHEMBL616343,,BAO_0000019,
1512,10576,,,8,,H,,,,Expert,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,1,,13343,CHEMBL616344,,BAO_0000019,
1513,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,1,,12132,CHEMBL616345,,BAO_0000357,
1514,10576,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,1,,15419,CHEMBL616346,,BAO_0000019,
1515,10576,,,8,,H,,Hippocampus,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,1,,1479,CHEMBL616347,,BAO_0000221,10000000.0
1516,10576,,,8,,H,,,,Expert,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,1,,14287,CHEMBL616348,,BAO_0000019,
1517,10576,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor,B,1,,13116,CHEMBL616349,,BAO_0000357,
1518,10576,,,9,,D,Membranes,,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,1,,2759,CHEMBL616152,,BAO_0000249,
1519,10576,,,8,,H,,,,Autocuration,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,1,,2759,CHEMBL616153,,BAO_0000249,
1520,10576,,,8,,H,,,,Expert,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,1,,14748,CHEMBL616154,,BAO_0000019,
1521,10576,,,8,,H,,,,Autocuration,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,1,,12304,CHEMBL616155,,BAO_0000019,
1522,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,1,,12409,CHEMBL616156,,BAO_0000221,10000000.0
1523,10576,,,9,,D,,Hippocampus,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,1,,12409,CHEMBL616157,,BAO_0000221,10000000.0
1524,10576,,,8,,H,,Hippocampus,,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,1,,13267,CHEMBL616158,,BAO_0000221,10000000.0
1525,10576,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,1,,15194,CHEMBL616159,,BAO_0000357,
1526,10576,,,8,,H,,,,Expert,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,1,,14256,CHEMBL616160,,BAO_0000357,
1527,10576,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,1,,16567,CHEMBL616161,,BAO_0000019,
1528,10576,,,8,,H,,,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,1,,15740,CHEMBL616162,,BAO_0000019,
1529,12687,,,9,,D,,,,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,1,,13278,CHEMBL616163,,BAO_0000357,
1530,10626,,,8,,H,Membranes,,,Expert,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,1,,1970,CHEMBL616164,,BAO_0000249,
1531,10576,,,8,,H,,Brain,,Autocuration,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,1,,10034,CHEMBL616165,,BAO_0000221,955.0
1532,51,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,1,,13348,CHEMBL616355,,BAO_0000019,
1533,10576,,,8,,H,,,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,1,,13630,CHEMBL616356,,BAO_0000019,
1534,10576,,,8,,H,,Brain,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,1,,10862,CHEMBL616357,,BAO_0000221,955.0
1535,10576,,,8,,H,,,,Autocuration,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,1,,12058,CHEMBL616358,,BAO_0000019,
1536,51,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,4639,CHEMBL616359,,BAO_0000357,
1537,51,,,8,,H,,,,Expert,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,1,,15453,CHEMBL616360,,BAO_0000357,
1538,51,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,4820,CHEMBL616361,,BAO_0000357,
1539,51,,,8,,H,,,,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,1,,1089,CHEMBL616362,,BAO_0000357,
1540,51,,,8,,H,Brain membranes,,,Autocuration,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,1,,386,CHEMBL616363,,BAO_0000249,
1541,51,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,1,,6011,CHEMBL616364,,BAO_0000357,
1542,51,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,1,,5014,CHEMBL616365,,BAO_0000357,
1543,51,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,1,,4402,CHEMBL616366,,BAO_0000357,
1544,51,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,1,,17066,CHEMBL872906,,BAO_0000357,
1545,51,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,1,,17515,CHEMBL616367,,BAO_0000357,
1546,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,2474,CHEMBL616368,,BAO_0000357,
1547,51,,,8,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,1,,4775,CHEMBL616369,,BAO_0000357,
1548,51,,,9,,D,,,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,1,,14294,CHEMBL616370,,BAO_0000357,
1549,51,,,9,,D,,,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,1,,14294,CHEMBL616371,,BAO_0000357,
1550,51,,,8,,H,,,CHO,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,1,,12249,CHEMBL616372,449.0,BAO_0000219,
1551,51,,,8,,H,,,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,1,,11376,CHEMBL616373,,BAO_0000219,
1552,51,,In vivo,8,,H,,,,Autocuration,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,1,,2474,CHEMBL616374,,BAO_0000218,
1553,51,,,8,,H,,Hippocampus,,Autocuration,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,1,,13311,CHEMBL616375,,BAO_0000221,10000000.0
1554,51,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,1,,4373,CHEMBL616376,,BAO_0000357,
1555,51,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,1,,1633,CHEMBL857064,,BAO_0000357,
1556,51,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,1,,11866,CHEMBL616377,,BAO_0000357,
1557,51,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,1,,4373,CHEMBL616378,,BAO_0000357,
1558,51,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,1,,4687,CHEMBL616379,,BAO_0000357,
1559,11863,,,8,,H,,,,Autocuration,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,1,,16946,CHEMBL616380,,BAO_0000357,
1560,11863,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,1,,13291,CHEMBL616381,,BAO_0000357,
1561,11863,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,1,,14159,CHEMBL616382,,BAO_0000357,
1562,11863,,,8,,H,,,,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,1,,10812,CHEMBL616383,,BAO_0000357,
1563,11863,,,9,,D,,,CHO,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,1,,3032,CHEMBL616350,449.0,BAO_0000219,
1564,11863,,,8,,H,,,,Autocuration,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,1,,16655,CHEMBL616351,,BAO_0000357,
1565,11863,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,1,,14532,CHEMBL616352,,BAO_0000357,
1566,11863,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,13944,CHEMBL616353,,BAO_0000357,
1567,11863,,,8,,H,,,,Autocuration,Binding affinity against serotonergic 5-HT1a receptor,B,1,,13033,CHEMBL616354,,BAO_0000357,
1568,11863,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,1,,10321,CHEMBL616508,,BAO_0000357,
1569,11863,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,B,1,,2968,CHEMBL616559,,BAO_0000357,
1570,11863,,,8,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor,B,1,,13964,CHEMBL616560,,BAO_0000357,
1571,11863,,,8,,H,,,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,1,,15527,CHEMBL616561,,BAO_0000357,
1572,11863,,,8,,H,,,CHO,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,1,,12248,CHEMBL616562,449.0,BAO_0000219,
1573,11863,,,8,,H,,,CHO,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,1,,12249,CHEMBL616563,449.0,BAO_0000219,
1574,11863,,,8,,H,,,,Autocuration,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,1,,15120,CHEMBL616564,,BAO_0000357,
1575,11863,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,1,,13313,CHEMBL616565,,BAO_0000357,
1576,11863,,,8,,H,,,,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,1,,2613,CHEMBL616566,,BAO_0000218,
1577,11863,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,1,,16700,CHEMBL616989,,BAO_0000357,
1578,11863,,,8,,H,,,,Autocuration,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,1,,2201,CHEMBL857975,,BAO_0000357,
1579,11863,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,1274,CHEMBL616990,,BAO_0000357,
1580,11863,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,1,,1317,CHEMBL616991,,BAO_0000357,
1581,11863,,,8,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 1A receptor,B,1,,12146,CHEMBL616992,,BAO_0000357,
1582,11863,,,8,,H,,,,Autocuration,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,14059,CHEMBL616993,,BAO_0000357,
1583,106,,,8,,H,,,,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,1,,14025,CHEMBL616994,,BAO_0000019,
1584,106,,,8,,H,,,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,1,,14025,CHEMBL616995,,BAO_0000019,
1585,105571,,,9,,D,,,HEK293,Intermediate,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,1,,14447,CHEMBL616996,722.0,BAO_0000219,
1586,106,,In vivo,8,,H,,,,Autocuration,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,1,,3025,CHEMBL616997,,BAO_0000218,
1587,106,,In vivo,8,,H,,,,Autocuration,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,1,,3025,CHEMBL616998,,BAO_0000218,
1588,106,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,1,,15329,CHEMBL616999,,BAO_0000019,
1589,106,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,1,,15329,CHEMBL617000,,BAO_0000019,
1590,106,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,1,,15847,CHEMBL617001,,BAO_0000019,
1591,106,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,1,,15847,CHEMBL858111,,BAO_0000019,
1592,106,,,8,,H,,,,Autocuration,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,1,,14165,CHEMBL617002,,BAO_0000019,
1593,106,,,8,,H,,,,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,1,,14214,CHEMBL617003,,BAO_0000019,
1594,106,,,8,,H,,,,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,1,,14214,CHEMBL617004,,BAO_0000019,
1595,106,,,9,,D,,,,Expert,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,1,,14214,CHEMBL617005,,BAO_0000019,
1596,106,,,9,,D,,,CHO-K1,Expert,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,1,,13729,CHEMBL616623,485.0,BAO_0000219,
1597,106,,,8,,H,,,CHO,Autocuration,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,1,,3025,CHEMBL616624,449.0,BAO_0000219,
1598,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,1,,2391,CHEMBL883243,,BAO_0000357,
1599,106,,,8,,H,,,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,1,,2391,CHEMBL616625,,BAO_0000019,
1600,106,,,8,,H,,,CHO,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,1,,14956,CHEMBL616626,449.0,BAO_0000219,
1601,106,,,8,,H,,,CHO,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,1,,2598,CHEMBL616627,449.0,BAO_0000219,
1602,106,,,8,,H,,,CHO,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,1,,2598,CHEMBL616628,449.0,BAO_0000219,
1603,106,,,8,,H,,,CHO,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,1,,2598,CHEMBL616629,449.0,BAO_0000219,
1604,106,,,8,,H,,,CHO,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,1,,2598,CHEMBL616630,449.0,BAO_0000219,
1605,106,,,8,,H,,,,Expert,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,1,,14956,CHEMBL616631,,BAO_0000019,
1606,106,,,8,,H,,,,Autocuration,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,1,,14956,CHEMBL616632,,BAO_0000019,
1607,106,,,9,,D,,,,Expert,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,1,,14214,CHEMBL616633,,BAO_0000357,
1608,106,,,8,,H,,,CHO,Expert,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,1,,3463,CHEMBL616634,449.0,BAO_0000219,
1609,106,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL616635,,BAO_0000357,
1610,106,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor,B,1,,16146,CHEMBL885358,,BAO_0000357,
1611,106,,,9,,D,,,CHO,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,1,,14159,CHEMBL616636,449.0,BAO_0000219,
1612,106,,,8,,H,,,CHO,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,1,,14158,CHEMBL616637,449.0,BAO_0000219,
1613,106,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,1,,14159,CHEMBL616638,,BAO_0000357,
1614,106,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,1,,15250,CHEMBL616639,449.0,BAO_0000219,
1615,106,,,8,,H,,,CHO,Expert,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,1,,15250,CHEMBL616640,449.0,BAO_0000219,
1616,106,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,1,,15331,CHEMBL616641,449.0,BAO_0000219,
1617,106,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,1,,15332,CHEMBL616642,449.0,BAO_0000219,
1618,106,,,8,,H,,,CHO,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,1,,14956,CHEMBL616643,449.0,BAO_0000219,
1619,106,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL616644,,BAO_0000357,
1620,106,,,8,,H,,,,Autocuration,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,1,,14875,CHEMBL616645,,BAO_0000357,
1621,105,,,8,,H,,,,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,1,,14454,CHEMBL616646,,BAO_0000019,
1622,105,,,8,,H,,,,Expert,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,1,,14454,CHEMBL616647,,BAO_0000019,
1623,105,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,1,,16288,CHEMBL616509,,BAO_0000357,
1624,105,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,1,,16288,CHEMBL616510,,BAO_0000357,
1625,105,,,8,,H,,,,Autocuration,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,1,,16312,CHEMBL616511,,BAO_0000357,
1626,105,,,8,,H,,,,Expert,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,1,,1348,CHEMBL616512,,BAO_0000357,
1627,105,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,1,,5834,CHEMBL616513,,BAO_0000357,
1628,105,,,8,,H,,Striatum,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,1,,13366,CHEMBL616514,,BAO_0000019,2435.0
1629,105,,,8,,H,,,,Expert,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,1,,1414,CHEMBL616515,,BAO_0000357,
1630,105,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,1,,14998,CHEMBL616516,,BAO_0000019,
1631,105,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,1,,11473,CHEMBL616517,,BAO_0000357,
1632,105,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,1,,11473,CHEMBL616518,,BAO_0000357,
1633,105,,,8,,H,,,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,1,,10639,CHEMBL616519,,BAO_0000357,
1634,105,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,1,,10639,CHEMBL616520,,BAO_0000357,
1635,105,,,8,,H,,,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,1,,1375,CHEMBL616521,,BAO_0000357,
1636,105,,,8,,H,,,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,1,,1375,CHEMBL616522,,BAO_0000357,
1637,105,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,1,,16532,CHEMBL884531,,BAO_0000357,
1638,105,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,1,,11147,CHEMBL616523,,BAO_0000357,
1639,105,,,8,,H,,Striatum,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,1,,13366,CHEMBL616731,,BAO_0000019,2435.0
1640,105,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,1,,10444,CHEMBL616732,,BAO_0000019,
1641,105,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,1,,16532,CHEMBL616733,,BAO_0000357,
1642,105,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,1,,16532,CHEMBL616734,,BAO_0000357,
1643,105,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,1,,12827,CHEMBL616735,,BAO_0000249,
1644,105,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,1,,12827,CHEMBL616736,,BAO_0000249,
1645,105,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,1,,12919,CHEMBL616737,,BAO_0000019,
1646,105,,,8,,H,,,,Autocuration,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,1,,14025,CHEMBL616738,,BAO_0000019,
1647,105,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,1,,12919,CHEMBL616739,,BAO_0000019,
1648,105,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,1,,12919,CHEMBL616740,,BAO_0000019,
1649,105,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,1,,12919,CHEMBL616741,,BAO_0000019,
1650,105,,,8,,H,,,HEK293,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,1,,14447,CHEMBL616742,722.0,BAO_0000219,
1651,105570,,,9,,D,,,,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,1,,1375,CHEMBL616743,,BAO_0000019,
1652,105570,,,9,,D,,,,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,1,,1375,CHEMBL616744,,BAO_0000019,
1653,105570,,,9,,D,,,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,1,,12409,CHEMBL616745,,BAO_0000019,
1654,105570,,,9,,D,,,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,1,,12409,CHEMBL616746,,BAO_0000019,
1655,105570,,,9,,D,,,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,1,,12409,CHEMBL616747,,BAO_0000019,
1656,105570,,,9,,D,,,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,1,,12409,CHEMBL616748,,BAO_0000019,
1657,105570,,,9,,D,,,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,1,,12409,CHEMBL616648,,BAO_0000019,
1658,105570,,,9,,D,,,,Intermediate,Binding affinity against 5-hydroxytryptamine 1D receptor,B,1,,11574,CHEMBL616649,,BAO_0000357,
1659,105570,,,9,,D,,,,Intermediate,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,1,,1558,CHEMBL616650,,BAO_0000357,
1660,105570,,,9,,D,,,,Intermediate,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,1,,12409,CHEMBL616651,,BAO_0000218,
1661,105570,,,9,,D,,,,Intermediate,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,1,,12409,CHEMBL616652,,BAO_0000218,
1662,105570,,,9,,D,,,,Intermediate,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,1,,12409,CHEMBL616653,,BAO_0000218,
1663,105570,,,9,,D,,,,Intermediate,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,1,,12409,CHEMBL616654,,BAO_0000218,
1664,105570,,,9,,D,,,,Intermediate,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,1,,12253,CHEMBL616655,,BAO_0000019,
1665,105570,,,9,,D,,,,Intermediate,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,1,,12936,CHEMBL616656,,BAO_0000357,
1666,105,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,1,,13181,CHEMBL616657,,BAO_0000019,
1667,105570,,,9,,D,,Striatum,,Intermediate,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,1,,12409,CHEMBL616658,,BAO_0000357,2435.0
1668,105570,,,9,,D,,,,Intermediate,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,1,,10639,CHEMBL616659,,BAO_0000357,
1669,51,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,B,1,,5254,CHEMBL616660,,BAO_0000357,
1670,106,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,1,,13051,CHEMBL616661,,BAO_0000357,
1671,105,,,8,,H,,,,Expert,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,1,,3463,CHEMBL616662,,BAO_0000019,
1672,105,,,8,,H,,,,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,1,,15315,CHEMBL616663,,BAO_0000019,
1673,105,,,8,,H,,,,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,1,,6011,CHEMBL616664,,BAO_0000019,
1674,105,,,9,,D,,,CHO,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,1,,14159,CHEMBL881820,449.0,BAO_0000219,
1675,105,,,8,,H,,,CHO,Autocuration,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,1,,14159,CHEMBL616665,449.0,BAO_0000219,
1676,105,,,8,,H,,,CHO,Expert,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,1,,15250,CHEMBL616666,449.0,BAO_0000219,
1677,105,,,8,,H,,,CHO,Autocuration,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,1,,15250,CHEMBL616667,449.0,BAO_0000219,
1678,105,,,8,,H,,,CHO,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,1,,15331,CHEMBL616668,449.0,BAO_0000219,
1679,105,,,9,,D,,,CHO,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,1,,15332,CHEMBL616669,449.0,BAO_0000219,
1680,105,,,8,,H,,,CHO,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,1,,15332,CHEMBL617040,449.0,BAO_0000219,
1681,105,,,8,,H,,,CHO,Autocuration,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,1,,3294,CHEMBL617041,449.0,BAO_0000219,
1682,105,,,8,,H,,,CHO,Expert,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,1,,14158,CHEMBL617042,449.0,BAO_0000219,
1683,105,,,8,,H,,,CHO,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,1,,14956,CHEMBL617043,449.0,BAO_0000219,
1684,105,,,8,,H,,,,Autocuration,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,1,,12469,CHEMBL617044,,BAO_0000019,
1685,105,,,8,,H,,,CHO,Expert,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,1,,3463,CHEMBL617045,449.0,BAO_0000219,
1686,105,,,9,,D,,,CHO,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,1,,15250,CHEMBL617046,449.0,BAO_0000219,
1687,105,,,9,,D,,,CHO,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,1,,15250,CHEMBL617047,449.0,BAO_0000219,
1688,105,,,8,,H,,,,Expert,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,1,,14956,CHEMBL617048,,BAO_0000019,
1689,105,,,8,,H,,,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,1,,14159,CHEMBL616897,,BAO_0000019,
1690,105,,,9,,D,,,,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,1,,14159,CHEMBL616898,,BAO_0000019,
1691,105,,,9,,D,,,CHO,Expert,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,1,,14499,CHEMBL858201,449.0,BAO_0000219,
1692,105,,,8,,H,,,,Autocuration,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,1,,15315,CHEMBL616899,,BAO_0000019,
1693,105,,In vitro,8,,H,,,,Autocuration,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,1,,3294,CHEMBL616900,,BAO_0000219,
1694,105,,,8,,H,,,CHO,Expert,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,1,,3463,CHEMBL616901,449.0,BAO_0000219,
1695,105,,,8,,H,,,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL616902,,BAO_0000357,
1696,105,,,9,,D,,,CHO,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,1,,14159,CHEMBL616903,449.0,BAO_0000219,
1697,105,,,8,,H,,,CHO,Expert,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,1,,14158,CHEMBL616904,449.0,BAO_0000219,
1698,105,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,1,,14159,CHEMBL616905,,BAO_0000357,
1699,105,,,8,,H,,,CHO,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,1,,15250,CHEMBL616906,449.0,BAO_0000219,
1700,105,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,1,,15250,CHEMBL616907,449.0,BAO_0000219,
1701,105,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,1,,15331,CHEMBL616908,449.0,BAO_0000219,
1702,105,,,9,,D,,,CHO,Expert,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,1,,15332,CHEMBL616909,449.0,BAO_0000219,
1703,105,,,9,,D,,,CHO,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,1,,14499,CHEMBL616910,449.0,BAO_0000219,
1704,105,,,8,,H,,,CHO,Expert,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,1,,15332,CHEMBL616911,449.0,BAO_0000219,
1705,105,,,8,,H,,,CHO,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,1,,14956,CHEMBL616912,449.0,BAO_0000219,
1706,105,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL616913,,BAO_0000357,
1707,105,,,9,,D,,,CHO,Expert,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,1,,6011,CHEMBL616914,449.0,BAO_0000219,
1708,105,,,8,,H,,,CHO,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,1,,16190,CHEMBL616915,449.0,BAO_0000219,
1709,105,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,1,,14165,CHEMBL616916,,BAO_0000019,
1710,105,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,1,,4234,CHEMBL616917,,BAO_0000357,
1711,105,,,8,,H,,,,Autocuration,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,1,,15527,CHEMBL616918,,BAO_0000357,
1712,105,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,1,,6328,CHEMBL616919,,BAO_0000219,
1713,105,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,1,,16209,CHEMBL616920,,BAO_0000357,
1714,105,,,8,,H,,,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,1,,14770,CHEMBL872914,,BAO_0000357,
1715,105,,,8,,H,,,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,1,,2598,CHEMBL616921,,BAO_0000357,
1716,105,,,8,,H,,,,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,1,,6897,CHEMBL616922,,BAO_0000357,
1717,105,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,1,,6013,CHEMBL616923,,BAO_0000357,
1718,105,,,8,,H,,,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,1,,5843,CHEMBL616924,,BAO_0000357,
1719,105,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,1,,14454,CHEMBL875909,,BAO_0000357,
1720,105,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,1,,14454,CHEMBL616925,,BAO_0000357,
1721,105,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,1,,14454,CHEMBL616926,,BAO_0000357,
1722,105,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,1,,15818,CHEMBL616927,,BAO_0000357,
1723,105,,,8,,H,,,CHO-K1,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,1,,13729,CHEMBL616928,485.0,BAO_0000219,
1724,105,,In vitro,9,,D,,,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,1,,6011,CHEMBL616929,,BAO_0000219,
1725,105,,,9,,D,,,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,1,,4234,CHEMBL616930,,BAO_0000357,
1726,105,,,8,,H,,,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,1,,17085,CHEMBL616931,,BAO_0000019,
1727,105,,,8,,H,,,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,1,,3025,CHEMBL616932,,BAO_0000357,
1728,105,,,8,,H,,,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,1,,15315,CHEMBL616933,,BAO_0000357,
1729,105,,,9,,D,,,,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,1,,14214,CHEMBL616934,,BAO_0000219,
1730,105,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,1,,3804,CHEMBL616935,,BAO_0000357,
1731,105,,,8,,H,,,,Autocuration,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,1,,16700,CHEMBL616936,,BAO_0000357,
1732,105,,,9,,D,,,,Expert,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,1,,2391,CHEMBL616937,,BAO_0000357,
1733,105,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,1,,4175,CHEMBL616938,,BAO_0000357,
1734,105,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,1,,17085,CHEMBL616939,,BAO_0000019,
1735,105,,,8,,H,,,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,1,,17085,CHEMBL616940,,BAO_0000019,
1736,105,,,9,,D,,,,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,1,,15926,CHEMBL616941,,BAO_0000357,
1737,105,,,8,,H,,,CHO-K1,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,1,,16312,CHEMBL616942,485.0,BAO_0000219,
1738,105,,,8,,H,,,CHO-K1,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,1,,16312,CHEMBL616943,485.0,BAO_0000219,
1739,104802,,,4,,H,,,CHO,Autocuration,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,1,,14956,CHEMBL616944,449.0,BAO_0000219,
1740,105,,,8,,H,,,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,1,,3294,CHEMBL616945,,BAO_0000019,
1741,105,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL616946,,BAO_0000357,
1742,105,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,1,,12861,CHEMBL616947,,BAO_0000019,
1743,105,,,8,,H,,,CHO-K1,Expert,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,1,,16312,CHEMBL616948,485.0,BAO_0000219,
1744,105,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,1,,5104,CHEMBL616851,,BAO_0000357,
1745,105,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,1,,5105,CHEMBL616852,,BAO_0000357,
1746,105,,,8,,H,,,,Autocuration,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,1,,14499,CHEMBL616853,,BAO_0000357,
1747,105,,,9,,D,,,,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor,B,1,,15926,CHEMBL616854,,BAO_0000357,
1748,105,,,9,,D,,,CHO,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,1,,4540,CHEMBL616855,449.0,BAO_0000219,
1749,105,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,1,,15779,CHEMBL616856,449.0,BAO_0000219,
1750,105,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL616857,449.0,BAO_0000219,
1751,105,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,1,,6166,CHEMBL616858,,BAO_0000357,
1752,105,,,8,,H,,,CHO,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL616859,449.0,BAO_0000219,
1753,105,,,8,,H,,,CHO,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,1,,15779,CHEMBL616860,449.0,BAO_0000219,
1754,105,,,8,,H,,,HEK293,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,1,,17451,CHEMBL616861,722.0,BAO_0000219,
1755,105,,,8,,H,,,HEK293,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,1,,17451,CHEMBL616541,722.0,BAO_0000219,
1756,105,,,8,,H,,,HEK293,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,1,,17451,CHEMBL616542,722.0,BAO_0000219,
1757,105,,,8,,H,,,CHO,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,1,,4199,CHEMBL616543,449.0,BAO_0000219,
1758,105,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,1,,14875,CHEMBL616544,,BAO_0000357,
1759,105,,,8,,H,,,CHO,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,1,,15146,CHEMBL616545,449.0,BAO_0000219,
1760,105,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,1,,5213,CHEMBL616546,,BAO_0000357,
1761,105,,,8,,H,,,CHO,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,1,,14818,CHEMBL616547,449.0,BAO_0000219,
1762,105,,,8,,H,,,CHO,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL616548,449.0,BAO_0000219,
1763,105,,,8,,H,,,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,1,,14454,CHEMBL616549,,BAO_0000019,
1764,105,,,8,,H,,,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,1,,14454,CHEMBL616550,,BAO_0000019,
1765,108,,,8,,H,,,,Autocuration,Binding affinity against 5-HT2C receptor,B,1,,5254,CHEMBL857066,,BAO_0000357,
1766,108,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,B,1,,5254,CHEMBL616551,,BAO_0000357,
1767,10577,,,8,,H,,,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,1,,10639,CHEMBL616552,,BAO_0000357,
1768,10577,,,8,,H,,,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,1,,10639,CHEMBL832876,,BAO_0000019,
1769,10577,,,8,,H,,,,Expert,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,1,,12352,CHEMBL616553,,BAO_0000019,
1770,10577,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT1B was determined,B,1,,9098,CHEMBL616554,,BAO_0000357,
1771,10577,,,8,,H,,,,Expert,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,1,,14430,CHEMBL616555,,BAO_0000019,
1772,10577,,,8,,H,,,,Expert,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,1,,13657,CHEMBL616556,,BAO_0000019,
1773,10577,,,8,,H,,,,Autocuration,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,1,,13657,CHEMBL616557,,BAO_0000019,
1774,10577,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,1,,15854,CHEMBL616558,,BAO_0000019,
1775,10577,,,9,,D,,,,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,1,,10639,CHEMBL616749,,BAO_0000019,
1776,10577,,,8,,H,,,,Autocuration,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,1,,10025,CHEMBL616750,,BAO_0000357,
1777,10577,,,8,,H,,,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,1,,10025,CHEMBL616751,,BAO_0000357,
1778,10577,,,8,,H,,,,Autocuration,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,1,,14286,CHEMBL616752,,BAO_0000249,
1779,10577,,,8,,H,,Striatum,,Autocuration,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,1,,3651,CHEMBL616753,,BAO_0000019,2435.0
1780,10577,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,1,,14178,CHEMBL616754,,BAO_0000357,
1781,10577,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,1,,10639,CHEMBL616755,,BAO_0000019,
1782,10577,,,8,,H,,Striatum,,Autocuration,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,1,,13605,CHEMBL616756,,BAO_0000019,2435.0
1783,10577,,,8,,H,,Striatum,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,1,,5834,CHEMBL616757,,BAO_0000019,2435.0
1784,10577,,,8,,H,,Striatum,,Autocuration,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,1,,10922,CHEMBL616758,,BAO_0000357,2435.0
1785,10577,,,8,,H,,,,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,1,,14286,CHEMBL616759,,BAO_0000249,
1786,10577,,,8,,H,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,1,,11825,CHEMBL616760,,BAO_0000357,
1787,10577,,,8,,H,,Striatum,,Autocuration,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,1,,14826,CHEMBL616761,,BAO_0000019,2435.0
1788,10577,,,8,,H,,Striatum,,Autocuration,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,1,,9699,CHEMBL616762,,BAO_0000019,2435.0
1789,10577,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,1,,14423,CHEMBL616763,,BAO_0000019,
1790,10577,,,8,,H,,,,Expert,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,1,,10062,CHEMBL872909,,BAO_0000357,
1791,10577,,,8,,H,,,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,1,,10062,CHEMBL616764,,BAO_0000357,
1792,10577,,,9,,D,,,,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,1,,12280,CHEMBL616765,,BAO_0000357,
1793,10577,,,8,,H,,Striatum,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,1,,15412,CHEMBL616766,,BAO_0000357,2435.0
1794,10577,,,8,,H,,Striatum,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,1,,15412,CHEMBL616767,,BAO_0000357,2435.0
1795,10577,,,8,,H,,,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,1,,10062,CHEMBL616768,,BAO_0000357,
1796,10577,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,1,,11147,CHEMBL616769,,BAO_0000357,
1797,10577,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,1,,9547,CHEMBL616770,,BAO_0000019,
1798,10577,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,1,,10444,CHEMBL616771,,BAO_0000019,
1799,10577,,,8,,H,,Striatum,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,1,,12469,CHEMBL616772,,BAO_0000019,2435.0
1800,10577,,,8,,H,,,,Expert,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,1,,9098,CHEMBL616773,,BAO_0000019,
1801,10577,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,1,,9098,CHEMBL616774,,BAO_0000019,
1802,10577,,,8,,H,,,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,1,,9699,CHEMBL616775,,BAO_0000357,
1803,10577,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,1,,10394,CHEMBL616776,,BAO_0000249,
1804,10577,,,8,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,1,,12092,CHEMBL616777,,BAO_0000357,
1805,10577,,,8,,H,,,,Autocuration,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,1,,16700,CHEMBL616778,,BAO_0000357,
1806,10577,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,1,,403,CHEMBL616779,,BAO_0000249,
1807,10577,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,1,,12771,CHEMBL616780,,BAO_0000357,
1808,10577,,,8,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,1,,11642,CHEMBL616781,,BAO_0000019,
1809,10577,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,1,,12953,CHEMBL616782,,BAO_0000357,
1810,10577,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,1,,12953,CHEMBL616783,,BAO_0000357,
1811,10577,,,8,,H,,Striatum,,Expert,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,1,,12953,CHEMBL616784,,BAO_0000019,2435.0
1812,10577,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL616785,,BAO_0000357,
1813,10577,,,8,,H,,Brain,,Autocuration,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,1,,9737,CHEMBL857067,,BAO_0000249,955.0
1814,10577,,,8,,H,,,,Autocuration,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,1,,9737,CHEMBL616786,,BAO_0000019,
1815,10577,,,8,,H,,Brain,,Autocuration,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,1,,9737,CHEMBL616787,,BAO_0000249,955.0
1816,10577,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,1,,12827,CHEMBL616788,,BAO_0000357,
1817,10577,,,8,,H,,,,Autocuration,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,1,,5033,CHEMBL616789,,BAO_0000357,
1818,10577,,,9,,D,,,,Expert,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,1,,9786,CHEMBL616790,,BAO_0000019,
1819,10577,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 1B receptor,B,1,,13116,CHEMBL616791,,BAO_0000357,
1820,10577,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,1,,16429,CHEMBL616792,,BAO_0000019,
1821,10577,,,9,,D,,,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,1,,12409,CHEMBL616793,,BAO_0000249,
1822,10577,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,1,,15194,CHEMBL616794,,BAO_0000357,
1823,10577,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,1,,15194,CHEMBL616795,,BAO_0000357,
1824,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,1,,5486,CHEMBL616796,,BAO_0000019,
1825,106,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,1,,4639,CHEMBL616797,,BAO_0000357,
1826,106,,,8,,H,Brain membranes,,,Autocuration,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,1,,386,CHEMBL616798,,BAO_0000249,
1827,106,,,8,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,1,,2474,CHEMBL616799,,BAO_0000357,
1828,106,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,1,,6011,CHEMBL616800,,BAO_0000357,
1829,106,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,1,,5014,CHEMBL616801,,BAO_0000357,
1830,106,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,1,,17515,CHEMBL616802,,BAO_0000357,
1831,106,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,1,,4373,CHEMBL616803,,BAO_0000357,
1832,106,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,1,,1633,CHEMBL857068,,BAO_0000357,
1833,106,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,1,,1633,CHEMBL616804,,BAO_0000357,
1834,106,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,1,,4373,CHEMBL616805,,BAO_0000357,
1835,106,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,1,,4687,CHEMBL616806,,BAO_0000357,
1836,106,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor,B,1,,11574,CHEMBL616807,,BAO_0000357,
1837,106,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,1,,10321,CHEMBL616808,,BAO_0000357,
1838,106,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,1,,15527,CHEMBL616809,,BAO_0000357,
1839,106,,,8,,H,,,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,1,,17200,CHEMBL616810,,BAO_0000357,
1840,104802,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,1,,14423,CHEMBL616811,,BAO_0000224,
1841,108,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,1,,5834,CHEMBL616812,,BAO_0000357,
1842,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,1,,11473,CHEMBL616813,,BAO_0000357,
1843,108,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,1,,11473,CHEMBL616814,,BAO_0000357,
1844,108,,,8,,H,,,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,1,,10639,CHEMBL616815,,BAO_0000357,
1845,108,,,8,,H,,,,Autocuration,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,1,,10639,CHEMBL616816,,BAO_0000357,
1846,108,,,8,,H,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,1,,14331,CHEMBL616817,,BAO_0000357,
1847,108,,,8,,H,,,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,1,,10796,CHEMBL616818,,BAO_0000357,
1848,108,,,8,,H,,,,Expert,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,1,,9098,CHEMBL616819,,BAO_0000357,
1849,108,,,8,,H,,,,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,1,,14331,CHEMBL616820,,BAO_0000357,
1850,108,,,8,,H,,,,Expert,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,1,,11828,CHEMBL616821,,BAO_0000019,
1851,108,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,1,,11866,CHEMBL616822,,BAO_0000357,
1852,108,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,1,,13047,CHEMBL616823,,BAO_0000019,
1853,12689,,,9,,D,,,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,1,,188,CHEMBL616824,,BAO_0000357,
1854,12689,,,9,,D,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,1,,11825,CHEMBL616825,,BAO_0000357,
1855,12689,,,9,,D,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,1,,11825,CHEMBL616826,,BAO_0000357,
1856,12689,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,1,,11624,CHEMBL616827,,BAO_0000019,
1857,12689,,,9,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,1,,11139,CHEMBL616828,,BAO_0000357,
1858,12689,,,9,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,1,,11147,CHEMBL616829,,BAO_0000357,
1859,12689,,,9,,D,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,1,,10444,CHEMBL616830,,BAO_0000019,
1860,12689,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor,B,1,,11624,CHEMBL616831,,BAO_0000357,
1861,12689,,,9,,D,,,,Autocuration,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,1,,11662,CHEMBL616832,,BAO_0000019,
1862,12689,,,9,,D,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,1,,11662,CHEMBL616833,,BAO_0000019,
1863,12689,,,9,,D,,,,Expert,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,1,,11662,CHEMBL616834,,BAO_0000019,
1864,12689,,,9,,D,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,1,,11662,CHEMBL829595,,BAO_0000019,
1865,12689,,,9,,D,,,,Autocuration,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,1,,9098,CHEMBL616835,,BAO_0000357,
1866,12689,,,9,,D,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,1,,10394,CHEMBL872910,,BAO_0000249,
1867,12689,,,8,,H,,,,Expert,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,1,,11933,CHEMBL616836,,BAO_0000357,
1868,12689,,,9,,D,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,1,,12092,CHEMBL616837,,BAO_0000357,
1869,12689,,,9,,D,,,,Autocuration,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,1,,12253,CHEMBL616466,,BAO_0000019,
1870,12689,,,9,,D,,,HEK293,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,1,,12253,CHEMBL616467,722.0,BAO_0000219,
1871,108,,,8,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,1,,1558,CHEMBL616468,,BAO_0000357,
1872,108,,,8,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,1,,2474,CHEMBL616469,,BAO_0000357,
1873,108,,,8,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,1,,2474,CHEMBL616470,,BAO_0000357,
1874,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,B,1,,11574,CHEMBL616471,,BAO_0000357,
1875,12689,,,8,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,1,,1558,CHEMBL616472,,BAO_0000357,
1876,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,B,1,,13944,CHEMBL616473,,BAO_0000357,
1877,12689,,,8,,H,,,,Autocuration,Binding affinity against serotonergic 5-HT1c receptor,B,1,,13033,CHEMBL616474,,BAO_0000357,
1878,12689,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,1,,10321,CHEMBL616475,,BAO_0000357,
1879,12689,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,1,,11866,CHEMBL616476,,BAO_0000357,
1880,105,,,8,,H,,,,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,1,,14454,CHEMBL616477,,BAO_0000019,
1881,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,1,,11574,CHEMBL616478,,BAO_0000224,
1882,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,1,,11574,CHEMBL616479,,BAO_0000224,
1883,104686,,,4,,H,,,,Autocuration,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,1,,13631,CHEMBL616480,,BAO_0000019,
1884,104686,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,1,,9630,CHEMBL616481,,BAO_0000019,
1885,104686,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,1,,8822,CHEMBL616482,,BAO_0000249,
1886,104686,,,5,,D,,Brain,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,1,,9064,CHEMBL884713,,BAO_0000221,955.0
1887,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,1,,8868,CHEMBL616483,,BAO_0000224,
1888,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,1,,9064,CHEMBL616484,,BAO_0000224,
1889,104686,,,4,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,1,,9806,CHEMBL616485,,BAO_0000019,
1890,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,1,,9098,CHEMBL616486,,BAO_0000224,
1891,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,1,,8868,CHEMBL616487,,BAO_0000224,
1892,104686,,,4,,H,,,,Autocuration,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,1,,12765,CHEMBL616488,,BAO_0000224,
1893,104686,,,4,,H,,,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,1,,11049,CHEMBL616489,,BAO_0000019,
1894,104686,,,4,,H,,,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,1,,11049,CHEMBL616490,,BAO_0000019,
1895,104686,,,4,,H,,,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,1,,11049,CHEMBL616491,,BAO_0000019,
1896,104686,,,4,,H,,,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,1,,11049,CHEMBL616492,,BAO_0000019,
1897,104686,,,4,,H,,,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,1,,11049,CHEMBL616493,,BAO_0000019,
1898,104686,,,4,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,1,,11473,CHEMBL616494,,BAO_0000019,
1899,104686,,,4,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,1,,11473,CHEMBL616495,,BAO_0000019,
1900,104686,,,4,,H,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,1,,3086,CHEMBL616496,,BAO_0000019,
1901,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,1,,11049,CHEMBL616497,,BAO_0000019,
1902,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,1,,11049,CHEMBL616498,,BAO_0000019,
1903,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,1,,10639,CHEMBL616499,,BAO_0000019,
1904,104686,,,4,,H,,,,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,1,,10922,CHEMBL616500,,BAO_0000019,
1905,104686,,,5,,D,,Brain,,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,1,,9064,CHEMBL616501,,BAO_0000221,955.0
1906,104686,,,4,,H,,Brain,,Autocuration,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,1,,10748,CHEMBL616502,,BAO_0000221,955.0
1907,104686,,,4,,H,Membranes,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,1,,11614,CHEMBL884529,,BAO_0000249,
1908,104686,,,4,,H,Membranes,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,1,,11615,CHEMBL616503,,BAO_0000249,
1909,104686,,,4,,H,,,,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,1,,11615,CHEMBL616964,,BAO_0000224,
1910,104686,,,4,,H,Membranes,,,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,1,,11614,CHEMBL616965,,BAO_0000249,
1911,104686,,,4,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,1,,11702,CHEMBL616966,,BAO_0000224,
1912,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,1,,11702,CHEMBL616967,,BAO_0000224,
1913,104686,,,5,,D,,,,Autocuration,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,1,,11702,CHEMBL616968,,BAO_0000224,
1914,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,1,,11702,CHEMBL616969,,BAO_0000224,
1915,104686,,,4,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,1,,13346,CHEMBL884530,,BAO_0000019,
1916,104686,,,4,,H,,,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,1,,10025,CHEMBL616970,,BAO_0000224,
1917,104686,,,4,,H,,,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,1,,10025,CHEMBL616971,,BAO_0000224,
1918,104686,,,4,,H,,,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,1,,10025,CHEMBL616972,,BAO_0000224,
1919,104686,,,4,,H,,,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,1,,9036,CHEMBL616973,,BAO_0000224,
1920,104686,,,4,,H,,,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,1,,9036,CHEMBL616974,,BAO_0000224,
1921,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,1,,9161,CHEMBL616975,,BAO_0000019,
1922,104686,,,4,,H,,,,Autocuration,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,1,,12304,CHEMBL616976,,BAO_0000019,
1923,104686,,,4,,H,,,,Autocuration,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,1,,13276,CHEMBL616977,,BAO_0000224,
1924,104686,,,4,,H,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,1,,11825,CHEMBL616978,,BAO_0000224,
1925,104686,,,4,,H,,,,Autocuration,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,1,,12443,CHEMBL616979,,BAO_0000224,
1926,104686,,,4,,H,,,,Autocuration,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,1,,13830,CHEMBL616980,,BAO_0000224,
1927,104686,,,4,,H,Membranes,,,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,1,,9592,CHEMBL616981,,BAO_0000249,
1928,104686,,,4,,H,Membranes,,,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,1,,9592,CHEMBL616982,,BAO_0000249,
1929,104686,,,4,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,1,,10881,CHEMBL616983,,BAO_0000224,
1930,104686,,,4,,H,,,,Autocuration,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,1,,13605,CHEMBL616984,,BAO_0000019,
1931,104686,,,5,,D,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,1,,11624,CHEMBL616985,,BAO_0000224,
1932,104686,,,4,,H,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,1,,4101,CHEMBL616986,,BAO_0000224,
1933,104686,,,4,,H,,,,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,1,,4101,CHEMBL616987,,BAO_0000224,
1934,104686,,,4,,H,,,,Autocuration,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,1,,15360,CHEMBL616988,,BAO_0000019,
1935,104686,,,4,,H,,,,Autocuration,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,1,,11576,CHEMBL617243,,BAO_0000019,
1936,104686,,,4,,H,,,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,1,,5834,CHEMBL617244,,BAO_0000019,
1937,104686,,,5,,D,,,CHO-K1,Autocuration,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,1,,2395,CHEMBL617245,485.0,BAO_0000219,
1938,104686,,,4,,H,Membranes,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,1,,11965,CHEMBL617246,,BAO_0000249,
1939,104686,,,4,,H,,,,Autocuration,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,1,,3967,CHEMBL617546,,BAO_0000224,
1940,104686,,,4,,H,Brain membranes,,,Autocuration,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,1,,11130,CHEMBL617547,,BAO_0000249,
1941,104686,,In vitro,4,,H,,,,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,1,,13427,CHEMBL617548,,BAO_0000219,
1942,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,9443,CHEMBL617549,,BAO_0000224,
1943,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,1,,9443,CHEMBL617550,,BAO_0000224,
1944,104686,,,4,,H,,,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,1,,11825,CHEMBL617551,,BAO_0000224,
1945,104686,,,4,,H,Membranes,,,Autocuration,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,1,,12120,CHEMBL617552,,BAO_0000249,
1946,104686,,,4,,H,Membranes,,,Autocuration,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,1,,12120,CHEMBL617553,,BAO_0000249,
1947,104686,,,4,,H,,Thoracic aorta,,Autocuration,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,1,,11963,CHEMBL617554,,BAO_0000019,1515.0
1948,104686,,,4,,H,,,,Autocuration,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,1,,9069,CHEMBL617555,,BAO_0000019,
1949,104686,,,4,,H,,,,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,1,,8868,CHEMBL617556,,BAO_0000224,
1950,10624,,,8,,H,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,1,,17200,CHEMBL617557,,BAO_0000357,
1951,10624,,,8,,H,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,1,,17200,CHEMBL617558,,BAO_0000357,
1952,17106,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,1,,13969,CHEMBL617559,,BAO_0000357,
1953,17106,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 1D receptor,B,1,,13392,CHEMBL617560,,BAO_0000357,
1954,17106,,,8,,H,,,,Autocuration,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,1,,1742,CHEMBL617561,,BAO_0000249,
1955,17106,,,8,,H,,,,Autocuration,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,1,,1742,CHEMBL617562,,BAO_0000249,
1956,17106,,,8,,H,,Striatum,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,1,,14331,CHEMBL617563,,BAO_0000357,2435.0
1957,17106,,,8,,H,,,,Autocuration,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,1,,12861,CHEMBL617564,,BAO_0000019,
1958,17106,,,8,,H,,,,Expert,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,1,,12861,CHEMBL617565,,BAO_0000019,
1959,17106,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL856076,,BAO_0000357,
1960,17106,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617566,,BAO_0000019,
1961,17106,,,8,,H,,,,Expert,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,1,,12861,CHEMBL875911,,BAO_0000019,
1962,17106,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,1,,12861,CHEMBL617567,,BAO_0000019,
1963,17106,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,1,,675,CHEMBL617568,,BAO_0000249,
1964,17106,,,8,,H,,,,Expert,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,1,,12490,CHEMBL617569,,BAO_0000019,
1965,17106,,,8,,H,,,,Expert,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,1,,11828,CHEMBL617570,,BAO_0000249,
1966,17106,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,1,,11866,CHEMBL617571,,BAO_0000357,
1967,105,,,8,,H,,,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,1,,773,CHEMBL617572,,BAO_0000357,
1968,105,,,8,,H,,,,Expert,The compound was tested for intrinsic activity against 5-HT1D receptor,B,1,,13047,CHEMBL617573,,BAO_0000357,
1969,105,,,8,,H,,,,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL617574,,BAO_0000019,
1970,105,,,8,,H,,,,Expert,The compound was tested for binding affinity against 5-HT1D receptor,B,1,,13047,CHEMBL617575,,BAO_0000357,
1971,10578,,,8,,H,,,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,1,,188,CHEMBL617576,,BAO_0000357,
1972,10578,,,8,,H,,,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,1,,10639,CHEMBL617577,,BAO_0000019,
1973,10578,,,8,,H,,,,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,1,,12438,CHEMBL617578,,BAO_0000019,
1974,10578,,,8,,H,,,,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,1,,12438,CHEMBL617579,,BAO_0000357,
1975,10578,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,1,,15854,CHEMBL617580,,BAO_0000019,
1976,10578,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,1,,10394,CHEMBL617581,,BAO_0000249,
1977,10578,,,8,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,1,,12092,CHEMBL617582,,BAO_0000357,
1978,10578,,,8,,H,,,,Expert,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,1,,3389,CHEMBL617583,,BAO_0000019,
1979,105,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,1,,6011,CHEMBL617584,,BAO_0000357,
1980,105,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,1,,4639,CHEMBL617585,,BAO_0000357,
1981,105,,,8,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,1,,2474,CHEMBL875912,,BAO_0000357,
1982,105,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,1,,5014,CHEMBL617586,,BAO_0000357,
1983,105,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,1,,17515,CHEMBL617587,,BAO_0000357,
1984,105,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,1,,11866,CHEMBL617588,,BAO_0000357,
1985,105,,,8,,H,,,,Autocuration,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,1,,4687,CHEMBL857980,,BAO_0000357,
1986,105,,,8,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 1D receptor,B,1,,12146,CHEMBL617589,,BAO_0000357,
1987,105,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,1,,10321,CHEMBL617590,,BAO_0000357,
1988,105,,,8,,H,,,HEK293,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,1,,13267,CHEMBL617591,722.0,BAO_0000219,
1989,105,,,9,,D,,,,Expert,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,1,,1274,CHEMBL617592,,BAO_0000357,
1990,105,,,8,,H,,,,Autocuration,,B,1,,15250,CHEMBL617593,,BAO_0000357,
1991,106,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,1,,13706,CHEMBL617594,485.0,BAO_0000219,
1992,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,1,,13706,CHEMBL617595,485.0,BAO_0000219,
1993,105,,,8,,H,,,HEK293,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,1,,13706,CHEMBL617596,722.0,BAO_0000219,
1994,105,,,8,,H,,,HEK293,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,1,,13706,CHEMBL617597,722.0,BAO_0000219,
1995,105,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,1,,13047,CHEMBL617598,,BAO_0000019,
1996,105,,,8,,H,,,,Autocuration,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,1,,13366,CHEMBL872916,,BAO_0000357,
1997,105,,,8,,H,,,,Expert,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,1,,13366,CHEMBL617599,,BAO_0000357,
1998,105,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,1,,1558,CHEMBL617091,,BAO_0000357,
1999,105,,,8,,H,,,CHO-K1,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,1,,12902,CHEMBL617092,485.0,BAO_0000219,
2000,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,1,,13706,CHEMBL617093,485.0,BAO_0000219,
2001,105,,,8,,H,,,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,1,,13706,CHEMBL617094,,BAO_0000019,
2002,105,,,8,,H,,,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,1,,13706,CHEMBL617095,,BAO_0000019,
2003,105,,,8,,H,,,,Autocuration,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,1,,14251,CHEMBL617096,,BAO_0000019,
2004,105,,,8,,H,,,,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,1,,14251,CHEMBL617097,,BAO_0000019,
2005,105,,,8,,H,,,,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,1,,14251,CHEMBL617098,,BAO_0000019,
2006,105,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,1,,13313,CHEMBL617301,,BAO_0000357,
2007,105,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,1,,13313,CHEMBL617302,,BAO_0000357,
2008,105,,,8,,H,,,,Autocuration,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,1,,13366,CHEMBL617303,,BAO_0000357,
2009,105,,,8,,H,,,,Expert,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,1,,13051,CHEMBL617304,,BAO_0000357,
2010,105,,,8,,H,,,CHO,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,1,,12903,CHEMBL617305,449.0,BAO_0000219,
2011,105,,,9,,D,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,1,,12469,CHEMBL617306,,BAO_0000219,
2012,17106,,,8,,H,,,,Autocuration,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,1,,5619,CHEMBL617307,,BAO_0000357,
2013,105,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL617308,,BAO_0000019,
2014,105,,,8,,H,,,,Autocuration,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,1,,16633,CHEMBL617309,,BAO_0000357,
2015,105,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,1,,16633,CHEMBL617310,,BAO_0000357,
2016,105,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,1,,16633,CHEMBL617311,,BAO_0000357,
2017,105,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,1,,16633,CHEMBL617312,,BAO_0000357,
2018,105,,,8,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,1,,3269,CHEMBL617313,,BAO_0000357,
2019,105,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,1,,12409,CHEMBL617314,,BAO_0000357,
2020,106,,,8,,H,,,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,1,,13706,CHEMBL617315,,BAO_0000019,
2021,106,,,8,,H,,,HEK293,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,1,,13706,CHEMBL617316,722.0,BAO_0000219,
2022,106,,,8,,H,,,HEK293,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,1,,13706,CHEMBL617317,722.0,BAO_0000219,
2023,106,,,8,,H,,,CHO,Autocuration,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,1,,12903,CHEMBL617318,449.0,BAO_0000219,
2024,106,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,1,,13047,CHEMBL617319,,BAO_0000019,
2025,106,,,9,,D,,,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,1,,13366,CHEMBL617320,,BAO_0000357,
2026,106,,,9,,D,,,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,1,,13366,CHEMBL617321,,BAO_0000357,
2027,106,,,9,,D,,,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,1,,13366,CHEMBL617322,,BAO_0000357,
2028,106,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,1,,13366,CHEMBL616862,,BAO_0000357,
2029,106,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,1,,13366,CHEMBL616863,,BAO_0000357,
2030,106,,,8,,H,,,CHO,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,1,,12469,CHEMBL616864,449.0,BAO_0000219,
2031,106,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,1,,13706,CHEMBL616865,485.0,BAO_0000219,
2032,106,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,1,,13706,CHEMBL616866,485.0,BAO_0000219,
2033,106,,,8,,H,,,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,1,,13706,CHEMBL616867,,BAO_0000019,
2034,106,,,8,,H,,,CHO-K1,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,1,,12902,CHEMBL616868,485.0,BAO_0000219,
2035,105,,,8,,H,,,,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,1,,13051,CHEMBL616869,,BAO_0000357,
2036,106,,,8,,H,,,CHO,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,1,,12903,CHEMBL616870,449.0,BAO_0000219,
2037,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,1,,1558,CHEMBL616871,485.0,BAO_0000219,
2038,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,1,,1558,CHEMBL616872,485.0,BAO_0000219,
2039,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,1,,1558,CHEMBL616873,485.0,BAO_0000219,
2040,105,,,8,,H,,,CHO-K1,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,1,,1558,CHEMBL616838,485.0,BAO_0000219,
2041,105,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,1,,1558,CHEMBL616839,,BAO_0000357,
2042,106,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL616840,,BAO_0000019,
2043,105,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,1,,13313,CHEMBL616841,,BAO_0000357,
2044,105,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,1,,13313,CHEMBL616842,,BAO_0000357,
2045,105,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,1,,12409,CHEMBL857976,,BAO_0000357,
2046,10618,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,1,,15250,CHEMBL616843,449.0,BAO_0000219,
2047,10618,,,9,,D,,,,Expert,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,1,,1348,CHEMBL616844,,BAO_0000357,
2048,10618,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,1,,1348,CHEMBL616845,,BAO_0000357,
2049,10618,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,1,,4234,CHEMBL616846,,BAO_0000357,
2050,10618,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,1,,16209,CHEMBL616847,,BAO_0000357,
2051,10618,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,1,,10444,CHEMBL616848,,BAO_0000019,
2052,10618,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,1,,3935,CHEMBL616849,,BAO_0000357,
2053,10618,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,1,,15818,CHEMBL872911,,BAO_0000357,
2054,10618,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,1,,17085,CHEMBL616850,,BAO_0000019,
2055,10618,,,9,,D,,,CHO,Expert,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,1,,12936,CHEMBL616699,449.0,BAO_0000219,
2056,10618,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,1,,6166,CHEMBL616700,,BAO_0000357,
2057,10618,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL616701,449.0,BAO_0000219,
2058,10618,,,8,,H,,,CHO,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL616702,449.0,BAO_0000219,
2059,10618,,,8,,H,,,CHO,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,1,,15779,CHEMBL616703,449.0,BAO_0000219,
2060,10618,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,1,,13181,CHEMBL616704,,BAO_0000357,
2061,10618,,,8,,H,,,CHO,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,1,,4199,CHEMBL616705,449.0,BAO_0000219,
2062,10618,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,1,,14875,CHEMBL616706,,BAO_0000357,
2063,10618,,,8,,H,,,CHO,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,1,,15146,CHEMBL616707,449.0,BAO_0000219,
2064,10618,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,1,,5213,CHEMBL616708,,BAO_0000357,
2065,10618,,,8,,H,,,,Autocuration,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,1,,12146,CHEMBL616709,,BAO_0000357,
2066,10618,,,8,,H,,,CHO,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,1,,13267,CHEMBL616710,449.0,BAO_0000219,
2067,10618,,,8,,H,,,CHO,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,1,,14818,CHEMBL616711,449.0,BAO_0000219,
2068,10618,,,8,,H,,,CHO,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL616712,449.0,BAO_0000219,
2069,10618,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,1,,4373,CHEMBL616713,,BAO_0000357,
2070,10618,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,1,,4373,CHEMBL616714,,BAO_0000357,
2071,10618,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,1,,14159,CHEMBL616715,,BAO_0000357,
2072,10618,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,1,,16633,CHEMBL616716,,BAO_0000357,
2073,279,,,8,,H,,,,Autocuration,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,1,,17085,CHEMBL616717,,BAO_0000019,
2074,279,,,8,,H,,,,Expert,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,1,,17085,CHEMBL616718,,BAO_0000019,
2075,279,,,8,,H,,,,Autocuration,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,1,,16209,CHEMBL875905,,BAO_0000019,
2076,279,,,8,,H,,,,Autocuration,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,1,,16209,CHEMBL616719,,BAO_0000019,
2077,279,,,8,,H,,,,Expert,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,1,,17085,CHEMBL616720,,BAO_0000019,
2078,279,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,1,,14159,CHEMBL616721,,BAO_0000357,
2079,279,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,1,,15250,CHEMBL616722,449.0,BAO_0000219,
2080,279,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL616723,,BAO_0000357,
2081,279,,,8,,H,,,CHO,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,1,,16190,CHEMBL616724,449.0,BAO_0000219,
2082,279,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,1,,16190,CHEMBL616725,,BAO_0000357,
2083,279,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,1,,16209,CHEMBL616726,,BAO_0000357,
2084,279,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,1,,16209,CHEMBL616727,,BAO_0000357,
2085,279,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,1,,16209,CHEMBL616728,,BAO_0000357,
2086,279,,,8,,H,,,,Autocuration,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,1,,6866,CHEMBL616729,,BAO_0000357,
2087,279,,,8,,H,,,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,1,,17085,CHEMBL616730,,BAO_0000019,
2088,279,,,8,,H,,,,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,1,,16312,CHEMBL617125,,BAO_0000357,
2089,279,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,1,,6166,CHEMBL857977,,BAO_0000357,
2090,279,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL617126,449.0,BAO_0000219,
2091,279,,,8,,H,,,CHO,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,1,,4199,CHEMBL617127,449.0,BAO_0000219,
2092,279,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,1,,14875,CHEMBL617128,,BAO_0000357,
2093,279,,,8,,H,,,CHO,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,1,,15146,CHEMBL617129,449.0,BAO_0000219,
2094,279,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,1,,5213,CHEMBL617130,,BAO_0000357,
2095,279,,,8,,H,,,CHO,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,1,,14818,CHEMBL617131,449.0,BAO_0000219,
2096,279,,,8,,H,,,CHO,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL617132,449.0,BAO_0000219,
2097,279,,,8,,H,,,CHO,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL617133,449.0,BAO_0000219,
2098,279,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,1,,4373,CHEMBL617134,,BAO_0000357,
2099,279,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,1,,4373,CHEMBL617135,,BAO_0000357,
2100,279,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,1,,5014,CHEMBL617136,,BAO_0000357,
2101,104686,,,4,,H,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,1,,11662,CHEMBL617137,,BAO_0000019,
2102,104686,,,4,,H,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,1,,11662,CHEMBL617138,,BAO_0000019,
2103,104686,,,4,,H,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,1,,11662,CHEMBL617139,,BAO_0000019,
2104,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,1,,14093,CHEMBL617140,,BAO_0000019,
2105,104686,,In vivo,4,,H,,,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,1,,11200,CHEMBL617141,,BAO_0000218,
2106,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL858112,,BAO_0000019,
2107,17005,,,8,,H,,,,Intermediate,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,1,,12352,CHEMBL617142,,BAO_0000019,
2108,22226,,,0,,U,,,,Autocuration,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,1,,13657,CHEMBL617143,,BAO_0000019,
2109,22226,,,0,,U,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,1,,14331,CHEMBL617144,,BAO_0000019,
2110,22226,,,0,,U,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,1,,14331,CHEMBL617145,,BAO_0000019,
2111,22226,,,0,,U,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,1,,14331,CHEMBL617146,,BAO_0000019,
2112,104784,,,4,,H,,,,Autocuration,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,1,,12685,CHEMBL617147,,BAO_0000019,
2113,104784,,,4,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,1,,14389,CHEMBL617148,,BAO_0000019,
2114,104784,,,4,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,1,,14386,CHEMBL617149,,BAO_0000019,
2115,104784,,,4,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,1,,5732,CHEMBL617150,,BAO_0000224,
2116,104784,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,1,,16293,CHEMBL617151,,BAO_0000224,
2117,104784,,,4,,H,,,,Autocuration,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,1,,2078,CHEMBL617201,,BAO_0000224,
2118,10209,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,1,,5486,CHEMBL617202,,BAO_0000357,
2119,104826,,In vivo,4,,H,,,,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,1,,11820,CHEMBL617203,,BAO_0000218,
2120,104826,,,4,,H,,,,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,1,,10297,CHEMBL617204,,BAO_0000019,
2121,104826,,,4,,H,,,,Autocuration,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,1,,13704,CHEMBL617205,,BAO_0000224,
2122,104826,,,5,,D,,,,Autocuration,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,1,,10297,CHEMBL617206,,BAO_0000019,
2123,104826,,In vivo,4,,H,,,,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,1,,11820,CHEMBL617207,,BAO_0000218,
2124,104826,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,1,,10297,CHEMBL617208,,BAO_0000019,
2125,104826,,,4,,H,,,,Autocuration,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,11555,CHEMBL617209,,BAO_0000224,
2126,104826,,,4,,H,,,,Autocuration,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,1,,11555,CHEMBL617210,,BAO_0000224,
2127,104826,,,4,,H,,,,Autocuration,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,1,,11555,CHEMBL617211,,BAO_0000224,
2128,104826,,,5,,D,,,,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,1,,10297,CHEMBL617212,,BAO_0000019,
2129,104784,,,4,,H,,,,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,1,,16688,CHEMBL617213,,BAO_0000224,
2130,104784,,,4,,H,,,,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,1,,16688,CHEMBL617214,,BAO_0000224,
2131,22226,,,0,,U,,,,Autocuration,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,1,,5333,CHEMBL617215,,BAO_0000221,
2132,22226,,,0,,U,,,,Autocuration,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,1,,4437,CHEMBL617216,,BAO_0000221,
2133,17005,,,8,,H,,,,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,1,,5033,CHEMBL617217,,BAO_0000357,
2134,104686,,,4,,H,,,,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,1,,15267,CHEMBL617218,,BAO_0000019,
2135,104686,,,4,,H,,,,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,1,,15267,CHEMBL872913,,BAO_0000019,
2136,104826,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,1,,11820,CHEMBL617219,,BAO_0000019,
2137,104686,,,4,,H,,,,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,1,,9069,CHEMBL873482,,BAO_0000224,
2138,104686,,,5,,D,,,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,1,,9162,CHEMBL617220,,BAO_0000019,
2139,104686,,,4,,H,,,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,1,,9162,CHEMBL617221,,BAO_0000019,
2140,104686,,,4,,H,,,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,1,,9162,CHEMBL617222,,BAO_0000019,
2141,104686,,,4,,H,,,,Autocuration,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,1,,10428,CHEMBL875906,,BAO_0000019,
2142,104686,,,4,,H,,,,Autocuration,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,1,,9628,CHEMBL617223,,BAO_0000019,
2143,104686,,,4,,H,,,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,1,,12704,CHEMBL617224,,BAO_0000224,
2144,104686,,,5,,D,,,,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,1,,15453,CHEMBL617225,,BAO_0000224,
2145,104686,,,4,,H,,,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,1,,188,CHEMBL617226,,BAO_0000224,
2146,104686,,,4,,H,,,,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,1,,10349,CHEMBL617227,,BAO_0000224,
2147,104686,,,4,,H,,,,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,1,,10349,CHEMBL617228,,BAO_0000224,
2148,104686,,,4,,H,,,,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,1,,8868,CHEMBL617229,,BAO_0000224,
2149,104686,,,4,,H,,,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,1,,10025,CHEMBL617230,,BAO_0000224,
2150,104686,,,4,,H,,,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,1,,10025,CHEMBL617231,,BAO_0000224,
2151,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,1,,11702,CHEMBL617232,,BAO_0000224,
2152,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,1,,11702,CHEMBL617233,,BAO_0000224,
2153,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,1,,11702,CHEMBL617234,,BAO_0000224,
2154,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,1,,11702,CHEMBL617235,,BAO_0000019,
2155,104686,,,4,,H,,,,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,1,,11702,CHEMBL617236,,BAO_0000019,
2156,104686,,,4,,H,,Hippocampus,,Autocuration,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,1,,10085,CHEMBL617237,,BAO_0000221,10000000.0
2157,104686,,,4,,H,,Hippocampus,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,1,,10085,CHEMBL617238,,BAO_0000221,10000000.0
2158,104686,,,5,,D,,Brain,,Autocuration,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,1,,9630,CHEMBL617239,,BAO_0000221,955.0
2159,104686,,,4,,H,,,,Autocuration,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,1,,11070,CHEMBL617240,,BAO_0000019,
2160,104686,,,4,,H,Membranes,,,Autocuration,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,1,,9841,CHEMBL617241,,BAO_0000249,
2161,104686,,,4,,H,Membranes,,,Autocuration,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,1,,9841,CHEMBL875907,,BAO_0000249,
2162,104686,,,4,,H,,,,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,1,,13291,CHEMBL617242,,BAO_0000019,
2163,104686,,,4,,H,,,,Autocuration,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,1,,10590,CHEMBL617152,,BAO_0000019,
2164,104686,,,5,,D,,Brain,,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,1,,9064,CHEMBL617153,,BAO_0000221,955.0
2165,104686,,,5,,D,Membranes,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,1,,12268,CHEMBL617154,,BAO_0000249,
2166,104686,,,4,,H,,Brain,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,1,,13508,CHEMBL617155,,BAO_0000221,955.0
2167,104686,,,4,,H,,,,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,1,,11279,CHEMBL617156,,BAO_0000019,
2168,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL617157,,BAO_0000019,
2169,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL617158,,BAO_0000019,
2170,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,1,,11200,CHEMBL617159,,BAO_0000019,
2171,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,1,,11200,CHEMBL617160,,BAO_0000019,
2172,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL858113,,BAO_0000019,
2173,104686,,,4,,H,,Brain,,Autocuration,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,1,,9231,CHEMBL617247,,BAO_0000220,955.0
2174,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,1,,9737,CHEMBL617248,,BAO_0000019,
2175,104686,,,4,,H,,Brain,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,1,,9737,CHEMBL617249,,BAO_0000249,955.0
2176,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,1,,9737,CHEMBL617250,,BAO_0000019,
2177,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,1,,9737,CHEMBL617251,,BAO_0000019,
2178,104686,,,5,,D,,,,Autocuration,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,1,,11828,CHEMBL617252,,BAO_0000019,
2179,104686,,,4,,H,,,,Autocuration,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,1,,12253,CHEMBL617006,,BAO_0000019,
2180,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,1,,12253,CHEMBL617007,,BAO_0000019,
2181,104686,,,4,,H,,,,Autocuration,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,1,,11279,CHEMBL617008,,BAO_0000019,
2182,104686,,,4,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,1,,11866,CHEMBL617009,,BAO_0000019,
2183,104686,,,5,,D,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,1,,14424,CHEMBL617010,,BAO_0000224,
2184,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,1,,15180,CHEMBL857978,,BAO_0000019,
2185,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,1,,15180,CHEMBL617011,,BAO_0000019,
2186,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,1,,9786,CHEMBL617012,,BAO_0000019,
2187,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,1,,12132,CHEMBL617013,,BAO_0000224,
2188,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,1,,5486,CHEMBL617014,,BAO_0000249,
2189,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,1,,15316,CHEMBL617015,,BAO_0000019,
2190,104686,,,4,,H,,,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,1,,16429,CHEMBL617016,,BAO_0000019,
2191,104686,,,4,,H,,,,Autocuration,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,1,,14617,CHEMBL617017,,BAO_0000224,
2192,104686,,,4,,H,,Brain,,Autocuration,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,1,,11351,CHEMBL617018,,BAO_0000221,955.0
2193,104686,,,4,,H,,,,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,1,,11279,CHEMBL617019,,BAO_0000019,
2194,105075,,,4,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617020,,BAO_0000019,
2195,105075,,,4,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617021,,BAO_0000019,
2196,105075,,,4,,H,,,,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617022,,BAO_0000019,
2197,105075,,,4,,H,,,,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617023,,BAO_0000019,
2198,105075,,,4,,H,,,,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617024,,BAO_0000019,
2199,105075,,,4,,H,,,,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,1,,9523,CHEMBL617025,,BAO_0000019,
2200,105075,,,4,,H,,,,Autocuration,Hill coefficient of compound was determined,B,1,,9523,CHEMBL617026,,BAO_0000224,
2201,22226,,,0,,U,,,,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,1,,4771,CHEMBL617027,,BAO_0000019,
2202,104686,,,5,,D,,,,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,1,,5033,CHEMBL617028,,BAO_0000019,
2203,12687,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,1,,10845,CHEMBL617029,,BAO_0000019,
2204,12687,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,1,,10845,CHEMBL875908,,BAO_0000019,
2205,12687,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,1,,16288,CHEMBL617030,,BAO_0000357,
2206,12687,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,1,,16288,CHEMBL617031,,BAO_0000019,
2207,12687,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,1,,16190,CHEMBL617032,,BAO_0000019,
2208,104686,,,5,,D,,,,Autocuration,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,1,,12463,CHEMBL617033,,BAO_0000224,
2209,104686,,,4,,H,,,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,1,,9699,CHEMBL617034,,BAO_0000224,
2210,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,1,,9699,CHEMBL617035,,BAO_0000224,
2211,104686,,,4,,H,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,1,,11662,CHEMBL617036,,BAO_0000019,
2212,104784,,,4,,H,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,1,,1205,CHEMBL617037,,BAO_0000224,
2213,22226,,,0,,U,,,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,1,,11376,CHEMBL617038,,BAO_0000219,
2214,104784,,,4,,H,,,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,1,,11376,CHEMBL617039,,BAO_0000219,
2215,104784,,,4,,H,,,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,1,,4639,CHEMBL617161,,BAO_0000224,
2216,104784,,,4,,H,,,,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,1,,2222,CHEMBL617162,,BAO_0000224,
2217,104784,,,4,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,1,,1558,CHEMBL617163,,BAO_0000224,
2218,104784,,,4,,H,,,,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,1,,1089,CHEMBL617164,,BAO_0000224,
2219,104784,,,4,,H,Brain membranes,,,Autocuration,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,1,,386,CHEMBL617165,,BAO_0000249,
2220,104784,,,4,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,1,,2474,CHEMBL617166,,BAO_0000224,
2221,104784,,,4,,H,,,,Autocuration,Binding affinity towards 5-HT2 receptor,B,1,,17066,CHEMBL617167,,BAO_0000224,
2222,104784,,,4,,H,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,1,,959,CHEMBL872912,,BAO_0000224,
2223,104784,,,4,,H,,,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,1,,6398,CHEMBL617168,,BAO_0000224,
2224,104686,,,4,,H,,,,Autocuration,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,1,,11889,CHEMBL617169,,BAO_0000224,
2225,104784,,,4,,H,,,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,1,,4221,CHEMBL617170,,BAO_0000224,
2226,104784,,,4,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,1,,11026,CHEMBL617171,,BAO_0000224,
2227,104784,,,4,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,1,,11866,CHEMBL617172,,BAO_0000224,
2228,104784,,,4,,H,,,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,1,,4221,CHEMBL617173,,BAO_0000224,
2229,22226,,,0,,U,,,,Autocuration,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,1,,13950,CHEMBL617174,,BAO_0000019,
2230,104784,,,4,,H,,,,Autocuration,5-hydroxytryptamine 2 receptor binding affinity,B,1,,1263,CHEMBL617175,,BAO_0000224,
2231,17005,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,1,,13291,CHEMBL617176,,BAO_0000357,
2232,17005,,,8,,H,,,,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,1,,10812,CHEMBL617177,,BAO_0000357,
2233,104784,,,4,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,1,,13020,CHEMBL617178,,BAO_0000224,
2234,104784,,,4,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,1,,13021,CHEMBL617179,,BAO_0000224,
2235,104784,,,4,,H,,,,Autocuration,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,1,,13020,CHEMBL617180,,BAO_0000224,
2236,17005,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,1,,14532,CHEMBL617181,,BAO_0000357,
2237,17005,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,B,1,,13944,CHEMBL617182,,BAO_0000357,
2238,17005,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,B,1,,14331,CHEMBL617183,,BAO_0000357,
2239,17005,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,1,,14118,CHEMBL617184,,BAO_0000357,
2240,17005,,,8,,H,,,,Autocuration,Binding affinity against serotonergic 5-HT2 receptor,B,1,,13033,CHEMBL617185,,BAO_0000357,
2241,17005,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,1,,10321,CHEMBL617186,,BAO_0000357,
2242,17005,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,1,,12918,CHEMBL617187,,BAO_0000357,
2243,17005,,,8,,H,,,,Autocuration,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,1,,15120,CHEMBL617188,,BAO_0000357,
2244,17005,,,8,,H,,,,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,1,,2613,CHEMBL617189,,BAO_0000218,
2245,104784,,,5,,D,,,,Autocuration,Inhibitory activity against cloned human 5-HT2 receptor,B,1,,13378,CHEMBL617190,,BAO_0000224,
2246,104784,,,5,,D,,,CHO,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,1,,2331,CHEMBL617191,449.0,BAO_0000219,
2247,104784,,,5,,D,,,CHO,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,1,,2331,CHEMBL617192,449.0,BAO_0000219,
2248,104784,,,5,,D,,,CHO,Autocuration,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,1,,2331,CHEMBL617193,449.0,BAO_0000219,
2249,104784,,,5,,D,,,CHO,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,1,,2331,CHEMBL617194,449.0,BAO_0000219,
2250,104784,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,4170,CHEMBL617195,,BAO_0000224,
2251,104784,,,4,,H,,,,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,1,,15453,CHEMBL881830,,BAO_0000224,
2252,17005,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,1479,CHEMBL617196,,BAO_0000357,
2253,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,1,,11139,CHEMBL617197,,BAO_0000224,
2254,17005,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,1,,13969,CHEMBL617198,,BAO_0000357,
2255,17005,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,13392,CHEMBL873476,,BAO_0000357,
2256,17005,,,8,,H,,,,Expert,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,1,,14430,CHEMBL617199,,BAO_0000019,
2257,107,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,1,,13181,CHEMBL617200,,BAO_0000357,
2258,51,,,8,,H,,,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617484,,BAO_0000357,
2259,107,,,8,,H,,,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617485,,BAO_0000357,
2260,51,,,8,,H,,,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617486,,BAO_0000357,
2261,107,,,8,,H,,,,Autocuration,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,1,,13463,CHEMBL858022,,BAO_0000357,
2262,107,,,8,,H,,,CHO,Autocuration,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,1,,6347,CHEMBL617049,449.0,BAO_0000219,
2263,107,,,9,,D,,,CHO,Expert,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,1,,6857,CHEMBL617050,449.0,BAO_0000219,
2264,107,,,8,,H,,,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,1,,4176,CHEMBL617051,,BAO_0000219,
2265,107,,,8,,H,,,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,1,,4176,CHEMBL617052,,BAO_0000219,
2266,107,,,8,,H,,,,Autocuration,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,1,,4176,CHEMBL617053,,BAO_0000219,
2267,107,,,8,,H,,,CHO,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,1,,6347,CHEMBL617054,449.0,BAO_0000219,
2268,107,,,8,,H,,,CHO,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,1,,6347,CHEMBL617055,449.0,BAO_0000219,
2269,107,,,8,,H,,,,Autocuration,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,1,,15331,CHEMBL882924,,BAO_0000357,
2270,107,,,9,,D,,,,Expert,Inhibition of human 5-hydroxytryptamine 2A receptor,B,1,,16146,CHEMBL617056,,BAO_0000357,
2271,107,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,1,,15250,CHEMBL617057,449.0,BAO_0000219,
2272,107,,,8,,H,,,,Expert,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,1,,13631,CHEMBL617058,,BAO_0000219,
2273,107,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL617059,,BAO_0000357,
2274,107,,,8,,H,,,CHO,Autocuration,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,1,,4011,CHEMBL617060,449.0,BAO_0000219,
2275,107,,,8,,H,,,CHO,Expert,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,1,,4012,CHEMBL617061,449.0,BAO_0000219,
2276,107,,,8,,H,,,L929,Expert,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,1,,6366,CHEMBL617062,307.0,BAO_0000219,
2277,107,,,8,,H,,,CHO,Expert,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,1,,15949,CHEMBL617063,449.0,BAO_0000219,
2278,107,,,8,,H,,,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,1,,14093,CHEMBL617064,,BAO_0000019,
2279,107,,,8,,H,,,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,1,,13481,CHEMBL617065,,BAO_0000019,
2280,107,,,8,,H,,,CHO,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,1,,6347,CHEMBL617066,449.0,BAO_0000219,
2281,107,,,8,,H,,,CHO,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,1,,6347,CHEMBL617067,449.0,BAO_0000219,
2282,107,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,1,,14093,CHEMBL617068,,BAO_0000019,
2283,107,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,1,,14093,CHEMBL617069,,BAO_0000019,
2284,107,,,8,,H,,,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,1,,13481,CHEMBL617070,,BAO_0000019,
2285,107,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,1,,14442,CHEMBL617071,,BAO_0000357,
2286,107,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,1,,14442,CHEMBL872915,,BAO_0000357,
2287,107,,,8,,H,,,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,1,,14755,CHEMBL617072,,BAO_0000357,
2288,107,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,1,,16441,CHEMBL617073,,BAO_0000357,
2289,107,,,8,,H,,,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,1,,14744,CHEMBL617074,,BAO_0000357,
2290,107,,,8,,H,,,CHO,Expert,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,1,,16659,CHEMBL617075,449.0,BAO_0000219,
2291,107,,,8,,H,,,,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,1,,3307,CHEMBL617076,,BAO_0000357,
2292,107,,,9,,D,,,,Expert,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,1,,6857,CHEMBL617077,,BAO_0000019,
2293,107,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,1,,5635,CHEMBL617078,,BAO_0000357,
2294,107,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,1,,4234,CHEMBL617079,,BAO_0000357,
2295,107,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,1,,15527,CHEMBL617080,,BAO_0000357,
2296,107,,,8,,H,,,CHO,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,1,,6588,CHEMBL617081,449.0,BAO_0000219,
2297,107,,,8,,H,,,,Expert,Binding affinity towards human 5-HT2A receptor in BEK cells,B,1,,13631,CHEMBL617082,,BAO_0000219,
2298,107,,,8,,H,,,,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,1,,17723,CHEMBL617083,,BAO_0000357,
2299,107,,,8,,H,,,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,1,,14770,CHEMBL617084,,BAO_0000357,
2300,107,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,1,,16293,CHEMBL617085,,BAO_0000357,
2301,107,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,1,,16209,CHEMBL617086,,BAO_0000357,
2302,107,,,8,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,1,,12469,CHEMBL617087,,BAO_0000219,
2303,107,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,1,,15363,CHEMBL617088,,BAO_0000357,
2304,107,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,1,,15363,CHEMBL617089,,BAO_0000357,
2305,107,,,8,,H,,,,Expert,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,1,,16441,CHEMBL617090,,BAO_0000019,
2306,107,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,1,,8,CHEMBL617513,,BAO_0000357,
2307,107,,,8,,H,,,HEK293,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,1,,4176,CHEMBL617514,722.0,BAO_0000219,
2308,107,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,1,,17085,CHEMBL617515,,BAO_0000019,
2309,107,,,8,,H,,,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617516,,BAO_0000357,
2310,107,,,9,,D,,,,Expert,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617517,,BAO_0000357,
2311,107,,,9,,D,,,CHO,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,1,,4013,CHEMBL617518,449.0,BAO_0000219,
2312,107,,,8,,H,,,,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,5088,CHEMBL617519,,BAO_0000357,
2313,107,,,9,,D,,,,Expert,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,1,,5088,CHEMBL617520,,BAO_0000357,
2314,107,,,8,,H,,,,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,1,,5088,CHEMBL617521,,BAO_0000357,
2315,107,,,9,,D,,,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,1,,5088,CHEMBL617522,,BAO_0000357,
2316,107,,,8,,H,,,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,1,,5088,CHEMBL617523,,BAO_0000357,
2317,107,,,8,,H,,,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,1,,5088,CHEMBL617524,,BAO_0000357,
2318,104686,,,4,,H,,,,Autocuration,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,1,,9786,CHEMBL617525,,BAO_0000019,
2319,104686,,,5,,D,,,,Autocuration,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,1,,9205,CHEMBL617526,,BAO_0000019,
2320,104686,,,4,,H,,,,Autocuration,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,1,,11257,CHEMBL617527,,BAO_0000224,
2321,104686,,,4,,H,,,,Autocuration,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,1,,9362,CHEMBL617528,,BAO_0000019,
2322,104686,,,4,,H,,,,Autocuration,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,1,,9362,CHEMBL617529,,BAO_0000019,
2323,104686,,,4,,H,,,,Autocuration,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,1,,10590,CHEMBL617530,,BAO_0000224,
2324,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,1,,10468,CHEMBL617531,,BAO_0000019,
2325,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,1,,13050,CHEMBL617532,,BAO_0000019,
2326,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,1,,11624,CHEMBL617533,,BAO_0000019,
2327,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,1,,10468,CHEMBL617534,,BAO_0000019,
2328,104686,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,1,,10330,CHEMBL617535,,BAO_0000224,
2329,104686,,,4,,H,,,,Autocuration,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,1,,10062,CHEMBL617536,,BAO_0000224,
2330,104686,,,4,,H,,,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,1,,11642,CHEMBL617537,,BAO_0000224,
2331,104686,,,4,,H,,,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,1,,10062,CHEMBL617538,,BAO_0000224,
2332,104686,,In vitro,4,,H,,,,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,1,,13427,CHEMBL617539,,BAO_0000219,
2333,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,1,,12280,CHEMBL617540,,BAO_0000224,
2334,104686,,,5,,D,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,1,,4101,CHEMBL617541,,BAO_0000224,
2335,104686,,,4,,H,,,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,1,,10062,CHEMBL617542,,BAO_0000224,
2336,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,1,,11147,CHEMBL617543,,BAO_0000224,
2337,104686,,,5,,D,,,CHO-K1,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,1,,2395,CHEMBL617544,485.0,BAO_0000219,
2338,104686,,,5,,D,,,CHO-K1,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,1,,2395,CHEMBL617545,485.0,BAO_0000219,
2339,104686,,,5,,D,,,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,1,,9098,CHEMBL617413,,BAO_0000019,
2340,104686,,,4,,H,,,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,1,,9098,CHEMBL617414,,BAO_0000019,
2341,104686,,,5,,D,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,1,,9098,CHEMBL617415,,BAO_0000019,
2342,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,9443,CHEMBL617416,,BAO_0000224,
2343,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,1,,9443,CHEMBL617417,,BAO_0000224,
2344,104686,,,4,,H,,,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,1,,9699,CHEMBL617418,,BAO_0000019,
2345,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,1,,9699,CHEMBL617419,,BAO_0000019,
2346,104686,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,1,,9098,CHEMBL617420,,BAO_0000224,
2347,104686,,,5,,D,,,,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor,B,1,,3070,CHEMBL617421,,BAO_0000224,
2348,104686,,,4,,H,,,,Autocuration,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,1,,9547,CHEMBL617422,,BAO_0000224,
2349,104686,,,4,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,1,,10444,CHEMBL617423,,BAO_0000019,
2350,104686,,,4,,H,,,,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,1,,14617,CHEMBL617424,,BAO_0000019,
2351,104686,,,4,,H,,,,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,1,,14617,CHEMBL617425,,BAO_0000019,
2352,104686,,,4,,H,,,,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,1,,11130,CHEMBL617426,,BAO_0000224,
2353,104686,,In vivo,4,,H,,,,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,1,,11130,CHEMBL617427,,BAO_0000218,
2354,104686,,,4,,H,,Brain,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,1,,14542,CHEMBL617428,,BAO_0000221,955.0
2355,104686,,,4,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,1,,2797,CHEMBL617429,,BAO_0000224,
2356,104686,,,4,,H,,,,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,1,,11332,CHEMBL617430,,BAO_0000019,
2357,104686,,,4,,H,,,,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,1,,11332,CHEMBL617431,,BAO_0000019,
2358,104686,,,4,,H,,Frontal cortex,,Autocuration,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,1,,10752,CHEMBL617432,,BAO_0000019,1870.0
2359,104686,,,4,,H,,,,Autocuration,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,1,,1185,CHEMBL617433,,BAO_0000224,
2360,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,1,,1185,CHEMBL617434,,BAO_0000224,
2361,104686,,,5,,D,,,,Autocuration,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,1,,11624,CHEMBL617435,,BAO_0000224,
2362,104686,,,4,,H,,,,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,1,,1344,CHEMBL617436,,BAO_0000019,
2363,104686,,,5,,D,,Striatum,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,1,,15453,CHEMBL617437,,BAO_0000019,2435.0
2364,104686,,,4,,H,,,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,1,,11662,CHEMBL617438,,BAO_0000019,
2365,104686,,,4,,H,,,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,1,,11662,CHEMBL617439,,BAO_0000019,
2366,104686,,,4,,H,,,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,1,,10796,CHEMBL617440,,BAO_0000224,
2367,104686,,,4,,H,,,,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,1,,9069,CHEMBL617441,,BAO_0000224,
2368,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,1,,8814,CHEMBL872918,,BAO_0000019,
2369,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,1,,8908,CHEMBL617442,,BAO_0000019,
2370,104686,,,4,,H,,,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,1,,9098,CHEMBL617443,,BAO_0000019,
2371,104686,,,4,,H,,,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,1,,9098,CHEMBL617444,,BAO_0000019,
2372,104686,,,4,,H,,,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,1,,9098,CHEMBL617445,,BAO_0000019,
2373,104686,,,4,,H,,,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,1,,9098,CHEMBL617446,,BAO_0000019,
2374,104686,,,4,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,1,,9098,CHEMBL617447,,BAO_0000249,
2375,104686,,,4,,H,,,,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,1,,9098,CHEMBL617448,,BAO_0000019,
2376,104686,,,4,,H,,,,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,1,,9098,CHEMBL617449,,BAO_0000019,
2377,104686,,,4,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,1,,9161,CHEMBL617450,,BAO_0000019,
2378,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,1,,9161,CHEMBL617451,,BAO_0000019,
2379,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,1,,9161,CHEMBL617452,,BAO_0000019,
2380,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,1,,9161,CHEMBL617453,,BAO_0000019,
2381,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,1,,9161,CHEMBL617660,,BAO_0000019,
2382,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,1,,9161,CHEMBL617661,,BAO_0000019,
2383,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,1,,9161,CHEMBL617662,,BAO_0000019,
2384,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,1,,9161,CHEMBL872919,,BAO_0000019,
2385,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,1,,9161,CHEMBL617663,,BAO_0000019,
2386,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,1,,9161,CHEMBL617664,,BAO_0000019,
2387,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,1,,9161,CHEMBL617665,,BAO_0000019,
2388,104686,,,4,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,1,,9161,CHEMBL617666,,BAO_0000019,
2389,104686,,,4,,H,,,,Autocuration,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,1,,12094,CHEMBL617667,,BAO_0000019,
2390,104686,,,4,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,1,,12018,CHEMBL617668,,BAO_0000249,
2391,104686,,,4,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,1,,10394,CHEMBL617669,,BAO_0000249,
2392,104686,,,4,,H,,,,Autocuration,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,1,,15260,CHEMBL617670,,BAO_0000224,
2393,104686,,,5,,D,,,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,1,,11624,CHEMBL617671,,BAO_0000224,
2394,104686,,,4,,H,,,,Autocuration,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,1,,13654,CHEMBL617672,,BAO_0000224,
2395,104686,,,4,,H,,,,Autocuration,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,1,,9541,CHEMBL617673,,BAO_0000019,
2396,104686,,,4,,H,,,,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,1,,11933,CHEMBL617674,,BAO_0000224,
2397,104686,,,4,,H,,,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,1,,15538,CHEMBL617675,,BAO_0000019,
2398,104686,,,4,,H,,,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,1,,15538,CHEMBL617676,,BAO_0000019,
2399,104686,,,4,,H,,,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,1,,15538,CHEMBL617677,,BAO_0000019,
2400,104686,,,5,,D,,,,Autocuration,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,1,,8841,CHEMBL617678,,BAO_0000019,
2401,104686,,,4,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,1,,1455,CHEMBL617679,,BAO_0000224,
2402,104686,,,4,,H,,,,Autocuration,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,1,,1455,CHEMBL617680,,BAO_0000224,
2403,104686,,,4,,H,,,,Autocuration,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,1,,11752,CHEMBL617681,,BAO_0000019,
2404,104686,,,4,,H,,Brain,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,1,,11642,CHEMBL617682,,BAO_0000221,955.0
2405,104686,,,4,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,1,,12092,CHEMBL617683,,BAO_0000224,
2406,104686,,,4,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,1,,3967,CHEMBL617684,,BAO_0000224,
2407,104686,,,5,,D,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,1,,12771,CHEMBL617685,,BAO_0000224,
2408,104686,,,4,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,1,,11642,CHEMBL617686,,BAO_0000019,
2409,104686,,,4,,H,,,,Autocuration,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,1,,11628,CHEMBL617687,,BAO_0000224,
2410,104686,,,4,,H,,,,Autocuration,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,1,,13654,CHEMBL617688,,BAO_0000224,
2411,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL617689,,BAO_0000019,
2412,104686,,,4,,H,,,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,1,,11200,CHEMBL617690,,BAO_0000019,
2413,104686,,In vivo,4,,H,,,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,1,,11200,CHEMBL617691,,BAO_0000218,
2414,104686,,In vivo,4,,H,,,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,1,,11200,CHEMBL617692,,BAO_0000218,
2415,104686,,In vivo,4,,H,,,,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,1,,11200,CHEMBL617693,,BAO_0000218,
2416,104686,,In vivo,4,,H,,,,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,1,,11200,CHEMBL617694,,BAO_0000218,
2417,12687,,,8,,H,,Brain,,Expert,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,1,,15436,CHEMBL857985,,BAO_0000221,955.0
2418,12687,,,9,,D,,,,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,1,,15436,CHEMBL617695,,BAO_0000019,
2419,12687,,,8,,H,,,,Autocuration,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,1,,14025,CHEMBL617696,,BAO_0000019,
2420,12687,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,1,,4342,CHEMBL617697,,BAO_0000357,
2421,12687,,,9,,D,,,,Expert,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,1,,13735,CHEMBL617257,,BAO_0000019,
2422,12687,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,1,,5816,CHEMBL617258,,BAO_0000357,
2423,12687,,,8,,H,,,,Expert,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,1,,14287,CHEMBL617259,,BAO_0000019,
2424,12687,,,8,,H,,,,Autocuration,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,1,,15738,CHEMBL617260,,BAO_0000357,
2425,12687,,,9,,D,,,,Expert,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,1,,15738,CHEMBL617261,,BAO_0000357,
2426,12687,,,8,,H,,,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,1,,15026,CHEMBL617262,,BAO_0000019,
2427,12687,,,8,,H,,,,Expert,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,1,,16647,CHEMBL617263,,BAO_0000019,
2428,12687,,,8,,H,,,,Autocuration,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,1,,16647,CHEMBL617264,,BAO_0000019,
2429,12687,,,9,,D,,,,Expert,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,1,,13345,CHEMBL617265,,BAO_0000019,
2430,12687,,,8,,H,Membranes,,,Autocuration,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,1,,1543,CHEMBL617266,,BAO_0000249,
2431,12687,,,8,,H,,,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,1,,12444,CHEMBL617267,,BAO_0000019,
2432,12687,,,8,,H,,,,Expert,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,1,,16404,CHEMBL617268,,BAO_0000019,
2433,12687,,,8,,H,,,CHO,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,1,,16404,CHEMBL617269,449.0,BAO_0000219,
2434,12687,,,8,,H,,,,Expert,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,1,,15577,CHEMBL617323,,BAO_0000357,
2435,12687,,,8,,H,,,,Autocuration,Serotonergic activity of the compound.,B,1,,15577,CHEMBL617324,,BAO_0000357,
2436,12687,,,8,,H,,,,Autocuration,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,1,,2495,CHEMBL617325,,BAO_0000249,
2437,12687,,,9,,D,,,,Expert,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,1,,15042,CHEMBL617326,,BAO_0000019,
2438,12687,,,8,,H,,,,Expert,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,1,,15026,CHEMBL617327,,BAO_0000249,
2439,12687,,,9,,D,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,1,,12919,CHEMBL617328,,BAO_0000019,
2440,12687,,,9,,D,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,1,,12919,CHEMBL617329,,BAO_0000019,
2441,12687,,,9,,D,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,1,,12919,CHEMBL617330,,BAO_0000019,
2442,12687,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,1,,15194,CHEMBL617331,,BAO_0000357,
2443,12687,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,1,,15194,CHEMBL617332,,BAO_0000357,
2444,107,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,4820,CHEMBL617333,,BAO_0000357,
2445,107,,,8,,H,,,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,1,,6736,CHEMBL617334,,BAO_0000357,
2446,107,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,1,,5163,CHEMBL617335,,BAO_0000357,
2447,107,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,1,,5163,CHEMBL617336,,BAO_0000357,
2448,107,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,1,,6011,CHEMBL617337,,BAO_0000357,
2449,107,,,9,,D,,,,Expert,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,1,,14294,CHEMBL617338,,BAO_0000357,
2450,107,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,1,,5014,CHEMBL617339,,BAO_0000357,
2451,107,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,17066,CHEMBL617340,,BAO_0000357,
2452,107,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,1,,17515,CHEMBL617341,,BAO_0000357,
2453,107,,,8,,H,,,,Expert,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,1,,6736,CHEMBL617342,,BAO_0000357,
2454,107,,,8,,H,,,,Expert,Affinity for 5-hydroxytryptamine 2A receptor,B,1,,5163,CHEMBL617343,,BAO_0000357,
2455,107,,,8,,H,,,NIH3T3,Expert,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,1,,16911,CHEMBL617344,723.0,BAO_0000219,
2456,107,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,1,,6841,CHEMBL617345,,BAO_0000357,
2457,107,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,1,,6119,CHEMBL617346,,BAO_0000357,
2458,107,,,8,,H,,,,Autocuration,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,1,,3962,CHEMBL617347,,BAO_0000357,
2459,107,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,1,,4373,CHEMBL617348,,BAO_0000357,
2460,107,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,1,,4373,CHEMBL617349,,BAO_0000357,
2461,107,,,8,,H,,,,Autocuration,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,1,,3962,CHEMBL617350,,BAO_0000019,
2462,107,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,1,,1633,CHEMBL872339,,BAO_0000357,
2463,107,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,1,,4373,CHEMBL617351,,BAO_0000357,
2464,107,,,8,,H,,,,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,1,,6576,CHEMBL617352,,BAO_0000357,
2465,107,,,8,,H,,,,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,4687,CHEMBL617353,,BAO_0000357,
2466,107,,,8,,H,,,,Autocuration,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,1,,16946,CHEMBL617354,,BAO_0000357,
2467,107,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,1,,14159,CHEMBL617355,,BAO_0000357,
2468,107,,,8,,H,,,CHO,Expert,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,1,,3032,CHEMBL617356,449.0,BAO_0000219,
2469,107,,,8,,H,,,,Autocuration,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,1,,16655,CHEMBL617357,,BAO_0000357,
2470,107,,,8,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 2A receptor,B,1,,13964,CHEMBL617358,,BAO_0000357,
2471,107,,,8,,H,,,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,1,,16989,CHEMBL617359,,BAO_0000357,
2472,107,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,1,,16117,CHEMBL617360,,BAO_0000357,
2473,107,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,1,,16700,CHEMBL875913,,BAO_0000357,
2474,107,,,8,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine 2A receptor,B,1,,3269,CHEMBL617361,,BAO_0000357,
2475,107,,,9,,D,,,,Expert,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,1,,1274,CHEMBL617362,,BAO_0000357,
2476,107,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,1,,1317,CHEMBL617363,,BAO_0000357,
2477,107,,,8,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 2A receptor,B,1,,12146,CHEMBL617364,,BAO_0000357,
2478,105075,,,4,,H,,,,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,1,,12652,CHEMBL617365,,BAO_0000224,
2479,105075,,,4,,H,,,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,1,,12652,CHEMBL617366,,BAO_0000224,
2480,105075,,,4,,H,,,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,1,,12652,CHEMBL617367,,BAO_0000224,
2481,105075,,,4,,H,,,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,1,,12652,CHEMBL617368,,BAO_0000224,
2482,107,,,8,,H,,,,Autocuration,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,1,,16647,CHEMBL617369,,BAO_0000357,
2483,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,1,,15851,CHEMBL617370,722.0,BAO_0000219,
2484,227,,,9,,D,,,CHO,Expert,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,1,,6857,CHEMBL617371,449.0,BAO_0000219,
2485,227,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL617372,,BAO_0000357,
2486,227,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,1,,6491,CHEMBL617373,,BAO_0000357,
2487,227,,,8,,H,,,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,1,,14093,CHEMBL617374,,BAO_0000019,
2488,227,,,8,,H,,,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,1,,13481,CHEMBL617375,,BAO_0000019,
2489,227,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,1,,14093,CHEMBL617376,,BAO_0000019,
2490,227,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,1,,14093,CHEMBL617377,,BAO_0000019,
2491,227,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,1,,14093,CHEMBL617378,,BAO_0000019,
2492,227,,,8,,H,,,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,1,,13481,CHEMBL617379,,BAO_0000019,
2493,227,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,1,,14442,CHEMBL617380,,BAO_0000357,
2494,227,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,1,,14442,CHEMBL617381,,BAO_0000357,
2495,227,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,1,,14442,CHEMBL617382,,BAO_0000357,
2496,107,,,8,,H,,,,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,1,,12369,CHEMBL617383,,BAO_0000357,
2497,107,,,8,,H,,,,Expert,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,1,,12369,CHEMBL617384,,BAO_0000357,
2498,107,,,8,,H,,,,Expert,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,1,,12369,CHEMBL617385,,BAO_0000357,
2499,107,,,8,,H,,,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,1,,14447,CHEMBL617386,,BAO_0000019,
2500,107,,,8,,H,,,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,1,,14447,CHEMBL617387,,BAO_0000019,
2501,107,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,1,,17451,CHEMBL617388,723.0,BAO_0000219,
2502,107,,,8,,H,,,CHO,Autocuration,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,1,,6857,CHEMBL617389,449.0,BAO_0000219,
2503,107,,,9,,D,,,CHO,Expert,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,1,,6857,CHEMBL617390,449.0,BAO_0000219,
2504,104817,,,4,,H,,,,Autocuration,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,1,,5635,CHEMBL617391,,BAO_0000224,
2505,107,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617392,,BAO_0000357,
2506,107,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617393,,BAO_0000019,
2507,107,,,8,,H,,,L929,Autocuration,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,1,,5105,CHEMBL617394,307.0,BAO_0000219,
2508,107,,,8,,H,,,L929,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,1,,5104,CHEMBL617395,307.0,BAO_0000219,
2509,107,,,8,,H,,,L929,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,1,,5105,CHEMBL617396,307.0,BAO_0000219,
2510,107,,,8,,H,,,L929,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,1,,5105,CHEMBL617397,307.0,BAO_0000219,
2511,107,,,8,,H,,,,Autocuration,Binding affinity against 5-HT2A receptor,B,1,,5254,CHEMBL617398,,BAO_0000357,
2512,107,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor,B,1,,5254,CHEMBL617399,,BAO_0000357,
2513,107,,,8,,H,,,HEK293,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,1,,13267,CHEMBL617400,722.0,BAO_0000219,
2514,107,,,8,,H,,,HEK293,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,1,,13267,CHEMBL617401,722.0,BAO_0000219,
2515,107,,,9,,D,,,HEK293,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,1,,14157,CHEMBL617402,722.0,BAO_0000219,
2516,107,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,1,,12936,CHEMBL617403,722.0,BAO_0000219,
2517,107,,,8,,H,,,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,1,,14068,CHEMBL617404,,BAO_0000357,
2518,107,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,1,,12936,CHEMBL857981,722.0,BAO_0000219,
2519,107,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,1,,12936,CHEMBL617405,722.0,BAO_0000219,
2520,107,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,1,,4540,CHEMBL617253,722.0,BAO_0000219,
2521,107,,,8,,H,,,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,1,,6166,CHEMBL617254,,BAO_0000357,
2522,107,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,1,,17296,CHEMBL617255,722.0,BAO_0000219,
2523,107,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,1,,17296,CHEMBL617256,722.0,BAO_0000219,
2524,107,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,1,,17296,CHEMBL616874,722.0,BAO_0000219,
2525,107,,,9,,D,,,HEK293,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,1,,15779,CHEMBL616875,722.0,BAO_0000219,
2526,107,,,8,,H,,,HEK293,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,1,,14391,CHEMBL616876,722.0,BAO_0000219,
2527,107,,,8,,H,,,HEK293,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,1,,15851,CHEMBL616877,722.0,BAO_0000219,
2528,107,,,9,,D,,,HEK293,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,1,,15851,CHEMBL616878,722.0,BAO_0000219,
2529,107,,,8,,H,,,HEK293,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,1,,3832,CHEMBL616879,722.0,BAO_0000219,
2530,107,,,8,,H,,,HEK293,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,1,,3833,CHEMBL616880,722.0,BAO_0000219,
2531,107,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,1,,12936,CHEMBL616881,722.0,BAO_0000219,
2532,107,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,1,,17451,CHEMBL616882,723.0,BAO_0000219,
2533,107,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,1,,17451,CHEMBL616883,723.0,BAO_0000219,
2534,107,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,1,,17451,CHEMBL616884,723.0,BAO_0000219,
2535,107,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,1,,4199,CHEMBL616885,722.0,BAO_0000219,
2536,107,,,8,,H,,,CHO-K1,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,1,,1883,CHEMBL616886,485.0,BAO_0000219,
2537,107,,,8,,H,,,CHO-K1,Expert,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,1,,1883,CHEMBL616887,485.0,BAO_0000219,
2538,107,,,9,,D,,,,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,1,,14875,CHEMBL616888,,BAO_0000357,
2539,107,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,1,,15146,CHEMBL616889,722.0,BAO_0000219,
2540,107,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,1,,5213,CHEMBL616890,722.0,BAO_0000219,
2541,107,,,9,,D,,,CHO,Expert,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,1,,16404,CHEMBL616891,449.0,BAO_0000219,
2542,107,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,1,,14818,CHEMBL616892,722.0,BAO_0000219,
2543,107,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,1,,4829,CHEMBL616893,722.0,BAO_0000219,
2544,10620,,,8,,H,,,NIH3T3,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,1,,12652,CHEMBL616894,723.0,BAO_0000219,
2545,107,,,8,,H,,,NIH3T3,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,1,,4682,CHEMBL616895,723.0,BAO_0000219,
2546,10620,,,8,,H,,,,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,1,,12652,CHEMBL616896,,BAO_0000019,
2547,10621,,,8,,H,,,,Autocuration,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,1,,4921,CHEMBL617099,,BAO_0000357,
2548,10621,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,1,,4921,CHEMBL617100,,BAO_0000357,
2549,107,,,8,,H,,,,Autocuration,Binding affinity against rabbit aorta 5-HT2A receptor,B,1,,16312,CHEMBL884532,,BAO_0000357,
2550,107,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,1,,14998,CHEMBL617101,,BAO_0000357,
2551,107,,,8,,H,,,,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,1,,14025,CHEMBL617102,,BAO_0000357,
2552,107,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,1,,13047,CHEMBL617103,,BAO_0000019,
2553,107,,,8,,H,,,,Expert,The compound was tested for binding affinity against 5-HT2A receptor,B,1,,13047,CHEMBL617104,,BAO_0000357,
2554,10576,,,8,,H,,,CHO-K1,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,1,,1883,CHEMBL857979,485.0,BAO_0000219,
2555,12687,,,8,,H,,,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,1,,13463,CHEMBL857502,,BAO_0000019,
2556,12687,,,8,,H,,,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,1,,13463,CHEMBL617105,,BAO_0000019,
2557,12687,,,8,,H,,Stomach,,Autocuration,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,1,,13463,CHEMBL858021,,BAO_0000019,945.0
2558,12687,,,9,,D,,Stomach,,Expert,Binding affinity for 5-HT 2A in rat stomach fundus,B,1,,13463,CHEMBL875910,,BAO_0000019,945.0
2559,12687,,,8,,H,,,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,1,,13463,CHEMBL617106,,BAO_0000019,
2560,12687,,,8,,H,,,NIH3T3,Expert,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,1,,16326,CHEMBL617107,723.0,BAO_0000219,
2561,12687,,,8,,H,,,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,1,,14093,CHEMBL617108,,BAO_0000019,
2562,12687,,,8,,H,,,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,1,,14093,CHEMBL617109,,BAO_0000019,
2563,12687,,,8,,H,,,,Autocuration,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,1,,15740,CHEMBL617110,,BAO_0000357,
2564,12687,,,8,,H,,,,Autocuration,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,1,,16633,CHEMBL617111,,BAO_0000357,
2565,12687,,,9,,D,,,,Expert,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,1,,17200,CHEMBL617112,,BAO_0000019,
2566,12687,,,8,,H,,,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,1,,17133,CHEMBL617113,,BAO_0000357,
2567,12687,,,8,,H,,,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,1,,17133,CHEMBL617114,,BAO_0000357,
2568,12687,,,8,,H,,,,Autocuration,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,1,,17133,CHEMBL617115,,BAO_0000357,
2569,12687,,,8,,H,,,,Autocuration,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,1,,17200,CHEMBL617116,,BAO_0000219,
2570,12687,,,8,,H,,,,Autocuration,Efficacy at 5-hydroxytryptamine 2A receptor,F,1,,15363,CHEMBL617117,,BAO_0000019,
2571,12687,,,8,,H,,,,Autocuration,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,1,,17200,CHEMBL617118,,BAO_0000357,
2572,12687,,,9,,D,,,,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,1,,17200,CHEMBL617119,,BAO_0000357,
2573,12687,,,9,,D,,,,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,1,,17200,CHEMBL617120,,BAO_0000357,
2574,12687,,,9,,D,,,,Expert,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,1,,17200,CHEMBL617121,,BAO_0000219,
2575,12687,,,8,,H,,,,Autocuration,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,1,,17200,CHEMBL617122,,BAO_0000219,
2576,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,1,,17211,CHEMBL617123,,BAO_0000019,
2577,12687,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,1,,17331,CHEMBL617124,,BAO_0000019,
2578,12687,,,8,,H,,,,Expert,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,1,,13565,CHEMBL617600,,BAO_0000249,
2579,12687,,,8,,H,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,1,,13730,CHEMBL617601,,BAO_0000357,
2580,12687,,,8,,H,,,,Expert,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,1,,12416,CHEMBL882923,,BAO_0000019,
2581,12687,,,8,,H,,,,Autocuration,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,15295,CHEMBL617602,,BAO_0000357,
2582,12687,,,8,,H,,,,Autocuration,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,1,,1742,CHEMBL617603,,BAO_0000019,
2583,12687,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,1,,15295,CHEMBL617604,,BAO_0000357,
2584,12687,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,1,,14970,CHEMBL617605,,BAO_0000019,
2585,12687,,,8,,H,,,,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,1,,16693,CHEMBL617606,,BAO_0000019,
2586,12687,,,9,,D,,,,Expert,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,1,,14776,CHEMBL617607,,BAO_0000019,
2587,12687,,,8,,H,,,,Autocuration,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,14286,CHEMBL617455,,BAO_0000249,
2588,12687,,,9,,D,,,,Expert,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,1,,17200,CHEMBL617456,,BAO_0000019,
2589,12687,,,8,,H,,,,Expert,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,1,,15306,CHEMBL617457,,BAO_0000357,
2590,12687,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,1,,14178,CHEMBL617458,,BAO_0000357,
2591,12687,,,9,,D,,,,Expert,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,1,,14229,CHEMBL617459,,BAO_0000019,
2592,12687,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,1,,12884,CHEMBL617460,,BAO_0000357,
2593,12687,,,8,,H,,,,Expert,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,1,,13149,CHEMBL617461,,BAO_0000357,
2594,12687,,,9,,D,,,,Expert,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,1,,15295,CHEMBL617462,,BAO_0000019,
2595,12687,,,8,,H,,,,Autocuration,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,1,,15740,CHEMBL617463,,BAO_0000357,
2596,12687,,,8,,H,,,,Autocuration,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,1,,15185,CHEMBL617464,,BAO_0000019,
2597,12687,,,8,,H,,,,Autocuration,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,1,,15185,CHEMBL617465,,BAO_0000019,
2598,12687,,,8,,H,,,,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,1,,17529,CHEMBL617466,,BAO_0000019,
2599,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,1,,14826,CHEMBL617467,,BAO_0000019,
2600,12687,,,8,,H,,,,Expert,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,1,,17211,CHEMBL617468,,BAO_0000019,
2601,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,1,,14826,CHEMBL617469,,BAO_0000019,
2602,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,1,,14093,CHEMBL617470,,BAO_0000019,
2603,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,1,,14093,CHEMBL617471,,BAO_0000019,
2604,12687,,,8,,H,,,NIH3T3,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,1,,13246,CHEMBL617472,723.0,BAO_0000219,
2605,12687,,,8,,H,,,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,1,,13246,CHEMBL617473,,BAO_0000357,
2606,12687,,,9,,D,,,,Expert,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,1,,15436,CHEMBL617474,,BAO_0000019,
2607,12687,,,9,,D,,,,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,1,,15436,CHEMBL617475,,BAO_0000019,
2608,12687,,,8,,H,,Brain,,Autocuration,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,1,,14442,CHEMBL617476,,BAO_0000221,955.0
2609,12687,,,8,,H,,,,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,1,,12457,CHEMBL617477,,BAO_0000357,
2610,12687,,,8,,H,,,NIH3T3,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,1,,12457,CHEMBL617478,723.0,BAO_0000219,
2611,12687,,,8,,H,,,,Autocuration,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,1,,14755,CHEMBL617479,,BAO_0000221,
2612,12687,,,8,,H,,,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,1,,4707,CHEMBL617480,,BAO_0000357,
2613,12687,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor,B,1,,13297,CHEMBL617481,,BAO_0000357,
2614,12687,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,1,,17331,CHEMBL617482,,BAO_0000019,
2615,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,1,,4664,CHEMBL617483,,BAO_0000019,
2616,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,1,,16633,CHEMBL621528,,BAO_0000357,
2617,12687,,,9,,D,,,NIH3T3,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,1,,4664,CHEMBL621529,723.0,BAO_0000219,
2618,12687,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,1,,16133,CHEMBL621530,,BAO_0000357,
2619,12687,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,1,,16133,CHEMBL621531,,BAO_0000357,
2620,12687,,,9,,D,,,,Expert,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,1,,14060,CHEMBL621532,,BAO_0000019,
2621,12687,,,8,,H,,,,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,1,,16326,CHEMBL621533,,BAO_0000357,
2622,12687,,,8,,H,,,CHO,Expert,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,1,,16659,CHEMBL621534,449.0,BAO_0000219,
2623,12687,,,8,,H,,,,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,1,,14776,CHEMBL621535,,BAO_0000019,
2624,12687,,,8,,H,,,,Autocuration,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,1,,13481,CHEMBL621536,,BAO_0000357,
2625,12687,,,8,,H,,,,Autocuration,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,1,,17386,CHEMBL621537,,BAO_0000357,
2626,12687,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor,B,1,,6611,CHEMBL621538,,BAO_0000357,
2627,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,1,,14423,CHEMBL621539,,BAO_0000019,
2628,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,1,,15412,CHEMBL621540,,BAO_0000019,
2629,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,1,,15412,CHEMBL621541,,BAO_0000019,
2630,12687,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,1,,6238,CHEMBL621542,,BAO_0000019,
2631,12687,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,1,,6648,CHEMBL621543,,BAO_0000357,
2632,12687,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,1,,5667,CHEMBL621544,,BAO_0000357,
2633,12687,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,1,,6611,CHEMBL621545,,BAO_0000357,
2634,12687,,,8,,H,,,,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,1,,13481,CHEMBL621546,,BAO_0000357,
2635,12687,,,8,,H,,,,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,1,,13481,CHEMBL621547,,BAO_0000357,
2636,12687,,,8,,H,,,NIH3T3,Expert,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,1,,15558,CHEMBL618692,723.0,BAO_0000219,
2637,12687,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,1,,6013,CHEMBL618693,,BAO_0000357,
2638,12687,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,1,,16633,CHEMBL872922,,BAO_0000357,
2639,12687,,,8,,H,,,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,1,,6013,CHEMBL618694,,BAO_0000357,
2640,12687,,,9,,D,,,,Expert,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,1,,6013,CHEMBL618695,,BAO_0000357,
2641,12687,,,8,,H,,,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,1,,6013,CHEMBL618696,,BAO_0000357,
2642,12687,,,8,,H,,,,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,1,,6013,CHEMBL618697,,BAO_0000357,
2643,12687,,,8,,H,,,,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,1,,6013,CHEMBL618892,,BAO_0000357,
2644,12687,,,8,,H,,,,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,1,,6013,CHEMBL618893,,BAO_0000357,
2645,12687,,,8,,H,,,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,1,,16293,CHEMBL618894,,BAO_0000357,
2646,12687,,,8,,H,,,NIH3T3,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,1,,17175,CHEMBL618895,723.0,BAO_0000219,
2647,12687,,,9,,D,,,,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,1,,13278,CHEMBL618896,,BAO_0000357,
2648,12687,,,8,,H,,Caudate-putamen,,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,1,,3682,CHEMBL618897,,BAO_0000019,5383.0
2649,12687,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,1,,2014,CHEMBL618898,,BAO_0000357,
2650,12687,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,1,,2014,CHEMBL618899,,BAO_0000357,
2651,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,1,,4932,CHEMBL618900,,BAO_0000357,
2652,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,1,,4932,CHEMBL618901,,BAO_0000019,
2653,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,1,,3935,CHEMBL618902,,BAO_0000357,
2654,12687,,,9,,D,,Hippocampus,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,1,,5432,CHEMBL618903,,BAO_0000221,10000000.0
2655,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,1,,15818,CHEMBL618904,,BAO_0000357,
2656,12687,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,1,,13672,CHEMBL618905,,BAO_0000357,
2657,12687,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,1,,13672,CHEMBL618906,,BAO_0000357,
2658,12687,,,8,,H,,,NIH3T3,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,1,,14749,CHEMBL618907,723.0,BAO_0000219,
2659,12687,,,8,,H,,,,Autocuration,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,1,,13462,CHEMBL618908,,BAO_0000019,
2660,12687,,,8,,H,,,,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,1,,15740,CHEMBL617909,,BAO_0000357,
2661,12687,,,8,,H,,,,Expert,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,1,,16647,CHEMBL617910,,BAO_0000019,
2662,12687,,,8,,H,,Brain,,Autocuration,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,1,,13345,CHEMBL617911,,BAO_0000221,955.0
2663,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,16740,CHEMBL872923,,BAO_0000249,
2664,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,16740,CHEMBL617912,,BAO_0000249,
2665,12687,,,9,,D,,,,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,1,,15535,CHEMBL617913,,BAO_0000019,
2666,12687,,,8,,H,,,,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,16740,CHEMBL617914,,BAO_0000249,
2667,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,16740,CHEMBL617915,,BAO_0000249,
2668,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,1,,16740,CHEMBL617916,,BAO_0000249,
2669,12687,,,9,,D,,,,Expert,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,1,,4795,CHEMBL617917,,BAO_0000019,
2670,12687,,,8,,H,,,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,1,,8,CHEMBL617918,,BAO_0000019,
2671,12687,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,1,,8,CHEMBL617919,,BAO_0000019,
2672,12687,,,9,,D,,,,Expert,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,1,,17200,CHEMBL617920,,BAO_0000019,
2673,12687,,,9,,D,,,,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,1,,2148,CHEMBL617921,,BAO_0000019,
2674,105102,,,5,,D,,,,Expert,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,1,,13345,CHEMBL617922,,BAO_0000224,
2675,12687,,,8,,H,,,,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,1,,5088,CHEMBL617923,,BAO_0000357,
2676,12687,,,8,,H,,,,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,1,,5088,CHEMBL617924,,BAO_0000357,
2677,12687,,,8,,H,,,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,1,,17133,CHEMBL617925,,BAO_0000357,
2678,12687,,,9,,D,,,,Expert,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,1,,17133,CHEMBL617926,,BAO_0000357,
2679,12687,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,1,,16532,CHEMBL617927,,BAO_0000357,
2680,12687,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,1,,15086,CHEMBL617928,,BAO_0000357,
2681,12687,,,9,,D,,,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,1,,2309,CHEMBL617929,,BAO_0000019,
2682,12687,,,8,,H,,,,Expert,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,1,,12953,CHEMBL617930,,BAO_0000019,
2683,12687,,,8,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,1,,12953,CHEMBL617931,,BAO_0000019,
2684,12687,,,8,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL617932,,BAO_0000019,
2685,12687,,,8,,H,,,CHO,Autocuration,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,1,,16659,CHEMBL617933,449.0,BAO_0000219,
2686,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,1,,16740,CHEMBL617934,,BAO_0000019,
2687,12687,,,8,,H,,,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,1,,16740,CHEMBL617935,,BAO_0000019,
2688,12687,,,8,,H,,,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,1,,17133,CHEMBL617936,,BAO_0000357,
2689,12687,,,8,,H,,,,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,1,,17211,CHEMBL617937,,BAO_0000019,
2690,12687,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,1,,17331,CHEMBL617938,,BAO_0000019,
2691,12687,,,8,,H,,,,Autocuration,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,1,,16633,CHEMBL617939,,BAO_0000218,
2692,12687,,,8,,H,,,,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,1,,16633,CHEMBL617940,,BAO_0000218,
2693,12687,,,8,,H,,,,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,1,,16633,CHEMBL617941,,BAO_0000218,
2694,12687,,,8,,H,,,,Expert,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,1,,15026,CHEMBL617942,,BAO_0000357,
2695,12687,,,8,,H,,,,Expert,Ratio of pKi of 5-HT2A to that of D2 receptor,B,1,,15026,CHEMBL617943,,BAO_0000357,
2696,105093,,,4,,H,,,,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,1,,16404,CHEMBL617944,,BAO_0000224,
2697,105093,,,4,,H,,,,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,1,,16404,CHEMBL617945,,BAO_0000224,
2698,105075,,,4,,H,,,,Expert,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,1,,16404,CHEMBL617946,,BAO_0000224,
2699,12687,,,8,,H,,,,Autocuration,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,1,,16404,CHEMBL617947,,BAO_0000357,
2700,12687,,,8,,H,,,,Expert,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,1,,16326,CHEMBL617948,,BAO_0000357,
2701,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,1,,15847,CHEMBL858116,,BAO_0000019,
2702,12687,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,1,,15847,CHEMBL617949,,BAO_0000019,
2703,12687,,,8,,H,,,,Autocuration,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,1,,15329,CHEMBL617950,,BAO_0000019,
2704,12687,,,8,,H,,Thoracic aorta,,Expert,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,1,,16404,CHEMBL617951,,BAO_0000019,1515.0
2705,12687,,,8,,H,,Thoracic aorta,,Expert,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,1,,16404,CHEMBL617952,,BAO_0000019,1515.0
2706,12687,,,8,,H,,Thoracic aorta,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,1,,16404,CHEMBL617953,,BAO_0000019,1515.0
2707,12687,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617954,,BAO_0000357,
2708,12687,,,8,,H,,,,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617955,,BAO_0000019,
2709,12687,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,1,,12861,CHEMBL857071,,BAO_0000019,
2710,12687,,,8,,H,,,,Expert,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,1,,12490,CHEMBL617270,,BAO_0000019,
2711,12687,,,8,,H,,,N1E-115,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,1,,12827,CHEMBL617271,339.0,BAO_0000219,
2712,12687,,,8,,H,,,N1E-115,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,1,,12827,CHEMBL617272,339.0,BAO_0000219,
2713,12687,,,8,,H,,,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,1,,12918,CHEMBL617273,,BAO_0000019,
2714,12687,,,9,,D,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,1,,12919,CHEMBL617274,,BAO_0000019,
2715,108,,,8,,H,,,,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,1,,17723,CHEMBL617275,,BAO_0000357,
2716,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,1,,6013,CHEMBL617276,,BAO_0000357,
2717,108,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,1,,16293,CHEMBL617277,,BAO_0000357,
2718,108,,,8,,H,,,,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,1,,3857,CHEMBL617278,,BAO_0000019,
2719,108,,,8,,H,,,,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,1,,3857,CHEMBL617279,,BAO_0000019,
2720,108,,,8,,H,,,,Expert,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,1,,3857,CHEMBL617280,,BAO_0000019,
2721,108,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,1,,15363,CHEMBL617281,,BAO_0000357,
2722,108,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,1,,15363,CHEMBL617282,,BAO_0000357,
2723,108,,,8,,H,,,,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,1,,16441,CHEMBL617283,,BAO_0000019,
2724,108,,,8,,H,,,,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,1,,16441,CHEMBL617284,,BAO_0000019,
2725,108,,,8,,H,,,HEK293,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,1,,4176,CHEMBL617285,722.0,BAO_0000219,
2726,108,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,1,,17085,CHEMBL617286,,BAO_0000019,
2727,108,,,9,,D,,,,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617287,,BAO_0000357,
2728,108,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,1,,5088,CHEMBL617288,,BAO_0000357,
2729,108,,,8,,H,,,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,1,,5088,CHEMBL617289,,BAO_0000357,
2730,108,,,8,,H,,,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,1,,5088,CHEMBL872917,,BAO_0000357,
2731,108,,,8,,H,,,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,1,,5088,CHEMBL617290,,BAO_0000357,
2732,108,,,8,,H,,,CHO,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,1,,16659,CHEMBL617291,449.0,BAO_0000219,
2733,108,,,8,,H,,,CHO,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,1,,16659,CHEMBL617292,449.0,BAO_0000219,
2734,108,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,1,,17451,CHEMBL617293,723.0,BAO_0000219,
2735,108,,,9,,D,,,CHO,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,1,,6857,CHEMBL617294,449.0,BAO_0000219,
2736,108,,,8,,H,,,,Expert,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,1,,3857,CHEMBL617295,,BAO_0000019,
2737,108,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617296,,BAO_0000357,
2738,108,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617297,,BAO_0000019,
2739,108,,,8,,H,,,CHO,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,1,,5104,CHEMBL617298,449.0,BAO_0000219,
2740,108,,,8,,H,,,CHO,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,1,,5105,CHEMBL617299,449.0,BAO_0000219,
2741,108,,,8,,H,,,CHO,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,1,,5105,CHEMBL617300,449.0,BAO_0000219,
2742,108,,,8,,H,,,,Autocuration,Binding affinity against 5-HT2C receptor,B,1,,5254,CHEMBL617454,,BAO_0000357,
2743,108,,,8,,H,,,HEK293,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,1,,13267,CHEMBL617505,722.0,BAO_0000219,
2744,108,,,9,,D,,,HEK293,Expert,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,1,,14157,CHEMBL617506,722.0,BAO_0000219,
2745,108,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,1,,12936,CHEMBL617507,722.0,BAO_0000219,
2746,108,,,8,,H,,,,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,1,,14068,CHEMBL617508,,BAO_0000357,
2747,108,,,9,,D,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,1,,12936,CHEMBL857982,722.0,BAO_0000219,
2748,108,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,1,,4540,CHEMBL617509,722.0,BAO_0000219,
2749,108,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,1,,4540,CHEMBL617510,722.0,BAO_0000219,
2750,108,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,1,,6166,CHEMBL617511,,BAO_0000357,
2751,108,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,1,,17296,CHEMBL617512,722.0,BAO_0000219,
2752,108,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,1,,17296,CHEMBL617749,722.0,BAO_0000219,
2753,108,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,1,,15779,CHEMBL617750,722.0,BAO_0000219,
2754,108,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,1,,15779,CHEMBL617751,722.0,BAO_0000219,
2755,108,,,8,,H,,,HEK293,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,1,,14391,CHEMBL617752,722.0,BAO_0000219,
2756,108,,,8,,H,,,HEK293,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,1,,15779,CHEMBL617753,722.0,BAO_0000219,
2757,108,,,8,,H,,,HEK293,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,1,,15851,CHEMBL617754,722.0,BAO_0000219,
2758,108,,,9,,D,,,HEK293,Expert,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,1,,15851,CHEMBL617755,722.0,BAO_0000219,
2759,108,,,8,,H,,,HEK293,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,1,,15779,CHEMBL617756,722.0,BAO_0000219,
2760,108,,,8,,H,,,HEK293,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,1,,3832,CHEMBL617757,722.0,BAO_0000219,
2761,108,,,8,,H,,,HEK293,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,1,,3833,CHEMBL617758,722.0,BAO_0000219,
2762,108,,,8,,H,,,NIH3T3,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,1,,17451,CHEMBL617759,723.0,BAO_0000219,
2763,108,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,1,,4199,CHEMBL617760,722.0,BAO_0000219,
2764,108,,,8,,H,,,CHO-K1,Expert,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,1,,1883,CHEMBL617761,485.0,BAO_0000219,
2765,108,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,B,1,,4321,CHEMBL617762,,BAO_0000357,
2766,108,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,1,,14875,CHEMBL617763,,BAO_0000357,
2767,108,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,1,,15146,CHEMBL857983,722.0,BAO_0000219,
2768,108,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,1,,5213,CHEMBL617764,722.0,BAO_0000219,
2769,108,,,8,,H,,,HeLa,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,1,,16404,CHEMBL617765,308.0,BAO_0000219,
2770,108,,,8,,H,,,,Autocuration,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,1,,13267,CHEMBL617766,,BAO_0000019,
2771,108,,,8,,H,,Hippocampus,,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,1,,13267,CHEMBL617767,,BAO_0000221,10000000.0
2772,108,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,1,,14818,CHEMBL617768,722.0,BAO_0000219,
2773,108,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,1,,4829,CHEMBL617769,722.0,BAO_0000219,
2774,11864,,,8,,H,,,,Autocuration,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,1,,13463,CHEMBL858023,,BAO_0000357,
2775,11864,,,8,,H,,Stomach,,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,1,,13463,CHEMBL617770,,BAO_0000019,945.0
2776,11864,,,8,,H,,Stomach,,Autocuration,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,1,,13463,CHEMBL617771,,BAO_0000019,945.0
2777,11864,,,8,,H,,,A9,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,1,,12652,CHEMBL617772,625.0,BAO_0000219,
2778,11864,,,8,,H,,,NIH3T3,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,1,,4682,CHEMBL617773,723.0,BAO_0000219,
2779,11864,,,8,,H,,,NIH3T3,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,1,,4682,CHEMBL617850,723.0,BAO_0000219,
2780,11864,,,8,,H,,,NIH3T3,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,1,,4682,CHEMBL617851,723.0,BAO_0000219,
2781,11864,,,8,,H,,,,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,1,,12652,CHEMBL617852,,BAO_0000019,
2782,12689,,,8,,H,,Stomach,,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,1,,13463,CHEMBL858024,,BAO_0000019,945.0
2783,12689,,,9,,D,,Stomach,,Expert,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,1,,13463,CHEMBL617853,,BAO_0000019,945.0
2784,108,,,8,,H,,,,Expert,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,1,,13969,CHEMBL617854,,BAO_0000357,
2785,108,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,B,1,,13392,CHEMBL873477,,BAO_0000357,
2786,108,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,1,,13392,CHEMBL617855,,BAO_0000357,
2787,108,,,8,,H,,,,Expert,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,1,,14430,CHEMBL617856,,BAO_0000019,
2788,108,,,8,,H,,,,Autocuration,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,1,,1742,CHEMBL617857,,BAO_0000019,
2789,108,,,8,,H,,,,Autocuration,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,1,,14286,CHEMBL617858,,BAO_0000249,
2790,108,,,8,,H,,,,Autocuration,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,1,,5619,CHEMBL617859,,BAO_0000357,
2791,108,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,1,,15086,CHEMBL617860,,BAO_0000357,
2792,108,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617861,,BAO_0000357,
2793,108,,,8,,H,,,,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617862,,BAO_0000019,
2794,108,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,1,,12861,CHEMBL617863,,BAO_0000019,
2795,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,1,,12827,CHEMBL617864,,BAO_0000249,
2796,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,1,,12827,CHEMBL617649,,BAO_0000249,
2797,108,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,1,,12919,CHEMBL617650,,BAO_0000019,
2798,108,,,8,,H,,,,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,1,,12919,CHEMBL617651,,BAO_0000019,
2799,108,,,8,,H,,,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,1,,16429,CHEMBL617652,,BAO_0000357,
2800,108,,,8,,H,,,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,1,,773,CHEMBL857072,,BAO_0000019,
2801,108,,,8,,H,,,,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,1,,5033,CHEMBL617653,,BAO_0000357,
2802,12687,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,1,,12861,CHEMBL617654,,BAO_0000019,
2803,12689,,,8,,H,,,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,1,,14093,CHEMBL617655,,BAO_0000019,
2804,12689,,,8,,H,,,,Expert,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,1,,14970,CHEMBL617656,,BAO_0000357,
2805,12689,,,8,,H,,,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,1,,14970,CHEMBL617657,,BAO_0000357,
2806,12689,,,8,,H,,,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,1,,14970,CHEMBL617658,,BAO_0000357,
2807,12689,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,1,,14178,CHEMBL617659,,BAO_0000357,
2808,12689,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,1,,14178,CHEMBL617838,,BAO_0000357,
2809,12689,,,9,,D,Brain membranes,,,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,1,,14229,CHEMBL617839,,BAO_0000249,
2810,12689,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,1,,16532,CHEMBL617840,,BAO_0000357,
2811,12689,,,8,,H,,,,Autocuration,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,1,,14826,CHEMBL617841,,BAO_0000019,
2812,12689,,,8,,H,,,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,1,,17211,CHEMBL875915,,BAO_0000019,
2813,12689,,In vitro,8,,H,,,,Expert,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,1,,17211,CHEMBL617842,,BAO_0000219,
2814,12689,,,8,,H,,,NIH3T3,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,1,,13246,CHEMBL617843,723.0,BAO_0000219,
2815,12689,,,8,,H,,,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,1,,13246,CHEMBL617844,,BAO_0000357,
2816,12689,,,8,,H,,,,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,1,,12457,CHEMBL617845,,BAO_0000357,
2817,12689,,,8,,H,,,NIH3T3,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,1,,12457,CHEMBL617846,723.0,BAO_0000219,
2818,12689,,,8,,H,,,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,1,,4707,CHEMBL617847,,BAO_0000357,
2819,12689,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,B,1,,13297,CHEMBL617848,,BAO_0000357,
2820,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,1,,16633,CHEMBL617849,,BAO_0000357,
2821,12689,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,1,,16133,CHEMBL621507,,BAO_0000357,
2822,12689,,,8,,H,,,,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,1,,16326,CHEMBL621508,,BAO_0000357,
2823,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,1,,14423,CHEMBL621509,,BAO_0000019,
2824,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,1,,15412,CHEMBL621510,,BAO_0000019,
2825,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,1,,15412,CHEMBL621511,,BAO_0000019,
2826,12689,,,8,,H,,,A9,Expert,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,1,,15558,CHEMBL621512,625.0,BAO_0000219,
2827,12689,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,1,,16633,CHEMBL621513,,BAO_0000357,
2828,12689,,,8,,H,,,,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,1,,6013,CHEMBL621514,,BAO_0000357,
2829,12689,,In vitro,8,,H,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,1,,17175,CHEMBL621515,,BAO_0000219,
2830,12689,,,8,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,1,,12469,CHEMBL621516,,BAO_0000219,
2831,12689,,,8,,H,,Caudate-putamen,,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,1,,3682,CHEMBL621517,,BAO_0000019,5383.0
2832,12689,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,1,,4932,CHEMBL621518,,BAO_0000357,
2833,12689,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,1,,4932,CHEMBL621519,,BAO_0000019,
2834,12689,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,1,,3935,CHEMBL621520,,BAO_0000357,
2835,12689,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,1,,15818,CHEMBL621521,,BAO_0000357,
2836,12689,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,1,,15818,CHEMBL621522,,BAO_0000357,
2837,12689,,,8,,H,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,1,,14749,CHEMBL621523,,BAO_0000219,
2838,12689,,,8,,H,,,,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,1,,15740,CHEMBL621524,,BAO_0000357,
2839,12689,,,9,,D,,,,Expert,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,1,,17133,CHEMBL621525,,BAO_0000357,
2840,12689,,,8,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,1,,16532,CHEMBL872921,,BAO_0000357,
2841,12689,,,8,,H,,,,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,1,,12369,CHEMBL621526,,BAO_0000357,
2842,12689,,,8,,H,,,,Expert,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,1,,12369,CHEMBL621527,,BAO_0000219,
2843,12689,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,1,,2309,CHEMBL617865,,BAO_0000019,
2844,12689,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,1,,12953,CHEMBL617866,,BAO_0000357,
2845,12689,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL617867,,BAO_0000019,
2846,12689,,,8,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL617487,,BAO_0000357,
2847,12689,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,B,1,,12953,CHEMBL617488,,BAO_0000357,
2848,12689,,,8,,H,,,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,1,,17133,CHEMBL617489,,BAO_0000357,
2849,12689,,,8,,H,,,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,1,,17211,CHEMBL617490,,BAO_0000019,
2850,12689,,,8,,H,,,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,1,,17211,CHEMBL617491,,BAO_0000019,
2851,12689,,,8,,H,,,,Autocuration,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,1,,14025,CHEMBL617492,,BAO_0000019,
2852,12689,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,1,,14998,CHEMBL617493,,BAO_0000019,
2853,12689,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,1,,4342,CHEMBL617494,,BAO_0000357,
2854,12689,,,9,,D,,,,Expert,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,1,,13735,CHEMBL617495,,BAO_0000019,
2855,12689,,,8,,H,,,,Autocuration,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,1,,13181,CHEMBL617496,,BAO_0000357,
2856,12689,,,8,,H,,,CHO-K1,Autocuration,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,1,,1883,CHEMBL617497,485.0,BAO_0000219,
2857,12689,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,1,,15194,CHEMBL617498,,BAO_0000357,
2858,12689,,,8,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,1,,15194,CHEMBL617499,,BAO_0000357,
2859,12689,,,8,,H,,,,Autocuration,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,1,,14579,CHEMBL617500,,BAO_0000019,
2860,108,,,8,,H,,,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,1,,4639,CHEMBL617501,,BAO_0000357,
2861,108,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,1,,4820,CHEMBL617502,,BAO_0000357,
2862,227,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,1,,14442,CHEMBL617503,,BAO_0000357,
2863,227,,,8,,H,,,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,1,,14755,CHEMBL617504,,BAO_0000357,
2864,227,,,8,,H,,,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,1,,14744,CHEMBL617406,,BAO_0000357,
2865,227,,,9,,D,,,,Expert,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,1,,6857,CHEMBL617407,,BAO_0000019,
2866,227,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,1,,16209,CHEMBL617408,,BAO_0000357,
2867,227,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,1,,15363,CHEMBL617409,,BAO_0000357,
2868,227,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,1,,15363,CHEMBL617410,,BAO_0000357,
2869,227,,,8,,H,,,,Autocuration,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,1,,15363,CHEMBL617411,,BAO_0000357,
2870,227,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,1,,17085,CHEMBL617412,,BAO_0000019,
2871,227,,,9,,D,,,,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,1,,17200,CHEMBL617774,,BAO_0000357,
2872,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,1,,15851,CHEMBL617775,722.0,BAO_0000219,
2873,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,1,,15851,CHEMBL617776,722.0,BAO_0000219,
2874,227,,,9,,D,,,CHO,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,1,,6857,CHEMBL617777,449.0,BAO_0000219,
2875,227,,,9,,D,,,CHO,Expert,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,1,,6857,CHEMBL617778,449.0,BAO_0000219,
2876,227,,,8,,H,,,HEK293,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,1,,15779,CHEMBL617779,722.0,BAO_0000219,
2877,227,,,8,,H,,,HEK293,Expert,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,1,,15851,CHEMBL617780,722.0,BAO_0000219,
2878,227,,,8,,H,,,HEK293,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,1,,15779,CHEMBL617781,722.0,BAO_0000219,
2879,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,1,,14157,CHEMBL617782,722.0,BAO_0000219,
2880,227,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,1,,4540,CHEMBL617783,722.0,BAO_0000219,
2881,227,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,1,,6166,CHEMBL617784,,BAO_0000357,
2882,227,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,1,,15779,CHEMBL617785,722.0,BAO_0000219,
2883,227,,,8,,H,,,HEK293,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,1,,14391,CHEMBL857984,722.0,BAO_0000219,
2884,227,,,8,,H,,,HEK293,Expert,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,1,,3832,CHEMBL617786,722.0,BAO_0000219,
2885,227,,,8,,H,,,HEK293,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,1,,3833,CHEMBL617787,722.0,BAO_0000219,
2886,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,1,,15851,CHEMBL617788,722.0,BAO_0000219,
2887,227,,,9,,D,,,HEK293,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,1,,15851,CHEMBL617789,722.0,BAO_0000219,
2888,227,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,1,,4199,CHEMBL617790,722.0,BAO_0000219,
2889,227,,,8,,H,,,CHO-K1,Expert,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,1,,1883,CHEMBL617791,485.0,BAO_0000219,
2890,227,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2B receptor,B,1,,4321,CHEMBL617608,,BAO_0000357,
2891,227,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,1,,15146,CHEMBL617609,722.0,BAO_0000219,
2892,227,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,1,,5213,CHEMBL617610,722.0,BAO_0000219,
2893,227,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,1,,14818,CHEMBL617611,722.0,BAO_0000219,
2894,227,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL617612,722.0,BAO_0000219,
2895,227,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,1,,4829,CHEMBL617613,722.0,BAO_0000219,
2896,227,,,8,,H,,,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,1,,14025,CHEMBL617614,,BAO_0000019,
2897,12688,,,8,,H,,Stomach,,Expert,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,1,,13463,CHEMBL617615,,BAO_0000019,945.0
2898,12688,,,8,,H,,Stomach,,Expert,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,1,,7259,CHEMBL858114,,BAO_0000357,945.0
2899,12688,,,8,,H,,Stomach,,Autocuration,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,1,,7259,CHEMBL617616,,BAO_0000357,945.0
2900,12688,,,9,,D,,Stomach,,Expert,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,1,,7185,CHEMBL617617,,BAO_0000019,945.0
2901,12688,,,9,,D,,,,Expert,Antagonistic against 5-hydroxytryptamine 2B receptor,F,1,,7185,CHEMBL875914,,BAO_0000019,
2902,12688,,,8,,H,,Stomach,,Autocuration,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,1,,13267,CHEMBL617618,,BAO_0000019,945.0
2903,12688,,,9,,D,,Stomach,,Expert,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,1,,13735,CHEMBL617619,,BAO_0000357,945.0
2904,12688,,,8,,H,,,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,1,,15738,CHEMBL617620,,BAO_0000019,
2905,12688,,,8,,H,,,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,1,,15738,CHEMBL617621,,BAO_0000019,
2906,12688,,,8,,H,,,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,1,,15738,CHEMBL617622,,BAO_0000019,
2907,12688,,,9,,D,,Stomach,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,1,,12936,CHEMBL617623,,BAO_0000357,945.0
2908,12688,,,9,,D,,Stomach,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,1,,12936,CHEMBL617624,,BAO_0000357,945.0
2909,12688,,,9,,D,,Stomach,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,1,,12936,CHEMBL617625,,BAO_0000357,945.0
2910,12688,,,9,,D,,Stomach,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,1,,12936,CHEMBL617626,,BAO_0000357,945.0
2911,12688,,,8,,H,,Stomach,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,1,,16404,CHEMBL617627,,BAO_0000019,945.0
2912,12688,,,8,,H,,Stomach,,Expert,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,1,,16404,CHEMBL617628,,BAO_0000019,945.0
2913,12688,,,8,,H,,Stomach,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,1,,16404,CHEMBL617629,,BAO_0000019,945.0
2914,12688,,,8,,H,,Stomach,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,1,,16404,CHEMBL858115,,BAO_0000019,945.0
2915,12688,,,9,,D,,Stomach,,Expert,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,1,,16404,CHEMBL617630,,BAO_0000019,945.0
2916,12688,,,8,,H,,Thoracic aorta,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,1,,16404,CHEMBL617631,,BAO_0000019,1515.0
2917,12688,,,8,,H,,,,Autocuration,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,1,,7483,CHEMBL617632,,BAO_0000357,
2918,12688,,,8,,H,,,,Expert,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,1,,7483,CHEMBL617633,,BAO_0000357,
2919,12688,,,8,,H,,,,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,1,,7483,CHEMBL617634,,BAO_0000357,
2920,12688,,,8,,H,,,,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,1,,7483,CHEMBL617635,,BAO_0000357,
2922,12688,,,9,,D,,Stomach,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,1,,16404,CHEMBL617637,,BAO_0000019,945.0
2923,227,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,B,1,,6347,CHEMBL617638,,BAO_0000357,
2924,227,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,1,,4373,CHEMBL617639,,BAO_0000357,
2925,227,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,1,,4373,CHEMBL617640,,BAO_0000357,
2926,227,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to 5-HT 2B receptor,B,1,,4687,CHEMBL617641,,BAO_0000357,
2927,227,,,8,,H,,,,Autocuration,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,1,,16946,CHEMBL617642,,BAO_0000357,
2928,227,,,8,,H,,,,Autocuration,Binding affinities against 5-hydroxytryptamine 2B receptor,B,1,,16633,CHEMBL617643,,BAO_0000357,
2929,227,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,1,,16633,CHEMBL617644,,BAO_0000357,
2930,227,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,1,,16633,CHEMBL617645,,BAO_0000357,
2931,108,,,8,,H,,,,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,1,,15026,CHEMBL617646,,BAO_0000357,
2932,108,,,8,,H,,,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,1,,15738,CHEMBL617647,,BAO_0000357,
2933,108,,,8,,H,,,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,1,,15738,CHEMBL617648,,BAO_0000357,
2934,108,,,8,,H,,,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,1,,15738,CHEMBL617875,,BAO_0000357,
2935,108,,,8,,H,,,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,1,,15738,CHEMBL617876,,BAO_0000357,
2936,108,,,8,,H,,,,Expert,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,1,,16404,CHEMBL617877,,BAO_0000357,
2937,108,,,8,,H,,,,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,1,,15026,CHEMBL617878,,BAO_0000357,
2938,108,,,8,,H,,,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,1,,15738,CHEMBL617879,,BAO_0000357,
2939,108,,,8,,H,,,,Autocuration,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,1,,16312,CHEMBL617880,,BAO_0000019,
2940,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,1,,5486,CHEMBL617881,,BAO_0000357,2435.0
2941,51,,,8,,H,,,,Autocuration,Binding affinity against 5-HT1A receptor,B,1,,5254,CHEMBL857073,,BAO_0000357,
2942,108,,,8,,H,,,CHO,Expert,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,1,,3857,CHEMBL617882,449.0,BAO_0000219,
2943,108,,,9,,D,,,CHO,Expert,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,1,,6857,CHEMBL617883,449.0,BAO_0000219,
2944,108,,,8,,H,,,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,1,,4176,CHEMBL617884,,BAO_0000219,
2945,108,,,8,,H,,,CHO,Autocuration,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,1,,6347,CHEMBL617885,449.0,BAO_0000219,
2946,108,,,8,,H,,,CHO,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,1,,6347,CHEMBL617886,449.0,BAO_0000219,
2947,108,,,9,,D,,,,Expert,Inhibition of human 5-hydroxytryptamine 2C receptor,B,1,,16146,CHEMBL617887,,BAO_0000357,
2948,108,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL617888,,BAO_0000357,
2949,108,,,8,,H,,,,Autocuration,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,1,,3857,CHEMBL617889,,BAO_0000019,
2950,108,,,8,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,1,,5635,CHEMBL617890,,BAO_0000357,
2951,108,,,8,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,1,,5635,CHEMBL617891,,BAO_0000357,
2952,108,,,8,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,1,,5635,CHEMBL617892,,BAO_0000357,
2953,108,,,8,,H,,,CHO,Expert,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,1,,4012,CHEMBL617893,449.0,BAO_0000219,
2954,108,,,8,,H,,,CHO,Expert,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,1,,6366,CHEMBL617894,449.0,BAO_0000219,
2955,108,,,8,,H,,,CHO,Expert,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,1,,15949,CHEMBL617895,449.0,BAO_0000219,
2956,108,,,8,,H,,,CHO,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,1,,17211,CHEMBL617896,449.0,BAO_0000219,
2957,108,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,1,,6491,CHEMBL617897,,BAO_0000357,
2958,108,,,8,,H,,,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,1,,14093,CHEMBL617898,,BAO_0000019,
2959,108,,,8,,H,,,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,1,,13481,CHEMBL617899,,BAO_0000019,
2960,108,,,8,,H,,,CHO,Expert,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,1,,6347,CHEMBL617900,449.0,BAO_0000219,
2961,108,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,1,,14093,CHEMBL617901,,BAO_0000019,
2962,108,,,8,,H,,,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,1,,14093,CHEMBL617902,,BAO_0000019,
2963,108,,,8,,H,,,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,1,,13481,CHEMBL617903,,BAO_0000019,
2964,108,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,1,,14442,CHEMBL617904,,BAO_0000357,
2965,108,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,1,,14442,CHEMBL617905,,BAO_0000357,
2966,108,,,8,,H,,,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,1,,14442,CHEMBL617906,,BAO_0000357,
2967,108,,,8,,H,,,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,1,,14755,CHEMBL617907,,BAO_0000357,
2968,108,,,8,,H,,,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,1,,14744,CHEMBL617908,,BAO_0000357,
2969,108,,,8,,H,,,CHO,Expert,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,1,,16659,CHEMBL620617,449.0,BAO_0000219,
2970,108,,,9,,D,,,,Expert,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,1,,6857,CHEMBL620618,,BAO_0000019,
2971,108,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,1,,5635,CHEMBL620619,,BAO_0000357,
2972,108,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,1,,4234,CHEMBL620620,,BAO_0000357,
2973,108,,,8,,H,,,,Autocuration,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,1,,16209,CHEMBL620621,,BAO_0000357,
2974,104698,,,7,,D,Membranes,,,Autocuration,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,1,,5778,CHEMBL872920,,BAO_0000249,
2975,104698,,,6,,H,,,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,1,,5094,CHEMBL620622,,BAO_0000223,
2976,104698,,,7,,D,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,1,,809,CHEMBL620623,,BAO_0000019,
2977,104698,,,6,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,1,,1578,CHEMBL620624,,BAO_0000019,
2978,104698,,,6,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,1,,809,CHEMBL620625,,BAO_0000019,
2979,104698,,,6,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,1,,12469,CHEMBL620626,,BAO_0000219,
2980,104698,,,6,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,1,,14290,CHEMBL621307,,BAO_0000019,
2981,104698,,,6,,H,,,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,1,,14290,CHEMBL621308,,BAO_0000019,
2982,104698,,,6,,H,,,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,1,,10609,CHEMBL621309,,BAO_0000223,
2983,104698,,,6,,H,,,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,1,,10609,CHEMBL621310,,BAO_0000223,
2984,104698,,,6,,H,,,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,1,,10609,CHEMBL621311,,BAO_0000223,
2985,104698,,,6,,H,,,,Autocuration,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,1,,15253,CHEMBL621502,,BAO_0000249,
2986,104698,,,6,,H,,,,Autocuration,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,1,,15253,CHEMBL621503,,BAO_0000249,
2987,104698,,,6,,H,Membranes,,,Autocuration,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,1,,11683,CHEMBL621504,,BAO_0000249,
2988,104698,,,6,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,1,,12092,CHEMBL621505,,BAO_0000223,
2989,104698,,,6,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,1,,1946,CHEMBL621506,,BAO_0000019,
2990,104698,,,6,,H,,,,Autocuration,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,1,,11623,CHEMBL619781,,BAO_0000223,
2991,104698,,,6,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,1,,11623,CHEMBL619782,,BAO_0000223,
2992,104698,,,6,,H,,,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,1,,14788,CHEMBL619783,,BAO_0000019,
2993,104698,,,7,,D,,,,Autocuration,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,1,,5432,CHEMBL619784,,BAO_0000019,
2994,104698,,,6,,H,,,,Autocuration,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,1,,14826,CHEMBL619785,,BAO_0000249,
2995,104698,,,6,,H,,,,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,1,,2222,CHEMBL619786,,BAO_0000223,
2996,104698,,,6,,H,,,,Autocuration,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,1,,11963,CHEMBL619787,,BAO_0000019,
2997,104698,,,6,,H,,,,Autocuration,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,1,,14145,CHEMBL872925,,BAO_0000019,
2998,104698,,,6,,H,,,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,1,,17819,CHEMBL619788,,BAO_0000019,
2999,104698,,,6,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,1,,10394,CHEMBL619789,,BAO_0000249,
3000,104698,,,6,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,1,,10394,CHEMBL619790,,BAO_0000249,
3001,104698,,,6,,H,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,1,,15034,CHEMBL619791,,BAO_0000019,
3002,104698,,,6,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,1,,691,CHEMBL619792,,BAO_0000019,
3003,104698,,,6,,H,Membranes,,,Autocuration,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,1,,12092,CHEMBL619793,,BAO_0000249,
3004,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,1,,11752,CHEMBL619794,,BAO_0000223,
3005,104698,,,6,,H,,Brain,,Autocuration,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,1,,11752,CHEMBL619795,,BAO_0000221,955.0
3006,104698,,,6,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,1,,301,CHEMBL619796,,BAO_0000019,
3007,104698,,,6,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,1,,16532,CHEMBL620448,,BAO_0000223,
3008,104698,,,6,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,1,,16532,CHEMBL620449,,BAO_0000223,
3009,104698,,,6,,H,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,1,,12092,CHEMBL620450,,BAO_0000223,
3010,104698,,,6,,H,,,,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,1,,11684,CHEMBL620451,,BAO_0000223,
3011,104698,,,6,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,1,,11684,CHEMBL620631,,BAO_0000223,
3012,104698,,,6,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,1,,12953,CHEMBL620632,,BAO_0000019,
3013,104698,,,6,,H,,,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,1,,12953,CHEMBL620633,,BAO_0000019,
3014,104698,,,6,,H,,,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,1,,12953,CHEMBL620634,,BAO_0000223,
3015,104698,,,6,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,1,,12861,CHEMBL620635,,BAO_0000019,
3016,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620636,,BAO_0000218,
3017,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,1,,11454,CHEMBL620637,,BAO_0000218,
3018,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620638,,BAO_0000218,
3019,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620639,,BAO_0000218,
3020,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620640,,BAO_0000218,
3021,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,1,,11454,CHEMBL620641,,BAO_0000218,
3022,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620642,,BAO_0000218,
3023,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620643,,BAO_0000218,
3024,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620644,,BAO_0000218,
3025,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620645,,BAO_0000218,
3026,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,1,,11454,CHEMBL620646,,BAO_0000218,
3027,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620647,,BAO_0000218,
3028,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620648,,BAO_0000218,
3029,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620649,,BAO_0000218,
3030,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL620650,,BAO_0000218,
3031,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,1,,11454,CHEMBL620651,,BAO_0000218,
3032,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,1,,11454,CHEMBL872875,,BAO_0000218,
3033,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,1,,11454,CHEMBL620652,,BAO_0000218,
3034,104698,,,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,1,,10609,CHEMBL620653,,BAO_0000019,
3035,104698,,,6,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,1,,12861,CHEMBL857076,,BAO_0000019,
3036,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,1,,12861,CHEMBL620654,,BAO_0000019,
3037,104698,,,6,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL620655,,BAO_0000223,
3038,104698,,,6,,H,Brain membranes,,,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,1,,10728,CHEMBL620656,,BAO_0000249,
3039,104698,,,6,,H,Brain membranes,,,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,1,,10728,CHEMBL620657,,BAO_0000249,
3040,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,1,,5163,CHEMBL620658,,BAO_0000357,
3041,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,1,,5163,CHEMBL620659,,BAO_0000357,
3042,108,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,1,,6011,CHEMBL620660,,BAO_0000357,
3043,108,,,8,,H,,,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,1,,5014,CHEMBL620661,,BAO_0000357,
3044,108,,,8,,H,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,1,,5635,CHEMBL620662,,BAO_0000357,
3045,108,,,8,,H,,,,Expert,Affinity for 5-hydroxytryptamine 2C receptor,B,1,,5163,CHEMBL620663,,BAO_0000357,
3046,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,1,,6841,CHEMBL620664,,BAO_0000357,
3047,108,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,1,,6119,CHEMBL620665,,BAO_0000357,
3048,108,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,1,,4373,CHEMBL620666,,BAO_0000357,
3049,108,,,8,,H,,,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,1,,1633,CHEMBL620667,,BAO_0000357,
3050,108,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,1,,1633,CHEMBL620668,,BAO_0000357,
3051,108,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,1,,4373,CHEMBL620669,,BAO_0000357,
3052,108,,,8,,H,,,,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,1,,6576,CHEMBL620670,,BAO_0000357,
3053,108,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,1,,4687,CHEMBL620671,,BAO_0000357,
3054,108,,,8,,H,,,,Autocuration,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,1,,12146,CHEMBL620672,,BAO_0000357,
3055,108,,,8,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,1,,12146,CHEMBL620673,,BAO_0000357,
3056,108,,,8,,H,,,,Autocuration,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,1,,16946,CHEMBL620674,,BAO_0000357,
3057,108,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,1,,14159,CHEMBL620675,,BAO_0000357,
3058,108,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,1,,16700,CHEMBL620676,,BAO_0000357,
3059,108,,,8,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine 2C receptor,B,1,,3269,CHEMBL621382,,BAO_0000357,
3060,108,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,B,1,,1274,CHEMBL621383,,BAO_0000357,
3061,108,,,8,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,1,,1317,CHEMBL621384,,BAO_0000357,
3062,144,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,1,,5834,CHEMBL621385,,BAO_0000357,
3063,144,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,1,,11147,CHEMBL617989,,BAO_0000357,
3064,104714,,,4,,H,,,,Expert,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,1,,14145,CHEMBL617990,,BAO_0000019,
3065,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,1,,10561,CHEMBL875085,,BAO_0000221,2116.0
3066,104714,,,4,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,1,,15847,CHEMBL617991,,BAO_0000019,
3067,104714,,,4,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,1,,15847,CHEMBL617992,,BAO_0000019,
3068,104714,,,4,,H,,Ileum,,Autocuration,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,1,,10561,CHEMBL617993,,BAO_0000221,2116.0
3069,104714,,,4,,H,,Ileum,,Autocuration,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,1,,11454,CHEMBL617994,,BAO_0000221,2116.0
3070,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,1,,4639,CHEMBL617995,,BAO_0000019,
3071,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,1,,4639,CHEMBL617996,,BAO_0000019,
3072,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,1,,4639,CHEMBL617997,,BAO_0000019,
3073,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,1,,4639,CHEMBL617998,,BAO_0000019,
3074,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,1,,4639,CHEMBL617999,,BAO_0000019,
3075,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,1,,4639,CHEMBL618000,,BAO_0000019,
3076,104714,,,4,,H,,Ileum,,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,1,,15253,CHEMBL617815,,BAO_0000221,2116.0
3077,104714,,,4,,H,,Ileum,,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,1,,15253,CHEMBL617816,,BAO_0000221,2116.0
3078,104714,,,4,,H,,Ileum,,Autocuration,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,1,,11963,CHEMBL617817,,BAO_0000221,2116.0
3079,104714,,,4,,H,,Ileum,,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,1,,1946,CHEMBL617818,,BAO_0000221,2116.0
3080,104714,,,4,,H,,Ileum,,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,1,,1946,CHEMBL617819,,BAO_0000221,2116.0
3081,104714,,,4,,H,,,,Autocuration,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,1,,12045,CHEMBL617820,,BAO_0000223,
3082,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,1,,1559,CHEMBL617821,,BAO_0000221,2116.0
3083,104714,,,4,,H,,Ileum,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,1,,273,CHEMBL617822,,BAO_0000221,2116.0
3084,104714,,,4,,H,,Ileum,,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,1,,273,CHEMBL617823,,BAO_0000221,2116.0
3085,104714,,,4,,H,,Ileum,,Autocuration,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,1,,188,CHEMBL617824,,BAO_0000221,2116.0
3086,104714,,,4,,H,,Ileum,,Autocuration,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,1,,12919,CHEMBL617825,,BAO_0000221,2116.0
3087,104714,,,4,,H,,Ileum,,Autocuration,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,1,,12918,CHEMBL617826,,BAO_0000221,2116.0
3088,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,1,,1559,CHEMBL617827,,BAO_0000221,2116.0
3089,104714,,,4,,H,,Ileum,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,1,,273,CHEMBL617828,,BAO_0000221,2116.0
3090,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,1,,1559,CHEMBL617829,,BAO_0000221,2116.0
3091,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,1,,1559,CHEMBL617830,,BAO_0000221,2116.0
3092,104714,,,4,,H,,Ileum,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,1,,1559,CHEMBL617831,,BAO_0000221,2116.0
3093,104714,,,4,,H,,Ileum,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,1,,14424,CHEMBL617832,,BAO_0000221,2116.0
3094,22226,,,0,,U,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,1,,13181,CHEMBL617833,,BAO_0000019,
3095,51,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,1,,5486,CHEMBL617834,,BAO_0000357,
3096,104714,,,5,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,1,,6491,CHEMBL617835,,BAO_0000223,
3097,104714,,,4,,H,,,,Autocuration,Binding affinity towards 5-HT3 receptor,B,1,,6013,CHEMBL617836,,BAO_0000223,
3098,104714,,,4,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617837,,BAO_0000223,
3099,104714,,,4,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,1,,12861,CHEMBL620392,,BAO_0000019,
3100,104714,,,4,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,1,,5104,CHEMBL620393,,BAO_0000223,
3101,104714,,,4,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,1,,5105,CHEMBL620394,,BAO_0000223,
3102,104714,,,4,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,1,,5104,CHEMBL620395,,BAO_0000223,
3103,22226,,,0,,U,,,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,1,,3935,CHEMBL620396,,BAO_0000019,
3104,105030,,,4,,H,,,NG108-15,Expert,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,1,,13657,CHEMBL620582,433.0,BAO_0000219,
3105,105030,,In vivo,4,,H,,,,Autocuration,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,1,,10369,CHEMBL620583,,BAO_0000218,
3106,105030,,,4,,H,,,,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,1,,10369,CHEMBL620584,,BAO_0000019,
3107,105030,,,4,,H,,,,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,1,,12918,CHEMBL620585,,BAO_0000224,
3108,105030,,,4,,H,,,,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,1,,12918,CHEMBL620586,,BAO_0000224,
3109,105030,,,4,,H,,,,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,1,,10369,CHEMBL620587,,BAO_0000019,
3110,105030,,,4,,H,,,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,1,,773,CHEMBL620588,,BAO_0000019,
3111,105030,,,4,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor agonism in mouse,F,1,,12918,CHEMBL620589,,BAO_0000218,
3112,105030,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,1,,10561,CHEMBL620590,,BAO_0000219,
3113,105030,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,1,,12827,CHEMBL617956,,BAO_0000019,
3114,105030,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,1,,12827,CHEMBL617957,,BAO_0000019,
3115,105030,,,4,,H,,,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,1,,12918,CHEMBL617958,,BAO_0000224,
3116,105030,,,4,,H,,,,Autocuration,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,1,,273,CHEMBL617959,,BAO_0000219,
3117,105030,,,4,,H,,,,Autocuration,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,1,,273,CHEMBL617960,,BAO_0000219,
3118,105030,,,4,,H,,,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,1,,10561,CHEMBL617961,,BAO_0000224,
3119,105030,,In vitro,4,,H,,,,Autocuration,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,1,,5033,CHEMBL617962,,BAO_0000219,
3120,105030,,,4,,H,,,N1E-115,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,1,,16429,CHEMBL617963,339.0,BAO_0000219,
3121,11765,,,8,,H,,,,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,1,,10322,CHEMBL617964,,BAO_0000019,
3122,11765,,,8,,H,,,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,1,,14331,CHEMBL617965,,BAO_0000219,
3123,10630,,,9,,D,,,,Autocuration,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,1,,13462,CHEMBL617966,,BAO_0000357,
3124,17106,,,8,,H,,,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,1,,12861,CHEMBL857074,,BAO_0000019,
3125,144,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,1,,15086,CHEMBL617967,,BAO_0000357,
3126,144,,,8,,H,,,,Autocuration,Binding activity radioligand.,B,1,,12861,CHEMBL617968,,BAO_0000357,
3127,104714,,,4,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,1,,10561,CHEMBL617969,,BAO_0000223,
3128,104714,,,4,,H,,,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,1,,10561,CHEMBL617970,,BAO_0000223,
3129,104714,,,4,,H,,,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,1,,10561,CHEMBL617971,,BAO_0000223,
3130,104714,,,4,,H,,,,Autocuration,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,1,,10561,CHEMBL617972,,BAO_0000019,
3131,104714,,,4,,H,,,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,1,,273,CHEMBL617973,,BAO_0000019,
3132,104714,,,4,,H,,,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,1,,273,CHEMBL617974,,BAO_0000019,
3133,104714,,,4,,H,,Ileum,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,1,,273,CHEMBL617975,,BAO_0000221,2116.0
3134,104714,,,4,,H,,,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,1,,273,CHEMBL617976,,BAO_0000019,
3135,104714,,,4,,H,,,,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,1,,273,CHEMBL617977,,BAO_0000019,
3136,104714,,,4,,H,,,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,1,,273,CHEMBL617978,,BAO_0000019,
3137,104714,,,4,,H,,,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,1,,273,CHEMBL617979,,BAO_0000019,
3138,104714,,,4,,H,,,CHO,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,1,,13047,CHEMBL617980,449.0,BAO_0000219,
3139,104698,,,7,,D,,,,Autocuration,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,1,,1650,CHEMBL617981,,BAO_0000019,
3140,12020,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,1,,16288,CHEMBL617982,,BAO_0000019,
3141,12020,,,8,,H,,,,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,1,,16288,CHEMBL617983,,BAO_0000357,
3142,104698,,,7,,D,,,,Autocuration,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,1,,10254,CHEMBL617984,,BAO_0000019,
3143,104698,,,6,,H,,,,Autocuration,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,1,,14532,CHEMBL617985,,BAO_0000019,
3144,104698,,In vivo,6,,H,,Heart,,Autocuration,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,1,,13392,CHEMBL617986,,BAO_0000218,948.0
3145,104698,,,6,,H,,Heart,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,1,,13392,CHEMBL617987,,BAO_0000019,948.0
3146,104698,,,6,,H,,Heart,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,1,,13392,CHEMBL617988,,BAO_0000019,948.0
3147,104698,,,6,,H,,Heart,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,1,,13392,CHEMBL617792,,BAO_0000019,948.0
3148,104698,,,6,,H,,Heart,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,1,,13392,CHEMBL617793,,BAO_0000019,948.0
3149,104698,,,6,,H,,,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,1,,13392,CHEMBL617794,,BAO_0000019,
3150,104698,,,6,,H,,,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,1,,13392,CHEMBL617795,,BAO_0000019,
3151,104698,,,6,,H,,,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,1,,13392,CHEMBL617796,,BAO_0000019,
3152,104698,,,6,,H,,,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,1,,13392,CHEMBL617797,,BAO_0000019,
3153,104698,,In vivo,7,,D,,,,Autocuration,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,1,,1089,CHEMBL617798,,BAO_0000218,
3154,104698,,In vivo,6,,H,,,,Autocuration,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,1,,1089,CHEMBL617799,,BAO_0000218,
3155,104698,,In vivo,7,,D,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617800,,BAO_0000218,
3156,104698,,,7,,D,,,,Autocuration,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,1,,11454,CHEMBL617801,,BAO_0000019,
3157,104698,,In vivo,7,,D,,,,Autocuration,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,1,,12205,CHEMBL617802,,BAO_0000218,
3158,104698,,,7,,D,,,,Autocuration,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,1,,1089,CHEMBL617803,,BAO_0000019,
3159,104698,,,6,,H,,,,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,1,,5094,CHEMBL617804,,BAO_0000019,
3160,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,1,,2622,CHEMBL617805,,BAO_0000019,
3161,104698,,,6,,H,,,,Autocuration,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,1,,245,CHEMBL617806,,BAO_0000223,
3162,104698,,,6,,H,,,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,1,,14788,CHEMBL617807,,BAO_0000019,
3163,104698,,,6,,H,,,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,1,,14788,CHEMBL617808,,BAO_0000019,
3164,104698,,,6,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,1,,3020,CHEMBL617809,,BAO_0000249,
3165,104698,,,6,,H,,,,Autocuration,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,1,,1742,CHEMBL617810,,BAO_0000019,
3166,104698,,,6,,H,,Brain,,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,1,,17394,CHEMBL617811,,BAO_0000249,955.0
3167,104698,,,6,,H,,Brain,,Autocuration,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,1,,17394,CHEMBL617812,,BAO_0000221,955.0
3168,104698,,,6,,H,,,,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,1,,17394,CHEMBL617813,,BAO_0000249,
3169,104698,,,6,,H,,,,Autocuration,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,1,,14286,CHEMBL617814,,BAO_0000249,
3170,104698,,,6,,H,,,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,1,,14178,CHEMBL617698,,BAO_0000019,
3171,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,1,,14178,CHEMBL617699,,BAO_0000019,
3172,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,1,,14178,CHEMBL617700,,BAO_0000019,
3173,104698,,,7,,D,,,,Autocuration,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,1,,14178,CHEMBL617701,,BAO_0000223,
3174,104698,,,6,,H,,,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,1,,15034,CHEMBL617702,,BAO_0000019,
3175,104698,,,6,,H,Membranes,,,Autocuration,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,1,,1089,CHEMBL617703,,BAO_0000249,
3176,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,1,,1089,CHEMBL617704,,BAO_0000019,
3177,104698,,,6,,H,,,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,1,,16532,CHEMBL617705,,BAO_0000223,
3178,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,1,,12801,CHEMBL617706,,BAO_0000223,
3179,104698,,,6,,H,,,NG108-15,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,1,,15194,CHEMBL617707,433.0,BAO_0000219,
3180,104698,,,6,,H,,,NG108-15,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,1,,15194,CHEMBL617708,433.0,BAO_0000219,
3181,104698,,,6,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,1,,15194,CHEMBL617709,,BAO_0000019,
3182,104698,,,6,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,1,,15194,CHEMBL617710,,BAO_0000019,
3183,104698,,,6,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,1,,15194,CHEMBL882925,,BAO_0000019,
3184,104698,,,6,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,1,,15194,CHEMBL617711,,BAO_0000019,
3185,104698,,,6,,H,,,,Autocuration,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,1,,10610,CHEMBL617712,,BAO_0000019,
3186,104698,,,7,,D,,,,Autocuration,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,1,,10355,CHEMBL617713,,BAO_0000019,
3187,104698,,,6,,H,,,,Autocuration,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,1,,691,CHEMBL617714,,BAO_0000019,
3188,104698,,,6,,H,,,,Autocuration,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,1,,10611,CHEMBL617715,,BAO_0000218,
3189,104698,,In vivo,6,,H,,,,Autocuration,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,1,,12801,CHEMBL617716,,BAO_0000218,
3190,104698,,,6,,H,,,,Autocuration,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,1,,10609,CHEMBL617717,,BAO_0000218,
3191,104698,,In vivo,6,,H,,,,Autocuration,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617718,,BAO_0000218,
3192,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617719,,BAO_0000218,
3193,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,1,,11454,CHEMBL617720,,BAO_0000218,
3194,104698,,In vivo,7,,D,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617721,,BAO_0000218,
3195,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617722,,BAO_0000218,
3196,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,1,,11454,CHEMBL617723,,BAO_0000218,
3197,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617724,,BAO_0000218,
3198,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617725,,BAO_0000218,
3199,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617726,,BAO_0000218,
3200,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617727,,BAO_0000218,
3201,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617728,,BAO_0000218,
3202,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617729,,BAO_0000218,
3203,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617730,,BAO_0000218,
3204,104698,,In vivo,6,,H,,,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617731,,BAO_0000218,
3205,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617732,,BAO_0000218,
3206,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617733,,BAO_0000218,
3207,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617734,,BAO_0000218,
3208,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,1,,11454,CHEMBL872874,,BAO_0000218,
3209,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,1,,11454,CHEMBL617735,,BAO_0000218,
3210,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,1,,11454,CHEMBL617736,,BAO_0000218,
3211,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,1,,11454,CHEMBL617737,,BAO_0000218,
3212,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,1,,11454,CHEMBL617738,,BAO_0000218,
3213,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617739,,BAO_0000218,
3214,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617740,,BAO_0000218,
3215,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617741,,BAO_0000218,
3216,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617742,,BAO_0000218,
3217,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617743,,BAO_0000218,
3218,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617744,,BAO_0000218,
3219,104698,,In vivo,6,,H,,,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,1,,11454,CHEMBL617745,,BAO_0000218,
3220,104698,,,6,,H,,,,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,1,,670,CHEMBL617746,,BAO_0000218,
3221,104698,,,6,,H,,,,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,1,,670,CHEMBL617747,,BAO_0000218,
3222,104698,,In vivo,6,,H,,,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,1,,10321,CHEMBL617748,,BAO_0000218,
3223,104698,,In vivo,6,,H,,,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,1,,10321,CHEMBL618909,,BAO_0000218,
3224,104698,,In vivo,6,,H,,,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,1,,10321,CHEMBL618910,,BAO_0000218,
3225,104698,,In vivo,6,,H,,,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,1,,10321,CHEMBL618911,,BAO_0000218,
3226,104698,,In vivo,6,,H,,,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,1,,10321,CHEMBL618912,,BAO_0000218,
3227,104698,,In vivo,6,,H,,,,Autocuration,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,1,,10322,CHEMBL618913,,BAO_0000218,
3228,104698,,,6,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,1,,15412,CHEMBL618914,,BAO_0000019,
3229,104698,,,6,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,1,,15412,CHEMBL618915,,BAO_0000019,
3230,104698,,,7,,D,,,,Autocuration,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,1,,15412,CHEMBL618916,,BAO_0000223,
3231,104698,,,6,,H,,,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,1,,15412,CHEMBL618917,,BAO_0000019,
3232,104698,,,7,,D,,Hippocampus,,Intermediate,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,1,,15412,CHEMBL618918,,BAO_0000221,10000000.0
3233,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,1,,15412,CHEMBL618919,,BAO_0000019,
3234,104698,,,7,,D,,,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,1,,17394,CHEMBL618920,,BAO_0000019,
3235,104698,,,6,,H,,,,Autocuration,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,1,,12457,CHEMBL618921,,BAO_0000223,
3236,104698,,,6,,H,,,,Autocuration,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,1,,12457,CHEMBL618922,,BAO_0000019,
3237,104698,,,6,,H,,,,Autocuration,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,1,,12205,CHEMBL618923,,BAO_0000019,
3238,104698,,,6,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,1,,14532,CHEMBL618924,,BAO_0000019,
3239,104698,,,6,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,1,,1122,CHEMBL618925,,BAO_0000019,
3240,104698,,,6,,H,,,,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,1,,5094,CHEMBL618926,,BAO_0000019,
3241,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,1,,809,CHEMBL618927,,BAO_0000221,2116.0
3242,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,1,,809,CHEMBL618928,,BAO_0000221,2116.0
3243,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,1,,14290,CHEMBL618929,,BAO_0000221,2116.0
3244,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,1,,14290,CHEMBL618930,,BAO_0000221,2116.0
3245,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,1,,14290,CHEMBL618931,,BAO_0000221,2116.0
3246,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,1,,14290,CHEMBL619594,,BAO_0000221,2116.0
3247,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,1,,14290,CHEMBL619595,,BAO_0000221,2116.0
3248,20033,,,9,,D,,Ileum,,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,1,,13961,CHEMBL619596,,BAO_0000221,2116.0
3249,20033,,,9,,D,,Ileum,,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,1,,13961,CHEMBL619755,,BAO_0000221,2116.0
3250,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,1,,809,CHEMBL619756,,BAO_0000221,2116.0
3251,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,1,,809,CHEMBL619757,,BAO_0000221,2116.0
3252,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,1,,809,CHEMBL619758,,BAO_0000221,2116.0
3253,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,1,,14290,CHEMBL619759,,BAO_0000221,2116.0
3254,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,1,,14290,CHEMBL619760,,BAO_0000221,2116.0
3255,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,1,,14290,CHEMBL619761,,BAO_0000221,2116.0
3256,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,1,,14290,CHEMBL619762,,BAO_0000221,2116.0
3257,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,1,,14290,CHEMBL619763,,BAO_0000221,2116.0
3258,20033,,,9,,D,,Ileum,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,1,,14290,CHEMBL617868,,BAO_0000221,2116.0
3259,20033,,,9,,D,,,,Intermediate,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,1,,15034,CHEMBL617869,,BAO_0000357,
3260,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,1,,5094,CHEMBL882926,,BAO_0000249,2435.0
3261,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,1,,5094,CHEMBL617870,,BAO_0000249,2435.0
3262,20033,,,9,,D,,Striatum,,Intermediate,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,1,,5399,CHEMBL617871,,BAO_0000357,2435.0
3263,20033,,,9,,D,,Striatum,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,1,,17394,CHEMBL617872,,BAO_0000357,2435.0
3264,20033,,,9,,D,,Striatum,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,1,,17394,CHEMBL617873,,BAO_0000357,2435.0
3265,20033,,,9,,D,,Striatum,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,1,,17394,CHEMBL617874,,BAO_0000357,2435.0
3266,20033,,,9,,D,,Ileum,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,1,,13961,CHEMBL619067,,BAO_0000221,2116.0
3267,20033,,,9,,D,,Ileum,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,1,,13961,CHEMBL619068,,BAO_0000221,2116.0
3268,20033,,,9,,D,,Ileum,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,1,,13961,CHEMBL619069,,BAO_0000221,2116.0
3269,20033,,,9,,D,,,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,1,,16946,CHEMBL619070,,BAO_0000357,
3270,20033,,,9,,D,,,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,1,,16946,CHEMBL619071,,BAO_0000357,
3271,20033,,,9,,D,,,,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,1,,15034,CHEMBL619072,,BAO_0000019,
3272,20033,,,9,,D,,,,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,1,,15034,CHEMBL619073,,BAO_0000019,
3273,20033,,,9,,D,,,,Intermediate,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,1,,12918,CHEMBL619074,,BAO_0000019,
3274,20033,,,9,,D,,,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,1,,16946,CHEMBL619075,,BAO_0000357,
3275,20033,,,9,,D,,Striatum,,Intermediate,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,1,,17394,CHEMBL619076,,BAO_0000357,2435.0
3276,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,1,,15034,CHEMBL619077,,BAO_0000357,2435.0
3277,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,1,,5094,CHEMBL619078,,BAO_0000249,2435.0
3278,20033,,,9,,D,,Striatum,,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,1,,5094,CHEMBL619079,,BAO_0000249,2435.0
3279,20033,,,9,,D,,Ileum,,Intermediate,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,1,,17358,CHEMBL619080,,BAO_0000221,2116.0
3280,20033,,,9,,D,,,,Expert,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,1,,12953,CHEMBL619081,,BAO_0000357,
3281,20033,,,9,,D,,,,Intermediate,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL619082,,BAO_0000357,
3282,20033,,,9,,D,,,,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,1,,12953,CHEMBL619083,,BAO_0000357,
3283,20033,,,9,,D,,,,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,1,,12953,CHEMBL619084,,BAO_0000357,
3284,20033,,,9,,D,,Ileum,,Intermediate,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,1,,273,CHEMBL859397,,BAO_0000221,2116.0
3285,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,1,,12918,CHEMBL619085,,BAO_0000221,2116.0
3286,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,1,,12919,CHEMBL619086,,BAO_0000221,2116.0
3287,20033,,,9,,D,,Ileum,,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,1,,273,CHEMBL619087,,BAO_0000221,2116.0
3288,20033,,,9,,D,,Ileum,,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,1,,273,CHEMBL619088,,BAO_0000221,2116.0
3289,20033,,,9,,D,,,,Intermediate,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,1,,13181,CHEMBL619089,,BAO_0000357,
3290,168,,,8,,H,,,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,1,,13181,CHEMBL619090,,BAO_0000357,
3291,20033,,,9,,D,,,,Intermediate,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,1,,15034,CHEMBL619091,,BAO_0000019,
3292,20033,,,9,,D,,,,Intermediate,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,1,,5033,CHEMBL619092,,BAO_0000357,
3293,20033,,,9,,D,,,,Intermediate,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,1,,1980,CHEMBL619093,,BAO_0000019,
3294,168,,,8,,H,,,HEK293,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,1,,13181,CHEMBL619094,722.0,BAO_0000219,
3295,20033,,,9,,D,,,,Intermediate,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,1,,14287,CHEMBL619095,,BAO_0000019,
3296,20033,,,9,,D,,,,Intermediate,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,1,,1317,CHEMBL857988,,BAO_0000357,
3297,20033,,,9,,D,,,,Intermediate,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,1,,15316,CHEMBL619096,,BAO_0000357,
3298,20033,,,9,,D,,Striatum,,Intermediate,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,1,,16429,CHEMBL619097,,BAO_0000357,2435.0
3299,20033,,,9,,D,,Hippocampus,,Intermediate,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,1,,14818,CHEMBL619098,,BAO_0000221,10000000.0
3300,20033,,,9,,D,,,,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,1,,15194,CHEMBL619751,,BAO_0000357,
3301,20033,,,9,,D,,,,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,1,,15194,CHEMBL619752,,BAO_0000357,
3302,20033,,,9,,D,,Ileum,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,1,,13961,CHEMBL875096,,BAO_0000221,2116.0
3303,108,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,1,,5486,CHEMBL619004,,BAO_0000357,
3304,168,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,1,,16209,CHEMBL619005,,BAO_0000357,
3305,168,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,1,,17085,CHEMBL619006,,BAO_0000019,
3306,168,,,8,,H,,,HeLa,Autocuration,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,1,,4199,CHEMBL619007,308.0,BAO_0000219,
3307,168,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,1,,15146,CHEMBL619008,,BAO_0000357,
3308,168,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,1,,5213,CHEMBL619009,,BAO_0000357,
3309,168,,,8,,H,,,HeLa,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,1,,4829,CHEMBL619010,308.0,BAO_0000219,
3310,10622,,,8,,H,,,,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,1,,17358,CHEMBL619011,,BAO_0000357,
3311,10622,,,8,,H,,,,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,1,,17358,CHEMBL619012,,BAO_0000357,
3312,10622,,,8,,H,,,,Autocuration,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,1,,16946,CHEMBL619013,,BAO_0000219,
3313,10622,,,8,,H,,,,Autocuration,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,1,,17358,CHEMBL619014,,BAO_0000357,
3314,11249,,,8,,H,,Cardiac atrium,,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,1,,268,CHEMBL857503,,BAO_0000019,2081.0
3315,11249,,,8,,H,,Cardiac atrium,,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,1,,268,CHEMBL619015,,BAO_0000019,2081.0
3316,11249,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,1,,15086,CHEMBL619016,,BAO_0000357,
3317,11249,,,8,,H,,Hippocampus,,Autocuration,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,1,,14875,CHEMBL619017,,BAO_0000221,10000000.0
3318,168,,,8,,H,,Hippocampus,,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,1,,13267,CHEMBL619018,,BAO_0000221,10000000.0
3319,168,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,1,,13047,CHEMBL619019,,BAO_0000019,
3320,10623,,,9,,D,,,,Expert,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,1,,1650,CHEMBL619020,,BAO_0000357,
3321,10623,,,8,,H,,,,Autocuration,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,1,,567,CHEMBL619021,,BAO_0000019,
3322,10623,,,8,,H,,,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,1,,17358,CHEMBL619022,,BAO_0000357,
3323,10623,,,8,,H,,,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,1,,188,CHEMBL619023,,BAO_0000357,
3324,10623,,,8,,H,,,,Autocuration,lntrinsic activity relative to 5-HT receptor,F,1,,670,CHEMBL619024,,BAO_0000019,
3325,10623,,,8,,H,,,,Autocuration,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,1,,204,CHEMBL619025,,BAO_0000019,
3326,10623,,,8,,H,,,,Expert,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,1,,1946,CHEMBL619026,,BAO_0000019,
3327,10623,,,8,,H,,,,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,1,,6398,CHEMBL619027,,BAO_0000019,
3328,10623,,,8,,H,,,,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,1,,6398,CHEMBL619028,,BAO_0000019,
3329,10623,,,8,,H,,,,Autocuration,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,1,,17358,CHEMBL619029,,BAO_0000019,
3330,10623,,,8,,H,,,,Autocuration,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,1,,6398,CHEMBL619030,,BAO_0000019,
3331,10623,,,8,,H,,,,Expert,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,1,,11752,CHEMBL619031,,BAO_0000357,
3332,10623,,,8,,H,,,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,1,,809,CHEMBL619032,,BAO_0000019,
3333,10623,,,9,,D,,,,Expert,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,1,,14178,CHEMBL619033,,BAO_0000357,
3334,10623,,,8,,H,,,,Autocuration,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,1,,567,CHEMBL619034,,BAO_0000357,
3335,10623,,,8,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,1,,1946,CHEMBL619035,,BAO_0000357,
3336,10623,,,8,,H,,,,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,1,,1946,CHEMBL619036,,BAO_0000357,
3337,10623,,,9,,D,,,,Expert,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,1,,13961,CHEMBL619037,,BAO_0000019,
3338,10623,,,8,,H,,Striatum,,Autocuration,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,1,,6238,CHEMBL619038,,BAO_0000249,2435.0
3339,10623,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,1,,14290,CHEMBL619039,,BAO_0000249,
3340,10623,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,1,,14290,CHEMBL619040,,BAO_0000249,
3341,10623,,,9,,D,,Striatum,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,1,,809,CHEMBL619041,,BAO_0000019,2435.0
3342,10623,,,8,,H,,Striatum,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,1,,1578,CHEMBL619042,,BAO_0000019,2435.0
3343,10623,,,8,,H,,Striatum,,Expert,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,1,,16709,CHEMBL619043,,BAO_0000249,2435.0
3344,10623,,,8,,H,,Striatum,,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,1,,1946,CHEMBL619044,,BAO_0000019,2435.0
3345,10623,,,8,,H,,Striatum,,Expert,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,1,,15253,CHEMBL619045,,BAO_0000249,2435.0
3346,10623,,,8,,H,,Striatum,,Expert,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,1,,4535,CHEMBL619046,,BAO_0000249,2435.0
3347,10623,,,8,,H,,,,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,1,,13961,CHEMBL619047,,BAO_0000249,
3348,10623,,,8,,H,,Brain,,Autocuration,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,1,,17358,CHEMBL619048,,BAO_0000221,955.0
3349,10623,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,1,,15847,CHEMBL859398,,BAO_0000019,
3350,10623,,,8,,H,,,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,1,,15847,CHEMBL619049,,BAO_0000019,
3351,10623,,,8,,H,,,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,1,,670,CHEMBL857886,,BAO_0000019,
3352,10623,,,8,,H,,,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,1,,670,CHEMBL619050,,BAO_0000019,
3353,10623,,,8,,H,,,,Autocuration,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,1,,1317,CHEMBL620591,,BAO_0000019,
3354,10623,,,9,,D,,,,Expert,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,1,,12936,CHEMBL620592,,BAO_0000357,
3355,10623,,,8,,H,,Striatum,,Expert,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,1,,4535,CHEMBL620593,,BAO_0000249,2435.0
3356,10623,,,9,,D,,,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,1,,14424,CHEMBL620594,,BAO_0000019,
3357,10623,,,8,,H,,,,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,1,,14424,CHEMBL875079,,BAO_0000019,
3358,10623,,,8,,H,,,,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,1,,14424,CHEMBL620595,,BAO_0000019,
3359,10623,,,9,,D,,,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,1,,14424,CHEMBL620596,,BAO_0000019,
3360,10623,,,8,,H,,,,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,1,,14424,CHEMBL620597,,BAO_0000019,
3361,10623,,,8,,H,,,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,1,,14424,CHEMBL620598,,BAO_0000019,
3362,10623,,,8,,H,,,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,1,,14424,CHEMBL620599,,BAO_0000218,
3363,10623,,,8,,H,,,,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,1,,14424,CHEMBL620600,,BAO_0000019,
3364,168,,,8,,H,,,,Autocuration,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,1,,1980,CHEMBL620601,,BAO_0000019,
3365,168,,,8,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,1,,4639,CHEMBL620602,,BAO_0000019,
3366,168,,,8,,H,,,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,1,,17358,CHEMBL620603,,BAO_0000357,
3367,168,,,8,,H,,,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,1,,17358,CHEMBL620604,,BAO_0000357,
3368,168,,,8,,H,,,,Autocuration,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,1,,17358,CHEMBL620605,,BAO_0000357,
3369,168,,,8,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,1,,1558,CHEMBL620606,,BAO_0000357,
3370,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,1,,17358,CHEMBL620607,,BAO_0000019,
3371,168,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-HT4 receptor was determined,B,1,,16117,CHEMBL620608,,BAO_0000357,
3372,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,1,,17358,CHEMBL620609,,BAO_0000019,
3373,168,,,8,,H,,,,Autocuration,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,1,,17358,CHEMBL620610,,BAO_0000019,
3374,168,,,8,,H,,,,Autocuration,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,1,,17358,CHEMBL620611,,BAO_0000357,
3375,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,1,,17358,CHEMBL620612,,BAO_0000357,
3376,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,1,,17358,CHEMBL620613,,BAO_0000357,
3377,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,1,,17358,CHEMBL620614,,BAO_0000357,
3378,168,,,8,,H,,,,Expert,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,1,,1274,CHEMBL620615,,BAO_0000357,
3379,104698,,,6,,H,Brain membranes,,,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,1,,10728,CHEMBL857075,,BAO_0000249,
3380,104698,,,6,,H,Brain membranes,,,Autocuration,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,1,,11695,CHEMBL620616,,BAO_0000249,
3381,104698,,,6,,H,Brain membranes,,,Autocuration,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,1,,11695,CHEMBL619411,,BAO_0000249,
3382,104698,,,6,,H,,,,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,1,,12490,CHEMBL619412,,BAO_0000019,
3383,104698,,,7,,D,,,,Autocuration,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,1,,11828,CHEMBL619413,,BAO_0000019,
3384,104698,,,6,,H,,Hippocampus,,Autocuration,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,1,,12253,CHEMBL619414,,BAO_0000221,10000000.0
3385,104698,,,6,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,1,,10561,CHEMBL619415,,BAO_0000019,
3386,104698,,,6,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,1,,10561,CHEMBL619416,,BAO_0000019,
3387,104698,,,6,,H,,,,Autocuration,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,1,,14432,CHEMBL619417,,BAO_0000019,
3388,104698,,,7,,D,,,,Autocuration,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,1,,12936,CHEMBL619418,,BAO_0000223,
3389,104698,,,7,,D,,,,Autocuration,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,1,,1274,CHEMBL619419,,BAO_0000223,
3390,104698,,,6,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,1,,1980,CHEMBL619420,,BAO_0000019,
3391,104698,,,6,,H,,,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,1,,670,CHEMBL619421,,BAO_0000249,
3392,104698,,,7,,D,,,,Autocuration,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,1,,968,CHEMBL619422,,BAO_0000019,
3393,104698,,,6,,H,,,,Autocuration,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,1,,14287,CHEMBL619423,,BAO_0000019,
3394,104698,,,6,,H,,,,Autocuration,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,1,,567,CHEMBL875080,,BAO_0000019,
3395,104698,,,6,,H,,,,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,1,,13267,CHEMBL619424,,BAO_0000019,
3396,104698,,,6,,H,,,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,1,,14826,CHEMBL619425,,BAO_0000249,
3397,104698,,,6,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,1,,15194,CHEMBL619426,,BAO_0000223,
3398,104698,,,6,,H,,,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,1,,15194,CHEMBL619427,,BAO_0000223,
3399,104698,,,7,,D,,,,Autocuration,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,1,,10394,CHEMBL619645,,BAO_0000223,
3400,10576,,,9,,D,,,,Expert,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,1,,13657,CHEMBL619646,,BAO_0000249,
3401,12020,,,8,,H,,Brain,,Autocuration,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,1,,1879,CHEMBL619647,,BAO_0000221,955.0
3402,12020,,,8,,H,,,,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,1,,1879,CHEMBL619648,,BAO_0000019,
3403,12020,,,8,,H,,,,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,1,,1879,CHEMBL619165,,BAO_0000019,
3404,12020,,In vivo,8,,H,,,,Autocuration,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,1,,204,CHEMBL620719,,BAO_0000218,
3405,12020,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,1,,1879,CHEMBL872924,,BAO_0000019,
3406,12020,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,1879,CHEMBL620720,,BAO_0000357,
3407,12020,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,1,,1879,CHEMBL620721,,BAO_0000019,
3408,12020,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,1,,1879,CHEMBL620722,,BAO_0000019,
3409,104698,,,6,,H,,,,Autocuration,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,1,,10641,CHEMBL620723,,BAO_0000019,
3410,12020,,,8,,H,,,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,1,,773,CHEMBL620724,,BAO_0000019,
3411,104698,,,6,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,1,,11952,CHEMBL620725,,BAO_0000249,
3412,12020,,,9,,D,,,,Autocuration,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,1,,14145,CHEMBL620726,,BAO_0000019,
3413,144,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,17066,CHEMBL620727,,BAO_0000357,
3414,104714,,,4,,H,,,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,1,,6398,CHEMBL620728,,BAO_0000223,
3415,22226,,,0,,U,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,1,,10321,CHEMBL620729,,BAO_0000019,
3416,104714,,,4,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,1,,511,CHEMBL858288,,BAO_0000019,
3417,104714,,,4,,H,,,,Autocuration,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,4639,CHEMBL620730,,BAO_0000223,
3418,104714,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,4639,CHEMBL620731,,BAO_0000223,
3419,104714,,,4,,H,,,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,1,,4639,CHEMBL620732,,BAO_0000019,
3420,104714,,,4,,H,,,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,1,,4639,CHEMBL618042,,BAO_0000019,
3421,104714,,,4,,H,,,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,1,,4639,CHEMBL618043,,BAO_0000019,
3422,104714,,,4,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,1,,1558,CHEMBL618044,,BAO_0000223,
3423,104714,,,4,,H,,,,Autocuration,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,1,,268,CHEMBL618045,,BAO_0000019,
3424,104714,,,4,,H,,,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,1,,2474,CHEMBL618046,,BAO_0000223,
3425,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,1,,5067,CHEMBL618047,,BAO_0000019,
3426,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,1,,5067,CHEMBL875084,,BAO_0000019,
3427,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,1,,5067,CHEMBL618048,,BAO_0000019,
3428,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,1,,5067,CHEMBL618049,,BAO_0000223,
3429,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,1,,5067,CHEMBL619764,,BAO_0000019,
3430,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,1,,5067,CHEMBL619765,,BAO_0000019,
3431,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,1,,5067,CHEMBL619766,,BAO_0000019,
3432,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,1,,5067,CHEMBL619767,,BAO_0000223,
3433,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,1,,5067,CHEMBL619768,,BAO_0000223,
3434,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,1,,5067,CHEMBL619769,,BAO_0000019,
3435,104714,,,4,,H,,,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,1,,5067,CHEMBL619770,,BAO_0000223,
3436,104714,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,5067,CHEMBL619771,,BAO_0000223,
3437,104714,,,4,,H,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,1,,14331,CHEMBL619772,,BAO_0000219,
3438,104714,,,4,,H,,,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,1,,5067,CHEMBL619773,,BAO_0000223,
3439,104714,,,4,,H,,,NG108-15,Autocuration,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,1,,6179,CHEMBL619774,433.0,BAO_0000219,
3440,104714,,,4,,H,,,,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,1,,4265,CHEMBL875083,,BAO_0000019,
3441,104714,,,4,,H,,,NG108-15,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,1,,4265,CHEMBL620718,433.0,BAO_0000219,
3442,104714,,,4,,H,,,,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,1,,17358,CHEMBL618127,,BAO_0000223,
3443,104714,,,4,,H,,,,Autocuration,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,1,,17358,CHEMBL618128,,BAO_0000223,
3444,104714,,In vitro,4,,H,,,,Autocuration,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,1,,13628,CHEMBL618129,,BAO_0000219,
3445,104714,,,4,,H,,,,Autocuration,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,1,,4612,CHEMBL618130,,BAO_0000223,
3446,104714,,,4,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,1,,17358,CHEMBL618131,,BAO_0000019,
3447,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,1,,4639,CHEMBL618132,,BAO_0000019,
3448,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,1,,4639,CHEMBL618133,,BAO_0000019,
3449,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,1,,4639,CHEMBL618134,,BAO_0000019,
3450,104714,,,4,,H,,,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,1,,4639,CHEMBL618135,,BAO_0000019,
3451,104714,,,4,,H,,,,Autocuration,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,1,,511,CHEMBL618136,,BAO_0000223,
3452,104714,,,4,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,1479,CHEMBL618137,,BAO_0000223,
3453,104714,,,4,,H,,,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,1,,1317,CHEMBL618138,,BAO_0000223,
3454,104714,,,4,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,1,,12146,CHEMBL618139,,BAO_0000223,
3455,104714,,,4,,H,,,,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,1,,12146,CHEMBL618140,,BAO_0000223,
3456,104714,,,4,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,1,,13969,CHEMBL618141,,BAO_0000223,
3457,108,,,8,,H,,,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,B,1,,13392,CHEMBL873478,,BAO_0000357,
3458,104698,,,6,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,13392,CHEMBL618142,,BAO_0000223,
3459,144,,,8,,H,,,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,1,,14159,CHEMBL618143,,BAO_0000357,
3460,144,,,8,,H,,,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,1,,1558,CHEMBL618144,,BAO_0000357,
3461,144,,,8,,H,,,,Autocuration,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,1,,16655,CHEMBL618145,,BAO_0000357,
3462,104714,,,4,,H,,,,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,1,,13020,CHEMBL618146,,BAO_0000223,
3463,104714,,,4,,H,,,,Autocuration,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,1,,13021,CHEMBL618147,,BAO_0000223,
3464,104714,,,4,,H,,,,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,1,,13020,CHEMBL618148,,BAO_0000223,
3465,144,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,1,,10321,CHEMBL618149,,BAO_0000019,
3466,144,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,15818,CHEMBL872927,,BAO_0000357,
3467,144,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,1,,15818,CHEMBL618150,,BAO_0000357,
3468,144,,,8,,H,,,,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,1,,17358,CHEMBL618151,,BAO_0000357,
3469,144,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,1,,2222,CHEMBL875094,,BAO_0000357,
3470,144,,,8,,H,,,,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,1,,10322,CHEMBL618152,,BAO_0000019,
3471,144,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,1,,16117,CHEMBL618153,,BAO_0000357,
3472,144,,,8,,H,,,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,1,,17200,CHEMBL618888,,BAO_0000357,
3473,144,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,1,,17358,CHEMBL618889,,BAO_0000019,
3474,144,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,1,,16700,CHEMBL618890,,BAO_0000357,
3475,144,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,1,,1980,CHEMBL618891,,BAO_0000019,
3476,144,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,1,,1980,CHEMBL619054,,BAO_0000019,
3477,104714,,,4,,H,,,,Autocuration,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,1,,12409,CHEMBL619055,,BAO_0000223,
3478,144,,,8,,H,,,,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,1,,4365,CHEMBL619056,,BAO_0000357,
3479,144,,,8,,H,,,,Autocuration,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,1,,4365,CHEMBL619057,,BAO_0000019,
3480,144,,,8,,H,,,,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,1,,4365,CHEMBL619058,,BAO_0000357,
3481,12020,,,9,,D,,,Oocytes,Expert,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,1,,6769,CHEMBL619059,,BAO_0000219,
3482,12020,,,9,,D,,,Oocytes,Expert,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,1,,6769,CHEMBL619060,,BAO_0000219,
3483,12020,,,9,,D,,,Oocytes,Expert,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,1,,6769,CHEMBL875095,,BAO_0000219,
3484,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,1,,809,CHEMBL619061,,BAO_0000221,2116.0
3485,20033,,,9,,D,,Ileum,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,1,,809,CHEMBL619062,,BAO_0000221,2116.0
3486,20033,,,9,,D,,,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,1,,14290,CHEMBL619063,,BAO_0000019,
3487,20033,,,9,,D,,Ileum,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,1,,17358,CHEMBL619064,,BAO_0000221,2116.0
3488,20033,,,9,,D,,,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,1,,17358,CHEMBL619065,,BAO_0000357,
3489,20033,,,9,,D,,Ileum,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,1,,17358,CHEMBL619066,,BAO_0000221,2116.0
3490,10209,,,8,,H,,Ileum,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,1,,17386,CHEMBL619775,,BAO_0000221,2116.0
3491,10209,,,8,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine 7 receptor,B,1,,3269,CHEMBL619776,,BAO_0000357,
3492,104841,,,4,,H,,,,Autocuration,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,1,,7721,CHEMBL619777,,BAO_0000224,
3493,104841,,,4,,H,,,,Autocuration,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,1,,7721,CHEMBL619778,,BAO_0000224,
3494,104841,,,4,,H,,Ileum,,Autocuration,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,1,,9117,CHEMBL619779,,BAO_0000221,2116.0
3495,104841,,,4,,H,,,,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,1,,7721,CHEMBL619780,,BAO_0000224,
3496,104841,,,4,,H,,,,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,1,,7721,CHEMBL619166,,BAO_0000224,
3497,104841,,,4,,H,,,,Autocuration,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,1,,15796,CHEMBL619167,,BAO_0000019,
3498,104841,,,4,,H,,,,Autocuration,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,1,,15796,CHEMBL619168,,BAO_0000019,
3499,168,,,9,,D,,Cardiac atrium,,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,1,,15650,CHEMBL619169,,BAO_0000219,2081.0
3500,168,,,9,,D,,Cardiac atrium,,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,1,,15650,CHEMBL619170,,BAO_0000219,2081.0
3501,104841,,,5,,D,,,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,1,,6866,CHEMBL619171,,BAO_0000019,
3502,168,,,9,,D,,Cardiac atrium,,Expert,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,1,,15650,CHEMBL619172,,BAO_0000219,2081.0
3503,22226,,,0,,U,,,,Autocuration,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,1,,10063,CHEMBL619173,,BAO_0000019,
3504,22226,,,0,,U,,,,Autocuration,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,1,,12665,CHEMBL619174,,BAO_0000019,
3505,104705,,,4,,H,,,,Autocuration,5-hydroxytryptamine receptor binding affinity was determined in rats,B,1,,7504,CHEMBL619175,,BAO_0000019,
3506,104705,,,4,,H,,,,Autocuration,Binding affinity at rat 5-hydroxytryptamine receptor.,B,1,,7504,CHEMBL619176,,BAO_0000224,
3507,104705,,,4,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,1,,7038,CHEMBL619177,,BAO_0000019,
3508,104705,,,4,,H,,,,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,1,,7626,CHEMBL619178,,BAO_0000224,
3509,104705,,,4,,H,,,,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,1,,7626,CHEMBL619179,,BAO_0000224,
3510,104705,,,4,,H,,Stomach,,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,1,,7185,CHEMBL619180,,BAO_0000019,945.0
3511,104705,,,4,,H,,Stomach,,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,1,,7185,CHEMBL619181,,BAO_0000019,945.0
3512,104705,,,4,,H,,,,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,1,,7185,CHEMBL619182,,BAO_0000019,
3513,104705,,,4,,H,,,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,1,,6960,CHEMBL619183,,BAO_0000224,
3514,104705,,,4,,H,,,,Autocuration,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,1,,6960,CHEMBL619184,,BAO_0000224,
3515,10576,,,8,,H,,Hippocampus,,Autocuration,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,1,,12416,CHEMBL619185,,BAO_0000221,10000000.0
3516,12198,,,8,,H,,,,Expert,Binding affinity for rat 5-hydroxytryptamine transporter.,B,1,,15753,CHEMBL619186,,BAO_0000357,
3517,104705,,,4,,H,,,,Autocuration,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,1,,8062,CHEMBL619187,,BAO_0000019,
3518,104705,,,5,,D,,,,Autocuration,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,1,,9036,CHEMBL619188,,BAO_0000019,
3519,104705,,,5,,D,,,,Autocuration,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,1,,15067,CHEMBL619189,,BAO_0000224,
3520,12198,,,9,,D,,Brain,,Expert,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,1,,15753,CHEMBL619190,,BAO_0000019,955.0
3521,12198,,,9,,D,,Cerebellum,,Expert,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,1,,15753,CHEMBL619191,,BAO_0000221,2037.0
3522,104705,,,5,,D,,,,Autocuration,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,1,,15295,CHEMBL619192,,BAO_0000019,
3523,104705,,,5,,D,,,,Autocuration,Percent binding affinity against 5-hydroxytryptamine receptor,B,1,,6347,CHEMBL619193,,BAO_0000224,
3524,22226,,,0,,U,,,,Autocuration,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,1,,6763,CHEMBL619194,,BAO_0000019,
3525,104705,,,5,,D,,,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,1,,12092,CHEMBL619195,,BAO_0000224,
3526,104705,,,5,,D,,,,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined,B,1,,1579,CHEMBL619196,,BAO_0000224,
3527,104705,,,5,,D,,Stomach,,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,1,,1579,CHEMBL619197,,BAO_0000019,945.0
3528,121,,In vitro,9,,D,,,,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,1,,5963,CHEMBL619198,,BAO_0000219,
3529,121,,In vitro,9,,D,,,,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,1,,5963,CHEMBL875081,,BAO_0000219,
3530,18065,,,8,,H,,,,Autocuration,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,1,,5030,CHEMBL884712,,BAO_0000357,
3531,121,,,8,,H,,,,Expert,Inhibition of 5-hydroxytryptamine reuptake,B,1,,15796,CHEMBL884710,,BAO_0000357,
3532,18065,,,8,,H,,,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,1,,15413,CHEMBL619199,,BAO_0000019,
3533,18065,,,8,,H,,,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,1,,15413,CHEMBL619200,,BAO_0000019,
3534,18065,,,8,,H,,,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,1,,15413,CHEMBL619201,,BAO_0000019,
3535,18065,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine receptor uptake,F,1,,12409,CHEMBL619202,,BAO_0000019,
3536,51,,,9,,D,,,CHO,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,1,,16909,CHEMBL619203,449.0,BAO_0000219,
3537,51,,,9,,D,,,,Expert,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,1,,16909,CHEMBL619204,,BAO_0000019,
3538,10576,,,8,,H,,,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,1,,15629,CHEMBL619205,,BAO_0000249,
3539,10576,,,8,,H,,,,Autocuration,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,1,,15629,CHEMBL619206,,BAO_0000357,
3540,10576,,,8,,H,,,,Expert,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,1,,15629,CHEMBL619207,,BAO_0000249,
3541,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,1,,10034,CHEMBL619208,,BAO_0000019,2435.0
3542,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,1,,10034,CHEMBL619209,,BAO_0000019,2435.0
3543,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,1,,10034,CHEMBL619210,,BAO_0000019,2435.0
3544,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,1,,10034,CHEMBL619211,,BAO_0000019,2435.0
3545,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,1,,10034,CHEMBL619212,,BAO_0000019,2435.0
3546,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,1,,10034,CHEMBL620681,,BAO_0000019,2435.0
3547,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,1,,10034,CHEMBL620682,,BAO_0000019,2435.0
3548,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,1,,10034,CHEMBL620683,,BAO_0000019,2435.0
3549,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,1,,10034,CHEMBL620684,,BAO_0000019,2435.0
3550,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,1,,10034,CHEMBL620685,,BAO_0000019,2435.0
3551,10825,,,8,,H,,Striatum,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,1,,10034,CHEMBL620686,,BAO_0000019,2435.0
3552,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,1,,10034,CHEMBL620687,,BAO_0000019,349.0
3553,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,1,,10034,CHEMBL620688,,BAO_0000019,349.0
3554,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,1,,10034,CHEMBL620689,,BAO_0000019,349.0
3555,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,1,,10034,CHEMBL620690,,BAO_0000019,349.0
3556,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,1,,10034,CHEMBL620691,,BAO_0000019,349.0
3557,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,1,,10034,CHEMBL620692,,BAO_0000019,349.0
3558,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,1,,10034,CHEMBL620693,,BAO_0000019,349.0
3559,168,,,8,,H,,,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,B,1,,1274,CHEMBL620694,,BAO_0000357,
3560,168,,,8,,H,,,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,1,,17358,CHEMBL857986,,BAO_0000019,
3561,168,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,1,,14532,CHEMBL620695,,BAO_0000357,
3562,168,,,8,,H,,,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,1,,16989,CHEMBL620696,,BAO_0000357,
3563,168,,,8,,H,,,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,1,,17200,CHEMBL620697,,BAO_0000357,
3564,168,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,1,,15779,CHEMBL620698,,BAO_0000357,
3565,168,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,1,,15779,CHEMBL620699,,BAO_0000357,
3566,168,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,1,,15779,CHEMBL620700,,BAO_0000357,
3567,168,,,8,,H,,,COS-7,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,1,,15650,CHEMBL620701,643.0,BAO_0000219,
3568,168,,,8,,H,,,COS-7,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,1,,15650,CHEMBL875082,643.0,BAO_0000219,
3569,168,,,8,,H,,,COS-7,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,1,,15650,CHEMBL620702,643.0,BAO_0000219,
3570,168,,,8,,H,,,COS-7,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,1,,15650,CHEMBL620703,643.0,BAO_0000219,
3571,168,,,8,,H,,,C6,Autocuration,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,1,,17046,CHEMBL620704,673.0,BAO_0000219,
3572,168,,,8,,H,,,C6,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,1,,17046,CHEMBL620705,673.0,BAO_0000219,
3573,168,,,8,,H,,,C6,Expert,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,1,,15650,CHEMBL620706,673.0,BAO_0000219,
3574,168,,,8,,H,,,C6,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,1,,17046,CHEMBL620707,673.0,BAO_0000219,
3575,10624,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,1,,17066,CHEMBL620708,,BAO_0000357,
3576,105,,,8,,H,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,1,,17200,CHEMBL620709,,BAO_0000357,
3577,10624,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 5A receptor,B,1,,16146,CHEMBL620710,,BAO_0000357,
3578,10624,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,1,,15250,CHEMBL620711,449.0,BAO_0000219,
3579,10624,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,1,,6491,CHEMBL620712,,BAO_0000357,
3580,10624,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,1,,17066,CHEMBL620713,,BAO_0000357,
3581,10624,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,1,,17066,CHEMBL620714,,BAO_0000357,
3582,10624,,,9,,D,,,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,1,,4234,CHEMBL620715,,BAO_0000357,
3583,10624,,,8,,H,,,,Autocuration,Binding affinity towards 5-HT5A receptor,B,1,,6013,CHEMBL620716,,BAO_0000357,
3584,10624,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,1,,17175,CHEMBL620717,,BAO_0000357,
3585,10624,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,1,,15818,CHEMBL618072,,BAO_0000357,
3586,10624,,,8,,H,,,,Autocuration,Binding affinity towards cloned human 5-HT5A receptor was determined,B,1,,6166,CHEMBL857987,,BAO_0000357,
3587,10624,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,1,,15779,CHEMBL618073,722.0,BAO_0000219,
3588,10624,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,1,,15779,CHEMBL618074,722.0,BAO_0000219,
3589,10624,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,1,,5213,CHEMBL618075,722.0,BAO_0000219,
3590,10625,,,9,,D,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,1,,17066,CHEMBL618076,,BAO_0000357,
3591,10625,,,9,,D,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,1,,17066,CHEMBL618077,,BAO_0000357,
3592,10625,,,9,,D,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,1,,17066,CHEMBL618078,,BAO_0000357,
3593,10625,,,9,,D,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,1,,17066,CHEMBL881821,,BAO_0000357,
3594,10625,,,9,,D,,,,Expert,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,1,,17066,CHEMBL618079,,BAO_0000357,
3595,10625,,,8,,H,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,1,,17175,CHEMBL618080,,BAO_0000357,
3596,10576,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,1,,16190,CHEMBL618081,722.0,BAO_0000219,
3597,10626,,,8,,H,,,HEK293,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,1,,16190,CHEMBL618082,722.0,BAO_0000219,
3598,10624,,,8,,H,,,,Expert,Binding affinity towards 5-HT5a receptor,B,1,,4820,CHEMBL618083,,BAO_0000357,
3599,10624,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,1,,17066,CHEMBL618084,,BAO_0000357,
3600,10624,,,8,,H,,,,Expert,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,1,,17066,CHEMBL618085,,BAO_0000357,
3601,10624,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,1,,17175,CHEMBL618086,,BAO_0000357,
3602,10624,,,8,,H,,,,Autocuration,Binding affinities against 5-hydroxytryptamine 5A receptor,B,1,,16633,CHEMBL875092,,BAO_0000357,
3603,10624,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,1,,16633,CHEMBL618087,,BAO_0000357,
3604,10624,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,1,,16700,CHEMBL872926,,BAO_0000357,
3605,104714,,,4,,H,,,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,1,,4639,CHEMBL618088,,BAO_0000019,
3606,104714,,,4,,H,,,,Autocuration,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,1,,5486,CHEMBL618089,,BAO_0000223,
3607,10627,,,9,,D,,,,Expert,Inhibition of human 5-hydroxytryptamine 6 receptor,B,1,,16146,CHEMBL618090,,BAO_0000357,
3608,10627,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,1,,17273,CHEMBL618091,,BAO_0000357,
3609,10627,,,8,,H,,,,Autocuration,Inhibition against human 5-hydroxytryptamine 6 receptor,B,1,,17687,CHEMBL618092,,BAO_0000357,
3610,10627,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,1,,6491,CHEMBL618093,,BAO_0000357,
3611,10627,,,8,,H,,,HeLa,Expert,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,1,,16190,CHEMBL618094,308.0,BAO_0000219,
3612,10627,,,9,,D,,,,Expert,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,1,,17066,CHEMBL618095,,BAO_0000357,
3613,10627,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,17066,CHEMBL875093,,BAO_0000357,
3614,10627,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,1,,17066,CHEMBL618096,,BAO_0000357,
3615,10627,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,1,,17066,CHEMBL618118,,BAO_0000357,
3616,10627,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 6 receptor,B,1,,3555,CHEMBL618119,,BAO_0000357,
3617,10627,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,5808,CHEMBL618120,,BAO_0000357,
3618,10627,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,6013,CHEMBL618121,,BAO_0000357,
3619,10627,,,8,,H,,,HEK293,Expert,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,1,,15818,CHEMBL618122,722.0,BAO_0000219,
3620,10627,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,1,,16209,CHEMBL618123,,BAO_0000357,
3621,10627,,,8,,H,,,HEK293,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,1,,3935,CHEMBL618124,722.0,BAO_0000219,
3622,10627,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,15818,CHEMBL618125,,BAO_0000357,
3623,10627,,,9,,D,,,HEK293,Expert,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,1,,3805,CHEMBL618126,722.0,BAO_0000219,
3624,10627,,,8,,H,,,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,1,,16441,CHEMBL618236,,BAO_0000019,
3625,10627,,,8,,H,,,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,1,,16441,CHEMBL618237,,BAO_0000019,
3626,10627,,,8,,H,,,COS-7,Expert,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,1,,6786,CHEMBL618238,643.0,BAO_0000219,
3627,10627,,,9,,D,,,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,1,,4234,CHEMBL618239,,BAO_0000357,
3628,10627,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,1,,17085,CHEMBL618240,,BAO_0000019,
3629,10627,,,8,,H,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,1,,17200,CHEMBL618241,,BAO_0000357,
3630,10627,,,8,,H,,,HEK293,Autocuration,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,1,,17451,CHEMBL859399,722.0,BAO_0000219,
3631,10627,,,8,,H,,,,Autocuration,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,1,,3935,CHEMBL618242,,BAO_0000019,
3632,10627,,,8,,H,,,,Autocuration,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,1,,5033,CHEMBL857991,,BAO_0000357,
3633,10627,,,8,,H,,,,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,1,,4540,CHEMBL619951,,BAO_0000357,
3634,10627,,,9,,D,,,HeLa,Expert,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,1,,4540,CHEMBL619952,308.0,BAO_0000219,
3635,10627,,,9,,D,,,HeLa,Expert,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,1,,4540,CHEMBL619953,308.0,BAO_0000219,
3636,10627,,,8,,H,,,HeLa,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,1,,17296,CHEMBL619954,308.0,BAO_0000219,
3637,10627,,,8,,H,,,HeLa,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,1,,17296,CHEMBL619955,308.0,BAO_0000219,
3638,10627,,,8,,H,,,HeLa,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,1,,17296,CHEMBL619956,308.0,BAO_0000219,
3639,10627,,,8,,H,,,CHO,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,1,,15779,CHEMBL619957,449.0,BAO_0000219,
3640,10627,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,1,,15779,CHEMBL619958,722.0,BAO_0000219,
3641,10627,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,1,,15779,CHEMBL620627,722.0,BAO_0000219,
3642,10627,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,1,,15779,CHEMBL620628,722.0,BAO_0000219,
3643,10627,,,8,,H,,,HeLa,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,1,,15779,CHEMBL620629,308.0,BAO_0000219,
3644,10627,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,6166,CHEMBL620630,,BAO_0000357,
3645,10627,,,8,,H,,,HeLa,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,1,,17451,CHEMBL620782,308.0,BAO_0000219,
3646,10627,,,8,,H,,,,Autocuration,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,1,,15316,CHEMBL620783,,BAO_0000357,
3647,10627,,,8,,H,,,,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,1,,4199,CHEMBL620784,,BAO_0000357,
3648,10627,,,8,,H,,,HeLa,Expert,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,1,,15146,CHEMBL620785,308.0,BAO_0000219,
3649,10627,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,1,,5213,CHEMBL857992,,BAO_0000357,
3650,10627,,,8,,H,,,,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,1,,16429,CHEMBL620786,,BAO_0000219,
3651,10627,,,8,,H,,,HeLa,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,1,,14818,CHEMBL620787,308.0,BAO_0000219,
3652,10627,,,8,,H,,,HeLa,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,1,,4829,CHEMBL620788,308.0,BAO_0000219,
3653,10627,,,8,,H,,,HeLa,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,1,,4829,CHEMBL620789,308.0,BAO_0000219,
3654,10627,,,8,,H,,,HeLa,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,1,,4829,CHEMBL620790,308.0,BAO_0000219,
3655,10628,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,1,,15250,CHEMBL620791,449.0,BAO_0000219,
3656,10628,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,1,,14423,CHEMBL620792,,BAO_0000019,
3657,10628,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,1,,15086,CHEMBL620793,,BAO_0000357,
3658,10628,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,1,,4342,CHEMBL620794,,BAO_0000357,
3659,10627,,,9,,D,,,HeLa,Autocuration,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,1,,16190,CHEMBL620795,308.0,BAO_0000219,
3660,10627,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,4820,CHEMBL620796,,BAO_0000357,
3661,10627,,,8,,H,,,,Autocuration,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,1,,4639,CHEMBL620797,,BAO_0000357,
3662,10627,,,9,,D,,,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,1,,17066,CHEMBL620798,,BAO_0000019,
3663,10627,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,1,,6011,CHEMBL620799,,BAO_0000357,
3664,10627,,,8,,H,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,1,,17066,CHEMBL620800,,BAO_0000357,
3665,10627,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,1,,17515,CHEMBL620801,,BAO_0000357,
3666,10627,,,8,,H,,,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,1,,5014,CHEMBL875100,,BAO_0000357,
3667,10627,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,1,,4373,CHEMBL620802,,BAO_0000357,
3668,10627,,,8,,H,,,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,1,,17066,CHEMBL620803,,BAO_0000019,
3669,10627,,,8,,H,,,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,1,,17066,CHEMBL620804,,BAO_0000019,
3670,10627,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,1,,4373,CHEMBL620805,,BAO_0000357,
3671,10627,,,8,,H,,,,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,1,,4687,CHEMBL620806,,BAO_0000357,
3672,10627,,,8,,H,,,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,1,,16946,CHEMBL620807,,BAO_0000357,
3673,10627,,,8,,H,,,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,1,,16946,CHEMBL620808,,BAO_0000357,
3674,10627,,,8,,H,,,,Autocuration,Binding affinities against 5-hydroxytryptamine 6 receptor,B,1,,16633,CHEMBL620809,,BAO_0000357,
3675,10627,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,1,,16633,CHEMBL620810,,BAO_0000357,
3676,10627,,,9,,D,,,,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,1,,17066,CHEMBL620811,,BAO_0000357,
3677,10627,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,1,,16700,CHEMBL620812,,BAO_0000357,
3678,10627,,,8,,H,,,,Autocuration,Affinity against 5-hydroxytryptamine 6 receptor,B,1,,3269,CHEMBL620813,,BAO_0000357,
3679,10627,,,8,,H,,,,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,1,,5486,CHEMBL620814,,BAO_0000357,
3680,10209,,,9,,D,,,,Expert,Inhibition of human 5-hydroxytryptamine 7 receptor,B,1,,16146,CHEMBL620815,,BAO_0000357,
3681,10209,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,1,,5014,CHEMBL620816,722.0,BAO_0000219,
3682,10209,,,8,,H,,,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,1,,15463,CHEMBL620817,,BAO_0000357,
3683,10209,,,8,,H,,,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,1,,3805,CHEMBL620818,,BAO_0000357,
3684,10209,,,8,,H,,,HEK293,Expert,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,1,,5014,CHEMBL620819,722.0,BAO_0000219,
3685,10209,,,9,,D,,,,Expert,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,1,,6491,CHEMBL620820,,BAO_0000357,
3686,10209,,,8,,H,,,CHO,Autocuration,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,1,,16190,CHEMBL620821,449.0,BAO_0000219,
3687,10209,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL620822,,BAO_0000357,
3688,10209,,,9,,D,,,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL620823,,BAO_0000357,
3689,10209,,,9,,D,,,,Expert,Binding affinity against 5-hydroxytryptamine 7 receptor,B,1,,3555,CHEMBL620824,,BAO_0000357,
3690,10209,,,8,,H,,,CHO,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,1,,6588,CHEMBL620825,449.0,BAO_0000219,
3691,10209,,,8,,H,,,,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,1,,15463,CHEMBL872930,,BAO_0000357,
3692,10209,,,8,,H,,,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,1,,6013,CHEMBL620826,,BAO_0000357,
3693,10209,,,8,,H,,,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,1,,16209,CHEMBL620827,,BAO_0000357,
3694,10209,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,1,,3935,CHEMBL620828,,BAO_0000357,
3695,10209,,,8,,H,,,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,1,,15818,CHEMBL620829,,BAO_0000357,
3696,10209,,,8,,H,,,HEK293,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,1,,5014,CHEMBL620830,722.0,BAO_0000219,
3697,10209,,,8,,H,,,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,1,,16441,CHEMBL620831,,BAO_0000019,
3698,10209,,,8,,H,,,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,1,,16441,CHEMBL620832,,BAO_0000019,
3699,10209,,,9,,D,,,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,1,,4234,CHEMBL621548,,BAO_0000357,
3700,10209,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,1,,17085,CHEMBL621549,,BAO_0000019,
3701,10209,,,8,,H,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,1,,17200,CHEMBL621550,,BAO_0000357,
3702,10209,,,8,,H,,,CHO,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,1,,17451,CHEMBL621551,449.0,BAO_0000219,
3703,10209,,,8,,H,,,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,1,,17085,CHEMBL621552,,BAO_0000019,
3704,10209,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,1,,5104,CHEMBL857077,,BAO_0000357,
3705,10209,,,8,,H,,,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,1,,5104,CHEMBL618158,,BAO_0000357,
3706,10209,,,9,,D,,,COS-7,Expert,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,1,,5033,CHEMBL618159,643.0,BAO_0000219,
3707,10209,,,8,,H,,,COS-7,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,1,,5486,CHEMBL875101,643.0,BAO_0000219,
3708,10209,,,9,,D,,,HEK293,Expert,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,1,,4540,CHEMBL618160,722.0,BAO_0000219,
3709,10209,,,8,,H,,,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,1,,6166,CHEMBL618161,,BAO_0000357,
3710,10209,,,8,,H,,,HEK293,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,1,,17342,CHEMBL618162,722.0,BAO_0000219,
3711,10209,,,8,,H,,,,Expert,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,1,,17342,CHEMBL618163,,BAO_0000357,
3712,10209,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,1,,17296,CHEMBL618164,,BAO_0000357,
3713,10209,,,8,,H,,,,Expert,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,1,,16429,CHEMBL618165,,BAO_0000219,
3714,10209,,,8,,H,,,HEK293,Autocuration,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,1,,15779,CHEMBL618166,722.0,BAO_0000219,
3715,10209,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,1,,15779,CHEMBL857989,722.0,BAO_0000219,
3716,10209,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,1,,15779,CHEMBL619888,722.0,BAO_0000219,
3717,10209,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,1,,15779,CHEMBL619889,722.0,BAO_0000219,
3718,10209,,,8,,H,,,HEK293,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,1,,15779,CHEMBL619890,722.0,BAO_0000219,
3719,10209,,,8,,H,,,CHO,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,1,,17451,CHEMBL619891,449.0,BAO_0000219,
3720,10209,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,1,,4199,CHEMBL619892,722.0,BAO_0000219,
3721,10209,,,9,,D,,,HEK293,Expert,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,1,,4199,CHEMBL619893,722.0,BAO_0000219,
3722,10209,,,8,,H,,,HEK293,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,1,,4199,CHEMBL619894,722.0,BAO_0000219,
3723,10209,,,9,,D,,,HEK293,Intermediate,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,1,,3680,CHEMBL619895,722.0,BAO_0000219,
3724,10209,,,9,,D,,,,Intermediate,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,1,,3680,CHEMBL619896,,BAO_0000357,
3725,10209,,,8,,H,,,COS-7,Autocuration,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,1,,15316,CHEMBL619897,643.0,BAO_0000219,
3726,10209,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,1,,15146,CHEMBL619898,722.0,BAO_0000219,
3727,10209,,,8,,H,,,HEK293,Expert,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,1,,5213,CHEMBL619899,722.0,BAO_0000219,
3728,10209,,,8,,H,,,HEK293,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,1,,5213,CHEMBL619900,722.0,BAO_0000219,
3729,10209,,,9,,D,,,HEK293,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,1,,14818,CHEMBL619901,722.0,BAO_0000219,
3730,10209,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,1,,14818,CHEMBL620580,722.0,BAO_0000219,
3731,10209,,,8,,H,,,HEK293,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,1,,14818,CHEMBL620581,722.0,BAO_0000219,
3732,10209,,,8,,H,,,HEK293,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,1,,4829,CHEMBL620733,722.0,BAO_0000219,
3733,10209,,,9,,D,,,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,1,,17200,CHEMBL620734,,BAO_0000357,
3734,10022,,,9,,D,,,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,1,,17066,CHEMBL620735,,BAO_0000357,
3735,10209,,,8,,H,,,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,1,,14025,CHEMBL620736,,BAO_0000019,
3736,11923,,,8,,H,,,CHO,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,1,,15250,CHEMBL620737,449.0,BAO_0000219,
3737,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,1,,16372,CHEMBL620738,449.0,BAO_0000219,
3738,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,1,,16372,CHEMBL620739,449.0,BAO_0000219,
3739,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,1,,16372,CHEMBL620740,449.0,BAO_0000219,
3740,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,1,,16372,CHEMBL620741,449.0,BAO_0000219,
3741,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,1,,16372,CHEMBL620742,449.0,BAO_0000219,
3742,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,1,,16372,CHEMBL620743,449.0,BAO_0000219,
3743,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,1,,16372,CHEMBL620744,449.0,BAO_0000219,
3744,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,1,,16372,CHEMBL620745,449.0,BAO_0000219,
3745,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,1,,16372,CHEMBL620746,449.0,BAO_0000219,
3746,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,1,,16372,CHEMBL620747,449.0,BAO_0000219,
3747,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,1,,16372,CHEMBL620748,449.0,BAO_0000219,
3748,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,1,,16372,CHEMBL620749,449.0,BAO_0000219,
3749,11923,,,8,,H,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL620750,,BAO_0000357,
3750,11923,,,9,,D,,,,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,1,,17066,CHEMBL620751,,BAO_0000357,
3751,11923,,,8,,H,,,,Expert,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,1,,17386,CHEMBL620752,,BAO_0000357,
3752,11923,,,8,,H,,,,Autocuration,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,1,,14423,CHEMBL872929,,BAO_0000019,
3753,11923,,,9,,D,,,,Expert,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,1,,15874,CHEMBL620753,,BAO_0000357,
3754,11923,,,9,,D,,,,Expert,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,1,,15874,CHEMBL620754,,BAO_0000357,
3755,11923,,,9,,D,,,CHO,Expert,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,1,,16372,CHEMBL620755,449.0,BAO_0000219,
3756,11923,,,8,,H,,,,Autocuration,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,1,,4622,CHEMBL620756,,BAO_0000357,
3757,11923,,,8,,H,,,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,1,,15086,CHEMBL620757,,BAO_0000357,
3758,11923,,,8,,H,,,CHO,Autocuration,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,1,,16372,CHEMBL620758,449.0,BAO_0000219,
3759,11923,,,8,,H,,,CHO,Autocuration,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,1,,16372,CHEMBL620759,449.0,BAO_0000219,
3760,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,1,,16372,CHEMBL620760,449.0,BAO_0000219,
3761,11923,,,8,,H,,,CHO,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,1,,16372,CHEMBL620761,449.0,BAO_0000219,
3762,11923,,,8,,H,,Ileum,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,1,,17386,CHEMBL620762,,BAO_0000221,2116.0
3763,11923,,,8,,H,,Ileum,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,1,,17386,CHEMBL620763,,BAO_0000221,2116.0
3764,11923,,,8,,H,,Ileum,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,1,,17386,CHEMBL620764,,BAO_0000221,2116.0
3765,11923,,,9,,D,Membranes,,,Expert,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,1,,5831,CHEMBL857990,,BAO_0000249,
3766,11923,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,1,,4342,CHEMBL620765,,BAO_0000357,
3767,11923,,,8,,H,,,,Expert,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,1,,17319,CHEMBL620766,,BAO_0000357,
3768,11923,,,8,,H,,Hypothalamus,,Expert,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,1,,17342,CHEMBL620767,,BAO_0000019,1898.0
3769,11923,,,8,,H,,,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,1,,17342,CHEMBL620768,,BAO_0000357,
3770,11923,,,8,,H,,Hypothalamus,,Expert,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,1,,3680,CHEMBL619051,,BAO_0000249,1898.0
3771,11923,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,1,,3680,CHEMBL619052,,BAO_0000357,
3772,11923,,,9,,D,,,HEK293,Expert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,1,,17319,CHEMBL619053,722.0,BAO_0000219,
3773,11923,,,9,,D,,,HEK293,Expert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,1,,17319,CHEMBL619703,722.0,BAO_0000219,
3774,11923,,,9,,D,,,HEK293,Autocuration,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,1,,17319,CHEMBL619704,722.0,BAO_0000219,
3775,10209,,,8,,H,,,,Expert,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,1,,4820,CHEMBL619851,,BAO_0000357,
3776,10209,,,8,,H,,,,Autocuration,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,1,,4639,CHEMBL619852,,BAO_0000357,
3777,10209,,,8,,H,,,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,1,,6011,CHEMBL619853,,BAO_0000357,
3778,10209,,,9,,D,,,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL619854,,BAO_0000357,
3779,10209,,,8,,H,,,,Expert,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL619855,,BAO_0000357,
3780,10209,,,8,,H,,,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,1,,17515,CHEMBL619856,,BAO_0000357,
3781,10209,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,1,,4373,CHEMBL619857,,BAO_0000357,
3782,10209,,,8,,H,,,,Expert,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,1,,17066,CHEMBL619858,,BAO_0000019,
3783,10209,,,8,,H,,,,Autocuration,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,1,,4373,CHEMBL619859,,BAO_0000357,
3784,10209,,,8,,H,,,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,1,,4373,CHEMBL619860,,BAO_0000357,
3785,10209,,,8,,H,,,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,1,,4687,CHEMBL619861,,BAO_0000357,
3786,10209,,,8,,H,,,,Expert,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,1,,17342,CHEMBL619862,,BAO_0000357,
3787,10209,,,8,,H,,,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,1,,16946,CHEMBL619863,,BAO_0000357,
3788,10209,,,8,,H,,,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,1,,16946,CHEMBL619864,,BAO_0000357,
3789,10209,,,8,,H,,,,Autocuration,Binding affinities against 5-hydroxytryptamine 7 receptor,B,1,,16633,CHEMBL872928,,BAO_0000357,
3790,10209,,,8,,H,,,,Autocuration,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,1,,16633,CHEMBL619865,,BAO_0000357,
3791,10209,,,8,,H,,,,Expert,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,1,,17066,CHEMBL619866,,BAO_0000357,
3792,10209,,,8,,H,,,,Autocuration,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,1,,16700,CHEMBL619867,,BAO_0000357,
3793,10209,,,8,,H,,Ileum,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,1,,17386,CHEMBL619868,,BAO_0000221,2116.0
3794,55,,,8,,H,,,,Autocuration,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,1,,14080,CHEMBL619869,,BAO_0000019,
3795,55,,,9,,D,,,,Expert,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,1,,14080,CHEMBL619870,,BAO_0000019,
3796,55,,,8,,H,,,,Autocuration,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,1,,409,CHEMBL619871,,BAO_0000357,
3797,55,,,8,,H,,,,Autocuration,In vitro inhibition of human recombinant lipoxygenase enzyme,B,1,,409,CHEMBL619872,,BAO_0000357,
3798,55,,,8,,H,,,,Autocuration,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,1,,409,CHEMBL619873,,BAO_0000357,
3799,55,,,8,,H,,Blood,,Expert,Inhibition of 5-lipoxygenase in human whole blood.,B,1,,11090,CHEMBL619874,,BAO_0000357,178.0
3800,55,,,8,,H,,Blood,,Expert,Inhibition of 5-lipoxygenase in human whole blood.,B,1,,11090,CHEMBL619875,,BAO_0000357,178.0
3801,55,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,1,,948,CHEMBL619876,,BAO_0000357,
3802,55,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,1,,948,CHEMBL619877,,BAO_0000357,
3803,55,,,8,,H,,,,Expert,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,1,,13622,CHEMBL619878,,BAO_0000219,
3804,55,,,8,,H,,Blood,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,1,,13622,CHEMBL619879,,BAO_0000019,178.0
3805,55,,,8,,H,,,,Autocuration,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,1,,9637,CHEMBL619880,,BAO_0000357,
3806,55,,,8,,H,,,,Autocuration,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,1,,11320,CHEMBL619881,,BAO_0000357,
3807,55,,,8,,H,,,,Expert,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,1,,11320,CHEMBL619882,,BAO_0000357,
3808,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,1,,6838,CHEMBL619883,,BAO_0000357,
3809,55,,,9,,D,,Blood,,Expert,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,1,,17667,CHEMBL619884,,BAO_0000357,178.0
3810,55,,,8,,H,,,,Autocuration,In vitro potency against human 5-Lipoxygenase,B,1,,12703,CHEMBL619885,,BAO_0000357,
3811,55,,,9,,D,,,,Expert,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,1,,14312,CHEMBL619886,,BAO_0000019,
3812,55,,,8,,H,,Blood,,Autocuration,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,1,,14312,CHEMBL619887,,BAO_0000019,178.0
3813,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,1,,5364,CHEMBL875097,,BAO_0000019,
3814,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,1,,951,CHEMBL618001,,BAO_0000219,
3815,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,1,,951,CHEMBL618002,,BAO_0000219,
3816,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,1,,951,CHEMBL618003,,BAO_0000219,
3817,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,1,,951,CHEMBL618004,,BAO_0000219,
3818,55,,,8,,H,,,,Autocuration,Inhibition of human 5-lipoxygenase in human cells,B,1,,12365,CHEMBL618005,,BAO_0000219,
3819,55,,,8,,H,,,,Expert,Inhibition of human neutrophil 5-lipoxygenase,B,1,,10603,CHEMBL618006,,BAO_0000357,
3820,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,1,,10501,CHEMBL875086,,BAO_0000019,
3821,55,,,8,,H,,Blood,,Expert,Inhibition of 5-lipoxygenase from human whole blood,B,1,,12281,CHEMBL618007,,BAO_0000357,178.0
3822,55,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,1,,2567,CHEMBL618008,,BAO_0000357,
3823,55,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,1,,2567,CHEMBL618009,,BAO_0000219,
3824,55,,,8,,H,,,,Expert,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,1,,10193,CHEMBL618010,,BAO_0000357,
3825,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,1,,10193,CHEMBL618011,,BAO_0000357,
3826,55,,,8,,H,,,,Expert,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,1,,13623,CHEMBL618012,,BAO_0000357,
3827,55,,,8,,H,,,,Autocuration,Tested against 5-lipoxygenase,B,1,,12780,CHEMBL882927,,BAO_0000357,
3828,55,,,8,,H,,,,Autocuration,Tested for activity against 5-Lipoxygenase (5-LO),B,1,,12780,CHEMBL618013,,BAO_0000357,
3829,55,,,8,,H,,,,Autocuration,Tested for activity against 5-lipoxygenase,B,1,,12780,CHEMBL618014,,BAO_0000357,
3830,55,,,8,,H,,,,Autocuration,Tested for inhibition of 5-HPETE production by human 5-LO,B,1,,11966,CHEMBL618015,,BAO_0000357,
3831,55,,,8,,H,,,,Autocuration,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,1,,5364,CHEMBL618016,,BAO_0000019,
3832,55,,,8,,H,,,,Expert,Inhibition of Human 5-lipoxygenase,B,1,,13165,CHEMBL618017,,BAO_0000357,
3833,55,,,8,,H,,,,Autocuration,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,1,,5364,CHEMBL618018,,BAO_0000019,
3834,55,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL875087,,BAO_0000219,
3835,55,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL618019,,BAO_0000219,
3836,55,,,8,,H,,,,Autocuration,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,1,,14863,CHEMBL618020,,BAO_0000019,
3837,55,,,8,,H,,,,Autocuration,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,1,,14863,CHEMBL618021,,BAO_0000019,
3838,55,,,8,,H,,Blood,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,1,,11087,CHEMBL618022,,BAO_0000357,178.0
3839,55,,,8,,H,,,,Autocuration,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,1,,455,CHEMBL618023,,BAO_0000357,
3840,55,,,8,,H,,,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,1,,13183,CHEMBL618024,,BAO_0000357,
3841,55,,,8,,H,,,,Expert,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,1,,10319,CHEMBL873950,,BAO_0000019,
3842,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,1,,10193,CHEMBL618025,,BAO_0000357,
3843,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,1,,951,CHEMBL618026,,BAO_0000219,
3844,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,1,,951,CHEMBL618027,,BAO_0000219,
3845,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,1,,951,CHEMBL618028,,BAO_0000219,
3846,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,1,,951,CHEMBL618029,,BAO_0000219,
3847,55,,,8,,H,,,,Expert,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,1,,9859,CHEMBL618030,,BAO_0000357,
3848,55,,,8,,H,,,,Expert,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,1,,9859,CHEMBL618031,,BAO_0000357,
3849,55,,,8,,H,,,,Autocuration,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,1,,9859,CHEMBL618032,,BAO_0000357,
3850,55,,,8,,H,,,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,1,,2567,CHEMBL618033,,BAO_0000357,
3851,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,1,,10193,CHEMBL618034,,BAO_0000357,
3852,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,1,,10193,CHEMBL875088,,BAO_0000357,
3853,55,,,8,,H,,,,Autocuration,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,1,,949,CHEMBL618035,,BAO_0000019,
3854,55,,,8,,H,,,,Autocuration,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,1,,949,CHEMBL618036,,BAO_0000019,
3855,55,,,8,,H,,,,Expert,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,1,,10603,CHEMBL618037,,BAO_0000357,
3856,55,,,8,,H,,,,Expert,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,1,,10603,CHEMBL618038,,BAO_0000357,
3857,55,,,8,,H,,,,Autocuration,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,1,,10603,CHEMBL618761,,BAO_0000019,
3858,55,,,8,,H,,,,Expert,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,1,,10603,CHEMBL618762,,BAO_0000357,
3859,55,,,8,,H,,,,Expert,Inhibition of lipoxygenase at the concentration of 1 uM,B,1,,10603,CHEMBL618763,,BAO_0000357,
3860,55,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,1,,10193,CHEMBL618764,,BAO_0000357,
3861,55,,,9,,D,,,,Expert,Inhibition of 5-Lipoxygenase (5-LOX),B,1,,14580,CHEMBL618765,,BAO_0000357,
3862,17087,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase in mouse macrophages.,B,1,,11090,CHEMBL618766,,BAO_0000357,
3863,17087,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase in mouse macrophages.,B,1,,11090,CHEMBL618767,,BAO_0000357,
3864,17087,,,8,,H,,,,Autocuration,Inhibitory activity against lipoxygenase-2 in mice,B,1,,6339,CHEMBL619380,,BAO_0000357,
3865,17087,,,8,,H,,,,Expert,Inhibitory activity against murine lipoxygenase-2.,B,1,,6339,CHEMBL619381,,BAO_0000357,
3866,17087,,,9,,D,,,,Expert,Inhibition of 5-lipoxygenase from mouse macrophage,B,1,,12281,CHEMBL619382,,BAO_0000357,
3867,17087,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,1,,11311,CHEMBL619383,,BAO_0000357,
3868,55,,,8,,H,,,,Autocuration,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,1,,11089,CHEMBL619384,,BAO_0000019,
3869,55,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,1,,10091,CHEMBL619385,,BAO_0000019,
3870,55,,,8,,H,,,,Autocuration,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,1,,14352,CHEMBL882928,,BAO_0000019,
3871,12166,,,9,,D,,,,Expert,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,1,,13329,CHEMBL619386,,BAO_0000019,
3872,12166,,,8,,H,,,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,1,,13329,CHEMBL619387,,BAO_0000019,
3873,12166,,,8,,H,,,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,1,,13329,CHEMBL619388,,BAO_0000019,
3874,12166,,,8,,H,,,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,1,,13329,CHEMBL619389,,BAO_0000019,
3875,12166,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,1,,13329,CHEMBL619390,,BAO_0000019,
3876,12166,,,8,,H,,,,Expert,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,1,,13329,CHEMBL619391,,BAO_0000019,
3877,12166,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,1,,13329,CHEMBL619392,,BAO_0000019,
3878,12166,,,8,,H,,,,Autocuration,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,1,,11311,CHEMBL619393,,BAO_0000019,
3879,12166,,,8,,H,,,,Autocuration,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,1,,11311,CHEMBL619394,,BAO_0000019,
3880,12166,,,8,,H,,,RBL-1,Autocuration,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,1,,105,CHEMBL619395,702.0,BAO_0000219,
3881,12166,,,8,,H,,,RBL-1,Autocuration,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,1,,105,CHEMBL619396,702.0,BAO_0000219,
3882,12166,,,8,,H,,,,Autocuration,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,1,,9138,CHEMBL619397,,BAO_0000357,
3883,12166,,,8,,H,,,,Autocuration,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,1,,9138,CHEMBL619398,,BAO_0000357,
3884,12166,,,8,,H,,,,Autocuration,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,1,,9138,CHEMBL619399,,BAO_0000357,
3885,12166,,,8,,H,,,,Autocuration,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,1,,14427,CHEMBL619400,,BAO_0000357,
3886,12166,,,8,,H,,,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,1,,13329,CHEMBL619401,,BAO_0000019,
3887,12166,,,8,,H,,,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,1,,13329,CHEMBL619402,,BAO_0000019,
3888,12166,,,9,,D,,,RBL-2H3,Expert,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,1,,14427,CHEMBL619403,663.0,BAO_0000219,
3889,12166,,,8,,H,,,,Autocuration,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,1,,14427,CHEMBL619404,,BAO_0000357,
3890,12166,,,8,,H,,,,Autocuration,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,1,,14427,CHEMBL619405,,BAO_0000357,
3891,12166,,,8,,H,,,RBL-1,Expert,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,1,,10293,CHEMBL619406,702.0,BAO_0000219,
3892,12166,,,9,,D,,,RBL-1,Expert,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,1,,338,CHEMBL619407,702.0,BAO_0000219,
3893,12166,,,8,,H,,,,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,1,,303,CHEMBL619408,,BAO_0000357,
3894,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,1,,303,CHEMBL619409,702.0,BAO_0000219,
3895,12166,,,8,,H,,,RBL-1,Expert,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,1,,9247,CHEMBL619410,702.0,BAO_0000219,
3896,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,1,,9247,CHEMBL619753,702.0,BAO_0000219,
3897,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,1,,137,CHEMBL619754,702.0,BAO_0000219,
3898,12166,,,8,,H,,,,Expert,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,1,,11481,CHEMBL619903,,BAO_0000357,
3899,12166,,,8,,H,,,,Expert,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,1,,11481,CHEMBL619904,,BAO_0000357,
3900,12166,,,8,,H,,,,Expert,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,1,,9029,CHEMBL619905,,BAO_0000357,
3901,12166,,,8,,H,,,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,1,,1701,CHEMBL619906,,BAO_0000019,
3902,12166,,,8,,H,,,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,1,,1701,CHEMBL619907,,BAO_0000019,
3903,12166,,,8,,H,,,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,1,,1701,CHEMBL619908,,BAO_0000019,
3904,12166,,,8,,H,,,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,1,,1701,CHEMBL619909,,BAO_0000019,
3905,12166,,,8,,H,,,RBL-1,Expert,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,1,,13358,CHEMBL619910,702.0,BAO_0000219,
3906,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,1,,1175,CHEMBL882929,702.0,BAO_0000219,
3907,12166,,,8,,H,,,RBL-1,Expert,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,1,,8797,CHEMBL619911,702.0,BAO_0000219,
3908,12166,,,8,,H,,,,Autocuration,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,1,,8797,CHEMBL619912,,BAO_0000019,
3909,12166,,,9,,D,,,,Expert,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,1,,577,CHEMBL619913,,BAO_0000357,
3910,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibitory activity against RBL-1 5-LO,B,1,,9295,CHEMBL619914,702.0,BAO_0000219,
3911,12166,,,8,,H,,,RBL-1,Autocuration,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,1,,9295,CHEMBL619915,702.0,BAO_0000219,
3912,12166,,,8,,H,,,RBL-1,Autocuration,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,1,,9295,CHEMBL619916,702.0,BAO_0000219,
3913,12166,,,8,,H,,,,Autocuration,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,1,,9295,CHEMBL619917,,BAO_0000218,
3914,12166,,,8,,H,,,,Autocuration,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,1,,9295,CHEMBL619918,,BAO_0000357,
3915,12166,,,8,,H,,,,Autocuration,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,1,,216,CHEMBL619919,,BAO_0000218,
3916,12166,,,8,,H,,,RBL-1,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,1,,11090,CHEMBL883710,702.0,BAO_0000219,
3917,12166,,,8,,H,,Blood,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,1,,11090,CHEMBL619920,,BAO_0000019,178.0
3918,12166,,,8,,H,,,,Expert,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,1,,10091,CHEMBL619921,,BAO_0000357,
3919,12166,,,8,,H,,,,Autocuration,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,1,,10274,CHEMBL619922,,BAO_0000019,
3920,12166,,,8,,H,,,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,1,,13622,CHEMBL619923,,BAO_0000219,
3921,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,1,,12118,CHEMBL619924,702.0,BAO_0000219,
3922,12166,,,8,,H,,,,Expert,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,1,,12576,CHEMBL619925,,BAO_0000357,
3923,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,1,,9546,CHEMBL619926,702.0,BAO_0000219,
3924,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,1,,9521,CHEMBL619927,702.0,BAO_0000219,
3925,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,1,,10626,CHEMBL619928,702.0,BAO_0000219,
3926,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase,B,1,,9225,CHEMBL619929,702.0,BAO_0000219,
3927,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,1,,9225,CHEMBL875089,702.0,BAO_0000219,
3928,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,1,,9225,CHEMBL619930,702.0,BAO_0000219,
3929,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,1,,9225,CHEMBL619931,702.0,BAO_0000219,
3930,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,1,,9225,CHEMBL619932,702.0,BAO_0000219,
3931,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,1,,9225,CHEMBL619933,702.0,BAO_0000219,
3932,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,1,,9225,CHEMBL619934,702.0,BAO_0000219,
3933,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,1,,9225,CHEMBL619935,702.0,BAO_0000219,
3934,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,1,,9225,CHEMBL619936,702.0,BAO_0000219,
3935,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,1,,9225,CHEMBL619937,702.0,BAO_0000219,
3936,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,1,,9225,CHEMBL619938,702.0,BAO_0000219,
3937,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,1,,9225,CHEMBL619939,702.0,BAO_0000219,
3938,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,1,,9225,CHEMBL619940,702.0,BAO_0000219,
3939,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,1,,9225,CHEMBL875090,702.0,BAO_0000219,
3940,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,1,,9225,CHEMBL619941,702.0,BAO_0000219,
3941,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,1,,9225,CHEMBL619942,702.0,BAO_0000219,
3942,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,1,,9225,CHEMBL883711,702.0,BAO_0000219,
3943,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,1,,9225,CHEMBL619943,702.0,BAO_0000219,
3944,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,1,,9225,CHEMBL619944,702.0,BAO_0000219,
3945,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,1,,9225,CHEMBL619945,702.0,BAO_0000219,
3946,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,1,,9225,CHEMBL619946,702.0,BAO_0000219,
3947,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,1,,9225,CHEMBL619947,702.0,BAO_0000219,
3948,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,1,,9225,CHEMBL619948,702.0,BAO_0000219,
3949,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,1,,9225,CHEMBL619949,702.0,BAO_0000219,
3950,12166,,,8,,H,,,,Expert,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,1,,9401,CHEMBL619950,,BAO_0000019,
3951,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,1,,10325,CHEMBL618050,,BAO_0000019,
3952,12166,,,8,,H,,,RBL-2H3,Expert,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,1,,1556,CHEMBL875091,663.0,BAO_0000219,
3953,12166,,,8,,H,,,RBL-2H3,Expert,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,1,,1556,CHEMBL618051,663.0,BAO_0000219,
3954,12166,,,9,,D,,,RBL-1,Expert,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,1,,961,CHEMBL618052,702.0,BAO_0000219,
3955,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,1,,6838,CHEMBL618053,,BAO_0000019,
3956,12166,,,8,,H,,,,Expert,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,1,,10325,CHEMBL618054,,BAO_0000019,
3957,12166,,,9,,D,,,RBL-1,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,1,,9209,CHEMBL618055,702.0,BAO_0000219,
3958,12166,,,8,,H,,,RBL-1,Expert,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,1,,11520,CHEMBL618056,702.0,BAO_0000219,
3959,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined,B,1,,137,CHEMBL618057,,BAO_0000357,
3960,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,1,,4717,CHEMBL618058,702.0,BAO_0000219,
3961,12166,,,8,,H,,,RBL-1,Expert,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,1,,10636,CHEMBL618059,702.0,BAO_0000219,
3962,12166,,,9,,D,,,,Expert,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,1,,14312,CHEMBL618060,,BAO_0000019,
3963,12166,,,8,,H,,,RBL-1,Autocuration,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,1,,1203,CHEMBL618061,702.0,BAO_0000219,
3964,12166,,,8,,H,,,,Autocuration,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,1,,1203,CHEMBL618062,,BAO_0000019,
3965,12166,,,8,,H,,,RBL-1,Expert,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,1,,13622,CHEMBL618063,702.0,BAO_0000219,
3966,12166,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,1,,9793,CHEMBL618064,,BAO_0000357,
3967,12166,,,9,,D,,,RBL-1,Expert,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,1,,1143,CHEMBL618065,702.0,BAO_0000219,
3968,12166,,,9,,D,,,RBL-1,Expert,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,1,,11854,CHEMBL618066,702.0,BAO_0000219,
3969,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,1,,3595,CHEMBL618067,702.0,BAO_0000219,
3970,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,1,,3595,CHEMBL618068,702.0,BAO_0000219,
3971,12166,,,9,,D,,,RBL-1,Expert,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,1,,10501,CHEMBL618069,702.0,BAO_0000219,
3972,12166,,,8,,H,,,RBL-1,Expert,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,1,,12526,CHEMBL618070,702.0,BAO_0000219,
3973,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,1,,10034,CHEMBL618071,,BAO_0000019,349.0
3974,10825,,,8,,H,,Limbic system,,Autocuration,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,1,,10034,CHEMBL619247,,BAO_0000019,349.0
3975,10825,,,8,,H,,,,Autocuration,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,1,,10034,CHEMBL619248,,BAO_0000019,
3976,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,1,,10046,CHEMBL619249,,BAO_0000221,10000000.0
3977,10576,,,8,,H,,Hippocampus,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,1,,10046,CHEMBL619250,,BAO_0000221,10000000.0
3978,10577,,,8,,H,,,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,1,,10046,CHEMBL619251,,BAO_0000019,
3979,55,,,8,,H,,Blood,,Autocuration,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,1,,12079,CHEMBL619252,,BAO_0000019,178.0
3980,55,,,8,,H,,Blood,,Autocuration,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,1,,12079,CHEMBL619253,,BAO_0000019,178.0
3981,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL619254,,BAO_0000219,
3982,17140,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,1,,12338,CHEMBL619255,,BAO_0000219,
3983,17140,,,8,,H,,,,Expert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,1,,12143,CHEMBL619256,,BAO_0000219,
3984,17140,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,1,,12143,CHEMBL875418,,BAO_0000219,
3985,17140,,,8,,H,,,,Expert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,1,,12143,CHEMBL619257,,BAO_0000219,
3986,17140,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,1,,12143,CHEMBL619258,,BAO_0000219,
3987,17140,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,1,,12365,CHEMBL619259,,BAO_0000357,
3988,17140,,,8,,H,,,,Expert,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,1,,13500,CHEMBL619260,,BAO_0000357,
3989,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619261,,BAO_0000218,178.0
3990,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619263,,BAO_0000218,178.0
3991,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619264,,BAO_0000218,178.0
3992,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619265,,BAO_0000218,178.0
3993,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619266,,BAO_0000218,178.0
3994,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619902,,BAO_0000218,178.0
3995,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620058,,BAO_0000218,178.0
3996,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620059,,BAO_0000218,178.0
3997,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620060,,BAO_0000218,178.0
3998,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620061,,BAO_0000218,178.0
3999,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620062,,BAO_0000218,178.0
4000,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620063,,BAO_0000218,178.0
4001,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620064,,BAO_0000218,178.0
4002,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620065,,BAO_0000218,178.0
4003,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620066,,BAO_0000218,178.0
4004,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620067,,BAO_0000218,178.0
4005,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620068,,BAO_0000218,178.0
4006,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620069,,BAO_0000218,178.0
4007,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620070,,BAO_0000218,178.0
4008,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620071,,BAO_0000218,178.0
4009,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620072,,BAO_0000218,178.0
4010,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620036,,BAO_0000218,178.0
4011,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL857702,,BAO_0000218,178.0
4012,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620037,,BAO_0000218,178.0
4013,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620038,,BAO_0000218,178.0
4014,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620039,,BAO_0000218,178.0
4015,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620040,,BAO_0000218,178.0
4016,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620041,,BAO_0000218,178.0
4017,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620042,,BAO_0000218,178.0
4018,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620043,,BAO_0000218,178.0
4019,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620044,,BAO_0000218,178.0
4020,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620045,,BAO_0000218,178.0
4021,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620046,,BAO_0000218,178.0
4022,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620047,,BAO_0000218,178.0
4023,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,1,,12832,CHEMBL620048,,BAO_0000218,178.0
4024,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL857703,,BAO_0000218,178.0
4025,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,1,,12832,CHEMBL620049,,BAO_0000218,178.0
4026,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620050,,BAO_0000218,178.0
4027,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL620051,,BAO_0000218,178.0
4028,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619213,,BAO_0000218,178.0
4029,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619214,,BAO_0000218,178.0
4030,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619804,,BAO_0000218,178.0
4031,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619805,,BAO_0000218,178.0
4032,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619806,,BAO_0000218,178.0
4033,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619807,,BAO_0000218,178.0
4034,55,,In vivo,8,,H,,Blood,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,1,,12832,CHEMBL619808,,BAO_0000218,178.0
4035,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,1,,3595,CHEMBL619809,,BAO_0000218,
4036,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,1,,3595,CHEMBL619810,,BAO_0000218,
4037,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,1,,3595,CHEMBL619811,,BAO_0000218,
4038,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,1,,3595,CHEMBL620769,,BAO_0000218,
4039,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,1,,3595,CHEMBL620770,,BAO_0000218,
4040,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,1,,3595,CHEMBL620771,,BAO_0000218,
4041,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,1,,3595,CHEMBL620772,,BAO_0000218,
4042,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,1,,3595,CHEMBL620773,,BAO_0000218,
4043,55,,,8,,H,,,,Autocuration,Ability to inhibit 5-lipoxygenase in guinea pig,B,1,,9203,CHEMBL620774,,BAO_0000357,
4044,55,,,8,,H,,,,Expert,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,1,,82,CHEMBL620775,,BAO_0000357,
4045,55,,,8,,H,,,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,1,,11090,CHEMBL620776,,BAO_0000357,
4046,55,,,8,,H,,Blood,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,1,,12832,CHEMBL620777,,BAO_0000218,178.0
4047,55,,,8,,H,,,,Autocuration,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,1,,1065,CHEMBL620778,,BAO_0000357,
4048,55,,,8,,H,,,,Autocuration,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,1,,1065,CHEMBL620779,,BAO_0000357,
4049,55,,,8,,H,,,,Expert,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,1,,12832,CHEMBL621500,,BAO_0000019,
4050,55,,,8,,H,,,,Expert,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,1,,12832,CHEMBL621501,,BAO_0000019,
4051,55,,,8,,H,,,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,1,,12832,CHEMBL618098,,BAO_0000019,
4052,55,,,8,,H,,,,Autocuration,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,1,,10504,CHEMBL618099,,BAO_0000019,
4053,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase,B,1,,7788,CHEMBL618100,,BAO_0000357,
4054,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,1,,10001,CHEMBL618101,,BAO_0000357,
4055,55,,,8,,H,,,,Autocuration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,1,,10193,CHEMBL618102,,BAO_0000357,
4056,55,,,8,,H,,,,Autocuration,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,1,,13243,CHEMBL618103,,BAO_0000357,
4057,55,,,8,,H,,,,Autocuration,Inhibitory activity uM,B,1,,13243,CHEMBL618104,,BAO_0000357,
4058,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,1,,969,CHEMBL883712,,BAO_0000219,
4059,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase at 10 uM,B,1,,10001,CHEMBL618105,,BAO_0000357,
4060,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,1,,7788,CHEMBL618106,,BAO_0000357,
4061,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,1,,10001,CHEMBL618107,,BAO_0000357,
4062,55,,,8,,H,,,,Autocuration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,1,,10193,CHEMBL618108,,BAO_0000357,
4063,55,,,8,,H,,,,Autocuration,Inhibitory activity uM,B,1,,13243,CHEMBL618109,,BAO_0000357,
4064,55,,,8,,H,,,,Autocuration,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,1,,13243,CHEMBL618110,,BAO_0000357,
4065,55,,,8,,H,,,,Expert,Inhibitory activity uM,B,1,,13243,CHEMBL618111,,BAO_0000357,
4066,55,,,8,,H,,,,Autocuration,Inhibitory activity uM,F,1,,13243,CHEMBL618112,,BAO_0000019,
4067,55,,,8,,H,,,,Autocuration,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,1,,10504,CHEMBL618113,,BAO_0000019,
4068,55,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,1,,7788,CHEMBL618114,,BAO_0000357,
4069,55,,,8,,H,,Ileum,,Expert,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,1,,10546,CHEMBL620871,,BAO_0000221,2116.0
4070,55,,,8,,H,,,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,1,,13183,CHEMBL620872,,BAO_0000357,
4071,55,,,8,,H,,,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,1,,13183,CHEMBL620873,,BAO_0000357,
4072,55,,,8,,H,,,,Autocuration,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,1,,2578,CHEMBL620874,,BAO_0000357,
4073,55,,,8,,H,,,,Expert,In vitro inhibition of human 5-Lipoxygenase.,B,1,,12780,CHEMBL620875,,BAO_0000357,
4074,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,1,,7411,CHEMBL620876,,BAO_0000251,2107.0
4075,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,1,,7411,CHEMBL620877,,BAO_0000251,2107.0
4076,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,1,,7411,CHEMBL857854,,BAO_0000251,2107.0
4077,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,1,,7411,CHEMBL620878,,BAO_0000251,2107.0
4078,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,1,,7411,CHEMBL620879,,BAO_0000251,2107.0
4079,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,1,,7411,CHEMBL620880,,BAO_0000251,2107.0
4080,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,1,,7411,CHEMBL620881,,BAO_0000251,2107.0
4081,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,1,,7411,CHEMBL620882,,BAO_0000251,2107.0
4082,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,1,,7411,CHEMBL620883,,BAO_0000251,2107.0
4083,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,1,,7411,CHEMBL620884,,BAO_0000251,2107.0
4084,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,1,,7411,CHEMBL620885,,BAO_0000251,2107.0
4085,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,1,,7411,CHEMBL620886,,BAO_0000251,2107.0
4086,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,1,,7411,CHEMBL620887,,BAO_0000251,2107.0
4087,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,1,,7411,CHEMBL618039,,BAO_0000251,2107.0
4088,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,1,,7411,CHEMBL618040,,BAO_0000251,2107.0
4089,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,1,,7411,CHEMBL618041,,BAO_0000251,2107.0
4090,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,1,,7411,CHEMBL618216,,BAO_0000251,2107.0
4091,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,1,,7411,CHEMBL618217,,BAO_0000251,2107.0
4092,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,1,,7411,CHEMBL618218,,BAO_0000251,2107.0
4093,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,1,,7411,CHEMBL618219,,BAO_0000251,2107.0
4094,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,1,,7411,CHEMBL618220,,BAO_0000251,2107.0
4095,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,1,,7411,CHEMBL618221,,BAO_0000251,2107.0
4096,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,1,,7411,CHEMBL618222,,BAO_0000251,2107.0
4097,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,1,,7411,CHEMBL618223,,BAO_0000251,2107.0
4098,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,1,,7411,CHEMBL618224,,BAO_0000251,2107.0
4099,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,1,,7411,CHEMBL618225,,BAO_0000251,2107.0
4100,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,1,,7411,CHEMBL618226,,BAO_0000251,2107.0
4101,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,1,,7411,CHEMBL618227,,BAO_0000251,2107.0
4102,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,1,,7411,CHEMBL618228,,BAO_0000251,2107.0
4103,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,1,,7411,CHEMBL618229,,BAO_0000251,2107.0
4104,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,1,,7411,CHEMBL618230,,BAO_0000251,2107.0
4105,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,1,,7411,CHEMBL618231,,BAO_0000251,2107.0
4106,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,1,,7411,CHEMBL618232,,BAO_0000251,2107.0
4107,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,1,,7411,CHEMBL618233,,BAO_0000251,2107.0
4108,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,1,,7411,CHEMBL618234,,BAO_0000251,2107.0
4109,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,1,,7411,CHEMBL618235,,BAO_0000251,2107.0
4110,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,1,,7411,CHEMBL618115,,BAO_0000251,2107.0
4111,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,1,,7411,CHEMBL618116,,BAO_0000251,2107.0
4112,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,1,,7411,CHEMBL618117,,BAO_0000251,2107.0
4113,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,1,,7411,CHEMBL619968,,BAO_0000251,2107.0
4114,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,1,,7411,CHEMBL619969,,BAO_0000251,2107.0
4115,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,1,,7411,CHEMBL619970,,BAO_0000251,2107.0
4116,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,1,,7411,CHEMBL619971,,BAO_0000251,2107.0
4117,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,1,,7411,CHEMBL619972,,BAO_0000251,2107.0
4118,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,1,,7411,CHEMBL619973,,BAO_0000251,2107.0
4119,22226,,,0,,U,Microsomes,Liver,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,1,,7411,CHEMBL619974,,BAO_0000251,2107.0
4120,22226,,,0,,U,Microsomes,Liver,,Autocuration,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,1,,7411,CHEMBL619975,,BAO_0000251,2107.0
4121,22226,,,0,,U,Microsomes,,,Autocuration,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,1,,7411,CHEMBL619976,,BAO_0000251,
4122,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,1,,7411,CHEMBL619977,,BAO_0000251,2107.0
4123,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,1,,7411,CHEMBL619978,,BAO_0000251,2107.0
4124,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,1,,7411,CHEMBL619979,,BAO_0000251,2107.0
4125,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,1,,7411,CHEMBL619980,,BAO_0000251,2107.0
4126,22226,,,0,,U,Microsomes,Liver,,Autocuration,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,1,,7411,CHEMBL619981,,BAO_0000251,2107.0
4127,80433,,,1,,N,,,RPMI-8226,Intermediate,In vitro inhibition of 7226/S myeloma cancer cell line,F,1,,10797,CHEMBL619982,741.0,BAO_0000219,
4128,80698,,,1,,N,,,BEL-7404 tumor cell line,Intermediate,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,1,,6881,CHEMBL619983,993.0,BAO_0000219,
4129,80640,,,1,,N,,,786-0,Intermediate,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,1,,3838,CHEMBL620031,391.0,BAO_0000219,
4130,80640,,,1,,N,,,786-0,Intermediate,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,1,,3838,CHEMBL620032,391.0,BAO_0000219,
4131,81264,,,1,,N,,,V79,Expert,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,1,,12981,CHEMBL620033,505.0,BAO_0000219,
4132,81264,,,1,,N,,,V79,Expert,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,1,,12981,CHEMBL620034,505.0,BAO_0000219,
4133,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,1,,7653,CHEMBL620035,1119.0,BAO_0000219,
4134,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,1,,7653,CHEMBL618318,1119.0,BAO_0000219,
4135,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,1,,7653,CHEMBL618319,1119.0,BAO_0000219,
4136,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,1,,7653,CHEMBL618320,1119.0,BAO_0000219,
4137,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,1,,7653,CHEMBL618321,1119.0,BAO_0000219,
4138,80635,,,1,,N,,,7800C1 cell line,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,1,,7653,CHEMBL883118,1119.0,BAO_0000219,
4139,80640,,,1,,N,,,786-0,Intermediate,In vitro antitumor activity against renal 786-0 tumor cell lines,F,1,,17229,CHEMBL883795,391.0,BAO_0000219,
4140,80640,,,1,,N,,,786-0,Intermediate,Cytotoxic activity against 786-0 Renal cancer cell line,F,1,,12858,CHEMBL618322,391.0,BAO_0000219,
4141,80640,,,1,,N,,,786-0,Intermediate,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,1,,16325,CHEMBL618323,391.0,BAO_0000219,
4142,80640,,,1,,N,,,786-0,Intermediate,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,1,,16325,CHEMBL618324,391.0,BAO_0000219,
4143,80640,,,1,,N,,,786-0,Intermediate,In vitro antitumor activity against human renal 786-0 cell line,F,1,,5858,CHEMBL618325,391.0,BAO_0000219,
4144,80640,,,1,,N,,,786-0,Intermediate,Inhibition of Renal cancer in 786-0 cancer cell lines,F,1,,16325,CHEMBL875416,391.0,BAO_0000219,
4145,80640,,,1,,N,,,786-0,Intermediate,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,1,,14696,CHEMBL618326,391.0,BAO_0000219,
4146,80640,,,1,,N,,,786-0,Intermediate,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,1,,3786,CHEMBL618327,391.0,BAO_0000219,
4147,80640,,,1,,N,,,786-0,Intermediate,inhibition of the growth of renal cancer(786-0) cell line,F,1,,14696,CHEMBL619215,391.0,BAO_0000219,
4148,80640,,,1,,N,,,786-0,Intermediate,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL619216,391.0,BAO_0000219,
4149,80640,,,1,,N,,,786-0,Intermediate,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,1,,15354,CHEMBL619217,391.0,BAO_0000219,
4150,80640,,,1,,N,,,786-0,Intermediate,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,1,,14255,CHEMBL619218,391.0,BAO_0000219,
4151,80640,,,1,,N,,,786-0,Intermediate,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,1,,14255,CHEMBL619219,391.0,BAO_0000219,
4152,80640,,,1,,N,,,786-0,Intermediate,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,1,,14255,CHEMBL619220,391.0,BAO_0000219,
4153,80640,,,1,,N,,,786-0,Intermediate,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,1,,14696,CHEMBL619221,391.0,BAO_0000219,
4154,80640,,,1,,N,,,786-0,Intermediate,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,1,,12016,CHEMBL619222,391.0,BAO_0000219,
4155,80640,,,1,,N,,,786-0,Intermediate,Compound was tested for growth inhibitory activity against 786-0 cell line,F,1,,2597,CHEMBL857454,391.0,BAO_0000219,
4156,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,1,,12526,CHEMBL619223,702.0,BAO_0000219,
4157,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,1,,12526,CHEMBL619224,702.0,BAO_0000219,
4158,12166,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,1,,14799,CHEMBL619225,,BAO_0000019,
4159,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,1,,3595,CHEMBL619226,702.0,BAO_0000219,
4160,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,1,,3595,CHEMBL619227,702.0,BAO_0000219,
4161,12166,,,8,,H,,,,Autocuration,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,1,,12767,CHEMBL619228,,BAO_0000357,
4162,12166,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,1,,10997,CHEMBL619229,,BAO_0000219,
4163,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,1,,11388,CHEMBL619230,702.0,BAO_0000219,
4164,12166,,,8,,H,,,,Autocuration,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,1,,167,CHEMBL619231,,BAO_0000357,
4165,12166,,,8,,H,,,,Autocuration,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,1,,167,CHEMBL619232,,BAO_0000357,
4166,12166,,,8,,H,,,,Expert,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,1,,13744,CHEMBL619233,,BAO_0000357,
4167,12166,,,8,,H,,,,Autocuration,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,1,,1630,CHEMBL619234,,BAO_0000357,
4168,12166,,,8,,H,,,,Autocuration,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,1,,1630,CHEMBL619235,,BAO_0000357,
4169,12166,,,9,,D,,,,Expert,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,1,,969,CHEMBL619236,,BAO_0000019,
4170,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,1,,13621,CHEMBL619237,702.0,BAO_0000219,
4171,12166,,,8,,H,,,,Autocuration,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,1,,10089,CHEMBL619238,,BAO_0000357,
4172,12166,,,8,,H,,,,Expert,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,1,,10193,CHEMBL619239,,BAO_0000357,
4173,12166,,,8,,H,,,,Autocuration,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,1,,11966,CHEMBL619240,,BAO_0000357,
4174,12166,,,8,,H,,,,Autocuration,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,1,,12251,CHEMBL875417,,BAO_0000019,
4175,12166,,,8,,H,,,RBL-1,Autocuration,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,1,,211,CHEMBL619241,702.0,BAO_0000219,
4176,12166,,,8,,H,,,,Expert,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,1,,12251,CHEMBL619242,,BAO_0000019,
4177,12166,,,8,,H,,,RBL-1,Autocuration,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,1,,12495,CHEMBL883796,702.0,BAO_0000219,
4178,12166,,,8,,H,,,,Autocuration,Tested for its inhibitory activity against 5-lipoxygenase,B,1,,414,CHEMBL619243,,BAO_0000357,
4179,12166,,,8,,H,,,,Autocuration,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,1,,414,CHEMBL619244,,BAO_0000357,
4180,12166,,,8,,H,,,,Expert,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,1,,10325,CHEMBL619245,,BAO_0000019,
4181,12166,,,8,,H,,,,Expert,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,1,,11966,CHEMBL619246,,BAO_0000019,
4182,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,1,,165,CHEMBL619984,702.0,BAO_0000219,
4183,12166,,,8,,H,,,RBL-1,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,1,,165,CHEMBL619985,702.0,BAO_0000219,
4184,12166,,,8,,H,,,RBL-1,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,1,,165,CHEMBL619986,702.0,BAO_0000219,
4185,12166,,,8,,H,,,RBL-1,Expert,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,1,,165,CHEMBL619987,702.0,BAO_0000219,
4186,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,1,,11311,CHEMBL619988,,BAO_0000218,
4187,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,1,,11311,CHEMBL619989,702.0,BAO_0000219,
4188,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,1,,11311,CHEMBL619990,702.0,BAO_0000219,
4189,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL619991,,BAO_0000219,
4190,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,1,,11311,CHEMBL619992,,BAO_0000219,
4191,12166,,In vivo,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,1,,11311,CHEMBL619993,,BAO_0000218,
4192,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,1,,11311,CHEMBL619994,663.0,BAO_0000219,
4193,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,1,,11311,CHEMBL619995,663.0,BAO_0000219,
4194,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,1,,11311,CHEMBL619996,,BAO_0000019,
4195,12166,,,8,,H,,,,Autocuration,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,1,,11732,CHEMBL619997,,BAO_0000019,
4196,12166,,,8,,H,,,,Expert,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,1,,11732,CHEMBL619998,,BAO_0000019,
4197,12166,,,8,,H,,,,Expert,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,1,,11087,CHEMBL619999,,BAO_0000019,
4198,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,1,,11087,CHEMBL620000,,BAO_0000019,
4199,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,1,,11087,CHEMBL620001,702.0,BAO_0000219,
4200,12166,,,9,,D,,,,Expert,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,1,,11087,CHEMBL620002,,BAO_0000357,
4201,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,1,,496,CHEMBL620003,702.0,BAO_0000219,
4202,12166,,,8,,H,,,RBL-1,Expert,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,1,,13986,CHEMBL620004,702.0,BAO_0000219,
4203,12166,,,8,,H,,,,Autocuration,Compound was evaluated for the inhibition of 5-lipoxygenase,B,1,,11520,CHEMBL874063,,BAO_0000357,
4204,12166,,,8,,H,,,RBL-1,Autocuration,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,1,,10293,CHEMBL620005,702.0,BAO_0000219,
4205,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,1,,303,CHEMBL620006,702.0,BAO_0000219,
4206,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,1,,303,CHEMBL620007,702.0,BAO_0000219,
4207,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,1,,9247,CHEMBL620008,702.0,BAO_0000219,
4208,12166,,,9,,D,,,RBL-1,Expert,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,1,,9247,CHEMBL620009,702.0,BAO_0000219,
4209,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,1,,9247,CHEMBL620010,702.0,BAO_0000219,
4210,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,1,,9247,CHEMBL620011,702.0,BAO_0000219,
4211,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,1,,9247,CHEMBL620677,702.0,BAO_0000219,
4212,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,1,,9247,CHEMBL620678,702.0,BAO_0000219,
4213,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,1,,9247,CHEMBL620679,702.0,BAO_0000219,
4214,12166,,,8,,H,,,RBL-1,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,1,,9247,CHEMBL620680,702.0,BAO_0000219,
4215,12166,,,9,,D,,,,Expert,Inhibitory activity against 5-lipoxygenase at 10 uM,B,1,,11481,CHEMBL620838,,BAO_0000357,
4216,12166,,,8,,H,,,,Autocuration,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,1,,105,CHEMBL620839,,BAO_0000357,
4217,12166,,,8,,H,,,,Expert,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,1,,9029,CHEMBL620840,,BAO_0000357,
4218,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,1,,1175,CHEMBL620841,702.0,BAO_0000219,
4219,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,1,,12118,CHEMBL620842,702.0,BAO_0000219,
4220,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,1,,12118,CHEMBL620843,702.0,BAO_0000219,
4221,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,1,,12118,CHEMBL620844,702.0,BAO_0000219,
4222,12166,,,8,,H,,,RBL-1,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,1,,9225,CHEMBL620845,702.0,BAO_0000219,
4223,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,1,,9401,CHEMBL620846,,BAO_0000019,
4224,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,1,,137,CHEMBL873951,,BAO_0000357,
4225,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,1,,137,CHEMBL620847,,BAO_0000357,
4226,12166,,,8,,H,,,RBL-1,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,1,,4717,CHEMBL620848,702.0,BAO_0000219,
4227,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,1,,3595,CHEMBL620849,702.0,BAO_0000219,
4228,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,1,,10501,CHEMBL620850,702.0,BAO_0000219,
4229,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,1,,10501,CHEMBL620851,702.0,BAO_0000219,
4230,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,1,,10501,CHEMBL620852,702.0,BAO_0000219,
4231,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,1,,12526,CHEMBL875098,702.0,BAO_0000219,
4232,12166,,,9,,D,,,RBL-1,Expert,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,1,,14799,CHEMBL620853,702.0,BAO_0000219,
4233,12166,,,8,,H,,,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,1,,14799,CHEMBL620854,,BAO_0000019,
4234,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,1,,3595,CHEMBL620855,702.0,BAO_0000219,
4235,12166,,,8,,H,,,RBL-1,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,1,,3595,CHEMBL839884,702.0,BAO_0000219,
4236,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,1,,12526,CHEMBL620856,702.0,BAO_0000219,
4237,12166,,,8,,H,,,RBL-1,Autocuration,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,1,,12526,CHEMBL620857,702.0,BAO_0000219,
4238,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,1,,10193,CHEMBL620858,,BAO_0000019,
4239,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,1,,10193,CHEMBL620859,,BAO_0000019,
4240,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,1,,10193,CHEMBL620860,,BAO_0000019,
4241,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,1,,10193,CHEMBL620861,,BAO_0000019,
4242,12166,,,8,,H,,,,Expert,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,1,,9138,CHEMBL620862,,BAO_0000357,
4243,12166,,,8,,H,,,,Autocuration,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,1,,9138,CHEMBL620863,,BAO_0000357,
4244,12166,,,8,,H,,,,Autocuration,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,1,,11966,CHEMBL620864,,BAO_0000019,
4245,12166,,,8,,H,,,RBL-1,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,1,,165,CHEMBL620865,702.0,BAO_0000219,
4246,12166,,,8,,H,,,RBL-1,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,1,,165,CHEMBL620866,702.0,BAO_0000219,
4247,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,1,,11311,CHEMBL620867,663.0,BAO_0000219,
4248,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,1,,11311,CHEMBL620868,663.0,BAO_0000219,
4249,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,1,,11311,CHEMBL620869,663.0,BAO_0000219,
4250,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,1,,11311,CHEMBL873952,,BAO_0000019,
4251,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibition of isolated 5-lipoxygenase,B,1,,11311,CHEMBL875099,,BAO_0000357,
4252,12166,,,8,,H,,,RBL-2H3,Autocuration,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,1,,11311,CHEMBL620870,663.0,BAO_0000219,
4253,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,1,,11087,CHEMBL618261,,BAO_0000019,
4254,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,1,,11087,CHEMBL618262,,BAO_0000019,
4255,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,1,,11087,CHEMBL619428,,BAO_0000019,
4256,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,1,,11087,CHEMBL619429,,BAO_0000019,
4257,12166,,,8,,H,,,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,1,,11087,CHEMBL619430,,BAO_0000019,
4258,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,1,,496,CHEMBL620017,702.0,BAO_0000219,
4259,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,1,,496,CHEMBL620018,702.0,BAO_0000219,
4260,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,1,,13986,CHEMBL620019,702.0,BAO_0000219,
4261,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,1,,13986,CHEMBL620020,702.0,BAO_0000219,
4262,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,1,,13986,CHEMBL620021,702.0,BAO_0000219,
4263,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,1,,13986,CHEMBL620022,702.0,BAO_0000219,
4264,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,1,,13986,CHEMBL620023,702.0,BAO_0000219,
4265,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,1,,13986,CHEMBL620024,702.0,BAO_0000219,
4266,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,1,,13986,CHEMBL620025,702.0,BAO_0000219,
4267,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,1,,13986,CHEMBL620026,702.0,BAO_0000219,
4268,12166,,,8,,H,,,RBL-1,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,1,,13986,CHEMBL620027,702.0,BAO_0000219,
4269,12166,,,9,,D,,,,Expert,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,1,,13986,CHEMBL620028,,BAO_0000019,
4270,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,1,,10193,CHEMBL620029,,BAO_0000357,
4271,12166,,,8,,H,,,,Autocuration,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,1,,9295,CHEMBL620030,,BAO_0000357,
4272,12166,,,8,,H,,,RBL-1,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,1,,4717,CHEMBL875415,702.0,BAO_0000219,
4273,12166,,,8,,H,,,RBL-1,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,1,,4717,CHEMBL618256,702.0,BAO_0000219,
4274,12166,,,8,,H,,,RBL-1,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,1,,11854,CHEMBL618257,702.0,BAO_0000219,
4275,12166,,,8,,H,,,RBL-1,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,1,,11854,CHEMBL618258,702.0,BAO_0000219,
4276,12166,,,8,,H,,,RBL-1,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,1,,11854,CHEMBL618259,702.0,BAO_0000219,
4277,12166,,,8,,H,,,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,1,,10193,CHEMBL618260,,BAO_0000019,
4278,12166,,,8,,H,,,RBL-1,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,1,,9295,CHEMBL618215,702.0,BAO_0000219,
4279,12166,,,8,,H,,,RBL-1,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,1,,9295,CHEMBL618390,702.0,BAO_0000219,
4280,12166,,,8,,H,,,RBL-1,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,1,,9295,CHEMBL618391,702.0,BAO_0000219,
4281,12166,,,8,,H,,,RBL-1,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,1,,9295,CHEMBL618392,702.0,BAO_0000219,
4282,12166,,,8,,H,,,RBL-1,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,1,,165,CHEMBL618393,702.0,BAO_0000219,
4283,12166,,,8,,H,,,,Autocuration,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,1,,11311,CHEMBL618394,,BAO_0000219,
4284,12166,,,8,,H,,,RBL-1,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,1,,10489,CHEMBL618395,702.0,BAO_0000219,
4285,12166,,,9,,D,,,RBL-1,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,1,,10489,CHEMBL618396,702.0,BAO_0000219,
4286,12166,,,9,,D,,,RBL-1,Expert,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,1,,10489,CHEMBL858253,702.0,BAO_0000219,
4287,12166,,,9,,D,,,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,1,,14799,CHEMBL618397,,BAO_0000019,
4288,12054,,,8,,H,,,,Autocuration,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,1,,9295,CHEMBL618398,,BAO_0000357,
4289,22226,,,0,,U,,,,Autocuration,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,1,,16811,CHEMBL618399,,BAO_0000019,
4290,55,,,8,,H,,,,Expert,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,1,,168,CHEMBL618400,,BAO_0000357,
4291,55,,,8,,H,,,,Autocuration,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,1,,6309,CHEMBL618401,,BAO_0000357,
4292,55,,,8,,H,,,,Autocuration,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,1,,6309,CHEMBL618402,,BAO_0000357,
4293,55,,,8,,H,,,RBL-1,Autocuration,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,1,,3092,CHEMBL876400,702.0,BAO_0000219,
4294,55,,,8,,H,,,,Expert,Inhibitory activity against 5-lipoxygenase.,B,1,,168,CHEMBL618403,,BAO_0000357,
4295,55,,,8,,H,,,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,1,,168,CHEMBL618404,,BAO_0000357,
4296,55,,,8,,H,,,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,1,,168,CHEMBL618405,,BAO_0000357,
4297,55,,,8,,H,,,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,1,,168,CHEMBL618406,,BAO_0000357,
4298,55,,,8,,H,,,,Expert,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,1,,12338,CHEMBL618407,,BAO_0000019,
4299,55,,,8,,H,,,,Autocuration,Tested for the inhibitory activity against 5-lipoxygenase,B,1,,4501,CHEMBL618408,,BAO_0000357,
4300,55,,,8,,H,,,,Autocuration,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,1,,1132,CHEMBL618409,,BAO_0000357,
4301,55,,,8,,H,,,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,1,,2117,CHEMBL618410,,BAO_0000357,
4302,55,,,8,,H,,,,Autocuration,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,1,,168,CHEMBL618411,,BAO_0000357,
4303,55,,,8,,H,,,,Autocuration,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,1,,168,CHEMBL618412,,BAO_0000357,
4304,12166,,,8,,H,,,RBL-1,Autocuration,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,1,,13575,CHEMBL618413,702.0,BAO_0000219,
4305,12166,,,8,,H,,,,Autocuration,,B,1,,11089,CHEMBL618414,,BAO_0000357,
4306,10102,,,8,,H,,,,Autocuration,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,1,,216,CHEMBL618415,,BAO_0000357,
4307,10102,,,8,,H,,,,Autocuration,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,1,,13165,CHEMBL618416,,BAO_0000019,
4308,10102,,,8,,H,,,,Autocuration,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,1,,3278,CHEMBL876401,,BAO_0000357,
4309,10102,,,8,,H,,,,Expert,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,1,,3278,CHEMBL618417,,BAO_0000357,
4310,10102,,,8,,H,,,,Autocuration,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,1,,11966,CHEMBL618418,,BAO_0000357,
4311,10102,,,8,,H,,,,Autocuration,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,1,,175,CHEMBL618419,,BAO_0000357,
4312,10102,,,8,,H,,,,Autocuration,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,1,,175,CHEMBL618420,,BAO_0000357,
4313,10102,,,8,,H,,,,Autocuration,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,1,,13449,CHEMBL618421,,BAO_0000357,
4314,11238,,,8,,H,,,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,1,,12014,CHEMBL618422,,BAO_0000019,
4315,11238,,,8,,H,,,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,1,,12014,CHEMBL618423,,BAO_0000019,
4316,11238,,,8,,H,,,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,1,,12014,CHEMBL618424,,BAO_0000019,
4317,100284,,,2,,S,,,,Intermediate,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,1,,99,CHEMBL618425,,BAO_0000220,
4318,22226,,,0,,U,,,,Autocuration,The dark toxicity against 543 human galactophore carcinoma cells,F,1,,4349,CHEMBL618426,,BAO_0000019,
4319,80623,,,1,,N,,,Panel (56 tumour cell lines),Expert,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,1,,4071,CHEMBL618427,390.0,BAO_0000219,
4320,80008,,,1,,N,,,5637,Expert,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,1,,17589,CHEMBL618428,345.0,BAO_0000219,
4321,80008,,,1,,N,,,5637,Intermediate,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,1,,15002,CHEMBL618429,345.0,BAO_0000219,
4322,80008,,,1,,N,,,5637,Intermediate,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,1,,13958,CHEMBL618430,345.0,BAO_0000219,
4323,80008,,,1,,N,,,5637,Expert,Growth inhibition against human 5637 cell lines,F,1,,17589,CHEMBL618431,345.0,BAO_0000219,
4324,80008,,,1,,N,,,5637,Expert,Antitumor activity against human bladder carcinoma 5637 cells.,F,1,,16748,CHEMBL883799,345.0,BAO_0000219,
4325,80008,,,1,,N,,,5637,Intermediate,Antitumor activity against human bladder carcinoma 5637 cells,F,1,,16747,CHEMBL618432,345.0,BAO_0000219,
4326,80008,,,1,,N,,,5637,Intermediate,Antitumor activity against human bladder carcinoma 5637 cells,F,1,,16747,CHEMBL618433,345.0,BAO_0000219,
4327,10443,,,9,,D,,,,Expert,In vitro inhibition of bovine trypsin(Trp).,B,1,,15285,CHEMBL618434,,BAO_0000357,
4328,240,,,8,,H,,,CV-1,Expert,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,1,,3726,CHEMBL618435,407.0,BAO_0000219,
4329,10577,,,8,,H,,,,Autocuration,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,1,,5033,CHEMBL876402,,BAO_0000357,
4330,104698,,,6,,H,,,,Autocuration,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,1,,11756,CHEMBL618436,,BAO_0000019,
4331,22226,,In vivo,0,,U,,,,Autocuration,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,1,,11953,CHEMBL618437,,BAO_0000218,
4332,20033,,,9,,D,,,,Intermediate,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,1,,5033,CHEMBL618438,,BAO_0000357,
4333,17045,,,8,,H,Microsomes,,,Expert,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,1,,11347,CHEMBL883800,,BAO_0000251,
4334,17045,,,8,,H,Microsomes,,,Expert,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,1,,11347,CHEMBL618439,,BAO_0000251,
4335,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,1,,1229,CHEMBL618440,,BAO_0000019,
4336,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,1,,1229,CHEMBL618441,,BAO_0000019,
4337,11938,,,8,,H,,,,Expert,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,1,,17588,CHEMBL618442,,BAO_0000019,
4338,11938,,,8,,H,,,,Autocuration,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,1,,17588,CHEMBL618443,,BAO_0000019,
4339,11938,,,8,,H,,,,Expert,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,1,,17588,CHEMBL619158,,BAO_0000019,
4340,11938,,,8,,H,,,,Autocuration,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,1,,17588,CHEMBL620974,,BAO_0000019,
4341,11938,,,8,,H,,,,Autocuration,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,1,,16485,CHEMBL620975,,BAO_0000357,
4342,22226,,,0,,U,,,,Intermediate,Average inhibitory concentration against 60 human cell lines was reported,F,1,,4337,CHEMBL620976,,BAO_0000019,
4343,22226,,,0,,U,,,,Expert,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,1,,4112,CHEMBL620977,,BAO_0000019,
4344,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Intermediate,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,1,,16160,CHEMBL620978,542.0,BAO_0000219,
4345,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Intermediate,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,1,,16160,CHEMBL620979,542.0,BAO_0000219,
4346,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Expert,In vitro mean growth inhibitory activity against 60-cell panel,F,1,,17376,CHEMBL620980,542.0,BAO_0000219,
4347,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Expert,In vitro mean growth lethal concentration against 60-cell panel,F,1,,17376,CHEMBL620981,542.0,BAO_0000219,
4348,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Expert,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,1,,17376,CHEMBL620982,542.0,BAO_0000219,
4349,80315,,,1,,N,,,Panel NCI-60 (60 carcinoma cell lines),Expert,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,1,,17376,CHEMBL620983,542.0,BAO_0000219,
4350,104775,,,4,,H,,,,Autocuration,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,1,,3241,CHEMBL620984,,BAO_0000019,
4351,104775,,,4,,H,,,,Autocuration,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,1,,3241,CHEMBL620985,,BAO_0000019,
4352,275,,,8,,H,,,,Expert,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,1,,3725,CHEMBL620986,,BAO_0000357,
4353,50425,,,1,,N,,,,Expert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,1,,10805,CHEMBL620987,,BAO_0000218,
4354,50425,,,1,,N,,,,Expert,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,1,,10805,CHEMBL620988,,BAO_0000218,
4355,50425,,,1,,N,,,,Expert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,1,,10805,CHEMBL620989,,BAO_0000218,
4356,50425,,,1,,N,,,,Expert,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,1,,10805,CHEMBL620990,,BAO_0000218,
4357,50425,,,1,,N,,,,Intermediate,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,1,,10805,CHEMBL620991,,BAO_0000218,
4358,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,1,,10144,CHEMBL620992,850.0,BAO_0000218,
4359,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,1,,10144,CHEMBL620993,850.0,BAO_0000218,
4360,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,1,,10144,CHEMBL620994,850.0,BAO_0000218,
4361,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,1,,10144,CHEMBL620995,850.0,BAO_0000218,
4362,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,1,,10144,CHEMBL620996,850.0,BAO_0000218,
4363,80628,,,1,,N,,,6C3HED,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,1,,10144,CHEMBL875581,850.0,BAO_0000218,
4364,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,1,,10685,CHEMBL620997,,BAO_0000218,
4365,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,1,,10685,CHEMBL620998,,BAO_0000218,
4366,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,1,,10685,CHEMBL620999,,BAO_0000218,
4367,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,1,,10685,CHEMBL621000,,BAO_0000218,
4368,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,1,,10685,CHEMBL621001,,BAO_0000218,
4369,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,1,,10685,CHEMBL621002,,BAO_0000218,
4370,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,1,,10685,CHEMBL621003,,BAO_0000218,
4371,22224,,In vivo,0,,U,,,,Autocuration,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,1,,10685,CHEMBL621004,,BAO_0000218,
4372,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,1,,10685,CHEMBL621005,,BAO_0000218,
4373,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,1,,10685,CHEMBL621006,,BAO_0000218,
4374,22224,,In vivo,0,,U,,,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,1,,10685,CHEMBL621007,,BAO_0000218,
4375,22224,,,0,,U,,,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,1,,10144,CHEMBL621008,,BAO_0000218,
4376,22224,,,0,,U,,,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,1,,10144,CHEMBL621009,,BAO_0000218,
4377,22224,,,0,,U,,,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,1,,10144,CHEMBL857705,,BAO_0000218,
4378,22224,,,0,,U,,,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,1,,10144,CHEMBL619828,,BAO_0000218,
4379,22224,,,0,,U,,,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,1,,10685,CHEMBL619829,,BAO_0000218,
4380,22224,,,0,,U,,,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,1,,10685,CHEMBL619830,,BAO_0000218,
4381,22224,,,0,,U,,,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,1,,10685,CHEMBL619831,,BAO_0000218,
4382,22224,,,0,,U,,,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,1,,10685,CHEMBL619832,,BAO_0000218,
4383,22224,,,0,,U,,,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,1,,10685,CHEMBL619833,,BAO_0000218,
4384,22224,,,0,,U,,,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,1,,10685,CHEMBL619834,,BAO_0000218,
4385,22224,,,0,,U,,,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,1,,10685,CHEMBL619835,,BAO_0000218,
4386,22224,,,0,,U,,,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,1,,10685,CHEMBL619836,,BAO_0000218,
4387,80628,,,1,,N,,,6C3HED,Intermediate,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,1,,8831,CHEMBL619837,850.0,BAO_0000218,
4388,22224,,In vivo,0,,U,,,,Autocuration,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,1,,11704,CHEMBL619838,,BAO_0000218,
4389,50594,,,1,,N,,,,Intermediate,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,1,,11704,CHEMBL619839,,BAO_0000218,
4390,80628,,In vivo,1,,N,,,6C3HED,Intermediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,1,,10685,CHEMBL619840,850.0,BAO_0000218,
4391,80628,,In vivo,1,,N,,,6C3HED,Intermediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,1,,10685,CHEMBL619841,850.0,BAO_0000218,
4392,80628,,,1,,N,,,6C3HED,Expert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,1,,11368,CHEMBL857704,850.0,BAO_0000218,
4393,80628,,,1,,N,,,6C3HED,Intermediate,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,1,,11368,CHEMBL619842,850.0,BAO_0000218,
4394,80628,,,1,,N,,,6C3HED,Expert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,1,,11368,CHEMBL619843,850.0,BAO_0000218,
4395,22226,,,0,,U,,,,Autocuration,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,1,,17763,CHEMBL619844,,BAO_0000019,
4396,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,1,,7411,CHEMBL857855,,BAO_0000251,2107.0
4397,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,1,,7411,CHEMBL619845,,BAO_0000251,2107.0
4398,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,1,,7411,CHEMBL619846,,BAO_0000251,2107.0
4399,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,1,,7411,CHEMBL619847,,BAO_0000251,2107.0
4400,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,1,,7411,CHEMBL619848,,BAO_0000251,2107.0
4401,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,1,,7411,CHEMBL620893,,BAO_0000251,2107.0
4402,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,1,,7411,CHEMBL620894,,BAO_0000251,2107.0
4403,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,1,,7411,CHEMBL620895,,BAO_0000251,2107.0
4404,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,1,,7411,CHEMBL620896,,BAO_0000251,2107.0
4405,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,1,,7411,CHEMBL620897,,BAO_0000251,2107.0
4406,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,1,,7411,CHEMBL620898,,BAO_0000251,2107.0
4407,22226,,,0,,U,Microsomes,Liver,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,1,,7411,CHEMBL620899,,BAO_0000251,2107.0
4408,22224,,In vivo,0,,U,,Plasma,,Autocuration,The apparent total plasma clearance in monkey,A,1,,347,CHEMBL620900,,BAO_0000218,1969.0
4409,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for Hepatic clearance in monkey,A,1,,3341,CHEMBL620901,,BAO_0000218,
4410,22224,,In vivo,0,,U,,,,Autocuration,Lower clearance in monkey (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL620902,,BAO_0000218,
4411,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in rhesus monkey,A,1,,4514,CHEMBL620903,,BAO_0000218,
4412,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL620904,,BAO_0000218,
4413,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance of compound was determined in monkey,A,1,,6821,CHEMBL620905,,BAO_0000218,
4414,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was calculated in rhesus monkey,A,1,,6057,CHEMBL620906,,BAO_0000218,
4415,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in rhesus monkey,A,1,,5145,CHEMBL875420,,BAO_0000218,
4416,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL620907,,BAO_0000218,
4417,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was evaluated in rhesus,A,1,,5472,CHEMBL620908,,BAO_0000218,
4418,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL620909,,BAO_0000218,
4419,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL620910,,BAO_0000218,
4420,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL620911,,BAO_0000218,
4421,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL620912,,BAO_0000218,
4422,22224,,In vivo,0,,U,,,,Autocuration,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,1,,17509,CHEMBL620913,,BAO_0000218,
4423,22224,,In vivo,0,,U,,,,Autocuration,Cmax in monkey after administration of 1 mg/kg iv,A,1,,6535,CHEMBL620914,,BAO_0000218,
4424,22224,,In vivo,0,,U,,,,Autocuration,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,1,,5668,CHEMBL620915,,BAO_0000218,
4425,22224,,In vivo,0,,U,,,,Autocuration,Cmax in cynomolgus monkey by iv administration,A,1,,5922,CHEMBL620916,,BAO_0000218,
4426,22224,,In vivo,0,,U,,,,Autocuration,Cmax in cynomolgus monkey by po administration,A,1,,5922,CHEMBL620917,,BAO_0000218,
4427,22224,,In vivo,0,,U,,,,Autocuration,Cmax value evaluated in monkey,A,1,,6078,CHEMBL620918,,BAO_0000218,
4428,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL620919,,BAO_0000218,
4429,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,1,,3249,CHEMBL620920,,BAO_0000218,1969.0
4430,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,1,,3249,CHEMBL620921,,BAO_0000218,1969.0
4431,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximal plasma concentration in squirrel monkeys,A,1,,5553,CHEMBL620922,,BAO_0000218,1969.0
4432,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL620923,,BAO_0000218,
4433,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,1,,6227,CHEMBL620924,,BAO_0000218,1969.0
4434,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,1,,4809,CHEMBL620925,,BAO_0000218,
4435,22224,,In vivo,0,,U,,,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,1,,5355,CHEMBL620926,,BAO_0000218,
4436,22224,,In vivo,0,,U,,,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,1,,5355,CHEMBL620927,,BAO_0000218,
4437,22224,,In vivo,0,,U,,,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,1,,5355,CHEMBL620928,,BAO_0000218,
4438,22224,,In vivo,0,,U,,,,Autocuration,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,1,,5355,CHEMBL620929,,BAO_0000218,
4439,22224,,In vivo,0,,U,,Plasma,,Autocuration,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,1,,6221,CHEMBL620930,,BAO_0000218,1969.0
4440,22224,,,0,,U,,,,Autocuration,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,1,,167,CHEMBL620931,,BAO_0000218,
4441,22224,,,0,,U,,,,Autocuration,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,1,,167,CHEMBL620932,,BAO_0000218,
4442,22224,,In vivo,0,,U,,,,Autocuration,Absolute bioavailability was evaluated in monkey,A,1,,4257,CHEMBL620933,,BAO_0000218,
4443,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,1,,6221,CHEMBL620934,,BAO_0000218,
4444,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,1,,17667,CHEMBL620935,,BAO_0000218,
4445,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability of compound was determined in rhesus monkey,A,1,,17267,CHEMBL620936,,BAO_0000218,
4446,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability determined after oral administration in marmoset,A,1,,4256,CHEMBL620937,,BAO_0000218,
4447,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in cynomolgus monkey,A,1,,4256,CHEMBL620938,,BAO_0000218,
4448,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL620939,,BAO_0000218,
4449,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was evaluated after oral administration in monkey,A,1,,16365,CHEMBL620940,,BAO_0000218,
4450,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL620941,,BAO_0000218,
4451,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL620942,,BAO_0000218,
4452,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL620943,,BAO_0000218,
4453,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability of the compound was determined in monkey,A,1,,17592,CHEMBL620944,,BAO_0000218,
4454,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in squirrel monkey (dose 5 mg/kg),A,1,,1399,CHEMBL620945,,BAO_0000218,
4455,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,1,,4809,CHEMBL620946,,BAO_0000218,
4456,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,3341,CHEMBL620947,,BAO_0000218,
4457,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for bioavailability in squirrel monkey,A,1,,64,CHEMBL620948,,BAO_0000218,
4458,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey,A,1,,5005,CHEMBL620949,,BAO_0000218,
4459,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,1,,5005,CHEMBL620950,,BAO_0000218,
4460,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,1,,5237,CHEMBL620951,,BAO_0000218,
4461,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,1,,5237,CHEMBL620952,,BAO_0000218,
4462,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey (dose 5 mg/kg),A,1,,5302,CHEMBL875421,,BAO_0000218,
4463,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability of compound at 5 mg/kg in monkey,A,1,,17667,CHEMBL620953,,BAO_0000218,
4464,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,1,,6161,CHEMBL873491,,BAO_0000218,
4465,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,1,,6161,CHEMBL620954,,BAO_0000218,
4466,50588,,,1,,N,,Plasma,,Intermediate,Plasma half life determined,A,1,,3854,CHEMBL620955,,BAO_0000218,1969.0
4467,50588,,,1,,N,,Plasma,,Intermediate,Plasma half life in dog,A,1,,993,CHEMBL618097,,BAO_0000218,1969.0
4468,50588,,,1,,N,,Plasma,,Intermediate,Plasma half-life in Beagle dogs,A,1,,4514,CHEMBL618268,,BAO_0000218,1969.0
4469,50588,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,1,,5334,CHEMBL618269,,BAO_0000218,1969.0
4470,50588,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,1,,5334,CHEMBL618270,,BAO_0000218,1969.0
4471,50588,,In vivo,1,,N,,,,Intermediate,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,1,,1466,CHEMBL618271,,BAO_0000218,
4472,50588,,In vivo,1,,N,,,,Intermediate,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,1,,1466,CHEMBL873493,,BAO_0000218,
4473,50588,,,1,,N,,,,Intermediate,Tested for the half life period in dog,A,1,,5313,CHEMBL621031,,BAO_0000218,
4474,50588,,In vivo,1,,N,,,,Intermediate,Tested for the half life period in dog at dosage of 10 mpk,A,1,,5313,CHEMBL621032,,BAO_0000218,
4475,50588,,,1,,N,,,,Intermediate,The compound was tested for half life in dog,A,1,,3880,CHEMBL621033,,BAO_0000218,
4476,50588,,,1,,N,,Plasma,,Intermediate,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,1,,3639,CHEMBL621034,,BAO_0000218,1969.0
4477,50588,,,1,,N,,,,Intermediate,The half life was determined,A,1,,3880,CHEMBL621035,,BAO_0000218,
4478,50588,,,1,,N,,Plasma,,Intermediate,The plasma half-life in dogs,A,1,,3918,CHEMBL621036,,BAO_0000218,1969.0
4479,50588,,,1,,N,,Plasma,,Intermediate,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,1,,16452,CHEMBL621037,,BAO_0000218,1969.0
4480,50588,,,1,,N,,,,Intermediate,Half life in dog,A,1,,17796,CHEMBL619812,,BAO_0000218,
4481,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,1,,5983,CHEMBL619813,,BAO_0000218,
4482,50588,,In vivo,1,,N,,,,Intermediate,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,1,,1466,CHEMBL873335,,BAO_0000218,
4483,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL619814,,BAO_0000218,
4484,50506,,In vivo,1,,N,,,,Expert,Cmax in ferrets after 30 mg/kg oral dose,A,1,,6113,CHEMBL619815,,BAO_0000218,
4485,50506,,In vivo,1,,N,,,,Expert,Emesis in ferrets at 30 mg/kg oral dose,F,1,,6113,CHEMBL619816,,BAO_0000218,
4486,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in cynomolgus monkey,A,1,,17796,CHEMBL619817,,BAO_0000218,
4487,100710,,In vivo,1,,N,,,,Intermediate,Volume of distribution in cynomolgus,A,1,,17796,CHEMBL619818,,BAO_0000218,
4488,22224,,,0,,U,,Plasma,,Autocuration,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,1,,5308,CHEMBL619819,,BAO_0000218,1969.0
4489,22224,,,0,,U,,,,Autocuration,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,1,,4877,CHEMBL619820,,BAO_0000218,
4490,22224,,,0,,U,,,,Autocuration,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,1,,4876,CHEMBL875419,,BAO_0000218,
4491,22224,,In vivo,0,,U,,Plasma,,Autocuration,AUC in guinea pig after 3mg/kg oral dose,A,1,,4878,CHEMBL619821,,BAO_0000218,1969.0
4492,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in guinea pig was tested,A,1,,5308,CHEMBL619822,,BAO_0000218,
4493,22224,,In vivo,0,,U,,,,Autocuration,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,1,,4877,CHEMBL619823,,BAO_0000218,
4494,22224,,In vivo,0,,U,,,,Autocuration,Tested for the oral bioavailability of the compound,A,1,,4876,CHEMBL619824,,BAO_0000218,
4495,22224,,In vivo,0,,U,,,,Autocuration,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,1,,4876,CHEMBL619825,,BAO_0000218,
4496,22224,,In vivo,0,,U,,,,Autocuration,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,1,,5308,CHEMBL619826,,BAO_0000218,
4497,22224,,In vivo,0,,U,,Lung,,Autocuration,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,1,,4877,CHEMBL619827,,BAO_0000218,2048.0
4498,22224,,In vivo,0,,U,,,,Autocuration,Cmax in guinea pig after 3mg/kg oral dose,A,1,,4878,CHEMBL618167,,BAO_0000218,
4499,22224,,,0,,U,,Blood,,Autocuration,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618168,,BAO_0000019,178.0
4500,22224,,,0,,U,,Brain,,Autocuration,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618169,,BAO_0000019,955.0
4501,22224,,,0,,U,,,,Autocuration,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618170,,BAO_0000019,
4502,22224,,,0,,U,,Intestine,,Autocuration,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618171,,BAO_0000019,160.0
4503,22224,,,0,,U,,Kidney,,Autocuration,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618172,,BAO_0000019,2113.0
4504,22224,,,0,,U,,Liver,,Autocuration,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618173,,BAO_0000019,2107.0
4505,22224,,,0,,U,,,,Autocuration,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL618174,,BAO_0000019,
4506,22224,,,0,,U,,Spleen,,Autocuration,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,1,,5689,CHEMBL875408,,BAO_0000019,2106.0
4507,22224,,In vivo,0,,U,,,,Autocuration,Elimination T1/2 in Guinea pig (PO dose),A,1,,14465,CHEMBL839827,,BAO_0000218,
4508,22224,,,0,,U,,,,Autocuration,Partition coefficient was measured as -log (counts per min ),A,1,,5689,CHEMBL618175,,BAO_0000019,
4509,22224,,In vivo,0,,U,,,,Autocuration,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,1,,611,CHEMBL618176,,BAO_0000218,
4510,22224,,In vivo,0,,U,,,,Autocuration,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,1,,611,CHEMBL618177,,BAO_0000218,
4511,22224,,In vivo,0,,U,,,,Autocuration,Elimination T1/2 in Guinea pig (PO dose),A,1,,14465,CHEMBL618178,,BAO_0000218,
4512,22224,,In vivo,0,,U,,,,Autocuration,"Tested for the half life period of the compound, intravenously",A,1,,4876,CHEMBL618179,,BAO_0000218,
4513,22224,,,0,,U,,,,Autocuration,Half-life was measured,A,1,,5689,CHEMBL873489,,BAO_0000019,
4514,22224,,,0,,U,,,,Autocuration,The time required for onset of inotropy after addition of a single dose of delta F75,A,1,,7515,CHEMBL618180,,BAO_0000019,
4515,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,1,,17667,CHEMBL618181,,BAO_0000218,
4516,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,1,,17667,CHEMBL618182,,BAO_0000218,
4517,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,1,,4727,CHEMBL618183,,BAO_0000218,
4518,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL618184,,BAO_0000218,
4519,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL618185,,BAO_0000218,
4520,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL618186,,BAO_0000218,
4521,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL618187,,BAO_0000218,
4522,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,1,,10107,CHEMBL618188,,BAO_0000218,
4523,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL875409,,BAO_0000218,
4524,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL618189,,BAO_0000218,
4525,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618190,,BAO_0000218,178.0
4526,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618191,,BAO_0000218,178.0
4527,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618192,,BAO_0000218,178.0
4528,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618193,,BAO_0000218,10000001.0
4529,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618194,,BAO_0000218,10000001.0
4530,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618195,,BAO_0000218,10000001.0
4531,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618196,,BAO_0000218,955.0
4532,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618197,,BAO_0000218,955.0
4533,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618198,,BAO_0000218,955.0
4534,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618199,,BAO_0000218,948.0
4535,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618200,,BAO_0000218,948.0
4536,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618201,,BAO_0000218,948.0
4537,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618202,,BAO_0000218,160.0
4538,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618203,,BAO_0000218,160.0
4539,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618204,,BAO_0000218,160.0
4540,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618205,,BAO_0000218,2113.0
4541,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618206,,BAO_0000218,2113.0
4542,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618207,,BAO_0000218,2113.0
4543,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618208,,BAO_0000218,2107.0
4544,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618932,,BAO_0000218,2107.0
4545,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618933,,BAO_0000218,2107.0
4546,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618934,,BAO_0000218,2048.0
4547,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618935,,BAO_0000218,2048.0
4548,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL618936,,BAO_0000218,2048.0
4549,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL618937,,BAO_0000218,2385.0
4550,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL618938,,BAO_0000218,2385.0
4551,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL619104,,BAO_0000218,2385.0
4552,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL619105,,BAO_0000218,2106.0
4553,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL619106,,BAO_0000218,2106.0
4554,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL619107,,BAO_0000218,2106.0
4555,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,1,,3655,CHEMBL875410,,BAO_0000218,945.0
4556,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,1,,3655,CHEMBL619108,,BAO_0000218,945.0
4557,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,1,,3655,CHEMBL619109,,BAO_0000218,945.0
4558,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,1,,16597,CHEMBL619110,,BAO_0000218,
4559,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,1,,16597,CHEMBL619111,,BAO_0000218,
4560,50594,,In vivo,1,,N,,,,Intermediate,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL619112,,BAO_0000218,
4561,50594,,In vivo,1,,N,,,,Intermediate,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL619113,,BAO_0000218,
4562,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL619114,,BAO_0000218,
4563,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,1,,17764,CHEMBL619115,,BAO_0000218,
4564,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,1,,3830,CHEMBL619116,478.0,BAO_0000219,
4565,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,1,,3829,CHEMBL619117,478.0,BAO_0000219,
4566,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,1,,2040,CHEMBL619118,478.0,BAO_0000219,
4567,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,1,,15684,CHEMBL619119,478.0,BAO_0000219,
4568,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,1,,15684,CHEMBL619120,478.0,BAO_0000219,
4569,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,1,,15684,CHEMBL619121,478.0,BAO_0000219,
4570,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,1,,15684,CHEMBL619122,478.0,BAO_0000219,
4571,81034,,,1,,N,,,A2780,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,1,,15684,CHEMBL619123,478.0,BAO_0000219,
4572,81034,,,1,,N,,,A2780,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,1,,15684,CHEMBL619124,478.0,BAO_0000219,
4573,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell line,F,1,,2859,CHEMBL619125,478.0,BAO_0000219,
4574,81034,,,1,,N,,,A2780,Intermediate,In vitro inhibitory activity against human tumor cell line A2780,F,1,,5618,CHEMBL875411,478.0,BAO_0000219,
4575,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,1,,15684,CHEMBL619126,478.0,BAO_0000219,
4576,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,1,,15684,CHEMBL619127,478.0,BAO_0000219,
4577,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,1,,15684,CHEMBL619128,478.0,BAO_0000219,
4578,81034,,,1,,N,,,A2780,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,1,,15684,CHEMBL619129,478.0,BAO_0000219,
4579,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,1,,2113,CHEMBL619130,478.0,BAO_0000219,
4580,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,1,,2113,CHEMBL619131,478.0,BAO_0000219,
4581,81034,,,1,,N,,,A2780,Intermediate,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,1,,16745,CHEMBL619132,478.0,BAO_0000219,
4582,81034,,,1,,N,,,A2780,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,1,,16597,CHEMBL619133,478.0,BAO_0000218,
4583,81034,,,1,,N,,,A2780,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,1,,15684,CHEMBL619134,478.0,BAO_0000219,
4584,81034,,,1,,N,,,A2780,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,1,,15684,CHEMBL619135,478.0,BAO_0000219,
4585,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,1,,2040,CHEMBL619136,478.0,BAO_0000219,
4586,81034,,,1,,N,,,A2780,Intermediate,Relative resistance factor in A2780 cisplatin-resistant line,F,1,,2040,CHEMBL619137,478.0,BAO_0000219,
4587,81034,,,1,,N,,,A2780,Intermediate,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,1,,16165,CHEMBL883713,478.0,BAO_0000219,
4588,81034,,,1,,N,,,A2780,Intermediate,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,1,,16165,CHEMBL875412,478.0,BAO_0000219,
4589,81034,,,1,,N,,,A2780,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,1,,16597,CHEMBL619138,478.0,BAO_0000218,
4590,81034,,,1,,N,,,A2780,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,1,,16597,CHEMBL619262,478.0,BAO_0000218,
4591,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,1,,3992,CHEMBL619139,478.0,BAO_0000219,
4592,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,1,,10553,CHEMBL619140,478.0,BAO_0000219,
4593,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,1,,15608,CHEMBL619141,478.0,BAO_0000219,
4594,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,1,,15608,CHEMBL619142,478.0,BAO_0000219,
4595,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,1,,15608,CHEMBL619143,478.0,BAO_0000219,
4596,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,1,,15608,CHEMBL619144,478.0,BAO_0000219,
4597,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,1,,15608,CHEMBL619145,478.0,BAO_0000219,
4598,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,1,,15608,CHEMBL619146,478.0,BAO_0000219,
4599,81034,,,1,,N,,,A2780,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,1,,15569,CHEMBL619147,478.0,BAO_0000219,
4600,81034,,,1,,N,,,A2780,Intermediate,Antiproliferative effect of compound on A2780/DX cell line,F,1,,17420,CHEMBL619148,478.0,BAO_0000219,
4601,81034,,,1,,N,,,A2780,Intermediate,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,1,,17420,CHEMBL619149,478.0,BAO_0000219,
4602,81034,,,1,,N,,,A2780,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,1,,15099,CHEMBL619150,478.0,BAO_0000219,
4603,81034,,,1,,N,,,A2780,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,1,,15099,CHEMBL619151,478.0,BAO_0000219,
4604,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,1,,17672,CHEMBL883794,478.0,BAO_0000219,
4605,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,1,,17672,CHEMBL619152,478.0,BAO_0000219,
4606,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against A2780ADR cell line,F,1,,17270,CHEMBL619153,478.0,BAO_0000219,
4607,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against A2780CIS cell line,F,1,,17270,CHEMBL619154,478.0,BAO_0000219,
4608,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,1,,5574,CHEMBL619155,478.0,BAO_0000219,
4609,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,1,,2113,CHEMBL619156,478.0,BAO_0000219,
4610,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,1,,16913,CHEMBL619157,478.0,BAO_0000219,
4611,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,1,,16913,CHEMBL619797,478.0,BAO_0000219,
4612,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability of compound in rhesus macaques,A,1,,17839,CHEMBL619798,,BAO_0000218,
4613,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,6821,CHEMBL619799,,BAO_0000218,
4614,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability evaluated in monkey,A,1,,6078,CHEMBL619800,,BAO_0000218,
4615,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,1,,6535,CHEMBL619801,,BAO_0000218,
4616,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey,A,1,,4449,CHEMBL619802,,BAO_0000218,
4617,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability was calculated in rhesus monkey,A,1,,6057,CHEMBL619803,,BAO_0000218,
4618,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in cynomolgus monkey,A,1,,5922,CHEMBL619965,,BAO_0000218,
4619,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,5940,CHEMBL619966,,BAO_0000218,
4620,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,6265,CHEMBL619967,,BAO_0000218,
4621,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey (dose 1 mg/kg),A,1,,6265,CHEMBL620073,,BAO_0000218,
4622,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey (dose 5 mg/kg),A,1,,6265,CHEMBL620074,,BAO_0000218,
4623,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,5940,CHEMBL620075,,BAO_0000218,
4624,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey,A,1,,5940,CHEMBL620076,,BAO_0000218,
4625,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rhesus monkey,A,1,,4514,CHEMBL620077,,BAO_0000218,
4626,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,1,,5546,CHEMBL620078,,BAO_0000218,
4627,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,1,,5553,CHEMBL620079,,BAO_0000218,
4628,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL620080,,BAO_0000218,
4629,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey,A,1,,5472,CHEMBL620081,,BAO_0000218,
4630,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,1,,5668,CHEMBL620082,,BAO_0000218,
4631,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in monkey at 10 mg/kg of the compound,A,1,,5711,CHEMBL620083,,BAO_0000218,
4632,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in Rhesus monkey,A,1,,5145,CHEMBL620084,,BAO_0000218,
4633,22224,,,0,,U,,,,Autocuration,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620085,,BAO_0000218,
4634,22224,,,0,,U,,,,Autocuration,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL874595,,BAO_0000218,
4635,22224,,In vivo,0,,U,,,,Autocuration,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,1,,3249,CHEMBL873352,,BAO_0000218,
4636,22224,,In vivo,0,,U,,,,Autocuration,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,1,,3249,CHEMBL620086,,BAO_0000218,
4637,22224,,In vivo,0,,U,,,,Autocuration,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,1,,5355,CHEMBL620087,,BAO_0000218,
4638,22224,,In vivo,0,,U,,,,Autocuration,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,1,,5355,CHEMBL620088,,BAO_0000218,
4639,22224,,In vivo,0,,U,,,,Autocuration,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,1,,5355,CHEMBL620089,,BAO_0000218,
4640,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,1,,4809,CHEMBL620090,,BAO_0000218,
4641,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,1,,4809,CHEMBL620091,,BAO_0000218,
4642,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL620092,,BAO_0000251,
4643,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,1,,14294,CHEMBL620093,,BAO_0000251,
4644,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,1,,14294,CHEMBL620094,,BAO_0000251,
4645,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL620095,,BAO_0000251,
4646,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620096,,BAO_0000218,
4647,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620097,,BAO_0000218,
4648,22224,,,0,,U,,,,Autocuration,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,1,,11271,CHEMBL620098,,BAO_0000019,
4649,22224,,,0,,U,,,,Autocuration,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620099,,BAO_0000218,
4650,22224,,,0,,U,,,,Autocuration,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620100,,BAO_0000218,
4651,22224,,,0,,U,,,,Autocuration,Elimination Half-life of compound was determined in monkey,A,1,,6821,CHEMBL620101,,BAO_0000019,
4652,22224,,,0,,U,,,,Autocuration,Half life of compound was determined in rhesus monkey,A,1,,17267,CHEMBL620102,,BAO_0000019,
4653,22224,,,0,,U,,Plasma,,Autocuration,Half life in monkey plasma,A,1,,5819,CHEMBL620103,,BAO_0000366,1969.0
4654,22224,,,0,,U,,Plasma,,Autocuration,Half life in monkey plasma; Not detected,A,1,,5819,CHEMBL620104,,BAO_0000366,1969.0
4655,22224,,In vivo,0,,U,,,,Autocuration,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL874596,,BAO_0000218,
4656,22224,,In vivo,0,,U,,,,Autocuration,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,1,,17509,CHEMBL873490,,BAO_0000218,
4657,22224,,,0,,U,,,,Autocuration,Terminal half life of the compound.,A,1,,1399,CHEMBL620105,,BAO_0000019,
4658,22224,,In vivo,0,,U,,,,Autocuration,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL620780,,BAO_0000218,
4659,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,1,,4809,CHEMBL620781,,BAO_0000218,
4660,22224,,,0,,U,,,,Autocuration,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL620956,,BAO_0000218,
4661,22224,,,0,,U,,Urine,,Autocuration,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620957,,BAO_0000218,1088.0
4662,22224,,,0,,U,,Urine,,Autocuration,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL620958,,BAO_0000218,1088.0
4663,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL620959,,BAO_0000218,
4664,22224,,In vivo,0,,U,,,,Autocuration,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,1,,6221,CHEMBL620960,,BAO_0000218,
4665,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was evaluated in rhesus,A,1,,5472,CHEMBL620961,,BAO_0000218,
4666,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,1,,4727,CHEMBL620962,,BAO_0000218,
4667,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,1,,4727,CHEMBL620963,,BAO_0000218,
4668,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in hamster was determined,A,1,,4727,CHEMBL620964,,BAO_0000218,
4669,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,1,,4727,CHEMBL620965,,BAO_0000218,
4670,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,1,,4727,CHEMBL620966,,BAO_0000218,
4671,22224,,,0,,U,,Blood,,Autocuration,Half life of compound was determined in hamster blood,A,1,,4727,CHEMBL620967,,BAO_0000221,178.0
4672,22224,,,0,,U,,,,Autocuration,Michaelis-Menten constant of the compound.,A,1,,1452,CHEMBL620968,,BAO_0000019,
4673,22224,,,0,,U,,,,Autocuration,Vmax value was measured at 0 uM concentration of silyl ether.,A,1,,1452,CHEMBL874597,,BAO_0000019,
4674,22224,,,0,,U,,,,Autocuration,Vmax value was measured at 10 uM concentration of silyl ether.,A,1,,1452,CHEMBL620969,,BAO_0000019,
4675,22224,,,0,,U,,,,Autocuration,Vmax value was measured at 5 uM concentration of silyl ether.,A,1,,1452,CHEMBL620970,,BAO_0000019,
4676,235,,,9,,D,,,,Expert,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,1,,11706,CHEMBL620971,,BAO_0000357,
4677,22224,,,0,,U,,,,Autocuration,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,1,,1916,CHEMBL620972,,BAO_0000218,
4678,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,1,,17791,CHEMBL620973,,BAO_0000019,
4679,22224,,,0,,U,,,,Autocuration,Active metabolite of ifosfamide determined in humans; A-Active,A,1,,7766,CHEMBL618243,,BAO_0000019,
4680,22224,,,0,,U,,,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,1,,6567,CHEMBL618244,,BAO_0000019,
4681,22224,,,0,,U,,,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,1,,6567,CHEMBL618245,,BAO_0000019,
4682,22224,,,0,,U,,,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,1,,6567,CHEMBL618246,,BAO_0000019,
4683,22224,,,0,,U,,,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,1,,6567,CHEMBL618247,,BAO_0000019,
4684,22224,,,0,,U,,,,Autocuration,Compound was evaluated for oral bioavailability in human,A,1,,17791,CHEMBL618248,,BAO_0000218,
4685,22224,,,0,,U,,Urine,,Autocuration,Metabolite of ifosfamide determined in urine; NF-Not found,A,1,,7766,CHEMBL618249,,BAO_0000019,1088.0
4686,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,1,,6852,CHEMBL618250,,BAO_0000019,
4687,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,1,,6852,CHEMBL874598,,BAO_0000019,
4688,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,1,,6852,CHEMBL618251,,BAO_0000019,
4689,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,1,,6852,CHEMBL618252,,BAO_0000019,
4690,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,1,,6852,CHEMBL618253,,BAO_0000019,
4691,22224,,,0,,U,,,,Autocuration,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,1,,6852,CHEMBL618254,,BAO_0000019,
4692,22224,,,0,,U,,,,Autocuration,Percent of compound in healthy individuals (Group D),A,1,,6852,CHEMBL618255,,BAO_0000019,
4693,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,1,,4397,CHEMBL618983,,BAO_0000251,2107.0
4694,22224,,,0,,U,,,,Autocuration,Binding towards human plasma protein at 10 uM,A,1,,17409,CHEMBL618984,,BAO_0000019,
4695,22224,,,0,,U,,,,Autocuration,Binding towards human plasma protein at 100 uM,A,1,,17409,CHEMBL618985,,BAO_0000019,
4696,22224,,,0,,U,,,,Autocuration,Human plasma protein binding activity was determined,A,1,,17176,CHEMBL618986,,BAO_0000019,
4697,22224,,,0,,U,,,,Autocuration,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,1,,15444,CHEMBL618987,,BAO_0000019,
4698,22224,,,0,,U,,,,Autocuration,Percent binding of compound towards human plasma protein was determined,A,1,,17267,CHEMBL618988,,BAO_0000019,
4699,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Plasma clearance in human liver microsomes,A,1,,5944,CHEMBL618989,,BAO_0000251,2107.0
4700,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,In vitro intrinsic clearance in human liver microsome,A,1,,5668,CHEMBL618990,,BAO_0000251,2107.0
4701,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,In vitro intrinsic clearance in human liver microsome,A,1,,5669,CHEMBL618991,,BAO_0000251,2107.0
4702,22224,,In vitro,0,,U,Microsomes,,,Autocuration,In vitro microsome metabolism clearance in human was determined,A,1,,5041,CHEMBL876725,,BAO_0000251,
4703,22224,,In vitro,0,,U,Microsomes,,,Autocuration,In vitro microsome metabolism clearance in human was determined; High,A,1,,5041,CHEMBL618992,,BAO_0000251,
4704,22224,,In vitro,0,,U,Microsomes,,,Autocuration,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,1,,5041,CHEMBL618993,,BAO_0000251,
4705,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Pharmacokinetic property (clearance) in human liver microsome,A,1,,5676,CHEMBL618994,,BAO_0000251,2107.0
4706,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Plasma clearance in human liver microsomes,A,1,,5944,CHEMBL618995,,BAO_0000251,2107.0
4707,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,In vitro clearance in human liver microsomes,A,1,,17538,CHEMBL618996,,BAO_0000251,2107.0
4708,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Intrinsic clearance in human liver microsomes was determined,A,1,,6331,CHEMBL618997,,BAO_0000251,2107.0
4709,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Intrinsic clearance in human liver microsomes was determined,A,1,,5948,CHEMBL618998,,BAO_0000251,2107.0
4710,22224,,In vivo,0,,U,,,,Autocuration,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,1,,5965,CHEMBL618999,,BAO_0000218,
4711,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,1,,1916,CHEMBL620223,,BAO_0000218,
4712,22224,,,0,,U,,,,Autocuration,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,1,,5965,CHEMBL620224,,BAO_0000218,
4713,22224,,,0,,U,,,,Autocuration,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,1,,1299,CHEMBL620225,,BAO_0000019,
4714,22224,,,0,,U,,,,Autocuration,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,1,,1299,CHEMBL620226,,BAO_0000019,
4715,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL620227,,BAO_0000019,1088.0
4716,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL876726,,BAO_0000019,1088.0
4717,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL620228,,BAO_0000019,1088.0
4718,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL620229,,BAO_0000019,1088.0
4719,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,1,,17764,CHEMBL620230,,BAO_0000218,
4720,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,1,,17764,CHEMBL620231,,BAO_0000218,
4721,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,1,,17764,CHEMBL620232,,BAO_0000218,
4722,50594,,In vivo,1,,N,,,,Intermediate,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,1,,17764,CHEMBL620233,,BAO_0000218,
4723,50594,,,1,,N,,,,Intermediate,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,1,,14294,CHEMBL620234,,BAO_0000218,
4724,50594,,,1,,N,,,,Intermediate,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL620235,,BAO_0000218,
4725,50594,,,1,,N,,,,Intermediate,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL620236,,BAO_0000218,
4726,50594,,,1,,N,,Liver,,Intermediate,In vitro metabolic potential in mouse liver microsomes,A,1,,6251,CHEMBL620237,,BAO_0000218,2107.0
4727,50594,,,1,,N,,,,Intermediate,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,1,,17582,CHEMBL620238,,BAO_0000218,
4728,50594,,,1,,N,,Adrenal gland,,Intermediate,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,1,,17811,CHEMBL620239,,BAO_0000218,2369.0
4729,50594,,,1,,N,,Brain,,Intermediate,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,1,,17811,CHEMBL620240,,BAO_0000218,955.0
4730,50594,,,1,,N,,Brain,,Intermediate,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,1,,17811,CHEMBL620241,,BAO_0000218,955.0
4731,50594,,,1,,N,,,,Intermediate,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,1,,17811,CHEMBL876727,,BAO_0000218,
4732,50594,,,1,,N,,Kidney,,Intermediate,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,1,,17811,CHEMBL620242,,BAO_0000218,2113.0
4733,50594,,,1,,N,,,,Intermediate,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,1,,17811,CHEMBL620243,,BAO_0000218,
4734,50594,,,1,,N,,,,Intermediate,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,1,,5288,CHEMBL620244,,BAO_0000218,
4735,50594,,,1,,N,,Serum,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,1,,2717,CHEMBL620245,,BAO_0000218,1977.0
4736,50594,,,1,,N,,Serum,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,1,,2717,CHEMBL620246,,BAO_0000218,1977.0
4737,50594,,,1,,N,,Serum,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,1,,2717,CHEMBL620247,,BAO_0000218,1977.0
4738,50594,,In vivo,1,,N,,Plasma,,Intermediate,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,1,,17753,CHEMBL620248,,BAO_0000218,1969.0
4739,50594,,In vivo,1,,N,,Plasma,,Intermediate,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,1,,17753,CHEMBL873497,,BAO_0000218,1969.0
4740,50594,,In vivo,1,,N,,Plasma,,Intermediate,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,1,,17753,CHEMBL620249,,BAO_0000218,1969.0
4741,50594,,In vivo,1,,N,,,,Intermediate,Half life after intraperitoneal administration in mice at 18 uM/kg,F,1,,17764,CHEMBL620250,,BAO_0000218,
4742,50594,,In vivo,1,,N,,,,Intermediate,Half life after intraperitoneal administration in mice at 23 uM/kg,F,1,,17764,CHEMBL620251,,BAO_0000218,
4743,50594,,In vivo,1,,N,,,,Intermediate,Half life after intraperitoneal administration in mice at 25 uM/kg,F,1,,17764,CHEMBL620252,,BAO_0000218,
4744,50594,,In vivo,1,,N,,,,Intermediate,Half life after intraperitoneal administration in mice at 26 uM/kg,F,1,,17764,CHEMBL620253,,BAO_0000218,
4745,50594,,In vivo,1,,N,,,,Intermediate,Half life after intravenous administration in mice at 23 uM/kg,F,1,,17764,CHEMBL620254,,BAO_0000218,
4746,50594,,In vivo,1,,N,,,,Intermediate,Half life after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL620255,,BAO_0000218,
4747,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,1,,16597,CHEMBL620256,,BAO_0000218,
4748,50594,,In vivo,1,,N,,,,Intermediate,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,1,,2675,CHEMBL876728,,BAO_0000218,
4749,50594,,In vivo,1,,N,,,,Intermediate,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,1,,2675,CHEMBL620257,,BAO_0000218,
4750,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,1,,16597,CHEMBL620258,,BAO_0000218,
4751,50594,,In vivo,1,,N,,,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,1,,4890,CHEMBL620259,,BAO_0000218,
4752,50594,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,1,,429,CHEMBL620260,,BAO_0000218,
4753,50594,,In vivo,1,,N,,Blood,,Intermediate,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,1,,17837,CHEMBL620261,,BAO_0000218,178.0
4754,50594,,In vivo,1,,N,,,,Intermediate,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL620262,,BAO_0000218,
4755,50594,,In vivo,1,,N,,,,Intermediate,Half life at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL620263,,BAO_0000218,
4756,50594,,,1,,N,,,,Intermediate,Half life in ob/ob mice,A,1,,6619,CHEMBL620264,,BAO_0000218,
4757,50594,,In vivo,1,,N,,,,Intermediate,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,1,,4066,CHEMBL620265,,BAO_0000218,
4758,50594,,,1,,N,,,,Intermediate,Half-life was measured in mouse,A,1,,4239,CHEMBL620266,,BAO_0000218,
4759,50594,,In vivo,1,,N,,,,Intermediate,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,1,,5969,CHEMBL620267,,BAO_0000218,
4760,50594,,,1,,N,,,,Intermediate,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,1,,8999,CHEMBL619364,,BAO_0000218,
4761,50594,,,1,,N,,,,Intermediate,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,1,,8999,CHEMBL619365,,BAO_0000218,
4762,50594,,,1,,N,,Brain,,Intermediate,T2 in brain of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL619366,,BAO_0000218,955.0
4763,50594,,,1,,N,,Kidney,,Intermediate,T2 in kidney of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL619367,,BAO_0000218,2113.0
4764,50594,,,1,,N,,Liver,,Intermediate,T2 in liver of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL619368,,BAO_0000218,2107.0
4765,50594,,,1,,N,,Lung,,Intermediate,T2 in lungs of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL619369,,BAO_0000218,2048.0
4766,50594,,,1,,N,,Spleen,,Intermediate,T2 in spleen of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL876729,,BAO_0000218,2106.0
4767,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,1,,16597,CHEMBL619370,,BAO_0000218,
4768,50594,,In vivo,1,,N,,,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,1,,4890,CHEMBL619371,,BAO_0000218,
4769,50594,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,1,,429,CHEMBL619372,,BAO_0000218,
4770,50594,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,1,,429,CHEMBL620012,,BAO_0000218,
4771,50594,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,1,,5969,CHEMBL620013,,BAO_0000218,
4772,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,1,,16913,CHEMBL620014,478.0,BAO_0000219,
4773,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,1,,16913,CHEMBL620015,478.0,BAO_0000219,
4774,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,1,,16913,CHEMBL621010,478.0,BAO_0000219,
4775,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,1,,16913,CHEMBL621011,478.0,BAO_0000219,
4776,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,1,,16913,CHEMBL621012,478.0,BAO_0000219,
4777,81034,,,1,,N,,,A2780,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,1,,16913,CHEMBL621013,478.0,BAO_0000219,
4778,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against A2780TAX cell line,F,1,,17270,CHEMBL621014,478.0,BAO_0000219,
4779,80017,,,1,,N,,,A2780cisR,Intermediate,In vitro inhibitory activity against human tumor cell line A2780cis,F,1,,5618,CHEMBL618154,481.0,BAO_0000219,
4780,81034,,,1,,N,,,A2780,Expert,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,1,,17777,CHEMBL618155,478.0,BAO_0000219,
4781,80017,,,1,,N,,,A2780cisR,Intermediate,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,1,,16112,CHEMBL618156,481.0,BAO_0000219,
4782,80017,,,1,,N,,,A2780cisR,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,1,,15748,CHEMBL618157,481.0,BAO_0000219,
4783,81034,,,1,,N,,,A2780,Intermediate,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,1,,6633,CHEMBL618328,478.0,BAO_0000219,
4784,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,1,,16930,CHEMBL618329,478.0,BAO_0000219,
4785,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,1,,17496,CHEMBL618330,478.0,BAO_0000219,
4786,81034,,,1,,N,,,A2780,Expert,In vitro antitumor activity against A2780cisR cell line.,F,1,,12989,CHEMBL618331,478.0,BAO_0000219,
4787,81034,,,1,,N,,,A2780,Intermediate,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,1,,4840,CHEMBL618332,478.0,BAO_0000219,
4788,81034,,,1,,N,,,A2780,Expert,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,1,,12989,CHEMBL618333,478.0,BAO_0000219,
4789,80017,,,1,,N,,,A2780cisR,Intermediate,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,1,,16745,CHEMBL618334,481.0,BAO_0000219,
4790,81034,,,1,,N,,,A2780,Expert,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,1,,16597,CHEMBL618335,478.0,BAO_0000219,
4791,11736,,,9,,D,,,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,1,,16547,CHEMBL618336,,BAO_0000019,
4792,11736,,,8,,H,,,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,1,,16547,CHEMBL618337,,BAO_0000019,
4793,11736,,,9,,D,,,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,1,,16547,CHEMBL618338,,BAO_0000019,
4794,278,,,9,,D,,,HEK293,Expert,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,1,,15856,CHEMBL618339,722.0,BAO_0000219,
4795,278,,,9,,D,,,HEK293,Expert,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,1,,15856,CHEMBL618340,722.0,BAO_0000219,
4796,11831,,,9,,D,,,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,1,,16547,CHEMBL618341,,BAO_0000019,
4797,11831,,,8,,H,,,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,1,,16547,CHEMBL618342,,BAO_0000019,
4798,11831,,,9,,D,,,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,1,,16547,CHEMBL618343,,BAO_0000019,
4799,280,,,8,,H,,,,Expert,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,1,,17402,CHEMBL621038,,BAO_0000357,
4800,22226,,,0,,U,,,T-cells,Autocuration,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,1,,11746,CHEMBL621039,574.0,BAO_0000219,
4801,22226,,,0,,U,,,T-cells,Autocuration,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,1,,11746,CHEMBL621040,574.0,BAO_0000219,
4802,80018,,,1,,N,,,A-375,Intermediate,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,1,,5455,CHEMBL621041,455.0,BAO_0000219,
4803,80018,,,1,,N,,,A-375,Intermediate,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,1,,2068,CHEMBL621042,455.0,BAO_0000219,
4804,80018,,,1,,N,,,A-375,Intermediate,In vitro antitumor activity against A375cell line extracted form melanoma,F,1,,2683,CHEMBL621043,455.0,BAO_0000219,
4805,80018,,,1,,N,,,A-375,Expert,Inhibition of cell growth in (A375) melan cell line,F,1,,15313,CHEMBL621044,455.0,BAO_0000219,
4806,80018,,,1,,N,,,A-375,Intermediate,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,1,,13739,CHEMBL621045,455.0,BAO_0000219,
4807,80018,,,1,,N,,,A-375,Intermediate,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,1,,13739,CHEMBL621046,455.0,BAO_0000219,
4808,80018,,,1,,N,,,A-375,Intermediate,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,1,,14750,CHEMBL621047,455.0,BAO_0000219,
4809,80019,,,1,,N,,,A-427,Intermediate,Antiproliferative activity measured against A427 human lung carcinoma,F,1,,14777,CHEMBL621048,797.0,BAO_0000219,
4810,80019,,,1,,N,,,A-427,Intermediate,Antiproliferative activity measured against A427 human lung carcinoma,F,1,,14777,CHEMBL883798,797.0,BAO_0000219,
4811,80019,,,1,,N,,,A-427,Intermediate,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,1,,17672,CHEMBL621049,797.0,BAO_0000219,
4812,80019,,,1,,N,,,A-427,Intermediate,Inhibition of large cell lung carcinoma (A427),F,1,,14368,CHEMBL621050,797.0,BAO_0000219,
4813,80019,,,1,,N,,,A-427,Intermediate,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,1,,14368,CHEMBL621051,797.0,BAO_0000219,
4814,80019,,,1,,N,,,A-427,Intermediate,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,1,,13866,CHEMBL621052,797.0,BAO_0000219,
4815,80019,,,1,,N,,,A-427,Intermediate,Inhibitory concentration in human lung carcinoma A427 cell line,F,1,,2545,CHEMBL621053,797.0,BAO_0000219,
4816,80019,,,1,,N,,,A-427,Intermediate,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,1,,2545,CHEMBL621054,797.0,BAO_0000219,
4817,22224,,In vivo,0,,U,,,,Autocuration,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL621055,,BAO_0000218,
4818,22224,,In vivo,0,,U,,,,Autocuration,Tested for volume of distribution upon iv administration to african green monkey,A,1,,4578,CHEMBL876398,,BAO_0000218,
4819,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution in monkey,A,1,,17592,CHEMBL621056,,BAO_0000218,
4820,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,1,,5005,CHEMBL621057,,BAO_0000218,
4821,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,1,,5005,CHEMBL621058,,BAO_0000218,
4822,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,1,,5922,CHEMBL621059,,BAO_0000218,
4823,22224,,In vivo,0,,U,,,,Autocuration,The distribution volume after intravenous administration in cynomolgus monkeys,A,1,,5355,CHEMBL621060,,BAO_0000218,
4824,22224,,In vivo,0,,U,,,,Autocuration,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,1,,5355,CHEMBL621061,,BAO_0000218,
4825,22224,,In vivo,0,,U,,,,Autocuration,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,1,,5355,CHEMBL621062,,BAO_0000218,
4826,22224,,In vivo,0,,U,,,,Autocuration,Volume displacement was calculated in rhesus monkey,A,1,,6057,CHEMBL621063,,BAO_0000218,
4827,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution in steady state was determined in rhesus monkey,A,1,,5145,CHEMBL621064,,BAO_0000218,
4828,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution of compound was determined in monkey,A,1,,6821,CHEMBL621065,,BAO_0000218,
4829,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL621066,,BAO_0000218,
4830,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL621067,,BAO_0000218,
4831,22224,,In vivo,0,,U,,,,Autocuration,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL621068,,BAO_0000218,
4832,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL876399,,BAO_0000218,
4833,22224,,In vivo,0,,U,,,,Autocuration,Volume distribution in monkey after administration of 1 mg/kg iv,A,1,,6535,CHEMBL621069,,BAO_0000218,
4834,22224,,In vivo,0,,U,,,,Autocuration,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,1,,4809,CHEMBL621070,,BAO_0000218,
4835,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL621071,,BAO_0000218,
4836,22224,,In vivo,0,,U,,,,Autocuration,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL621072,,BAO_0000218,
4837,22224,,In vivo,0,,U,,,,Autocuration,Oral systemic bioavailability upon iv administration to african green monkey,A,1,,4578,CHEMBL618209,,BAO_0000218,
4838,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,1,,4809,CHEMBL618210,,BAO_0000218,
4839,22224,,,0,,U,,,,Autocuration,Baboon plasma free fraction. ,A,1,,11271,CHEMBL618211,,BAO_0000019,
4840,22224,,,0,,U,,,,Autocuration,Area under the curve was calculated in rhesus monkey after iv administration,A,1,,6057,CHEMBL618212,,BAO_0000218,
4841,22224,,,0,,U,,,,Autocuration,Area under the curve was calculated in rhesus monkey after peroral administration,A,1,,6057,CHEMBL618213,,BAO_0000019,
4842,22224,,,0,,U,,,,Autocuration,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL618214,,BAO_0000019,
4843,22224,,In vivo,0,,U,,,,Autocuration,Half life period in monkey after 5 mg/kg dose,A,1,,5302,CHEMBL873492,,BAO_0000218,
4844,22224,,In vivo,0,,U,,,,Autocuration,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,1,,4257,CHEMBL618272,,BAO_0000218,
4845,22224,,In vivo,0,,U,,,,Autocuration,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,1,,4257,CHEMBL618273,,BAO_0000218,
4846,22224,,In vivo,0,,U,,Plasma,,Autocuration,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,1,,13501,CHEMBL618274,,BAO_0000218,1969.0
4847,22224,,In vivo,0,,U,,,,Autocuration,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,1,,5394,CHEMBL618275,,BAO_0000218,
4848,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL618276,,BAO_0000218,
4849,22224,,,0,,U,,,,Autocuration,Compound was evaluated for terminal half life in monkey,A,1,,3341,CHEMBL618277,,BAO_0000019,
4850,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,1,,3045,CHEMBL618278,,BAO_0000218,
4851,22224,,In vivo,0,,U,,Plasma,,Autocuration,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,1,,5005,CHEMBL618279,,BAO_0000218,1969.0
4852,22224,,,0,,U,,,,Autocuration,Half life of compound was determined in squirrel monkey,A,1,,4847,CHEMBL618280,,BAO_0000019,
4853,22224,,In vivo,0,,U,,,,Autocuration,Half life after iv administration in cynomolgus monkey,A,1,,4256,CHEMBL618281,,BAO_0000218,
4854,22224,,In vivo,0,,U,,Plasma,,Autocuration,Half life in monkey plasma after administration of 1 mg/kg iv,A,1,,6535,CHEMBL618282,,BAO_0000218,1969.0
4855,22224,,,0,,U,,,,Autocuration,Half life was calculated in rhesus monkey,A,1,,6057,CHEMBL618283,,BAO_0000019,
4856,22224,,,0,,U,,,,Autocuration,Half life in monkey,A,1,,17592,CHEMBL618284,,BAO_0000019,
4857,22224,,In vivo,0,,U,,,,Autocuration,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL618285,,BAO_0000218,
4858,22224,,,0,,U,,,,Autocuration,Half life was evaluated in rhesus,A,1,,5472,CHEMBL618286,,BAO_0000019,
4859,22224,,In vivo,0,,U,,,,Autocuration,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,1,,6221,CHEMBL618287,,BAO_0000218,
4860,22224,,In vivo,0,,U,,,,Autocuration,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,1,,5668,CHEMBL618288,,BAO_0000218,
4861,22224,,In vivo,0,,U,,,,Autocuration,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,1,,4809,CHEMBL876393,,BAO_0000218,
4862,22224,,In vivo,0,,U,,,,Autocuration,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL618289,,BAO_0000218,
4863,22224,,In vivo,0,,U,,,,Autocuration,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,1,,5553,CHEMBL618290,,BAO_0000218,
4864,22224,,,0,,U,,,,Autocuration,Half-life was calculated in monkey,A,1,,6078,CHEMBL618291,,BAO_0000019,
4865,22224,,,0,,U,,,,Autocuration,Half-life in Squirrel monkey,A,1,,5147,CHEMBL618292,,BAO_0000019,
4866,22224,,,0,,U,,,,Autocuration,Half-life in rhesus monkey,A,1,,5145,CHEMBL618293,,BAO_0000019,
4867,22224,,In vivo,0,,U,,,,Autocuration,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL618294,,BAO_0000218,
4868,22224,,In vivo,0,,U,,,,Autocuration,Half-life period after intravenous administration in cynomolgus monkeys,A,1,,5355,CHEMBL618295,,BAO_0000218,
4869,22224,,In vivo,0,,U,,,,Autocuration,Half-life period after oral administration in cynomolgus monkeys,A,1,,5355,CHEMBL618296,,BAO_0000218,
4870,22224,,In vivo,0,,U,,,,Autocuration,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,1,,5355,CHEMBL618297,,BAO_0000218,
4871,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL618298,,BAO_0000019,1088.0
4872,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL618299,,BAO_0000019,1088.0
4873,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL618300,,BAO_0000019,1088.0
4874,22224,,,0,,U,,Urine,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,1,,7766,CHEMBL618301,,BAO_0000019,1088.0
4875,22224,,,0,,U,,Urine,,Autocuration,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,1,,7766,CHEMBL618302,,BAO_0000019,1088.0
4876,22224,,,0,,U,,Urine,,Autocuration,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,1,,7766,CHEMBL876394,,BAO_0000019,1088.0
4877,22224,,,0,,U,,Urine,,Autocuration,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,1,,7766,CHEMBL618303,,BAO_0000019,1088.0
4878,22224,,,0,,U,,Urine,,Autocuration,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,1,,7766,CHEMBL618304,,BAO_0000019,1088.0
4879,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,1,,1916,CHEMBL618305,,BAO_0000218,
4880,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in human,A,1,,16643,CHEMBL618306,,BAO_0000218,
4881,22224,,,0,,U,,,,Autocuration,Compound was tested for human plasma protein binding,A,1,,17248,CHEMBL618307,,BAO_0000019,
4882,22224,,,0,,U,,,,Autocuration,Compound was tested for human plasma protein binding; Not determined,A,1,,17248,CHEMBL618308,,BAO_0000019,
4883,22224,,,0,,U,,,,Autocuration,Protein binding activity of compound in human plasma; % Free,A,1,,6241,CHEMBL618309,,BAO_0000019,
4884,22224,,,0,,U,,,,Autocuration,Unbound fraction (plasma),A,1,,17716,CHEMBL618310,,BAO_0000019,
4885,22224,,,0,,U,,Plasma,,Autocuration,Half life for the hydrolysis of compound in human blood serum,A,1,,17605,CHEMBL873353,,BAO_0000366,1969.0
4886,22224,,,0,,U,,Plasma,,Autocuration,Half life period in human plasma using phosphate buffer (0.08 M),A,1,,17625,CHEMBL618311,,BAO_0000366,1969.0
4887,22224,,,0,,U,,Plasma,,Autocuration,Half life period in human plasma using phosphate buffer (0.1 M),A,1,,17625,CHEMBL618312,,BAO_0000366,1969.0
4888,22224,,,0,,U,,Plasma,,Autocuration,Half-life in human plasma was determined,A,1,,17747,CHEMBL618313,,BAO_0000366,1969.0
4889,22224,,,0,,U,,,,Autocuration,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,1,,15613,CHEMBL618314,,BAO_0000019,
4890,22224,,,0,,U,,,,Autocuration,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,1,,354,CHEMBL618315,,BAO_0000019,
4891,22224,,,0,,U,,,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,1,,3741,CHEMBL618316,,BAO_0000019,
4892,22224,,,0,,U,,,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,1,,3741,CHEMBL618317,,BAO_0000019,
4893,22224,,,0,,U,,,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,1,,3741,CHEMBL620138,,BAO_0000019,
4894,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,17599,CHEMBL858280,,BAO_0000019,
4895,22224,,,0,,U,,,,Autocuration,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,1,,5486,CHEMBL620139,,BAO_0000019,
4896,22224,,,0,,U,Microsomes,,,Autocuration,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,1,,5600,CHEMBL620140,,BAO_0000251,
4897,22224,,,0,,U,,,,Autocuration,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL620141,,BAO_0000019,
4898,22224,,,0,,U,,,,Autocuration,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,1,,14294,CHEMBL620142,,BAO_0000019,
4899,22224,,,0,,U,,,,Autocuration,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,1,,14294,CHEMBL620143,,BAO_0000019,
4900,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL620144,,BAO_0000251,
4901,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL620145,,BAO_0000251,
4902,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in human microsomes; Trace,A,1,,14294,CHEMBL620146,,BAO_0000251,
4903,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,1,,6260,CHEMBL620147,,BAO_0000251,2107.0
4904,22224,,,0,,U,Microsomes,,,Autocuration,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,1,,6187,CHEMBL620148,,BAO_0000251,
4905,22224,,,0,,U,Microsomes,Liver,,Autocuration,In vitro metabolic potential in human liver microsomes,A,1,,6251,CHEMBL620149,,BAO_0000251,2107.0
4906,22224,,,0,,U,,,,Autocuration,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,1,,3246,CHEMBL876412,,BAO_0000019,
4907,22224,,,0,,U,,,,Autocuration,Tested for human plasma protein binding of the compound; Not tested,A,1,,17313,CHEMBL619352,,BAO_0000019,
4908,22224,,,0,,U,,,,Autocuration,Compound was tested for percent protein binding (PB) in human,A,1,,6227,CHEMBL619353,,BAO_0000019,
4909,22224,,,0,,U,,Plasma,,Autocuration,Protein binding in human plasma,A,1,,5530,CHEMBL619354,,BAO_0000019,1969.0
4910,22224,,,0,,U,,,,Autocuration,Permeability coefficient (B to A) in Caco-2 cell,A,1,,6108,CHEMBL619355,,BAO_0000019,
4911,22224,,,0,,U,,,,Autocuration,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,1,,6108,CHEMBL619356,,BAO_0000019,
4912,22224,,,0,,U,,,,Autocuration,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,1,,2774,CHEMBL619357,,BAO_0000019,
4913,22224,,,0,,U,,,,Autocuration,In vitro rate of absorption observed as Caco-2 permeability in humans,A,1,,16643,CHEMBL619358,,BAO_0000019,
4914,22224,,,0,,U,,,Caco-2,Autocuration,Cellular permeability of compound was determined in Caco-2 cells; High,A,1,,17582,CHEMBL619359,495.0,BAO_0000219,
4915,22224,,,0,,U,,,Caco-2,Autocuration,Permeability in Caco-2 cells of compound,A,1,,6838,CHEMBL619360,495.0,BAO_0000219,
4916,22224,,,0,,U,,,,Autocuration,Permeability coefficient (A to B) in Caco-2 cell,A,1,,6108,CHEMBL619361,,BAO_0000019,
4917,22224,,,0,,U,,,,Autocuration,Permeability coefficient (B to A) in Caco-2 cell,A,1,,6108,CHEMBL619362,,BAO_0000019,
4918,22224,,,0,,U,,,,Autocuration,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,1,,6108,CHEMBL619363,,BAO_0000019,
4919,22224,,,0,,U,,,,Autocuration,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,1,,2146,CHEMBL618942,,BAO_0000019,
4920,22224,,,0,,U,,,,Autocuration,Compound was tested for protein binding in human plasma,A,1,,4514,CHEMBL618943,,BAO_0000019,
4921,22224,,,0,,U,,,,Autocuration,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,1,,6108,CHEMBL618944,,BAO_0000019,
4922,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,1,,7766,CHEMBL618945,,BAO_0000019,1088.0
4923,50594,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,1,,5969,CHEMBL618946,,BAO_0000218,
4924,50594,,In vivo,1,,N,,,,Intermediate,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,1,,3277,CHEMBL876413,,BAO_0000218,
4925,50594,,In vivo,1,,N,,,,Intermediate,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,1,,3802,CHEMBL618947,,BAO_0000218,
4926,50594,,In vivo,1,,N,,Plasma,,Intermediate,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,1,,2862,CHEMBL618948,,BAO_0000218,1969.0
4927,50594,,In vivo,1,,N,,Plasma,,Intermediate,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL618949,,BAO_0000218,1969.0
4928,50594,,In vivo,1,,N,,,,Intermediate,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,1,,17764,CHEMBL618950,,BAO_0000218,
4929,50594,,In vivo,1,,N,,,,Intermediate,Tmax after oral administration at 30 mg/kg in ICR mouse,A,1,,5781,CHEMBL618951,,BAO_0000218,
4930,50594,,In vivo,1,,N,,,,Intermediate,Tmax after peroral administration in mice at 2.4 uM/kg,A,1,,17764,CHEMBL618952,,BAO_0000218,
4931,50594,,In vivo,1,,N,,,,Intermediate,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,1,,4066,CHEMBL618953,,BAO_0000218,
4932,50594,,In vivo,1,,N,,Brain,,Intermediate,Tmax in brain of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL618954,,BAO_0000218,955.0
4933,50594,,In vivo,1,,N,,Kidney,,Intermediate,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL618955,,BAO_0000218,2113.0
4934,50594,,In vivo,1,,N,,Liver,,Intermediate,Tmax in liver of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL618956,,BAO_0000218,2107.0
4935,50594,,In vivo,1,,N,,Lung,,Intermediate,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL618957,,BAO_0000218,2048.0
4936,50594,,In vivo,1,,N,,,,Intermediate,Tmax in mice at 18 uM/kg i.p. administration,F,1,,17764,CHEMBL618958,,BAO_0000218,
4937,50594,,In vivo,1,,N,,,,Intermediate,Tmax in mice at 23 uM/kg i.v. administration,F,1,,17764,CHEMBL618959,,BAO_0000218,
4938,50594,,In vivo,1,,N,,,,Intermediate,Tmax in mice at 25 uM/kg i.p. administration,F,1,,17764,CHEMBL618960,,BAO_0000218,
4939,50594,,In vivo,1,,N,,,,Intermediate,Tmax in mice at 26 uM/kg i.p. administration,F,1,,17764,CHEMBL876723,,BAO_0000218,
4940,50594,,In vivo,1,,N,,Spleen,,Intermediate,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL618961,,BAO_0000218,2106.0
4941,50594,,In vivo,1,,N,,,,Intermediate,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL618962,,BAO_0000218,
4942,50594,,In vivo,1,,N,,,,Intermediate,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL618963,,BAO_0000218,
4943,50594,,,1,,N,,,,Intermediate,Tmax value in IRC mice,A,1,,5951,CHEMBL618964,,BAO_0000218,
4944,50594,,In vivo,1,,N,,,,Intermediate,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL618965,,BAO_0000218,
4945,50594,,In vivo,1,,N,,,,Intermediate,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL618966,,BAO_0000218,
4946,50594,,,1,,N,,Urine,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,1,,429,CHEMBL618967,,BAO_0000218,1088.0
4947,50594,,,1,,N,,Urine,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,1,,429,CHEMBL618968,,BAO_0000218,1088.0
4948,50594,,,1,,N,,Urine,,Intermediate,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,1,,4066,CHEMBL618969,,BAO_0000218,1088.0
4949,50594,,,1,,N,,,,Intermediate,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL618970,,BAO_0000218,
4950,50594,,,1,,N,,,,Intermediate,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL618971,,BAO_0000218,
4951,50594,,In vivo,1,,N,,,,Intermediate,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL618972,,BAO_0000218,
4952,50594,,In vivo,1,,N,,,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,1,,5969,CHEMBL618973,,BAO_0000218,
4953,50594,,In vivo,1,,N,,,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,1,,5969,CHEMBL618974,,BAO_0000218,
4954,50594,,In vivo,1,,N,,,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,1,,5969,CHEMBL618975,,BAO_0000218,
4955,50594,,In vivo,1,,N,,,,Intermediate,Vd in mice,A,1,,5980,CHEMBL618976,,BAO_0000218,
4956,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution in mouse,A,1,,17592,CHEMBL618977,,BAO_0000218,
4957,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL876724,,BAO_0000218,
4958,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,1,,17753,CHEMBL618978,,BAO_0000218,
4959,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,1,,17753,CHEMBL618979,,BAO_0000218,
4960,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,1,,17753,CHEMBL618980,,BAO_0000218,
4961,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (vdss) was measured in mouse,A,1,,4239,CHEMBL618981,,BAO_0000218,
4962,50594,,In vivo,1,,N,,,,Intermediate,Value distribution upon iv administration in mouse,A,1,,2862,CHEMBL618982,,BAO_0000218,
4963,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL620150,,BAO_0000218,
4964,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution was evaluated in mice after intravenous administration,A,1,,2675,CHEMBL620151,,BAO_0000218,
4965,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution was evaluated in mice after oral administration,A,1,,2675,CHEMBL620152,,BAO_0000218,
4966,50594,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,1,,17837,CHEMBL620153,,BAO_0000218,
4967,50594,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution was determined in mice,A,1,,5727,CHEMBL876395,,BAO_0000218,
4968,50594,,In vivo,1,,N,,,,Intermediate,Volume distribution (steady state) of compound was determined in mouse,A,1,,17852,CHEMBL620154,,BAO_0000218,
4969,50594,,In vivo,1,,N,,,,Intermediate,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL620155,,BAO_0000218,
4970,50594,,In vivo,1,,N,,,,Intermediate,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL620156,,BAO_0000218,
4971,50594,,In vivo,1,,N,,,,Intermediate,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL620157,,BAO_0000218,
4972,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of compound (oxidized form) in in kidney tissue,A,1,,16438,CHEMBL620158,,BAO_0000218,2113.0
4973,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,1,,16438,CHEMBL620159,,BAO_0000218,178.0
4974,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,1,,16438,CHEMBL620160,,BAO_0000218,178.0
4975,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL620161,,BAO_0000218,178.0
4976,80019,,,1,,N,,,A-427,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL620162,797.0,BAO_0000219,
4977,80852,,,1,,N,,,A-431,Expert,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,1,,16597,CHEMBL620163,500.0,BAO_0000219,
4978,80852,,,1,,N,,,A-431,Expert,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,1,,16062,CHEMBL620833,500.0,BAO_0000219,
4979,80852,,,1,,N,,,A-431,Expert,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,1,,16062,CHEMBL876396,500.0,BAO_0000219,
4980,80852,,,1,,N,,,A-431,Expert,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,1,,16958,CHEMBL620834,500.0,BAO_0000219,
4981,80852,,,1,,N,,,A-431,Expert,Inhibition of A431 human carcinoma cell proliferation,F,1,,6700,CHEMBL620835,500.0,BAO_0000219,
4982,80852,,,1,,N,,,A-431,Expert,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,1,,17226,CHEMBL620836,500.0,BAO_0000219,
4983,80852,,,1,,N,,,A-431,Intermediate,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,1,,6828,CHEMBL620837,500.0,BAO_0000219,
4984,80852,,,1,,N,,,A-431,Intermediate,In vitro cytotoxicity against epidermoid carcinoma cell line,F,1,,12314,CHEMBL621017,500.0,BAO_0000219,
4985,9,,,9,,D,,,A-431,Expert,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,1,,13412,CHEMBL621018,500.0,BAO_0000218,
4986,80852,,,1,,N,,,A-431,Intermediate,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,1,,13299,CHEMBL621019,500.0,BAO_0000219,
4987,80852,,,1,,N,,,A-431,Intermediate,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,1,,17420,CHEMBL621020,500.0,BAO_0000219,
4988,80852,,,1,,N,,,A-431,Intermediate,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,1,,13678,CHEMBL621021,500.0,BAO_0000219,
4989,9,,,8,,H,,,A-431,Expert,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,1,,14171,CHEMBL621022,500.0,BAO_0000219,
4990,80852,,,1,,N,,,A-431,Expert,Tested for antiproliferative activity against human A431 cells,F,1,,6333,CHEMBL621023,500.0,BAO_0000219,
4991,9,,,9,,D,,,A-431,Expert,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,1,,2356,CHEMBL621024,500.0,BAO_0000219,
4992,80852,,,1,,N,,,A-431,Expert,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,1,,15578,CHEMBL621025,500.0,BAO_0000219,
4993,80852,,,1,,N,,,A-431,Expert,Inhibition of A431 cell proliferation,F,1,,5126,CHEMBL621026,500.0,BAO_0000219,
4994,80852,,,1,,N,,,A-431,Expert,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,1,,6844,CHEMBL621027,500.0,BAO_0000219,
4995,80852,,,1,,N,,,A-431,Expert,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,1,,6844,CHEMBL876397,500.0,BAO_0000219,
4996,80852,,,1,,N,,,A-431,Intermediate,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,1,,4925,CHEMBL883797,500.0,BAO_0000219,
4997,80852,,,1,,N,,,A-431,Intermediate,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,1,,4925,CHEMBL621028,500.0,BAO_0000219,
4998,80852,,,1,,N,,,A-431,Intermediate,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,1,,13978,CHEMBL621029,500.0,BAO_0000219,
4999,80852,,,1,,N,,,A-431,Intermediate,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,1,,16786,CHEMBL621030,500.0,BAO_0000219,
5000,9,,,8,,H,,,A-431,Expert,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,1,,13412,CHEMBL621147,500.0,BAO_0000219,
5001,80852,,,1,,N,,,A-431,Intermediate,In vivo antiproliferative activity against A431 cell line,F,1,,17824,CHEMBL621148,500.0,BAO_0000218,
5002,9,,,9,,D,,,A-431,Expert,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,1,,12751,CHEMBL621149,500.0,BAO_0000219,
5003,80852,,,1,,N,,,A-431,Expert,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,1,,12380,CHEMBL621150,500.0,BAO_0000219,
5004,9,,,9,,D,,,A-431,Expert,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,1,,4959,CHEMBL621151,500.0,BAO_0000219,
5005,80852,,,1,,N,,,A-431,Intermediate,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,1,,6333,CHEMBL621152,500.0,BAO_0000219,
5006,80852,,,1,,N,,,A-431,Intermediate,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,1,,6333,CHEMBL621153,500.0,BAO_0000219,
5007,80852,,,1,,N,,,A-431,Intermediate,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,1,,6333,CHEMBL884000,500.0,BAO_0000219,
5008,9,,,9,,D,,,,Expert,Inhibition of EGFR overexpressing A431 cell proliferation,F,1,,5296,CHEMBL621154,,BAO_0000019,
5009,80852,,,1,,N,,,A-431,Expert,Inhibition of A431 cell proliferation,F,1,,12624,CHEMBL621155,500.0,BAO_0000219,
5010,9,,,9,,D,,,A-431,Expert,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,1,,14926,CHEMBL621156,500.0,BAO_0000219,
5011,9,,,9,,D,,,A-431,Expert,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,1,,14926,CHEMBL621157,500.0,BAO_0000219,
5012,9,,,8,,H,,,A-431,Expert,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,1,,14926,CHEMBL621158,500.0,BAO_0000219,
5013,80852,,,1,,N,,,A-431,Intermediate,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,1,,15144,CHEMBL621159,500.0,BAO_0000219,
5014,80852,,,1,,N,,,A-431,Intermediate,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,1,,15144,CHEMBL621160,500.0,BAO_0000219,
5015,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,1,,5245,CHEMBL621161,500.0,BAO_0000219,
5016,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,1,,5245,CHEMBL621162,500.0,BAO_0000219,
5017,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,1,,5245,CHEMBL621163,500.0,BAO_0000219,
5018,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,1,,5245,CHEMBL621164,500.0,BAO_0000219,
5019,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,1,,5245,CHEMBL621165,500.0,BAO_0000219,
5020,22224,,,0,,U,,,,Autocuration,Half-life period in cynomolgus monkey,A,1,,5922,CHEMBL619159,,BAO_0000019,
5021,22224,,In vitro,0,,U,,Plasma,,Autocuration,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,1,,1116,CHEMBL619160,,BAO_0000366,1969.0
5022,22224,,In vivo,0,,U,,,,Autocuration,Longer half-life in monkey (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL619161,,BAO_0000218,
5023,22224,,,0,,U,,Plasma,,Autocuration,Plasma half life in monkey,A,1,,993,CHEMBL619162,,BAO_0000366,1969.0
5024,22224,,,0,,U,,Plasma,,Autocuration,Plasma half-life in rhesus monkey,A,1,,4514,CHEMBL619163,,BAO_0000366,1969.0
5025,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL619164,,BAO_0000218,1969.0
5026,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,1,,5334,CHEMBL619320,,BAO_0000218,1969.0
5027,22224,,In vivo,0,,U,,,,Autocuration,Tested for half life upon iv administration to african green monkey,A,1,,4578,CHEMBL619321,,BAO_0000218,
5028,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL873336,,BAO_0000218,
5029,22224,,In vivo,0,,U,,,,Autocuration,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,1,,5355,CHEMBL619322,,BAO_0000218,
5030,22224,,In vivo,0,,U,,,,Autocuration,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,1,,5355,CHEMBL619323,,BAO_0000218,
5031,22224,,In vivo,0,,U,,,,Autocuration,The time for peak concentration value after oral administration in cynomolgus monkeys,A,1,,5355,CHEMBL619324,,BAO_0000218,
5032,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,1,,11271,CHEMBL619325,,BAO_0000019,
5033,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,1,,11271,CHEMBL876411,,BAO_0000019,
5034,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,1,,11271,CHEMBL619326,,BAO_0000019,
5035,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,1,,11271,CHEMBL619327,,BAO_0000019,
5036,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,1,,11271,CHEMBL619328,,BAO_0000019,
5037,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,1,,11271,CHEMBL619329,,BAO_0000019,
5038,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,1,,11271,CHEMBL619330,,BAO_0000019,
5039,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,1,,11271,CHEMBL619331,,BAO_0000019,
5040,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,1,,11271,CHEMBL619332,,BAO_0000019,
5041,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,1,,11271,CHEMBL619333,,BAO_0000019,
5042,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,1,,11271,CHEMBL619334,,BAO_0000019,
5043,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,1,,11271,CHEMBL619335,,BAO_0000019,
5044,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,1,,11271,CHEMBL619336,,BAO_0000019,
5045,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,1,,11271,CHEMBL619337,,BAO_0000019,
5046,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,1,,11271,CHEMBL619338,,BAO_0000019,
5047,22224,,,0,,U,,,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,1,,11271,CHEMBL619339,,BAO_0000019,
5048,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,1,,5809,CHEMBL619340,,BAO_0000218,
5049,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL873496,,BAO_0000218,1969.0
5050,50597,,,1,,N,,Plasma,,Intermediate,AUC value in rat after IV administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619341,,BAO_0000218,1969.0
5051,50597,,,1,,N,,Plasma,,Intermediate,AUC value in rat after oral administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619342,,BAO_0000218,1969.0
5052,50597,,In vivo,1,,N,,,,Intermediate,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619343,,BAO_0000218,
5053,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619344,,BAO_0000218,
5054,50597,,In vivo,1,,N,,,,Intermediate,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619345,,BAO_0000218,
5055,50597,,,1,,N,,,,Intermediate,Vc value in rat after IV administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619346,,BAO_0000218,
5056,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after IV administration at a dose of 10 mg/kg,A,1,,3546,CHEMBL619347,,BAO_0000218,
5057,22224,,,0,,U,,,,Autocuration,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,1,,10625,CHEMBL619348,,BAO_0000019,
5058,22224,,,0,,U,,,,Autocuration,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,1,,10625,CHEMBL619349,,BAO_0000019,
5059,22224,,,0,,U,,,,Autocuration,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,1,,10625,CHEMBL619350,,BAO_0000019,
5060,22224,,,0,,U,,,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,1,,10625,CHEMBL619351,,BAO_0000019,
5061,22224,,,0,,U,,,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,1,,10625,CHEMBL875953,,BAO_0000019,
5062,22224,,,0,,U,,,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,1,,10625,CHEMBL621716,,BAO_0000019,
5063,22224,,,0,,U,,,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,1,,10625,CHEMBL621717,,BAO_0000019,
5064,22224,,,0,,U,,,,Autocuration,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,1,,10625,CHEMBL621718,,BAO_0000019,
5065,22224,,,0,,U,,,,Autocuration,Area under curve after 1 mpk peroral administration to beagles,A,1,,3510,CHEMBL621719,,BAO_0000019,
5066,22224,,,0,,U,,,,Autocuration,Area under curve after 2 mpk peroral administration to beagles,A,1,,3510,CHEMBL621720,,BAO_0000019,
5067,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after 1 mpk peroral administration to beagles,A,1,,3510,CHEMBL621721,,BAO_0000218,
5068,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,1,,7766,CHEMBL621722,,BAO_0000019,1088.0
5069,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,1,,7766,CHEMBL621723,,BAO_0000019,1088.0
5070,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,1,,7766,CHEMBL621724,,BAO_0000019,1088.0
5071,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,1,,7766,CHEMBL623443,,BAO_0000019,1088.0
5072,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,1,,7766,CHEMBL623444,,BAO_0000019,1088.0
5073,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,1,,7766,CHEMBL623445,,BAO_0000019,1088.0
5074,22224,,,0,,U,,Urine,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,1,,7766,CHEMBL623446,,BAO_0000019,1088.0
5075,22224,,,0,,U,Microsomes,Liver,,Autocuration,Metabolic stability observed at 30 min after administration in human liver microsomes,A,1,,16643,CHEMBL623447,,BAO_0000251,2107.0
5076,22224,,,0,,U,,,,Autocuration,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,1,,6852,CHEMBL623448,,BAO_0000019,
5077,22224,,,0,,U,,,,Autocuration,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,1,,6852,CHEMBL623449,,BAO_0000019,
5078,22224,,,0,,U,,,,Autocuration,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,1,,6852,CHEMBL623450,,BAO_0000019,
5079,22224,,,0,,U,Microsomes,Liver,,Autocuration,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,1,,6567,CHEMBL623451,,BAO_0000251,2107.0
5080,22224,,,0,,U,,,,Autocuration,Metabolic stability (% remaining at 30 mins) in human S9.,A,1,,6570,CHEMBL623452,,BAO_0000019,
5081,22224,,,0,,U,,,,Autocuration,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,1,,6570,CHEMBL623453,,BAO_0000019,
5082,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,1,,5237,CHEMBL623454,,BAO_0000251,2107.0
5083,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,1,,5237,CHEMBL623455,,BAO_0000251,2107.0
5084,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,1,,5237,CHEMBL624371,,BAO_0000251,2107.0
5085,22224,,,0,,U,,,,Autocuration,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,1,,5202,CHEMBL624372,,BAO_0000218,
5086,22224,,,0,,U,,,,Autocuration,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,1,,5481,CHEMBL624373,,BAO_0000019,
5087,22224,,,0,,U,,,,Autocuration,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,1,,5481,CHEMBL624374,,BAO_0000019,
5088,22224,,,0,,U,,,,Autocuration,The percent remaining in human plasma after 30 min was determined,A,1,,3956,CHEMBL624556,,BAO_0000019,
5089,22224,,,0,,U,,Plasma,,Autocuration,Conversion rate of the prodrug in human plasma,A,1,,5074,CHEMBL624557,,BAO_0000366,1969.0
5090,22224,,,0,,U,,Plasma,,Autocuration,Conversion rate of the prodrug in human plasma; ND means no data,A,1,,5074,CHEMBL624558,,BAO_0000366,1969.0
5091,22224,,,0,,U,,Blood,,Autocuration,Half life of compound was determined in human blood,A,1,,4727,CHEMBL624559,,BAO_0000221,178.0
5092,22224,,,0,,U,,,,Autocuration,Half life of compound was determined in man with once daily dosing,A,1,,5965,CHEMBL624560,,BAO_0000019,
5093,22224,,In vitro,0,,U,Microsomes,,,Autocuration,Half life in human microsomes,A,1,,5732,CHEMBL624561,,BAO_0000251,
5094,22224,,,0,,U,,Plasma,,Autocuration,Half life in human plasma,A,1,,5819,CHEMBL624562,,BAO_0000366,1969.0
5095,22224,,,0,,U,,Plasma,,Autocuration,Half life in human plasma; Not detected,A,1,,5819,CHEMBL624563,,BAO_0000366,1969.0
5096,22224,,In vivo,0,,U,,,,Autocuration,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,1,,1916,CHEMBL624564,,BAO_0000218,
5097,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,1,,6597,CHEMBL624565,,BAO_0000251,2107.0
5098,22224,,,0,,U,,Plasma,,Autocuration,Half-life in human plasma,A,1,,5229,CHEMBL875152,,BAO_0000366,1969.0
5099,22224,,,0,,U,,Plasma,,Autocuration,Half-life of the parent prodrug in plasma,A,1,,5229,CHEMBL624566,,BAO_0000366,1969.0
5100,22224,,In vitro,0,,U,,Plasma,,Autocuration,In vitro half life in human plasma was determined,A,1,,2192,CHEMBL873805,,BAO_0000366,1969.0
5101,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,The compound was tested In Vitro for half life in human liver microsomes.,A,1,,3032,CHEMBL624567,,BAO_0000251,2107.0
5102,22224,,In vivo,0,,U,,,,Autocuration,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,1,,1916,CHEMBL624568,,BAO_0000218,
5103,22224,,In vivo,0,,U,,,,Autocuration,Observed volume of distribution,A,1,,17716,CHEMBL624569,,BAO_0000218,
5104,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in human,A,1,,15778,CHEMBL624570,,BAO_0000218,
5105,22224,,,0,,U,,,,Autocuration,Tested for human plasma protein binding of the compound,A,1,,17313,CHEMBL624571,,BAO_0000019,
5106,22224,,,0,,U,,,,Autocuration,"First order rate constant, k was determined in human plasma",A,1,,4231,CHEMBL624572,,BAO_0000019,
5107,22224,,,0,,U,,,,Autocuration,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,1,,4755,CHEMBL624573,,BAO_0000019,
5108,22224,,,0,,U,,,,Autocuration,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,1,,4755,CHEMBL875153,,BAO_0000019,
5109,22224,,,0,,U,Microsomes,Liver,,Autocuration,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,1,,16907,CHEMBL624574,,BAO_0000251,2107.0
5110,22224,,,0,,U,,,,Autocuration,The compound was tested for the plasma binding in human,A,1,,10839,CHEMBL624575,,BAO_0000019,
5111,22224,,,0,,U,,,,Autocuration,Plasma protein binding (human),A,1,,10839,CHEMBL624576,,BAO_0000019,
5112,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Compound was evaluated for half-life in human liver microsomes,A,1,,3199,CHEMBL624577,,BAO_0000251,2107.0
5113,22224,,In vitro,0,,U,,Blood,,Autocuration,Half life measured in vitro for its stability in human blood,A,1,,1345,CHEMBL624578,,BAO_0000221,178.0
5114,22224,,,0,,U,,Serum,,Autocuration,Half life in human serum,A,1,,4297,CHEMBL622796,,BAO_0000019,1977.0
5115,22224,,,0,,U,,Serum,,Autocuration,Half life in human serum; ND=not determined,A,1,,4297,CHEMBL622797,,BAO_0000019,1977.0
5116,22224,,,0,,U,,,,Autocuration,Half life were determined in CEM-SS cell extract in decomposition step 1,A,1,,4297,CHEMBL622798,,BAO_0000019,
5117,22224,,,0,,U,,,,Autocuration,Half life were determined in CEM-SS cell extract in decomposition step 2,A,1,,4297,CHEMBL622799,,BAO_0000019,
5118,22224,,,0,,U,,Plasma,,Autocuration,Half life of the in human plasma,A,1,,4231,CHEMBL622800,,BAO_0000366,1969.0
5119,22224,,In vitro,0,,U,S9,,,Autocuration,Half life period in human hepatic S9 fraction was determined,A,1,,5633,CHEMBL622801,,BAO_0000220,
5120,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Half life period in human liver microsome was determined,A,1,,5633,CHEMBL622802,,BAO_0000251,2107.0
5121,22224,,,0,,U,,,,Autocuration,Half life period was determined; 6-7,A,1,,17791,CHEMBL622803,,BAO_0000019,
5122,22224,,,0,,U,,,,Autocuration,Half life period was evaluated in human,A,1,,17791,CHEMBL875154,,BAO_0000019,
5123,22224,,,0,,U,,Plasma,,Autocuration,Half life time in human plasma,A,1,,3160,CHEMBL622804,,BAO_0000366,1969.0
5124,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622805,,BAO_0000218,955.0
5125,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622611,,BAO_0000218,948.0
5126,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622612,,BAO_0000218,948.0
5127,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL875160,,BAO_0000218,2113.0
5128,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,1,,16438,CHEMBL622613,,BAO_0000218,2113.0
5129,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622614,,BAO_0000218,2113.0
5130,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622615,,BAO_0000218,2107.0
5131,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,1,,16438,CHEMBL622616,,BAO_0000218,2107.0
5132,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622617,,BAO_0000218,2107.0
5133,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,1,,16438,CHEMBL622618,,BAO_0000218,2106.0
5134,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,1,,16438,CHEMBL622619,,BAO_0000218,2106.0
5135,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622620,,BAO_0000218,2106.0
5136,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622621,,BAO_0000218,955.0
5137,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of compound (oxidized form) in blood tissue,A,1,,16438,CHEMBL622622,,BAO_0000218,178.0
5138,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622623,,BAO_0000218,178.0
5139,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL622624,,BAO_0000218,178.0
5140,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622625,,BAO_0000218,178.0
5141,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622626,,BAO_0000218,178.0
5142,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL622627,,BAO_0000218,178.0
5143,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of compound (oxidized form) in brain tissue of mice,A,1,,16438,CHEMBL622628,,BAO_0000218,955.0
5144,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622629,,BAO_0000218,955.0
5145,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622630,,BAO_0000218,955.0
5146,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622631,,BAO_0000218,955.0
5147,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL622632,,BAO_0000218,955.0
5148,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL622633,,BAO_0000218,955.0
5149,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of compound (oxidized form) in heart tissue of mice,A,1,,16438,CHEMBL622634,,BAO_0000218,948.0
5150,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL622635,,BAO_0000218,948.0
5151,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL875161,,BAO_0000218,948.0
5152,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622636,,BAO_0000218,948.0
5153,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL623335,,BAO_0000218,948.0
5154,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL623336,,BAO_0000218,948.0
5155,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL623337,,BAO_0000218,2113.0
5156,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL623338,,BAO_0000218,2113.0
5157,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL623339,,BAO_0000218,2113.0
5158,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL623524,,BAO_0000218,2113.0
5159,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL623525,,BAO_0000218,2113.0
5160,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of compound (oxidized form) in liver tissue,A,1,,16438,CHEMBL623526,,BAO_0000218,2107.0
5161,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL623527,,BAO_0000218,2107.0
5162,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL623528,,BAO_0000218,2107.0
5163,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,1,,5245,CHEMBL624615,500.0,BAO_0000219,
5164,80852,,,1,,N,,,A-431,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,1,,5245,CHEMBL621672,500.0,BAO_0000219,
5165,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,1,,16289,CHEMBL621673,500.0,BAO_0000218,
5166,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,1,,16289,CHEMBL621674,500.0,BAO_0000218,
5167,9,,,9,,D,,,A-431,Expert,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,1,,16093,CHEMBL884002,500.0,BAO_0000219,
5168,80852,,,1,,N,,,A-431,Intermediate,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,1,,16825,CHEMBL621850,500.0,BAO_0000219,
5169,80852,,,1,,N,,,A-431,Intermediate,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,1,,4848,CHEMBL621851,500.0,BAO_0000219,
5170,9,,,9,,D,,,A-431,Expert,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,1,,14827,CHEMBL621852,500.0,BAO_0000219,
5171,9,,,9,,D,,,A-431,Expert,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,1,,14827,CHEMBL621853,500.0,BAO_0000219,
5172,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,1,,16289,CHEMBL621854,500.0,BAO_0000218,
5173,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,1,,16289,CHEMBL621855,500.0,BAO_0000218,
5174,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,1,,16289,CHEMBL623724,500.0,BAO_0000218,
5175,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,1,,16289,CHEMBL623725,500.0,BAO_0000218,
5176,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,1,,16289,CHEMBL623726,500.0,BAO_0000218,
5177,9,,,9,,D,,,A-431,Expert,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,1,,16289,CHEMBL623727,500.0,BAO_0000219,
5178,9,,,8,,H,,,A-431,Expert,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,1,,16289,CHEMBL623728,500.0,BAO_0000219,
5179,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,1,,16289,CHEMBL623729,500.0,BAO_0000218,
5180,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,1,,16289,CHEMBL623730,500.0,BAO_0000218,
5181,80852,,,1,,N,,,A-431,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,1,,16289,CHEMBL623731,500.0,BAO_0000218,
5182,80852,,,1,,N,,,A-431,Expert,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,1,,14555,CHEMBL623732,500.0,BAO_0000218,
5183,80852,,,1,,N,,,A-431,Expert,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,1,,14555,CHEMBL623733,500.0,BAO_0000218,
5184,80852,,,1,,N,,,A-431,Expert,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,1,,14555,CHEMBL623734,500.0,BAO_0000218,
5185,80852,,,1,,N,,,A-431,Expert,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,1,,14555,CHEMBL623735,500.0,BAO_0000218,
5186,80852,,,1,,N,,,A-431,Expert,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,1,,1937,CHEMBL623736,500.0,BAO_0000219,
5187,80852,,,1,,N,,,A-431,Intermediate,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,1,,13739,CHEMBL623737,500.0,BAO_0000219,
5188,80852,,,1,,N,,,A-431,Intermediate,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,1,,3558,CHEMBL623738,500.0,BAO_0000219,
5189,80852,,,1,,N,,,A-431,Intermediate,Dose giving a 50% decrease in the living cell number (A437 cells),F,1,,3558,CHEMBL875168,500.0,BAO_0000219,
5190,80682,,,1,,N,,,A549,Expert,In vitro inhibitory concentration against proliferation of A459 cell line.,F,1,,17686,CHEMBL623739,646.0,BAO_0000219,
5191,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,1,,5305,CHEMBL623740,646.0,BAO_0000219,
5192,80682,,,1,,N,,,A549,Intermediate,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,1,,3614,CHEMBL624424,646.0,BAO_0000219,
5193,80021,,,1,,N,,,A498,Intermediate,In vitro antitumor activity against renal A498 tumor cell lines,F,1,,17229,CHEMBL624425,624.0,BAO_0000219,
5194,80021,,,1,,N,,,A498,Intermediate,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,1,,15935,CHEMBL624426,624.0,BAO_0000219,
5195,80021,,,1,,N,,,A498,Intermediate,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,1,,15935,CHEMBL624427,624.0,BAO_0000219,
5196,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,1,,15560,CHEMBL624428,624.0,BAO_0000219,
5197,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,1,,13891,CHEMBL624429,624.0,BAO_0000219,
5198,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,1,,13891,CHEMBL624620,624.0,BAO_0000219,
5199,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity on kidney carcinoma (A-498) cell line,F,1,,13788,CHEMBL624621,624.0,BAO_0000219,
5200,80021,,,1,,N,,,A498,Intermediate,Compound was evaluated against Human cell line renal A498,F,1,,15403,CHEMBL624622,624.0,BAO_0000219,
5201,80021,,,1,,N,,,A498,Intermediate,Compound was tested for inhibition of A498 human renal cancer cell line,F,1,,1009,CHEMBL624623,624.0,BAO_0000219,
5202,80021,,,1,,N,,,A498,Intermediate,Growth inhibitory activity against A498 human cancer cell line,F,1,,1043,CHEMBL874365,624.0,BAO_0000219,
5203,80021,,,1,,N,,,A498,Intermediate,In vitro antitumor activity against human renal A498 cell line,F,1,,5858,CHEMBL624624,624.0,BAO_0000219,
5204,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxic activity against renal (A498) cell line,F,1,,5958,CHEMBL624625,624.0,BAO_0000219,
5205,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,1,,5506,CHEMBL624626,624.0,BAO_0000219,
5206,80021,,,1,,N,,,A498,Intermediate,Tested for cytostatic activity against renal A498 cell line,F,1,,12781,CHEMBL624627,624.0,BAO_0000219,
5207,80021,,,1,,N,,,A498,Intermediate,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,1,,14399,CHEMBL883157,624.0,BAO_0000219,
5208,80021,,,1,,N,,,A498,Expert,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,1,,5958,CHEMBL624628,624.0,BAO_0000219,
5209,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after 2 mpk peroral administration to beagles,A,1,,3510,CHEMBL624629,,BAO_0000218,
5210,22224,,In vivo,0,beagle,U,,,,Autocuration,Bioavailability,A,1,,3510,CHEMBL623551,,BAO_0000218,
5211,22224,,In vivo,0,beagle,U,,,,Autocuration,Bioavailability after 1 mpk peroral administration to beagles,A,1,,3510,CHEMBL623552,,BAO_0000218,
5212,22224,,In vivo,0,beagle,U,,,,Autocuration,Bioavailability after 2 mpk peroral administration to beagles,A,1,,3510,CHEMBL623553,,BAO_0000218,
5213,22224,,,0,,U,,,,Autocuration,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,1,,3085,CHEMBL623554,,BAO_0000019,
5214,22224,,,0,,U,,,,Autocuration,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,1,,3085,CHEMBL623555,,BAO_0000019,
5215,22224,,,0,,U,,,,Autocuration,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,1,,3085,CHEMBL623556,,BAO_0000019,
5216,22224,,,0,,U,,,,Autocuration,Solubility against bovine alpha-chymotrypsin,A,1,,9372,CHEMBL623557,,BAO_0000019,
5217,22224,,,0,,U,,,,Autocuration,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,1,,3085,CHEMBL623558,,BAO_0000019,
5218,22224,,,0,,U,,,,Autocuration,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,1,,3085,CHEMBL623559,,BAO_0000019,
5219,22224,,,0,,U,,Spleen,,Autocuration,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,1,,1469,CHEMBL623560,,BAO_0000221,2106.0
5220,22224,,,0,,U,,,,Autocuration,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,1,,4297,CHEMBL623561,,BAO_0000019,
5221,22224,,,0,,U,,,,Autocuration,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,1,,4297,CHEMBL623562,,BAO_0000019,
5222,22224,,,0,,U,,,,Autocuration,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,1,,17585,CHEMBL623563,,BAO_0000019,
5223,22224,,,0,,U,,Spleen,,Autocuration,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,1,,1336,CHEMBL623564,,BAO_0000221,2106.0
5224,22224,,,0,,U,,,,Autocuration,Half life in presence of 2 mg/mL BSA at pH 8.8,A,1,,3085,CHEMBL873806,,BAO_0000019,
5225,22224,,,0,,U,,,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,1,,2857,CHEMBL623565,,BAO_0000019,
5226,22224,,,0,,U,,,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,1,,2857,CHEMBL623566,,BAO_0000019,
5227,22224,,,0,,U,,,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,1,,2857,CHEMBL623567,,BAO_0000019,
5228,22224,,,0,,U,,,,Autocuration,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,1,,1540,CHEMBL623568,,BAO_0000019,
5229,50588,,,1,,N,,Plasma,,Intermediate,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,1,,6316,CHEMBL623569,,BAO_0000218,1969.0
5230,50588,,,1,,N,,Plasma,,Intermediate,AUC after administration at 100 mg/kg/day in dogs,A,1,,17594,CHEMBL623570,,BAO_0000218,1969.0
5231,50588,,,1,,N,,Plasma,,Intermediate,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,1,,4953,CHEMBL624254,,BAO_0000218,1969.0
5232,50588,,,1,,N,,Plasma,,Intermediate,AUC value after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL624255,,BAO_0000218,1969.0
5233,50588,,,1,,N,,Plasma,,Intermediate,AUC value after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL624256,,BAO_0000218,1969.0
5234,50588,,,1,,N,,Plasma,,Intermediate,AUC value after administration of 4 mg/Kg oral dose in dog,A,1,,2959,CHEMBL624257,,BAO_0000218,1969.0
5235,50588,,,1,,N,,Plasma,,Intermediate,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,1,,17594,CHEMBL624258,,BAO_0000218,1969.0
5236,50588,,,1,,N,,,,Intermediate,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,1,,5356,CHEMBL875277,,BAO_0000218,
5237,50588,,,1,,N,,,,Intermediate,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,1,,16807,CHEMBL622667,,BAO_0000218,
5238,50588,,,1,,N,,,,Intermediate,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,1,,4527,CHEMBL622668,,BAO_0000218,
5239,50588,,,1,,N,,,,Intermediate,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,1,,4527,CHEMBL622669,,BAO_0000218,
5240,50588,,,1,,N,,,,Intermediate,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,1,,15660,CHEMBL622670,,BAO_0000218,
5241,50588,,,1,,N,,,,Intermediate,Area under curve determined in dogs after oral administration of 10 mg/kg,A,1,,15660,CHEMBL622671,,BAO_0000218,
5242,50588,,,1,,N,,,,Intermediate,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,1,,5802,CHEMBL622672,,BAO_0000218,
5243,50588,,,1,,N,,,,Expert,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL622673,,BAO_0000218,
5244,50588,,,1,,N,,,,Expert,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL622674,,BAO_0000218,
5245,50588,,,1,,N,,,,Intermediate,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,1,,5944,CHEMBL622675,,BAO_0000218,
5246,50588,,,1,,N,,,,Intermediate,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,1,,5944,CHEMBL622676,,BAO_0000218,
5247,50588,,,1,,N,,,,Intermediate,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,1,,5944,CHEMBL622677,,BAO_0000218,
5248,50588,,,1,,N,,,,Intermediate,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,1,,5944,CHEMBL622678,,BAO_0000218,
5249,50588,,,1,,N,,,,Intermediate,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,1,,4186,CHEMBL622679,,BAO_0000218,
5250,50588,,,1,,N,,,,Intermediate,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,1,,5007,CHEMBL622680,,BAO_0000218,
5251,50588,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 10 mpk in dog,A,1,,5668,CHEMBL622681,,BAO_0000218,
5252,50588,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 5 mpk in dog,A,1,,5668,CHEMBL875278,,BAO_0000218,
5253,50588,,,1,,N,,,,Intermediate,Area under curve was determined,A,1,,5006,CHEMBL622682,,BAO_0000218,
5254,50588,,,1,,N,,,,Intermediate,Area under curve in dogs,A,1,,5006,CHEMBL622683,,BAO_0000218,
5255,50588,,,1,,N,,,,Intermediate,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,1,,3771,CHEMBL622684,,BAO_0000218,
5256,50588,,,1,,N,,,,Intermediate,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,1,,3771,CHEMBL622685,,BAO_0000218,
5257,50588,,,1,,N,,,,Intermediate,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,1,,3771,CHEMBL622686,,BAO_0000218,
5258,50588,,,1,,N,,,,Intermediate,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL618344,,BAO_0000218,
5259,50588,,,1,,N,,,,Intermediate,Area under curve value in dog at a dose of 5 mg/kg,A,1,,5302,CHEMBL875582,,BAO_0000218,
5260,50588,,,1,,N,,,,Intermediate,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,1,,5600,CHEMBL618345,,BAO_0000218,
5261,50588,,,1,,N,,,,Intermediate,Area under curve was determined after 0.3 mg/kg po administration in dog,A,1,,5600,CHEMBL618346,,BAO_0000218,
5262,50588,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL618347,,BAO_0000218,
5263,50588,,,1,,N,,,,Intermediate,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,1,,4368,CHEMBL618348,,BAO_0000218,
5264,22224,,,0,,U,,,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,1,,5318,CHEMBL618349,,BAO_0000019,
5265,22224,,,0,,U,,,,Autocuration,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,1,,5318,CHEMBL618350,,BAO_0000019,
5266,22224,,,0,,U,,,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,1,,5318,CHEMBL618351,,BAO_0000019,
5267,22224,,,0,,U,,,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,1,,5318,CHEMBL618352,,BAO_0000019,
5268,22224,,,0,,U,,Blood,,Autocuration,Time taken to reduce 50% of the concentration of compound in blood plasma,A,1,,14518,CHEMBL873494,,BAO_0000221,178.0
5269,22224,,,0,,U,,Plasma,,Autocuration,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,1,,2209,CHEMBL618353,,BAO_0000366,1969.0
5270,22224,,,0,,U,,Plasma,,Autocuration,Half life in human plasma,A,1,,6787,CHEMBL618354,,BAO_0000366,1969.0
5271,22224,,,0,,U,,Plasma,,Autocuration,Half life in human plasma was reported,A,1,,4898,CHEMBL875583,,BAO_0000366,1969.0
5272,22224,,,0,,U,,Serum,,Autocuration,Half life in human serum,A,1,,6072,CHEMBL618355,,BAO_0000019,1977.0
5273,22224,,,0,,U,,Plasma,,Autocuration,Half life upon exposure to human plasma,A,1,,16907,CHEMBL618356,,BAO_0000366,1969.0
5274,22224,,In vitro,0,,U,Microsomes,,,Autocuration,t1/2 in human microsomes,A,1,,5656,CHEMBL618357,,BAO_0000251,
5275,22224,,,0,,U,,Plasma,,Autocuration,Half life period in 80% human plasma at 37 degree Centigrade,A,1,,4755,CHEMBL618358,,BAO_0000366,1969.0
5276,22224,,,0,,U,,Zone of skin,,Autocuration,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,1,,17503,CHEMBL618359,,BAO_0000221,14.0
5277,22224,,In vitro,0,,U,,Plasma,,Autocuration,Half-life measured in in vitro Cathepsin B assay in human plasma,A,1,,12357,CHEMBL618360,,BAO_0000366,1969.0
5278,22224,,,0,,U,,,,Autocuration,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,1,,3076,CHEMBL618361,,BAO_0000019,
5279,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,1,,6410,CHEMBL618362,,BAO_0000251,2107.0
5280,22224,,,0,,U,,Plasma,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,1,,3741,CHEMBL618363,,BAO_0000366,1969.0
5281,22224,,,0,,U,,Plasma,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,1,,3741,CHEMBL618364,,BAO_0000366,1969.0
5282,22224,,,0,,U,,Plasma,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,1,,3741,CHEMBL875584,,BAO_0000366,1969.0
5283,22224,,,0,,U,,,,Autocuration,Half-life in the CEM cell extracts,A,1,,1540,CHEMBL618365,,BAO_0000019,
5284,22224,,,0,,U,,Plasma,,Autocuration,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,1,,2905,CHEMBL873495,,BAO_0000366,1969.0
5285,22224,,,0,,U,,Plasma,,Autocuration,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,1,,2905,CHEMBL618366,,BAO_0000366,1969.0
5286,22224,,,0,,U,,,,Autocuration,Half-life was determined,A,1,,5523,CHEMBL618367,,BAO_0000019,
5287,22224,,,0,,U,,Blood,,Autocuration,Half-life (human blood stability),A,1,,1499,CHEMBL618368,,BAO_0000221,178.0
5288,22224,,,0,,U,,Blood,,Autocuration,Half-life (human blood stability); no data,A,1,,1499,CHEMBL618369,,BAO_0000221,178.0
5289,22224,,,0,,U,,Plasma,,Autocuration,Half-life in human plasma,A,1,,17065,CHEMBL618370,,BAO_0000366,1969.0
5290,22224,,,0,,U,,,,Autocuration,CYP3A4 metabolism half-life (t1/2),A,1,,6861,CHEMBL618371,,BAO_0000019,
5291,22224,,,0,,U,,Blood,,Autocuration,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,1,,1499,CHEMBL618372,,BAO_0000221,178.0
5292,22224,,In vitro,0,,U,,Plasma,,Autocuration,In vitro half life in human plasma,A,1,,530,CHEMBL618373,,BAO_0000366,1969.0
5293,22224,,In vitro,0,,U,,Plasma,,Autocuration,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,1,,1116,CHEMBL618374,,BAO_0000366,1969.0
5294,22224,,In vitro,0,,U,,Plasma,,Autocuration,In vitro hydrolysis in human plasma,A,1,,6695,CHEMBL618375,,BAO_0000366,1969.0
5295,22224,,In vitro,0,,U,,Plasma,,Autocuration,In vitro hydrolysis in human plasma; no data,A,1,,6695,CHEMBL618376,,BAO_0000366,1969.0
5296,22224,,In vitro,0,,U,Microsomes,Liver,,Autocuration,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,1,,10,CHEMBL618377,,BAO_0000251,2107.0
5297,22224,,,0,,U,,Plasma,,Autocuration,Plasma half life in human,A,1,,993,CHEMBL618378,,BAO_0000366,1969.0
5298,22224,,,0,,U,,Plasma,,Autocuration,Stability after incubation with human plasma (at 37 degree C),A,1,,15429,CHEMBL618379,,BAO_0000366,1969.0
5299,22224,,,0,,U,,Plasma,,Autocuration,T1/2 was evaluated in human plasma,A,1,,1675,CHEMBL618380,,BAO_0000366,1969.0
5300,22224,,,0,,U,,Plasma,,Autocuration,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,1,,2209,CHEMBL618381,,BAO_0000366,1969.0
5301,22224,,,0,,U,,Plasma,,Autocuration,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,1,,2209,CHEMBL618382,,BAO_0000366,1969.0
5302,22224,,,0,,U,,,,Autocuration,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,1,,5318,CHEMBL618383,,BAO_0000019,
5303,22224,,In vitro,0,,U,,,,Autocuration,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,1,,2412,CHEMBL618384,,BAO_0000019,
5304,22224,,In vitro,0,,U,,,,Autocuration,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,1,,2412,CHEMBL618385,,BAO_0000019,
5305,22224,,,0,,U,,Plasma,,Autocuration,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,1,,2906,CHEMBL619099,,BAO_0000366,1969.0
5306,22224,,,0,,U,,Plasma,,Autocuration,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,1,,2906,CHEMBL619100,,BAO_0000366,1969.0
5307,22224,,,0,,U,,,,Autocuration,Time taken for 50% to be consumed by serum PON1 was determined,A,1,,5495,CHEMBL619101,,BAO_0000019,
5308,22224,,,0,,U,,,,Autocuration,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,1,,5495,CHEMBL619102,,BAO_0000019,
5309,22224,,,0,,U,Microsomes,Liver,,Autocuration,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,1,,4397,CHEMBL619103,,BAO_0000251,2107.0
5310,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL619268,,BAO_0000218,
5311,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL619269,,BAO_0000218,
5312,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL619270,,BAO_0000218,
5313,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL619271,,BAO_0000218,
5314,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL875585,,BAO_0000218,
5315,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,1,,2413,CHEMBL619272,,BAO_0000218,
5316,80640,,,1,,N,,,786-0,Intermediate,Compound tested for growth inhibition of renal cancer cell line 786-0,F,1,,6058,CHEMBL619273,391.0,BAO_0000219,
5317,80640,,,1,,N,,,786-0,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,1,,17708,CHEMBL619274,391.0,BAO_0000219,
5318,80640,,,1,,N,,,786-0,Expert,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,1,,14017,CHEMBL619275,391.0,BAO_0000219,
5319,80640,,,1,,N,,,786-0,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,1,,16818,CHEMBL619276,391.0,BAO_0000219,
5320,80640,,,1,,N,,,786-0,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,1,,16818,CHEMBL619277,391.0,BAO_0000219,
5321,80640,,,1,,N,,,786-0,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,1,,16818,CHEMBL619278,391.0,BAO_0000219,
5322,80640,,,1,,N,,,786-0,Intermediate,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,1,,11970,CHEMBL619279,391.0,BAO_0000219,
5323,80640,,,1,,N,,,786-0,Intermediate,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,1,,12400,CHEMBL858458,391.0,BAO_0000219,
5324,80640,,,1,,N,,,786-0,Expert,Cytotoxic effect on renal cancer line 786-0,F,1,,12888,CHEMBL619280,391.0,BAO_0000219,
5325,80640,,,1,,N,,,786-0,Intermediate,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,1,,15300,CHEMBL619281,391.0,BAO_0000219,
5326,80640,,,1,,N,,,786-0,Intermediate,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL619282,391.0,BAO_0000219,
5327,80640,,,1,,N,,,786-0,Intermediate,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,1,,15895,CHEMBL619283,391.0,BAO_0000219,
5328,80640,,,1,,N,,,786-0,Intermediate,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,1,,17376,CHEMBL619284,391.0,BAO_0000219,
5329,80640,,,1,,N,,,786-0,Intermediate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,1,,14882,CHEMBL619285,391.0,BAO_0000219,
5330,80640,,,1,,N,,,786-0,Intermediate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,1,,14882,CHEMBL619286,391.0,BAO_0000219,
5331,80640,,,1,,N,,,786-0,Intermediate,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,1,,15176,CHEMBL619287,391.0,BAO_0000219,
5332,80640,,,1,,N,,,786-0,Intermediate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,1,,12696,CHEMBL857455,391.0,BAO_0000219,
5333,80640,,,1,,N,,,786-0,Intermediate,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,1,,2496,CHEMBL883801,391.0,BAO_0000219,
5334,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,1,,11831,CHEMBL619288,972.0,BAO_0000219,
5335,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,1,,11831,CHEMBL619289,972.0,BAO_0000219,
5336,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,1,,11831,CHEMBL619290,972.0,BAO_0000219,
5337,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,1,,11831,CHEMBL619291,972.0,BAO_0000219,
5338,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,1,,11831,CHEMBL619292,972.0,BAO_0000219,
5339,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,1,,11831,CHEMBL619293,972.0,BAO_0000219,
5340,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,1,,11831,CHEMBL619294,972.0,BAO_0000219,
5341,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,1,,11831,CHEMBL619295,972.0,BAO_0000219,
5342,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,1,,11831,CHEMBL619296,972.0,BAO_0000219,
5343,80641,,,1,,N,,,791T cell line,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,1,,11831,CHEMBL619297,972.0,BAO_0000219,
5344,80640,,,1,,N,,,786-0,Intermediate,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,1,,12782,CHEMBL619298,391.0,BAO_0000219,
5345,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,1,,1229,CHEMBL619299,,BAO_0000019,
5346,80433,,,1,,N,,,RPMI-8226,Expert,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,1,,15313,CHEMBL619300,741.0,BAO_0000219,
5347,80433,,,1,,N,,,RPMI-8226,Expert,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,1,,15313,CHEMBL619301,741.0,BAO_0000219,
5348,80433,,,1,,N,,,RPMI-8226,Intermediate,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,1,,11544,CHEMBL619302,741.0,BAO_0000219,
5349,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,1,,9424,CHEMBL619303,741.0,BAO_0000219,
5350,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,1,,9424,CHEMBL619304,741.0,BAO_0000219,
5351,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL857706,741.0,BAO_0000219,
5352,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL619305,741.0,BAO_0000219,
5353,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL619306,741.0,BAO_0000219,
5354,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,1,,9424,CHEMBL619307,741.0,BAO_0000219,
5355,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,1,,9424,CHEMBL619308,741.0,BAO_0000219,
5356,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,1,,9424,CHEMBL619309,741.0,BAO_0000219,
5357,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL619310,741.0,BAO_0000219,
5358,80021,,,1,,N,,,A498,Intermediate,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL619311,624.0,BAO_0000219,
5359,80021,,,1,,N,,,A498,Intermediate,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,1,,15354,CHEMBL619312,624.0,BAO_0000219,
5360,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,1,,17445,CHEMBL619313,624.0,BAO_0000219,
5361,80021,,,1,,N,,,A498,Intermediate,In vitro inhibitory concentration against renal cancer cell line A498,F,1,,4337,CHEMBL619314,624.0,BAO_0000219,
5362,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity against A 498 tumor cell line,F,1,,15277,CHEMBL619959,624.0,BAO_0000219,
5363,80021,,,1,,N,,,A498,Intermediate,In vitro antitumor activity against A498 human cancer cell line,F,1,,4812,CHEMBL619960,624.0,BAO_0000219,
5364,80021,,,1,,N,,,A498,Intermediate,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,1,,4812,CHEMBL619961,624.0,BAO_0000219,
5365,80021,,,1,,N,,,A498,Intermediate,Inhibitory dose required against A498 human tumor cell lines,F,1,,4995,CHEMBL619962,624.0,BAO_0000219,
5366,80021,,,1,,N,,,A498,Intermediate,Anticancer activity against one renal cancer (A498 cell line),F,1,,5847,CHEMBL875586,624.0,BAO_0000219,
5367,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity against melanoma A498 cell line,F,1,,6557,CHEMBL619963,624.0,BAO_0000219,
5368,80021,,,1,,N,,,A498,Intermediate,Compound was tested for growth inhibitory activity against A498 cell line,F,1,,2597,CHEMBL619964,624.0,BAO_0000219,
5369,80021,,,1,,N,,,A498,Intermediate,Compound tested for growth inhibition of renal cancer cell line A498,F,1,,6058,CHEMBL620108,624.0,BAO_0000219,
5370,80021,,,1,,N,,,A498,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,1,,17708,CHEMBL620109,624.0,BAO_0000219,
5371,80021,,,1,,N,,,A498,Intermediate,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,1,,15176,CHEMBL620110,624.0,BAO_0000219,
5372,80021,,,1,,N,,,A498,Intermediate,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,1,,15300,CHEMBL620111,624.0,BAO_0000219,
5373,80021,,,1,,N,,,A498,Intermediate,Tested for cytotoxicity against A498 cell lines in renal cancer,F,1,,11970,CHEMBL620112,624.0,BAO_0000219,
5374,80021,,,1,,N,,,A498,Intermediate,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,1,,12400,CHEMBL620113,624.0,BAO_0000219,
5375,80021,,,1,,N,,,A498,Expert,Cytotoxic effect on renal cancer lines A498,F,1,,12888,CHEMBL620114,624.0,BAO_0000219,
5376,80021,,,1,,N,,,A498,Intermediate,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,1,,3030,CHEMBL620115,624.0,BAO_0000219,
5377,80021,,,1,,N,,,A498,Intermediate,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL620116,624.0,BAO_0000219,
5378,80021,,,1,,N,,,A498,Intermediate,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,1,,17376,CHEMBL620117,624.0,BAO_0000219,
5379,80021,,,1,,N,,,A498,Intermediate,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,1,,16558,CHEMBL620118,624.0,BAO_0000219,
5380,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,1,,5194,CHEMBL620119,624.0,BAO_0000219,
5381,80021,,,1,,N,,,A498,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL620120,624.0,BAO_0000219,
5382,80682,,,1,,N,,,A549,Expert,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,1,,16880,CHEMBL620121,646.0,BAO_0000219,
5383,80682,,,1,,N,,,A549,Intermediate,Antitumor activity against A549 human lung carcinoma cell line,F,1,,10196,CHEMBL620122,646.0,BAO_0000219,
5384,80682,,,1,,N,,,A549,Intermediate,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,1,,10196,CHEMBL620123,646.0,BAO_0000219,
5385,80682,,,1,,N,,,A549,Intermediate,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,1,,10196,CHEMBL620124,646.0,BAO_0000219,
5386,80682,,,1,,N,,,A549,Intermediate,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,1,,12083,CHEMBL620125,646.0,BAO_0000219,
5387,80682,,,1,,N,,,A549,Expert,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,1,,16464,CHEMBL620126,646.0,BAO_0000219,
5388,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL883027,646.0,BAO_0000219,
5389,80682,,,1,,N,,,A549,Expert,In vitro cytotoxic activity against human lung A549 cell line,F,1,,16470,CHEMBL620127,646.0,BAO_0000219,
5390,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,1,,16470,CHEMBL620128,646.0,BAO_0000219,
5391,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against human lung A549 cell line),F,1,,16470,CHEMBL620129,646.0,BAO_0000219,
5392,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,1,,16470,CHEMBL620130,646.0,BAO_0000219,
5393,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,1,,16582,CHEMBL620131,646.0,BAO_0000219,
5394,80682,,,1,,N,,,A549,Intermediate,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,1,,15935,CHEMBL620132,646.0,BAO_0000219,
5395,80682,,,1,,N,,,A549,Intermediate,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,1,,15935,CHEMBL620133,646.0,BAO_0000219,
5396,80682,,,1,,N,,,A549,Expert,Inhibition of A549 human lung carcinoma cell proliferation,F,1,,16597,CHEMBL620134,646.0,BAO_0000219,
5397,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line,F,1,,17376,CHEMBL620135,646.0,BAO_0000219,
5398,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,1,,16496,CHEMBL620136,646.0,BAO_0000219,
5399,80682,,,1,,N,,,A549,Intermediate,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,1,,16152,CHEMBL620137,646.0,BAO_0000219,
5400,80682,,,1,,N,,,A549,Intermediate,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,1,,16152,CHEMBL620268,646.0,BAO_0000219,
5401,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL620269,646.0,BAO_0000219,
5402,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,1,,2288,CHEMBL620270,646.0,BAO_0000219,
5403,80682,,,1,,N,,,A549,Intermediate,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,1,,17350,CHEMBL620271,646.0,BAO_0000219,
5404,80682,,,1,,N,,,A549,Expert,Inhibition of A549 cancer cell proliferation,F,1,,4090,CHEMBL620272,646.0,BAO_0000219,
5405,80682,,,1,,N,,,A549,Expert,Inhibition of A549 cancer cell proliferation (Not tested),F,1,,4090,CHEMBL620273,646.0,BAO_0000219,
5406,80682,,,1,,N,,,A549,Intermediate,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,1,,17350,CHEMBL620274,646.0,BAO_0000219,
5407,80682,,,1,,N,,,A549,Intermediate,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,1,,4197,CHEMBL620275,646.0,BAO_0000219,
5408,80682,,,1,,N,,,A549,Intermediate,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,1,,17072,CHEMBL620276,646.0,BAO_0000219,
5409,80682,,,1,,N,,,A549,Intermediate,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,1,,17072,CHEMBL620277,646.0,BAO_0000219,
5410,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against Renal cell lines A549 was determined,F,1,,5194,CHEMBL620278,646.0,BAO_0000219,
5411,50588,,,1,,N,,,,Intermediate,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,1,,4257,CHEMBL620279,,BAO_0000218,
5412,50588,,,1,,N,,,,Intermediate,Area under curve was determined in dog after oral administration at 1 mg/kg,A,1,,6123,CHEMBL620280,,BAO_0000218,
5413,50588,,,1,,N,,,,Intermediate,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL620281,,BAO_0000218,
5414,50588,,,1,,N,,,,Intermediate,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL620282,,BAO_0000218,
5415,50588,,,1,,N,,,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,1,,8833,CHEMBL621134,,BAO_0000218,
5416,50588,,,1,,N,,,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,1,,8833,CHEMBL621135,,BAO_0000218,
5417,50588,,,1,,N,,,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,1,,8833,CHEMBL621136,,BAO_0000218,
5418,50588,,,1,,N,,,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,1,,8833,CHEMBL621137,,BAO_0000218,
5419,50588,,,1,,N,,Plasma,,Intermediate,Area under plasma concentration time curve in dog upon oral administration,A,1,,17657,CHEMBL621138,,BAO_0000218,1969.0
5420,50588,,,1,,N,,Plasma,,Intermediate,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,1,,17650,CHEMBL875587,,BAO_0000218,1969.0
5421,50588,,,1,,N,,,,Intermediate,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,1,,1977,CHEMBL621139,,BAO_0000218,
5422,50588,,,1,,N,,,,Intermediate,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,1,,1977,CHEMBL621140,,BAO_0000218,
5423,50588,,,1,,N,,,,Intermediate,Area under the curve for the compound was obtained when tested in dog,A,1,,3132,CHEMBL621141,,BAO_0000218,
5424,50588,,,1,,N,,,,Intermediate,Area under the curve at a dose of 1 mg/kg,A,1,,5473,CHEMBL621142,,BAO_0000218,
5425,50588,,,1,,N,,,,Intermediate,Area under the curve at a dose of 1 mg/kg (oral),A,1,,5474,CHEMBL621143,,BAO_0000218,
5426,50588,,,1,,N,,,,Intermediate,Area under the curve at i.v. dose of 0.2 mg/kg,A,1,,5474,CHEMBL621144,,BAO_0000218,
5427,50588,,,1,,N,,,,Intermediate,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL621145,,BAO_0000218,
5428,50588,,,1,,N,,,,Intermediate,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL621146,,BAO_0000218,
5429,50588,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,1,,2652,CHEMBL622567,,BAO_0000218,
5430,50588,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,1,,2652,CHEMBL622568,,BAO_0000218,
5431,50588,,,1,,N,,,,Intermediate,Compound was evaluated for area under the curve in dog blood.,A,1,,2877,CHEMBL622569,,BAO_0000218,
5432,50588,,,1,,N,,,,Intermediate,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,1,,5444,CHEMBL622570,,BAO_0000218,
5433,50588,,,1,,N,,Plasma,,Intermediate,AUC in dog after oral dose (1 mg/kg),A,1,,5130,CHEMBL622571,,BAO_0000218,1969.0
5434,50588,,,1,,N,,,,Intermediate,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,1,,6265,CHEMBL622572,,BAO_0000218,
5435,50588,,,1,,N,,,,Intermediate,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,1,,4657,CHEMBL622573,,BAO_0000218,
5436,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,1,,16367,CHEMBL622574,,BAO_0000218,
5437,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC after oral administration to dogs,A,1,,16367,CHEMBL622575,,BAO_0000218,
5438,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,1,,9579,CHEMBL622576,,BAO_0000218,
5439,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,1,,9579,CHEMBL622577,,BAO_0000218,
5440,50588,,,1,,N,,,,Intermediate,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,1,,5983,CHEMBL622578,,BAO_0000218,
5441,50588,,,1,,N,,,,Intermediate,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,1,,6241,CHEMBL622579,,BAO_0000218,
5442,50588,,,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,1,,5313,CHEMBL622580,,BAO_0000218,
5443,50588,,,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,1,,5313,CHEMBL622581,,BAO_0000218,
5444,50588,,,1,,N,,,,Intermediate,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,1,,6642,CHEMBL622582,,BAO_0000218,
5445,50588,,,1,,N,,,,Intermediate,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,1,,6642,CHEMBL622583,,BAO_0000218,
5446,50588,,,1,,N,,,,Intermediate,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,1,,6641,CHEMBL622584,,BAO_0000218,
5447,50588,,,1,,N,,,,Intermediate,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,1,,6642,CHEMBL622585,,BAO_0000218,
5448,50588,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in dog; 90-100,A,1,,17791,CHEMBL622586,,BAO_0000218,
5449,50588,,,1,,N,,,,Intermediate,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,1,,17655,CHEMBL623281,,BAO_0000218,
5450,50588,,,1,,N,,,,Intermediate,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,1,,17655,CHEMBL623282,,BAO_0000218,
5451,50588,,,1,,N,,,,Intermediate,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,1,,6596,CHEMBL623283,,BAO_0000218,
5452,50588,,,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3880,CHEMBL623284,,BAO_0000218,
5453,50588,,,1,,N,,,,Intermediate,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,1,,16367,CHEMBL623285,,BAO_0000218,
5454,50588,,,1,,N,,Plasma,,Intermediate,Plasma protein binding towards dog plasma at 10 uM,A,1,,17409,CHEMBL623463,,BAO_0000218,1969.0
5455,50588,,,1,,N,,Plasma,,Intermediate,Plasma protein binding towards dog plasma at 100 uM,A,1,,17409,CHEMBL875952,,BAO_0000218,1969.0
5456,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 4 mg/kg p.o.),A,1,,2959,CHEMBL621705,,BAO_0000218,
5457,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,1,,13501,CHEMBL621706,,BAO_0000218,
5458,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,1,,4527,CHEMBL621707,,BAO_0000218,
5459,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dogs,A,1,,15145,CHEMBL621708,,BAO_0000218,
5460,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability,A,1,,4219,CHEMBL621709,,BAO_0000218,
5461,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),A,1,,17538,CHEMBL621710,,BAO_0000218,
5462,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,1,,17538,CHEMBL621711,,BAO_0000218,
5463,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,1,,1466,CHEMBL621712,,BAO_0000218,
5464,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,1,,17650,CHEMBL621713,,BAO_0000218,
5465,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,1,,3132,CHEMBL621714,,BAO_0000218,
5466,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL621715,,BAO_0000218,
5467,22224,,,0,,U,,Liver,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL623717,,BAO_0000218,2107.0
5468,22224,,,0,,U,,Liver,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,1,,2413,CHEMBL623718,,BAO_0000218,2107.0
5469,22224,,,0,,U,,Liver,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL623719,,BAO_0000218,2107.0
5470,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL623720,,BAO_0000218,
5471,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL623721,,BAO_0000218,
5472,22224,,,0,,U,,Muscle tissue,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL623722,,BAO_0000218,2385.0
5473,22224,,,0,,U,,Muscle tissue,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,1,,2413,CHEMBL623723,,BAO_0000218,2385.0
5474,22224,,,0,,U,,Muscle tissue,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL618543,,BAO_0000218,2385.0
5475,22224,,,0,,U,,Spleen,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL618544,,BAO_0000218,2106.0
5476,22224,,,0,,U,,Spleen,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL875155,,BAO_0000218,2106.0
5477,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,1,,2413,CHEMBL618545,,BAO_0000218,
5478,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,1,,2413,CHEMBL618546,,BAO_0000218,
5479,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL623529,,BAO_0000218,
5480,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,1,,2413,CHEMBL623530,,BAO_0000218,
5481,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,1,,2413,CHEMBL621764,,BAO_0000218,
5482,22224,,,0,,U,,,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,1,,17827,CHEMBL621765,,BAO_0000019,
5483,22224,,,0,,U,,Cerebellum,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,1,,17827,CHEMBL621766,,BAO_0000019,2037.0
5484,22224,,,0,,U,,Frontal cortex,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,1,,17827,CHEMBL621767,,BAO_0000019,1870.0
5485,22224,,,0,,U,,,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,1,,17827,CHEMBL621768,,BAO_0000019,
5486,22224,,,0,,U,,Striatum,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,1,,17827,CHEMBL621769,,BAO_0000019,2435.0
5487,22224,,,0,,U,,,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,1,,17827,CHEMBL621770,,BAO_0000019,
5488,22224,,,0,,U,,Cerebellum,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,1,,17827,CHEMBL621771,,BAO_0000019,2037.0
5489,22224,,,0,,U,,Frontal cortex,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,1,,17827,CHEMBL621772,,BAO_0000019,1870.0
5490,22224,,,0,,U,,,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,1,,17827,CHEMBL621773,,BAO_0000019,
5491,22224,,,0,,U,,Striatum,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,1,,17827,CHEMBL621774,,BAO_0000019,2435.0
5492,22224,,,0,,U,,,,Autocuration,Compound was evaluated for oral bioavailability in rats,A,1,,17791,CHEMBL621775,,BAO_0000218,
5493,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,1,,17667,CHEMBL621776,,BAO_0000218,1969.0
5494,22224,,,0,,U,,,,Autocuration,Half life period was evaluated in monkey,A,1,,17791,CHEMBL621777,,BAO_0000019,
5495,22224,,In vivo,0,,U,,,,Autocuration,Half-life in rhesus monkeys by intravenous administration of dose,A,1,,110,CHEMBL875162,,BAO_0000218,
5496,50594,,,1,,N,,Plasma,,Intermediate,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,1,,5781,CHEMBL621778,,BAO_0000218,1969.0
5497,50594,,,1,,N,,Plasma,,Intermediate,AUC after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL621779,,BAO_0000218,1969.0
5498,50594,,,1,,N,,Plasma,,Intermediate,AUC value was determined after oral administration,A,1,,17718,CHEMBL622479,,BAO_0000218,1969.0
5499,50594,,,1,,N,,,,Intermediate,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,1,,4573,CHEMBL622480,,BAO_0000218,
5500,50594,,,1,,N,,,,Intermediate,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,1,,3277,CHEMBL622481,,BAO_0000218,
5501,50594,,,1,,N,,,,Intermediate,Area under curve by ioral administration in mouse,A,1,,2862,CHEMBL622482,,BAO_0000218,
5502,50594,,,1,,N,,,,Intermediate,Area under curve by iv administration in mouse,A,1,,2862,CHEMBL622483,,BAO_0000218,
5503,50594,,,1,,N,,,,Intermediate,Area under curve at 0-8 hr in IRC mice after peroral administration,A,1,,5951,CHEMBL622484,,BAO_0000218,
5504,50594,,,1,,N,,,,Intermediate,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,1,,17729,CHEMBL622641,,BAO_0000218,
5505,50594,,,1,,N,,,,Intermediate,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,1,,17728,CHEMBL622642,,BAO_0000218,
5506,50594,,,1,,N,,,,Intermediate,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,1,,17728,CHEMBL622643,,BAO_0000218,
5507,50594,,,1,,N,,,,Intermediate,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,1,,17729,CHEMBL622644,,BAO_0000218,
5508,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,1,,9424,CHEMBL622645,741.0,BAO_0000219,
5509,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,1,,9424,CHEMBL622646,741.0,BAO_0000219,
5510,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL621238,741.0,BAO_0000219,
5511,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL621239,741.0,BAO_0000219,
5512,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL621240,741.0,BAO_0000219,
5513,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,1,,9424,CHEMBL621241,741.0,BAO_0000219,
5514,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,1,,9424,CHEMBL621242,741.0,BAO_0000219,
5515,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL620350,741.0,BAO_0000219,
5516,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,1,,9424,CHEMBL620351,741.0,BAO_0000219,
5517,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,1,,9424,CHEMBL620352,741.0,BAO_0000219,
5518,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL620353,741.0,BAO_0000219,
5519,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,1,,9424,CHEMBL620354,741.0,BAO_0000219,
5520,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL620355,741.0,BAO_0000219,
5521,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,1,,9424,CHEMBL620356,741.0,BAO_0000219,
5522,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,1,,9424,CHEMBL620357,741.0,BAO_0000219,
5523,80433,,,1,,N,,,RPMI-8226,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,1,,9424,CHEMBL620358,741.0,BAO_0000219,
5524,80433,,,1,,N,,,RPMI-8226,Expert,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,1,,9424,CHEMBL620359,741.0,BAO_0000219,
5525,80433,,,1,,N,,,RPMI-8226,Intermediate,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,1,,11544,CHEMBL620360,741.0,BAO_0000219,
5526,80433,,,1,,N,,,RPMI-8226,Intermediate,Cytotoxicity of compound against 8226/DOX1V cells,F,1,,17378,CHEMBL620361,741.0,BAO_0000219,
5527,80433,,,1,,N,,,RPMI-8226,Intermediate,Cytotoxicity of compound against 8226/S cells,F,1,,17378,CHEMBL620362,741.0,BAO_0000219,
5528,80433,,,1,,N,,,RPMI-8226,Intermediate,Inhibitory concentration against 8226 myeloma cancer cell line,F,1,,17079,CHEMBL620363,741.0,BAO_0000219,
5529,80433,,,1,,N,,,RPMI-8226,Intermediate,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,1,,17079,CHEMBL620364,741.0,BAO_0000219,
5530,80647,,,1,,N,,,833K,Intermediate,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,1,,13466,CHEMBL620365,854.0,BAO_0000219,
5531,80647,,,1,,N,,,833K,Intermediate,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,1,,13466,CHEMBL620366,854.0,BAO_0000219,
5532,80647,,,1,,N,,,833K,Expert,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,1,,2392,CHEMBL620367,854.0,BAO_0000219,
5533,80647,,,1,,N,,,833K,Intermediate,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,1,,2392,CHEMBL620368,854.0,BAO_0000219,
5534,22226,,,0,,U,,,,Autocuration,Inhibitory activity against caspase-1,B,1,,6608,CHEMBL620369,,BAO_0000019,
5535,45,,,8,,H,,,,Autocuration,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,1,,10199,CHEMBL620370,,BAO_0000357,
5536,80648,,,1,,N,,,8701-BC,Intermediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,1,,17749,CHEMBL620371,705.0,BAO_0000219,
5537,80648,,,1,,N,,,8701-BC,Intermediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,1,,17749,CHEMBL620372,705.0,BAO_0000219,
5538,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,1,,1229,CHEMBL876492,,BAO_0000019,
5539,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,1,,1229,CHEMBL620373,,BAO_0000019,
5540,22226,,,0,,U,,,,Intermediate,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,1,,1229,CHEMBL620374,,BAO_0000019,
5541,22226,,,0,,U,,,,Autocuration,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,1,,6390,CHEMBL620375,,BAO_0000019,
5542,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1,,16219,CHEMBL857902,,BAO_0000019,
5543,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1,,16219,CHEMBL620376,,BAO_0000019,
5544,11922,,,8,,H,,,,Autocuration,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,1,,17043,CHEMBL620377,,BAO_0000357,
5545,81115,,,1,,N,,,KB ,Intermediate,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,1,,6929,CHEMBL620378,324.0,BAO_0000219,
5546,81115,,,1,,N,,,KB ,Intermediate,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,1,,6929,CHEMBL620379,324.0,BAO_0000219,
5547,22226,,,0,,U,,,,Autocuration,In vitro cytotoxicity of compound was tested against 9KB cells.,F,1,,7083,CHEMBL620380,,BAO_0000219,
5548,80653,,,1,,N,,,9L,Intermediate,Cytotoxic concentration against 9L cells was determined on day 3,F,1,,12446,CHEMBL884006,392.0,BAO_0000219,
5549,80653,,,1,,N,,,9L,Expert,Tested in vitro for anticancer activity against 9L cells,F,1,,15345,CHEMBL620381,392.0,BAO_0000219,
5550,80653,,,1,,N,,,9L,Expert,Tested in vitro for anticancer activity against 9L cells; Not determined,F,1,,15345,CHEMBL620382,392.0,BAO_0000219,
5551,80682,,,1,,N,,,A549,Intermediate,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,1,,6301,CHEMBL620383,646.0,BAO_0000219,
5552,80682,,,1,,N,,,A549,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,1,,4833,CHEMBL876493,646.0,BAO_0000219,
5553,80682,,,1,,N,,,A549,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,1,,4833,CHEMBL620384,646.0,BAO_0000219,
5554,80682,,,1,,N,,,A549,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,1,,4833,CHEMBL620385,646.0,BAO_0000219,
5555,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human lung carcinoma A549 cell line,F,1,,13330,CHEMBL620386,646.0,BAO_0000219,
5556,25,,,9,,D,,,A549,Expert,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,1,,17517,CHEMBL620387,646.0,BAO_0000219,
5557,25,,,9,,D,,,A549,Expert,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,1,,17517,CHEMBL621404,646.0,BAO_0000219,
5558,80682,,,1,,N,,,A549,Intermediate,"In vitro growth inhibition of A549, lung carcinoma",F,1,,14425,CHEMBL621405,646.0,BAO_0000219,
5559,80682,,,1,,N,,,A549,Intermediate,"In vitro growth inhibition of A549, lung carcinoma.",F,1,,14425,CHEMBL621406,646.0,BAO_0000219,
5560,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,1,,5228,CHEMBL621407,646.0,BAO_0000219,
5561,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity against human lung cancer A549 cell line was determined,F,1,,5351,CHEMBL621408,646.0,BAO_0000219,
5562,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,1,,12198,CHEMBL885345,646.0,BAO_0000219,
5563,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,1,,13891,CHEMBL621409,646.0,BAO_0000219,
5564,80682,,,1,,N,,,A549,Expert,Cytotoxicity in A549 (human carcinoma) cell line.,F,1,,5677,CHEMBL876034,646.0,BAO_0000219,
5565,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity on lung carcinoma (A-549) cell line,F,1,,13788,CHEMBL621410,646.0,BAO_0000219,
5566,80682,,,1,,N,,,A549,Expert,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,1,,13384,CHEMBL621411,646.0,BAO_0000219,
5567,80682,,,1,,N,,,A549,Intermediate,Effective dose of compound against replication of A549 cell line was evaluated,F,1,,6726,CHEMBL621412,646.0,BAO_0000219,
5568,80682,,,1,,N,,,A549,Expert,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,1,,3455,CHEMBL621413,646.0,BAO_0000219,
5569,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,1,,5726,CHEMBL621414,646.0,BAO_0000219,
5570,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,1,,5726,CHEMBL621415,646.0,BAO_0000219,
5571,80682,,,1,,N,,,A549,Intermediate,The compound was evaluated for antiproliferative activity against A549 cell line,F,1,,3936,CHEMBL621416,646.0,BAO_0000219,
5572,80682,,,1,,N,,,A549,Intermediate,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,1,,14991,CHEMBL621417,646.0,BAO_0000219,
5573,80682,,,1,,N,,,A549,Intermediate,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,1,,5243,CHEMBL621418,646.0,BAO_0000219,
5574,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,1,,12858,CHEMBL621419,646.0,BAO_0000219,
5575,80682,,,1,,N,,,A549,Intermediate,Growth inhibition against A549 cell line was evaluated,F,1,,6776,CHEMBL621420,646.0,BAO_0000219,
5576,80682,,,1,,N,,,A549,Intermediate,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,1,,16558,CHEMBL875823,646.0,BAO_0000219,
5577,80682,,,1,,N,,,A549,Expert,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,1,,4583,CHEMBL621421,646.0,BAO_0000219,
5578,80682,,,1,,N,,,A549,Intermediate,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,1,,13514,CHEMBL621422,646.0,BAO_0000219,
5579,80682,,,1,,N,,,A549,Expert,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,1,,15166,CHEMBL884014,646.0,BAO_0000219,
5580,80682,,,1,,N,,,A549,Intermediate,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,1,,13873,CHEMBL621423,646.0,BAO_0000219,
5581,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,1,,6447,CHEMBL621424,646.0,BAO_0000219,
5582,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,1,,2068,CHEMBL621425,646.0,BAO_0000219,
5583,80682,,,1,,N,,,A549,Expert,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,1,,1863,CHEMBL621426,646.0,BAO_0000219,
5584,80682,,,1,,N,,,A549,Intermediate,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,1,,13873,CHEMBL621427,646.0,BAO_0000219,
5585,80682,,,1,,N,,,A549,Intermediate,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,1,,13873,CHEMBL621428,646.0,BAO_0000219,
5586,80682,,,1,,N,,,A549,Expert,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,1,,13873,CHEMBL621429,646.0,BAO_0000219,
5587,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,1,,579,CHEMBL621430,646.0,BAO_0000219,
5588,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,1,,579,CHEMBL621431,646.0,BAO_0000219,
5589,80682,,,1,,N,,,A549,Intermediate,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,1,,4584,CHEMBL621432,646.0,BAO_0000219,
5590,80682,,,1,,N,,,A549,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,1,,5421,CHEMBL621433,646.0,BAO_0000219,
5591,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,1,,5421,CHEMBL875824,646.0,BAO_0000219,
5592,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,1,,5421,CHEMBL621434,646.0,BAO_0000219,
5593,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,1,,5421,CHEMBL621435,646.0,BAO_0000219,
5594,80682,,,1,,N,,,A549,Intermediate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,1,,14188,CHEMBL621436,646.0,BAO_0000219,
5595,80682,,,1,,N,,,A549,Intermediate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,1,,14188,CHEMBL621437,646.0,BAO_0000219,
5596,80682,,,1,,N,,,A549,Intermediate,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,1,,15354,CHEMBL621438,646.0,BAO_0000219,
5597,80682,,,1,,N,,,A549,Expert,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,1,,14253,CHEMBL621439,646.0,BAO_0000219,
5598,80682,,,1,,N,,,A549,Intermediate,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,1,,13873,CHEMBL621440,646.0,BAO_0000219,
5599,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (conscious),A,1,,3043,CHEMBL621441,,BAO_0000218,
5600,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,1,,3045,CHEMBL621442,,BAO_0000218,
5601,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,1,,3022,CHEMBL621443,,BAO_0000218,
5602,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,4453,CHEMBL621444,,BAO_0000218,
5603,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,1696,CHEMBL625133,,BAO_0000218,
5604,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5045,CHEMBL625134,,BAO_0000218,
5605,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (fasted),A,1,,5356,CHEMBL625135,,BAO_0000218,
5606,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL625136,,BAO_0000218,
5607,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6448,CHEMBL625137,,BAO_0000218,
5608,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,1475,CHEMBL625138,,BAO_0000218,
5609,50588,,In vivo,1,,N,,,,Intermediate,Percent bioavailability in dog,A,1,,3788,CHEMBL625139,,BAO_0000218,
5610,50588,,In vivo,1,,N,,,,Intermediate,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,1,,3639,CHEMBL872264,,BAO_0000218,
5611,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,13397,CHEMBL625140,,BAO_0000218,
5612,50588,,In vivo,1,,N,,,,Intermediate,The compound was evaluated for bioavailability in dogs; 34-44,A,1,,2137,CHEMBL624436,,BAO_0000218,
5613,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 4 mg/kg p.o.),A,1,,2959,CHEMBL624437,,BAO_0000218,
5614,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6448,CHEMBL872261,,BAO_0000218,
5615,50588,,,1,,N,,,,Intermediate,8 hour trough Blood level in dog was measured after administration of compound,A,1,,6084,CHEMBL624438,,BAO_0000218,
5616,50588,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,1,,3639,CHEMBL624439,,BAO_0000218,1969.0
5617,50588,,,1,,N,,,,Intermediate,C24 after oral administration at 5 mg/kg,A,1,,6316,CHEMBL624440,,BAO_0000218,
5618,50588,,,1,,N,,,,Intermediate,Clearance after oral and iv dosing in dogs,A,1,,5238,CHEMBL624441,,BAO_0000218,
5619,50588,,,1,,N,,Plasma,,Intermediate,Clearance of the drug was measured in the plasma of dog,A,1,,17796,CHEMBL624442,,BAO_0000218,1969.0
5620,50588,,,1,,N,,,,Intermediate,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,1,,2652,CHEMBL624443,,BAO_0000218,
5621,50588,,In vivo,1,,N,,,,Intermediate,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,1,,5654,CHEMBL624444,,BAO_0000218,
5622,50588,,In vivo,1,,N,,,,Intermediate,Clearance of compound was determined in dogs,A,1,,6621,CHEMBL624445,,BAO_0000218,
5623,50588,,In vivo,1,,N,,,,Intermediate,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,1,,6505,CHEMBL624446,,BAO_0000218,
5624,50588,,In vivo,1,,N,,,,Intermediate,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,1,,5802,CHEMBL624447,,BAO_0000218,
5625,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog was determined,A,1,,17267,CHEMBL624448,,BAO_0000218,
5626,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,1,,4521,CHEMBL624449,,BAO_0000218,
5627,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,1,,6535,CHEMBL624450,,BAO_0000218,
5628,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog after administration of 1 mg/kg iv,A,1,,6535,CHEMBL875942,,BAO_0000218,
5629,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dogs,A,1,,6535,CHEMBL624451,,BAO_0000218,
5630,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,1,,5542,CHEMBL624452,,BAO_0000218,
5631,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,1,,5199,CHEMBL624453,,BAO_0000218,
5632,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL624454,,BAO_0000218,
5633,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL624455,,BAO_0000218,
5634,50588,,In vivo,1,,N,,,,Intermediate,Plasma administration to dogs,A,1,,16367,CHEMBL624456,,BAO_0000218,
5635,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined,A,1,,5505,CHEMBL624457,,BAO_0000218,
5636,50588,,In vivo,1,,N,,,,Intermediate,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,1,,6215,CHEMBL624458,,BAO_0000218,
5637,50588,,In vivo,1,,N,,,,Intermediate,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,1,,1466,CHEMBL624459,,BAO_0000218,
5638,102164,,In vitro,2,,S,Microsomes,Liver,,Intermediate,Intrinsic clearance in human liver microsomes,A,1,,5007,CHEMBL624460,,BAO_0000251,2107.0
5639,102164,,In vitro,2,,S,Microsomes,Liver,,Intermediate,Intrinsic clearance in human liver microsomes,A,1,,5007,CHEMBL624461,,BAO_0000251,2107.0
5640,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,1,,16452,CHEMBL875943,,BAO_0000218,
5641,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,1,,16452,CHEMBL624462,,BAO_0000218,
5642,50588,,In vivo,1,,N,,,,Intermediate,Clearance in dog (dose 1 mg/kg i.v.),A,1,,16452,CHEMBL624463,,BAO_0000218,
5643,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,1,,6221,CHEMBL624464,,BAO_0000218,
5644,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,1,,5007,CHEMBL624465,,BAO_0000218,
5645,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 10 mpk in dog,A,1,,5668,CHEMBL624466,,BAO_0000218,
5646,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 5 mpk in dog,A,1,,5668,CHEMBL624467,,BAO_0000218,
5647,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 5 mg/kg in dog,A,1,,5668,CHEMBL624468,,BAO_0000218,
5648,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was measured in dog,A,1,,15660,CHEMBL624469,,BAO_0000218,
5649,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was measured in dog,A,1,,15660,CHEMBL624470,,BAO_0000218,
5650,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,1,,5983,CHEMBL624471,,BAO_0000218,
5651,50588,,In vivo,1,,N,,,,Intermediate,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,1,,5600,CHEMBL624472,,BAO_0000218,
5652,50588,,In vivo,1,,N,,,,Intermediate,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL622775,,BAO_0000218,
5653,50588,,In vivo,1,,N,,,,Intermediate,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,1,,6039,CHEMBL622776,,BAO_0000218,
5654,50588,,In vivo,1,,N,,,,Intermediate,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,1,,6039,CHEMBL622777,,BAO_0000218,
5655,50588,,In vivo,1,,N,,,,Intermediate,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,1,,6039,CHEMBL622778,,BAO_0000218,
5656,50588,,In vivo,1,,N,,,,Intermediate,Clearance by intravenous administration of 1.2 mg/kg in dog,A,1,,4368,CHEMBL622779,,BAO_0000218,
5657,50588,,In vivo,1,,N,,,,Intermediate,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,1,,4305,CHEMBL622780,,BAO_0000218,
5658,50588,,In vivo,1,,N,,Plasma,,Intermediate,Clearance value was evaluated in dog plasma,A,1,,1918,CHEMBL622781,,BAO_0000218,1969.0
5659,50588,,In vivo,1,,N,,,,Intermediate,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,1,,6005,CHEMBL622782,,BAO_0000218,
5660,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in dog,A,1,,4839,CHEMBL622783,,BAO_0000218,1969.0
5661,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in dog,A,1,,4239,CHEMBL622784,,BAO_0000218,
5662,50594,,,1,,N,,,,Intermediate,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,1,,17729,CHEMBL622785,,BAO_0000218,
5663,50594,,,1,,N,,,,Intermediate,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,1,,17728,CHEMBL622786,,BAO_0000218,
5664,50594,,,1,,N,,,,Intermediate,Area under curve value in mouse at a dose of 10 mg/kg,A,1,,5302,CHEMBL622787,,BAO_0000218,
5665,50594,,,1,,N,,,,Intermediate,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL875949,,BAO_0000218,
5666,50594,,,1,,N,,,,Intermediate,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL622788,,BAO_0000218,
5667,50594,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,1,,17764,CHEMBL622789,,BAO_0000218,
5668,50594,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,1,,17764,CHEMBL622790,,BAO_0000218,
5669,50594,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,1,,17764,CHEMBL622791,,BAO_0000218,
5670,50594,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,1,,17764,CHEMBL622792,,BAO_0000218,
5671,50594,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL622793,,BAO_0000218,
5672,50594,,,1,,N,,,,Intermediate,Area under curve was determined for the compound at 24 mg/Kg,A,1,,17753,CHEMBL622794,,BAO_0000218,
5673,50594,,,1,,N,,,,Intermediate,Area under curve was determined for the compound at 40 mg/Kg,A,1,,17753,CHEMBL622795,,BAO_0000218,
5674,50594,,,1,,N,,,,Intermediate,Area under curve was determined for the compound at 5 mg/Kg,A,1,,17753,CHEMBL621803,,BAO_0000218,
5675,50594,,,1,,N,,,,Intermediate,Area under the curve for the compound is obtained at dose 25 mg/kg,A,1,,3132,CHEMBL621804,,BAO_0000218,
5676,50594,,,1,,N,,,,Intermediate,Area under the curve for the compound was obtained when tested in mouse,A,1,,3132,CHEMBL621805,,BAO_0000218,
5677,50594,,,1,,N,,,,Intermediate,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,1,,17837,CHEMBL621806,,BAO_0000218,
5678,50594,,,1,,N,,,,Intermediate,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,1,,17837,CHEMBL621807,,BAO_0000218,
5679,50594,,,1,,N,,,,Intermediate,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL621808,,BAO_0000218,
5680,50594,,,1,,N,,,,Intermediate,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,1,,4066,CHEMBL621809,,BAO_0000218,
5681,50594,,,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,1,,16597,CHEMBL621810,,BAO_0000218,
5682,50594,,,1,,N,,,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,1,,14239,CHEMBL875164,,BAO_0000218,
5683,50594,,,1,,N,,,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,1,,14239,CHEMBL621811,,BAO_0000218,
5684,50594,,,1,,N,,,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,1,,4890,CHEMBL621812,,BAO_0000218,
5685,50594,,,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,1,,429,CHEMBL621813,,BAO_0000218,
5686,50594,,,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,1,,429,CHEMBL621814,,BAO_0000218,
5687,50594,,,1,,N,,,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,1,,5969,CHEMBL621815,,BAO_0000218,
5688,50594,,,1,,N,,,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,1,,5969,CHEMBL621816,,BAO_0000218,
5689,50594,,,1,,N,,,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,1,,5969,CHEMBL621817,,BAO_0000218,
5690,50594,,,1,,N,,,,Intermediate,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,1,,6091,CHEMBL621818,,BAO_0000218,
5691,50594,,,1,,N,,,,Intermediate,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,1,,6091,CHEMBL621819,,BAO_0000218,
5692,50594,,,1,,N,,,,Intermediate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,1,,6091,CHEMBL621820,,BAO_0000218,
5693,50594,,,1,,N,,,,Intermediate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,1,,6091,CHEMBL621821,,BAO_0000218,
5694,50594,,,1,,N,,,,Intermediate,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,1,,6178,CHEMBL621822,,BAO_0000218,
5695,50594,,,1,,N,,,,Intermediate,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,1,,6178,CHEMBL619474,,BAO_0000218,
5696,50594,,,1,,N,,,,Intermediate,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,1,,6619,CHEMBL619475,,BAO_0000218,
5697,50594,,,1,,N,,,,Intermediate,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,1,,6619,CHEMBL619476,,BAO_0000218,
5698,50594,,,1,,N,,,,Intermediate,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,1,,3760,CHEMBL619477,,BAO_0000218,
5699,50594,,,1,,N,,,,Intermediate,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,1,,3760,CHEMBL619478,,BAO_0000218,
5700,50594,,,1,,N,,,,Intermediate,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,1,,3760,CHEMBL619479,,BAO_0000218,
5701,50594,,,1,,N,,,,Intermediate,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,1,,3760,CHEMBL619480,,BAO_0000218,
5702,50594,,,1,,N,,,,Intermediate,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,1,,3192,CHEMBL619481,,BAO_0000218,
5703,50594,,,1,,N,,,,Intermediate,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,1,,3192,CHEMBL619482,,BAO_0000218,
5704,50594,,,1,,N,,,,Intermediate,Area under the curve was evaluated in mice after intravenous administration,A,1,,2675,CHEMBL619483,,BAO_0000218,
5705,50594,,,1,,N,,,,Intermediate,Area under the curve was evaluated in mice after oral administration,A,1,,2675,CHEMBL619484,,BAO_0000218,
5706,50594,,,1,,N,,Plasma,,Intermediate,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL619485,,BAO_0000218,1969.0
5707,50594,,,1,,N,,Plasma,,Intermediate,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL619486,,BAO_0000218,1969.0
5708,50594,,,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,1,,16597,CHEMBL619487,,BAO_0000218,
5709,50594,,,1,,N,,,,Intermediate,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL619488,,BAO_0000218,
5710,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620106,,BAO_0000218,178.0
5711,80653,,,1,,N,,,9L,Intermediate,The compound was tested in vitro for anticancer activity against 9L cells,F,1,,15345,CHEMBL620107,392.0,BAO_0000219,
5712,22226,,,0,,U,,,,Autocuration,Anti proliferation activity determined; Weak effect,F,1,,2181,CHEMBL620283,,BAO_0000019,
5713,22226,,,0,,U,,,,Autocuration,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,1,,2181,CHEMBL875176,,BAO_0000219,
5714,22226,,,0,,U,,,,Autocuration,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,1,,2181,CHEMBL620284,,BAO_0000219,
5715,22226,,,0,,U,,,,Autocuration,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,1,,2181,CHEMBL623515,,BAO_0000219,
5716,22226,,,0,,U,,,,Autocuration,The cytotoxic activity was in vitro tested by 9PS assay method,F,1,,10486,CHEMBL623516,,BAO_0000019,
5717,22226,,,0,,U,,,,Autocuration,The cytotoxic activity was in vitro tested by 9PS assay method.,F,1,,10486,CHEMBL623517,,BAO_0000019,
5718,22224,,,0,,U,,,,Autocuration,Partition coefficient (logD6.5),A,1,,15508,CHEMBL857878,,BAO_0000019,
5719,81034,,,1,,N,,,A2780,Expert,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,1,,5242,CHEMBL623518,478.0,BAO_0000219,
5720,80018,,,1,,N,,,A-375,Intermediate,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,1,,16167,CHEMBL624195,455.0,BAO_0000219,
5721,80852,,,1,,N,,,A-431,Expert,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,1,,4782,CHEMBL624196,500.0,BAO_0000219,
5722,9,,,9,,D,,,A-431,Expert,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,1,,16093,CHEMBL624197,500.0,BAO_0000219,
5723,80021,,,1,,N,,,A498,Intermediate,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,1,,2596,CHEMBL624198,624.0,BAO_0000219,
5724,80021,,,1,,N,,,A498,Intermediate,in vitro cytotoxicity against A 498 cancer cell line,F,1,,2596,CHEMBL621287,624.0,BAO_0000219,
5725,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,1,,3239,CHEMBL621288,624.0,BAO_0000219,
5726,80021,,,1,,N,,,A498,Intermediate,Cytotoxic activity against A 498 renal cancer cell lines.,F,1,,1847,CHEMBL876496,624.0,BAO_0000219,
5727,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,1,,10553,CHEMBL621289,624.0,BAO_0000219,
5728,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1,,16219,CHEMBL621290,,BAO_0000019,
5729,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1,,16219,CHEMBL621291,,BAO_0000019,
5730,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1,,16219,CHEMBL621292,,BAO_0000019,
5731,22226,,,0,,U,,,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1,,16219,CHEMBL621293,,BAO_0000019,
5732,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration required against A 549 lung cancer cell line,F,1,,4782,CHEMBL621294,646.0,BAO_0000219,
5733,80682,,,1,,N,,,A549,Intermediate,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,1,,11805,CHEMBL621295,646.0,BAO_0000219,
5734,80682,,,1,,N,,,A549,Intermediate,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,1,,11805,CHEMBL884007,646.0,BAO_0000219,
5735,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against lung cancer A 549 cell lines,F,1,,2007,CHEMBL621296,646.0,BAO_0000219,
5736,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its cytotoxicity against A 549 cell line,F,1,,4594,CHEMBL621297,646.0,BAO_0000219,
5737,80682,,,1,,N,,,A549,Expert,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,1,,6018,CHEMBL839828,646.0,BAO_0000219,
5738,80682,,,1,,N,,,A549,Intermediate,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,1,,6018,CHEMBL620397,646.0,BAO_0000219,
5739,80682,,,1,,N,,,A549,Expert,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,1,,3599,CHEMBL620398,646.0,BAO_0000219,
5740,80682,,,1,,N,,,A549,Intermediate,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,1,,2551,CHEMBL620399,646.0,BAO_0000219,
5741,80682,,,1,,N,,,A549,Expert,In vitro inhibition of A549 (human lung cancer) cell growth.,F,1,,16132,CHEMBL620400,646.0,BAO_0000219,
5742,80682,,,1,,N,,,A549,Intermediate,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,1,,16132,CHEMBL620401,646.0,BAO_0000219,
5743,80682,,,1,,N,,,A549,Expert,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,1,,2551,CHEMBL620402,646.0,BAO_0000219,
5744,80682,,,1,,N,,,A549,Expert,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,1,,2551,CHEMBL620403,646.0,BAO_0000219,
5745,22226,,,0,,U,,,,Autocuration,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,1,,11913,CHEMBL620404,,BAO_0000218,
5746,104694,,In vivo,4,,H,,,,Autocuration,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,1,,12621,CHEMBL620405,,BAO_0000218,
5747,104694,,In vivo,4,,H,,,,Autocuration,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,1,,12621,CHEMBL620406,,BAO_0000218,
5748,104694,,In vivo,4,,H,,,,Autocuration,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,1,,12621,CHEMBL620407,,BAO_0000218,
5749,104694,,In vivo,4,,H,,,,Autocuration,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,1,,12621,CHEMBL620408,,BAO_0000218,
5750,104694,,In vivo,4,,H,,,,Autocuration,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,1,,12621,CHEMBL620409,,BAO_0000218,
5751,80021,,,1,,N,,,A498,Expert,Inhibition of A-498 human Renal cell proliferation,F,1,,3600,CHEMBL620410,624.0,BAO_0000219,
5752,22226,,,0,,U,,,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,1,,1796,CHEMBL620411,,BAO_0000019,
5753,22226,,,0,,U,,,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,1,,1796,CHEMBL620412,,BAO_0000019,
5754,22226,,,0,,U,,,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,1,,1796,CHEMBL876596,,BAO_0000019,
5755,80012,,,1,,N,,,A 172,Expert,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,1,,16464,CHEMBL620413,622.0,BAO_0000219,
5756,80012,,,1,,N,,,A 172,Intermediate,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL620414,622.0,BAO_0000219,
5757,80012,,,1,,N,,,A 172,Intermediate,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL620415,622.0,BAO_0000219,
5758,80682,,,1,,N,,,A549,Expert,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,1,,13617,CHEMBL620416,646.0,BAO_0000219,
5759,80682,,,1,,N,,,A549,Intermediate,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,1,,4584,CHEMBL620417,646.0,BAO_0000219,
5760,80682,,,1,,N,,,A549,Expert,Cytotoxic activity evaluated against A549 tumor cells,F,1,,13799,CHEMBL620418,646.0,BAO_0000219,
5761,80682,,,1,,N,,,A549,Intermediate,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,1,,16726,CHEMBL620419,646.0,BAO_0000219,
5762,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,1,,16109,CHEMBL620420,646.0,BAO_0000219,
5763,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,1,,16109,CHEMBL620421,646.0,BAO_0000219,
5764,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,1,,15474,CHEMBL620422,646.0,BAO_0000219,
5765,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity of compound against A549 cell line,F,1,,6851,CHEMBL620423,646.0,BAO_0000219,
5766,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human lung cell carcinoma A549 cell line,F,1,,17534,CHEMBL620424,646.0,BAO_0000219,
5767,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,1,,2621,CHEMBL620425,646.0,BAO_0000219,
5768,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,1,,830,CHEMBL620426,646.0,BAO_0000219,
5769,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,1,,14255,CHEMBL620427,646.0,BAO_0000219,
5770,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,1,,14255,CHEMBL620428,646.0,BAO_0000219,
5771,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,1,,1590,CHEMBL620429,646.0,BAO_0000219,
5772,80682,,,1,,N,,,A549,Expert,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,1,,6146,CHEMBL620430,646.0,BAO_0000219,
5773,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,1,,17427,CHEMBL839887,646.0,BAO_0000219,
5774,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,1,,5280,CHEMBL620431,646.0,BAO_0000219,
5775,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,1,,16786,CHEMBL884010,646.0,BAO_0000219,
5776,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against A549 (human lung cancer),F,1,,5895,CHEMBL620538,646.0,BAO_0000219,
5777,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,1,,14297,CHEMBL620539,646.0,BAO_0000219,
5778,80682,,,1,,N,,,A549,Intermediate,In vivo antiproliferative activity against A549 cell line,F,1,,17824,CHEMBL623373,646.0,BAO_0000218,
5779,80682,,,1,,N,,,A549,Intermediate,Inhibition of non-small-cell lung adenocarcinoma (A549),F,1,,14368,CHEMBL623374,646.0,BAO_0000219,
5780,80682,,,1,,N,,,A549,Intermediate,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,1,,14368,CHEMBL623375,646.0,BAO_0000219,
5781,80682,,,1,,N,,,A549,Intermediate,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,1,,14254,CHEMBL623376,646.0,BAO_0000219,
5782,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,1,,15897,CHEMBL623377,646.0,BAO_0000219,
5783,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,1,,13866,CHEMBL623378,646.0,BAO_0000219,
5784,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,1,,13370,CHEMBL623379,646.0,BAO_0000219,
5785,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 lung cancer cell line,F,1,,4862,CHEMBL623380,646.0,BAO_0000219,
5786,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,1,,4862,CHEMBL623381,646.0,BAO_0000219,
5787,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,1,,4862,CHEMBL623382,646.0,BAO_0000219,
5788,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration against A549 (lung cancer) cell line,F,1,,15970,CHEMBL623383,646.0,BAO_0000219,
5789,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,1,,17713,CHEMBL623384,646.0,BAO_0000219,
5790,80682,,,1,,N,,,A549,Intermediate,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,1,,4833,CHEMBL623385,646.0,BAO_0000219,
5791,80682,,,1,,N,,,A549,Expert,Activity against A549 cancer cell line.,F,1,,13736,CHEMBL623386,646.0,BAO_0000219,
5792,80682,,,1,,N,,,A549,Intermediate,The compound was evaluated for cytotoxicity against A549 cell line,F,1,,4312,CHEMBL884105,646.0,BAO_0000219,
5793,80682,,,1,,N,,,A549,Intermediate,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,1,,5421,CHEMBL623387,646.0,BAO_0000219,
5794,80682,,,1,,N,,,A549,Intermediate,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,1,,5421,CHEMBL621568,646.0,BAO_0000219,
5795,80682,,,1,,N,,,A549,Intermediate,Growth inhibitory activity was measured for human A549 tumor cell line.,F,1,,14717,CHEMBL621569,646.0,BAO_0000219,
5796,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 lung cancer cell line,F,1,,4634,CHEMBL621570,646.0,BAO_0000219,
5797,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 cell line; inactive,F,1,,1149,CHEMBL621571,646.0,BAO_0000219,
5798,80682,,,1,,N,,,A549,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,1,,5421,CHEMBL621572,646.0,BAO_0000219,
5799,80682,,,1,,N,,,A549,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,1,,5421,CHEMBL621573,646.0,BAO_0000219,
5800,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,1,,5421,CHEMBL621574,646.0,BAO_0000219,
5801,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,1,,3320,CHEMBL621575,646.0,BAO_0000219,
5802,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,1,,3320,CHEMBL621576,646.0,BAO_0000219,
5803,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,1,,3320,CHEMBL621577,646.0,BAO_0000219,
5804,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,1,,3320,CHEMBL621578,646.0,BAO_0000219,
5805,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,1,,3320,CHEMBL621579,646.0,BAO_0000219,
5806,80682,,,1,,N,,,A549,Intermediate,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,1,,5726,CHEMBL621580,646.0,BAO_0000219,
5807,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance (in vivo) in mongrel dogs was determined,A,1,,17800,CHEMBL621581,,BAO_0000218,
5808,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was measured in dog,A,1,,5985,CHEMBL621582,,BAO_0000218,
5809,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,1,,5530,CHEMBL621583,,BAO_0000218,
5810,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,1,,5530,CHEMBL621584,,BAO_0000218,
5811,50588,,In vivo,1,,N,,Plasma,,Intermediate,Tested for plasma clearance in dog,A,1,,4839,CHEMBL621585,,BAO_0000218,1969.0
5812,50588,,In vivo,1,,N,,,,Intermediate,The compound was tested for clearance in dog plasma.,A,1,,3639,CHEMBL621586,,BAO_0000218,
5813,50588,,In vivo,1,,N,,,,Intermediate,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,1,,4838,CHEMBL875835,,BAO_0000218,
5814,50588,,In vivo,1,,N,,,,Intermediate,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,1,,4137,CHEMBL621587,,BAO_0000218,
5815,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,1,,5017,CHEMBL621588,,BAO_0000218,1969.0
5816,50588,,In vitro,1,,N,Microsomes,Liver,,Intermediate,In vitro clearance in dog liver microsomes,A,1,,17538,CHEMBL621589,,BAO_0000218,2107.0
5817,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,1,,6161,CHEMBL621590,,BAO_0000218,
5818,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,1,,6161,CHEMBL621591,,BAO_0000218,
5819,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog,A,1,,1696,CHEMBL621592,,BAO_0000218,
5820,50588,,In vivo,1,,N,,,,Intermediate,Clearance rate in dog,A,1,,6762,CHEMBL621593,,BAO_0000218,
5821,50588,,In vivo,1,,N,,Plasma,,Intermediate,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,1,,5932,CHEMBL621594,,BAO_0000218,1969.0
5822,50588,,In vivo,1,,N,,,,Intermediate,Clearance in dogs,A,1,,6305,CHEMBL621595,,BAO_0000218,
5823,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dogs,A,1,,4942,CHEMBL621596,,BAO_0000218,
5824,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined,A,1,,4219,CHEMBL621597,,BAO_0000218,
5825,50588,,In vivo,1,,N,,,,Intermediate,Lower clearance in dog (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL621598,,BAO_0000218,
5826,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in Beagle dogs,A,1,,4514,CHEMBL621599,,BAO_0000218,
5827,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance (Clp) in dog,A,1,,6448,CHEMBL875836,,BAO_0000218,
5828,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,1,,6227,CHEMBL621600,,BAO_0000218,
5829,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,1,,6227,CHEMBL621601,,BAO_0000218,
5830,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL618474,,BAO_0000218,
5831,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance of compound was determined in dog,A,1,,6821,CHEMBL618475,,BAO_0000218,
5832,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL624524,,BAO_0000218,
5833,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,1,,4521,CHEMBL624525,,BAO_0000218,
5834,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog was determined,A,1,,5374,CHEMBL624526,,BAO_0000218,
5835,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was calculated in dog,A,1,,6057,CHEMBL624527,,BAO_0000218,
5836,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance at the dose of 2 mg/kg in dog,A,1,,4727,CHEMBL624528,,BAO_0000218,
5837,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog,A,1,,5145,CHEMBL624529,,BAO_0000218,
5838,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog,A,1,,17657,CHEMBL624530,,BAO_0000218,
5839,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog; Unable to calculate,A,1,,17657,CHEMBL624531,,BAO_0000218,
5840,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rhesus monkey,A,1,,5145,CHEMBL624532,,BAO_0000218,
5841,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,1,,6642,CHEMBL624533,,BAO_0000218,
5842,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL624534,,BAO_0000218,
5843,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6642,CHEMBL624535,,BAO_0000218,
5844,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in dog,A,1,,5472,CHEMBL624536,,BAO_0000218,
5845,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in dog; Not tested,A,1,,5472,CHEMBL624537,,BAO_0000218,
5846,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in rhesus,A,1,,5472,CHEMBL624538,,BAO_0000218,
5847,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in rhesus; Not tested,A,1,,5472,CHEMBL624539,,BAO_0000218,
5848,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL624540,,BAO_0000218,
5849,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL624541,,BAO_0000218,
5850,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL624542,,BAO_0000218,
5851,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL624543,,BAO_0000218,
5852,50588,,In vivo,1,,N,,,,Intermediate,Clearance value at a dose of 0.2 mg/kg i.v.,A,1,,5474,CHEMBL624544,,BAO_0000218,
5853,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,1,,6316,CHEMBL624545,,BAO_0000218,1969.0
5854,50588,,In vivo,1,,N,,,,Intermediate,Cmax after oral dose of compound at 3 mg/kg in dogs,A,1,,17594,CHEMBL624546,,BAO_0000218,
5855,50588,,In vivo,1,,N,,,,Intermediate,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,1,,17594,CHEMBL875957,,BAO_0000218,
5856,50588,,In vivo,1,,N,,,,Intermediate,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,1,,5802,CHEMBL624547,,BAO_0000218,
5857,50588,,In vivo,1,,N,,,,Intermediate,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,1,,6535,CHEMBL624548,,BAO_0000218,
5858,50588,,In vivo,1,,N,,,,Intermediate,Cmax in dog after administration of 1 mg/kg iv,A,1,,6535,CHEMBL624549,,BAO_0000218,
5859,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,1,,1466,CHEMBL624550,,BAO_0000218,1969.0
5860,50588,,In vivo,1,,N,,,,Intermediate,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,1,,6505,CHEMBL621613,,BAO_0000218,
5861,50588,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 10 mpk in dog,A,1,,5668,CHEMBL621614,,BAO_0000218,
5862,50588,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 5 mpk in dog,A,1,,5668,CHEMBL623431,,BAO_0000218,
5863,50588,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 5 mg/kg in dog,A,1,,5668,CHEMBL623432,,BAO_0000218,
5864,50588,,In vivo,1,,N,,,,Intermediate,Cmax after 0.3 mg/kg po administration in dog,A,1,,5600,CHEMBL623433,,BAO_0000218,
5865,50588,,In vivo,1,,N,,,,Intermediate,Cmax after peroral administration in dogs at 2.4 uM/kg,A,1,,17764,CHEMBL623434,,BAO_0000218,
5866,50588,,In vivo,1,,N,,,,Intermediate,Cmax in dog after oral administration at 1 mg/kg,A,1,,6123,CHEMBL623435,,BAO_0000218,
5867,50588,,In vivo,1,,N,,,,Intermediate,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,1,,6123,CHEMBL623436,,BAO_0000218,
5868,50588,,In vivo,1,,N,,,,Intermediate,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,1,,6757,CHEMBL875958,,BAO_0000218,
5869,50588,,In vivo,1,,N,,,,Intermediate,Cmax value after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL623437,,BAO_0000218,
5870,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623438,,BAO_0000218,178.0
5871,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623439,,BAO_0000218,178.0
5872,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623440,,BAO_0000218,10000001.0
5873,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623441,,BAO_0000218,10000001.0
5874,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623442,,BAO_0000218,10000001.0
5875,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623469,,BAO_0000218,
5876,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623470,,BAO_0000218,
5877,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623471,,BAO_0000218,
5878,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623472,,BAO_0000218,948.0
5879,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623473,,BAO_0000218,948.0
5880,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623474,,BAO_0000218,948.0
5881,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623475,,BAO_0000218,2113.0
5882,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623476,,BAO_0000218,2113.0
5883,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL623477,,BAO_0000218,2113.0
5884,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621896,,BAO_0000218,160.0
5885,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621897,,BAO_0000218,160.0
5886,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621898,,BAO_0000218,160.0
5887,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621899,,BAO_0000218,2107.0
5888,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621900,,BAO_0000218,2107.0
5889,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621901,,BAO_0000218,2107.0
5890,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621902,,BAO_0000218,2048.0
5891,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL621903,,BAO_0000218,2048.0
5892,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL622587,,BAO_0000218,2048.0
5893,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620285,,BAO_0000218,2385.0
5894,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL875285,,BAO_0000218,2385.0
5895,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620286,,BAO_0000218,2385.0
5896,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620287,,BAO_0000218,
5897,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620288,,BAO_0000218,
5898,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620289,,BAO_0000218,
5899,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620290,,BAO_0000218,160.0
5900,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620291,,BAO_0000218,160.0
5901,50594,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620292,,BAO_0000218,160.0
5902,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620293,,BAO_0000218,2106.0
5903,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL620294,,BAO_0000218,2106.0
5904,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL618614,,BAO_0000218,2106.0
5905,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL618615,,BAO_0000218,945.0
5906,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL618616,,BAO_0000218,945.0
5907,80012,,,1,,N,,,A 172,Expert,Cytotoxicity against A-172 human tumor cell lines,F,1,,2036,CHEMBL618617,622.0,BAO_0000219,
5908,80012,,,1,,N,,,A 172,Intermediate,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,1,,2357,CHEMBL618618,622.0,BAO_0000219,
5909,80014,,,1,,N,,,A204,Intermediate,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,1,,1457,CHEMBL618619,623.0,BAO_0000219,
5910,81034,,,1,,N,,,A2780,Intermediate,Tested for antiproliferative activity against A-2780 tumoral cell line,F,1,,4379,CHEMBL618620,478.0,BAO_0000219,
5911,80018,,,1,,N,,,A-375,Intermediate,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,1,,1093,CHEMBL618621,455.0,BAO_0000219,
5912,80018,,,1,,N,,,A-375,Intermediate,Tested in vitro against A-375 cell line human melanoma,F,1,,12152,CHEMBL618622,455.0,BAO_0000219,
5913,80019,,,1,,N,,,A-427,Expert,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,1,,16464,CHEMBL618623,797.0,BAO_0000219,
5914,80019,,,1,,N,,,A-427,Intermediate,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL618624,797.0,BAO_0000219,
5915,80019,,,1,,N,,,A-427,Expert,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,1,,16582,CHEMBL618625,797.0,BAO_0000219,
5916,80019,,,1,,N,,,A-427,Intermediate,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,1,,16464,CHEMBL618626,797.0,BAO_0000219,
5917,80019,,,1,,N,,,A-427,Intermediate,Antitumor activity on A-427 lung carcinoma cell lines,F,1,,10413,CHEMBL618627,797.0,BAO_0000219,
5918,80019,,,1,,N,,,A-427,Intermediate,Cytotoxic activity against human A-427 lung tumor cell line,F,1,,6418,CHEMBL618628,797.0,BAO_0000219,
5919,80019,,,1,,N,,,A-427,Expert,In vitro antitumor effects against human A-427 cell lines.,F,1,,17134,CHEMBL618629,797.0,BAO_0000219,
5920,80019,,,1,,N,,,A-427,Expert,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,1,,16132,CHEMBL618630,797.0,BAO_0000219,
5921,80019,,,1,,N,,,A-427,Intermediate,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,1,,16132,CHEMBL618631,797.0,BAO_0000219,
5922,80019,,,1,,N,,,A-427,Intermediate,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,1,,16780,CHEMBL618632,797.0,BAO_0000219,
5923,80852,,,1,,N,,,A-431,Expert,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,1,,4085,CHEMBL618633,500.0,BAO_0000219,
5924,80021,,,1,,N,,,A498,Intermediate,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,1,,1276,CHEMBL619315,624.0,BAO_0000219,
5925,80021,,,1,,N,,,A498,Expert,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,1,,3498,CHEMBL619316,624.0,BAO_0000219,
5926,80021,,,1,,N,,,A498,Intermediate,Cytotoxicity against human kidney carcinoma A-498cell lines,F,1,,1169,CHEMBL619317,624.0,BAO_0000219,
5927,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,1,,4450,CHEMBL619318,624.0,BAO_0000219,
5928,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,1,,3311,CHEMBL619319,624.0,BAO_0000219,
5929,80021,,,1,,N,,,A498,Intermediate,Antitumor cytotoxic activity against A-498 cell line was determined,F,1,,4461,CHEMBL619739,624.0,BAO_0000219,
5930,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,1,,3311,CHEMBL619740,624.0,BAO_0000219,
5931,80021,,,1,,N,,,A498,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,1,,3311,CHEMBL883158,624.0,BAO_0000219,
5932,80021,,,1,,N,,,A498,Intermediate,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,1,,1457,CHEMBL884012,624.0,BAO_0000219,
5933,80021,,,1,,N,,,A498,Intermediate,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,1,,3664,CHEMBL619741,624.0,BAO_0000219,
5934,80021,,,1,,N,,,A498,Intermediate,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,1,,15895,CHEMBL619742,624.0,BAO_0000219,
5935,80682,,,1,,N,,,A549,Intermediate,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,1,,11843,CHEMBL876610,646.0,BAO_0000219,
5936,80682,,,1,,N,,,A549,Intermediate,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,1,,11843,CHEMBL619743,646.0,BAO_0000219,
5937,80682,,,1,,N,,,A549,Intermediate,In vitro antiproliferative activity against human A-549 NSCL cell line,F,1,,17705,CHEMBL619744,646.0,BAO_0000219,
5938,80682,,,1,,N,,,A549,Intermediate,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,1,,17705,CHEMBL619745,646.0,BAO_0000219,
5939,80682,,,1,,N,,,A549,Intermediate,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,1,,4369,CHEMBL619746,646.0,BAO_0000219,
5940,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,1,,4369,CHEMBL619747,646.0,BAO_0000219,
5941,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,1,,4369,CHEMBL619748,646.0,BAO_0000219,
5942,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,1,,4369,CHEMBL619749,646.0,BAO_0000219,
5943,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,1,,4369,CHEMBL619750,646.0,BAO_0000219,
5944,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,1,,4369,CHEMBL624014,646.0,BAO_0000219,
5945,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,1,,4369,CHEMBL624015,646.0,BAO_0000219,
5946,80682,,,1,,N,,,A549,Expert,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,1,,4787,CHEMBL885344,646.0,BAO_0000219,
5947,80682,,,1,,N,,,A549,Intermediate,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,1,,4787,CHEMBL623224,646.0,BAO_0000219,
5948,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity against A-549 cell line,F,1,,6513,CHEMBL623225,646.0,BAO_0000219,
5949,80682,,,1,,N,,,A549,Intermediate,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,1,,6690,CHEMBL622698,646.0,BAO_0000219,
5950,80682,,,1,,N,,,A549,Intermediate,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,1,,6690,CHEMBL622699,646.0,BAO_0000219,
5951,80682,,,1,,N,,,A549,Expert,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,1,,12263,CHEMBL622700,646.0,BAO_0000219,
5952,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,1,,1054,CHEMBL622701,646.0,BAO_0000219,
5953,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,1,,1359,CHEMBL622702,646.0,BAO_0000219,
5954,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,1,,3547,CHEMBL622703,646.0,BAO_0000219,
5955,80682,,,1,,N,,,A549,Expert,Cytotoxic activity towards A-549 cells,F,1,,5771,CHEMBL622704,646.0,BAO_0000219,
5956,80682,,,1,,N,,,A549,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.",F,1,,14425,CHEMBL622705,646.0,BAO_0000219,
5957,80682,,,1,,N,,,A549,Intermediate,"In vitro percent inhibition of A549, lung carcinoma",F,1,,14425,CHEMBL622706,646.0,BAO_0000219,
5958,80682,,,1,,N,,,A549,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.",F,1,,14425,CHEMBL622707,646.0,BAO_0000219,
5959,80682,,,1,,N,,,A549,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,1,,14425,CHEMBL622708,646.0,BAO_0000219,
5960,80682,,,1,,N,,,A549,Intermediate,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,1,,5280,CHEMBL622709,646.0,BAO_0000219,
5961,80682,,,1,,N,,,A549,Intermediate,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,1,,15176,CHEMBL622710,646.0,BAO_0000219,
5962,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,1,,15300,CHEMBL622711,646.0,BAO_0000219,
5963,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,1,,17824,CHEMBL622712,646.0,BAO_0000218,
5964,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,1,,17824,CHEMBL622713,646.0,BAO_0000218,
5965,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,1,,17824,CHEMBL622714,646.0,BAO_0000218,
5966,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,1,,17824,CHEMBL622715,646.0,BAO_0000218,
5967,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,1,,17824,CHEMBL622716,646.0,BAO_0000218,
5968,80682,,,1,,N,,,A549,Intermediate,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,1,,17824,CHEMBL622717,646.0,BAO_0000219,
5969,80682,,,1,,N,,,A549,Intermediate,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,1,,17528,CHEMBL622718,646.0,BAO_0000218,
5970,80682,,,1,,N,,,A549,Expert,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,1,,6870,CHEMBL622719,646.0,BAO_0000219,
5971,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,1,,6870,CHEMBL622720,646.0,BAO_0000219,
5972,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,1,,6870,CHEMBL622721,646.0,BAO_0000219,
5973,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,1,,6870,CHEMBL622722,646.0,BAO_0000219,
5974,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,1,,16726,CHEMBL876030,646.0,BAO_0000219,
5975,80682,,,1,,N,,,A549,Intermediate,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,1,,6170,CHEMBL620206,646.0,BAO_0000219,
5976,80682,,,1,,N,,,A549,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,1,,6583,CHEMBL620207,646.0,BAO_0000219,
5977,80682,,,1,,N,,,A549,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,1,,6583,CHEMBL620208,646.0,BAO_0000219,
5978,80682,,,1,,N,,,A549,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,1,,6583,CHEMBL620209,646.0,BAO_0000219,
5979,80682,,,1,,N,,,A549,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,1,,6583,CHEMBL620210,646.0,BAO_0000219,
5980,80682,,,1,,N,,,A549,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,1,,6583,CHEMBL621639,646.0,BAO_0000219,
5981,80682,,,1,,N,,,A549,Intermediate,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,1,,17321,CHEMBL621640,646.0,BAO_0000219,
5982,80682,,,1,,N,,,A549,Expert,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,1,,17528,CHEMBL621641,646.0,BAO_0000219,
5983,80682,,,1,,N,,,A549,Expert,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,1,,12888,CHEMBL621642,646.0,BAO_0000219,
5984,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,1,,4312,CHEMBL621643,646.0,BAO_0000219,
5985,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,1,,4312,CHEMBL621644,646.0,BAO_0000219,
5986,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,1,,4312,CHEMBL621645,646.0,BAO_0000219,
5987,80682,,,1,,N,,,A549,Intermediate,In vitro antiproliferative activity against A549 cell line,F,1,,17737,CHEMBL621646,646.0,BAO_0000219,
5988,80682,,,1,,N,,,A549,Intermediate,Synergism with indomethacin in A549 cells,F,1,,6630,CHEMBL621647,646.0,BAO_0000219,
5989,80682,,,1,,N,,,A549,Intermediate,Synergism with tolmetin in A549 cells,F,1,,6630,CHEMBL621648,646.0,BAO_0000219,
5990,80682,,,1,,N,,,A549,Intermediate,Synergism with sulindac in A549 cells,F,1,,6630,CHEMBL621649,646.0,BAO_0000219,
5991,80682,,,1,,N,,,A549,Intermediate,Antagonism of indomethacin in A549 cells,F,1,,6630,CHEMBL621650,646.0,BAO_0000219,
5992,80682,,,1,,N,,,A549,Intermediate,Antagonism of sulindac in A549 cells,F,1,,6630,CHEMBL621651,646.0,BAO_0000219,
5993,80682,,,1,,N,,,A549,Intermediate,Antagonism of tolmetin in A549 cells,F,1,,6630,CHEMBL621652,646.0,BAO_0000219,
5994,80682,,,1,,N,,,A549,Intermediate,Synergism with indomethacin in A549 cells,F,1,,6630,CHEMBL621653,646.0,BAO_0000219,
5995,80682,,,1,,N,,,A549,Intermediate,Synergism with sulindac in A549 cells,F,1,,6630,CHEMBL621654,646.0,BAO_0000219,
5996,80682,,,1,,N,,,A549,Intermediate,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,1,,6630,CHEMBL621655,646.0,BAO_0000219,
5997,50588,,In vivo,1,,N,,,,Intermediate,Cmax value after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL621656,,BAO_0000218,
5998,50588,,In vivo,1,,N,,,,Intermediate,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,1,,5944,CHEMBL621657,,BAO_0000218,
5999,50588,,In vivo,1,,N,,,,Intermediate,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,1,,5944,CHEMBL621658,,BAO_0000218,
6000,50588,,In vivo,1,,N,,,,Intermediate,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,1,,5944,CHEMBL621659,,BAO_0000218,
6001,50588,,In vivo,1,,N,,,,Intermediate,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,1,,5944,CHEMBL621660,,BAO_0000218,
6002,50588,,In vivo,1,,N,,,,Intermediate,Cmax value after administration of 4 mg/Kg oral dose in dog,A,1,,2959,CHEMBL621661,,BAO_0000218,
6003,50588,,In vivo,1,,N,,,,Intermediate,Cmax value in dog,A,1,,6241,CHEMBL621662,,BAO_0000218,
6004,50588,,In vivo,1,,N,,,,Intermediate,Cmax value in dogs after oral administration at 1 mg/kg,A,1,,6241,CHEMBL621663,,BAO_0000218,
6005,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,1,,2652,CHEMBL621664,,BAO_0000218,
6006,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,1,,1806,CHEMBL621665,,BAO_0000218,1969.0
6007,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,1,,1806,CHEMBL621666,,BAO_0000218,1969.0
6008,50588,,In vivo,1,,N,,,,Intermediate,Concentration maxima after oral dosing in dogs,A,1,,1021,CHEMBL621667,,BAO_0000218,
6009,50588,,In vivo,1,,N,,,,Intermediate,Concentration maxima after oral dosing in dogs; not available,A,1,,1021,CHEMBL876738,,BAO_0000218,
6010,50588,,In vivo,1,,N,,,,Intermediate,Concentration maxima after oral dosing in dogs; not available,A,1,,1021,CHEMBL621668,,BAO_0000218,
6011,50588,,In vivo,1,,N,,,,Intermediate,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,1,,5444,CHEMBL621669,,BAO_0000218,
6012,50588,,In vivo,1,,N,,,,Intermediate,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,1,,5444,CHEMBL621670,,BAO_0000218,
6013,50588,,In vivo,1,,N,,,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,1,,5444,CHEMBL621671,,BAO_0000218,
6014,50588,,In vivo,1,,N,,,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,1,,5444,CHEMBL622360,,BAO_0000218,
6015,50588,,In vivo,1,,N,,,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,1,,5444,CHEMBL622361,,BAO_0000218,
6016,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in dog plasma after oral dose (1 mg/kg),A,1,,5130,CHEMBL622362,,BAO_0000218,1969.0
6017,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,1,,3249,CHEMBL622363,,BAO_0000218,1969.0
6018,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration at a dose of 1 mg/kg,A,1,,5473,CHEMBL622364,,BAO_0000218,1969.0
6019,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,1,,5474,CHEMBL622365,,BAO_0000218,1969.0
6020,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,1,,4657,CHEMBL622533,,BAO_0000218,1969.0
6021,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration of compound in dog was evaluated.,A,1,,3031,CHEMBL622534,,BAO_0000218,
6022,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,1,,4527,CHEMBL622535,,BAO_0000218,
6023,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,1,,4186,CHEMBL876739,,BAO_0000218,
6024,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,1,,5007,CHEMBL622536,,BAO_0000218,
6025,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration obtained in dog plasma was determined,A,1,,3132,CHEMBL622537,,BAO_0000218,1969.0
6026,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration was determined,A,1,,5006,CHEMBL622538,,BAO_0000218,
6027,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration at the dose of 2 mg/kg in dog,A,1,,4727,CHEMBL627867,,BAO_0000218,
6028,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL627868,,BAO_0000218,
6029,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration was evaluated in dog plasma,A,1,,1918,CHEMBL627869,,BAO_0000218,1969.0
6030,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration was evaluated after 75 min after administration in dog,A,1,,3045,CHEMBL627870,,BAO_0000218,
6031,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration determined in dog after oral administration of 17b,A,1,,9579,CHEMBL627871,,BAO_0000218,1969.0
6032,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration determined in dog after oral administration of 2b,A,1,,9579,CHEMBL627872,,BAO_0000218,1969.0
6033,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in dog,A,1,,933,CHEMBL627873,,BAO_0000218,1969.0
6034,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,1,,17839,CHEMBL627874,,BAO_0000218,1969.0
6035,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,1,,17839,CHEMBL627875,,BAO_0000218,1969.0
6036,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,1,,17839,CHEMBL627876,,BAO_0000218,1969.0
6037,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,1,,17839,CHEMBL627877,,BAO_0000218,1969.0
6038,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL627878,,BAO_0000218,1969.0
6039,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,1,,16367,CHEMBL627879,,BAO_0000218,1969.0
6040,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL875355,,BAO_0000218,1969.0
6041,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL627880,,BAO_0000218,1969.0
6042,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,1,,5199,CHEMBL627881,,BAO_0000218,1969.0
6043,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,1,,17650,CHEMBL627882,,BAO_0000218,1969.0
6044,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,1,,6679,CHEMBL627883,,BAO_0000218,1969.0
6045,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,1,,5356,CHEMBL628526,,BAO_0000218,1969.0
6046,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,1,,5356,CHEMBL628527,,BAO_0000218,1969.0
6047,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,1,,6227,CHEMBL628528,,BAO_0000218,1969.0
6048,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,1,,6227,CHEMBL628529,,BAO_0000218,1969.0
6049,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,1,,6227,CHEMBL628530,,BAO_0000218,1969.0
6050,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,1,,6227,CHEMBL625243,,BAO_0000218,1969.0
6051,50588,,In vivo,1,,N,,Plasma,,Expert,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL625244,,BAO_0000218,1969.0
6052,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,1,,4368,CHEMBL625245,,BAO_0000218,
6053,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,1,,6265,CHEMBL625246,,BAO_0000218,
6054,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL625247,,BAO_0000218,945.0
6055,50594,,In vivo,1,,N,,Urine,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,1,,7767,CHEMBL625248,,BAO_0000218,1088.0
6056,50594,,In vivo,1,,N,,Urine,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,1,,7767,CHEMBL625249,,BAO_0000218,1088.0
6057,50594,,In vivo,1,,N,,Urine,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,1,,7767,CHEMBL625250,,BAO_0000218,1088.0
6058,50594,,,1,,N,,,,Intermediate,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,1,,17811,CHEMBL625251,,BAO_0000218,
6059,50594,,,1,,N,,,,Intermediate,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,1,,17811,CHEMBL875356,,BAO_0000218,
6060,50594,,,1,,N,,,,Intermediate,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,1,,17827,CHEMBL625252,,BAO_0000218,
6061,50594,,,1,,N,,Blood,,Intermediate,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,1,,17827,CHEMBL625253,,BAO_0000218,178.0
6062,50594,,,1,,N,,,,Intermediate,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,1,,17827,CHEMBL625254,,BAO_0000218,
6063,50594,,,1,,N,,,,Intermediate,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,1,,17827,CHEMBL625255,,BAO_0000218,
6064,50594,,,1,,N,,,,Intermediate,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,1,,17827,CHEMBL625256,,BAO_0000218,
6065,50594,,,1,,N,,Blood,,Intermediate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,1,,17827,CHEMBL625257,,BAO_0000218,178.0
6066,50594,,,1,,N,,Blood,,Intermediate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,1,,17827,CHEMBL625258,,BAO_0000218,178.0
6067,50594,,,1,,N,,,,Intermediate,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,1,,17827,CHEMBL625259,,BAO_0000218,
6068,50594,,,1,,N,,,,Intermediate,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,1,,17827,CHEMBL625260,,BAO_0000218,
6069,50594,,,1,,N,,,,Intermediate,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,1,,17827,CHEMBL625261,,BAO_0000218,
6070,50594,,,1,,N,,,,Intermediate,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,1,,17827,CHEMBL625262,,BAO_0000218,
6071,50594,,,1,,N,,,,Intermediate,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,1,,17827,CHEMBL622639,,BAO_0000218,
6072,50594,,,1,,N,,,,Intermediate,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,1,,17257,CHEMBL622640,,BAO_0000218,
6073,50594,,,1,,N,,,,Intermediate,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,1,,17257,CHEMBL622812,,BAO_0000218,
6074,50594,,,1,,N,,,,Intermediate,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,1,,17257,CHEMBL622813,,BAO_0000218,
6075,50594,,,1,,N,,,,Intermediate,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,1,,17257,CHEMBL622814,,BAO_0000218,
6076,50594,,,1,,N,,,,Intermediate,Time at maximum activity in mice (Radiolabeled compound),A,1,,17827,CHEMBL622815,,BAO_0000218,
6077,50594,,,1,,N,,,,Intermediate,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,1,,3760,CHEMBL625342,,BAO_0000218,
6078,50594,,,1,,N,,,,Intermediate,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,1,,3760,CHEMBL625343,,BAO_0000218,
6079,50594,,,1,,N,,,,Intermediate,Binding towards mouse plasma protein at 10 uM,A,1,,17409,CHEMBL877591,,BAO_0000218,
6080,50594,,,1,,N,,,,Intermediate,Binding towards mouse plasma protein at 100 uM,A,1,,17409,CHEMBL625344,,BAO_0000218,
6081,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in mice after intravenous administration,A,1,,2675,CHEMBL625345,,BAO_0000218,
6082,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in mice after oral administration,A,1,,2675,CHEMBL625346,,BAO_0000218,
6083,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,1,,3132,CHEMBL625347,,BAO_0000218,
6084,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,1,,3132,CHEMBL625348,,BAO_0000218,
6085,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL625349,,BAO_0000218,
6086,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse,A,1,,2862,CHEMBL625350,,BAO_0000218,
6087,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL882952,,BAO_0000218,
6088,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL625351,,BAO_0000218,955.0
6089,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL625352,,BAO_0000218,955.0
6090,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL877592,,BAO_0000218,955.0
6091,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL625353,,BAO_0000218,955.0
6092,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL625354,,BAO_0000218,955.0
6093,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL626019,,BAO_0000218,955.0
6094,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL626020,,BAO_0000218,948.0
6095,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL626021,,BAO_0000218,948.0
6096,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL626022,,BAO_0000218,948.0
6097,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL626192,,BAO_0000218,948.0
6098,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,1,,1276,CHEMBL626193,646.0,BAO_0000219,
6099,80682,,,1,,N,,,A549,Expert,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,1,,3498,CHEMBL626194,646.0,BAO_0000219,
6100,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against human lung carcinoma A-549 cell lines,F,1,,1169,CHEMBL626195,646.0,BAO_0000219,
6101,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,1,,4450,CHEMBL626196,646.0,BAO_0000219,
6102,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,1,,358,CHEMBL626197,646.0,BAO_0000219,
6103,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,1,,358,CHEMBL626198,646.0,BAO_0000219,
6104,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,1,,358,CHEMBL626199,646.0,BAO_0000219,
6105,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,1,,358,CHEMBL626200,646.0,BAO_0000219,
6106,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,1,,358,CHEMBL626201,646.0,BAO_0000219,
6107,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,1,,358,CHEMBL626202,646.0,BAO_0000219,
6108,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,1,,358,CHEMBL626203,646.0,BAO_0000219,
6109,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against A-549 human lung cancer cells,F,1,,15167,CHEMBL626204,646.0,BAO_0000219,
6110,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,1,,4139,CHEMBL624701,646.0,BAO_0000219,
6111,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,1,,833,CHEMBL624702,646.0,BAO_0000219,
6112,80682,,,1,,N,,,A549,Expert,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,1,,15718,CHEMBL624703,646.0,BAO_0000219,
6113,80682,,,1,,N,,,A549,Intermediate,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,1,,12373,CHEMBL624704,646.0,BAO_0000219,
6114,80682,,,1,,N,,,A549,Intermediate,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,1,,637,CHEMBL624705,646.0,BAO_0000219,
6115,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,1,,14867,CHEMBL624706,646.0,BAO_0000219,
6116,80682,,,1,,N,,,A549,Intermediate,Antitumor cytotoxic activity against A-549 cell line was determined,F,1,,4461,CHEMBL624707,646.0,BAO_0000219,
6117,80682,,,1,,N,,,A549,Intermediate,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,1,,5406,CHEMBL624708,646.0,BAO_0000219,
6118,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,1,,4457,CHEMBL624709,646.0,BAO_0000219,
6119,80682,,,1,,N,,,A549,Expert,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,1,,1386,CHEMBL884107,646.0,BAO_0000219,
6120,80682,,,1,,N,,,A549,Intermediate,Antitumoral activity was assayed against A-549 cell line,F,1,,3265,CHEMBL624710,646.0,BAO_0000219,
6121,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,1,,2359,CHEMBL624711,646.0,BAO_0000219,
6122,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,1,,4457,CHEMBL624712,646.0,BAO_0000219,
6123,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,1,,12454,CHEMBL624713,646.0,BAO_0000219,
6124,80682,,,1,,N,,,A549,Intermediate,Compound was tested for inhibition of cell growth of A-549 cells,F,1,,1481,CHEMBL624714,646.0,BAO_0000219,
6125,80682,,,1,,N,,,A549,Intermediate,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,1,,1750,CHEMBL624715,646.0,BAO_0000219,
6126,80682,,,1,,N,,,A549,Intermediate,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,1,,5065,CHEMBL624716,646.0,BAO_0000219,
6127,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,1,,808,CHEMBL619505,646.0,BAO_0000219,
6128,80682,,,1,,N,,,A549,Expert,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,1,,16364,CHEMBL619506,646.0,BAO_0000219,
6129,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity against A-549 cell lines.,F,1,,1847,CHEMBL619507,646.0,BAO_0000219,
6130,80682,,,1,,N,,,A549,Expert,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,1,,1747,CHEMBL619508,646.0,BAO_0000219,
6131,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against human A549 non small cell lung cell lines,F,1,,1003,CHEMBL619509,646.0,BAO_0000219,
6132,80682,,,1,,N,,,A549,Expert,Inhibition of cell growth in (A-549) lung cell line,F,1,,15313,CHEMBL619510,646.0,BAO_0000219,
6133,80682,,,1,,N,,,A549,Intermediate,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,1,,3122,CHEMBL619511,646.0,BAO_0000219,
6134,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against A-549 tumor cells.,F,1,,16049,CHEMBL619512,646.0,BAO_0000219,
6135,80682,,,1,,N,,,A549,Expert,In vitro antitumor effects against human A-549 cell lines.,F,1,,17134,CHEMBL619513,646.0,BAO_0000219,
6136,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxic activity of compound against A-549 cell line,F,1,,6406,CHEMBL619514,646.0,BAO_0000219,
6137,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,1,,627,CHEMBL619515,646.0,BAO_0000219,
6138,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,1,,12307,CHEMBL619516,646.0,BAO_0000219,
6139,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,1,,17861,CHEMBL884005,646.0,BAO_0000219,
6140,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,1,,6682,CHEMBL619517,646.0,BAO_0000219,
6141,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration of compound against A-549 cell line,F,1,,6663,CHEMBL619518,646.0,BAO_0000219,
6142,80682,,,1,,N,,,A549,Intermediate,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,1,,2454,CHEMBL619519,646.0,BAO_0000219,
6143,80682,,,1,,N,,,A549,Intermediate,cytotoxic activity against leukemia (A-549) cancer cell line,F,1,,14709,CHEMBL876489,646.0,BAO_0000219,
6144,80682,,,1,,N,,,A549,Expert,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,1,,15718,CHEMBL619520,646.0,BAO_0000219,
6145,80682,,,1,,N,,,A549,Intermediate,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,1,,15718,CHEMBL619521,646.0,BAO_0000219,
6146,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,1,,17130,CHEMBL619522,646.0,BAO_0000219,
6147,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,1,,17130,CHEMBL619523,646.0,BAO_0000219,
6148,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,1,,17130,CHEMBL619524,646.0,BAO_0000219,
6149,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,1,,17130,CHEMBL619525,646.0,BAO_0000219,
6150,80682,,,1,,N,,,A549,Intermediate,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,1,,6630,CHEMBL619526,646.0,BAO_0000219,
6151,80682,,,1,,N,,,A549,Intermediate,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,1,,16726,CHEMBL619527,646.0,BAO_0000219,
6152,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against A549 cells; No cytotoxicity,F,1,,17846,CHEMBL619528,646.0,BAO_0000219,
6153,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human lung carcinoma (A549) cell lines,F,1,,3415,CHEMBL619529,646.0,BAO_0000219,
6154,80682,,,1,,N,,,A549,Expert,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,1,,3415,CHEMBL619530,646.0,BAO_0000219,
6155,80682,,,1,,N,,,A549,Intermediate,In vitro anticancer activity against human lung (A549) cell line,F,1,,5609,CHEMBL876490,646.0,BAO_0000219,
6156,80682,,,1,,N,,,A549,Intermediate,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,1,,17206,CHEMBL619531,646.0,BAO_0000219,
6157,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619532,646.0,BAO_0000219,
6158,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619533,646.0,BAO_0000219,
6159,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619534,646.0,BAO_0000219,
6160,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,1,,17206,CHEMBL620164,646.0,BAO_0000219,
6161,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,1,,17206,CHEMBL620165,646.0,BAO_0000219,
6162,80682,,,1,,N,,,A549,Expert,Inhibition of A549 human lung tumor cell proliferation,F,1,,16295,CHEMBL620166,646.0,BAO_0000219,
6163,80682,,,1,,N,,,A549,Intermediate,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,1,,16825,CHEMBL620167,646.0,BAO_0000219,
6164,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against human tumor cell line A549,F,1,,3439,CHEMBL620168,646.0,BAO_0000219,
6165,80682,,,1,,N,,,A549,Intermediate,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,1,,10870,CHEMBL620338,646.0,BAO_0000219,
6166,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,1,,4845,CHEMBL620339,646.0,BAO_0000219,
6167,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,1,,5822,CHEMBL620340,646.0,BAO_0000219,
6168,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,1,,5822,CHEMBL620341,646.0,BAO_0000219,
6169,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,1,,5822,CHEMBL876491,646.0,BAO_0000219,
6170,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,1,,16381,CHEMBL620342,646.0,BAO_0000219,
6171,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,1,,16381,CHEMBL620343,646.0,BAO_0000219,
6172,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,1,,16381,CHEMBL620344,646.0,BAO_0000219,
6173,80682,,,1,,N,,,A549,Intermediate,In vitro anticancer activity against human lung (A549) cell line,F,1,,5609,CHEMBL620345,646.0,BAO_0000219,
6174,80682,,,1,,N,,,A549,Intermediate,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,1,,4644,CHEMBL620346,646.0,BAO_0000219,
6175,80682,,,1,,N,,,A549,Intermediate,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,1,,4644,CHEMBL620347,646.0,BAO_0000219,
6176,80682,,,1,,N,,,A549,Intermediate,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,1,,4644,CHEMBL620348,646.0,BAO_0000219,
6177,80682,,,1,,N,,,A549,Intermediate,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,1,,4644,CHEMBL620349,646.0,BAO_0000219,
6178,80682,,,1,,N,,,A549,Intermediate,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,1,,5822,CHEMBL618667,646.0,BAO_0000219,
6179,80682,,,1,,N,,,A549,Expert,Percentage inhibition of human lung carcinoma (A549) cell lines,F,1,,3415,CHEMBL618668,646.0,BAO_0000219,
6180,80682,,,1,,N,,,A549,Intermediate,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,1,,16726,CHEMBL876031,646.0,BAO_0000219,
6181,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,1,,17206,CHEMBL618759,646.0,BAO_0000219,
6182,80682,,,1,,N,,,A549,Intermediate,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,1,,17206,CHEMBL618760,646.0,BAO_0000219,
6183,80682,,,1,,N,,,A549,Intermediate,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,1,,17206,CHEMBL619000,646.0,BAO_0000219,
6184,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,1,,17206,CHEMBL619001,646.0,BAO_0000219,
6185,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,1,,17206,CHEMBL619002,646.0,BAO_0000219,
6186,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,1,,17206,CHEMBL619003,646.0,BAO_0000219,
6187,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,1,,17206,CHEMBL619597,646.0,BAO_0000219,
6188,80682,,,1,,N,,,A549,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,1,,17206,CHEMBL619598,646.0,BAO_0000219,
6189,80682,,,1,,N,,,A549,Intermediate,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,1,,17206,CHEMBL619599,646.0,BAO_0000219,
6190,80682,,,1,,N,,,A549,Intermediate,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,1,,17206,CHEMBL619600,646.0,BAO_0000219,
6191,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,1,,16726,CHEMBL619601,646.0,BAO_0000219,
6192,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619602,646.0,BAO_0000219,
6193,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619603,646.0,BAO_0000219,
6194,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619604,646.0,BAO_0000219,
6195,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619605,646.0,BAO_0000219,
6196,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,1,,6084,CHEMBL619606,,BAO_0000218,
6197,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic activity (Cmax) in dog,A,1,,6084,CHEMBL876032,,BAO_0000218,
6198,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,1,,4809,CHEMBL619607,,BAO_0000218,
6199,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,1,,5983,CHEMBL619608,,BAO_0000218,
6200,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,1,,6251,CHEMBL619609,,BAO_0000218,
6201,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in dog plasma after 30mg/kg oral dose,A,1,,5932,CHEMBL619610,,BAO_0000218,1969.0
6202,50588,,In vivo,1,,N,,Blood,,Intermediate,Tested for the peak blood level in dog,A,1,,4273,CHEMBL619611,,BAO_0000218,178.0
6203,50588,,In vivo,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,1,,5313,CHEMBL619612,,BAO_0000218,
6204,50588,,In vivo,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,1,,5313,CHEMBL619613,,BAO_0000218,
6205,50588,,In vivo,1,,N,,Blood,,Intermediate,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,1,,6221,CHEMBL619614,,BAO_0000218,178.0
6206,50588,,,1,,N,,,,Intermediate,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL619615,,BAO_0000218,
6207,50588,,,1,,N,,,,Intermediate,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,1,,167,CHEMBL619616,,BAO_0000218,
6208,50588,,,1,,N,,Plasma,,Intermediate,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,1,,6241,CHEMBL619617,,BAO_0000218,1969.0
6209,50588,,,1,,N,,,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,1,,344,CHEMBL619618,,BAO_0000218,
6210,50588,,,1,,N,,,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,1,,344,CHEMBL876033,,BAO_0000218,
6211,50588,,,1,,N,,,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,1,,344,CHEMBL619619,,BAO_0000218,
6212,50588,,,1,,N,,,,Intermediate,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,1,,2189,CHEMBL619620,,BAO_0000218,
6213,50588,,,1,,N,,Urine,,Intermediate,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,1,,2189,CHEMBL619621,,BAO_0000218,1088.0
6214,50588,,,1,,N,,Urine,,Intermediate,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,1,,2189,CHEMBL619622,,BAO_0000218,1088.0
6215,50588,,,1,,N,,Urine,,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,1,,2189,CHEMBL618874,,BAO_0000218,1088.0
6216,50588,,In vivo,1,,N,,,,Intermediate,Absolute bioavailability was evaluated in dog,A,1,,4257,CHEMBL618875,,BAO_0000218,
6217,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,1,,6221,CHEMBL618876,,BAO_0000218,
6218,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,1,,6215,CHEMBL618877,,BAO_0000218,
6219,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,17267,CHEMBL618878,,BAO_0000218,
6220,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,6621,CHEMBL618879,,BAO_0000218,
6221,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability after intravenous administration in dogs,A,1,,3854,CHEMBL618880,,BAO_0000218,
6222,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability after peroral administration in dogs,A,1,,3854,CHEMBL618881,,BAO_0000218,
6223,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,1,,5007,CHEMBL618882,,BAO_0000218,
6224,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,1,,4333,CHEMBL624226,,BAO_0000218,
6225,50588,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,1,,4333,CHEMBL624227,,BAO_0000218,1969.0
6226,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability,A,1,,5006,CHEMBL624228,,BAO_0000218,
6227,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability,A,1,,5199,CHEMBL624229,,BAO_0000218,
6228,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,1,,4368,CHEMBL624230,,BAO_0000218,
6229,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,3771,CHEMBL624231,,BAO_0000218,
6230,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,4953,CHEMBL624232,,BAO_0000218,
6231,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,5064,CHEMBL625127,,BAO_0000218,
6232,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,17657,CHEMBL625128,,BAO_0000218,
6233,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,17796,CHEMBL621675,,BAO_0000218,
6234,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL621676,,BAO_0000218,
6235,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,1,,4521,CHEMBL621677,,BAO_0000218,
6236,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,1,,4521,CHEMBL621678,,BAO_0000218,
6237,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,5006,CHEMBL621679,,BAO_0000218,
6238,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated after oral administration in dog,A,1,,16365,CHEMBL621680,,BAO_0000218,
6239,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL621681,,BAO_0000218,
6240,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in dog,A,1,,1918,CHEMBL876740,,BAO_0000218,
6241,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,4239,CHEMBL621682,,BAO_0000218,
6242,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,6505,CHEMBL621683,,BAO_0000218,
6243,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,1,,5334,CHEMBL621684,,BAO_0000218,
6244,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,1,,5334,CHEMBL621685,,BAO_0000218,
6245,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,1,,4809,CHEMBL621686,,BAO_0000218,
6246,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL621687,,BAO_0000218,
6247,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,1,,6005,CHEMBL621688,,BAO_0000218,
6248,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability of compound in dog was determined after peroral administration,A,1,,17804,CHEMBL621689,,BAO_0000218,
6249,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3184,CHEMBL621690,,BAO_0000218,
6250,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,1,,1806,CHEMBL621691,,BAO_0000218,
6251,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,1,,1806,CHEMBL875941,,BAO_0000218,
6252,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,1,,1806,CHEMBL621692,,BAO_0000218,
6253,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,4839,CHEMBL621693,,BAO_0000218,
6254,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,1,,5017,CHEMBL621694,,BAO_0000218,
6255,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL621695,,BAO_0000218,948.0
6256,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL621696,,BAO_0000218,948.0
6257,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL621697,,BAO_0000218,2113.0
6258,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL621698,,BAO_0000218,2113.0
6259,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623420,,BAO_0000218,2113.0
6260,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623421,,BAO_0000218,2113.0
6261,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623422,,BAO_0000218,2113.0
6262,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623423,,BAO_0000218,2113.0
6263,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623424,,BAO_0000218,2107.0
6264,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623425,,BAO_0000218,2107.0
6265,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623426,,BAO_0000218,2107.0
6266,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623427,,BAO_0000218,2107.0
6267,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623428,,BAO_0000218,2107.0
6268,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL875947,,BAO_0000218,2107.0
6269,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623429,,BAO_0000218,2048.0
6270,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL623430,,BAO_0000218,2048.0
6271,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL622588,,BAO_0000218,2048.0
6272,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL622589,,BAO_0000218,2048.0
6273,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL622751,,BAO_0000218,2048.0
6274,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,1,,846,CHEMBL622752,,BAO_0000218,2048.0
6275,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL622753,42.0,BAO_0000218,
6276,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL622647,42.0,BAO_0000218,
6277,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL875163,42.0,BAO_0000218,
6278,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL622648,42.0,BAO_0000218,
6279,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL622649,42.0,BAO_0000218,
6280,50594,,,1,,N,,Brain,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL622650,42.0,BAO_0000218,955.0
6281,50594,,,1,,N,,Brain,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL622651,42.0,BAO_0000218,955.0
6282,50594,,,1,,N,,Brain,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL622652,42.0,BAO_0000218,955.0
6283,50594,,,1,,N,,Brain,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL622653,42.0,BAO_0000218,955.0
6284,50594,,,1,,N,,Brain,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL622654,42.0,BAO_0000218,955.0
6285,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL622655,42.0,BAO_0000218,948.0
6286,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL622656,42.0,BAO_0000218,948.0
6287,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL622657,42.0,BAO_0000218,948.0
6288,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL622658,42.0,BAO_0000218,948.0
6289,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL622659,42.0,BAO_0000218,948.0
6290,50594,,,1,,N,,Kidney,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL624630,42.0,BAO_0000218,2113.0
6291,50594,,,1,,N,,Kidney,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL624631,42.0,BAO_0000218,2113.0
6292,50594,,,1,,N,,Kidney,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL624632,42.0,BAO_0000218,2113.0
6293,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,1,,17130,CHEMBL624633,646.0,BAO_0000219,
6294,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,1,,17130,CHEMBL624634,646.0,BAO_0000219,
6295,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,1,,17130,CHEMBL624635,646.0,BAO_0000219,
6296,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,1,,17130,CHEMBL624636,646.0,BAO_0000219,
6297,80682,,,1,,N,,,A549,Expert,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,1,,3263,CHEMBL857055,646.0,BAO_0000219,
6298,80682,,,1,,N,,,A549,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,1,,6663,CHEMBL624637,646.0,BAO_0000219,
6299,80682,,,1,,N,,,A549,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,1,,6663,CHEMBL624638,646.0,BAO_0000219,
6300,80682,,,1,,N,,,A549,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,1,,6663,CHEMBL874366,646.0,BAO_0000219,
6301,80682,,,1,,N,,,A549,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,1,,6663,CHEMBL624639,646.0,BAO_0000219,
6302,80682,,,1,,N,,,A549,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,1,,6663,CHEMBL624640,646.0,BAO_0000219,
6303,80682,,,1,,N,,,A549,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,1,,6663,CHEMBL624641,646.0,BAO_0000219,
6304,80682,,,1,,N,,,A549,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,1,,6663,CHEMBL624642,646.0,BAO_0000219,
6305,80682,,,1,,N,,,A549,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,1,,6663,CHEMBL624643,646.0,BAO_0000219,
6306,80682,,,1,,N,,,A549,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,1,,6663,CHEMBL624644,646.0,BAO_0000219,
6307,80682,,,1,,N,,,A549,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,1,,6663,CHEMBL624645,646.0,BAO_0000219,
6308,80682,,,1,,N,,,A549,Intermediate,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,1,,3983,CHEMBL619445,646.0,BAO_0000219,
6309,80682,,,1,,N,,,A549,Expert,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,1,,11141,CHEMBL839886,646.0,BAO_0000219,
6310,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 tumor cell line.,F,1,,5076,CHEMBL619446,646.0,BAO_0000219,
6311,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,1,,3311,CHEMBL619447,646.0,BAO_0000219,
6312,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,1,,3311,CHEMBL619448,646.0,BAO_0000219,
6313,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,1,,3311,CHEMBL619449,646.0,BAO_0000219,
6314,80682,,,1,,N,,,A549,Intermediate,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,1,,5076,CHEMBL619450,646.0,BAO_0000219,
6315,80682,,,1,,N,,,A549,Intermediate,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,1,,4150,CHEMBL619451,646.0,BAO_0000219,
6316,80682,,,1,,N,,,A549,Expert,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,1,,2150,CHEMBL619452,646.0,BAO_0000219,
6317,80682,,,1,,N,,,A549,Intermediate,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,1,,4644,CHEMBL619453,646.0,BAO_0000219,
6318,80682,,,1,,N,,,A549,Intermediate,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,1,,263,CHEMBL874367,646.0,BAO_0000219,
6319,80682,,,1,,N,,,A549,Intermediate,Cytotoxic concentration against A-549 tumor cells.,F,1,,11333,CHEMBL619454,646.0,BAO_0000219,
6320,80682,,,1,,N,,,A549,Intermediate,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,1,,11333,CHEMBL619455,646.0,BAO_0000219,
6321,80682,,,1,,N,,,A549,Intermediate,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,1,,15895,CHEMBL619456,646.0,BAO_0000219,
6322,50191,,,1,,N,,,,Expert,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,1,,16677,CHEMBL619457,,BAO_0000218,
6323,50192,,,1,,N,,,,Intermediate,Activity against Acinetobacter calcoaceticus (AC54),F,1,,10624,CHEMBL619458,,BAO_0000218,
6324,50274,,,1,,N,,,,Expert,In vitro antifungal activity against Aspergillus flavus CM74,F,1,,16717,CHEMBL619459,,BAO_0000218,
6325,50274,,,1,,N,,,,Expert,In vitro antifungal activity against Aspergillus flavus CM74,F,1,,16717,CHEMBL619460,,BAO_0000218,
6326,50416,,,1,,N,,,,Intermediate,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,1,,5513,CHEMBL619461,,BAO_0000218,
6327,50416,,,1,,N,,,,Intermediate,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,1,,15962,CHEMBL619462,,BAO_0000218,
6328,50416,,,1,,N,,,,Intermediate,Antimicrobial activity against Aspergillus fumigatus (MIC),F,1,,15962,CHEMBL620388,,BAO_0000218,
6329,50416,,,1,,N,,,,Intermediate,Antimicrobial activity against Aspergillus fumigatus (MIC),F,1,,15962,CHEMBL620389,,BAO_0000218,
6330,50416,,,1,,N,,,,Intermediate,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,1,,15962,CHEMBL620390,,BAO_0000218,
6331,50416,,,1,,N,,,,Expert,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,1,,16717,CHEMBL620391,,BAO_0000218,
6332,50416,,,1,,N,,,,Expert,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,1,,16717,CHEMBL621073,,BAO_0000218,
6333,50296,,,1,,N,,,,Intermediate,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,1,,8117,CHEMBL621074,,BAO_0000218,
6334,50366,,,1,,N,,,,Intermediate,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,1,,8117,CHEMBL621075,,BAO_0000218,
6335,50535,,,1,,N,,,,Intermediate,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,1,,15472,CHEMBL619554,,BAO_0000218,
6336,50535,,,1,,N,,,,Intermediate,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,1,,15472,CHEMBL619555,,BAO_0000218,
6337,50169,,,1,,N,,,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,1,,16443,CHEMBL619556,,BAO_0000218,
6338,50169,,,1,,N,,,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,1,,16443,CHEMBL619557,,BAO_0000218,
6339,50169,,,1,,N,,,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,1,,16443,CHEMBL619558,,BAO_0000218,
6340,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619559,646.0,BAO_0000219,
6341,80682,,,1,,N,,,A549,Intermediate,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619560,646.0,BAO_0000219,
6342,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,1,,16381,CHEMBL619561,646.0,BAO_0000219,
6343,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,1,,16381,CHEMBL619562,646.0,BAO_0000219,
6344,80682,,,1,,N,,,A549,Intermediate,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,1,,16381,CHEMBL619563,646.0,BAO_0000219,
6345,80682,,,1,,N,,,A549,Intermediate,GI values against A549 cells (lung cancer),F,1,,16381,CHEMBL857457,646.0,BAO_0000219,
6346,80682,,,1,,N,,,A549,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,1,,17206,CHEMBL619564,646.0,BAO_0000219,
6347,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 human adenocarcinoma,F,1,,16325,CHEMBL619565,646.0,BAO_0000219,
6348,80682,,,1,,N,,,A549,Intermediate,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,1,,10708,CHEMBL619566,646.0,BAO_0000218,
6349,80682,,,1,,N,,,A549,Intermediate,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,1,,10708,CHEMBL619567,646.0,BAO_0000218,
6350,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line,F,1,,17376,CHEMBL619568,646.0,BAO_0000219,
6351,80682,,,1,,N,,,A549,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,1,,17376,CHEMBL619569,646.0,BAO_0000219,
6352,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity against human A549 lung cells,F,1,,17488,CHEMBL619570,646.0,BAO_0000219,
6353,80682,,,1,,N,,,A549,Intermediate,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,1,,17404,CHEMBL619571,646.0,BAO_0000218,
6354,80682,,,1,,N,,,A549,Expert,Growth inhibition of A549 (human lung carcinoma) cell line.,F,1,,10958,CHEMBL619572,646.0,BAO_0000219,
6355,80682,,,1,,N,,,A549,Expert,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,1,,17099,CHEMBL619573,646.0,BAO_0000219,
6356,80682,,,1,,N,,,A549,Intermediate,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,1,,17099,CHEMBL619574,646.0,BAO_0000219,
6357,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,1,,4096,CHEMBL619575,646.0,BAO_0000219,
6358,80682,,,1,,N,,,A549,Expert,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,1,,4096,CHEMBL619576,646.0,BAO_0000219,
6359,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,1,,4096,CHEMBL619577,646.0,BAO_0000219,
6360,80682,,,1,,N,,,A549,Intermediate,In vitro inhibitory activity against A549 tumor cell culture,F,1,,2525,CHEMBL619578,646.0,BAO_0000219,
6361,80682,,,1,,N,,,A549,Intermediate,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,1,,2525,CHEMBL884009,646.0,BAO_0000219,
6362,80682,,,1,,N,,,A549,Intermediate,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,1,,5302,CHEMBL619579,646.0,BAO_0000219,
6363,80682,,,1,,N,,,A549,Intermediate,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,1,,16325,CHEMBL619580,646.0,BAO_0000219,
6364,80682,,,1,,N,,,A549,Intermediate,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,1,,16939,CHEMBL619581,646.0,BAO_0000219,
6365,80682,,,1,,N,,,A549,Intermediate,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,1,,17229,CHEMBL619582,646.0,BAO_0000219,
6366,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,1,,17380,CHEMBL619583,646.0,BAO_0000219,
6367,80682,,,1,,N,,,A549,Intermediate,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,1,,17380,CHEMBL876502,646.0,BAO_0000219,
6368,80682,,,1,,N,,,A549,Intermediate,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,1,,1903,CHEMBL619584,646.0,BAO_0000219,
6369,80682,,,1,,N,,,A549,Intermediate,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,1,,3838,CHEMBL619585,646.0,BAO_0000219,
6370,80682,,,1,,N,,,A549,Intermediate,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,1,,14696,CHEMBL619586,646.0,BAO_0000219,
6371,80682,,,1,,N,,,A549,Intermediate,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,1,,3838,CHEMBL619587,646.0,BAO_0000219,
6372,80682,,,1,,N,,,A549,Intermediate,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,1,,1522,CHEMBL619588,646.0,BAO_0000219,
6373,80682,,,1,,N,,,A549,Intermediate,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,1,,12400,CHEMBL619589,646.0,BAO_0000219,
6374,80682,,,1,,N,,,A549,Intermediate,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,1,,14696,CHEMBL619590,646.0,BAO_0000219,
6375,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,1,,14769,CHEMBL619591,646.0,BAO_0000219,
6376,80682,,,1,,N,,,A549,Intermediate,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,1,,14696,CHEMBL619592,646.0,BAO_0000219,
6377,80682,,,1,,N,,,A549,Intermediate,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,1,,1888,CHEMBL619593,646.0,BAO_0000219,
6378,80682,,,1,,N,,,A549,Intermediate,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,1,,12016,CHEMBL620217,646.0,BAO_0000219,
6379,80682,,,1,,N,,,A549,Intermediate,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,1,,6058,CHEMBL620218,646.0,BAO_0000219,
6380,80682,,,1,,N,,,A549,Intermediate,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,1,,17708,CHEMBL620219,646.0,BAO_0000219,
6381,80682,,,1,,N,,,A549,Intermediate,Antitumor activity against A549/ATCC cell line,F,1,,12301,CHEMBL620220,646.0,BAO_0000219,
6382,80682,,,1,,N,,,A549,Intermediate,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,1,,11970,CHEMBL625141,646.0,BAO_0000219,
6383,80682,,,1,,N,,,A549,Expert,In vitro cytotoxicity against A549/ATCC cell line.,F,1,,11818,CHEMBL625142,646.0,BAO_0000219,
6384,80682,,,1,,N,,,A549,Intermediate,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,1,,12400,CHEMBL625143,646.0,BAO_0000219,
6385,80682,,,1,,N,,,A549,Intermediate,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,1,,3381,CHEMBL625144,646.0,BAO_0000219,
6386,80682,,,1,,N,,,A549,Intermediate,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,1,,17376,CHEMBL622474,646.0,BAO_0000219,
6387,80682,,,1,,N,,,A549,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL884104,646.0,BAO_0000219,
6388,22226,,,0,,U,,,,Autocuration,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,1,,2964,CHEMBL622475,,BAO_0000219,
6389,22224,,In vivo,0,,U,,,,Intermediate,Compound was tested for oral bioavailability in dogs,A,1,,5005,CHEMBL622476,,BAO_0000218,
6390,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,1,,6229,CHEMBL875831,,BAO_0000218,
6391,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,1,,6229,CHEMBL622477,,BAO_0000218,
6392,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5374,CHEMBL622478,,BAO_0000218,
6393,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested for the oral bioavailability in dog; No availability,A,1,,5374,CHEMBL623172,,BAO_0000218,
6394,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),A,1,,6265,CHEMBL623173,,BAO_0000218,
6395,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,1,,5654,CHEMBL623174,,BAO_0000218,
6396,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,1,,5654,CHEMBL623175,,BAO_0000218,
6397,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,1,,16456,CHEMBL623340,,BAO_0000218,
6398,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),A,1,,5302,CHEMBL623341,,BAO_0000218,
6399,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,1,,3624,CHEMBL623342,,BAO_0000218,
6400,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of active FTIs in dogs,A,1,,16452,CHEMBL623343,,BAO_0000218,
6401,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,1,,5802,CHEMBL623344,,BAO_0000218,
6402,50588,,In vivo,1,,N,,,,Expert,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL623345,,BAO_0000218,
6403,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,17839,CHEMBL875832,,BAO_0000218,
6404,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6762,CHEMBL623346,,BAO_0000218,
6405,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6821,CHEMBL623347,,BAO_0000218,
6406,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound was determined in dog; Not tested,A,1,,6821,CHEMBL623348,,BAO_0000218,
6407,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5210,CHEMBL623349,,BAO_0000218,
6408,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (10 mg/kg) was determined in dog,A,1,,6227,CHEMBL623350,,BAO_0000218,
6409,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,761,CHEMBL623351,,BAO_0000218,
6410,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,1,,761,CHEMBL623352,,BAO_0000218,
6411,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability administered in solution in rats,A,1,,761,CHEMBL623353,,BAO_0000218,
6412,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL875833,,BAO_0000218,
6413,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability at a dose of 1 mg/kg in dogs,A,1,,5474,CHEMBL623354,,BAO_0000218,
6414,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,1,,6535,CHEMBL623355,,BAO_0000218,
6415,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Dog; ND = not determined,A,1,,6535,CHEMBL623356,,BAO_0000218,
6416,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3352,CHEMBL623357,,BAO_0000218,
6417,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6168,CHEMBL623358,,BAO_0000218,
6418,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5988,CHEMBL623359,,BAO_0000218,
6419,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,4942,CHEMBL623360,,BAO_0000218,
6420,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dogs; No data,A,1,,4942,CHEMBL623361,,BAO_0000218,
6421,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability measured in dogs,A,1,,14541,CHEMBL623362,,BAO_0000218,
6422,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,4449,CHEMBL623363,,BAO_0000218,
6423,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in dog,A,1,,6057,CHEMBL623364,,BAO_0000218,
6424,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after 0.3 mg/kg po administration in dog,A,1,,5600,CHEMBL875834,,BAO_0000218,
6425,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (i.v. dosing),A,1,,5542,CHEMBL623365,,BAO_0000218,
6426,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5542,CHEMBL623366,,BAO_0000218,
6427,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,1,,5546,CHEMBL623367,,BAO_0000218,
6428,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Beagle dogs,A,1,,4514,CHEMBL623368,,BAO_0000218,
6429,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3624,CHEMBL623369,,BAO_0000218,
6430,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3854,CHEMBL623370,,BAO_0000218,
6431,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5836,CHEMBL623371,,BAO_0000218,
6432,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5940,CHEMBL623372,,BAO_0000218,
6433,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6168,CHEMBL621351,,BAO_0000218,
6434,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6227,CHEMBL621352,,BAO_0000218,
6435,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6251,CHEMBL621353,,BAO_0000218,
6436,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6448,CHEMBL621354,,BAO_0000218,
6437,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6647,CHEMBL621355,,BAO_0000218,
6438,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5940,CHEMBL621356,,BAO_0000218,
6439,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,933,CHEMBL621357,,BAO_0000218,
6440,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5210,CHEMBL621358,,BAO_0000218,
6441,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,1,,6642,CHEMBL621359,,BAO_0000218,
6442,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,1,,6641,CHEMBL621360,,BAO_0000218,
6443,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,1,,6642,CHEMBL621361,,BAO_0000218,
6444,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5472,CHEMBL621362,,BAO_0000218,
6445,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5985,CHEMBL621363,,BAO_0000218,
6446,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,15660,CHEMBL621364,,BAO_0000218,
6447,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,1,,5530,CHEMBL621166,,BAO_0000218,
6448,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,1,,5530,CHEMBL621167,,BAO_0000218,
6449,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (F) in dogs,A,1,,6305,CHEMBL621168,,BAO_0000218,
6450,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,5210,CHEMBL621169,,BAO_0000218,
6451,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,5238,CHEMBL875950,,BAO_0000218,
6452,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),A,1,,5668,CHEMBL621170,,BAO_0000218,
6453,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after peroral administration at 5 mpk in Dog,A,1,,5668,CHEMBL621171,,BAO_0000218,
6454,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),A,1,,5668,CHEMBL621172,,BAO_0000218,
6455,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),A,1,,6084,CHEMBL621173,,BAO_0000218,
6456,50594,,,1,,N,,Kidney,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621174,42.0,BAO_0000218,2113.0
6457,50594,,,1,,N,,Kidney,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621175,42.0,BAO_0000218,2113.0
6458,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621176,42.0,BAO_0000218,2107.0
6459,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621177,42.0,BAO_0000218,2107.0
6460,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621178,42.0,BAO_0000218,2107.0
6461,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621179,42.0,BAO_0000218,2107.0
6462,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621180,42.0,BAO_0000218,2107.0
6463,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL875951,42.0,BAO_0000218,2048.0
6464,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621181,42.0,BAO_0000218,2048.0
6465,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621182,42.0,BAO_0000218,2048.0
6466,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621183,42.0,BAO_0000218,2048.0
6467,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621184,42.0,BAO_0000218,2048.0
6468,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621185,42.0,BAO_0000218,
6469,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621186,42.0,BAO_0000218,
6470,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621187,42.0,BAO_0000218,
6471,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621188,42.0,BAO_0000218,
6472,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621189,42.0,BAO_0000218,
6473,50594,,,1,,N,,Spleen,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621190,42.0,BAO_0000218,2106.0
6474,50594,,,1,,N,,Spleen,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL618520,42.0,BAO_0000218,2106.0
6475,50594,,,1,,N,,Spleen,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621739,42.0,BAO_0000218,2106.0
6476,50594,,,1,,N,,Spleen,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621740,42.0,BAO_0000218,2106.0
6477,50594,,,1,,N,,Spleen,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621741,42.0,BAO_0000218,2106.0
6478,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621742,42.0,BAO_0000218,
6479,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621743,42.0,BAO_0000218,
6480,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621744,42.0,BAO_0000218,
6481,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621745,42.0,BAO_0000218,
6482,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621746,42.0,BAO_0000218,
6483,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621747,42.0,BAO_0000218,
6484,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621748,42.0,BAO_0000218,
6485,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL621749,42.0,BAO_0000218,
6486,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621750,42.0,BAO_0000218,
6487,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621751,42.0,BAO_0000218,
6488,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621752,42.0,BAO_0000218,948.0
6489,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL621753,42.0,BAO_0000218,948.0
6490,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL875955,42.0,BAO_0000218,948.0
6491,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL621754,42.0,BAO_0000218,948.0
6492,50594,,,1,,N,,Heart,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL621755,42.0,BAO_0000218,948.0
6493,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL621756,42.0,BAO_0000218,2107.0
6494,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL624199,42.0,BAO_0000218,2107.0
6495,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL624200,42.0,BAO_0000218,2107.0
6496,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL624375,42.0,BAO_0000218,2107.0
6497,50594,,,1,,N,,Liver,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL624376,42.0,BAO_0000218,2107.0
6498,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL624377,42.0,BAO_0000218,2048.0
6499,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL624378,42.0,BAO_0000218,2048.0
6500,50067,,,1,,N,,,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,1,,12269,CHEMBL857901,,BAO_0000218,
6501,50067,,,1,,N,,,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,1,,12269,CHEMBL875274,,BAO_0000218,
6502,50067,,,1,,N,,,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,1,,12269,CHEMBL624379,,BAO_0000218,
6503,50067,,,1,,N,,,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,1,,12269,CHEMBL624380,,BAO_0000218,
6504,50192,,,1,,N,,,,Intermediate,Activity against Acinetobacter calcoaceticus (AC54),F,1,,10624,CHEMBL624381,,BAO_0000218,
6505,50714,,,1,,N,,,,Intermediate,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,1,,17216,CHEMBL624382,,BAO_0000218,
6506,50714,,,1,,N,,,,Intermediate,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,1,,17216,CHEMBL624383,,BAO_0000218,
6507,50296,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,1,,9560,CHEMBL624384,,BAO_0000218,
6508,50296,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,1,,9560,CHEMBL624385,,BAO_0000218,
6509,50296,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,1,,9560,CHEMBL624386,,BAO_0000218,
6510,50296,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,1,,9560,CHEMBL624387,,BAO_0000218,
6511,50296,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii 631,F,1,,9560,CHEMBL624388,,BAO_0000218,
6512,50296,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii N/9,F,1,,9560,CHEMBL624389,,BAO_0000218,
6513,50296,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii B74,F,1,,9560,CHEMBL624390,,BAO_0000218,
6514,50296,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii N/3,F,1,,9560,CHEMBL875275,,BAO_0000218,
6515,50056,,,1,,N,,,,Intermediate,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,1,,114,CHEMBL624391,,BAO_0000218,
6516,50056,,,1,,N,,,,Intermediate,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,1,,114,CHEMBL623636,,BAO_0000218,
6517,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,1,,10841,CHEMBL623637,,BAO_0000218,
6518,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,1,,10841,CHEMBL623638,,BAO_0000218,
6519,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,1,,10841,CHEMBL623639,,BAO_0000218,
6520,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,1,,10841,CHEMBL623640,,BAO_0000218,
6521,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,1,,10841,CHEMBL623641,,BAO_0000218,
6522,50532,,,1,,N,,,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,1,,10841,CHEMBL623642,,BAO_0000218,
6523,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,1,,10841,CHEMBL623643,,BAO_0000218,
6524,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,1,,10841,CHEMBL623644,,BAO_0000218,
6525,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,1,,10841,CHEMBL623645,,BAO_0000218,
6526,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,1,,10841,CHEMBL623646,,BAO_0000218,
6527,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,1,,10841,CHEMBL623647,,BAO_0000218,
6528,50532,,,1,,N,,,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,1,,10841,CHEMBL623648,,BAO_0000218,
6529,50366,,,1,,N,,,,Intermediate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1,,8117,CHEMBL623649,,BAO_0000218,
6530,50366,,,1,,N,,,,Intermediate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1,,8117,CHEMBL623650,,BAO_0000218,
6531,50366,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,1,,9560,CHEMBL623651,,BAO_0000218,
6532,50366,,,1,,N,,,,Expert,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,1,,9560,CHEMBL623652,,BAO_0000218,
6533,50366,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,1,,9560,CHEMBL623653,,BAO_0000218,
6534,50366,,,1,,N,,,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,1,,9560,CHEMBL623654,,BAO_0000218,
6535,50366,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces viscosus 8A06,F,1,,9560,CHEMBL623655,,BAO_0000218,
6536,50366,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces viscosus M-100,F,1,,9560,CHEMBL623656,,BAO_0000218,
6537,50366,,,1,,N,,,,Expert,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,1,,9560,CHEMBL623657,,BAO_0000218,
6538,50366,,,1,,N,,,,Intermediate,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1,,9560,CHEMBL623658,,BAO_0000218,
6539,50366,,,1,,N,,,,Intermediate,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1,,9560,CHEMBL623659,,BAO_0000218,
6540,50366,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces viscosus 626,F,1,,9560,CHEMBL623660,,BAO_0000218,
6541,50366,,,1,,N,,,,Intermediate,Plaque bactericidal index against Actinomyces viscosus T14V,F,1,,9560,CHEMBL623661,,BAO_0000218,
6542,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL875281,,BAO_0000218,
6543,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL623662,,BAO_0000218,
6544,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL623663,,BAO_0000218,
6545,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL623664,,BAO_0000218,
6546,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL623665,,BAO_0000218,
6547,80023,,,1,,N,,,A673,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL621856,165.0,BAO_0000219,
6548,80661,,,1,,N,,,A704,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL620432,645.0,BAO_0000219,
6549,22226,,,0,,U,,,,Autocuration,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,1,,416,CHEMBL620433,,BAO_0000219,
6550,80024,,,1,,N,,,A9,Intermediate,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,1,,14354,CHEMBL620434,625.0,BAO_0000219,
6551,80024,,,1,,N,,,A9,Intermediate,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,1,,14354,CHEMBL620435,625.0,BAO_0000219,
6552,80024,,,1,,N,,,A9,Intermediate,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,1,,5116,CHEMBL620436,625.0,BAO_0000219,
6553,80024,,,1,,N,,,A9,Intermediate,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,1,,5116,CHEMBL876597,625.0,BAO_0000219,
6554,81037,,,1,,N,,,Human ovarian carcinoma cell line,Expert,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,1,,15694,CHEMBL620437,874.0,BAO_0000219,
6555,80024,,,1,,N,,,A9,Expert,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,1,,13038,CHEMBL620438,625.0,BAO_0000219,
6556,80024,,,1,,N,,,A9,Expert,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,1,,13038,CHEMBL620439,625.0,BAO_0000219,
6557,80024,,,1,,N,,,A9,Expert,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,1,,10923,CHEMBL619657,625.0,BAO_0000219,
6558,80024,,,1,,N,,,A9,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,1,,10923,CHEMBL619658,625.0,BAO_0000219,
6559,80024,,,1,,N,,,A9,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,1,,10923,CHEMBL619659,625.0,BAO_0000219,
6560,10649,,,8,,H,,,,Expert,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,1,,10923,CHEMBL619660,,BAO_0000019,
6561,80024,,,1,,N,,,A9,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,1,,10923,CHEMBL619661,625.0,BAO_0000219,
6562,80024,,,1,,N,,,A9,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,1,,10923,CHEMBL619662,625.0,BAO_0000219,
6563,80663,,,1,,N,,,AA6,Intermediate,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,1,,8158,CHEMBL619663,975.0,BAO_0000219,
6564,22226,,,0,,U,,,,Autocuration,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,1,,15494,CHEMBL619664,,BAO_0000219,
6565,22226,,,0,,U,,,,Autocuration,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,1,,15494,CHEMBL619665,,BAO_0000219,
6566,80662,,,1,,N,,,AA5,Intermediate,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,1,,12348,CHEMBL883244,974.0,BAO_0000219,
6567,80662,,,1,,N,,,AA5,Intermediate,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,1,,12348,CHEMBL884011,974.0,BAO_0000219,
6568,80662,,,1,,N,,,AA5,Intermediate,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,1,,2726,CHEMBL619666,974.0,BAO_0000219,
6569,80566,,,1,,N,,,U-937,Intermediate,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,1,,2726,CHEMBL619667,379.0,BAO_0000219,
6570,80578,,,1,,N,,,UV4,Intermediate,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,1,,10747,CHEMBL619668,274.0,BAO_0000219,
6571,80089,,,1,,N,,,CHO-AA8,Expert,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,1,,11005,CHEMBL619669,185.0,BAO_0000219,
6572,80089,,,1,,N,,,CHO-AA8,Intermediate,Average intracellular compound concentration when the hypoxic SER=1.6,F,1,,12687,CHEMBL876608,185.0,BAO_0000219,
6573,80089,,,1,,N,,,CHO-AA8,Intermediate,Average intracellular compound concentration when the hypoxic SER=1.6.,F,1,,12687,CHEMBL619670,185.0,BAO_0000219,
6574,80089,,,1,,N,,,CHO-AA8,Intermediate,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,1,,12687,CHEMBL619671,185.0,BAO_0000219,
6575,80089,,,1,,N,,,CHO-AA8,Intermediate,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,1,,12687,CHEMBL619672,185.0,BAO_0000219,
6576,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,1,,12687,CHEMBL619673,185.0,BAO_0000219,
6577,80089,,,1,,N,,,CHO-AA8,Intermediate,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,1,,13436,CHEMBL619674,185.0,BAO_0000219,
6578,80089,,,1,,N,,,CHO-AA8,Intermediate,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,1,,13435,CHEMBL619675,185.0,BAO_0000219,
6579,80089,,,1,,N,,,CHO-AA8,Intermediate,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,1,,13302,CHEMBL619676,185.0,BAO_0000219,
6580,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,1,,12687,CHEMBL619677,185.0,BAO_0000219,
6581,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,1,,12687,CHEMBL619678,185.0,BAO_0000219,
6582,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,1,,12687,CHEMBL619679,185.0,BAO_0000219,
6583,80089,,,1,,N,,,CHO-AA8,Expert,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,1,,12878,CHEMBL619680,185.0,BAO_0000219,
6584,80089,,,1,,N,,,CHO-AA8,Intermediate,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,1,,12878,CHEMBL621457,185.0,BAO_0000219,
6585,80089,,,1,,N,,,CHO-AA8,Expert,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,1,,14367,CHEMBL876609,185.0,BAO_0000219,
6586,80089,,,1,,N,,,CHO-AA8,Intermediate,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,1,,14367,CHEMBL621458,185.0,BAO_0000219,
6587,80089,,,1,,N,,,CHO-AA8,Expert,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,1,,12398,CHEMBL621459,185.0,BAO_0000219,
6588,80089,,,1,,N,,,CHO-AA8,Expert,Aerobic growth inhibition in Chinese hamster cell line AA8,F,1,,12878,CHEMBL621460,185.0,BAO_0000219,
6589,80089,,,1,,N,,,CHO-AA8,Expert,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,1,,13820,CHEMBL621461,185.0,BAO_0000219,
6590,80089,,,1,,N,,,CHO-AA8,Expert,Inhibition of growth under aerobic conditions in AA8 cells,F,1,,13436,CHEMBL621462,185.0,BAO_0000219,
6591,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),A,1,,6084,CHEMBL621463,,BAO_0000218,
6592,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog at 10 mg/kg of the compound,A,1,,5711,CHEMBL621464,,BAO_0000218,
6593,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),A,1,,4353,CHEMBL621465,,BAO_0000218,
6594,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),A,1,,4353,CHEMBL621466,,BAO_0000218,
6595,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (mongrel),A,1,,17800,CHEMBL621467,,BAO_0000218,
6596,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),A,1,,3994,CHEMBL621468,,BAO_0000218,
6597,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),F,1,,3994,CHEMBL876734,,BAO_0000218,
6598,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,5145,CHEMBL618476,,BAO_0000218,
6599,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),A,1,,16452,CHEMBL618477,,BAO_0000218,
6600,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,1,,16452,CHEMBL618478,,BAO_0000218,
6601,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,1,,5983,CHEMBL618479,,BAO_0000218,
6602,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,4273,CHEMBL618480,,BAO_0000218,
6603,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 3-10 mg/kg),A,1,,12500,CHEMBL618481,,BAO_0000218,
6604,50588,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,1,,12500,CHEMBL618482,,BAO_0000218,1969.0
6605,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3639,CHEMBL618483,,BAO_0000218,
6606,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,3880,CHEMBL618484,,BAO_0000218,
6607,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog,A,1,,4838,CHEMBL618485,,BAO_0000218,
6608,50588,,In vivo,1,,N,,,,Intermediate,oral bioavailability was measured in dogs,A,1,,15600,CHEMBL618486,,BAO_0000218,
6609,50588,,,1,,N,,,,Intermediate,Compound was tested for plasma protein binding in dog; Not determined,A,1,,17248,CHEMBL618487,,BAO_0000218,
6610,50588,,,1,,N,,,,Intermediate,Compound was tested for plasma protein binding of dog,A,1,,17248,CHEMBL618488,,BAO_0000218,
6611,50588,,,1,,N,,,,Intermediate,Compound was tested for plasma protein binding of dog; Not determined,A,1,,17248,CHEMBL876735,,BAO_0000218,
6612,50588,,,1,,N,,,,Intermediate,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,1,,17443,CHEMBL618489,,BAO_0000218,
6613,50588,,In vivo,1,,N,,,,Intermediate,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,1,,4186,CHEMBL618490,,BAO_0000218,
6614,50588,,,1,,N,,,,Intermediate,Half life was determined,A,1,,3749,CHEMBL618491,,BAO_0000218,
6615,50588,,In vivo,1,,N,,,,Intermediate,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,1,,3249,CHEMBL618492,,BAO_0000218,
6616,50588,,,1,,N,,,,Intermediate,Half life was evaluated in dog,A,1,,3022,CHEMBL873354,,BAO_0000218,
6617,50588,,,1,,N,,,,Intermediate,Half life was determined,A,1,,3749,CHEMBL618493,,BAO_0000218,
6618,50588,,In vivo,1,,N,,,,Intermediate,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618494,,BAO_0000218,
6619,50588,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618495,,BAO_0000218,948.0
6620,50588,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618496,,BAO_0000218,2113.0
6621,50588,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618497,,BAO_0000218,2107.0
6622,50588,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618498,,BAO_0000218,2048.0
6623,50588,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,1,,2517,CHEMBL618499,,BAO_0000218,2106.0
6624,50588,,,1,,N,,,,Intermediate,LogP in dog,A,1,,3639,CHEMBL876736,,BAO_0000218,
6625,50588,,,1,,N,,,,Intermediate,Partition coefficient (logP),A,1,,6227,CHEMBL618500,,BAO_0000218,
6626,50588,,,1,,N,,,,Intermediate,Partition coefficient in dog,A,1,,6227,CHEMBL857831,,BAO_0000218,
6627,50588,,In vivo,1,,N,,,,Intermediate,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL618501,,BAO_0000218,
6628,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,1,,4809,CHEMBL618502,,BAO_0000218,
6629,50588,,,1,,N,,,,Intermediate,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,1,,5600,CHEMBL618503,,BAO_0000218,
6630,50588,,,1,,N,,,,Intermediate,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,1,,14294,CHEMBL618504,,BAO_0000218,
6631,50588,,,1,,N,,,,Intermediate,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL618505,,BAO_0000218,
6632,50588,,,1,,N,,,,Intermediate,Metabolism of compound in dog S9 microsomes; Trace,A,1,,14294,CHEMBL618506,,BAO_0000218,
6633,50588,,,1,,N,,Liver,,Intermediate,In vitro metabolic potential in dog liver microsomes,A,1,,6251,CHEMBL618507,,BAO_0000218,2107.0
6634,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,1,,3748,CHEMBL876737,,BAO_0000218,
6635,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,2713,CHEMBL618508,,BAO_0000218,
6636,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6512,CHEMBL618509,,BAO_0000218,
6637,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL618510,,BAO_0000218,
6638,50588,,In vivo,1,,N,,,,Intermediate,The compound was tested for bioavailability in dogs,A,1,,3749,CHEMBL618511,,BAO_0000218,
6639,50588,,In vivo,1,,N,,,,Intermediate,The compound was tested for oral bioavailability in dogs,A,1,,3749,CHEMBL618512,,BAO_0000218,
6640,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog,A,1,,6742,CHEMBL618513,,BAO_0000218,
6641,50588,,,1,,N,,,,Intermediate,Compound was tested for percent protein binding (PB) in dog,A,1,,6227,CHEMBL618514,,BAO_0000218,
6642,50588,,,1,,N,,,,Intermediate,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,1,,6874,CHEMBL620052,,BAO_0000218,
6643,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma clearance.,A,1,,2877,CHEMBL620053,,BAO_0000218,1969.0
6644,50588,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for plasma clearance in dog,A,1,,12500,CHEMBL620054,,BAO_0000218,1969.0
6645,50588,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,1,,12500,CHEMBL620055,,BAO_0000218,1969.0
6646,50588,,,1,,N,,,,Intermediate,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL620056,,BAO_0000218,
6647,50588,,,1,,N,,Liver,,Intermediate,In vitro relative rate of metabolism was determined in dog liver microsomes,A,1,,5542,CHEMBL620057,,BAO_0000218,2107.0
6648,50588,,In vivo,1,,N,,,,Intermediate,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,1,,17594,CHEMBL618939,,BAO_0000218,
6649,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,1,,2652,CHEMBL618940,,BAO_0000218,
6650,50588,,In vivo,1,,N,,,,Intermediate,Half life after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL618941,,BAO_0000218,
6651,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL624473,42.0,BAO_0000218,2048.0
6652,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL624474,42.0,BAO_0000218,2048.0
6653,50594,,,1,,N,,Lung,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL624475,42.0,BAO_0000218,2048.0
6654,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,1,,6599,CHEMBL624476,42.0,BAO_0000218,
6655,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,1,,6599,CHEMBL623478,42.0,BAO_0000218,
6656,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,1,,6599,CHEMBL623479,42.0,BAO_0000218,
6657,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,1,,6599,CHEMBL623480,42.0,BAO_0000218,
6658,50594,,,1,,N,,,CCRF S-180,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,1,,6599,CHEMBL623481,42.0,BAO_0000218,
6659,50594,,,1,,N,,Brain,,Intermediate,C2 in brain of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623482,,BAO_0000218,955.0
6660,50594,,,1,,N,,Kidney,,Intermediate,C2 in kidney of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623483,,BAO_0000218,2113.0
6661,50594,,,1,,N,,Liver,,Intermediate,C2 in liver of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623484,,BAO_0000218,2107.0
6662,50594,,,1,,N,,Lung,,Intermediate,C2 in lungs of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623485,,BAO_0000218,2048.0
6663,50594,,,1,,N,,Spleen,,Intermediate,C2 in spleen of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623486,,BAO_0000218,2106.0
6664,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance in mouse,A,1,,17852,CHEMBL623487,,BAO_0000218,
6665,50594,,In vivo,1,,N,,,,Intermediate,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,1,,17764,CHEMBL623488,,BAO_0000218,
6666,50594,,In vivo,1,,N,,,,Intermediate,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,1,,17837,CHEMBL623489,,BAO_0000218,
6667,50594,,In vivo,1,,N,,,,Intermediate,Clearance was evaluated in mice after intravenous administration,A,1,,2675,CHEMBL875157,,BAO_0000218,
6668,50594,,In vivo,1,,N,,,,Intermediate,Clearance was evaluated in mice after oral administration,A,1,,2675,CHEMBL623490,,BAO_0000218,
6669,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,1,,4239,CHEMBL623491,,BAO_0000218,
6670,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance of compound was determined at 40 mg/Kg,A,1,,17753,CHEMBL623492,,BAO_0000218,
6671,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance of at 24 mg/Kg,A,1,,17753,CHEMBL623493,,BAO_0000218,
6672,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance at 24 mg/Kg,A,1,,17753,CHEMBL623494,,BAO_0000218,
6673,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance at 5 mg/Kg,A,1,,17753,CHEMBL623495,,BAO_0000218,
6674,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance in mice,A,1,,5727,CHEMBL623496,,BAO_0000218,
6675,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance value upon iv administration in mouse,A,1,,2862,CHEMBL623497,,BAO_0000218,
6676,50594,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance in mice,A,1,,5980,CHEMBL623498,,BAO_0000218,1969.0
6677,50594,,In vivo,1,,N,,,,Intermediate,Clearance in mouse,A,1,,17592,CHEMBL623499,,BAO_0000218,
6678,50594,,In vivo,1,,N,,,,Intermediate,Clearance value was determined,A,1,,17718,CHEMBL623500,,BAO_0000218,
6679,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL623501,,BAO_0000218,
6680,22229,,,0,,U,,,,Intermediate,Calculated partition coefficient (clogP),P,1,,17384,CHEMBL875158,,BAO_0000100,
6681,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL623502,,BAO_0000218,
6682,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL623503,,BAO_0000218,
6683,50594,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL623504,,BAO_0000218,
6684,50594,,In vivo,1,,N,,,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,1,,5969,CHEMBL623505,,BAO_0000218,
6685,50594,,In vivo,1,,N,,,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,1,,5969,CHEMBL623506,,BAO_0000218,
6686,50594,,In vivo,1,,N,,,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,1,,5969,CHEMBL623507,,BAO_0000218,
6687,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,1,,16597,CHEMBL623508,,BAO_0000218,
6688,50594,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at 30 mg/kg in ICR mouse,A,1,,5781,CHEMBL623509,,BAO_0000218,
6689,50594,,In vivo,1,,N,,,,Intermediate,Cmax after peroral administration in mice at 2.4 uM/kg,A,1,,17764,CHEMBL875159,,BAO_0000218,
6690,50594,,In vivo,1,,N,,Brain,,Intermediate,Cmax in brain of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623510,,BAO_0000218,955.0
6691,50594,,In vivo,1,,N,,Kidney,,Intermediate,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623511,,BAO_0000218,2113.0
6692,50594,,In vivo,1,,N,,Liver,,Intermediate,Cmax in liver of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623512,,BAO_0000218,2107.0
6693,50594,,In vivo,1,,N,,Lung,,Intermediate,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL623513,,BAO_0000218,2048.0
6694,50594,,In vivo,1,,N,,,,Intermediate,Cmax in mice at 18 uM/kg i.p. administration,F,1,,17764,CHEMBL623514,,BAO_0000218,
6695,50594,,In vivo,1,,N,,,,Intermediate,Cmax in mice at 23 uM/kg i.v. administration,F,1,,17764,CHEMBL622609,,BAO_0000218,
6696,50594,,In vivo,1,,N,,,,Intermediate,Cmax in mice at 24 uM/kg i.p. administration,F,1,,17764,CHEMBL622610,,BAO_0000218,
6697,50594,,In vivo,1,,N,,,,Intermediate,Cmax in mice at 25 uM/kg i.p. administration,F,1,,17764,CHEMBL621823,,BAO_0000218,
6698,50594,,In vivo,1,,N,,,,Intermediate,Cmax in mice at 26 uM/kg i.p. administration,F,1,,17764,CHEMBL621824,,BAO_0000218,
6699,50594,,In vivo,1,,N,,Spleen,,Intermediate,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,1,,17641,CHEMBL621825,,BAO_0000218,2106.0
6700,50594,,In vivo,1,,N,,,,Intermediate,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,1,,16597,CHEMBL621826,,BAO_0000218,
6701,50594,,In vivo,1,,N,,,,Intermediate,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,1,,16597,CHEMBL621827,,BAO_0000218,
6702,50594,,In vivo,1,,N,,,,Intermediate,Cmax value was determined,A,1,,5727,CHEMBL621828,,BAO_0000218,
6703,50594,,In vivo,1,,N,,,,Intermediate,Cmax value in IRC mice,A,1,,5951,CHEMBL621829,,BAO_0000218,
6704,50594,,In vivo,1,,N,,,,Intermediate,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL621830,,BAO_0000218,
6705,50594,,In vivo,1,,N,,,,Intermediate,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,1,,5506,CHEMBL621831,,BAO_0000218,
6706,50594,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,1,,14239,CHEMBL621832,,BAO_0000218,1969.0
6707,50594,,In vivo,1,,N,,Plasma,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,1,,4890,CHEMBL624579,,BAO_0000218,1969.0
6708,50594,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,1,,429,CHEMBL624580,,BAO_0000218,
6709,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL624581,,BAO_0000218,
6710,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL624582,,BAO_0000218,
6711,50535,,,1,,N,,,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,1,,10986,CHEMBL624583,,BAO_0000218,
6712,80018,,,1,,N,,,A-375,Intermediate,Inhibitory activity against human tumor cell line A0375 melanoma.,F,1,,13227,CHEMBL624584,455.0,BAO_0000219,
6713,12512,,,9,,D,Brain membranes,,,Expert,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,1,,4481,CHEMBL624585,,BAO_0000249,
6714,114,,,9,,D,,,,Expert,Forskolin-induced cAMP production at human A1 adenosine receptor,F,1,,16931,CHEMBL875165,,BAO_0000019,
6715,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL619490,449.0,BAO_0000219,
6716,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,1,,3850,CHEMBL619491,449.0,BAO_0000219,
6717,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,1,,3850,CHEMBL619492,449.0,BAO_0000219,
6718,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,1,,3850,CHEMBL619493,449.0,BAO_0000219,
6719,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,1,,3850,CHEMBL619494,449.0,BAO_0000219,
6720,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,1,,3850,CHEMBL619495,449.0,BAO_0000219,
6721,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL619496,449.0,BAO_0000219,
6722,114,,,9,,D,,,CHO,Expert,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,1,,3850,CHEMBL619497,449.0,BAO_0000219,
6723,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,1,,3850,CHEMBL619498,449.0,BAO_0000219,
6724,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL619499,449.0,BAO_0000219,
6725,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,1,,3850,CHEMBL619500,449.0,BAO_0000219,
6726,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL619501,449.0,BAO_0000219,
6727,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,1,,3850,CHEMBL619502,449.0,BAO_0000219,
6728,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,1,,3850,CHEMBL619503,449.0,BAO_0000219,
6729,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,1,,3850,CHEMBL619504,449.0,BAO_0000219,
6730,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL621298,449.0,BAO_0000219,
6731,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,1,,3850,CHEMBL621299,449.0,BAO_0000219,
6732,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,1,,3850,CHEMBL621300,449.0,BAO_0000219,
6733,114,,,8,,H,,,CHO,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,1,,3850,CHEMBL621301,449.0,BAO_0000219,
6734,114,,,8,,H,,,CHO,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,1,,3850,CHEMBL621302,449.0,BAO_0000219,
6735,80013,,,1,,N,,,A10,Intermediate,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,1,,12680,CHEMBL621303,164.0,BAO_0000219,
6736,22226,,,0,,U,,,A10,Autocuration,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,1,,1313,CHEMBL621304,164.0,BAO_0000219,
6737,22226,,,0,,U,,,A10,Autocuration,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,1,,1313,CHEMBL621305,164.0,BAO_0000219,
6738,80013,,,1,,N,,,A10,Intermediate,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,1,,17567,CHEMBL621306,164.0,BAO_0000219,
6739,80013,,,1,,N,,,A10,Intermediate,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,1,,17567,CHEMBL618444,164.0,BAO_0000219,
6740,80013,,,1,,N,,,A10,Intermediate,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,1,,11819,CHEMBL618445,164.0,BAO_0000219,
6741,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,1,,13436,CHEMBL618446,185.0,BAO_0000219,
6742,80089,,,1,,N,,,CHO-AA8,Intermediate,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,1,,12687,CHEMBL618447,185.0,BAO_0000219,
6743,80089,,,1,,N,,,CHO-AA8,Intermediate,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,1,,12651,CHEMBL618448,185.0,BAO_0000219,
6744,80089,,,1,,N,,,CHO-AA8,Intermediate,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,1,,13300,CHEMBL618449,185.0,BAO_0000219,
6745,80089,,,1,,N,,,CHO-AA8,Intermediate,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,1,,15296,CHEMBL618637,185.0,BAO_0000219,
6746,80089,,,1,,N,,,CHO-AA8,Intermediate,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,1,,15328,CHEMBL618638,185.0,BAO_0000219,
6747,80089,,,1,,N,,,CHO-AA8,Intermediate,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,1,,13302,CHEMBL618639,185.0,BAO_0000219,
6748,80089,,,1,,N,,,CHO-AA8,Expert,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,1,,14367,CHEMBL618640,185.0,BAO_0000219,
6749,80089,,,1,,N,,,CHO-AA8,Expert,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,1,,17002,CHEMBL618641,185.0,BAO_0000219,
6750,80089,,,1,,N,,,CHO-AA8,Intermediate,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,1,,13436,CHEMBL618642,185.0,BAO_0000219,
6751,80089,,,1,,N,,,CHO-AA8,Intermediate,Inhibitory activity against aerobic growth of AA8 cells.,F,1,,13435,CHEMBL618643,185.0,BAO_0000219,
6752,80089,,,1,,N,,,CHO-AA8,Intermediate,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,1,,10503,CHEMBL884013,185.0,BAO_0000219,
6753,80089,,,1,,N,,,CHO-AA8,Expert,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,1,,10503,CHEMBL622723,185.0,BAO_0000219,
6754,80089,,,1,,N,,,CHO-AA8,Intermediate,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,1,,10503,CHEMBL622724,185.0,BAO_0000219,
6755,80089,,,1,,N,,,CHO-AA8,Expert,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,1,,15090,CHEMBL622725,185.0,BAO_0000219,
6756,80089,,,1,,N,,,CHO-AA8,Expert,Cytotoxicity against AA8 cell line,F,1,,10368,CHEMBL622726,185.0,BAO_0000219,
6757,80089,,,1,,N,,,CHO-AA8,Intermediate,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,1,,12651,CHEMBL622727,185.0,BAO_0000219,
6758,80089,,,1,,N,,,CHO-AA8,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,1,,12687,CHEMBL622728,185.0,BAO_0000219,
6759,80089,,,1,,N,,,CHO-AA8,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,1,,12687,CHEMBL622729,185.0,BAO_0000219,
6760,80089,,,1,,N,,,CHO-AA8,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,1,,12687,CHEMBL622730,185.0,BAO_0000219,
6761,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,1,,1890,CHEMBL622731,185.0,BAO_0000219,
6762,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,1,,10747,CHEMBL622732,185.0,BAO_0000219,
6763,80089,,,1,,N,,,CHO-AA8,Intermediate,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,1,,10747,CHEMBL622733,185.0,BAO_0000219,
6764,22224,,,0,,U,,,,Autocuration,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,1,,11616,CHEMBL622734,,BAO_0000218,
6765,80089,,,1,,N,,,CHO-AA8,Expert,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,1,,11616,CHEMBL622735,185.0,BAO_0000219,
6766,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,1,,3471,CHEMBL618746,185.0,BAO_0000219,
6767,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,1,,3471,CHEMBL618747,185.0,BAO_0000219,
6768,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,1,,3471,CHEMBL620540,185.0,BAO_0000219,
6769,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,1,,3471,CHEMBL620541,185.0,BAO_0000219,
6770,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,1,,3471,CHEMBL620542,185.0,BAO_0000219,
6771,22224,,,0,,U,,,CHO-AA8,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,1,,3471,CHEMBL620543,185.0,BAO_0000219,
6772,22224,,,0,,U,,,CHO-AA8,Autocuration,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,1,,3471,CHEMBL618832,185.0,BAO_0000219,
6773,80089,,,1,,N,,,CHO-AA8,Expert,Concentration required to reduce AA8 cell survival by 10%,F,1,,11616,CHEMBL618833,185.0,BAO_0000219,
6774,22224,,,0,,U,,,CHO-AA8,Autocuration,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,1,,2656,CHEMBL618834,185.0,BAO_0000219,
6775,22224,,,0,,U,,,CHO-AA8,Autocuration,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,1,,10518,CHEMBL618835,185.0,BAO_0000219,
6776,22224,,,0,,U,,,CHO-AA8,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,1,,10518,CHEMBL618836,185.0,BAO_0000219,
6777,22224,,,0,,U,,,CHO-AA8,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,1,,10518,CHEMBL618837,185.0,BAO_0000219,
6778,22224,,,0,,U,,,CHO-AA8,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,1,,10518,CHEMBL618838,185.0,BAO_0000219,
6779,22224,,,0,,U,,,CHO-AA8,Autocuration,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,1,,16156,CHEMBL618839,185.0,BAO_0000219,
6780,22224,,,0,,U,,,CHO-AA8,Autocuration,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,1,,2656,CHEMBL618840,185.0,BAO_0000219,
6781,22224,,,0,,U,,,,Autocuration,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,1,,11005,CHEMBL618841,,BAO_0000019,
6782,22224,,,0,,U,,,CHO-AA8,Autocuration,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,1,,11942,CHEMBL618842,185.0,BAO_0000219,
6783,22224,,,0,,U,,,CHO-AA8,Autocuration,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,1,,2128,CHEMBL618843,185.0,BAO_0000219,
6784,50588,,In vivo,1,,N,,,,Intermediate,Half life period after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL618844,,BAO_0000218,
6785,50588,,In vivo,1,,N,,,,Intermediate,Half life period after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL618845,,BAO_0000218,
6786,50588,,In vivo,1,,N,,,,Intermediate,Half life was measured after oral 2b administration (tested in 6 dogs),A,1,,9579,CHEMBL618846,,BAO_0000218,
6787,50588,,In vivo,1,,N,,,,Intermediate,Half life was measured in dog after oral 17b administration,A,1,,9579,CHEMBL618847,,BAO_0000218,
6788,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,1,,9579,CHEMBL618848,,BAO_0000218,
6789,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,1,,9579,CHEMBL618849,,BAO_0000218,
6790,50588,,In vivo,1,,N,,,,Intermediate,Tmax value after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL618850,,BAO_0000218,
6791,50588,,In vivo,1,,N,,,,Intermediate,Tmax value after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL618851,,BAO_0000218,
6792,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its half life when administered intravenously in dog,A,1,,3184,CHEMBL873815,,BAO_0000218,
6793,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,1,,5017,CHEMBL618852,,BAO_0000218,1969.0
6794,50588,,,1,,N,,,,Intermediate,Elimination Half-life of compound was determined in dog,A,1,,6821,CHEMBL618853,,BAO_0000218,
6795,50588,,In vivo,1,,N,,,,Intermediate,Half life of compound in dog following oral administration,A,1,,17839,CHEMBL618854,,BAO_0000218,
6796,50588,,,1,,N,,,,Intermediate,Half life of compound was determined in dog,A,1,,17267,CHEMBL618855,,BAO_0000218,
6797,50588,,,1,,N,,Blood,,Intermediate,Half life of compound was determined in dog blood,A,1,,4727,CHEMBL618856,,BAO_0000218,178.0
6798,50588,,In vivo,1,,N,,,,Intermediate,Half life after oral and iv dosing in dogs,A,1,,5238,CHEMBL875827,,BAO_0000218,
6799,50588,,,1,,N,,,,Intermediate,Half life in dogs in hours,A,1,,4942,CHEMBL618857,,BAO_0000218,
6800,50588,,In vivo,1,,N,,,,Intermediate,Half life on i.v. administration of 2 mg/kg was measured in dog,A,1,,6505,CHEMBL618858,,BAO_0000218,
6801,50588,,In vivo,1,,N,,,,Intermediate,t1/2 in dog after oral dose (1 mg/kg),A,1,,5130,CHEMBL618859,,BAO_0000218,
6802,50588,,,1,,N,,,,Intermediate,Half life was evaluated in dog,A,1,,1475,CHEMBL618860,,BAO_0000218,
6803,50588,,In vivo,1,,N,,,,Intermediate,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,1,,17804,CHEMBL618861,,BAO_0000218,
6804,50588,,In vivo,1,,N,,,,Intermediate,Half life period of compound was determined after peroral administration at 2 mg/kg,A,1,,17804,CHEMBL622539,,BAO_0000218,
6805,50588,,In vivo,1,,N,,,,Intermediate,Half life period (10 mg/kg) was determined in dog,A,1,,6084,CHEMBL622540,,BAO_0000218,
6806,50588,,In vivo,1,,N,,,,Intermediate,Half life period (10 mg/kg) was determined in dog,A,1,,6084,CHEMBL873803,,BAO_0000218,
6807,50588,,In vivo,1,,N,,,,Intermediate,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,1,,5542,CHEMBL873804,,BAO_0000218,
6808,50588,,In vivo,1,,N,,,,Intermediate,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,1,,5542,CHEMBL624311,,BAO_0000218,
6809,50588,,,1,,N,,,,Intermediate,Half life period in dog,A,1,,6084,CHEMBL624312,,BAO_0000218,
6810,50588,,In vivo,1,,N,,,,Intermediate,Half life period in dogs after oral administration at 1 mg/kg,A,1,,6241,CHEMBL624313,,BAO_0000218,
6811,50588,,In vivo,1,,N,,,,Intermediate,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL624314,,BAO_0000218,
6812,50588,,,1,,N,,,,Intermediate,Half-life of compound was determined in dogs,A,1,,6621,CHEMBL624315,,BAO_0000218,
6813,50588,,,1,,N,,Plasma,,Intermediate,Half-life in dog plasma,A,1,,1696,CHEMBL624316,,BAO_0000218,1969.0
6814,50588,,,1,,N,,,,Intermediate,Half-life in mongrel dogs was determined,A,1,,17800,CHEMBL624317,,BAO_0000218,
6815,50588,,In vivo,1,,N,,,,Intermediate,Half-life in dog upon oral administration,A,1,,17657,CHEMBL624318,,BAO_0000218,
6816,50588,,In vivo,1,,N,,,,Intermediate,Half-life in dog upon oral administration; Unable to calculate,A,1,,17657,CHEMBL624319,,BAO_0000218,
6817,50588,,,1,,N,,,,Intermediate,Half-life was measured in dog,A,1,,4239,CHEMBL624496,,BAO_0000218,
6818,50588,,,1,,N,,,,Intermediate,Half-life was measured in dog,A,1,,5985,CHEMBL624497,,BAO_0000218,
6819,50588,,,1,,N,,,,Intermediate,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,1,,9932,CHEMBL624498,,BAO_0000218,
6820,50588,,In vivo,1,,N,,,,Intermediate,Oral half life was determined,A,1,,5199,CHEMBL624499,,BAO_0000218,
6821,50588,,In vivo,1,,N,,Plasma,,Intermediate,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,1,,5199,CHEMBL624500,,BAO_0000218,1969.0
6822,50588,,,1,,N,,Plasma,,Intermediate,Plasma half life was evaluated,A,1,,1475,CHEMBL624501,,BAO_0000218,1969.0
6823,50588,,,1,,N,,Plasma,,Intermediate,Plasma half life was evaluated in Dog,A,1,,1475,CHEMBL623666,,BAO_0000218,1969.0
6824,50588,,,1,,N,,Plasma,,Intermediate,Plasma half life was evaluated in dog,A,1,,1475,CHEMBL623667,,BAO_0000218,1969.0
6825,50588,,In vivo,1,,N,,,,Intermediate,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,1,,6316,CHEMBL623668,,BAO_0000218,
6826,50588,,,1,,N,,,,Intermediate,Tested for the half life value in dog,A,1,,4883,CHEMBL623669,,BAO_0000218,
6827,50588,,In vivo,1,,N,,,,Intermediate,Maximum time at the dose of 2 mg/kg in dog,A,1,,4727,CHEMBL623670,,BAO_0000218,
6828,50588,,In vivo,1,,N,,,,Intermediate,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL623671,,BAO_0000218,
6829,50588,,In vivo,1,,N,,Blood,,Intermediate,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL875945,,BAO_0000218,178.0
6830,50588,,In vivo,1,,N,,Blood,,Intermediate,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL623672,,BAO_0000218,178.0
6831,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,1,,6265,CHEMBL623673,,BAO_0000218,
6832,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,1,,4809,CHEMBL623674,,BAO_0000218,
6833,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,1,,5983,CHEMBL623675,,BAO_0000218,
6834,50588,,,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,1,,5313,CHEMBL872526,,BAO_0000218,
6835,50588,,In vivo,1,,N,,,,Intermediate,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,1,,5313,CHEMBL623676,,BAO_0000218,
6836,50588,,In vivo,1,,N,,Plasma,,Intermediate,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,1,,17650,CHEMBL623677,,BAO_0000218,1969.0
6837,50588,,In vivo,1,,N,,Plasma,,Intermediate,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,1,,5199,CHEMBL623678,,BAO_0000218,1969.0
6838,50588,,,1,,N,,Plasma,,Intermediate,Time taken for maximum plasma concentration in dog,A,1,,933,CHEMBL623679,,BAO_0000218,1969.0
6839,50588,,In vivo,1,,N,,,,Intermediate,Time to reach Cmax after oral administration to dogs,A,1,,16367,CHEMBL623680,,BAO_0000218,
6840,50588,,In vivo,1,,N,,Plasma,,Intermediate,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL623681,,BAO_0000218,1969.0
6841,50588,,In vivo,1,,N,,,,Intermediate,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,1,,6316,CHEMBL623682,,BAO_0000218,
6842,50588,,In vivo,1,,N,,,,Intermediate,Tmax after peroral administration (1 mg/kg) was determined in dog,A,1,,6215,CHEMBL623683,,BAO_0000218,
6843,50588,,In vivo,1,,N,,,,Expert,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL623684,,BAO_0000218,
6844,50588,,In vivo,1,,N,,,,Intermediate,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,1,,4527,CHEMBL622745,,BAO_0000218,
6845,50588,,In vivo,1,,N,,,,Intermediate,Tmax after peroral administration in dogs at 2.4 uM/kg,A,1,,17764,CHEMBL622746,,BAO_0000218,
6846,50594,,In vivo,1,,N,,,,Intermediate,In vivo Cmax in mice at dose of 100 mg/kg,A,1,,5969,CHEMBL622747,,BAO_0000218,
6847,50594,,In vivo,1,,N,,,,Intermediate,In vivo Cmax in mice at dose of 50 mg/kg,A,1,,5969,CHEMBL622748,,BAO_0000218,
6848,50594,,In vivo,1,,N,,,,Intermediate,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,1,,4573,CHEMBL622749,,BAO_0000218,
6849,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,1,,3277,CHEMBL622750,,BAO_0000218,1969.0
6850,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL623411,,BAO_0000218,1969.0
6851,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration obtained in mouse plasma was determined,A,1,,3132,CHEMBL875946,,BAO_0000218,1969.0
6852,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,1,,3132,CHEMBL623412,,BAO_0000218,1969.0
6853,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL623413,,BAO_0000218,1969.0
6854,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,1,,17729,CHEMBL623414,,BAO_0000218,1969.0
6855,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,1,,17729,CHEMBL623415,,BAO_0000218,1969.0
6856,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,1,,17729,CHEMBL623416,,BAO_0000218,1969.0
6857,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,1,,17728,CHEMBL623417,,BAO_0000218,1969.0
6858,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,1,,17728,CHEMBL623418,,BAO_0000218,1969.0
6859,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,1,,17728,CHEMBL623419,,BAO_0000218,1969.0
6860,50594,,In vivo,1,,N,,,,Intermediate,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,1,,4066,CHEMBL622816,,BAO_0000218,
6861,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,1,,6178,CHEMBL623313,,BAO_0000218,
6862,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,1,,6178,CHEMBL623314,,BAO_0000218,
6863,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,1,,3760,CHEMBL876788,,BAO_0000218,
6864,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,1,,3760,CHEMBL623315,,BAO_0000218,
6865,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,1,,3760,CHEMBL623316,,BAO_0000218,
6866,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,1,,3760,CHEMBL623317,,BAO_0000218,
6868,50594,,In vivo,1,,N,,,,Intermediate,Cmax in male mice after 2 mg/kg oral dose,A,1,,5961,CHEMBL623319,,BAO_0000218,
6869,50594,,In vivo,1,,N,,,,Intermediate,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,1,,6137,CHEMBL623320,,BAO_0000218,
6870,50594,,In vivo,1,,N,,,,Intermediate,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,1,,3802,CHEMBL623321,,BAO_0000218,
6871,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,1,,3535,CHEMBL623322,,BAO_0000218,
6872,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,1,,3535,CHEMBL623323,,BAO_0000218,
6873,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,1,,3535,CHEMBL623324,,BAO_0000218,
6874,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,1,,3535,CHEMBL623325,,BAO_0000218,
6875,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,1,,3535,CHEMBL623326,,BAO_0000218,
6876,50594,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,1,,3535,CHEMBL623327,,BAO_0000218,
6877,50594,,,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma upon oral administration in mouse,A,1,,2862,CHEMBL623328,,BAO_0000218,1969.0
6878,50594,,,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in mice after oral administration,A,1,,2675,CHEMBL623329,,BAO_0000218,1969.0
6879,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,1,,2675,CHEMBL623330,,BAO_0000218,1969.0
6880,50594,,,1,,N,,,,Intermediate,Dose at which the compound induced fecal excretion in mice,A,1,,5399,CHEMBL876789,,BAO_0000218,
6893,80013,,,1,,N,,,A10,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,1,,11819,CHEMBL623333,164.0,BAO_0000219,
6894,80013,,,1,,N,,,A10,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,1,,11819,CHEMBL623334,164.0,BAO_0000219,
6895,80013,,,1,,N,,,A10,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,1,,11819,CHEMBL627536,164.0,BAO_0000219,
6896,80013,,,1,,N,,,A10,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,1,,11819,CHEMBL627537,164.0,BAO_0000219,
6897,80013,,,1,,N,,,A10,Intermediate,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,1,,16361,CHEMBL627538,164.0,BAO_0000219,
6898,80655,,,1,,N,,,A121,Intermediate,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,1,,2288,CHEMBL884106,393.0,BAO_0000219,
6899,80655,,,1,,N,,,A121,Intermediate,Anticancer activity against human ovarian carcinoma A121 cells,F,1,,10404,CHEMBL625294,393.0,BAO_0000219,
6900,80655,,,1,,N,,,A121,Intermediate,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,1,,14790,CHEMBL625295,393.0,BAO_0000219,
6901,80655,,,1,,N,,,A121,Intermediate,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,1,,14790,CHEMBL625296,393.0,BAO_0000219,
6902,80655,,,1,,N,,,A121,Expert,Growth inhibition of human ovarian carcinoma (A121) cell line,F,1,,14253,CHEMBL625297,393.0,BAO_0000219,
6903,80655,,,1,,N,,,A121,Expert,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,1,,13617,CHEMBL625298,393.0,BAO_0000219,
6904,80655,,,1,,N,,,A121,Intermediate,Cytotoxicity against human A121 ovarian cells,F,1,,1003,CHEMBL625960,393.0,BAO_0000219,
6905,80655,,,1,,N,,,A121,Intermediate,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,1,,830,CHEMBL625961,393.0,BAO_0000219,
6906,80655,,,1,,N,,,A121,Intermediate,In vitro cytotoxicity against human ovarian carcinoma A21,F,1,,12307,CHEMBL625962,393.0,BAO_0000219,
6907,80655,,,1,,N,,,A121,Intermediate,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,1,,14254,CHEMBL624717,393.0,BAO_0000219,
6908,80655,,,1,,N,,,A121,Intermediate,Inhibitory activity of compound against human A121 ovarian cell line.,F,1,,13370,CHEMBL624718,393.0,BAO_0000219,
6909,80655,,,1,,N,,,A121,Intermediate,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,1,,14790,CHEMBL624719,393.0,BAO_0000219,
6910,80655,,,1,,N,,,A121,Intermediate,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,1,,3614,CHEMBL624720,393.0,BAO_0000219,
6911,80012,,,1,,N,,,A 172,Intermediate,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,1,,2664,CHEMBL624721,622.0,BAO_0000219,
6912,80012,,,1,,N,,,A 172,Expert,In vitro cytotoxicity against A172 human tumor cell lines.,F,1,,2037,CHEMBL624722,622.0,BAO_0000219,
6913,80012,,,1,,N,,,A 172,Intermediate,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,1,,14539,CHEMBL877597,622.0,BAO_0000219,
6914,80012,,,1,,N,,,A 172,Intermediate,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,1,,2836,CHEMBL624723,622.0,BAO_0000219,
6915,80012,,,1,,N,,,A 172,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,1,,10708,CHEMBL624724,622.0,BAO_0000219,
6916,104729,,,4,,H,,,,Autocuration,Association constant against A2 adenosine receptor,B,1,,8975,CHEMBL624725,,BAO_0000224,
6917,80656,,,1,,N,,,A2,Intermediate,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,1,,7645,CHEMBL624726,1085.0,BAO_0000219,
6918,104713,,,5,,D,,,,Autocuration,Ratio of Ki for adenosine A2 and A1 receptor binding,B,1,,11377,CHEMBL857535,,BAO_0000224,
6919,80014,,,1,,N,,,A204,Expert,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,1,,13528,CHEMBL624727,623.0,BAO_0000219,
6920,80014,,,1,,N,,,A204,Expert,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,1,,10160,CHEMBL624728,623.0,BAO_0000219,
6921,80015,,,1,,N,,,A2058,Intermediate,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,1,,15144,CHEMBL624729,404.0,BAO_0000219,
6922,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition against Human squamous cell line(A 253),F,1,,13160,CHEMBL624730,973.0,BAO_0000219,
6923,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,1,,12898,CHEMBL624731,973.0,BAO_0000219,
6924,80657,,,1,,N,,,A253 cell line,Intermediate,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,1,,13069,CHEMBL624732,973.0,BAO_0000219,
6925,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition of A253 cell lines.,F,1,,15984,CHEMBL883245,973.0,BAO_0000219,
6926,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,1,,15564,CHEMBL624733,973.0,BAO_0000219,
6927,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,1,,15564,CHEMBL624734,973.0,BAO_0000219,
6928,80657,,,1,,N,,,A253 cell line,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,1,,15564,CHEMBL624735,973.0,BAO_0000219,
6929,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,1,,4720,CHEMBL621780,478.0,BAO_0000219,
6930,81034,,,1,,N,,,A2780,Intermediate,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,1,,16112,CHEMBL877598,478.0,BAO_0000219,
6931,81034,,,1,,N,,,A2780,Expert,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,1,,16597,CHEMBL621781,478.0,BAO_0000219,
6932,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,1,,16378,CHEMBL621782,478.0,BAO_0000219,
6933,81034,,,1,,N,,,A2780,Expert,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,1,,16085,CHEMBL621783,478.0,BAO_0000219,
6934,81034,,,1,,N,,,A2780,Intermediate,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,1,,16317,CHEMBL621784,478.0,BAO_0000219,
6935,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,1,,15748,CHEMBL621785,478.0,BAO_0000219,
6936,81034,,,1,,N,,,A2780,Expert,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,1,,16597,CHEMBL621968,478.0,BAO_0000219,
6937,81034,,,1,,N,,,A2780,Expert,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,1,,16597,CHEMBL621969,478.0,BAO_0000219,
6938,81034,,,1,,N,,,A2780,Expert,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,1,,16597,CHEMBL621970,478.0,BAO_0000219,
6939,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,1,,15608,CHEMBL621971,478.0,BAO_0000219,
6940,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,1,,15608,CHEMBL621972,478.0,BAO_0000219,
6941,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,1,,15608,CHEMBL884108,478.0,BAO_0000219,
6942,22224,,,0,,U,,,,Autocuration,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,1,,15296,CHEMBL623826,,BAO_0000019,
6943,22224,,,0,,U,,,CHO-AA8,Autocuration,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,1,,10251,CHEMBL623827,185.0,BAO_0000219,
6944,22224,,,0,,U,,,CHO-AA8,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,1,,10251,CHEMBL623828,185.0,BAO_0000219,
6945,22224,,,0,,U,,,CHO-AA8,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,1,,10251,CHEMBL623829,185.0,BAO_0000219,
6946,22224,,,0,,U,,,CHO-AA8,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,1,,10251,CHEMBL623830,185.0,BAO_0000219,
6947,22224,,,0,,U,,,,Autocuration,Growth inhibition against CHO-derived cell line AA8,F,1,,11858,CHEMBL623831,,BAO_0000019,
6948,22224,,,0,,U,,,CHO-AA8,Autocuration,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,1,,11858,CHEMBL623832,185.0,BAO_0000219,
6949,80089,,,1,,N,,,CHO-AA8,Expert,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,1,,11616,CHEMBL623833,185.0,BAO_0000219,
6950,80089,,,1,,N,,,CHO-AA8,Expert,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,1,,11616,CHEMBL623834,185.0,BAO_0000219,
6951,22224,,,0,,U,,,CHO-AA8,Autocuration,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,1,,10518,CHEMBL623835,185.0,BAO_0000219,
6952,22224,,,0,,U,,,CHO-AA8,Autocuration,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,1,,11396,CHEMBL623836,185.0,BAO_0000219,
6953,22224,,,0,,U,,,CHO-AA8,Autocuration,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,1,,10518,CHEMBL623837,185.0,BAO_0000219,
6954,80089,,,1,,N,,,CHO-AA8,Expert,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,1,,11616,CHEMBL623838,185.0,BAO_0000219,
6955,12675,,,8,,H,,,,Autocuration,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,1,,14837,CHEMBL623839,,BAO_0000019,
6956,12675,,,8,,H,,,,Autocuration,Number of binding sites (n) of isolated serum protein AAG,F,1,,14837,CHEMBL623840,,BAO_0000019,
6957,22222,,,3,,M,,,,Intermediate,Association constant for binding to AATT duplex,B,1,,16037,CHEMBL623841,,BAO_0000225,
6958,100090,,,1,,N,,,ABAE,Expert,Inhibition of ABAE human fibroblast cell proliferation,F,1,,16597,CHEMBL623842,416.0,BAO_0000219,
6959,80668,,,1,,N,,,AC755,Intermediate,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,1,,8831,CHEMBL623843,1064.0,BAO_0000218,
6960,102444,,,9,,D,,,,Expert,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,1,,13419,CHEMBL618669,,BAO_0000218,
6961,102444,,In vivo,9,,D,,,,Expert,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,1,,13419,CHEMBL618670,,BAO_0000218,
6962,69,,,8,,H,,,,Autocuration,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,1,,15778,CHEMBL618671,,BAO_0000357,
6963,69,,,8,,H,,,,Autocuration,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,1,,15778,CHEMBL618672,,BAO_0000357,
6964,80669,,,1,,N,,,ACH-2 cell line,Intermediate,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,1,,12988,CHEMBL618673,978.0,BAO_0000219,
6965,80669,,,1,,N,,,ACH-2 cell line,Intermediate,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,1,,12988,CHEMBL618674,978.0,BAO_0000219,
6966,22224,,,0,,U,,,T cell line,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,1,,12988,CHEMBL618675,998.0,BAO_0000219,
6967,22224,,,0,,U,,,T cell line,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,1,,12988,CHEMBL618676,998.0,BAO_0000219,
6968,22224,,,0,,U,,,T cell line,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,1,,12988,CHEMBL618677,998.0,BAO_0000219,
6969,80025,,,1,,N,,,ACHN,Intermediate,Inhibition of growth of renal cancer ACHN cell line,F,1,,11843,CHEMBL618678,626.0,BAO_0000219,
6970,80025,,,1,,N,,,ACHN,Intermediate,Inhibition of growth of ACHN renal cancer cell line,F,1,,16939,CHEMBL618679,626.0,BAO_0000219,
6971,80025,,,1,,N,,,ACHN,Intermediate,Inhibitory concentration required against ACHN renal cancer cell line,F,1,,4782,CHEMBL618680,626.0,BAO_0000219,
6972,80025,,,1,,N,,,ACHN,Expert,Concentration required to inhibit growth of human renal (ACHN) cell line,F,1,,6310,CHEMBL618681,626.0,BAO_0000219,
6973,80025,,,1,,N,,,ACHN,Intermediate,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,1,,6310,CHEMBL618682,626.0,BAO_0000219,
6974,80025,,,1,,N,,,ACHN,Intermediate,Cytotoxic activity against ACHN Renal cancer cell line,F,1,,12858,CHEMBL618683,626.0,BAO_0000219,
6975,80025,,,1,,N,,,ACHN,Intermediate,Cytotoxicity evaluation against ACHN renal cancer cells,F,1,,17380,CHEMBL618684,626.0,BAO_0000219,
6976,80025,,,1,,N,,,ACHN,Intermediate,In vitro antitumor activity against human renal ACHN cell line,F,1,,5858,CHEMBL618685,626.0,BAO_0000219,
6977,80025,,,1,,N,,,ACHN,Intermediate,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,1,,3838,CHEMBL876499,626.0,BAO_0000219,
6978,80025,,,1,,N,,,ACHN,Intermediate,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,1,,3838,CHEMBL618686,626.0,BAO_0000219,
6979,80025,,,1,,N,,,ACHN,Intermediate,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,1,,5406,CHEMBL618687,626.0,BAO_0000219,
6980,80025,,,1,,N,,,ACHN,Intermediate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,1,,4071,CHEMBL618688,626.0,BAO_0000219,
6981,80025,,,1,,N,,,ACHN,Expert,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,1,,4071,CHEMBL618689,626.0,BAO_0000219,
6982,80025,,,1,,N,,,ACHN,Intermediate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,1,,4071,CHEMBL618690,626.0,BAO_0000219,
6983,80025,,,1,,N,,,ACHN,Intermediate,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,1,,15002,CHEMBL618691,626.0,BAO_0000219,
6984,80025,,,1,,N,,,ACHN,Intermediate,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL619373,626.0,BAO_0000219,
6985,80025,,,1,,N,,,ACHN,Intermediate,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,1,,13958,CHEMBL884008,626.0,BAO_0000219,
6986,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,1,,1665,CHEMBL619374,626.0,BAO_0000219,
6987,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,1,,15354,CHEMBL619375,626.0,BAO_0000219,
6988,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,1,,15354,CHEMBL619376,626.0,BAO_0000219,
6989,80025,,,1,,N,,,ACHN,Intermediate,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,1,,13978,CHEMBL619377,626.0,BAO_0000219,
6990,80025,,,1,,N,,,ACHN,Intermediate,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,1,,6798,CHEMBL619378,626.0,BAO_0000219,
6991,50588,,In vivo,1,,N,,,,Intermediate,Tmax value after administration of 4 mg/Kg oral dose in dog,A,1,,2959,CHEMBL872527,,BAO_0000218,
6992,50588,,,1,,N,,,,Intermediate,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,1,,9932,CHEMBL876500,,BAO_0000218,
6993,50588,,,1,,N,,,,Intermediate,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL619379,,BAO_0000218,
6994,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution after 15 mg/kg iv dose in Dogs,A,1,,16907,CHEMBL619538,,BAO_0000218,
6995,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution after 30 mg/kg po dose in Dogs,A,1,,16907,CHEMBL619539,,BAO_0000218,
6996,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL619540,,BAO_0000218,
6997,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,1,,4305,CHEMBL619541,,BAO_0000218,
6998,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was evaluated in dog,A,1,,5472,CHEMBL619542,,BAO_0000218,
6999,50588,,In vivo,1,,N,,,,Intermediate,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL619543,,BAO_0000218,
7000,50588,,,1,,N,,,,Expert,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL619544,,BAO_0000218,
7001,50588,,In vivo,1,,N,,,,Intermediate,The compound was tested for volume of distribution in dog,A,1,,12500,CHEMBL619545,,BAO_0000218,
7002,50588,,In vivo,1,,N,,,,Intermediate,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,1,,12500,CHEMBL619546,,BAO_0000218,
7003,50588,,In vivo,1,,N,,,,Intermediate,Vd (1 mg/kg) was determined in dog (in vivo),A,1,,6227,CHEMBL619547,,BAO_0000218,
7004,50588,,In vivo,1,,N,,,,Intermediate,Vd in dog,A,1,,6227,CHEMBL619548,,BAO_0000218,
7005,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution was determined,A,1,,4219,CHEMBL619549,,BAO_0000218,
7006,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution in dog,A,1,,1696,CHEMBL619550,,BAO_0000218,
7007,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution by as 4 fold increase by iv administration in dogs,A,1,,5542,CHEMBL876501,,BAO_0000218,
7008,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,1,,5199,CHEMBL619551,,BAO_0000218,
7009,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL619552,,BAO_0000218,
7010,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution at the dose of 2 mg/kg in dog,A,1,,4727,CHEMBL619553,,BAO_0000218,
7011,50588,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution was determined,A,1,,16367,CHEMBL618722,,BAO_0000218,
7012,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,1,,2652,CHEMBL618723,,BAO_0000218,
7013,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,1,,16452,CHEMBL618724,,BAO_0000218,
7014,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,1,,16452,CHEMBL618725,,BAO_0000218,
7015,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),A,1,,16452,CHEMBL618726,,BAO_0000218,
7016,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,1,,5334,CHEMBL618727,,BAO_0000218,
7017,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (vdss) was measured in dog,A,1,,4239,CHEMBL624233,,BAO_0000218,
7018,50588,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL624234,,BAO_0000218,
7019,50588,,In vivo,1,,N,,,,Intermediate,Vdss was determined after iv 0.1 mg/kg administration in dog,A,1,,5600,CHEMBL624235,,BAO_0000218,
7020,50588,,In vivo,1,,N,,,,Intermediate,Volume displacement was calculated in dog,A,1,,6057,CHEMBL624236,,BAO_0000218,
7021,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,1,,5654,CHEMBL624237,,BAO_0000218,
7022,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution constant was determined,A,1,,5505,CHEMBL624238,,BAO_0000218,
7023,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution at a dose of 1 uM/kg in dog was determined,A,1,,4527,CHEMBL624239,,BAO_0000218,
7024,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,1,,4521,CHEMBL875829,,BAO_0000218,
7025,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,1,,4521,CHEMBL624240,,BAO_0000218,
7026,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution (Vdss) was measured in dog,A,1,,15660,CHEMBL624241,,BAO_0000218,
7027,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution (Vdss) was measured in dog,A,1,,15660,CHEMBL624242,,BAO_0000218,
7028,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL624243,,BAO_0000218,
7029,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in dog,A,1,,5145,CHEMBL624244,,BAO_0000218,
7030,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound was determined in dog,A,1,,6821,CHEMBL624245,,BAO_0000218,
7031,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,1,,4137,CHEMBL624246,,BAO_0000218,
7032,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,1,,5334,CHEMBL624247,,BAO_0000218,
7033,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution (Vdss) was measured in dog,A,1,,15660,CHEMBL624248,,BAO_0000218,
7034,50588,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,1,,6642,CHEMBL624249,,BAO_0000218,
7035,50588,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL624250,,BAO_0000218,
7036,50588,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6642,CHEMBL624251,,BAO_0000218,
7037,50588,,,1,,N,,,,Intermediate,Maximum rate of depolarization of the upstroke of the action potential,A,1,,11659,CHEMBL624252,,BAO_0000218,
7038,50588,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution in dog,A,1,,6448,CHEMBL624253,,BAO_0000218,
7039,50588,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,1,,5474,CHEMBL624950,,BAO_0000218,
7040,50588,,In vivo,1,,N,,,,Intermediate,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,1,,1466,CHEMBL624951,,BAO_0000218,
7041,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,1,,6535,CHEMBL875830,,BAO_0000218,
7042,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution in dog after administration of 1 mg/kg iv,A,1,,6535,CHEMBL624952,,BAO_0000218,
7043,50588,,In vivo,1,,N,,,,Intermediate,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,1,,17764,CHEMBL624953,,BAO_0000218,
7044,50588,,In vivo,1,,N,,,,Intermediate,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,1,,6215,CHEMBL624954,,BAO_0000218,
7045,50588,,In vivo,1,,N,,,,Intermediate,Vss on i.v. administration of 2 mg/kg was measured in dog,A,1,,6505,CHEMBL624955,,BAO_0000218,
7046,50588,,,1,,N,,,,Intermediate,Vss was determined,A,1,,3639,CHEMBL624956,,BAO_0000218,
7047,50588,,,1,,N,,,,Intermediate,Vss in dog,A,1,,3639,CHEMBL625129,,BAO_0000218,
7048,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL625130,,BAO_0000218,
7049,50588,,In vivo,1,,N,,,,Intermediate,Volume distribution in dogs,A,1,,4942,CHEMBL625131,,BAO_0000218,
7050,50588,,In vivo,1,,N,,,,Intermediate,Volume of distribution in dog,A,1,,17796,CHEMBL625132,,BAO_0000218,
7051,50588,,In vivo,1,,N,,,,Intermediate,Tested for the oral bioavailability in dog,A,1,,4883,CHEMBL872263,,BAO_0000218,
7060,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,1,,17837,CHEMBL624336,,BAO_0000218,
7061,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,1,,17729,CHEMBL624337,,BAO_0000218,
7062,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,1,,17729,CHEMBL624338,,BAO_0000218,
7063,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in mouse,A,1,,4239,CHEMBL624339,,BAO_0000218,
7064,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability in mouse,A,1,,17592,CHEMBL624340,,BAO_0000218,
7065,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL624341,,BAO_0000218,
7066,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability in mouse,A,1,,2801,CHEMBL624342,,BAO_0000218,
7067,50594,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,1,,2801,CHEMBL624343,,BAO_0000218,
7068,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse,A,1,,17718,CHEMBL624344,,BAO_0000218,
7069,50594,,In vivo,1,,N,,,,Intermediate,Oral availability at 50 mg/kg po in male mice,A,1,,5727,CHEMBL624345,,BAO_0000218,
7070,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse (dose 10 mg/kg),A,1,,5302,CHEMBL624346,,BAO_0000218,
7071,50594,,In vivo,1,,N,,,,Expert,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL624347,,BAO_0000218,
7072,50594,,In vivo,1,,N,,,,Intermediate,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,1,,5961,CHEMBL624348,,BAO_0000218,
7074,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse,A,1,,6091,CHEMBL622754,,BAO_0000218,
7075,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in vivo in mice;ND=Not determined,A,1,,6091,CHEMBL622755,,BAO_0000218,
7076,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse at 10 mg/kg of the compound,A,1,,5711,CHEMBL622756,,BAO_0000218,
7077,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,1,,17728,CHEMBL622757,,BAO_0000218,
7078,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,1,,17728,CHEMBL622758,,BAO_0000218,
7079,50594,,In vivo,1,,N,,,,Intermediate,Tested for bioavailability of the compound,A,1,,3802,CHEMBL622759,,BAO_0000218,
7080,50594,,In vivo,1,,N,,,,Intermediate,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,1,,3802,CHEMBL622760,,BAO_0000218,
7081,50594,,,1,,N,,Plasma,,Intermediate,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,1,,14029,CHEMBL622761,,BAO_0000218,1969.0
7082,50594,,,1,,N,,Plasma,,Intermediate,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,1,,14029,CHEMBL622762,,BAO_0000218,1969.0
7083,50594,,,1,,N,,Plasma,,Intermediate,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,1,,14029,CHEMBL622763,,BAO_0000218,1969.0
7084,50594,,,1,,N,,Plasma,,Intermediate,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,1,,14029,CHEMBL622764,,BAO_0000218,1969.0
7085,50594,,,1,,N,,Plasma,,Intermediate,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,1,,14029,CHEMBL622765,,BAO_0000218,1969.0
7086,50594,,,1,,N,,,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,1,,17753,CHEMBL622766,,BAO_0000218,
7087,50594,,,1,,N,,,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,1,,17753,CHEMBL622767,,BAO_0000218,
7088,50594,,,1,,N,,,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,1,,17753,CHEMBL622768,,BAO_0000218,
7089,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL875948,,BAO_0000218,178.0
7090,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL622769,,BAO_0000218,178.0
7091,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL622770,,BAO_0000218,178.0
7092,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL622771,,BAO_0000218,178.0
7093,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL622772,,BAO_0000218,178.0
7094,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL622773,,BAO_0000218,178.0
7095,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL622774,,BAO_0000218,178.0
7096,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL621725,,BAO_0000218,10000001.0
7097,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,1,,10107,CHEMBL621726,,BAO_0000218,10000001.0
7098,81034,,,1,,N,,,A2780,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,1,,15608,CHEMBL621727,478.0,BAO_0000219,
7099,81034,,,1,,N,,,A2780,Expert,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,1,,3290,CHEMBL622413,478.0,BAO_0000219,
7100,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell line,F,1,,2859,CHEMBL622414,478.0,BAO_0000219,
7101,81034,,,1,,N,,,A2780,Expert,Inhibition of A2780 cell clonogenic assay,F,1,,15688,CHEMBL622415,478.0,BAO_0000219,
7102,81034,,,1,,N,,,A2780,Expert,Cytotoxic effect on ovarian cancer cell line (A2780),F,1,,5642,CHEMBL884001,478.0,BAO_0000219,
7103,81034,,,1,,N,,,A2780,Intermediate,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,1,,6633,CHEMBL622416,478.0,BAO_0000219,
7104,81034,,,1,,N,,,A2780,Intermediate,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,1,,3906,CHEMBL622417,478.0,BAO_0000219,
7105,81034,,,1,,N,,,A2780,Expert,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,1,,6788,CHEMBL622590,478.0,BAO_0000219,
7106,81034,,,1,,N,,,A2780,Expert,Antiproliferative activity against human A2780 cells,F,1,,17582,CHEMBL622591,478.0,BAO_0000219,
7107,81034,,,1,,N,,,A2780,Expert,Inhibition of human A2780 cell proliferation,F,1,,17764,CHEMBL622592,478.0,BAO_0000219,
7108,81034,,,1,,N,,,A2780,Expert,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,1,,17764,CHEMBL622593,478.0,BAO_0000219,
7109,81034,,,1,,N,,,A2780,Expert,Inhibition of human A2780 cell proliferation (No data),F,1,,17764,CHEMBL622594,478.0,BAO_0000219,
7110,81034,,,1,,N,,,A2780,Intermediate,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,1,,2815,CHEMBL622595,478.0,BAO_0000219,
7111,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,1,,16930,CHEMBL622596,478.0,BAO_0000219,
7112,81034,,,1,,N,,,A2780,Expert,Growth inhibition against A2780 wild-type ovarian cell lines,F,1,,17777,CHEMBL622597,478.0,BAO_0000219,
7113,81034,,,1,,N,,,A2780,Intermediate,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,1,,17777,CHEMBL622598,478.0,BAO_0000219,
7114,104766,,,5,,D,,,,Autocuration,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,1,,16936,CHEMBL622599,,BAO_0000019,
7115,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,1,,13759,CHEMBL622600,478.0,BAO_0000219,
7116,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,1,,13759,CHEMBL622601,478.0,BAO_0000219,
7117,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,1,,13759,CHEMBL622602,478.0,BAO_0000219,
7118,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,1,,13759,CHEMBL622603,478.0,BAO_0000219,
7119,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,1,,15292,CHEMBL622604,478.0,BAO_0000219,
7120,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,1,,15292,CHEMBL622605,478.0,BAO_0000219,
7121,81034,,,1,,N,,,A2780,Expert,In vitro inhibition of human ovarian cell line A2780,F,1,,15069,CHEMBL622606,478.0,BAO_0000219,
7122,81034,,,1,,N,,,A2780,Expert,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,1,,15069,CHEMBL619463,478.0,BAO_0000219,
7123,81034,,,1,,N,,,A2780,Intermediate,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,1,,14073,CHEMBL619464,478.0,BAO_0000219,
7124,81034,,,1,,N,,,A2780,Expert,Concentration required to inhibit A2780-cell growth by 50%,F,1,,14553,CHEMBL619465,478.0,BAO_0000219,
7125,81034,,,1,,N,,,A2780,Expert,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,1,,13040,CHEMBL619466,478.0,BAO_0000219,
7126,81034,,,1,,N,,,A2780,Expert,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,1,,6891,CHEMBL619467,478.0,BAO_0000219,
7127,81034,,,1,,N,,,A2780,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,1,,15569,CHEMBL619468,478.0,BAO_0000219,
7128,81034,,,1,,N,,,A2780,Expert,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,1,,14190,CHEMBL619469,478.0,BAO_0000219,
7129,81034,,,1,,N,,,A2780,Expert,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,1,,15014,CHEMBL619470,478.0,BAO_0000219,
7130,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,1,,15014,CHEMBL619471,478.0,BAO_0000219,
7131,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,1,,17496,CHEMBL619472,478.0,BAO_0000219,
7132,81034,,,1,,N,,,A2780,Intermediate,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,1,,13617,CHEMBL619473,478.0,BAO_0000219,
7133,81034,,,1,,N,,,A2780,Intermediate,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,1,,13617,CHEMBL874368,478.0,BAO_0000219,
7134,81034,,,1,,N,,,A2780,Intermediate,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,1,,13617,CHEMBL884003,478.0,BAO_0000219,
7135,81034,,,1,,N,,,A2780,Intermediate,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,1,,13617,CHEMBL622690,478.0,BAO_0000219,
7136,81034,,,1,,N,,,A2780,Intermediate,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,1,,17672,CHEMBL622691,478.0,BAO_0000219,
7137,81034,,,1,,N,,,A2780,Intermediate,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,1,,4544,CHEMBL622692,478.0,BAO_0000219,
7138,81034,,,1,,N,,,A2780,Intermediate,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,1,,4544,CHEMBL623406,478.0,BAO_0000219,
7139,81034,,,1,,N,,,A2780,Intermediate,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,1,,16317,CHEMBL884004,478.0,BAO_0000219,
7140,81034,,,1,,N,,,A2780,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,1,,15099,CHEMBL623407,478.0,BAO_0000219,
7141,81034,,,1,,N,,,A2780,Intermediate,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,1,,13978,CHEMBL623408,478.0,BAO_0000219,
7142,81034,,,1,,N,,,A2780,Expert,In vitro antitumor activity against A2780 cell line.,F,1,,12989,CHEMBL623409,478.0,BAO_0000219,
7143,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,1,,5574,CHEMBL623410,478.0,BAO_0000219,
7144,81034,,,1,,N,,,A2780,Expert,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,1,,13528,CHEMBL623576,478.0,BAO_0000219,
7145,80025,,,1,,N,,,ACHN,Intermediate,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,1,,12782,CHEMBL623577,626.0,BAO_0000219,
7146,80025,,,1,,N,,,ACHN,Intermediate,The IC50 value was measured on ACHN cell line in renal tumor type.,F,1,,14255,CHEMBL623578,626.0,BAO_0000219,
7147,80025,,,1,,N,,,ACHN,Intermediate,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,1,,16364,CHEMBL623579,626.0,BAO_0000219,
7148,80025,,,1,,N,,,ACHN,Expert,In vitro lethal concentration against most sensitive ACHN cell line,F,1,,17376,CHEMBL623580,626.0,BAO_0000219,
7149,80025,,,1,,N,,,ACHN,Intermediate,Tested for cytotoxic activity against renal cancer ACHN cell line,F,1,,12016,CHEMBL623581,626.0,BAO_0000219,
7150,80025,,,1,,N,,,ACHN,Intermediate,Compound tested for growth inhibition of renal cancer cell line ACHN,F,1,,6058,CHEMBL857456,626.0,BAO_0000219,
7151,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,1,,17708,CHEMBL623582,626.0,BAO_0000219,
7152,80025,,,1,,N,,,ACHN,Intermediate,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,1,,15176,CHEMBL623583,626.0,BAO_0000219,
7153,80025,,,1,,N,,,ACHN,Intermediate,In vitro anticancer activity against ACHN renal cancer cell line,F,1,,2806,CHEMBL623584,626.0,BAO_0000219,
7154,80025,,,1,,N,,,ACHN,Intermediate,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,1,,15300,CHEMBL623585,626.0,BAO_0000219,
7155,80025,,,1,,N,,,ACHN,Intermediate,Percent selectivity was evaluated in renal ACHN cell lines,F,1,,16364,CHEMBL623586,626.0,BAO_0000219,
7156,80025,,,1,,N,,,ACHN,Intermediate,In vitro inhibitory activity against renal ACHN cancer cell line,F,1,,13859,CHEMBL623587,626.0,BAO_0000219,
7157,80025,,,1,,N,,,ACHN,Intermediate,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,1,,11970,CHEMBL875279,626.0,BAO_0000219,
7158,80025,,,1,,N,,,ACHN,Intermediate,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,1,,2450,CHEMBL623588,626.0,BAO_0000219,
7159,80025,,,1,,N,,,ACHN,Intermediate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,1,,12696,CHEMBL623589,626.0,BAO_0000219,
7160,80025,,,1,,N,,,ACHN,Intermediate,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,1,,12400,CHEMBL623590,626.0,BAO_0000219,
7161,80025,,,1,,N,,,ACHN,Expert,Cytotoxic effect on renal cancer line ACHN,F,1,,12888,CHEMBL623591,626.0,BAO_0000219,
7162,80025,,,1,,N,,,ACHN,Intermediate,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,1,,3156,CHEMBL623592,626.0,BAO_0000219,
7163,80025,,,1,,N,,,ACHN,Intermediate,In vitro inhibition of Renal Cancer ACHN cell lines,F,1,,3381,CHEMBL623593,626.0,BAO_0000219,
7164,80025,,,1,,N,,,ACHN,Intermediate,Antitumor activity against human renal adenocarcinoma ACHN cells,F,1,,16747,CHEMBL623594,626.0,BAO_0000219,
7165,80025,,,1,,N,,,ACHN,Expert,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,1,,16748,CHEMBL621833,626.0,BAO_0000219,
7166,80025,,,1,,N,,,ACHN,Intermediate,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,1,,12062,CHEMBL621834,626.0,BAO_0000219,
7167,80025,,,1,,N,,,ACHN,Intermediate,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,1,,14769,CHEMBL621835,626.0,BAO_0000219,
7168,80025,,,1,,N,,,ACHN,Intermediate,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,1,,15895,CHEMBL621836,626.0,BAO_0000219,
7169,80025,,,1,,N,,,ACHN,Intermediate,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,1,,17376,CHEMBL621837,626.0,BAO_0000219,
7170,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,1,,14882,CHEMBL875280,626.0,BAO_0000219,
7171,80025,,,1,,N,,,ACHN,Intermediate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,1,,14882,CHEMBL621838,626.0,BAO_0000219,
7172,80025,,,1,,N,,,ACHN,Intermediate,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,1,,15661,CHEMBL621839,626.0,BAO_0000219,
7173,22224,,,0,,U,,,,Autocuration,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,1,,9680,CHEMBL621840,,BAO_0000019,
7174,10647,,,8,,H,,,,Autocuration,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,1,,14579,CHEMBL621841,,BAO_0000019,
7175,50529,,,1,,N,,,HEL,Expert,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,1,,17290,CHEMBL622979,468.0,BAO_0000218,
7176,50529,,,1,,N,,,,Intermediate,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,1,,17290,CHEMBL876595,,BAO_0000218,
7177,12159,,,8,,H,,,,Autocuration,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,1,,15891,CHEMBL620221,,BAO_0000357,
7178,12159,,,8,,H,,,,Autocuration,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,1,,15890,CHEMBL620222,,BAO_0000357,
7179,80670,,,1,,N,,,ADDP cell line,Intermediate,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,1,,3801,CHEMBL620506,979.0,BAO_0000219,
7180,80671,,,1,,N,,,ADJ/PC6,Intermediate,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,1,,9222,CHEMBL620507,980.0,BAO_0000219,
7181,80671,,,1,,N,,,ADJ/PC6,Intermediate,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,1,,9222,CHEMBL620508,980.0,BAO_0000219,
7182,80671,,,1,,N,,,ADJ/PC6,Intermediate,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,1,,7257,CHEMBL620509,980.0,BAO_0000219,
7183,80671,,,1,,N,,,ADJ/PC6,Intermediate,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,1,,7257,CHEMBL620510,980.0,BAO_0000219,
7184,80671,,,1,,N,,,ADJ/PC6,Intermediate,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,1,,7257,CHEMBL620511,980.0,BAO_0000219,
7185,80671,,,1,,N,,,ADJ/PC6,Intermediate,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,1,,8084,CHEMBL620512,980.0,BAO_0000219,
7186,22224,,,0,,U,,,,Autocuration,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,1,,14943,CHEMBL620513,,BAO_0000019,
7187,22224,,,0,,U,,,,Autocuration,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,1,,14943,CHEMBL620514,,BAO_0000019,
7188,22224,,,0,,U,,,,Autocuration,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,1,,14943,CHEMBL620515,,BAO_0000019,
7189,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1,,10524,CHEMBL620516,,BAO_0000218,
7190,50588,,,1,,N,,Plasma,,Intermediate,AUC value in dog after IV administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL620517,,BAO_0000218,1969.0
7191,50588,,,1,,N,,Plasma,,Intermediate,AUC value in dog after oral administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL620518,,BAO_0000218,1969.0
7192,50588,,In vivo,1,,N,,,,Intermediate,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL620519,,BAO_0000218,
7193,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL621386,,BAO_0000218,
7194,50588,,In vivo,1,,N,,,,Intermediate,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL621387,,BAO_0000218,
7195,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its clearance when administered intravenously in dog,A,1,,3184,CHEMBL621388,,BAO_0000218,
7196,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL621389,,BAO_0000218,
7197,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,1,,4809,CHEMBL621390,,BAO_0000218,
7198,22229,,,0,,U,,,,Intermediate,Calculated partition coefficient (clogP),P,1,,4219,CHEMBL621391,,BAO_0000100,
7199,50588,,,1,,N,,,,Intermediate,Half life in dog,A,1,,3748,CHEMBL621392,,BAO_0000218,
7200,50588,,,1,,N,,,,Intermediate,Time taken for EC90 was determined when tested in dog,A,1,,3132,CHEMBL621393,,BAO_0000218,
7201,50588,,,1,,N,,,,Intermediate,Half life (iv) was determined,A,1,,4219,CHEMBL621394,,BAO_0000218,
7202,50588,,,1,,N,,Liver,,Intermediate,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,1,,16907,CHEMBL621395,,BAO_0000218,2107.0
7203,50588,,,1,,N,,,,Intermediate,Area under the curve was calculated in dog after iv administration,A,1,,6057,CHEMBL621396,,BAO_0000218,
7204,50588,,,1,,N,,,,Intermediate,Area under the curve was calculated in dog after peroral administration,A,1,,6057,CHEMBL621397,,BAO_0000218,
7205,50588,,,1,,N,,,,Intermediate,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL621398,,BAO_0000218,
7206,50588,,,1,,N,,,,Intermediate,pKa was evaluated in dog,A,1,,3639,CHEMBL618818,,BAO_0000218,
7207,50588,,,1,,N,,,,Intermediate,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,1,,14541,CHEMBL618819,,BAO_0000218,
7208,50588,,In vivo,1,,N,,,,Intermediate,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL618820,,BAO_0000218,
7209,50588,,In vivo,1,,N,,,,Intermediate,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL873810,,BAO_0000218,
7210,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,1,,2652,CHEMBL876606,,BAO_0000218,
7211,50588,,,1,,N,,,,Intermediate,Compound was evaluated for the half-life (t 1/2) in hours,A,1,,3624,CHEMBL618821,,BAO_0000218,
7212,50588,,In vivo,1,,N,,Blood,,Intermediate,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL618822,,BAO_0000218,178.0
7213,50588,,In vivo,1,,N,,Blood,,Intermediate,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,1,,1337,CHEMBL618823,,BAO_0000218,178.0
7214,50588,,In vivo,1,,N,,,,Intermediate,Half life after intravenous administration of 1 mg/kg in dog,A,1,,4709,CHEMBL618824,,BAO_0000218,
7215,50588,,,1,,N,,,,Intermediate,Half life was measured in dog,A,1,,15660,CHEMBL618825,,BAO_0000218,
7216,50588,,In vivo,1,,N,,,,Intermediate,Half life period in dog after 5 mg/kg dose,A,1,,5302,CHEMBL618826,,BAO_0000218,
7217,50588,,,1,,N,,,,Intermediate,Half life period was evaluated in dog; 4-4.8,A,1,,17791,CHEMBL618827,,BAO_0000218,
7218,50588,,In vivo,1,,N,,,,Intermediate,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,1,,6348,CHEMBL618828,,BAO_0000218,
7219,50588,,In vivo,1,,N,,,,Intermediate,Half-life was determined in dog after a3 mg/kg of iv dose,A,1,,4257,CHEMBL618829,,BAO_0000218,
7220,50588,,,1,,N,,,,Intermediate,Half-life was determined,A,1,,3771,CHEMBL618830,,BAO_0000218,
7221,50588,,,1,,N,,,,Intermediate,Half life in dogs,A,1,,6305,CHEMBL618831,,BAO_0000218,
7222,50588,,In vivo,1,,N,,Plasma,,Intermediate,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,1,,13501,CHEMBL619489,,BAO_0000218,1969.0
7223,50588,,In vivo,1,,N,,,,Intermediate,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,1,,17594,CHEMBL619649,,BAO_0000218,
7224,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,1,,3045,CHEMBL876607,,BAO_0000218,
7225,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the half life period after oral administration in conscious dog.,A,1,,3043,CHEMBL619650,,BAO_0000218,
7226,50588,,,1,,N,,,,Intermediate,Compound was tested for half life in dog,A,1,,4839,CHEMBL619651,,BAO_0000218,
7227,50588,,,1,,N,,,,Intermediate,Compound was tested for its half life in dog,A,1,,4839,CHEMBL619652,,BAO_0000218,
7228,50588,,In vivo,1,,N,,,,Intermediate,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,1,,5802,CHEMBL619653,,BAO_0000218,
7229,50588,,,1,,N,,,,Intermediate,Half life of compound in dog was determined,A,1,,17839,CHEMBL619654,,BAO_0000218,
7230,50588,,In vivo,1,,N,,,,Intermediate,Half life (iv) was determined,A,1,,4219,CHEMBL619655,,BAO_0000218,
7231,50588,,,1,,N,,Blood,,Intermediate,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,1,,13966,CHEMBL619656,,BAO_0000218,178.0
7232,50588,,In vivo,1,,N,,Plasma,,Intermediate,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,1,,3994,CHEMBL873812,,BAO_0000218,1969.0
7233,50588,,In vivo,1,,N,,Plasma,,Intermediate,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,1,,3994,CHEMBL621365,,BAO_0000218,1969.0
7234,50588,,,1,,N,,,,Intermediate,Half life in dog,A,1,,4453,CHEMBL621366,,BAO_0000218,
7235,50588,,,1,,N,,Plasma,,Intermediate,Half life in dog plasma,A,1,,6535,CHEMBL621367,,BAO_0000218,1969.0
7236,50588,,In vivo,1,,N,,Plasma,,Intermediate,Half life in dog plasma after administration of 0.25 mg/kg iv,A,1,,6535,CHEMBL621368,,BAO_0000218,1969.0
7237,50588,,In vivo,1,,N,,Plasma,,Intermediate,Half life in dog plasma after administration of 1 mg/kg iv,A,1,,6535,CHEMBL621369,,BAO_0000218,1969.0
7238,50588,,In vivo,1,,N,,Plasma,,Intermediate,Half life in dog plasma was determined at dose 10 mg/kg,A,1,,3132,CHEMBL621370,,BAO_0000218,1969.0
7239,50588,,,1,,N,,,,Intermediate,Half life in dog was determined,A,1,,5374,CHEMBL621371,,BAO_0000218,
7240,50588,,In vivo,1,,N,,,,Intermediate,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,1,,5007,CHEMBL621372,,BAO_0000218,
7241,50588,,,1,,N,,Plasma,,Intermediate,Half life upon exposure to human plasma,A,1,,16907,CHEMBL621373,,BAO_0000218,1969.0
7242,50588,,,1,,N,,,,Intermediate,Half life was calculated in dog,A,1,,6057,CHEMBL621374,,BAO_0000218,
7243,50588,,,1,,N,,,,Intermediate,Half life was determined,A,1,,5006,CHEMBL621375,,BAO_0000218,
7244,50588,,,1,,N,,,,Intermediate,Half life was determined,A,1,,5473,CHEMBL621376,,BAO_0000218,
7245,50588,,In vivo,1,,N,,,,Intermediate,Half life by intravenous administration of 1.2 mg/kg in dog,A,1,,4368,CHEMBL619624,,BAO_0000218,
7246,50588,,,1,,N,,,,Intermediate,Half life in dog,A,1,,6448,CHEMBL875840,,BAO_0000218,
7247,50588,,,1,,N,,,,Intermediate,Half life in dog after intra venous administration of the compound,A,1,,4353,CHEMBL619625,,BAO_0000218,
7248,50588,,,1,,N,,,,Intermediate,Half life in dog after intra venous administration of the compound; ND means Not determined,A,1,,4353,CHEMBL619626,,BAO_0000218,
7249,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog after po administration of the compound,A,1,,4353,CHEMBL619627,,BAO_0000218,
7250,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog after po administration of the compound; ND means Not determined,A,1,,4353,CHEMBL873817,,BAO_0000218,
7251,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog at the single oral dose of 1 mg/kg,A,1,,6265,CHEMBL619628,,BAO_0000218,
7252,50588,,,1,,N,,,,Intermediate,Half life in dogs,A,1,,5006,CHEMBL619629,,BAO_0000218,
7253,50588,,In vivo,1,,N,,,,Intermediate,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,1,,5356,CHEMBL619630,,BAO_0000218,
7254,50588,,,1,,N,,,,Intermediate,Half life in rat,A,1,,405,CHEMBL619631,,BAO_0000218,
7255,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,1,,6642,CHEMBL619632,,BAO_0000218,
7256,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL619633,,BAO_0000218,10000001.0
7257,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL875841,,BAO_0000218,10000001.0
7258,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL619634,,BAO_0000218,10000001.0
7259,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL619635,,BAO_0000218,10000001.0
7260,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL619636,,BAO_0000218,10000001.0
7261,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL619637,,BAO_0000218,10000004.0
7262,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL619638,,BAO_0000218,10000004.0
7263,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL619639,,BAO_0000218,10000004.0
7264,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL619640,,BAO_0000218,10000004.0
7265,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL619641,,BAO_0000218,10000004.0
7266,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL619642,,BAO_0000218,10000004.0
7267,50594,,In vivo,1,,N,,Gut,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL619643,,BAO_0000218,10000004.0
7268,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL619644,,BAO_0000218,948.0
7269,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL621112,,BAO_0000218,948.0
7270,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL621113,,BAO_0000218,948.0
7271,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL621114,,BAO_0000218,948.0
7272,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL621115,,BAO_0000218,948.0
7273,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL621116,,BAO_0000218,948.0
7274,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL621117,,BAO_0000218,948.0
7275,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL621118,,BAO_0000218,2113.0
7276,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,1,,10107,CHEMBL621119,,BAO_0000218,2113.0
7277,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL621120,,BAO_0000218,2113.0
7278,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL621757,,BAO_0000218,2113.0
7279,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL621758,,BAO_0000218,2113.0
7280,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL621759,,BAO_0000218,2113.0
7281,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL621760,,BAO_0000218,2113.0
7282,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL621761,,BAO_0000218,2107.0
7283,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL621762,,BAO_0000218,2107.0
7284,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL621763,,BAO_0000218,2107.0
7285,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL624502,,BAO_0000218,2107.0
7286,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL624503,,BAO_0000218,2107.0
7287,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL624504,,BAO_0000218,2107.0
7288,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL624505,,BAO_0000218,2107.0
7289,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL624506,,BAO_0000218,2048.0
7290,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against A2780 (human ovarian cancer),F,1,,5895,CHEMBL624507,478.0,BAO_0000219,
7291,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,1,,6338,CHEMBL624508,478.0,BAO_0000219,
7292,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,1,,15163,CHEMBL624509,478.0,BAO_0000219,
7293,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,1,,15163,CHEMBL624510,478.0,BAO_0000219,
7294,81034,,,1,,N,,,A2780,Expert,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,1,,15000,CHEMBL875956,478.0,BAO_0000219,
7295,81034,,,1,,N,,,A2780,Expert,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,1,,15000,CHEMBL839885,478.0,BAO_0000219,
7296,81034,,,1,,N,,,A2780,Expert,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,1,,14729,CHEMBL624511,478.0,BAO_0000219,
7297,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity against A2780 cell line,F,1,,17270,CHEMBL624512,478.0,BAO_0000219,
7298,81034,,,1,,N,,,A2780,Intermediate,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,1,,5685,CHEMBL624513,478.0,BAO_0000219,
7299,81034,,,1,,N,,,A2780,Intermediate,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,1,,3563,CHEMBL624514,478.0,BAO_0000219,
7300,81034,,,1,,N,,,A2780,Intermediate,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,1,,17753,CHEMBL618547,478.0,BAO_0000218,
7301,81034,,,1,,N,,,A2780,Intermediate,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,1,,16317,CHEMBL618548,478.0,BAO_0000219,
7302,81034,,,1,,N,,,A2780,Intermediate,Inhibition of tubulin polymerization in analogy of ca.,F,1,,16936,CHEMBL618549,478.0,BAO_0000219,
7303,81034,,,1,,N,,,A2780,Intermediate,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,1,,3801,CHEMBL618550,478.0,BAO_0000219,
7304,81034,,,1,,N,,,A2780,Expert,Cytotoxic effect in ovarian cancer cell line (A2780),F,1,,6181,CHEMBL618551,478.0,BAO_0000219,
7305,81034,,,1,,N,,,A2780,Intermediate,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,1,,5318,CHEMBL618552,478.0,BAO_0000219,
7306,81034,,,1,,N,,,A2780,Intermediate,Tested for the cytotoxicity in A2780 ovarian cell line,F,1,,4840,CHEMBL618553,478.0,BAO_0000219,
7307,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,1,,15748,CHEMBL618554,478.0,BAO_0000219,
7308,81034,,,1,,N,,,A2780,Intermediate,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,1,,15748,CHEMBL618555,478.0,BAO_0000219,
7309,80017,,,1,,N,,,A2780cisR,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,1,,15748,CHEMBL618556,481.0,BAO_0000219,
7310,80017,,,1,,N,,,A2780cisR,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,1,,15748,CHEMBL618557,481.0,BAO_0000219,
7311,80017,,,1,,N,,,A2780cisR,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,1,,15748,CHEMBL618558,481.0,BAO_0000219,
7312,80017,,,1,,N,,,A2780cisR,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,1,,15748,CHEMBL618559,481.0,BAO_0000219,
7313,81034,,,1,,N,,,A2780,Intermediate,In vivo log of cells killed after administration of compound in A2780 cell line,F,1,,17753,CHEMBL618560,478.0,BAO_0000218,
7314,81034,,In vivo,1,,N,,,A2780,Intermediate,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,1,,17753,CHEMBL618561,478.0,BAO_0000218,
7315,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,1,,16936,CHEMBL618562,478.0,BAO_0000219,
7316,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,1,,16936,CHEMBL618563,478.0,BAO_0000219,
7317,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,1,,16936,CHEMBL618564,478.0,BAO_0000219,
7318,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,1,,16936,CHEMBL618565,478.0,BAO_0000219,
7319,81034,,,1,,N,,,A2780,Intermediate,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,1,,17528,CHEMBL618566,478.0,BAO_0000218,
7320,81034,,,1,,N,,,A2780,Intermediate,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,1,,6633,CHEMBL618567,478.0,BAO_0000219,
7321,81034,,,1,,N,,,A2780,Expert,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,1,,15000,CHEMBL618568,478.0,BAO_0000219,
7322,81034,,,1,,N,,,A2780,Expert,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,1,,17528,CHEMBL618569,478.0,BAO_0000219,
7323,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,1,,16936,CHEMBL621857,478.0,BAO_0000219,
7324,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,1,,16936,CHEMBL621858,478.0,BAO_0000219,
7325,81034,,,1,,N,,,A2780,Intermediate,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,1,,16936,CHEMBL621859,478.0,BAO_0000219,
7326,81034,,,1,,N,,,A2780,Intermediate,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,1,,16936,CHEMBL621860,478.0,BAO_0000219,
7327,81034,,,1,,N,,,A2780,Intermediate,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,1,,16936,CHEMBL621861,478.0,BAO_0000219,
7328,81034,,,1,,N,,,A2780,Expert,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,1,,16936,CHEMBL621862,478.0,BAO_0000219,
7329,81034,,,1,,N,,,A2780,Intermediate,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,1,,16936,CHEMBL621863,478.0,BAO_0000219,
7330,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,1,,16936,CHEMBL621864,478.0,BAO_0000219,
7331,81034,,,1,,N,,,A2780,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,1,,16936,CHEMBL621865,478.0,BAO_0000219,
7332,81034,,,1,,N,,,A2780,Intermediate,In vitro antiproliferative activity against A2780 cell line,F,1,,17737,CHEMBL621866,478.0,BAO_0000219,
7333,81034,,,1,,N,,,A2780,Expert,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,1,,17764,CHEMBL621867,478.0,BAO_0000219,
7334,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,1,,3830,CHEMBL621868,478.0,BAO_0000219,
7335,81034,,,1,,N,,,A2780,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,1,,3829,CHEMBL875282,478.0,BAO_0000219,
7336,50588,,,1,,N,,,,Intermediate,Vc value in dog after IV administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL621869,,BAO_0000218,
7337,50588,,In vivo,1,,N,,,,Intermediate,Half life period in dog after IV administration at a dose of 5 mg/kg,A,1,,3546,CHEMBL621870,,BAO_0000218,
7338,22224,,,0,,U,,,,Autocuration,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,1,,5668,CHEMBL621871,,BAO_0000019,
7339,22224,,,0,,U,,Plasma,,Autocuration,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL621243,,BAO_0000218,1969.0
7340,22224,,,0,,U,,Plasma,,Autocuration,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL621244,,BAO_0000218,1969.0
7341,22224,,In vivo,0,,U,,,,Autocuration,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,1,,4256,CHEMBL621245,,BAO_0000218,
7342,22224,,In vivo,0,,U,,,,Autocuration,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,1,,4256,CHEMBL621246,,BAO_0000218,
7343,22224,,In vivo,0,,U,,,,Autocuration,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,1,,4256,CHEMBL621247,,BAO_0000218,
7344,22224,,In vivo,0,,U,,,,Autocuration,Oral Bioavailability in rat,A,1,,4256,CHEMBL618386,,BAO_0000218,
7345,22224,,,0,,U,,,,Autocuration,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL618387,,BAO_0000218,
7346,22224,,,0,,U,,,,Autocuration,Area under curve value in monkey at a dose of 5 mg/kg,A,1,,5302,CHEMBL618388,,BAO_0000218,
7347,22224,,,0,,U,,,,Autocuration,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,1,,4257,CHEMBL618389,,BAO_0000218,
7348,22224,,,0,,U,,,,Autocuration,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,1,,5355,CHEMBL618574,,BAO_0000019,
7349,22224,,,0,,U,,,,Autocuration,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,1,,5355,CHEMBL618575,,BAO_0000019,
7350,22224,,,0,,U,,,,Autocuration,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,1,,5355,CHEMBL618576,,BAO_0000019,
7351,22224,,,0,,U,,,,Autocuration,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,1,,6078,CHEMBL618577,,BAO_0000218,
7352,22224,,,0,,U,,,,Autocuration,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,1,,6078,CHEMBL876487,,BAO_0000218,
7353,22224,,,0,,U,,,,Autocuration,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL618578,,BAO_0000218,
7354,22224,,,0,,U,,,,Autocuration,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL618579,,BAO_0000218,
7355,22224,,,0,,U,,,,Autocuration,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL618580,,BAO_0000019,
7356,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,1,,5394,CHEMBL618581,,BAO_0000218,
7357,22224,,,0,,U,,,,Autocuration,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,1,,4397,CHEMBL618582,,BAO_0000218,
7358,22224,,,0,,U,,,,Autocuration,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,1,,17509,CHEMBL618583,,BAO_0000218,
7359,22224,,,0,,U,,,,Autocuration,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,1,,17509,CHEMBL618584,,BAO_0000218,
7360,22224,,In vivo,0,,U,,,,Autocuration,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,1,,6641,CHEMBL618585,,BAO_0000218,
7361,22224,,,0,,U,,,,Autocuration,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,1,,5355,CHEMBL618586,,BAO_0000218,
7362,22224,,In vivo,0,,U,,,,Autocuration,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL618587,,BAO_0000218,
7363,22224,,In vivo,0,,U,,,,Autocuration,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,1,,3443,CHEMBL618588,,BAO_0000218,
7364,22224,,,0,,U,,,,Autocuration,Binding towards monkey plasma protein at 10 uM,A,1,,17409,CHEMBL618589,,BAO_0000019,
7365,22224,,,0,,U,,,,Autocuration,Binding towards monkey plasma protein at 100 uM,A,1,,17409,CHEMBL618590,,BAO_0000019,
7366,22224,,In vivo,0,,U,,,,Autocuration,Apparent bioavailability in squirrel monkey was determined,A,1,,1052,CHEMBL872262,,BAO_0000218,
7367,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,1,,13501,CHEMBL618591,,BAO_0000218,
7368,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (dose 2 mg/kg),A,1,,17509,CHEMBL618592,,BAO_0000218,
7369,22224,,In vivo,0,,U,,,,Autocuration,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,1,,5394,CHEMBL876488,,BAO_0000218,
7370,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL618593,,BAO_0000218,
7371,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (i.d. dosing),A,1,,11219,CHEMBL618594,,BAO_0000218,
7372,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,1,,3045,CHEMBL618595,,BAO_0000218,
7373,22224,,,0,,U,,,,Autocuration,Clearance of the drug was measured in cynomolgus,A,1,,17796,CHEMBL621469,,BAO_0000019,
7374,22224,,In vivo,0,,U,,,,Autocuration,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,1,,1399,CHEMBL621470,,BAO_0000218,
7375,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,1,,2661,CHEMBL621471,,BAO_0000218,
7376,22224,,In vivo,0,,U,,Plasma,,Autocuration,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,1,,5005,CHEMBL621472,,BAO_0000218,1969.0
7377,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in rhesus monkey was determined,A,1,,17267,CHEMBL621473,,BAO_0000218,
7378,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in monkey after administration of 1 mg/kg iv,A,1,,6535,CHEMBL621474,,BAO_0000218,
7379,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance in cynomolgus monkey,A,1,,5922,CHEMBL621475,,BAO_0000218,
7380,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,1,,6221,CHEMBL621476,,BAO_0000218,
7381,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,1,,5668,CHEMBL624290,,BAO_0000218,
7382,22224,,In vivo,0,,U,,,,Autocuration,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,1,,5355,CHEMBL624291,,BAO_0000218,
7383,22224,,In vivo,0,,U,,,,Autocuration,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,1,,5355,CHEMBL624292,,BAO_0000218,
7384,22224,,In vivo,0,,U,,,,Autocuration,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,1,,5355,CHEMBL624293,,BAO_0000218,
7385,22224,,In vivo,0,,U,,,,Autocuration,Tested for Clearance upon iv administration to african green monkey,A,1,,4578,CHEMBL624294,,BAO_0000218,
7386,22224,,In vivo,0,,U,,,,Autocuration,Clearance in monkey,A,1,,17592,CHEMBL624295,,BAO_0000218,
7387,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6641,CHEMBL624296,,BAO_0000218,
7388,50588,,In vivo,1,,N,,,,Intermediate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,1,,6642,CHEMBL624297,,BAO_0000218,
7389,50588,,In vivo,1,,N,,,,Intermediate,Half life was evaluated after intravenous administration to dogs,A,1,,16367,CHEMBL624298,,BAO_0000218,
7390,50588,,,1,,N,,,,Intermediate,Half life was evaluated in dog,A,1,,5472,CHEMBL624299,,BAO_0000218,
7391,50588,,,1,,N,,,,Intermediate,Half life was evaluated in dog,A,1,,5474,CHEMBL624300,,BAO_0000218,
7392,50588,,In vivo,1,,N,,,,Intermediate,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,1,,5654,CHEMBL624301,,BAO_0000218,
7393,50588,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,1,,6227,CHEMBL624302,,BAO_0000218,
7394,50588,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration in dog,A,1,,6227,CHEMBL876026,,BAO_0000218,
7395,50588,,In vivo,1,,N,,,,Intermediate,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,1,,6221,CHEMBL624303,,BAO_0000218,
7396,50588,,,1,,N,,,,Intermediate,Half life period at a dose of 1 uM/kg in dog was determined,A,1,,4527,CHEMBL624304,,BAO_0000218,
7397,50588,,In vivo,1,,N,,,,Intermediate,Half life period was determine after peroral administration at 10 mpk in dog,A,1,,5668,CHEMBL624305,,BAO_0000218,
7398,50588,,In vivo,1,,N,,,,Intermediate,Half life period was determine after peroral administration at 5 mpk in dog,A,1,,5668,CHEMBL624306,,BAO_0000218,
7399,50588,,,1,,N,,,,Intermediate,Half life period was determined,A,1,,3854,CHEMBL624307,,BAO_0000218,
7400,50588,,,1,,N,,,,Intermediate,Half life period was determined,A,1,,5505,CHEMBL624308,,BAO_0000218,
7401,50588,,In vivo,1,,N,,,,Intermediate,Half life period by iv administration in dog at a dose of 6 mg/kg,A,1,,6251,CHEMBL624309,,BAO_0000218,
7402,50588,,,1,,N,,,,Intermediate,Half life period was evaluated in dog,A,1,,1918,CHEMBL624310,,BAO_0000218,
7403,50588,,In vivo,1,,N,,,,Intermediate,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL625003,,BAO_0000218,
7404,50588,,In vivo,1,,N,,,,Intermediate,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,1,,4809,CHEMBL625004,,BAO_0000218,
7405,50588,,In vivo,1,,N,,,,Intermediate,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,1,,6215,CHEMBL625005,,BAO_0000218,
7406,50588,,In vivo,1,,N,,,,Intermediate,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,1,,4527,CHEMBL873813,,BAO_0000218,
7407,50588,,In vivo,1,,N,,,,Intermediate,Half-life after oral dose of compound at 3 mg/kg in dogs,A,1,,17594,CHEMBL625006,,BAO_0000218,
7408,50588,,In vivo,1,,N,,,,Intermediate,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,1,,17839,CHEMBL625007,,BAO_0000218,
7409,50588,,In vivo,1,,N,,,,Intermediate,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,1,,17839,CHEMBL876027,,BAO_0000218,
7410,50588,,In vivo,1,,N,,,,Intermediate,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,1,,17839,CHEMBL625008,,BAO_0000218,
7411,50588,,In vivo,1,,N,,,,Intermediate,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,1,,17839,CHEMBL625009,,BAO_0000218,
7412,50588,,,1,,N,,Plasma,,Intermediate,Half-life of compound in plasma of dog was determined,A,1,,5210,CHEMBL625010,,BAO_0000218,1969.0
7413,50588,,,1,,N,,,,Intermediate,Half-life of compound was determined in dogs,A,1,,5210,CHEMBL625011,,BAO_0000218,
7414,50588,,In vivo,1,,N,,,,Intermediate,Half-life after administration of 4 mg/Kg oral dose in dog,A,1,,2959,CHEMBL621553,,BAO_0000218,
7415,50588,,In vivo,1,,N,,,,Intermediate,Half-life after intravenous administration of 1 mg/kg/h in dog,A,1,,4137,CHEMBL621554,,BAO_0000218,
7416,50588,,,1,,N,,,,Intermediate,Half-life in Dog,A,1,,5064,CHEMBL621555,,BAO_0000218,
7417,50588,,,1,,N,,,,Intermediate,Half-life in Dog,A,1,,5147,CHEMBL621556,,BAO_0000218,
7418,50588,,,1,,N,,,,Intermediate,Half-life in dog,A,1,,5145,CHEMBL621557,,BAO_0000218,
7419,50588,,In vivo,1,,N,,,,Intermediate,Half-life in dog after oral administration at 1 mg/kg,A,1,,6123,CHEMBL621558,,BAO_0000218,
7420,50588,,In vivo,1,,N,,,,Intermediate,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,1,,6123,CHEMBL621559,,BAO_0000218,
7421,50588,,,1,,N,,,,Intermediate,Half-life in dogs,A,1,,4333,CHEMBL621560,,BAO_0000218,
7422,50588,,,1,,N,,,,Intermediate,Half-life in dogs; ND indicates not determined,A,1,,4333,CHEMBL876028,,BAO_0000218,
7423,50588,,,1,,N,,Plasma,,Intermediate,Half-life in plasma of dog,A,1,,12500,CHEMBL621561,,BAO_0000218,1969.0
7424,50588,,,1,,N,,Plasma,,Intermediate,Half-life in plasma of dog at dose of 3-10 mgkg,A,1,,12500,CHEMBL621562,,BAO_0000218,1969.0
7425,50588,,In vivo,1,,N,,,,Intermediate,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,1,,6005,CHEMBL621563,,BAO_0000218,
7426,50588,,In vivo,1,,N,,,,Intermediate,Half-life was measured in dog after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL621564,,BAO_0000218,
7427,50588,,In vivo,1,,N,,,,Intermediate,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,1,,17650,CHEMBL621565,,BAO_0000218,
7428,50588,,In vivo,1,,N,,,,Intermediate,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,1,,5530,CHEMBL621566,,BAO_0000218,
7429,50588,,In vivo,1,,N,,,,Intermediate,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,1,,5530,CHEMBL621567,,BAO_0000218,
7430,50588,,In vivo,1,,N,,,,Intermediate,Half-life of the compound after 0.3 mg/kg po administration in dog,A,1,,5600,CHEMBL622978,,BAO_0000218,
7431,50588,,In vivo,1,,N,,,,Intermediate,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,1,,6039,CHEMBL873814,,BAO_0000218,
7432,50588,,In vivo,1,,N,,,,Intermediate,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,1,,6039,CHEMBL623219,,BAO_0000218,
7433,50588,,In vivo,1,,N,,,,Intermediate,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,1,,6039,CHEMBL624477,,BAO_0000218,
7434,50588,,,1,,N,,,,Intermediate,t1/2 in dog,A,1,,6227,CHEMBL624478,,BAO_0000218,
7435,50588,,,1,,N,,,,Intermediate,Half-life period measured in dogs,A,1,,14541,CHEMBL624479,,BAO_0000218,
7436,50588,,In vivo,1,,N,,,,Intermediate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,1,,4521,CHEMBL624480,,BAO_0000218,
7437,50588,,In vivo,1,,N,,,,Intermediate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,1,,4521,CHEMBL623595,,BAO_0000218,
7438,50588,,In vivo,1,,N,,,,Intermediate,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL623596,,BAO_0000218,
7439,50588,,In vitro,1,,N,,Plasma,,Intermediate,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,1,,1116,CHEMBL623597,,BAO_0000218,1969.0
7440,50588,,In vivo,1,,N,,,,Intermediate,In vivo half life period was calculated at 1 mg/kg in dog,A,1,,5444,CHEMBL623598,,BAO_0000218,
7441,50588,,In vivo,1,,N,,,,Intermediate,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,1,,5444,CHEMBL623599,,BAO_0000218,
7442,50588,,In vivo,1,,N,,,,Intermediate,Longer half-life in dog (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL623600,,BAO_0000218,
7443,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),A,1,,4353,CHEMBL623601,,BAO_0000218,
7444,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,1,,16452,CHEMBL623602,,BAO_0000218,
7445,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,1,,16452,CHEMBL623603,,BAO_0000218,
7446,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),A,1,,16452,CHEMBL623604,,BAO_0000218,
7447,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,1,,10107,CHEMBL623605,,BAO_0000218,2048.0
7448,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL623606,,BAO_0000218,2048.0
7449,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL623607,,BAO_0000218,2048.0
7450,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL623608,,BAO_0000218,2048.0
7451,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL623609,,BAO_0000218,2048.0
7452,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL623610,,BAO_0000218,2048.0
7453,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL623611,,BAO_0000218,2385.0
7454,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,1,,10107,CHEMBL623612,,BAO_0000218,2385.0
7455,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL623613,,BAO_0000218,2385.0
7456,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL623614,,BAO_0000218,2385.0
7457,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL623615,,BAO_0000218,2385.0
7458,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL623616,,BAO_0000218,2385.0
7459,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL623617,,BAO_0000218,2385.0
7460,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL875944,,BAO_0000218,14.0
7461,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL623618,,BAO_0000218,14.0
7462,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL623619,,BAO_0000218,14.0
7463,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL623620,,BAO_0000218,14.0
7464,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL623621,,BAO_0000218,14.0
7465,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL623622,,BAO_0000218,14.0
7466,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL623623,,BAO_0000218,14.0
7467,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL623624,,BAO_0000218,2106.0
7468,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL618521,,BAO_0000218,2106.0
7469,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL618522,,BAO_0000218,2106.0
7470,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL618523,,BAO_0000218,2106.0
7471,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL618524,,BAO_0000218,2106.0
7472,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL618525,,BAO_0000218,2106.0
7473,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL624586,,BAO_0000218,2106.0
7474,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,1,,10107,CHEMBL624587,,BAO_0000218,945.0
7475,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,1,,10107,CHEMBL624588,,BAO_0000218,945.0
7476,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,1,,10107,CHEMBL624589,,BAO_0000218,945.0
7477,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,1,,10107,CHEMBL624590,,BAO_0000218,945.0
7478,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,1,,10107,CHEMBL624591,,BAO_0000218,945.0
7479,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,1,,10107,CHEMBL624592,,BAO_0000218,945.0
7480,50594,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,1,,10107,CHEMBL624593,,BAO_0000218,945.0
7481,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4689,CHEMBL624594,,BAO_0000218,
7482,50597,,In vivo,1,,N,,,,Intermediate,Tested for the bioavailability in rat,A,1,,4950,CHEMBL624595,,BAO_0000218,
7483,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,1,,5328,CHEMBL624596,,BAO_0000218,
7484,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,406,CHEMBL624597,,BAO_0000218,
7485,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,12500,CHEMBL624598,,BAO_0000218,
7486,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 3-10 mg/kg),A,1,,12500,CHEMBL624599,,BAO_0000218,
7487,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5247,CHEMBL875166,,BAO_0000218,
7488,50597,,In vivo,1,,N,,Plasma,,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL624600,,BAO_0000218,1969.0
7489,50597,,In vivo,1,,N,,Plasma,,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL624601,,BAO_0000218,1969.0
7490,50597,,In vivo,1,,N,,,,Intermediate,Half life after oral administration was determined in rats at 6 mg/kg,A,1,,6647,CHEMBL624602,,BAO_0000218,
7491,50597,,,1,,N,,,,Intermediate,Half life was determined,A,1,,6484,CHEMBL624603,,BAO_0000218,
7492,50597,,In vivo,1,,N,,,,Intermediate,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,1,,3249,CHEMBL624604,,BAO_0000218,
7493,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,1,,6281,CHEMBL624605,,BAO_0000218,1969.0
7494,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,3307,CHEMBL624606,,BAO_0000218,
7495,50597,,In vivo,1,,N,,Blood,,Intermediate,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,1,,12058,CHEMBL624607,,BAO_0000218,178.0
7496,50597,,,1,,N,,,,Intermediate,Hill coefficient of the compound,A,1,,8833,CHEMBL624608,,BAO_0000218,
7497,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,1,,3193,CHEMBL624609,,BAO_0000218,178.0
7498,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,1,,3193,CHEMBL624610,,BAO_0000218,178.0
7499,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,1,,3193,CHEMBL624611,,BAO_0000218,178.0
7500,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,1,,3193,CHEMBL624612,,BAO_0000218,178.0
7501,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,1,,3193,CHEMBL875167,,BAO_0000218,178.0
7502,50597,,,1,,N,,Blood,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,1,,3193,CHEMBL624613,,BAO_0000218,178.0
7503,50597,,,1,,N,,Blood,,Intermediate,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,1,,3193,CHEMBL624614,,BAO_0000218,178.0
7504,50597,,,1,,N,,,,Intermediate,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,1,,5960,CHEMBL624392,,BAO_0000218,
7505,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624393,,BAO_0000218,955.0
7506,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624394,,BAO_0000218,955.0
7507,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624395,,BAO_0000218,955.0
7508,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624396,,BAO_0000218,955.0
7509,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624397,,BAO_0000218,955.0
7510,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624398,,BAO_0000218,2046.0
7511,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624399,,BAO_0000218,2046.0
7512,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624400,,BAO_0000218,2046.0
7513,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624401,,BAO_0000218,2046.0
7514,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,1,,13950,CHEMBL624402,,BAO_0000218,2046.0
7515,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL624403,,BAO_0000218,178.0
7516,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL624404,,BAO_0000218,178.0
7517,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL624405,,BAO_0000218,178.0
7518,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL624406,,BAO_0000218,10000001.0
7519,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL624407,,BAO_0000218,10000001.0
7520,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL624408,,BAO_0000218,10000001.0
7521,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL618644,,BAO_0000218,948.0
7522,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL618645,,BAO_0000218,948.0
7523,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL618646,,BAO_0000218,948.0
7524,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL618647,,BAO_0000218,2113.0
7525,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL618648,,BAO_0000218,2113.0
7526,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL618649,,BAO_0000218,2113.0
7527,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL618650,,BAO_0000218,2107.0
7528,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL618651,,BAO_0000218,2107.0
7529,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL876497,,BAO_0000218,2107.0
7530,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL618652,,BAO_0000218,2048.0
7531,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL618653,,BAO_0000218,2048.0
7532,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL618654,,BAO_0000218,2048.0
7533,50597,,,1,,N,,,,Intermediate,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,1,,6351,CHEMBL618655,,BAO_0000218,
7534,50597,,,1,,N,,,,Intermediate,Compound was tested for solubility in water,A,1,,1465,CHEMBL618656,,BAO_0000218,
7535,22229,,,0,,U,,,,Intermediate,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,1,,5182,CHEMBL618657,,BAO_0000100,
7536,50597,,,1,,N,,,,Intermediate,Solubility was determined,A,1,,17847,CHEMBL618658,,BAO_0000218,
7537,50597,,,1,,N,,,,Intermediate,solubility in water (ug/mL) at 37 degree C.,A,1,,15339,CHEMBL618659,,BAO_0000218,
7538,50597,,,1,,N,,,,Intermediate,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,1,,5202,CHEMBL618660,,BAO_0000218,
7539,50597,,,1,,N,,,,Intermediate,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,1,,1088,CHEMBL618661,,BAO_0000218,
7540,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,3169,CHEMBL873807,,BAO_0000218,
7541,50597,,,1,,N,,,,Intermediate,Half life in Dawley rat,A,1,,5353,CHEMBL618662,,BAO_0000218,
7542,50597,,In vivo,1,,N,,,,Intermediate,Half life period after 3 mg/kg iv administration,A,1,,2864,CHEMBL618663,,BAO_0000218,
7543,50597,,In vivo,1,,N,,,,Intermediate,Half life period after 3 mg/kg iv administration in rat,A,1,,2864,CHEMBL618664,,BAO_0000218,
7544,50597,,In vivo,1,,N,,,,Intermediate,Half life period after 3 mg/kg iv administration in the rat,A,1,,2864,CHEMBL618665,,BAO_0000218,
7545,50597,,,1,,N,,,,Intermediate,Half life period in female Sprague-Dawley rats,A,1,,6362,CHEMBL876498,,BAO_0000218,
7546,50597,,,1,,N,,,,Intermediate,Half life period in rat,A,1,,6249,CHEMBL618666,,BAO_0000218,
7547,50597,,,1,,N,,,,Intermediate,Half-life in rats was determined,A,1,,3169,CHEMBL620440,,BAO_0000218,
7548,50597,,,1,,N,,,,Intermediate,Half-life in rats with metabolic oxidation,A,1,,3169,CHEMBL620441,,BAO_0000218,
7549,50597,,,1,,N,,,,Intermediate,Half-life in rats,A,1,,3169,CHEMBL620442,,BAO_0000218,
7550,50597,,In vivo,1,,N,,,,Intermediate,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,1,,17260,CHEMBL620443,,BAO_0000218,
7551,50597,,In vivo,1,,N,,,,Intermediate,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,1,,17260,CHEMBL620444,,BAO_0000218,
7552,50597,,In vivo,1,,N,,,,Intermediate,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,1,,17260,CHEMBL620445,,BAO_0000218,
7553,50597,,In vivo,1,,N,,,,Intermediate,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,1,,17260,CHEMBL620446,,BAO_0000218,
7554,50597,,,1,,N,,Plasma,,Intermediate,Biological half-life measured in plasma of rat,A,1,,2879,CHEMBL620447,,BAO_0000218,1969.0
7555,50597,,,1,,N,,Plasma,,Intermediate,Biological half-life measured in plasma of rat; 22-25,A,1,,2879,CHEMBL621129,,BAO_0000218,1969.0
7556,50597,,,1,,N,,Plasma,,Intermediate,Biological half-life measured in plasma of rat; 9-16,A,1,,2879,CHEMBL621130,,BAO_0000218,1969.0
7557,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its half life when administered intravenously in rat,A,1,,3184,CHEMBL873808,,BAO_0000218,
7558,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,1,,4891,CHEMBL876598,,BAO_0000218,
7559,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,1,,429,CHEMBL621131,,BAO_0000218,
7560,50597,,In vivo,1,,N,,,,Intermediate,Half life (T1/2) after oral administration in rat,A,1,,5656,CHEMBL621132,,BAO_0000218,
7561,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound after iv administration of 20 mg/kg dose in rat,A,1,,4413,CHEMBL621133,,BAO_0000218,
7562,50597,,In vivo,1,,N,,,,Expert,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL621312,,BAO_0000218,
7563,50597,,,1,,N,,,,Intermediate,Half life of compound was determined in rat,A,1,,17267,CHEMBL621313,,BAO_0000218,
7564,50597,,,1,,N,,Blood,,Intermediate,Half life of compound was determined in rat blood,A,1,,4727,CHEMBL621314,,BAO_0000218,178.0
7565,50597,,In vivo,1,,N,,,,Intermediate,Half life at 1 mg/kg was determined in rat,A,1,,17651,CHEMBL621315,,BAO_0000218,
7566,50597,,In vivo,1,,N,,,,Intermediate,Half life at 10 mg/kg was determined in rat,A,1,,17651,CHEMBL621316,,BAO_0000218,
7567,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,401,CHEMBL621317,,BAO_0000218,
7568,50597,,,1,,N,,,,Intermediate,Half life in rats in hours,A,1,,4942,CHEMBL621318,,BAO_0000218,
7569,50597,,In vivo,1,,N,,,,Intermediate,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,1,,17735,CHEMBL621319,,BAO_0000218,
7570,50597,,In vivo,1,,N,,,,Intermediate,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,1,,6056,CHEMBL621377,,BAO_0000218,
7571,50597,,,1,,N,,,,Intermediate,Half life was determined,A,1,,5213,CHEMBL621378,,BAO_0000218,
7572,50597,,In vivo,1,,N,,,,Intermediate,Half life after i.v. administration,A,1,,6616,CHEMBL876599,,BAO_0000218,
7573,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,1,,5937,CHEMBL621379,,BAO_0000218,
7574,50597,,,1,,N,,Plasma,,Intermediate,Half life in rat plasma,A,1,,5819,CHEMBL621380,,BAO_0000218,1969.0
7575,50597,,,1,,N,,Plasma,,Intermediate,Half life in rat plasma; Not detected,A,1,,5819,CHEMBL621381,,BAO_0000218,1969.0
7576,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,6803,CHEMBL618515,,BAO_0000218,
7577,50597,,In vivo,1,,N,,,,Intermediate,Half life period of compound was determined after peroral administration,A,1,,17804,CHEMBL618516,,BAO_0000218,
7578,50597,,In vivo,1,,N,,,,Intermediate,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,1,,17804,CHEMBL618517,,BAO_0000218,
7579,50597,,,1,,N,,,,Intermediate,Half life period in rat,A,1,,5948,CHEMBL618518,,BAO_0000218,
7580,50597,,In vivo,1,,N,,,,Intermediate,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,1,,1916,CHEMBL618519,,BAO_0000218,
7581,50597,,In vivo,1,,N,,,,Intermediate,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL618698,,BAO_0000218,
7582,50597,,In vivo,1,,N,,,,Intermediate,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,1,,1916,CHEMBL618862,,BAO_0000218,
7583,50597,,In vivo,1,,N,,,,Intermediate,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL618863,,BAO_0000218,
7584,50597,,In vivo,1,,N,,,,Intermediate,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL618864,,BAO_0000218,
7585,50597,,In vivo,1,,N,,,,Intermediate,Half life time in rat the dose of 2 mg/kg,A,1,,4727,CHEMBL618865,,BAO_0000218,
7586,50597,,In vivo,1,,N,,,,Intermediate,Half-life 24 hr after 10 mg/kg iv administration in rats,A,1,,17509,CHEMBL618866,,BAO_0000218,
7587,50597,,In vivo,1,,N,,,,Intermediate,Half-life 24 hr after 2 mg/kg iv administration in rats,A,1,,17509,CHEMBL618867,,BAO_0000218,
7588,50597,,,1,,N,,,,Intermediate,Half-life consistent with the observed metabolic steady state in rats,A,1,,6597,CHEMBL875828,,BAO_0000218,
7589,50597,,In vivo,1,,N,,,,Intermediate,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,1,,17735,CHEMBL618868,,BAO_0000218,
7590,50597,,,1,,N,,,,Intermediate,Half-life for oxidative metabolic stability was determined using male human,A,1,,6597,CHEMBL618869,,BAO_0000218,
7591,50597,,In vivo,1,,N,,,,Intermediate,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,1,,17670,CHEMBL618870,,BAO_0000218,
7592,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma,A,1,,1696,CHEMBL618871,,BAO_0000218,1969.0
7593,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma was determined,A,1,,1742,CHEMBL618872,,BAO_0000218,1969.0
7594,50597,,,1,,N,,,,Intermediate,Half-life in rats was determined,A,1,,17800,CHEMBL873816,,BAO_0000218,
7595,22224,,,0,,U,,,,Autocuration,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,1,,12923,CHEMBL618873,,BAO_0000218,
7596,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 0.1 mg//kg,A,1,,11954,CHEMBL621602,,BAO_0000019,
7597,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 0.3 mg/kg,A,1,,11954,CHEMBL621603,,BAO_0000218,
7598,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 1 mg/kg,A,1,,11954,CHEMBL621604,,BAO_0000218,
7599,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 10 mg/kg,A,1,,11954,CHEMBL621605,,BAO_0000218,
7600,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 23.4 mg/kg,A,1,,11954,CHEMBL621606,,BAO_0000218,
7601,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 3 mg/kg,A,1,,11954,CHEMBL621607,,BAO_0000218,
7602,22224,,,0,,U,,,,Autocuration,Area under curve after oral dose of 3.87 mg/kg,A,1,,11954,CHEMBL621608,,BAO_0000218,
7603,22224,,,0,,U,,,,Autocuration,Area under curve was determined,A,1,,5237,CHEMBL621609,,BAO_0000019,
7604,22224,,,0,,U,,,,Autocuration,Area under curve at a dose of 10 mg/kg,A,1,,4026,CHEMBL621610,,BAO_0000218,
7605,50597,,,1,,N,,,,Intermediate,Area under curve was determined; ND=No data,A,1,,5237,CHEMBL621611,,BAO_0000218,
7606,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL621612,,BAO_0000218,
7607,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,1,,14793,CHEMBL622308,,BAO_0000218,
7608,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622309,,BAO_0000218,
7609,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,1,,14793,CHEMBL622310,,BAO_0000218,
7610,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622311,,BAO_0000218,
7611,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,1,,14793,CHEMBL622312,,BAO_0000218,
7612,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622931,,BAO_0000218,
7613,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,1,,14793,CHEMBL622932,,BAO_0000218,
7614,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622736,,BAO_0000218,1969.0
7615,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,1,,14793,CHEMBL622737,,BAO_0000218,1969.0
7616,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622738,,BAO_0000218,1969.0
7617,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,1,,14793,CHEMBL622739,,BAO_0000218,1969.0
7618,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622740,,BAO_0000218,1969.0
7619,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,1,,14793,CHEMBL622741,,BAO_0000218,1969.0
7620,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,1,,14793,CHEMBL622742,,BAO_0000218,1969.0
7621,50597,,,1,,N,,Plasma,,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,1,,14793,CHEMBL622743,,BAO_0000218,1969.0
7622,50594,,,1,,N,,Plasma,,Intermediate,AUC in mice,A,1,,11637,CHEMBL622744,,BAO_0000218,1969.0
7623,22224,,,0,,U,,,,Autocuration,Area under curve was measured from the graph obtained from concentration Vs time,A,1,,11149,CHEMBL624134,,BAO_0000019,
7624,22224,,,0,,U,,,,Autocuration,Area under curve value of compound per hour after oral administration,A,1,,10016,CHEMBL624135,,BAO_0000019,
7625,50597,,,1,,N,,,,Intermediate,Area under curve was determined after oral administration in rats,A,1,,17796,CHEMBL624136,,BAO_0000218,
7626,50597,,,1,,N,,,,Intermediate,Area under curve was determined after oral administration in rats; No data,A,1,,17796,CHEMBL624137,,BAO_0000218,
7627,50597,,,1,,N,,,,Intermediate,Area under curve was determined after oral administration in rats;No data,A,1,,17796,CHEMBL624320,,BAO_0000218,
7628,50588,,,1,,N,,,,Intermediate,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,1,,12923,CHEMBL624321,,BAO_0000218,
7629,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,1,,15372,CHEMBL624322,,BAO_0000218,
7630,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,1,,15372,CHEMBL624323,,BAO_0000218,
7631,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,1,,15372,CHEMBL624324,,BAO_0000218,
7632,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,1,,15372,CHEMBL624325,,BAO_0000218,
7633,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,1,,15372,CHEMBL624326,,BAO_0000218,
7634,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,1,,15372,CHEMBL624327,,BAO_0000218,
7635,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,1,,15372,CHEMBL624328,,BAO_0000218,
7636,50588,,,1,,N,,,,Intermediate,Area under curve was determined in Dogs after peroral administration,A,1,,14169,CHEMBL627848,,BAO_0000218,
7637,50597,,,1,,N,,,,Intermediate,Area under curve was determined in Rats after peroral administration,A,1,,14169,CHEMBL627849,,BAO_0000218,
7638,50597,,,1,,N,,,,Intermediate,Area under curve was determined in carotid blood of rat when administered intradermally,A,1,,14258,CHEMBL627850,,BAO_0000218,
7639,50597,,,1,,N,,,,Intermediate,Area under curve was determined in portal blood of rat when administered intradermally,A,1,,14258,CHEMBL627851,,BAO_0000218,
7640,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627852,,BAO_0000218,
7641,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627853,,BAO_0000218,
7642,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,1,,15011,CHEMBL627854,,BAO_0000218,
7643,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627855,,BAO_0000218,
7644,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,1,,15011,CHEMBL627856,,BAO_0000218,
7645,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL875339,,BAO_0000218,
7646,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,1,,15011,CHEMBL627857,,BAO_0000218,
7647,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,1,,11195,CHEMBL627858,,BAO_0000218,2106.0
7648,50597,,,1,,N,,Blood,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,1,,10130,CHEMBL627859,,BAO_0000218,178.0
7649,50597,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,1,,10130,CHEMBL627860,,BAO_0000218,955.0
7650,50597,,,1,,N,,Heart,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,1,,10130,CHEMBL627019,,BAO_0000218,948.0
7651,50597,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,1,,10130,CHEMBL627020,,BAO_0000218,2107.0
7652,50597,,,1,,N,,Lung,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,1,,10130,CHEMBL627021,,BAO_0000218,2048.0
7653,50597,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,1,,10130,CHEMBL627022,,BAO_0000218,2385.0
7654,50597,,,1,,N,,,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,1,,10130,CHEMBL627023,,BAO_0000218,
7655,50597,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,1,,10130,CHEMBL627024,,BAO_0000218,2106.0
7656,50597,,,1,,N,,Thyroid gland,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,1,,10130,CHEMBL627025,,BAO_0000218,2046.0
7657,50597,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,1,,10130,CHEMBL627026,,BAO_0000218,2113.0
7658,50597,,,1,,N,,Blood,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,1,,10130,CHEMBL627027,,BAO_0000218,178.0
7659,50597,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,1,,10130,CHEMBL627028,,BAO_0000218,955.0
7660,50597,,,1,,N,,Heart,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,1,,10130,CHEMBL627029,,BAO_0000218,948.0
7661,50597,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,1,,10130,CHEMBL627030,,BAO_0000218,2113.0
7662,50597,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,1,,10130,CHEMBL627031,,BAO_0000218,2107.0
7663,50597,,,1,,N,,Lung,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,1,,10130,CHEMBL627032,,BAO_0000218,2048.0
7664,50597,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,1,,10130,CHEMBL627033,,BAO_0000218,2385.0
7665,50597,,,1,,N,,,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,1,,10130,CHEMBL627034,,BAO_0000218,
7666,50597,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,1,,10130,CHEMBL627035,,BAO_0000218,2106.0
7667,50597,,,1,,N,,Thyroid gland,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,1,,10130,CHEMBL627036,,BAO_0000218,2046.0
7668,50597,,,1,,N,,Blood,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,1,,10130,CHEMBL875340,,BAO_0000218,178.0
7669,50597,,,1,,N,,Heart,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,1,,10130,CHEMBL627037,,BAO_0000218,948.0
7670,50597,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,1,,10130,CHEMBL627038,,BAO_0000218,2113.0
7671,50597,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,1,,10130,CHEMBL627039,,BAO_0000218,2107.0
7672,50597,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,1,,10130,CHEMBL627040,,BAO_0000218,2385.0
7673,50597,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,1,,10130,CHEMBL624663,,BAO_0000218,2106.0
7674,50597,,,1,,N,,Thyroid gland,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,1,,10130,CHEMBL625963,,BAO_0000218,2046.0
7675,50597,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,1,,10130,CHEMBL876799,,BAO_0000218,955.0
7676,50597,,,1,,N,,Lung,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,1,,10130,CHEMBL626133,,BAO_0000218,2048.0
7677,50597,,,1,,N,,,,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,1,,10130,CHEMBL626134,,BAO_0000218,
7678,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,1,,6295,CHEMBL626135,,BAO_0000218,
7679,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,1,,6296,CHEMBL626136,,BAO_0000218,
7680,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,1,,6296,CHEMBL626137,,BAO_0000218,
7681,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,1,,6295,CHEMBL626138,,BAO_0000218,
7682,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,1,,6296,CHEMBL626139,,BAO_0000218,
7683,50597,,In vivo,1,,N,,,,Intermediate,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,1,,17260,CHEMBL626140,,BAO_0000218,
7684,50597,,In vivo,1,,N,,,,Intermediate,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,1,,17260,CHEMBL626141,,BAO_0000218,
7685,50597,,,1,,N,,,,Intermediate,C24h in rat p.o. at 20 mg/kg concentration,A,1,,17686,CHEMBL626142,,BAO_0000218,
7686,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL627930,,BAO_0000218,2385.0
7687,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL627931,,BAO_0000218,2385.0
7688,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL627932,,BAO_0000218,2385.0
7689,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,1,,9866,CHEMBL627933,,BAO_0000218,2106.0
7690,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,1,,9866,CHEMBL627934,,BAO_0000218,2106.0
7691,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,1,,9866,CHEMBL627935,,BAO_0000218,2106.0
7692,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,1,,9866,CHEMBL627936,,BAO_0000218,178.0
7693,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL627937,,BAO_0000218,178.0
7694,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,1,,9866,CHEMBL627938,,BAO_0000218,178.0
7695,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL627939,,BAO_0000218,178.0
7696,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,1,,9866,CHEMBL627940,,BAO_0000218,178.0
7697,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,1,,9866,CHEMBL627941,,BAO_0000218,178.0
7698,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,1,,9866,CHEMBL876800,,BAO_0000218,178.0
7699,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL627942,,BAO_0000218,178.0
7700,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,1,,9866,CHEMBL627943,,BAO_0000218,178.0
7701,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,1,,9866,CHEMBL627944,,BAO_0000218,178.0
7702,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL627945,,BAO_0000218,178.0
7703,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,1,,9866,CHEMBL628584,,BAO_0000218,178.0
7704,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,1,,9866,CHEMBL628585,,BAO_0000218,178.0
7705,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,1,,9866,CHEMBL628586,,BAO_0000218,178.0
7706,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,1,,9866,CHEMBL628587,,BAO_0000218,178.0
7707,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,1,,9866,CHEMBL628588,,BAO_0000218,178.0
7708,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,1,,9866,CHEMBL628589,,BAO_0000218,178.0
7709,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,1,,9866,CHEMBL625304,,BAO_0000218,178.0
7710,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,1,,9866,CHEMBL625305,,BAO_0000218,178.0
7711,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,1,,9866,CHEMBL625306,,BAO_0000218,178.0
7712,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,1,,9866,CHEMBL625307,,BAO_0000218,178.0
7713,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,1,,9866,CHEMBL625308,,BAO_0000218,178.0
7714,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,1,,9866,CHEMBL627740,,BAO_0000218,178.0
7715,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,1,,9866,CHEMBL627741,,BAO_0000218,178.0
7716,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,1,,9866,CHEMBL627742,,BAO_0000218,178.0
7717,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL627743,,BAO_0000218,178.0
7718,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL627744,,BAO_0000218,178.0
7719,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL627745,,BAO_0000218,10000001.0
7720,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,1,,9866,CHEMBL627746,,BAO_0000218,10000001.0
7721,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,1,,9866,CHEMBL627747,,BAO_0000218,10000001.0
7722,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL876810,,BAO_0000218,10000001.0
7723,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,1,,9866,CHEMBL627748,,BAO_0000218,10000001.0
7724,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,1,,9866,CHEMBL627749,,BAO_0000218,10000001.0
7725,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,1,,9866,CHEMBL627750,,BAO_0000218,10000001.0
7726,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL618728,,BAO_0000218,10000001.0
7727,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,1,,9866,CHEMBL618729,,BAO_0000218,10000001.0
7728,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,1,,9866,CHEMBL618730,,BAO_0000218,10000001.0
7729,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,1,,9866,CHEMBL618731,,BAO_0000218,10000001.0
7730,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,1,,9866,CHEMBL618732,,BAO_0000218,10000001.0
7731,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,1,,9866,CHEMBL618733,,BAO_0000218,10000001.0
7732,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,1,,9866,CHEMBL618734,,BAO_0000218,10000001.0
7733,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,1,,9866,CHEMBL618735,,BAO_0000218,10000001.0
7734,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,1,,9866,CHEMBL876602,,BAO_0000218,10000001.0
7735,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,1,,9866,CHEMBL618736,,BAO_0000218,10000001.0
7736,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,1,,9866,CHEMBL618737,,BAO_0000218,10000001.0
7737,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,1,,9866,CHEMBL618738,,BAO_0000218,10000001.0
7738,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,1,,9866,CHEMBL618739,,BAO_0000218,10000001.0
7739,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,1,,9866,CHEMBL618740,,BAO_0000218,10000001.0
7740,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,1,,9866,CHEMBL618741,,BAO_0000218,10000001.0
7741,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL618742,,BAO_0000218,10000001.0
7742,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL618743,,BAO_0000218,10000001.0
7743,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,1,,17752,CHEMBL618744,,BAO_0000218,1969.0
7744,50597,,,1,,N,,,,Intermediate,Half-life in male rat,A,1,,5610,CHEMBL618745,,BAO_0000218,
7745,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat after peroral administration at 10 mg/kg concentration,A,1,,5939,CHEMBL620479,,BAO_0000218,
7746,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat after peroral administration at 5 mg/kg concentration,A,1,,5939,CHEMBL620480,,BAO_0000218,
7747,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat at a dose of 3 mg/kg,A,1,,17771,CHEMBL620481,,BAO_0000218,
7748,50597,,,1,,N,,,,Intermediate,Half-life was evaluated in rats,A,1,,1974,CHEMBL620482,,BAO_0000218,
7749,50597,,,1,,N,,,,Intermediate,Half-life was measured in rat,A,1,,4239,CHEMBL876603,,BAO_0000218,
7750,50597,,In vivo,1,,N,,,,Intermediate,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,1,,6681,CHEMBL620483,,BAO_0000218,
7751,50597,,In vivo,1,,N,,,,Intermediate,Half-life period in rats after intravenous administration at 5 mg/kg,A,1,,17752,CHEMBL620484,,BAO_0000218,
7752,50597,,In vivo,1,,N,,,,Intermediate,Half-life period in rat at 10 mg/kg,A,1,,6046,CHEMBL620485,,BAO_0000218,
7753,50597,,In vivo,1,,N,,,,Intermediate,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,1,,6685,CHEMBL620486,,BAO_0000218,
7754,50597,,In vivo,1,,N,,,,Intermediate,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,1,,6685,CHEMBL620487,,BAO_0000218,
7755,50597,,In vivo,1,,N,,,,Intermediate,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,1,,6685,CHEMBL620488,,BAO_0000218,
7756,50597,,In vivo,1,,N,,,,Intermediate,Half-life time in rat the dose of 2 mg/kg,A,1,,4727,CHEMBL620489,,BAO_0000218,
7757,50597,,In vivo,1,,N,,,,Intermediate,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,1,,1088,CHEMBL620490,,BAO_0000218,
7758,50597,,In vivo,1,,N,,,,Intermediate,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,1,,5610,CHEMBL620491,,BAO_0000218,
7759,50597,,In vivo,1,,N,,Plasma,,Intermediate,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,1,,3032,CHEMBL876604,,BAO_0000218,1969.0
7760,50597,,In vivo,1,,N,,,,Intermediate,Oral half life was determined,A,1,,5199,CHEMBL620492,,BAO_0000218,
7761,50597,,In vivo,1,,N,,,,Intermediate,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL620493,,BAO_0000218,
7762,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (t1/2) in rat,A,1,,4408,CHEMBL620494,,BAO_0000218,
7763,50597,,,1,,N,,Plasma,,Intermediate,Plasma elimination half-life was determined,A,1,,2552,CHEMBL620495,,BAO_0000218,1969.0
7764,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,1,,5199,CHEMBL620496,,BAO_0000218,1969.0
7765,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half life was observed after intravenous administration in rat,A,1,,15662,CHEMBL620497,,BAO_0000218,1969.0
7766,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life was determined,A,1,,1465,CHEMBL620498,,BAO_0000218,1969.0
7767,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half-life following oral administration in Fisher rats,A,1,,1446,CHEMBL620499,,BAO_0000218,1969.0
7768,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life in rat,A,1,,6824,CHEMBL620500,,BAO_0000218,1969.0
7769,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasmatic Half-life after intravenous administration to rat,A,1,,17533,CHEMBL873809,,BAO_0000218,1969.0
7770,50597,,In vivo,1,,N,,,,Intermediate,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,1,,5979,CHEMBL620501,,BAO_0000218,
7771,50597,,In vivo,1,,N,,,,Intermediate,Terminal half life after intravenous administration (1 mg/kg) in rat,A,1,,4689,CHEMBL620502,,BAO_0000218,
7772,50597,,In vivo,1,,N,,,,Intermediate,Terminal half life in Rat at a oral dose of 5 mg/kg,A,1,,4689,CHEMBL620503,,BAO_0000218,
7773,50597,,In vivo,1,,N,,,,Intermediate,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,1,,2463,CHEMBL620504,,BAO_0000218,
7774,50597,,In vivo,1,,N,,,,Intermediate,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,1,,4883,CHEMBL876605,,BAO_0000218,
7775,50597,,In vivo,1,,N,,,,Intermediate,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,1,,4883,CHEMBL620505,,BAO_0000218,
7776,50597,,In vivo,1,,N,,Plasma,,Intermediate,plasma half life was observed after intravenous administration in rat,A,1,,15662,CHEMBL873811,,BAO_0000218,1969.0
7777,50597,,In vivo,1,,N,,,,Expert,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL624016,,BAO_0000218,
7778,50597,,,1,,N,,,,Intermediate,Half life of compound determined in rat,A,1,,4576,CHEMBL624017,,BAO_0000218,
7779,50597,,,1,,N,,,,Intermediate,Mean residence time determined in rat,A,1,,4576,CHEMBL624018,,BAO_0000218,
7780,50597,,,1,,N,,,,Intermediate,Plasma half life determined in rat,A,1,,4576,CHEMBL624019,,BAO_0000218,
7781,50597,,In vivo,1,,N,,Brain,,Intermediate,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,1,,4910,CHEMBL624020,,BAO_0000218,955.0
7782,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for pharmacokinetic parameter maximum time period,A,1,,4891,CHEMBL624201,,BAO_0000218,
7783,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,1,,429,CHEMBL872528,,BAO_0000218,
7784,50597,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624202,,BAO_0000218,
7785,50597,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624203,,BAO_0000218,
7786,50597,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624350,,BAO_0000218,
7787,50597,,In vivo,1,,N,,,,Intermediate,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL621320,,BAO_0000218,
7788,50597,,In vivo,1,,N,,,,Intermediate,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,1,,17582,CHEMBL621321,,BAO_0000218,
7789,50597,,,1,,N,,,,Intermediate,Maximum time (Tmax) required to reach Cmax in rats,A,1,,4026,CHEMBL621322,,BAO_0000218,
7790,50597,,In vivo,1,,N,,,,Intermediate,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL621323,,BAO_0000218,
7791,50597,,In vivo,1,,N,,,,Intermediate,Maximum time of clearance of compound in rats after peroral administration,A,1,,6571,CHEMBL621324,,BAO_0000218,
7792,50597,,,1,,N,,,,Intermediate,Maximum time at the dose of 2 mg/kg in rat,A,1,,4727,CHEMBL621325,,BAO_0000218,
7793,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,1,,17651,CHEMBL875837,,BAO_0000218,1969.0
7794,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,1,,17651,CHEMBL621326,,BAO_0000218,1969.0
7795,50597,,In vivo,1,,N,,,,Intermediate,Tmax in Guinea pig (PO dose),A,1,,14465,CHEMBL621327,,BAO_0000218,
7796,50597,,In vivo,1,,N,,,,Intermediate,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL621328,,BAO_0000218,
7797,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Tmax) in rat,A,1,,5960,CHEMBL621329,,BAO_0000218,
7798,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Tmax) was estimated,A,1,,5022,CHEMBL621330,,BAO_0000218,
7799,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Tmax) in rat,A,1,,4408,CHEMBL621331,,BAO_0000218,
7800,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,1,,5983,CHEMBL621332,,BAO_0000218,
7801,50597,,In vivo,1,,N,,,,Intermediate,T max in Rat at a oral dose of 5 mg/kg,A,1,,4689,CHEMBL621333,,BAO_0000218,
7802,50597,,In vivo,1,,N,,,,Intermediate,T max was determined at 10 mg/kg po dose in rats,A,1,,2792,CHEMBL621334,,BAO_0000218,
7803,50594,,,1,,N,,,,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,1,,15011,CHEMBL621335,,BAO_0000218,
7804,50588,,,1,,N,,,,Intermediate,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,1,,14180,CHEMBL621336,,BAO_0000218,
7805,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,1,,14180,CHEMBL621337,,BAO_0000218,
7806,50588,,,1,,N,,,,Intermediate,Area under curve was measured after i.v. administration into Beagle dog.,A,1,,14599,CHEMBL621338,,BAO_0000218,
7807,50588,,,1,,N,,,,Intermediate,Area under curve was measured after iv administration into Beagle dog,A,1,,14599,CHEMBL875838,,BAO_0000218,
7808,50588,,,1,,N,,,,Intermediate,Area under curve was measured after po administration into Beagle dog,A,1,,14599,CHEMBL621339,,BAO_0000218,
7809,50588,,,1,,N,,,,Intermediate,Area under curve was measured after po administration into Beagle dog.,A,1,,14599,CHEMBL621340,,BAO_0000218,
7810,22224,,,0,,U,,,,Autocuration,Area under curve was measured at peroral dose of 3 mg/kg,A,1,,15675,CHEMBL621341,,BAO_0000218,
7811,22224,,,0,,U,,,,Autocuration,Area under curve was measured by using concentration Vs time,A,1,,12706,CHEMBL621342,,BAO_0000019,
7812,22224,,,0,,U,,,,Autocuration,Area under curve was measured by using concentration Vs time; not tested,A,1,,12706,CHEMBL621343,,BAO_0000019,
7813,50594,,,1,,N,,,,Intermediate,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,1,,9750,CHEMBL621344,,BAO_0000218,
7814,50594,,,1,,N,,,,Intermediate,Area under curve(AUC) was measured in mice after oral administration.,A,1,,9750,CHEMBL621345,,BAO_0000218,
7815,22224,,,0,,U,,,,Autocuration,Area under curve(AUC) value of the compound,A,1,,14691,CHEMBL621346,,BAO_0000019,
7816,22224,,,0,,U,,,,Autocuration,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,1,,14691,CHEMBL621347,,BAO_0000218,
7817,50588,,,1,,N,,,,Intermediate,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,1,,14691,CHEMBL621348,,BAO_0000218,
7818,22224,,,0,,U,,Blood,,Autocuration,Area under curve(carotid artery) was determined by the availability in blood,A,1,,2939,CHEMBL621349,,BAO_0000019,178.0
7819,22224,,,0,,U,,Blood,,Autocuration,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,1,,2939,CHEMBL621350,,BAO_0000019,178.0
7820,22224,,,0,,U,,Blood,,Autocuration,Area under curve(carotid artery) was determined by the availability in blood; No data,A,1,,2939,CHEMBL875839,,BAO_0000019,178.0
7821,22224,,,0,,U,,Blood,,Autocuration,Area under curve(portal vein) was determined by the availability in blood,A,1,,2939,CHEMBL620211,,BAO_0000019,178.0
7822,22224,,,0,,U,,Blood,,Autocuration,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,1,,2939,CHEMBL620212,,BAO_0000019,178.0
7823,22224,,,0,,U,,Blood,,Autocuration,Area under curve(portal vein) was determined by the availability in blood; No data,A,1,,2939,CHEMBL620213,,BAO_0000019,178.0
7824,50797,,,1,,N,,Plasma,,Intermediate,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,1,,9552,CHEMBL620214,,BAO_0000218,1969.0
7825,50797,,,1,,N,,Plasma,,Intermediate,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,1,,9552,CHEMBL620215,,BAO_0000218,1969.0
7826,50797,,,1,,N,,Plasma,,Intermediate,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,1,,9552,CHEMBL620216,,BAO_0000218,1969.0
7827,50588,,,1,,N,,Plasma,,Intermediate,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,1,,9552,CHEMBL620888,,BAO_0000218,1969.0
7828,50588,,,1,,N,,Plasma,,Intermediate,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,1,,9552,CHEMBL620889,,BAO_0000218,1969.0
7829,22224,,,0,,U,,Plasma,,Autocuration,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,1,,9552,CHEMBL620890,,BAO_0000019,1969.0
7830,50597,,,1,,N,,Plasma,,Intermediate,Area under plasma time curve determined in male rat,A,1,,11911,CHEMBL620891,,BAO_0000218,1969.0
7831,22224,,,0,,U,,,,Autocuration,Area under the MAP curve measured over 5 min.,A,1,,16618,CHEMBL620892,,BAO_0000019,
7832,50594,,,1,,N,,,,Intermediate,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,1,,14387,CHEMBL621079,,BAO_0000218,
7833,50594,,,1,,N,,,,Intermediate,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,1,,14387,CHEMBL621080,,BAO_0000218,
7834,50588,,,1,,N,,,,Intermediate,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,1,,12836,CHEMBL621081,,BAO_0000218,
7835,100712,,,1,,N,,,,Intermediate,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,1,,12836,CHEMBL621082,,BAO_0000218,
7836,50597,,,1,,N,,,,Intermediate,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,1,,12836,CHEMBL621083,,BAO_0000218,
7837,50588,,,1,,N,,,,Intermediate,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,1,,14339,CHEMBL621084,,BAO_0000218,
7838,50588,,,1,,N,,,,Intermediate,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,1,,14339,CHEMBL621085,,BAO_0000218,
7839,50588,,,1,,N,,,,Intermediate,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,1,,14339,CHEMBL621086,,BAO_0000218,
7840,50588,,,1,,N,,,,Intermediate,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1,,10524,CHEMBL621087,,BAO_0000218,
7841,50588,,,1,,N,,,,Intermediate,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,1,,9994,CHEMBL622607,,BAO_0000218,
7842,50588,,,1,,N,,,,Intermediate,Serum AUC in marmosets (IV dose),A,1,,11325,CHEMBL622608,,BAO_0000218,
7843,22224,,,0,,U,,,,Autocuration,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,1,,12536,CHEMBL624481,,BAO_0000019,
7844,22224,,,0,,U,,,,Autocuration,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,1,,12536,CHEMBL624482,,BAO_0000019,
7845,22224,,,0,,U,,,,Autocuration,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,1,,12536,CHEMBL624483,,BAO_0000019,
7846,22224,,,0,,U,,,,Autocuration,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,1,,12536,CHEMBL624484,,BAO_0000019,
7847,22224,,,0,,U,,,,Autocuration,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,1,,12536,CHEMBL624485,,BAO_0000019,
7848,50597,,,1,,N,,,,Intermediate,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,1,,15556,CHEMBL624486,,BAO_0000218,
7849,22224,,,0,,U,,,,Autocuration,Area under the curve for the compound was calculated.,A,1,,2809,CHEMBL624487,,BAO_0000019,
7850,22224,,,0,,U,,,,Autocuration,Area under the curve in concentration/ time,A,1,,9511,CHEMBL624488,,BAO_0000019,
7851,50597,,,1,,N,,,,Intermediate,Area under the curve administered intraintestinal in rats.,A,1,,12818,CHEMBL624489,,BAO_0000218,
7852,50597,,,1,,N,,,,Intermediate,Area under the curve administered intravenously in rats.,A,1,,12818,CHEMBL625184,,BAO_0000218,
7853,22224,,,0,,U,,,,Autocuration,Area under the curve during intravenous administration,A,1,,15118,CHEMBL625185,,BAO_0000019,
7854,22224,,,0,,U,,,,Autocuration,Area under the curve during intravenous administration; Not determined,A,1,,15118,CHEMBL875954,,BAO_0000019,
7855,22224,,,0,,U,,,,Autocuration,Area under the curve during systemic administration,A,1,,15118,CHEMBL625186,,BAO_0000019,
7856,22224,,,0,,U,,,,Autocuration,Area under the curve during systemic administration; Not determined,A,1,,15118,CHEMBL625187,,BAO_0000019,
7857,22224,,,0,,U,,,,Autocuration,Area under the curve was calculated for the compound.,A,1,,2632,CHEMBL625188,,BAO_0000019,
7858,50588,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,1,,14346,CHEMBL625189,,BAO_0000218,
7859,50588,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,1,,14346,CHEMBL625190,,BAO_0000218,
7860,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,1,,14346,CHEMBL621733,,BAO_0000218,
7861,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,1,,14346,CHEMBL621734,,BAO_0000218,
7862,50597,,,1,,N,,,,Intermediate,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,1,,11149,CHEMBL621735,,BAO_0000218,
7863,50597,,,1,,N,,Plasma,,Intermediate,Clearance of the drug was measured in the plasma of rat; No data,A,1,,17796,CHEMBL621736,,BAO_0000218,1969.0
7864,50597,,,1,,N,,Plasma,,Intermediate,The pharmacokinetic parameter plasma clearance in vivo in rats,A,1,,5247,CHEMBL621737,,BAO_0000218,1969.0
7865,50597,,,1,,N,,,,Intermediate,Plasma clearance at the dose of 2 mg/kg in rat,A,1,,4727,CHEMBL621738,,BAO_0000218,
7866,50597,,In vivo,1,,N,,,,Intermediate,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,1,,5654,CHEMBL622806,,BAO_0000218,
7867,50597,,In vivo,1,,N,,,,Intermediate,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,1,,5654,CHEMBL623519,,BAO_0000218,
7868,50597,,In vivo,1,,N,,,,Intermediate,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,1,,17260,CHEMBL623520,,BAO_0000218,
7869,50597,,In vivo,1,,N,,,,Intermediate,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,1,,17065,CHEMBL623521,,BAO_0000218,
7870,50597,,In vivo,1,,N,,,,Intermediate,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,1,,17671,CHEMBL623522,,BAO_0000218,
7871,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate in rat,A,1,,6672,CHEMBL623523,,BAO_0000218,
7872,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate in rat,A,1,,6673,CHEMBL623690,,BAO_0000218,
7873,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL623691,,BAO_0000218,
7874,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL623692,,BAO_0000218,
7875,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL623693,,BAO_0000218,
7876,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL623694,,BAO_0000218,
7877,50597,,In vivo,1,,N,,,,Intermediate,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,1,,4413,CHEMBL623695,,BAO_0000218,
7878,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,1,,2661,CHEMBL623696,,BAO_0000218,
7879,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,1,,2661,CHEMBL623697,,BAO_0000218,
7880,22224,,In vivo,0,,U,,Plasma,,Intermediate,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,1,,5005,CHEMBL623698,,BAO_0000218,1969.0
7881,22224,,In vivo,0,,U,,Plasma,,Intermediate,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,1,,5005,CHEMBL623699,,BAO_0000218,1969.0
7882,50597,,In vivo,1,,N,,,,Intermediate,Mean (%CV) PK parameters for CL(mL/min/kg).,A,1,,15765,CHEMBL623700,,BAO_0000218,
7883,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,1,,3747,CHEMBL623701,,BAO_0000218,
7884,50597,,In vivo,1,,N,,Plasma,,Intermediate,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,1,,16366,CHEMBL623702,,BAO_0000218,1969.0
7885,50597,,In vivo,1,,N,,,,Intermediate,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,1,,4199,CHEMBL623703,,BAO_0000218,
7886,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat was determined,A,1,,17267,CHEMBL623704,,BAO_0000218,
7887,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL623705,,BAO_0000218,
7888,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL623706,,BAO_0000218,
7889,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined,A,1,,5041,CHEMBL623707,,BAO_0000218,
7890,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,5960,CHEMBL623708,,BAO_0000218,
7891,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,1,,5937,CHEMBL623709,,BAO_0000218,
7892,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat by iv administration,A,1,,5871,CHEMBL623710,,BAO_0000218,
7893,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,1,,5874,CHEMBL623711,,BAO_0000218,
7894,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat p.o.,A,1,,6504,CHEMBL623712,,BAO_0000218,
7895,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats,A,1,,6803,CHEMBL623713,,BAO_0000218,
7896,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined; ND denotes no data,A,1,,5041,CHEMBL623714,,BAO_0000218,
7897,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined; ND denotes not determined,A,1,,5041,CHEMBL623715,,BAO_0000218,
7898,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,1,,1916,CHEMBL623716,,BAO_0000218,
7899,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,1,,5199,CHEMBL622980,,BAO_0000218,
7900,50597,,In vivo,1,,N,,,,Intermediate,Plasma administration to rats,A,1,,16367,CHEMBL622981,,BAO_0000218,
7901,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance of the compound in female Sprague-Dawley rats,A,1,,6362,CHEMBL622982,,BAO_0000218,
7902,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was observed after intravenous administration in rat,A,1,,15662,CHEMBL622983,,BAO_0000218,
7903,50597,,In vivo,1,,N,,,,Intermediate,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,1,,6215,CHEMBL622984,,BAO_0000218,
7904,50597,,In vivo,1,,N,,,,Intermediate,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,1,,1466,CHEMBL622985,,BAO_0000218,
7905,50597,,In vivo,1,,N,,Plasma,,Intermediate,plasma clearance was observed after intravenous administration in rat,A,1,,15662,CHEMBL623631,,BAO_0000218,1969.0
7906,50597,,In vivo,1,,N,,,,Intermediate,In vivo CL/F determined,A,1,,4723,CHEMBL623632,,BAO_0000218,
7907,50597,,In vivo,1,,N,,Plasma,,Intermediate,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL623633,,BAO_0000218,1969.0
7908,50597,,In vivo,1,,N,,Plasma,,Intermediate,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL623634,,BAO_0000218,1969.0
7909,50597,,In vivo,1,,N,,,,Intermediate,Compound was tested for the lower blood clearance in rat,A,1,,5213,CHEMBL623635,,BAO_0000218,
7910,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for the low clearance in rat (in vivo),A,1,,4687,CHEMBL621195,,BAO_0000218,
7911,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (CLb)of the compound was determined in rat,A,1,,3371,CHEMBL621196,,BAO_0000218,
7912,50597,,In vivo,1,,N,,,,Intermediate,Rapid clearance after intravenous administration in rat was determined,A,1,,4690,CHEMBL875287,,BAO_0000218,
7913,50597,,In vivo,1,,N,,,,Intermediate,Clearance measured in rat,A,1,,5702,CHEMBL621197,,BAO_0000218,
7914,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma clearance in rat,A,1,,740,CHEMBL621198,,BAO_0000218,1969.0
7915,50597,,In vivo,1,,N,,Plasma,,Intermediate,Low plasma clearance was calculated in rat,A,1,,4853,CHEMBL621199,,BAO_0000218,1969.0
7916,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Clp) in rat,A,1,,5789,CHEMBL621200,,BAO_0000218,
7917,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,1,,4527,CHEMBL621201,,BAO_0000218,
7918,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,1,,4527,CHEMBL621202,,BAO_0000218,
7919,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,1,,6518,CHEMBL621203,,BAO_0000218,
7920,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after IV dosing at 1 mg/kg in rat,A,1,,6518,CHEMBL621204,,BAO_0000218,
7921,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,1,,9866,CHEMBL621205,,BAO_0000218,948.0
7922,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL621206,,BAO_0000218,948.0
7923,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,1,,9866,CHEMBL621207,,BAO_0000218,948.0
7924,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,1,,9866,CHEMBL621208,,BAO_0000218,948.0
7925,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL621209,,BAO_0000218,948.0
7926,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,1,,9866,CHEMBL876484,,BAO_0000218,948.0
7927,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,1,,9866,CHEMBL621210,,BAO_0000218,948.0
7928,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL621211,,BAO_0000218,948.0
7929,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,1,,9866,CHEMBL621212,,BAO_0000218,948.0
7930,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,1,,9866,CHEMBL621213,,BAO_0000218,948.0
7931,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,1,,9866,CHEMBL621214,,BAO_0000218,948.0
7932,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,1,,9866,CHEMBL621215,,BAO_0000218,948.0
7933,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,1,,9866,CHEMBL621216,,BAO_0000218,948.0
7934,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,1,,9866,CHEMBL621217,,BAO_0000218,948.0
7935,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,1,,9866,CHEMBL621218,,BAO_0000218,948.0
7936,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,1,,9866,CHEMBL621219,,BAO_0000218,948.0
7937,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,1,,9866,CHEMBL621220,,BAO_0000218,948.0
7938,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,1,,9866,CHEMBL621221,,BAO_0000218,948.0
7939,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,1,,9866,CHEMBL621222,,BAO_0000218,948.0
7940,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,1,,9866,CHEMBL621223,,BAO_0000218,948.0
7941,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,1,,9866,CHEMBL876485,,BAO_0000218,948.0
7942,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,1,,9866,CHEMBL621224,,BAO_0000218,948.0
7943,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL621225,,BAO_0000218,948.0
7944,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL621226,,BAO_0000218,948.0
7945,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL621227,,BAO_0000218,2113.0
7946,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,1,,9866,CHEMBL621228,,BAO_0000218,2113.0
7947,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,1,,9866,CHEMBL621229,,BAO_0000218,2113.0
7948,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL621230,,BAO_0000218,2113.0
7949,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,1,,9866,CHEMBL621231,,BAO_0000218,2113.0
7950,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,1,,9866,CHEMBL621232,,BAO_0000218,2113.0
7951,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,1,,9866,CHEMBL621233,,BAO_0000218,2113.0
7952,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL621234,,BAO_0000218,2113.0
7953,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,1,,9866,CHEMBL621235,,BAO_0000218,2113.0
7954,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,1,,9866,CHEMBL621236,,BAO_0000218,2113.0
7955,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL621237,,BAO_0000218,2113.0
7956,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL876486,,BAO_0000218,2113.0
7957,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,1,,9866,CHEMBL622436,,BAO_0000218,160.0
7958,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL622437,,BAO_0000218,160.0
7959,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,1,,9866,CHEMBL622438,,BAO_0000218,160.0
7960,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,1,,9866,CHEMBL622439,,BAO_0000218,2107.0
7961,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL622440,,BAO_0000218,2107.0
7962,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL622441,,BAO_0000218,2107.0
7963,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,1,,9866,CHEMBL622442,,BAO_0000218,2107.0
7964,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL622443,,BAO_0000218,2107.0
7965,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,1,,9866,CHEMBL622444,,BAO_0000218,2107.0
7966,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,1,,9866,CHEMBL622445,,BAO_0000218,2107.0
7967,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,1,,9866,CHEMBL622446,,BAO_0000218,2107.0
7968,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,1,,9866,CHEMBL622447,,BAO_0000218,2107.0
7969,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL622448,,BAO_0000218,2107.0
7970,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,1,,9866,CHEMBL622449,,BAO_0000218,2107.0
7971,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL622450,,BAO_0000218,2107.0
7972,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,1,,9866,CHEMBL622451,,BAO_0000218,2107.0
7973,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,1,,9866,CHEMBL622452,,BAO_0000218,2107.0
7974,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,1,,9866,CHEMBL622453,,BAO_0000218,2107.0
7975,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,1,,9866,CHEMBL622454,,BAO_0000218,2107.0
7976,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,1,,9866,CHEMBL622455,,BAO_0000218,2107.0
7977,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,1,,9866,CHEMBL876024,,BAO_0000218,2107.0
7978,50597,,In vivo,1,,N,,,,Intermediate,T max was determined at 3 mg/kg po dose in rats,A,1,,2792,CHEMBL622456,,BAO_0000218,
7979,50597,,In vivo,1,,N,,,,Intermediate,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622457,,BAO_0000218,
7980,50597,,In vivo,1,,N,,,,Intermediate,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622458,,BAO_0000218,
7981,50597,,,1,,N,,,,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,1,,15022,CHEMBL622459,,BAO_0000218,
7982,50597,,,1,,N,,,,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,1,,15022,CHEMBL873343,,BAO_0000218,
7983,50597,,,1,,N,,,,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,1,,15022,CHEMBL622460,,BAO_0000218,
7984,50597,,,1,,N,,Plasma,,Intermediate,Time for maximum plasma concentration determined in rat,A,1,,4576,CHEMBL622461,,BAO_0000218,1969.0
7985,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,1,,6681,CHEMBL622462,,BAO_0000218,1969.0
7986,50597,,In vivo,1,,N,,,,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,1,,16365,CHEMBL622463,,BAO_0000218,
7987,50597,,In vivo,1,,N,,,,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,1,,16365,CHEMBL622464,,BAO_0000218,
7988,50597,,In vivo,1,,N,,,,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,1,,16365,CHEMBL622465,,BAO_0000218,
7989,50597,,In vivo,1,,N,,,,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,1,,16365,CHEMBL622466,,BAO_0000218,
7990,50597,,In vivo,1,,N,,,,Intermediate,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,1,,16365,CHEMBL622467,,BAO_0000218,
7991,50597,,,1,,N,,Plasma,,Intermediate,Time of maximum plasma concentration in rat,A,1,,6824,CHEMBL622468,,BAO_0000218,1969.0
7992,50597,,,1,,N,,Plasma,,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,1,,6685,CHEMBL876025,,BAO_0000218,1969.0
7993,50597,,,1,,N,,Plasma,,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,1,,6685,CHEMBL622469,,BAO_0000218,1969.0
7994,50597,,,1,,N,,Plasma,,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,1,,6685,CHEMBL622470,,BAO_0000218,1969.0
7995,50597,,In vivo,1,,N,,,,Intermediate,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,1,,15662,CHEMBL622471,,BAO_0000218,
7996,50597,,,1,,N,,Plasma,,Intermediate,Time required to reach maximum concentration in rat plasma,A,1,,1742,CHEMBL622472,,BAO_0000218,1969.0
7997,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,1,,2774,CHEMBL622473,,BAO_0000218,1969.0
7998,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,1,,5199,CHEMBL624282,,BAO_0000218,1969.0
7999,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,1,,12873,CHEMBL624283,,BAO_0000218,1969.0
8000,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,1,,12873,CHEMBL624284,,BAO_0000218,1969.0
8001,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL624285,,BAO_0000218,1969.0
8002,50597,,In vivo,1,,N,,,,Intermediate,Time to reach Cmax after oral administration to rats,A,1,,16367,CHEMBL624286,,BAO_0000218,
8003,50597,,In vivo,1,,N,,,,Intermediate,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,1,,16366,CHEMBL624287,,BAO_0000218,
8004,50597,,,1,,N,,,,Intermediate,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,1,,216,CHEMBL624288,,BAO_0000218,
8005,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,1,,6410,CHEMBL624289,,BAO_0000218,1969.0
8006,50597,,In vivo,1,,N,,Plasma,,Intermediate,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL873344,,BAO_0000218,1969.0
8007,50597,,In vivo,1,,N,,,,Intermediate,Tmax after peroral administration (10 mg/kg) was determined in rat,A,1,,6215,CHEMBL619623,,BAO_0000218,
8008,50597,,In vivo,1,,N,,,,Expert,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL621399,,BAO_0000218,
8009,50597,,In vivo,1,,N,,,,Intermediate,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,1,,4527,CHEMBL621400,,BAO_0000218,
8010,50597,,In vivo,1,,N,,,,Intermediate,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,1,,17670,CHEMBL621401,,BAO_0000218,
8011,50597,,,1,,N,,,,Intermediate,Tmax was determined,A,1,,1465,CHEMBL621402,,BAO_0000218,
8012,50597,,,1,,N,,,,Intermediate,Tmax was determined,A,1,,2552,CHEMBL621403,,BAO_0000218,
8013,50597,,In vivo,1,,N,,,,Intermediate,Tmax after oral administration in rat,A,1,,5656,CHEMBL621121,,BAO_0000218,
8014,50597,,In vivo,1,,N,,,,Intermediate,Tmax after peroral administration in rats at 2.4 uM/kg,A,1,,17764,CHEMBL872525,,BAO_0000218,
8015,50597,,,1,,N,,,,Intermediate,Tmax in male rat,A,1,,5610,CHEMBL621122,,BAO_0000218,
8016,50597,,In vivo,1,,N,,,,Intermediate,Tmax in rat at 10 mg/kg,A,1,,6046,CHEMBL621123,,BAO_0000218,
8017,50597,,In vivo,1,,N,,,,Intermediate,Tmax in rat by po administration at a dose of 40 mg/kg,A,1,,5874,CHEMBL621124,,BAO_0000218,
8018,50597,,,1,,N,,,,Intermediate,Tmax in rats,A,1,,17596,CHEMBL621125,,BAO_0000218,
8019,50597,,In vivo,1,,N,,,,Intermediate,Tmax was measured in rats after peroral administration at 5 mg/kg,A,1,,17804,CHEMBL621126,,BAO_0000218,
8020,50597,,In vivo,1,,N,,,,Intermediate,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,1,,1908,CHEMBL621127,,BAO_0000218,
8021,50597,,In vivo,1,,N,,,,Intermediate,Tmax value after administration of 20 mg/Kg oral dose in rat,A,1,,2959,CHEMBL621128,,BAO_0000218,
8022,50597,,In vivo,1,,N,,,,Intermediate,Tmax value at a dose of 10 mg/kg in male SD rats,A,1,,6757,CHEMBL618263,,BAO_0000218,
8023,50597,,In vivo,1,,N,,,,Intermediate,Tmax value at a dose of 100 mg/kg in male SD rats,A,1,,6757,CHEMBL618264,,BAO_0000218,
8024,50597,,In vivo,1,,N,,,,Intermediate,Tmax value at a dose of 50 mg/kg in male SD rats,A,1,,6757,CHEMBL618265,,BAO_0000218,
8025,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL618266,,BAO_0000218,1969.0
8026,50597,,In vivo,1,,N,,,,Intermediate,time required to reach maximum concentration (Cmax) after oral administration in rat,A,1,,15662,CHEMBL618267,,BAO_0000218,
8027,50597,,,1,,N,,Urine,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,1,,429,CHEMBL618450,,BAO_0000218,1088.0
8028,50597,,,1,,N,,Urine,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,1,,429,CHEMBL618451,,BAO_0000218,1088.0
8029,50597,,,1,,N,,,,Intermediate,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL618452,,BAO_0000218,
8030,50597,,,1,,N,,Urine,,Intermediate,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,1,,3173,CHEMBL618453,,BAO_0000218,1088.0
8031,50597,,,1,,N,,Urine,,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,1,,3173,CHEMBL618454,,BAO_0000218,1088.0
8032,50597,,,1,,N,,Urine,,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,1,,3173,CHEMBL618455,,BAO_0000218,1088.0
8033,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL618456,,BAO_0000218,
8034,50597,,In vivo,1,,N,,,,Intermediate,Compound distribution in rat tissues was determined,A,1,,6011,CHEMBL618457,,BAO_0000218,
8035,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was evaluated in rat,A,1,,5472,CHEMBL618458,,BAO_0000218,
8036,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,1,,14346,CHEMBL618459,,BAO_0000218,
8037,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,1,,14346,CHEMBL876733,,BAO_0000218,
8038,50588,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,1,,14346,CHEMBL618460,,BAO_0000218,
8039,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,1,,14346,CHEMBL618461,,BAO_0000218,
8040,22224,,,0,,U,,,,Autocuration,Area under the curve was determined after oral administration (300 uM/Kg),A,1,,15469,CHEMBL618462,,BAO_0000019,
8041,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,1,,14346,CHEMBL618463,,BAO_0000218,
8042,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,1,,14346,CHEMBL618464,,BAO_0000218,
8043,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,1,,14346,CHEMBL618465,,BAO_0000218,
8044,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,1,,14346,CHEMBL618466,,BAO_0000218,
8045,50597,,,1,,N,,,,Intermediate,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,1,,14346,CHEMBL618467,,BAO_0000218,
8046,50597,,,1,,N,,,,Intermediate,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,1,,15372,CHEMBL618468,,BAO_0000218,
8047,50588,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,1,,12935,CHEMBL618469,,BAO_0000218,1969.0
8048,50588,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,1,,12935,CHEMBL618470,,BAO_0000218,1969.0
8049,22224,,,0,,U,,,,Autocuration,Plasma drug AUC in rat (PO dose),A,1,,14813,CHEMBL618471,,BAO_0000218,
8050,50594,,,1,,N,,,,Intermediate,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,1,,15792,CHEMBL618472,,BAO_0000218,
8051,22224,,,0,,U,,,,Autocuration,Area under was determined at a dose of 30 mg/kg,A,1,,3579,CHEMBL618473,,BAO_0000218,
8052,50506,,,1,,N,,,,Intermediate,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,1,,12487,CHEMBL621699,,BAO_0000218,
8053,50597,,,1,,N,,,,Intermediate,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,1,,12487,CHEMBL621700,,BAO_0000218,
8054,50597,,,1,,N,,,,Intermediate,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,1,,12487,CHEMBL621701,,BAO_0000218,
8055,50506,,,1,,N,,,,Intermediate,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,1,,12487,CHEMBL621702,,BAO_0000218,
8056,50588,,,1,,N,,,,Intermediate,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,1,,12487,CHEMBL621703,,BAO_0000218,
8057,50588,,,1,,N,,,,Intermediate,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,1,,12487,CHEMBL621704,,BAO_0000218,
8058,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,1,,12902,CHEMBL624259,,BAO_0000218,
8059,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,1,,12902,CHEMBL624260,,BAO_0000218,
8060,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,1,,12902,CHEMBL624430,,BAO_0000218,
8061,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,1,,12902,CHEMBL624431,,BAO_0000218,
8062,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,1,,12902,CHEMBL624432,,BAO_0000218,
8063,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,1,,12902,CHEMBL624433,,BAO_0000218,
8064,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,1,,12902,CHEMBL624434,,BAO_0000218,
8065,50597,,,1,,N,,,,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,1,,12902,CHEMBL624435,,BAO_0000218,
8066,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,1,,12745,CHEMBL618570,,BAO_0000218,
8067,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,1,,12745,CHEMBL618571,,BAO_0000218,
8068,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,1,,12745,CHEMBL618572,,BAO_0000218,
8069,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,1,,12745,CHEMBL618573,,BAO_0000218,
8070,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,1,,12745,CHEMBL619267,,BAO_0000218,
8071,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,1,,12745,CHEMBL619431,,BAO_0000218,
8072,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,1,,12745,CHEMBL619432,,BAO_0000218,
8073,50594,,,1,,N,,,,Intermediate,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,1,,12745,CHEMBL619433,,BAO_0000218,
8074,22224,,,0,,U,,Plasma,,Autocuration,AUC in mice after oral dose (50 mg/kg),A,1,,13298,CHEMBL619434,,BAO_0000218,1969.0
8075,50594,,,1,,N,,Serum,,Intermediate,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,1,,12226,CHEMBL619435,,BAO_0000218,1977.0
8076,22224,,,0,,U,,Plasma,,Autocuration,AUC (0-4 hr) ug/ml/h,A,1,,12634,CHEMBL619436,,BAO_0000019,1969.0
8077,50597,,,1,,N,,,,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,1,,14810,CHEMBL619437,,BAO_0000218,
8078,22224,,,0,,U,,,,Autocuration,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,1,,13889,CHEMBL619438,,BAO_0000218,
8079,50594,,,1,,N,,,,Intermediate,Compound was evaluated for Area under curve in mice,A,1,,10018,CHEMBL619439,,BAO_0000218,
8080,50597,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,1,,8758,CHEMBL619440,,BAO_0000218,
8081,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,1,,8758,CHEMBL619441,,BAO_0000218,
8082,50597,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,1,,8758,CHEMBL619442,,BAO_0000218,
8083,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,1,,2249,CHEMBL875156,,BAO_0000019,
8084,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,1,,2249,CHEMBL619443,,BAO_0000019,
8085,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,1,,2249,CHEMBL619444,,BAO_0000019,
8086,22224,,,0,,U,,,,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,1,,2249,CHEMBL623464,,BAO_0000019,
8087,50594,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve when administered through oral route in mouse,A,1,,15115,CHEMBL623465,,BAO_0000218,
8088,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,1,,6518,CHEMBL623466,,BAO_0000218,
8089,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,1,,6518,CHEMBL623467,,BAO_0000218,
8090,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,6249,CHEMBL623468,,BAO_0000218,
8091,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,1,,2463,CHEMBL622660,,BAO_0000218,
8092,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate in Sprague-Dawley rats,A,1,,4969,CHEMBL622661,,BAO_0000218,
8093,50597,,In vivo,1,,N,,,,Intermediate,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,1,,17720,CHEMBL622662,,BAO_0000218,
8094,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (total body clearance) in rat,A,1,,3457,CHEMBL622663,,BAO_0000218,
8095,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,1,,5983,CHEMBL622664,,BAO_0000218,
8096,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,1,,6295,CHEMBL622665,,BAO_0000218,
8097,50597,,,1,,N,,,,Intermediate,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,1,,6296,CHEMBL622666,,BAO_0000218,
8098,50597,,In vivo,1,,N,,,,Intermediate,Cl in rat i.v. at 2 mg/kg concentration,A,1,,17686,CHEMBL621615,,BAO_0000218,
8099,50597,,In vivo,1,,N,,,,Intermediate,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL621616,,BAO_0000218,
8100,50597,,In vivo,1,,N,,,,Intermediate,Clearance was determined,A,1,,5503,CHEMBL621617,,BAO_0000218,
8101,50597,,In vivo,1,,N,,,,Intermediate,Clearance by intravenous administration of 3.4 mg/kg in rat,A,1,,4368,CHEMBL621618,,BAO_0000218,
8102,50597,,In vivo,1,,N,,,,Intermediate,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,1,,6005,CHEMBL621619,,BAO_0000218,
8103,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate after i.v. administration in rats,A,1,,5031,CHEMBL621620,,BAO_0000218,
8104,50597,,In vivo,1,,N,,,,Intermediate,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL621786,,BAO_0000218,
8105,50597,,In vivo,1,,N,,,,Intermediate,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,1,,5182,CHEMBL621787,,BAO_0000218,
8106,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,1,,5979,CHEMBL621788,,BAO_0000218,
8107,50597,,In vivo,1,,N,,,,Intermediate,Clearance (Cl) after oral administration in rat,A,1,,5656,CHEMBL621789,,BAO_0000218,
8108,50597,,In vivo,1,,N,,,,Intermediate,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,1,,17804,CHEMBL621790,,BAO_0000218,
8109,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in rat,A,1,,4839,CHEMBL621791,,BAO_0000218,1969.0
8110,50597,,In vitro,1,,N,Microsomes,,,Intermediate,In vitro microsome metabolism clearance in rat was determined,A,1,,5041,CHEMBL621792,,BAO_0000218,
8111,50597,,In vitro,1,,N,Microsomes,,,Intermediate,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,1,,5041,CHEMBL621793,,BAO_0000218,
8112,50597,,In vivo,1,,N,,,,Intermediate,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL621794,,BAO_0000218,
8113,50597,,In vivo,1,,N,,Plasma,,Intermediate,In vivo plasma clearance was determined,A,1,,5496,CHEMBL621795,,BAO_0000218,1969.0
8114,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,1,,5739,CHEMBL621796,,BAO_0000218,
8115,50597,,In vivo,1,,N,,Liver,Hepatocyte,Intermediate,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,1,,5676,CHEMBL621797,401.0,BAO_0000218,2107.0
8116,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in rat,A,1,,4239,CHEMBL621798,,BAO_0000218,
8117,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (clearance) in rat i.v.,A,1,,5676,CHEMBL621799,,BAO_0000218,
8118,50597,,In vivo,1,,N,,,,Intermediate,"Plasma Clearance was evaluated in rats, iv",A,1,,1918,CHEMBL621800,,BAO_0000218,
8119,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance (in vivo) in rats was determined,A,1,,17800,CHEMBL621801,,BAO_0000218,
8120,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,1,,6056,CHEMBL621802,,BAO_0000218,
8121,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined,A,1,,5496,CHEMBL618596,,BAO_0000218,
8122,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,1,,5939,CHEMBL618597,,BAO_0000218,
8123,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,1,,5939,CHEMBL618598,,BAO_0000218,
8124,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats,A,1,,17752,CHEMBL618599,,BAO_0000218,
8125,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate determined in rat,A,1,,4576,CHEMBL618600,,BAO_0000218,
8126,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in rat,A,1,,6011,CHEMBL618601,,BAO_0000218,
8127,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined,A,1,,5510,CHEMBL618602,,BAO_0000218,
8128,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance value in rat,A,1,,5948,CHEMBL618603,,BAO_0000218,
8129,50597,,Ex vivo,1,,N,,Liver,,Intermediate,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,1,,6125,CHEMBL618604,,BAO_0000218,2107.0
8130,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat,A,1,,4839,CHEMBL618605,,BAO_0000218,
8131,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance in rat i.v. at 2 mg/kg concentration,A,1,,17686,CHEMBL618606,,BAO_0000218,
8132,50597,,In vivo,1,,N,,,,Intermediate,Clearance of compound in rats after intravenous administration,A,1,,6571,CHEMBL618607,,BAO_0000218,
8133,50597,,In vivo,1,,N,,,,Intermediate,Clearance after iv administration to rats,A,1,,3364,CHEMBL618608,,BAO_0000218,
8134,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,1,,13569,CHEMBL618609,,BAO_0000218,
8135,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,1,,13569,CHEMBL618610,,BAO_0000218,
8136,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,1,,13569,CHEMBL618611,,BAO_0000218,
8137,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,1,,13569,CHEMBL618612,,BAO_0000218,
8138,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,1,,13569,CHEMBL618613,,BAO_0000218,
8139,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,1,,13569,CHEMBL621076,,BAO_0000218,
8140,50597,,In vivo,1,,N,,,,Intermediate,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,1,,13569,CHEMBL621077,,BAO_0000218,
8141,50597,,In vivo,1,,N,,,,Intermediate,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,1,,17670,CHEMBL621078,,BAO_0000218,
8142,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat,A,1,,5970,CHEMBL621251,,BAO_0000218,
8143,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat after oral administration at 10 mg/kg,A,1,,6495,CHEMBL621252,,BAO_0000218,
8144,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat.,A,1,,4590,CHEMBL621253,,BAO_0000218,
8145,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate following an oral dose of 20 mg/kg in rats,A,1,,6193,CHEMBL621254,,BAO_0000218,
8146,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,1,,2832,CHEMBL621255,,BAO_0000218,
8147,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,1,,1052,CHEMBL621256,,BAO_0000218,1969.0
8148,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,1,,9866,CHEMBL621257,,BAO_0000218,2107.0
8149,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,1,,9866,CHEMBL621258,,BAO_0000218,2107.0
8150,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,1,,9866,CHEMBL621259,,BAO_0000218,2107.0
8151,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,1,,9866,CHEMBL621260,,BAO_0000218,2107.0
8152,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,1,,9866,CHEMBL876494,,BAO_0000218,2107.0
8153,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,1,,9866,CHEMBL621261,,BAO_0000218,2107.0
8154,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,1,,9866,CHEMBL621262,,BAO_0000218,2107.0
8155,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,1,,9866,CHEMBL621263,,BAO_0000218,2107.0
8156,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL621264,,BAO_0000218,2107.0
8157,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL621265,,BAO_0000218,2385.0
8158,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,1,,9866,CHEMBL621266,,BAO_0000218,2385.0
8159,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,1,,9866,CHEMBL621267,,BAO_0000218,2385.0
8160,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL621268,,BAO_0000218,2385.0
8161,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,1,,9866,CHEMBL621269,,BAO_0000218,2385.0
8162,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,1,,9866,CHEMBL621270,,BAO_0000218,2385.0
8163,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,1,,9866,CHEMBL621271,,BAO_0000218,2385.0
8164,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,1,,9866,CHEMBL621272,,BAO_0000218,2385.0
8165,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,1,,9866,CHEMBL621273,,BAO_0000218,2385.0
8166,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,1,,9866,CHEMBL621274,,BAO_0000218,2385.0
8167,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,1,,9866,CHEMBL876495,,BAO_0000218,2385.0
8168,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,1,,9866,CHEMBL621275,,BAO_0000218,2385.0
8169,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL621276,,BAO_0000218,2385.0
8170,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL621277,,BAO_0000218,2385.0
8171,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL621278,,BAO_0000218,160.0
8172,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,1,,9866,CHEMBL621279,,BAO_0000218,160.0
8173,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,1,,9866,CHEMBL621280,,BAO_0000218,160.0
8174,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,1,,9866,CHEMBL621281,,BAO_0000218,2106.0
8175,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,1,,9866,CHEMBL621282,,BAO_0000218,2106.0
8176,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,1,,9866,CHEMBL621283,,BAO_0000218,2106.0
8177,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,1,,9866,CHEMBL621284,,BAO_0000218,2106.0
8178,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,1,,9866,CHEMBL621285,,BAO_0000218,2106.0
8179,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL621286,,BAO_0000218,2106.0
8180,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,1,,9866,CHEMBL623220,,BAO_0000218,2106.0
8181,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,1,,9866,CHEMBL623221,,BAO_0000218,2106.0
8182,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,1,,9866,CHEMBL876029,,BAO_0000218,2106.0
8183,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,1,,9866,CHEMBL623222,,BAO_0000218,945.0
8184,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,1,,9866,CHEMBL623223,,BAO_0000218,945.0
8185,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,1,,9866,CHEMBL621445,,BAO_0000218,945.0
8186,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621446,,BAO_0000218,178.0
8187,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621447,,BAO_0000218,178.0
8188,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619681,,BAO_0000218,178.0
8189,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619682,,BAO_0000218,178.0
8190,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619683,,BAO_0000218,178.0
8191,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619684,,BAO_0000218,955.0
8192,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619685,,BAO_0000218,955.0
8193,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619686,,BAO_0000218,955.0
8194,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619687,,BAO_0000218,955.0
8195,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619688,,BAO_0000218,955.0
8196,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619689,,BAO_0000218,948.0
8197,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619690,,BAO_0000218,948.0
8198,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619691,,BAO_0000218,948.0
8199,50597,,In vivo,1,,N,,,,Intermediate,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL619692,,BAO_0000218,
8200,50597,,,1,,N,,,,Expert,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL619693,,BAO_0000218,
8201,50597,,In vivo,1,,N,,,,Intermediate,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,1,,1908,CHEMBL619694,,BAO_0000218,
8202,50597,,In vivo,1,,N,,,,Intermediate,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,1,,17596,CHEMBL619695,,BAO_0000218,
8203,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,1,,4891,CHEMBL619696,,BAO_0000218,
8204,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for volume of distribution in rat,A,1,,740,CHEMBL619697,,BAO_0000218,
8205,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution was determined; steady state(ss),A,1,,16366,CHEMBL619698,,BAO_0000218,
8206,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution after iv administration to rats,A,1,,3364,CHEMBL619699,,BAO_0000218,
8207,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution dosing at 3 mg/kg iv,A,1,,2552,CHEMBL619700,,BAO_0000218,
8208,50597,,In vivo,1,,N,,,,Intermediate,The compound was evaluated for volume of distribution in rat,A,1,,406,CHEMBL619701,,BAO_0000218,
8209,50597,,In vivo,1,,N,,,,Intermediate,The compound was tested for volume of distribution in rat,A,1,,12500,CHEMBL619702,,BAO_0000218,
8210,50597,,In vivo,1,,N,,,,Intermediate,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,1,,12500,CHEMBL620335,,BAO_0000218,
8211,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution (VD) after oral administration in rat,A,1,,5656,CHEMBL620336,,BAO_0000218,
8212,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,1,,17671,CHEMBL620337,,BAO_0000218,
8213,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat,A,1,,1094,CHEMBL620520,,BAO_0000218,
8214,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat,A,1,,5833,CHEMBL620521,,BAO_0000218,
8215,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after peroral administration at 10 mg/kg,A,1,,5939,CHEMBL875825,,BAO_0000218,
8216,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after peroral administration at 5 mg/kg,A,1,,5939,CHEMBL620522,,BAO_0000218,
8217,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,1,,6005,CHEMBL620523,,BAO_0000218,
8218,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat.,A,1,,1696,CHEMBL620524,,BAO_0000218,
8219,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat,A,1,,6672,CHEMBL620525,,BAO_0000218,
8220,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat,A,1,,6673,CHEMBL620526,,BAO_0000218,
8221,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat by iv administration,A,1,,5871,CHEMBL620527,,BAO_0000218,
8222,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rats,A,1,,6803,CHEMBL620528,,BAO_0000218,
8223,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,1,,5199,CHEMBL620529,,BAO_0000218,
8224,50597,,,1,,N,,,,Intermediate,Volume distribution at the dose of 2 mg/kg in rat,A,1,,4727,CHEMBL620530,,BAO_0000218,
8225,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution was determined,A,1,,16367,CHEMBL620531,,BAO_0000218,
8226,22224,,In vivo,0,,U,,,,Intermediate,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,1,,5005,CHEMBL620532,,BAO_0000218,
8227,22224,,In vivo,0,,U,,,,Intermediate,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,1,,5005,CHEMBL620533,,BAO_0000218,
8228,22224,,In vivo,0,,U,,,,Intermediate,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,1,,5005,CHEMBL620534,,BAO_0000218,
8229,50597,,In vivo,1,,N,,,,Intermediate,Mean (%CV) PK parameters for Vdss(mL/kg).,A,1,,15765,CHEMBL620535,,BAO_0000218,
8230,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL875826,,BAO_0000218,
8231,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL620536,,BAO_0000218,
8232,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL620537,,BAO_0000218,
8233,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,1,,5334,CHEMBL618526,,BAO_0000218,
8234,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,1,,5739,CHEMBL618527,,BAO_0000218,
8235,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Vdss) in rat,A,1,,5789,CHEMBL618528,,BAO_0000218,
8236,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (vdss) was measured in rat,A,1,,4239,CHEMBL618529,,BAO_0000218,
8237,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL618530,,BAO_0000218,
8238,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat,A,1,,6642,CHEMBL618531,,BAO_0000218,
8239,50597,,In vivo,1,,N,,,,Intermediate,The pharmacokinetic parameter volume of distribution in vivo in rats,A,1,,5247,CHEMBL618532,,BAO_0000218,
8240,50597,,In vivo,1,,N,,,,Intermediate,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,1,,17720,CHEMBL618533,,BAO_0000218,
8241,50597,,In vivo,1,,N,,,,Intermediate,Vdss in rat i.v. at 2 mg/kg concentration,A,1,,17686,CHEMBL618534,,BAO_0000218,
8242,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution after intravenous administration (1 mg/kg) in rat,A,1,,4689,CHEMBL618535,,BAO_0000218,
8243,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,1,,5654,CHEMBL618536,,BAO_0000218,
8244,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,1,,5654,CHEMBL618537,,BAO_0000218,
8245,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution at a dose of 10 uM/kg in rat was determined,A,1,,4527,CHEMBL618538,,BAO_0000218,
8246,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,1,,4521,CHEMBL618539,,BAO_0000218,
8247,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution was calculated in rat,A,1,,6057,CHEMBL618540,,BAO_0000218,
8248,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution was determined,A,1,,5510,CHEMBL618541,,BAO_0000218,
8249,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution after intravenous administration was evaluated in rat,A,1,,2938,CHEMBL618542,,BAO_0000218,
8250,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL622544,,BAO_0000218,
8251,50597,,In vivo,1,,N,,,,Intermediate,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,1,,6685,CHEMBL622545,,BAO_0000218,
8252,50597,,In vivo,1,,N,,,,Intermediate,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,1,,6685,CHEMBL622546,,BAO_0000218,
8253,50597,,In vivo,1,,N,,,,Intermediate,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,1,,6685,CHEMBL622547,,BAO_0000218,
8254,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in rat,A,1,,5145,CHEMBL622548,,BAO_0000218,
8255,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,1,,6467,CHEMBL622549,,BAO_0000218,
8256,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,1,,6467,CHEMBL622550,,BAO_0000218,
8257,50594,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve when administered through oral route to mouse,A,1,,15115,CHEMBL622551,,BAO_0000218,
8258,50597,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,1,,8758,CHEMBL622552,,BAO_0000218,
8259,50597,,,1,,N,,,,Intermediate,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,1,,8758,CHEMBL622553,,BAO_0000218,
8260,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,1,,8267,CHEMBL622554,,BAO_0000218,
8261,50588,,,1,,N,,,,Intermediate,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,1,,8267,CHEMBL622555,,BAO_0000218,
8262,50594,,,1,,N,,,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,1,,14239,CHEMBL622556,,BAO_0000218,
8263,50594,,,1,,N,,,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,1,,14239,CHEMBL622557,,BAO_0000218,
8264,50594,,,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,1,,10754,CHEMBL622558,,BAO_0000218,178.0
8265,50594,,,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,1,,10754,CHEMBL622559,,BAO_0000218,178.0
8266,50588,,,1,,N,,,,Intermediate,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,1,,10754,CHEMBL622560,,BAO_0000218,
8267,50597,,,1,,N,,,,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,1,,14681,CHEMBL622561,,BAO_0000218,
8268,50597,,,1,,N,,,,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,1,,14681,CHEMBL622562,,BAO_0000218,
8269,50597,,,1,,N,,,,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,1,,14681,CHEMBL622563,,BAO_0000218,
8270,22224,,,0,,U,,,,Autocuration,Concentration of compound in Central nervous system,A,1,,13118,CHEMBL622564,,BAO_0000019,
8271,22224,,,0,,U,,,,Autocuration,Concentration of compound in Central nervous system; Not detectable,A,1,,13118,CHEMBL622565,,BAO_0000019,
8272,50594,,,1,,N,,,,Intermediate,"Concentration of diester in the blood, following oral administration in mice",A,1,,13318,CHEMBL622566,,BAO_0000218,
8273,50594,,,1,,N,,,,Intermediate,"Concentration of monoester in the blood, following oral administration in mice",A,1,,13318,CHEMBL624515,,BAO_0000218,
8274,50594,,,1,,N,,,,Intermediate,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,1,,13318,CHEMBL624516,,BAO_0000218,
8275,22224,,,0,,U,,,,Autocuration,Evaluated for Pharmacokinetic property: Area under the curve,A,1,,15692,CHEMBL624517,,BAO_0000019,
8276,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,1,,14839,CHEMBL624518,,BAO_0000218,
8277,100710,,,1,,N,,,,Intermediate,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,1,,14839,CHEMBL624519,,BAO_0000218,
8278,100710,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL624520,,BAO_0000218,
8279,100710,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL624521,,BAO_0000218,
8280,100710,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL624522,,BAO_0000218,
8281,100710,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL624523,,BAO_0000218,
8282,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,1,,14839,CHEMBL624409,,BAO_0000218,
8283,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,1,,14839,CHEMBL624410,,BAO_0000218,
8284,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,1,,14839,CHEMBL624411,,BAO_0000218,
8285,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,1,,14839,CHEMBL623531,,BAO_0000218,
8286,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,1,,14839,CHEMBL623532,,BAO_0000218,
8287,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,1,,14839,CHEMBL623533,,BAO_0000218,
8288,100710,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,1,,14839,CHEMBL623534,,BAO_0000218,
8289,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623535,,BAO_0000218,
8290,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623536,,BAO_0000218,
8291,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623537,,BAO_0000218,
8292,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623538,,BAO_0000218,
8293,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623539,,BAO_0000218,
8294,50594,,,1,,N,,,,Intermediate,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,1,,14839,CHEMBL623540,,BAO_0000218,
8295,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,1,,14839,CHEMBL623541,,BAO_0000218,
8296,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,1,,14839,CHEMBL623542,,BAO_0000218,
8297,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,1,,14839,CHEMBL623543,,BAO_0000218,
8298,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,1,,14839,CHEMBL623544,,BAO_0000218,
8299,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,1,,14839,CHEMBL623545,,BAO_0000218,
8300,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,1,,14839,CHEMBL623546,,BAO_0000218,
8301,50597,,In vivo,1,,N,,Plasma,,Intermediate,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,1,,5408,CHEMBL623547,,BAO_0000218,1969.0
8302,50597,,In vivo,1,,N,,,,Intermediate,High i.v. clearance in Dawley rats,A,1,,6827,CHEMBL623548,,BAO_0000218,
8303,50597,,In vitro,1,,N,Microsomes,Liver,,Intermediate,In vitro clearance in rat liver microsomes,A,1,,17538,CHEMBL623549,,BAO_0000218,2107.0
8304,50597,,In vitro,1,,N,Microsomes,Liver,,Intermediate,Intrinsic clearance in rat liver microsomes was determined,A,1,,6331,CHEMBL623550,,BAO_0000218,2107.0
8305,50597,,In vitro,1,,N,,Liver,Hepatocyte,Intermediate,Intrinsic clearance in rat hepatocytes was determined,A,1,,5948,CHEMBL875276,401.0,BAO_0000218,2107.0
8306,50597,,In vivo,1,,N,,,,Intermediate,Plasma Clearance was determined,A,1,,4026,CHEMBL621872,,BAO_0000218,
8307,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,1,,6647,CHEMBL621873,,BAO_0000218,
8308,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat.,A,1,,1696,CHEMBL621874,,BAO_0000218,
8309,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats,A,1,,6597,CHEMBL621875,,BAO_0000218,
8310,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,1,,347,CHEMBL621876,,BAO_0000218,
8311,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,1,,16423,CHEMBL621877,,BAO_0000218,
8312,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was measured in rat,A,1,,2879,CHEMBL621878,,BAO_0000218,
8313,50597,,In vivo,1,,N,,,,Intermediate,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,1,,4883,CHEMBL621879,,BAO_0000218,
8314,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,1,,5328,CHEMBL621880,,BAO_0000218,1969.0
8315,50597,,In vivo,1,,N,,,,Intermediate,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,1,,5160,CHEMBL621881,,BAO_0000218,
8316,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,1,,17582,CHEMBL621882,,BAO_0000218,
8317,50597,,In vivo,1,,N,,,,Intermediate,Total clearance at 1 mg/kg was determined in rat,A,1,,17651,CHEMBL875283,,BAO_0000218,
8318,50597,,In vivo,1,,N,,,,Intermediate,Total clearance at 10 mg/kg was determined in rat,A,1,,17651,CHEMBL621883,,BAO_0000218,
8319,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat,A,1,,6596,CHEMBL621884,,BAO_0000218,
8320,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate determined in rats,A,1,,4796,CHEMBL621885,,BAO_0000218,
8321,50597,,In vivo,1,,N,,,,Intermediate,Clearance of compound in rat was evaluated,A,1,,6850,CHEMBL621886,,BAO_0000218,
8322,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,1,,5932,CHEMBL621887,,BAO_0000218,1969.0
8323,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (blood clearance) in rat,A,1,,3371,CHEMBL621888,,BAO_0000218,
8324,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,2083,CHEMBL621889,,BAO_0000218,
8325,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats,A,1,,4942,CHEMBL621890,,BAO_0000218,
8326,50597,,In vitro,1,,N,Microsomes,Liver,,Intermediate,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,1,,6838,CHEMBL621891,,BAO_0000218,2107.0
8327,50597,,In vivo,1,,N,,,,Intermediate,Clearance in Dawley rat,A,1,,5353,CHEMBL621892,,BAO_0000218,
8328,50597,,In vivo,1,,N,,,,Intermediate,Clearance rat,A,1,,6641,CHEMBL621893,,BAO_0000218,
8329,50597,,In vivo,1,,N,,,,Intermediate,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,1,,6641,CHEMBL621894,,BAO_0000218,
8330,50597,,In vivo,1,,N,,,,Intermediate,Clearance rat; Not determined,A,1,,6641,CHEMBL621895,,BAO_0000218,
8331,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,1,,6444,CHEMBL875284,,BAO_0000218,
8332,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,1,,6444,CHEMBL618699,,BAO_0000218,
8333,50597,,In vivo,1,,N,,,,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,1,,6444,CHEMBL618700,,BAO_0000218,
8334,50597,,In vivo,1,,N,,,,Intermediate,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,1,,6211,CHEMBL618701,,BAO_0000218,
8335,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,1,,12873,CHEMBL876600,,BAO_0000218,1969.0
8336,50597,,In vivo,1,,N,,,,Intermediate,Clearance of compound in rat after 1 mg/kg i.v. administration,A,1,,6570,CHEMBL618702,,BAO_0000218,
8337,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for Hepatic clearance in rat,A,1,,3341,CHEMBL618703,,BAO_0000218,
8338,50597,,In vivo,1,,N,,,,Intermediate,In vivo clearance after 5 mg/kg dose,A,1,,4891,CHEMBL618704,,BAO_0000218,
8339,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in rats,A,1,,1094,CHEMBL618705,,BAO_0000218,1969.0
8340,50597,,In vivo,1,,N,,,,Intermediate,Hepatic clearance after intravenous administration was evaluated in rat,A,1,,2938,CHEMBL618706,,BAO_0000218,
8341,50597,,In vivo,1,,N,,,,Intermediate,Lower clearance in rat (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL618707,,BAO_0000218,
8342,50597,,In vivo,1,,N,,Plasma,,Intermediate,Pharmacokinetic parameter expressed as plasma clearance in rat,A,1,,6049,CHEMBL618708,,BAO_0000218,1969.0
8343,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Clp) in rat,A,1,,5789,CHEMBL618709,,BAO_0000218,
8344,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in Sprague-Dawley rats,A,1,,4514,CHEMBL618710,,BAO_0000218,
8345,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance (Clp) in rat,A,1,,6448,CHEMBL618711,,BAO_0000218,
8346,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL618712,,BAO_0000218,
8347,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,1,,5710,CHEMBL618713,,BAO_0000218,
8348,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL618714,,BAO_0000218,
8349,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,1,,4521,CHEMBL618715,,BAO_0000218,
8350,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat was determined,A,1,,1742,CHEMBL618716,,BAO_0000218,
8351,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance measured in rat,A,1,,6057,CHEMBL876601,,BAO_0000218,
8352,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was calculated in rat,A,1,,6057,CHEMBL618717,,BAO_0000218,
8353,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,5145,CHEMBL618718,,BAO_0000218,
8354,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,5833,CHEMBL618719,,BAO_0000218,
8355,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,6453,CHEMBL618720,,BAO_0000218,
8356,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,6640,CHEMBL618721,,BAO_0000218,
8357,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats,A,1,,6305,CHEMBL621477,,BAO_0000218,
8358,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,6642,CHEMBL621478,,BAO_0000218,
8359,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in rat,A,1,,5472,CHEMBL621479,,BAO_0000218,
8360,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated in rat; Not tested,A,1,,5472,CHEMBL621480,,BAO_0000218,
8361,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate was determined for the compound in rat,A,1,,5144,CHEMBL621481,,BAO_0000218,
8362,50597,,In vivo,1,,N,,,,Intermediate,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,1,,6685,CHEMBL621482,,BAO_0000218,
8363,50597,,In vivo,1,,N,,,,Intermediate,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,1,,6685,CHEMBL621483,,BAO_0000218,
8364,50597,,In vivo,1,,N,,,,Intermediate,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,1,,6685,CHEMBL621484,,BAO_0000218,
8365,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621485,,BAO_0000218,948.0
8366,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621486,,BAO_0000218,948.0
8367,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621487,,BAO_0000218,160.0
8368,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621488,,BAO_0000218,160.0
8369,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621489,,BAO_0000218,160.0
8370,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621490,,BAO_0000218,160.0
8371,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621491,,BAO_0000218,160.0
8372,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621492,,BAO_0000218,2113.0
8373,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621493,,BAO_0000218,2113.0
8374,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621494,,BAO_0000218,2113.0
8375,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621495,,BAO_0000218,2113.0
8376,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621496,,BAO_0000218,2113.0
8377,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621497,,BAO_0000218,2107.0
8378,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621498,,BAO_0000218,2107.0
8379,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL621499,,BAO_0000218,2107.0
8380,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL618634,,BAO_0000218,2107.0
8381,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL618635,,BAO_0000218,2107.0
8382,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL618636,,BAO_0000218,2048.0
8383,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619737,,BAO_0000218,2048.0
8384,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL619738,,BAO_0000218,2048.0
8385,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624329,,BAO_0000218,2048.0
8386,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624330,,BAO_0000218,2048.0
8387,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624331,,BAO_0000218,2385.0
8388,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624332,,BAO_0000218,2385.0
8389,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624333,,BAO_0000218,2385.0
8390,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624334,,BAO_0000218,2385.0
8391,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL624335,,BAO_0000218,2385.0
8392,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620016,,BAO_0000218,2106.0
8393,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620169,,BAO_0000218,2106.0
8394,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620170,,BAO_0000218,2106.0
8395,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620171,,BAO_0000218,2106.0
8396,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620172,,BAO_0000218,2106.0
8397,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620173,,BAO_0000218,945.0
8398,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620174,,BAO_0000218,945.0
8399,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620175,,BAO_0000218,945.0
8400,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620176,,BAO_0000218,945.0
8401,50597,,In vivo,1,,N,,Stomach,,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620177,,BAO_0000218,945.0
8402,50597,,,1,,N,,Cerebellum,,Intermediate,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620178,,BAO_0000218,2037.0
8403,50597,,,1,,N,,Cerebellum,,Intermediate,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620179,,BAO_0000218,2037.0
8404,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620180,,BAO_0000218,
8405,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,1,,6570,CHEMBL620181,,BAO_0000218,
8406,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution of compound in rats after intravenous administration,A,1,,6571,CHEMBL620182,,BAO_0000218,
8407,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat,A,1,,6453,CHEMBL620183,,BAO_0000218,
8408,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,1,,6444,CHEMBL620184,,BAO_0000218,
8409,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,1,,6444,CHEMBL620185,,BAO_0000218,
8410,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,1,,6444,CHEMBL620186,,BAO_0000218,
8411,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined in Dawley rat,A,1,,5353,CHEMBL620187,,BAO_0000218,
8412,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL620188,,BAO_0000218,
8413,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was reported in Sprague-Dawley rat,A,1,,5334,CHEMBL620189,,BAO_0000218,
8414,50597,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in rat after peroral administration,A,1,,6641,CHEMBL620190,,BAO_0000218,
8415,50597,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in rat after po administration,A,1,,6641,CHEMBL620191,,BAO_0000218,
8416,50597,,In vivo,1,,N,,,,Intermediate,Volumes of distribution in rat after po administration; Not determined,A,1,,6641,CHEMBL620192,,BAO_0000218,
8417,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Volume) in rat i.v.,A,1,,5676,CHEMBL620193,,BAO_0000218,
8418,50597,,In vivo,1,,N,,,,Intermediate,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,1,,6410,CHEMBL620194,,BAO_0000218,
8419,50597,,In vivo,1,,N,,,,Intermediate,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,1,,17670,CHEMBL876730,,BAO_0000218,
8420,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after oral administration at 10 mg/kg,A,1,,6495,CHEMBL620195,,BAO_0000218,
8421,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,1,,5408,CHEMBL620196,,BAO_0000218,
8422,50597,,In vivo,1,,N,,,,Intermediate,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,1,,4883,CHEMBL620197,,BAO_0000218,
8423,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,1,,6647,CHEMBL620198,,BAO_0000218,
8424,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rats,A,1,,6495,CHEMBL620199,,BAO_0000218,
8425,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,1,,2661,CHEMBL620200,,BAO_0000218,
8426,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,1,,2661,CHEMBL620201,,BAO_0000218,
8427,50597,,In vivo,1,,N,,,,Intermediate,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL620202,,BAO_0000218,
8428,50597,,In vivo,1,,N,,,,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL620203,,BAO_0000218,
8429,50597,,In vivo,1,,N,,,,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,1,,5974,CHEMBL620204,,BAO_0000218,
8430,50597,,In vivo,1,,N,,,,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL620205,,BAO_0000218,
8431,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Vss) in rat,A,1,,5960,CHEMBL624664,,BAO_0000218,
8432,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Volume) in rat i.v.,A,1,,5676,CHEMBL624665,,BAO_0000218,
8433,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property (Vss) in rat,A,1,,5948,CHEMBL624666,,BAO_0000218,
8434,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,1,,5979,CHEMBL624667,,BAO_0000218,
8435,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL624668,,BAO_0000218,
8436,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL624669,,BAO_0000218,
8437,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL624670,,BAO_0000218,
8438,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL624671,,BAO_0000218,
8439,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume distribution in rat,A,1,,6448,CHEMBL624672,,BAO_0000218,
8440,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,1,,12873,CHEMBL624673,,BAO_0000218,1969.0
8441,50597,,In vivo,1,,N,,,,Intermediate,Steady state volume of distribution determined in rat,A,1,,4576,CHEMBL624674,,BAO_0000218,
8442,50597,,In vivo,1,,N,,,,Intermediate,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,1,,17582,CHEMBL624675,,BAO_0000218,
8443,50597,,In vivo,1,,N,,,,Intermediate,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,1,,1466,CHEMBL621728,,BAO_0000218,
8444,50597,,,1,,N,,,,Intermediate,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,1,,5182,CHEMBL621729,,BAO_0000218,
8445,50597,,,1,,N,,,,Intermediate,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,1,,5182,CHEMBL621730,,BAO_0000218,
8446,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL621731,,BAO_0000218,
8447,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL621732,,BAO_0000218,
8448,50597,,In vivo,1,,N,,,,Intermediate,Volume in steady state distribution value was determined,A,1,,5041,CHEMBL621908,,BAO_0000218,
8449,50597,,In vivo,1,,N,,,,Intermediate,Volume in steady state distribution value was determined; ND denotes no data,A,1,,5041,CHEMBL875347,,BAO_0000218,
8450,50597,,In vivo,1,,N,,,,Intermediate,Volume in steady state distribution value was determined; ND denotes not determined,A,1,,5041,CHEMBL621909,,BAO_0000218,
8451,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,1,,17065,CHEMBL621910,,BAO_0000218,
8452,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution at steady state was evaluated in rats,A,1,,6597,CHEMBL621911,,BAO_0000218,
8453,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution at steady state was observed after intravenous administration in rat,A,1,,15662,CHEMBL621912,,BAO_0000218,
8454,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in rat,A,1,,6485,CHEMBL621913,,BAO_0000218,
8455,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in steady state was determined in rat,A,1,,17655,CHEMBL621914,,BAO_0000218,
8456,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution after i.v. administration,A,1,,6616,CHEMBL621915,,BAO_0000218,
8457,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,1,,1916,CHEMBL621916,,BAO_0000218,
8458,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL621917,,BAO_0000218,2107.0
8459,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL621918,,BAO_0000218,2107.0
8460,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of compound (oxidized form) in spleen tissue,A,1,,16438,CHEMBL621919,,BAO_0000218,2106.0
8461,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL621920,,BAO_0000218,2106.0
8462,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL621921,,BAO_0000218,2106.0
8463,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622401,,BAO_0000218,2106.0
8464,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,1,,16438,CHEMBL875348,,BAO_0000218,2106.0
8465,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,1,,16438,CHEMBL622402,,BAO_0000218,2106.0
8466,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,1,,16438,CHEMBL622403,,BAO_0000218,178.0
8467,50594,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622404,,BAO_0000218,178.0
8468,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,1,,16438,CHEMBL622405,,BAO_0000218,955.0
8469,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622406,,BAO_0000218,955.0
8470,50594,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622407,,BAO_0000218,955.0
8471,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,1,,16438,CHEMBL622408,,BAO_0000218,948.0
8472,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622409,,BAO_0000218,948.0
8473,50594,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL622410,,BAO_0000218,948.0
8474,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,1,,16438,CHEMBL622411,,BAO_0000218,2113.0
8475,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,1,,16438,CHEMBL627864,,BAO_0000218,2113.0
8476,50594,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL627865,,BAO_0000218,2113.0
8477,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,1,,16438,CHEMBL627866,,BAO_0000218,2107.0
8478,50594,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL627751,,BAO_0000218,2107.0
8479,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,1,,16438,CHEMBL627752,,BAO_0000218,2106.0
8480,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,1,,16438,CHEMBL627753,,BAO_0000218,2106.0
8481,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,1,,16438,CHEMBL627754,,BAO_0000218,2106.0
8482,50594,,,1,,N,,,,Intermediate,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,1,,12467,CHEMBL627755,,BAO_0000218,
8483,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627756,,BAO_0000218,955.0
8484,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627757,,BAO_0000218,955.0
8485,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627758,,BAO_0000218,955.0
8486,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627759,,BAO_0000218,955.0
8487,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627760,,BAO_0000218,955.0
8488,50594,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627761,,BAO_0000218,955.0
8489,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL876811,,BAO_0000218,948.0
8490,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627762,,BAO_0000218,948.0
8491,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627763,,BAO_0000218,948.0
8492,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627764,,BAO_0000218,948.0
8493,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627765,,BAO_0000218,948.0
8494,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627766,,BAO_0000218,948.0
8495,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627767,,BAO_0000218,2113.0
8496,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627768,,BAO_0000218,2113.0
8497,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL628422,,BAO_0000218,2113.0
8498,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL628423,,BAO_0000218,2113.0
8499,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,1,,5089,CHEMBL628424,,BAO_0000218,
8500,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,1,,5089,CHEMBL628425,,BAO_0000218,
8501,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,1,,4257,CHEMBL628426,,BAO_0000218,
8502,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL628427,,BAO_0000218,
8503,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL626938,,BAO_0000218,
8504,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,1,,6141,CHEMBL626939,,BAO_0000218,
8505,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL626940,,BAO_0000218,
8506,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL626941,,BAO_0000218,
8507,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was reported in Sprague-Dawley rat,A,1,,5334,CHEMBL626942,,BAO_0000218,
8508,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,1,,4689,CHEMBL876812,,BAO_0000218,
8509,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance of compound in rats was evaluated,A,1,,6848,CHEMBL626943,,BAO_0000218,
8510,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,1,,6848,CHEMBL626944,,BAO_0000218,
8511,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,1,,6467,CHEMBL626945,,BAO_0000218,
8512,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,1,,6467,CHEMBL626946,,BAO_0000218,
8513,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate in Sprague-Dawley rats,A,1,,4956,CHEMBL626856,,BAO_0000218,
8514,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,1,,5529,CHEMBL626857,,BAO_0000218,
8515,50597,,In vivo,1,,N,,Plasma,,Intermediate,The compound was evaluated for plasma clearance in rat,A,1,,406,CHEMBL626858,,BAO_0000218,1969.0
8516,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance in rat,A,1,,17655,CHEMBL627018,,BAO_0000218,1969.0
8517,50597,,In vivo,1,,N,,Blood,,Intermediate,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,1,,3293,CHEMBL625331,,BAO_0000218,178.0
8518,50597,,In vivo,1,,N,,Blood,,Intermediate,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,1,,4075,CHEMBL625332,,BAO_0000218,178.0
8519,50597,,In vivo,1,,N,,,,Intermediate,C max was determined at 10 mg/kg po dose in rats,A,1,,2792,CHEMBL877590,,BAO_0000218,
8520,50597,,In vivo,1,,N,,,,Intermediate,C max was determined at 3 mg/kg po dose in rats,A,1,,2792,CHEMBL625333,,BAO_0000218,
8521,50597,,In vivo,1,,N,,,,Intermediate,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,1,,17594,CHEMBL625334,,BAO_0000218,
8522,50597,,In vivo,1,,N,,,,Intermediate,Cmax after single intravenous bolus of 1 mg/kg in rats,A,1,,17594,CHEMBL625335,,BAO_0000218,
8523,50597,,In vivo,1,,N,,,,Intermediate,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,1,,4762,CHEMBL625336,,BAO_0000218,
8524,50597,,In vivo,1,,N,,,,Intermediate,Cmax 24 hr after 10 mg/kg oral administration in rats,A,1,,17509,CHEMBL625337,,BAO_0000218,
8525,50597,,In vivo,1,,N,,,,Intermediate,Cmax 24 hr after 2 mg/kg oral administration in rats,A,1,,17509,CHEMBL625338,,BAO_0000218,
8526,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,1,,1466,CHEMBL625339,,BAO_0000218,1969.0
8527,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL625340,,BAO_0000218,
8528,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat after administration of 2 mg/kg iv,A,1,,6535,CHEMBL625341,,BAO_0000218,
8529,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,1,,3169,CHEMBL622687,,BAO_0000218,
8530,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,1,,6515,CHEMBL622688,,BAO_0000218,1969.0
8531,50597,,In vivo,1,,N,,Blood,,Intermediate,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,1,,11149,CHEMBL622689,,BAO_0000218,178.0
8532,50597,,In vivo,1,,N,,Blood,,Intermediate,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,1,,11149,CHEMBL620295,,BAO_0000218,178.0
8533,50597,,In vivo,1,,N,,,,Intermediate,Cmax after 10 mg/kg oral administration in rat,A,1,,17858,CHEMBL620296,,BAO_0000218,
8534,50597,,In vivo,1,,N,,,,Intermediate,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,1,,6518,CHEMBL620297,,BAO_0000218,
8535,50597,,In vivo,1,,N,,,,Intermediate,Cmax after IV dosing at 1 mg/kg in rat; no data,A,1,,6518,CHEMBL620298,,BAO_0000218,
8536,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at 20 mpk in rats,A,1,,4426,CHEMBL620299,,BAO_0000218,
8537,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at 20 mpk in rats; Not performed.,A,1,,4426,CHEMBL620300,,BAO_0000218,
8538,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,1,,4426,CHEMBL620301,,BAO_0000218,
8539,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration in rat,A,1,,5656,CHEMBL620302,,BAO_0000218,
8540,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at a dose of 2 mg/kg in rat,A,1,,6518,CHEMBL620303,,BAO_0000218,
8541,50597,,In vivo,1,,N,,,,Intermediate,Cmax after oral administration at a dose of 4 mg/kg in rat,A,1,,6518,CHEMBL620304,,BAO_0000218,
8542,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats after 20 mg/kg oral dose,A,1,,6113,CHEMBL620305,,BAO_0000218,
8543,50597,,In vivo,1,,N,,,,Intermediate,Cmax after peroral administration in rats at 2.4 uM/kg,A,1,,17764,CHEMBL620306,,BAO_0000218,
8544,50597,,In vivo,1,,N,,,,Intermediate,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL620307,,BAO_0000218,
8545,50597,,In vivo,1,,N,,,,Intermediate,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL620308,,BAO_0000218,
8546,50597,,In vivo,1,,N,,,,Intermediate,Cmax by administering at 20 mg/kg p.o. in rats,A,1,,6402,CHEMBL620309,,BAO_0000218,
8547,50597,,In vivo,1,,N,,,,Intermediate,Cmax in male rat,A,1,,5610,CHEMBL620310,,BAO_0000218,
8548,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat,A,1,,5207,CHEMBL620311,,BAO_0000218,
8549,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat,A,1,,6011,CHEMBL620312,,BAO_0000218,
8550,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat,A,1,,6504,CHEMBL620313,,BAO_0000218,
8551,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat at 10 mg/kg,A,1,,6046,CHEMBL620314,,BAO_0000218,
8552,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat at the dose of 1 mg/kg i.v.,A,1,,6504,CHEMBL620315,,BAO_0000218,
8553,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat by po administration at a dose of 40 mg/kg,A,1,,5874,CHEMBL620316,,BAO_0000218,
8554,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat p.o. at 20 mg/kg concentration,A,1,,17686,CHEMBL620317,,BAO_0000218,
8555,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats,A,1,,5836,CHEMBL620318,,BAO_0000218,
8556,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats,A,1,,17596,CHEMBL620319,,BAO_0000218,
8557,50597,,In vivo,1,,N,,,,Intermediate,Cmax was evaluated after 20 uM/kg of peroral administration,A,1,,16423,CHEMBL620320,,BAO_0000218,
8558,50597,,In vivo,1,,N,,,,Intermediate,Cmax was measured in rats after peroral administration at 3 mg/kg,A,1,,17804,CHEMBL620321,,BAO_0000218,
8559,50597,,In vivo,1,,N,,,,Intermediate,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,1,,1908,CHEMBL620322,,BAO_0000218,
8560,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620323,,BAO_0000218,
8561,50597,,,1,,N,,Frontal cortex,,Intermediate,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620324,,BAO_0000218,1870.0
8562,50597,,,1,,N,,Frontal cortex,,Intermediate,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620325,,BAO_0000218,1870.0
8563,50597,,,1,,N,,Hippocampus,,Intermediate,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620326,,BAO_0000218,10000000.0
8564,50597,,,1,,N,,Hippocampus,,Intermediate,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620327,,BAO_0000218,10000000.0
8565,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620328,,BAO_0000218,
8566,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620329,,BAO_0000218,
8567,50597,,,1,,N,,Midbrain,,Intermediate,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620330,,BAO_0000218,1891.0
8568,50597,,,1,,N,,Midbrain,,Intermediate,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL875286,,BAO_0000218,1891.0
8569,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620331,,BAO_0000218,
8570,50597,,,1,,N,,,,Intermediate,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620332,,BAO_0000218,
8571,50597,,,1,,N,,Striatum,,Intermediate,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620333,,BAO_0000218,2435.0
8572,50597,,,1,,N,,Striatum,,Intermediate,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,1,,13950,CHEMBL620334,,BAO_0000218,2435.0
8573,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL621015,,BAO_0000218,178.0
8574,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL621016,,BAO_0000218,178.0
8575,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL621191,,BAO_0000218,178.0
8576,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL621192,,BAO_0000218,178.0
8577,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL621193,,BAO_0000218,178.0
8578,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL621194,,BAO_0000218,178.0
8579,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL624204,,BAO_0000218,178.0
8580,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL624205,,BAO_0000218,178.0
8581,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL624206,,BAO_0000218,178.0
8582,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL624207,,BAO_0000218,178.0
8583,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL624208,,BAO_0000218,178.0
8584,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL624209,,BAO_0000218,178.0
8585,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL624210,,BAO_0000218,178.0
8586,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL624211,,BAO_0000218,178.0
8587,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL624212,,BAO_0000218,178.0
8588,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL624213,,BAO_0000218,178.0
8589,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL876611,,BAO_0000218,178.0
8590,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL624214,,BAO_0000218,178.0
8591,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL624215,,BAO_0000218,178.0
8592,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL624216,,BAO_0000218,178.0
8593,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL624217,,BAO_0000218,178.0
8594,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL624218,,BAO_0000218,178.0
8595,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL624219,,BAO_0000218,178.0
8596,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL624220,,BAO_0000218,178.0
8597,50597,,,1,,N,,Blood,,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL624221,,BAO_0000218,178.0
8598,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL624222,,BAO_0000218,
8599,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL624223,,BAO_0000218,
8600,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL624224,,BAO_0000218,
8601,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL624225,,BAO_0000218,
8602,50597,,In vivo,1,,N,,,,Intermediate,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL622420,,BAO_0000218,
8603,50597,,In vivo,1,,N,,,,Intermediate,Volume of steady state distribution after i.v. administration in rats,A,1,,5031,CHEMBL622421,,BAO_0000218,
8604,50597,,In vivo,1,,N,,,,Intermediate,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,1,,6215,CHEMBL622422,,BAO_0000218,
8605,50597,,In vivo,1,,N,,,,Intermediate,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,1,,17671,CHEMBL622423,,BAO_0000218,
8606,50597,,In vivo,1,,N,,,,Intermediate,Vss was determined,A,1,,17752,CHEMBL622424,,BAO_0000218,
8607,50597,,In vivo,1,,N,,,,Intermediate,Vss in rat,A,1,,6596,CHEMBL622425,,BAO_0000218,
8608,50597,,In vivo,1,,N,,,,Intermediate,Vss was evaluated after 10 uM/kg of intra arterial administration,A,1,,16423,CHEMBL876612,,BAO_0000218,
8609,50597,,In vivo,1,,N,,,,Intermediate,volume of distribution at steady state was observed after intravenous administration in rat,A,1,,15662,CHEMBL622426,,BAO_0000218,
8610,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL622427,,BAO_0000218,
8611,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic (PK) parameter Vz in rat,A,1,,5874,CHEMBL622428,,BAO_0000218,
8612,50597,,In vivo,1,,N,,,,Intermediate,Volume distribution in rats,A,1,,4942,CHEMBL622429,,BAO_0000218,
8613,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in rat; No data,A,1,,17796,CHEMBL622430,,BAO_0000218,
8614,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL622431,,BAO_0000218,
8615,50597,,,1,,N,,Ileum,,Intermediate,% absorption predicted from in vitro rat ileum transport studies,A,1,,15765,CHEMBL622432,,BAO_0000218,2116.0
8616,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,1,,13569,CHEMBL622433,,BAO_0000218,
8617,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,1,,13569,CHEMBL622434,,BAO_0000218,
8618,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,1,,13569,CHEMBL622435,,BAO_0000218,
8619,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,1,,13569,CHEMBL618748,,BAO_0000218,
8620,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,1,,13569,CHEMBL618749,,BAO_0000218,
8621,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,1,,13569,CHEMBL618750,,BAO_0000218,
8622,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,1,,13569,CHEMBL618751,,BAO_0000218,
8623,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,1,,13569,CHEMBL618752,,BAO_0000218,
8624,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4576,CHEMBL618753,,BAO_0000218,
8625,50597,,In vivo,1,,N,,Plasma,,Intermediate,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,1,,750,CHEMBL618754,,BAO_0000218,1969.0
8626,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,750,CHEMBL618755,,BAO_0000218,
8627,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4590,CHEMBL618756,,BAO_0000218,
8628,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,1716,CHEMBL618757,,BAO_0000218,
8629,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,1974,CHEMBL618758,,BAO_0000218,
8630,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 30 mg/kg),A,1,,4502,CHEMBL621088,,BAO_0000218,
8631,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property (cLogP) in rat,A,1,,3371,CHEMBL621089,,BAO_0000218,
8632,50597,,,1,,N,,Blood,,Intermediate,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,1,,9099,CHEMBL621090,,BAO_0000218,178.0
8633,50597,,,1,,N,,Blood,,Intermediate,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,1,,9099,CHEMBL621091,,BAO_0000218,178.0
8634,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat.,A,1,,4590,CHEMBL876731,,BAO_0000218,
8635,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its clearance when administered intravenously in rat,A,1,,3184,CHEMBL621092,,BAO_0000218,
8636,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL621093,,BAO_0000218,
8637,50597,,,1,,N,,,,Intermediate,Blood: Brain distribution ratio is determined in rat,A,1,,4199,CHEMBL621094,,BAO_0000218,
8638,50597,,,1,,N,,,,Intermediate,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,1,,4199,CHEMBL621095,,BAO_0000218,
8639,50597,,,1,,N,,,,Intermediate,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,1,,4199,CHEMBL621096,,BAO_0000218,
8640,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL621097,,BAO_0000218,2113.0
8641,50597,,,1,,N,,,,Intermediate,Percent dose excreted in 0-48 hours administered ip to male rat,F,1,,7449,CHEMBL621098,,BAO_0000218,
8642,50597,,,1,,N,,Cerebellum,,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621099,,BAO_0000218,2037.0
8643,50597,,,1,,N,,Cerebellum,,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621100,,BAO_0000218,2037.0
8644,50597,,,1,,N,,Cerebellum,,Intermediate,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL621101,,BAO_0000218,2037.0
8645,50597,,,1,,N,,Cerebellum,,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621102,,BAO_0000218,2037.0
8646,50597,,,1,,N,,Cerebellum,,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL876732,,BAO_0000218,2037.0
8647,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621103,,BAO_0000218,
8648,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621104,,BAO_0000218,
8649,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL621105,,BAO_0000218,
8650,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621106,,BAO_0000218,
8651,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621107,,BAO_0000218,
8652,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621108,,BAO_0000218,
8653,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621109,,BAO_0000218,
8654,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL621110,,BAO_0000218,2113.0
8655,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL621111,,BAO_0000218,2113.0
8656,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL622541,,BAO_0000218,2107.0
8657,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL622542,,BAO_0000218,2107.0
8658,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL622543,,BAO_0000218,2107.0
8659,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624412,,BAO_0000218,2107.0
8660,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624413,,BAO_0000218,2107.0
8661,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624414,,BAO_0000218,2107.0
8662,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624415,,BAO_0000218,2048.0
8663,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624416,,BAO_0000218,2048.0
8664,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624417,,BAO_0000218,2048.0
8665,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624418,,BAO_0000218,2048.0
8666,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624419,,BAO_0000218,2048.0
8667,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624420,,BAO_0000218,2048.0
8668,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624421,,BAO_0000218,2385.0
8669,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624422,,BAO_0000218,2385.0
8670,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL624423,,BAO_0000218,2385.0
8671,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL625123,,BAO_0000218,2385.0
8672,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL625124,,BAO_0000218,2385.0
8673,50594,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL625125,,BAO_0000218,2385.0
8674,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL625126,,BAO_0000218,14.0
8675,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626947,,BAO_0000218,14.0
8676,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626948,,BAO_0000218,14.0
8677,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626949,,BAO_0000218,14.0
8678,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626950,,BAO_0000218,14.0
8679,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626951,,BAO_0000218,14.0
8680,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626952,,BAO_0000218,2106.0
8681,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626953,,BAO_0000218,2106.0
8682,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626954,,BAO_0000218,2106.0
8683,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626955,,BAO_0000218,2106.0
8684,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626956,,BAO_0000218,2106.0
8685,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626957,,BAO_0000218,2106.0
8686,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626958,,BAO_0000218,178.0
8687,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626959,,BAO_0000218,178.0
8688,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626960,,BAO_0000218,178.0
8689,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL626961,,BAO_0000218,178.0
8690,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627589,,BAO_0000218,178.0
8691,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,1,,17208,CHEMBL627590,,BAO_0000218,178.0
8692,50594,,,1,,N,,,,Intermediate,Time taken for EC90 was determined when tested in mouse,A,1,,3132,CHEMBL627591,,BAO_0000218,
8693,50594,,,1,,N,,,,Intermediate,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,1,,3132,CHEMBL627592,,BAO_0000218,
8694,50594,,In vivo,1,,N,,,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,1,,16597,CHEMBL627593,,BAO_0000218,
8695,50594,,,1,,N,,,,Intermediate,Half life in mice,A,1,,5727,CHEMBL627594,,BAO_0000218,
8696,50594,,In vivo,1,,N,,,,Intermediate,Half life period in mouse after 10 mg/Kg dose,A,1,,5302,CHEMBL876813,,BAO_0000218,
8697,50594,,In vivo,1,,N,,,,Intermediate,Half life period in mouse after 10 mg/kg dose,A,1,,5302,CHEMBL627595,,BAO_0000218,
8698,50594,,In vivo,1,,N,,,,Intermediate,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,1,,6348,CHEMBL627596,,BAO_0000218,
8699,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at 5 mg/kg po was determined in rat,A,1,,5964,CHEMBL627597,,BAO_0000218,
8700,50597,,In vivo,1,,N,,,,Intermediate,Cmax value evaluated in rat,A,1,,6078,CHEMBL627598,,BAO_0000218,
8701,50597,,In vivo,1,,N,,Brain,,Intermediate,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,1,,5206,CHEMBL627599,,BAO_0000218,955.0
8702,50597,,In vivo,1,,N,,,,Intermediate,Cmax value after administration of 20 mg/Kg oral dose in rat,A,1,,2959,CHEMBL627600,,BAO_0000218,
8703,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at 1 mg/kg po in rat,A,1,,5964,CHEMBL627601,,BAO_0000218,
8704,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at 5 mg/kg po in rat,A,1,,5964,CHEMBL627776,,BAO_0000218,
8705,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at a dose of 10 mg/kg in male SD rats,A,1,,6757,CHEMBL627777,,BAO_0000218,
8706,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at a dose of 100 mg/kg in male SD rats,A,1,,6757,CHEMBL627778,,BAO_0000218,
8707,50597,,In vivo,1,,N,,,,Intermediate,Cmax value at a dose of 50 mg/kg in male SD rats,A,1,,6757,CHEMBL627779,,BAO_0000218,
8708,50597,,In vivo,1,,N,,,,Intermediate,Cmax value in rats at 10 mg/kg,A,1,,17617,CHEMBL876814,,BAO_0000218,
8709,50597,,In vivo,1,,N,,,,Intermediate,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,1,,1445,CHEMBL627780,,BAO_0000218,
8710,50597,,In vivo,1,,N,,,,Intermediate,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,1,,6082,CHEMBL627781,,BAO_0000218,
8711,50597,,In vivo,1,,N,,,,Intermediate,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,1,,1446,CHEMBL627782,,BAO_0000218,
8712,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,1,,5407,CHEMBL627783,,BAO_0000218,1969.0
8713,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,1,,2690,CHEMBL627784,,BAO_0000218,1969.0
8714,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,1,,2661,CHEMBL627785,,BAO_0000218,
8715,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,1,,2661,CHEMBL627786,,BAO_0000218,
8716,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,1,,4891,CHEMBL627787,,BAO_0000218,1969.0
8717,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,1,,2807,CHEMBL627788,,BAO_0000218,1969.0
8718,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,1,,2807,CHEMBL626579,,BAO_0000218,1969.0
8719,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,1,,2807,CHEMBL626580,,BAO_0000218,1969.0
8720,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,1,,3634,CHEMBL876815,,BAO_0000218,
8721,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,1,,1881,CHEMBL626581,,BAO_0000218,1969.0
8722,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,1,,1881,CHEMBL626582,,BAO_0000218,1969.0
8723,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,1,,429,CHEMBL626583,,BAO_0000218,
8724,50597,,In vivo,1,,N,,,,Intermediate,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL626205,,BAO_0000218,
8725,50597,,In vivo,1,,N,,,,Intermediate,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL626206,,BAO_0000218,
8726,50597,,In vivo,1,,N,,,,Intermediate,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL626207,,BAO_0000218,
8727,50597,,In vivo,1,,N,,,,Intermediate,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL623882,,BAO_0000218,
8728,50597,,In vivo,1,,N,,,,Intermediate,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,1,,17582,CHEMBL623883,,BAO_0000218,
8729,50597,,In vivo,1,,N,,,,Intermediate,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,1,,17582,CHEMBL623884,,BAO_0000218,
8730,50597,,In vivo,1,,N,,Plasma,,Intermediate,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,1,,3032,CHEMBL623885,,BAO_0000218,1969.0
8731,50597,,In vivo,1,,N,,Plasma,,Intermediate,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,1,,6295,CHEMBL623886,,BAO_0000218,1969.0
8732,50597,,In vivo,1,,N,,,,Intermediate,Maximal concentration in rat was determined,A,1,,6619,CHEMBL623887,,BAO_0000218,
8733,50597,,In vivo,1,,N,,,,Intermediate,Maximal concentration after i.v. administration,A,1,,6616,CHEMBL623888,,BAO_0000218,
8734,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,1,,3249,CHEMBL623889,,BAO_0000218,1969.0
8735,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,1,,17791,CHEMBL623890,,BAO_0000218,1969.0
8736,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in rat plasma after oral dose (50 mg/Kg),A,1,,17791,CHEMBL623891,,BAO_0000218,1969.0
8737,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration was determined.,A,1,,1360,CHEMBL623892,,BAO_0000218,1969.0
8738,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma drug concentration was determined,A,1,,2552,CHEMBL623893,,BAO_0000218,1969.0
8739,50597,,In vivo,1,,N,,,,Intermediate,Maximal concentration in rats after peroral administration,A,1,,6571,CHEMBL877616,,BAO_0000218,
8740,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in rat after 2 mg/kg peroral administration,A,1,,6570,CHEMBL623894,,BAO_0000218,
8741,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,1,,6567,CHEMBL623895,,BAO_0000218,1969.0
8742,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration of compound in rat was evaluated.,A,1,,3031,CHEMBL623896,,BAO_0000218,
8743,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,1,,3436,CHEMBL623897,,BAO_0000218,
8744,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,1,,3436,CHEMBL623898,,BAO_0000218,
8745,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,1,,2083,CHEMBL623899,,BAO_0000218,
8746,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,1,,3436,CHEMBL623900,,BAO_0000218,
8747,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,1,,4527,CHEMBL623901,,BAO_0000218,
8748,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was evaluated in rats,A,1,,1974,CHEMBL623902,,BAO_0000218,
8749,50597,,In vivo,1,,N,,Cerebrospinal fluid,,Intermediate,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,1,,3307,CHEMBL623903,,BAO_0000218,1359.0
8750,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,1,,3307,CHEMBL623904,,BAO_0000218,1969.0
8751,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,1,,1916,CHEMBL877617,,BAO_0000218,1969.0
8752,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,1,,1500,CHEMBL623905,,BAO_0000218,
8753,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,1,,1500,CHEMBL623906,,BAO_0000218,
8754,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL623907,,BAO_0000218,1969.0
8755,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL623908,,BAO_0000218,
8756,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL623909,,BAO_0000218,
8757,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL623910,,BAO_0000218,
8758,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL623911,,BAO_0000218,
8759,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL623912,,BAO_0000218,
8760,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL624616,,BAO_0000218,
8761,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL624617,,BAO_0000218,
8762,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL624618,,BAO_0000218,
8763,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL624619,,BAO_0000218,
8764,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL624794,,BAO_0000218,
8765,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL624795,,BAO_0000218,
8766,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL623921,,BAO_0000218,
8767,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL623922,,BAO_0000218,
8768,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL623923,,BAO_0000218,
8769,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL623924,,BAO_0000218,
8770,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL623925,,BAO_0000218,
8771,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL623926,,BAO_0000218,
8772,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL623927,,BAO_0000218,
8773,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL623928,,BAO_0000218,
8774,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL623929,,BAO_0000218,
8775,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL623930,,BAO_0000218,
8776,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL623931,,BAO_0000218,955.0
8777,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL622165,,BAO_0000218,955.0
8778,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL621249,,BAO_0000218,955.0
8779,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL621250,,BAO_0000218,955.0
8780,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL621448,,BAO_0000218,955.0
8781,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL621449,,BAO_0000218,955.0
8782,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL621450,,BAO_0000218,955.0
8783,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL621451,,BAO_0000218,955.0
8784,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL621452,,BAO_0000218,955.0
8785,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL621453,,BAO_0000218,955.0
8786,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL621454,,BAO_0000218,955.0
8787,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL621455,,BAO_0000218,955.0
8788,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL621456,,BAO_0000218,955.0
8789,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL625145,,BAO_0000218,955.0
8790,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL875847,,BAO_0000218,955.0
8791,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL625146,,BAO_0000218,955.0
8792,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL625147,,BAO_0000218,955.0
8793,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL625148,,BAO_0000218,955.0
8794,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL625149,,BAO_0000218,955.0
8795,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL625150,,BAO_0000218,955.0
8796,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL625151,,BAO_0000218,955.0
8797,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL625152,,BAO_0000218,955.0
8798,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL625153,,BAO_0000218,955.0
8799,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL625154,,BAO_0000218,955.0
8800,50597,,,1,,N,,Brain,,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL625155,,BAO_0000218,955.0
8801,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL625156,,BAO_0000218,
8802,50597,,,1,,N,,,,Intermediate,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624354,,BAO_0000218,
8803,50597,,,1,,N,,Hippocampus,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624355,,BAO_0000218,10000000.0
8804,50597,,,1,,N,,Hippocampus,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624356,,BAO_0000218,10000000.0
8805,50597,,,1,,N,,Hippocampus,,Intermediate,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624357,,BAO_0000218,10000000.0
8806,50597,,,1,,N,,Hippocampus,,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624358,,BAO_0000218,10000000.0
8807,50597,,,1,,N,,Striatum,,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624359,,BAO_0000218,2435.0
8808,50597,,,1,,N,,Striatum,,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624360,,BAO_0000218,2435.0
8809,50597,,,1,,N,,Striatum,,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL624361,,BAO_0000218,2435.0
8810,50597,,,1,,N,,Striatum,,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624362,,BAO_0000218,2435.0
8811,50597,,,1,,N,,Striatum,,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624363,,BAO_0000218,2435.0
8812,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624364,,BAO_0000218,178.0
8813,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624365,,BAO_0000218,178.0
8814,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624366,,BAO_0000218,178.0
8815,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624367,,BAO_0000218,178.0
8816,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624368,,BAO_0000218,955.0
8817,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL624369,,BAO_0000218,955.0
8818,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL624370,,BAO_0000218,955.0
8819,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625069,,BAO_0000218,955.0
8820,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625070,,BAO_0000218,955.0
8821,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626051,,BAO_0000218,948.0
8822,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626052,,BAO_0000218,948.0
8823,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL626053,,BAO_0000218,948.0
8824,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626054,,BAO_0000218,948.0
8825,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626055,,BAO_0000218,948.0
8826,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626056,,BAO_0000218,2113.0
8827,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626057,,BAO_0000218,2113.0
8828,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625193,,BAO_0000218,2113.0
8829,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625194,,BAO_0000218,2113.0
8830,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625195,,BAO_0000218,2107.0
8831,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625196,,BAO_0000218,2107.0
8832,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL625197,,BAO_0000218,2107.0
8833,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625198,,BAO_0000218,2107.0
8834,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL627929,,BAO_0000218,2107.0
8835,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL627074,,BAO_0000218,2048.0
8836,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL627075,,BAO_0000218,2048.0
8837,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL627076,,BAO_0000218,2048.0
8838,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL627077,,BAO_0000218,2048.0
8839,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL627078,,BAO_0000218,2048.0
8840,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL627079,,BAO_0000218,2385.0
8841,50594,,In vivo,1,,N,,,,Intermediate,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,1,,4573,CHEMBL873824,,BAO_0000218,
8842,50594,,In vivo,1,,N,,Plasma,,Intermediate,Half life in mouse plasma was determined at dose 25 mg/kg,A,1,,3132,CHEMBL627080,,BAO_0000218,1969.0
8843,50594,,,1,,N,,,,Intermediate,Half life was determined,A,1,,17718,CHEMBL627081,,BAO_0000218,
8844,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,1,,17728,CHEMBL627082,,BAO_0000218,
8845,50594,,In vivo,1,,N,,,,Intermediate,Half-life in male mice after 1 mg/kg intravenous dose,A,1,,5961,CHEMBL627083,,BAO_0000218,
8847,50594,,,1,,N,,Plasma,,Intermediate,Half life in mice plasma,A,1,,17731,CHEMBL627085,,BAO_0000218,1969.0
8848,50594,,,1,,N,,,,Intermediate,Half life in mouse,A,1,,17592,CHEMBL627086,,BAO_0000218,
8849,50594,,In vivo,1,,N,,Plasma,,Intermediate,Half life in mouse plasma at dose 25 mg/kg,A,1,,3132,CHEMBL627087,,BAO_0000218,1969.0
8850,50594,,In vivo,1,,N,,,,Intermediate,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,1,,17729,CHEMBL627088,,BAO_0000218,
8851,50594,,In vivo,1,,N,,,,Intermediate,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,1,,17729,CHEMBL627089,,BAO_0000218,
8852,50594,,In vivo,1,,N,,,,Intermediate,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,1,,17729,CHEMBL627090,,BAO_0000218,
8853,50594,,In vivo,1,,N,,,,Intermediate,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,1,,3277,CHEMBL627091,,BAO_0000218,
8854,50594,,In vivo,1,,N,,,,Intermediate,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,1,,3760,CHEMBL627092,,BAO_0000218,
8855,50594,,In vivo,1,,N,,,,Intermediate,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,1,,3760,CHEMBL876785,,BAO_0000218,
8856,50594,,In vivo,1,,N,,,,Intermediate,Half-life by iv administration in mouse,A,1,,2862,CHEMBL627093,,BAO_0000218,
8857,50594,,In vivo,1,,N,,,,Intermediate,Half-life by oral administration in mouse,A,1,,2862,CHEMBL627094,,BAO_0000218,
8858,50594,,,1,,N,,,,Intermediate,Half-life in mice,A,1,,5980,CHEMBL627095,,BAO_0000218,
8859,50594,,,1,,N,,Brain,,Intermediate,Half-life using mouse brain homogenate,A,1,,6159,CHEMBL627096,,BAO_0000218,955.0
8860,50594,,,1,,N,,,,Intermediate,Half-life was measured in mice,A,1,,6254,CHEMBL627097,,BAO_0000218,
8861,50594,,In vivo,1,,N,,,,Intermediate,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL627098,,BAO_0000218,
8862,50594,,,1,,N,,Blood,,Intermediate,Half-life period was determined in mouse blood,A,1,,1574,CHEMBL627099,,BAO_0000218,178.0
8863,50594,,,1,,N,,Brain,,Intermediate,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,1,,56,CHEMBL627100,,BAO_0000218,955.0
8864,50594,,,1,,N,,Plasma,,Intermediate,Plasma half life in mouse,A,1,,993,CHEMBL627101,,BAO_0000218,1969.0
8865,50594,,,1,,N,,,,Intermediate,Stability of the peptide in the presence of mouse serum,A,1,,6652,CHEMBL627102,,BAO_0000218,
8866,50594,,,1,,N,,,,Intermediate,Terminal half life of compound was determined in mouse,A,1,,17852,CHEMBL627103,,BAO_0000218,
8867,50594,,In vivo,1,,N,,,,Intermediate,Terminal half life was evaluated in mice after intravenous administration,A,1,,2675,CHEMBL627104,,BAO_0000218,
8868,50594,,In vivo,1,,N,,,,Intermediate,Terminal half life was evaluated in mice after oral administration,A,1,,2675,CHEMBL627105,,BAO_0000218,
8869,50594,,,1,,N,,,,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,1,,499,CHEMBL876786,,BAO_0000218,
8870,50594,,,1,,N,,,,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,1,,499,CHEMBL873825,,BAO_0000218,
8871,50594,,,1,,N,,,,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,1,,499,CHEMBL627106,,BAO_0000218,
8872,50594,,In vivo,1,,N,,,,Intermediate,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,1,,14239,CHEMBL626336,,BAO_0000218,
8873,50594,,In vivo,1,,N,,,,Intermediate,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,1,,5506,CHEMBL877462,,BAO_0000218,
8874,50594,,In vivo,1,,N,,,,Intermediate,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,1,,5506,CHEMBL626337,,BAO_0000218,
8875,50594,,,1,,N,,,,Intermediate,Half life after intraperitoneal administration of 100 mg/kg in mice,A,1,,17734,CHEMBL626338,,BAO_0000218,
8876,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,1,,17728,CHEMBL626339,,BAO_0000218,
8877,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,1,,17728,CHEMBL626340,,BAO_0000218,
8878,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,1,,17728,CHEMBL625377,,BAO_0000218,
8879,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,1,,17728,CHEMBL625378,,BAO_0000218,
8880,50594,,In vivo,1,,N,,,,Intermediate,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,1,,17728,CHEMBL625379,,BAO_0000218,
8881,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL625380,,BAO_0000251,
8882,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL625381,,BAO_0000251,
8883,22224,,,0,,U,,,,Autocuration,Stability to porcine renal DHP-I,A,1,,6056,CHEMBL625382,,BAO_0000019,
8884,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,1,,1317,CHEMBL873828,,BAO_0000218,
8885,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,1,,1317,CHEMBL625383,,BAO_0000218,
8886,22224,,,0,,U,,,,Autocuration,Half-life of the parent prodrug in porcine esterase solution,A,1,,5229,CHEMBL625384,,BAO_0000019,
8887,22224,,,0,,U,,,,Autocuration,"First order rate constant, k was determined in in pig liver Esterase",A,1,,4231,CHEMBL625385,,BAO_0000019,
8888,22224,,,0,,U,,Liver,,Autocuration,Half life of the in pig liver Esterase,A,1,,4231,CHEMBL625386,,BAO_0000221,2107.0
8889,22224,,,0,,U,,Liver,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,1,,5318,CHEMBL623571,,BAO_0000221,2107.0
8890,22224,,,0,,U,,Liver,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,1,,5318,CHEMBL623572,,BAO_0000221,2107.0
8891,22224,,,0,,U,,Liver,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,1,,5318,CHEMBL623573,,BAO_0000221,2107.0
8892,22224,,,0,,U,,Liver,,Autocuration,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,1,,3305,CHEMBL623574,,BAO_0000221,2107.0
8893,22224,,,0,,U,,Liver,,Autocuration,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,1,,3305,CHEMBL623575,,BAO_0000221,2107.0
8894,22224,,,0,,U,,Liver,,Autocuration,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,1,,2842,CHEMBL623749,,BAO_0000221,2107.0
8895,22224,,,0,,U,,Liver,,Autocuration,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,1,,2842,CHEMBL623750,,BAO_0000221,2107.0
8896,22224,,In vitro,0,,U,,Liver,,Autocuration,Half-life in vitro in pig liver,A,1,,889,CHEMBL623751,,BAO_0000221,2107.0
8897,22224,,,0,,U,,Liver,,Autocuration,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,1,,1904,CHEMBL623752,,BAO_0000221,2107.0
8898,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL623753,,BAO_0000218,1969.0
8899,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,1,,2774,CHEMBL623754,,BAO_0000218,1969.0
8900,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in rat plasma was determined,A,1,,1742,CHEMBL623755,,BAO_0000218,1969.0
8901,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in rats,A,1,,3169,CHEMBL623756,,BAO_0000218,
8902,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in rats at 1-2 hours,A,1,,3169,CHEMBL623757,,BAO_0000218,
8903,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,1,,2081,CHEMBL623758,,BAO_0000218,
8904,50597,,In vivo,1,,N,,Brain,,Intermediate,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,1,,3307,CHEMBL623759,,BAO_0000218,955.0
8905,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at the dose of 2 mg/kg in rat,A,1,,4727,CHEMBL623760,,BAO_0000218,
8906,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was evaluated in rats,A,1,,6597,CHEMBL623761,,BAO_0000218,
8907,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,1,,16365,CHEMBL623762,,BAO_0000218,1969.0
8908,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,1,,16365,CHEMBL877594,,BAO_0000218,1969.0
8909,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,1,,16365,CHEMBL623763,,BAO_0000218,1969.0
8910,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,1,,16365,CHEMBL623764,,BAO_0000218,1969.0
8911,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,1,,16365,CHEMBL623765,,BAO_0000218,1969.0
8912,50597,,In vivo,1,,N,,Blood,,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,1,,2591,CHEMBL623766,,BAO_0000218,178.0
8913,50597,,In vivo,1,,N,,Blood,,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,1,,2591,CHEMBL623767,,BAO_0000218,178.0
8914,50597,,In vivo,1,,N,,Blood,,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,1,,2591,CHEMBL623768,,BAO_0000218,178.0
8915,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623769,,BAO_0000218,1969.0
8916,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623770,,BAO_0000218,1969.0
8917,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623771,,BAO_0000218,1969.0
8918,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623772,,BAO_0000218,1969.0
8919,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623773,,BAO_0000218,1969.0
8920,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623774,,BAO_0000218,1969.0
8921,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,1,,5978,CHEMBL623775,,BAO_0000218,1969.0
8922,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat (PO dose),A,1,,14465,CHEMBL623776,,BAO_0000218,
8923,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL622191,,BAO_0000218,1969.0
8924,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL622192,,BAO_0000218,1969.0
8925,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration determined in rat,A,1,,4576,CHEMBL622193,,BAO_0000218,1969.0
8926,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,1,,12873,CHEMBL622194,,BAO_0000218,1969.0
8927,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,1,,12873,CHEMBL622195,,BAO_0000218,1969.0
8928,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in rat,A,1,,6824,CHEMBL622196,,BAO_0000218,1969.0
8929,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,1,,17065,CHEMBL622197,,BAO_0000218,1969.0
8930,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,1,,2932,CHEMBL622198,,BAO_0000218,1969.0
8931,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,1,,2932,CHEMBL622199,,BAO_0000218,1969.0
8932,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was measured in rat,A,1,,2879,CHEMBL622200,,BAO_0000218,1969.0
8933,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,1,,2864,CHEMBL622201,,BAO_0000218,1969.0
8934,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration after oral administration to rats,A,1,,16367,CHEMBL623990,,BAO_0000218,1969.0
8935,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL623991,,BAO_0000218,1969.0
8936,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,1,,17717,CHEMBL623992,,BAO_0000218,1969.0
8937,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL623993,,BAO_0000218,1969.0
8938,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,1,,17717,CHEMBL623994,,BAO_0000218,1969.0
8939,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,1,,17720,CHEMBL623995,,BAO_0000218,1969.0
8940,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,1,,17720,CHEMBL623996,,BAO_0000218,1969.0
8941,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,1,,17720,CHEMBL623997,,BAO_0000218,1969.0
8942,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration dosed orally in rats,A,1,,4516,CHEMBL623998,,BAO_0000218,1969.0
8943,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration dosed orally in rats after 6 hours,A,1,,4516,CHEMBL623999,,BAO_0000218,1969.0
8944,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,1,,4516,CHEMBL624000,,BAO_0000218,1969.0
8945,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,1,,5199,CHEMBL624001,,BAO_0000218,1969.0
8946,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in rat after po administration,A,1,,17538,CHEMBL624002,,BAO_0000218,1969.0
8947,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,1,,6685,CHEMBL624003,,BAO_0000218,1969.0
8948,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,1,,6685,CHEMBL624004,,BAO_0000218,1969.0
8949,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL624005,,BAO_0000218,948.0
8950,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL624006,,BAO_0000218,948.0
8951,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL624007,,BAO_0000218,948.0
8952,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL624008,,BAO_0000218,948.0
8953,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL624009,,BAO_0000218,948.0
8954,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL874387,,BAO_0000218,948.0
8955,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL624010,,BAO_0000218,948.0
8956,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL624011,,BAO_0000218,948.0
8957,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL624012,,BAO_0000218,948.0
8958,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL624013,,BAO_0000218,948.0
8959,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL624736,,BAO_0000218,948.0
8960,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL624737,,BAO_0000218,948.0
8961,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL624738,,BAO_0000218,948.0
8962,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL624739,,BAO_0000218,948.0
8963,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL624740,,BAO_0000218,948.0
8964,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL624896,,BAO_0000218,948.0
8965,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL624897,,BAO_0000218,948.0
8966,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL624108,,BAO_0000218,948.0
8967,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL624109,,BAO_0000218,948.0
8968,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL624110,,BAO_0000218,948.0
8969,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL624111,,BAO_0000218,948.0
8970,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL624112,,BAO_0000218,948.0
8971,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL624113,,BAO_0000218,948.0
8972,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL619709,,BAO_0000218,948.0
8973,50597,,,1,,N,,Heart,,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL619710,,BAO_0000218,948.0
8974,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL619711,,BAO_0000218,2113.0
8975,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL619712,,BAO_0000218,2113.0
8976,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL619713,,BAO_0000218,2113.0
8977,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL619714,,BAO_0000218,2113.0
8978,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL619715,,BAO_0000218,2113.0
8979,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL619716,,BAO_0000218,2113.0
8980,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL619717,,BAO_0000218,2113.0
8981,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL619718,,BAO_0000218,2113.0
8982,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL619719,,BAO_0000218,2113.0
8983,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL875329,,BAO_0000218,2113.0
8984,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL619720,,BAO_0000218,2113.0
8985,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL619721,,BAO_0000218,2113.0
8986,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL619722,,BAO_0000218,2113.0
8987,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL619723,,BAO_0000218,2113.0
8988,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL619724,,BAO_0000218,2113.0
8989,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL619725,,BAO_0000218,2113.0
8990,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL619726,,BAO_0000218,2113.0
8991,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL619727,,BAO_0000218,2113.0
8992,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL619728,,BAO_0000218,2113.0
8993,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL619729,,BAO_0000218,2113.0
8994,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL619730,,BAO_0000218,2385.0
8995,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL619731,,BAO_0000218,2385.0
8996,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL619732,,BAO_0000218,2385.0
8997,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL619733,,BAO_0000218,2385.0
8998,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL619734,,BAO_0000218,2385.0
8999,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL619735,,BAO_0000218,14.0
9000,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL875330,,BAO_0000218,14.0
9001,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL628465,,BAO_0000218,14.0
9002,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628466,,BAO_0000218,14.0
9003,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628467,,BAO_0000218,14.0
9004,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628468,,BAO_0000218,2106.0
9005,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628469,,BAO_0000218,2106.0
9006,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL628470,,BAO_0000218,2106.0
9007,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628471,,BAO_0000218,2106.0
9008,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL628472,,BAO_0000218,2106.0
9009,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625191,,BAO_0000218,2046.0
9010,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL625192,,BAO_0000218,2046.0
9011,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,1,,11977,CHEMBL875337,,BAO_0000218,2046.0
9012,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626341,,BAO_0000218,2046.0
9013,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL626342,,BAO_0000218,2046.0
9014,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,1,,11977,CHEMBL621943,,BAO_0000218,2107.0
9015,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,3748,CHEMBL621944,,BAO_0000218,
9016,50597,,,1,,N,,,,Intermediate,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,1,,15765,CHEMBL621945,,BAO_0000218,
9017,50597,,,1,,N,,,,Intermediate,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,1,,4871,CHEMBL621946,,BAO_0000218,
9018,50597,,,1,,N,,,,Intermediate,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,1,,4871,CHEMBL621947,,BAO_0000218,
9019,50597,,,1,,N,,,,Intermediate,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,1,,4872,CHEMBL621948,,BAO_0000218,
9020,50597,,,1,,N,,,,Intermediate,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,1,,4872,CHEMBL621949,,BAO_0000218,
9021,50597,,,1,,N,,,,Intermediate,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,1,,5413,CHEMBL621950,,BAO_0000218,
9022,50597,,,1,,N,,,,Intermediate,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,1,,5413,CHEMBL621951,,BAO_0000218,
9023,50597,,In vivo,1,,N,,Blood,,Intermediate,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,1,,15272,CHEMBL621952,,BAO_0000218,178.0
9024,50597,,,1,,N,,Liver,,Intermediate,Stability (%) in rat liver microsomes,A,1,,4689,CHEMBL621953,,BAO_0000218,2107.0
9025,50597,,,1,,N,,,,Intermediate,Area under curve was calculated after intravenous administration,A,1,,6057,CHEMBL621954,,BAO_0000218,
9026,50597,,,1,,N,,,,Intermediate,Area under the curve was calculated after iv administration in rat,A,1,,6057,CHEMBL621955,,BAO_0000218,
9027,50597,,,1,,N,,,,Intermediate,Area under the curve was calculated in rat after peroral administration,A,1,,6057,CHEMBL621956,,BAO_0000218,
9028,50597,,,1,,N,,,,Intermediate,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,1,,6211,CHEMBL621957,,BAO_0000218,
9029,50597,,,1,,N,,,,Intermediate,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,1,,5710,CHEMBL621958,,BAO_0000218,
9030,50597,,,1,,N,,,,Intermediate,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,1,,5710,CHEMBL621959,,BAO_0000218,
9031,50597,,,1,,N,,,,Intermediate,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL621960,,BAO_0000218,
9032,50597,,,1,,N,,,,Intermediate,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL621961,,BAO_0000218,
9033,50597,,,1,,N,,,,Intermediate,p value of the compound,A,1,,15765,CHEMBL621962,,BAO_0000218,
9034,50597,,,1,,N,,,,Intermediate,p value of the compound,F,1,,15765,CHEMBL876787,,BAO_0000218,
9035,50597,,,1,,N,,,,Intermediate,p value of the compound,A,1,,15765,CHEMBL621963,,BAO_0000218,
9036,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL622637,,BAO_0000218,945.0
9037,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL622638,,BAO_0000218,945.0
9038,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL626561,,BAO_0000218,945.0
9039,22224,,,0,,U,,,,Autocuration,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,1,,7991,CHEMBL626562,,BAO_0000019,
9040,22224,,,0,,U,,,,Autocuration,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,1,,429,CHEMBL626563,,BAO_0000218,
9041,22224,,,0,,U,,,,Autocuration,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,1,,429,CHEMBL626564,,BAO_0000218,
9042,22224,,In vivo,0,,U,,,,Autocuration,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,1,,6253,CHEMBL626565,,BAO_0000218,
9043,22224,,In vivo,0,,U,,,,Autocuration,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,1,,6253,CHEMBL626566,,BAO_0000218,
9044,22224,,In vivo,0,,U,,,,Autocuration,Clearance rate in rabbits,A,1,,3615,CHEMBL626567,,BAO_0000218,
9045,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,1,,4059,CHEMBL626568,,BAO_0000218,
9046,22224,,In vivo,0,,U,,,,Autocuration,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,1,,5124,CHEMBL626569,,BAO_0000218,
9047,22224,,In vivo,0,,U,,,,Autocuration,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,1,,5124,CHEMBL626570,,BAO_0000218,
9048,22224,,In vivo,0,,U,,,,Autocuration,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,1,,5124,CHEMBL626571,,BAO_0000218,
9049,22224,,In vivo,0,,U,,,,Autocuration,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,1,,429,CHEMBL626572,,BAO_0000218,
9050,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,1,,4059,CHEMBL626573,,BAO_0000218,1969.0
9051,22224,,,0,,U,Microsomes,Liver,,Autocuration,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,1,,9659,CHEMBL626574,,BAO_0000251,2107.0
9052,22224,,,0,,U,Microsomes,Liver,,Autocuration,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,1,,9659,CHEMBL626575,,BAO_0000251,2107.0
9053,22224,,,0,,U,,,,Autocuration,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,1,,3639,CHEMBL626576,,BAO_0000218,
9054,22224,,,0,,U,,,,Autocuration,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,1,,3639,CHEMBL626577,,BAO_0000218,
9055,22224,,In vivo,0,,U,,,,Autocuration,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,1,,3639,CHEMBL626578,,BAO_0000218,
9056,22224,,In vivo,0,,U,,,,Autocuration,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,1,,5124,CHEMBL625263,,BAO_0000218,
9057,22224,,In vivo,0,,U,,,,Autocuration,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,1,,5124,CHEMBL625264,,BAO_0000218,
9058,22224,,In vivo,0,,U,,,,Autocuration,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,1,,5124,CHEMBL625265,,BAO_0000218,
9059,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL625266,,BAO_0000251,
9060,22224,,,0,,U,Microsomes,,,Autocuration,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL876796,,BAO_0000251,
9061,22224,,In vivo,0,,U,,,,Autocuration,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,1,,429,CHEMBL625267,,BAO_0000218,
9062,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,1,,5124,CHEMBL625268,,BAO_0000218,1969.0
9063,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,1,,5124,CHEMBL625269,,BAO_0000218,1969.0
9064,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,1,,5124,CHEMBL624689,,BAO_0000218,1969.0
9065,22224,,In vivo,0,,U,,,,Autocuration,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,1,,429,CHEMBL624690,,BAO_0000218,
9066,22224,,,0,,U,,Urine,,Autocuration,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,1,,429,CHEMBL624691,,BAO_0000218,1088.0
9067,22224,,,0,,U,,Urine,,Autocuration,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,1,,429,CHEMBL624692,,BAO_0000218,1088.0
9068,22224,,In vivo,0,,U,,,,Autocuration,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,1,,4059,CHEMBL624693,,BAO_0000218,
9069,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,1,,4137,CHEMBL624694,,BAO_0000218,
9070,22224,,In vitro,0,,U,,,,Autocuration,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,1,,11672,CHEMBL877596,,BAO_0000221,
9071,22224,,,0,,U,,,,Autocuration,Time within which only 10% of the drug was degraded,A,1,,12886,CHEMBL624695,,BAO_0000019,
9072,22224,,,0,,U,,Liver,,Autocuration,Half life period in rabbit liver homogenate,A,1,,3853,CHEMBL624696,,BAO_0000221,2107.0
9073,22224,,,0,,U,,,,Autocuration,Half life value in rabbits,A,1,,3615,CHEMBL624697,,BAO_0000019,
9074,22224,,In vivo,0,,U,,Blood,,Autocuration,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,1,,6253,CHEMBL624698,,BAO_0000218,178.0
9075,22224,,In vivo,0,,U,,Blood,,Autocuration,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,1,,6253,CHEMBL624699,,BAO_0000218,178.0
9076,22224,,In vivo,0,,U,,,,Autocuration,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,1,,6077,CHEMBL624700,,BAO_0000218,
9077,50597,,,1,,N,,Plasma,,Intermediate,AUC 0-8 hr value in rats at 10 mg/kg,A,1,,17617,CHEMBL622903,,BAO_0000218,1969.0
9078,50597,,,1,,N,,Plasma,,Intermediate,AUC after administration at 2000 mg/kg/day in rats,A,1,,17594,CHEMBL622904,,BAO_0000218,1969.0
9079,50597,,,1,,N,,Plasma,,Intermediate,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,1,,6149,CHEMBL622905,,BAO_0000218,1969.0
9080,50597,,,1,,N,,Plasma,,Intermediate,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,1,,17260,CHEMBL622906,,BAO_0000218,1969.0
9081,50597,,,1,,N,,Plasma,,Intermediate,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,1,,17260,CHEMBL622907,,BAO_0000218,1969.0
9082,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat after oral administration at 10.5 mg/kg dose,A,1,,6644,CHEMBL622908,,BAO_0000218,1969.0
9083,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat after oral administration at 11.2 mg/kg dose,A,1,,6644,CHEMBL622909,,BAO_0000218,1969.0
9084,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat after oral administration at 9.7 mg/kg dose,A,1,,6644,CHEMBL622910,,BAO_0000218,1969.0
9085,50597,,,1,,N,,Brain,,Intermediate,AUC in rat brain after oral administration at 10 mg/kg,A,1,,6495,CHEMBL622911,,BAO_0000218,955.0
9086,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat p.o.,A,1,,6504,CHEMBL622912,,BAO_0000218,1969.0
9087,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat p.o. at 20 mg/kg concentration,A,1,,17686,CHEMBL622913,,BAO_0000218,1969.0
9088,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat plasma after oral administration at 10 mg/kg,A,1,,6495,CHEMBL622914,,BAO_0000218,1969.0
9089,50597,,,1,,N,,Plasma,,Intermediate,AUC in rats,A,1,,216,CHEMBL622915,,BAO_0000218,1969.0
9090,50597,,,1,,N,,Plasma,,Intermediate,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,1,,1908,CHEMBL622916,,BAO_0000218,1969.0
9091,50597,,,1,,N,,Plasma,,Intermediate,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,1,,1908,CHEMBL622917,,BAO_0000218,1969.0
9092,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,1,,6685,CHEMBL622918,,BAO_0000218,1969.0
9093,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,1,,216,CHEMBL622919,,BAO_0000218,1969.0
9094,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in rat,A,1,,6049,CHEMBL622920,,BAO_0000218,1969.0
9095,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,1,,2463,CHEMBL622921,,BAO_0000218,1969.0
9096,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,1,,6679,CHEMBL622922,,BAO_0000218,1969.0
9097,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,1,,6681,CHEMBL622923,,BAO_0000218,1969.0
9098,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL877604,,BAO_0000218,1969.0
9099,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,1,,6410,CHEMBL622924,,BAO_0000218,1969.0
9100,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL622925,,BAO_0000218,1969.0
9101,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,1,,16366,CHEMBL622926,,BAO_0000218,1969.0
9102,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,1,,6227,CHEMBL623625,,BAO_0000218,1969.0
9103,50597,,In vivo,1,,N,,Plasma,,Expert,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL623626,,BAO_0000218,1969.0
9104,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma drug concentration was determined,A,1,,1465,CHEMBL623627,,BAO_0000218,1969.0
9105,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,1,,4368,CHEMBL623628,,BAO_0000218,
9106,50597,,In vivo,1,,N,,Plasma,,Intermediate,Mean peak plasma concentration was observed after intravenous administration in rat,A,1,,15662,CHEMBL623629,,BAO_0000218,1969.0
9107,50597,,In vivo,1,,N,,Plasma,,Intermediate,Mean peak plasma concentration was observed after oral administration in rat,A,1,,15662,CHEMBL623630,,BAO_0000218,1969.0
9108,50597,,In vivo,1,,N,,,,Intermediate,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,1,,5355,CHEMBL623804,,BAO_0000218,
9109,50597,,In vivo,1,,N,,,,Intermediate,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,1,,5355,CHEMBL623805,,BAO_0000218,
9110,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak oral plasma concentration was determined in rats by oral administration,A,1,,1567,CHEMBL623806,,BAO_0000218,1969.0
9111,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration (Cmax) was determined,A,1,,4026,CHEMBL623807,,BAO_0000218,1969.0
9112,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,1,,6193,CHEMBL623808,,BAO_0000218,1969.0
9113,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration (Cmax) in rats,A,1,,4026,CHEMBL623809,,BAO_0000218,1969.0
9114,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration at 1 mg/kg peroral administration,A,1,,6485,CHEMBL623810,,BAO_0000218,1969.0
9115,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration in rat,A,1,,17655,CHEMBL623811,,BAO_0000218,1969.0
9116,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL623812,,BAO_0000218,1969.0
9117,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,1,,5394,CHEMBL877605,,BAO_0000218,
9118,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Cmax) in rat,A,1,,4408,CHEMBL623813,,BAO_0000218,
9119,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,1,,5983,CHEMBL623814,,BAO_0000218,
9120,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat after 3mg/kg oral dose,A,1,,4878,CHEMBL623815,,BAO_0000218,
9121,50597,,In vivo,1,Sprague-Dawley,N,,,,Intermediate,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,1,,5862,CHEMBL623816,,BAO_0000218,
9122,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats after 20 mg/kg oral dose,A,1,,4517,CHEMBL623145,,BAO_0000218,
9123,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in rat plasma after 30mg/kg oral dose,A,1,,5932,CHEMBL623146,,BAO_0000218,1969.0
9124,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma concentration after oral administration of 100 mg/kg to rats,A,1,,5436,CHEMBL623147,,BAO_0000218,1969.0
9125,50597,,In vivo,1,,N,,Brain,,Intermediate,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,1,,4910,CHEMBL623042,,BAO_0000218,955.0
9126,50597,,In vivo,1,,N,,,,Intermediate,Tested for the Cmax in rat at 10 mg/kg per orally,A,1,,4950,CHEMBL623043,,BAO_0000218,
9127,50597,,In vivo,1,,N,,,,Intermediate,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL623044,,BAO_0000218,
9128,50597,,In vivo,1,,N,,,,Intermediate,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL623045,,BAO_0000218,
9129,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability as oral Cmax in rats at 30 mins,A,1,,3360,CHEMBL623046,,BAO_0000218,
9130,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability as oral Cmax in rats at 6hr,A,1,,3360,CHEMBL623226,,BAO_0000218,
9131,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,1,,15022,CHEMBL623227,,BAO_0000218,
9132,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,1,,15022,CHEMBL623228,,BAO_0000218,
9133,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,1,,15022,CHEMBL623229,,BAO_0000218,
9134,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma levels for the compounds were determined by LC-MS.,A,1,,5160,CHEMBL623230,,BAO_0000218,1969.0
9135,50597,,In vivo,1,,N,,Plasma,,Intermediate,mean peak plasma concentration was observed after intravenous administration in rat,A,1,,15662,CHEMBL623231,,BAO_0000218,1969.0
9136,50597,,In vivo,1,,N,,Plasma,,Intermediate,mean peak plasma concentration was observed after oral administration in rat,A,1,,15662,CHEMBL623232,,BAO_0000218,1969.0
9137,50597,,,1,,N,,,,Intermediate,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL623233,,BAO_0000218,
9138,50597,,,1,,N,,,,Intermediate,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,1,,3535,CHEMBL623234,,BAO_0000218,
9139,50597,,,1,,N,,,,Intermediate,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,1,,3535,CHEMBL623235,,BAO_0000218,
9140,50597,,,1,,N,,,,Intermediate,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,1,,3535,CHEMBL623236,,BAO_0000218,
9141,50597,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,1,,3535,CHEMBL623237,,BAO_0000218,
9142,50597,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,1,,3535,CHEMBL623238,,BAO_0000218,
9143,50597,,,1,,N,,,,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,1,,3535,CHEMBL623239,,BAO_0000218,
9144,22224,,In vivo,0,,U,,Plasma,,Intermediate,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,1,,5005,CHEMBL623240,,BAO_0000218,1969.0
9145,50597,,,1,,N,,Hypothalamus,,Intermediate,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,1,,6326,CHEMBL623241,,BAO_0000218,1898.0
9146,50597,,,1,,N,,Hypothalamus,,Intermediate,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,1,,6326,CHEMBL623242,,BAO_0000218,1898.0
9147,50597,,,1,,N,,,,Intermediate,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,1,,6326,CHEMBL874394,,BAO_0000218,
9148,50597,,,1,,N,,,,Intermediate,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,1,,6326,CHEMBL623243,,BAO_0000218,
9149,50597,,,1,,N,,,,Intermediate,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL623244,,BAO_0000218,
9150,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL623245,,BAO_0000218,2113.0
9151,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL623246,,BAO_0000218,2113.0
9152,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL623247,,BAO_0000218,2113.0
9153,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL623248,,BAO_0000218,2113.0
9154,50597,,,1,,N,,Kidney,,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL623249,,BAO_0000218,2113.0
9155,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL625072,,BAO_0000218,2107.0
9156,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL625073,,BAO_0000218,2107.0
9157,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL625074,,BAO_0000218,2107.0
9158,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL625075,,BAO_0000218,2107.0
9159,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL625076,,BAO_0000218,2107.0
9160,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL625077,,BAO_0000218,2107.0
9161,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL625078,,BAO_0000218,2107.0
9162,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL874395,,BAO_0000218,2107.0
9163,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL625079,,BAO_0000218,2107.0
9164,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL625080,,BAO_0000218,2107.0
9165,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL625081,,BAO_0000218,2107.0
9166,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL625082,,BAO_0000218,2107.0
9167,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL625083,,BAO_0000218,2107.0
9168,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL625084,,BAO_0000218,2107.0
9169,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL625085,,BAO_0000218,2107.0
9170,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL625086,,BAO_0000218,2107.0
9171,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL625087,,BAO_0000218,2107.0
9172,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL625088,,BAO_0000218,2107.0
9173,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL622205,,BAO_0000218,2107.0
9174,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL622206,,BAO_0000218,2107.0
9175,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL622207,,BAO_0000218,2107.0
9176,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL622366,,BAO_0000218,2107.0
9177,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL622367,,BAO_0000218,2107.0
9178,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL875331,,BAO_0000218,2107.0
9179,50597,,,1,,N,,Liver,,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL622368,,BAO_0000218,2107.0
9180,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL622369,,BAO_0000218,2048.0
9181,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL622370,,BAO_0000218,2048.0
9182,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL622371,,BAO_0000218,2048.0
9183,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL622372,,BAO_0000218,2048.0
9184,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL622373,,BAO_0000218,2048.0
9185,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL622374,,BAO_0000218,2048.0
9186,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL622375,,BAO_0000218,2048.0
9187,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL622376,,BAO_0000218,2048.0
9188,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL622377,,BAO_0000218,2048.0
9189,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL622378,,BAO_0000218,2048.0
9190,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL622379,,BAO_0000218,2048.0
9191,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL622380,,BAO_0000218,2048.0
9192,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL622381,,BAO_0000218,2048.0
9193,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL622382,,BAO_0000218,2048.0
9194,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL622383,,BAO_0000218,2048.0
9195,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL875332,,BAO_0000218,945.0
9196,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL622384,,BAO_0000218,945.0
9197,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL622385,,BAO_0000218,945.0
9198,50597,,,1,,N,,Stomach,,Intermediate,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,1,,6175,CHEMBL622386,,BAO_0000218,945.0
9199,50597,,,1,,N,,,,Intermediate,The compound was tested for the plasma binding in rat,A,1,,10839,CHEMBL622387,,BAO_0000218,
9200,50597,,,1,,N,,,,Intermediate,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,1,,16459,CHEMBL622388,,BAO_0000218,
9201,50597,,,1,,N,,,,Intermediate,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,1,,16459,CHEMBL622389,,BAO_0000218,
9202,50597,,,1,,N,,,,Intermediate,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,1,,16459,CHEMBL622390,,BAO_0000218,
9203,50597,,,1,,N,,,,Intermediate,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,1,,16459,CHEMBL622391,,BAO_0000218,
9204,50597,,,1,,N,,,,Intermediate,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,1,,16459,CHEMBL622392,,BAO_0000218,
9205,50597,,,1,,N,,,,Intermediate,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,1,,16459,CHEMBL622393,,BAO_0000218,
9206,50597,,,1,,N,,,,Intermediate,Plasma level at 2 hr after administration of the compound,A,1,,3278,CHEMBL622394,,BAO_0000218,
9207,50597,,,1,,N,,,,Intermediate,plasma level at 2 hr after administration of the compound,A,1,,3278,CHEMBL622395,,BAO_0000218,
9208,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 1 min,A,1,,4684,CHEMBL622396,,BAO_0000218,1977.0
9209,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 10 min,A,1,,4684,CHEMBL624894,,BAO_0000218,1977.0
9210,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 10 mins,A,1,,4684,CHEMBL624895,,BAO_0000218,1977.0
9211,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 2 hr,A,1,,4684,CHEMBL624058,,BAO_0000218,1977.0
9212,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 3 min,A,1,,4684,CHEMBL624059,,BAO_0000218,1977.0
9213,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 3 mins,A,1,,4684,CHEMBL624060,,BAO_0000218,1977.0
9214,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 5 min,A,1,,4684,CHEMBL624061,,BAO_0000218,1977.0
9215,50597,,,1,,N,,Serum,,Intermediate,Stability in rat serum measured as % recovery at 5 mins,A,1,,4684,CHEMBL624062,,BAO_0000218,1977.0
9216,50597,,In vivo,1,,N,,,,Intermediate,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL624063,,BAO_0000218,
9217,50597,,In vivo,1,,N,,,,Intermediate,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL624064,,BAO_0000218,
9218,50597,,,1,,N,,Plasma,,Intermediate,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,1,,723,CHEMBL624065,,BAO_0000218,1969.0
9219,50597,,,1,,N,,Plasma,,Intermediate,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,1,,723,CHEMBL624066,,BAO_0000218,1969.0
9220,50597,,In vivo,1,,N,,,,Intermediate,Half life tested in mature male rat at a dose of 30 mg/kg,A,1,,5160,CHEMBL877490,,BAO_0000218,
9221,50597,,In vivo,1,,N,,,,Intermediate,Half life after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL874442,,BAO_0000218,
9222,50597,,In vivo,1,,N,,,,Intermediate,Half life period after administration (30 mg/kg) in rat,A,1,,5633,CHEMBL626890,,BAO_0000218,
9223,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after 5 mg/Kg dose,A,1,,5302,CHEMBL626891,,BAO_0000218,
9224,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after 5 mg/kg dose,A,1,,5302,CHEMBL626892,,BAO_0000218,
9225,50597,,,1,,N,,,,Intermediate,Half life period was determined,A,1,,17791,CHEMBL626893,,BAO_0000218,
9226,50597,,,1,,N,,,,Intermediate,Half life period was evaluated in rat,A,1,,17791,CHEMBL626894,,BAO_0000218,
9227,50597,,,1,,N,,,,Intermediate,Half life period was evaluated in rat; 0.5-1.0,A,1,,17791,CHEMBL626895,,BAO_0000218,
9228,50597,,,1,,N,,,,Intermediate,Half life period was evaluated in rat; 5.9-7.5,A,1,,17791,CHEMBL626896,,BAO_0000218,
9229,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma,A,1,,14512,CHEMBL626897,,BAO_0000218,1969.0
9230,50597,,,1,,N,,,,Intermediate,Half-life time in rat was determined,A,1,,6230,CHEMBL626898,,BAO_0000218,
9231,50597,,In vivo,1,,N,,,,Intermediate,Terminal half-life after iv administration to rats,A,1,,3364,CHEMBL626899,,BAO_0000218,
9232,50597,,In vivo,1,,N,,,,Intermediate,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,1,,6874,CHEMBL626900,,BAO_0000218,
9233,50597,,,1,,N,,,,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,1,,857,CHEMBL626901,,BAO_0000218,
9234,50597,,In vivo,1,,N,,,,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,1,,858,CHEMBL626902,,BAO_0000218,
9235,50597,,In vivo,1,,N,,,,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,1,,858,CHEMBL626903,,BAO_0000218,
9236,50597,,In vivo,1,,N,,,,Intermediate,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,1,,5355,CHEMBL874443,,BAO_0000218,
9237,50597,,In vivo,1,,N,,,,Intermediate,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,1,,5355,CHEMBL626904,,BAO_0000218,
9238,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,6305,CHEMBL626905,,BAO_0000218,
9239,50597,,In vivo,1,,N,,Plasma,,Intermediate,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,1,,13501,CHEMBL873830,,BAO_0000218,1969.0
9240,50597,,In vivo,1,,N,,,,Intermediate,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,1,,17594,CHEMBL626906,,BAO_0000218,
9241,50597,,In vivo,1,,N,,Plasma,,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL631076,,BAO_0000218,1969.0
9242,50597,,,1,,N,,Plasma,,Intermediate,Biological half-life was measured in plasma of rats,A,1,,2932,CHEMBL631077,,BAO_0000218,1969.0
9243,50597,,In vivo,1,,N,,,,Intermediate,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,1,,17065,CHEMBL631078,,BAO_0000218,
9244,50597,,In vivo,1,,N,,,,Intermediate,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,1,,15765,CHEMBL631079,,BAO_0000218,
9245,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,1,,2713,CHEMBL631080,,BAO_0000218,
9246,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,1,,2661,CHEMBL631081,,BAO_0000218,
9247,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,1,,2661,CHEMBL631239,,BAO_0000218,
9248,50597,,,1,,N,,Plasma,,Intermediate,Compound was evaluated for plasma half life in rat,A,1,,740,CHEMBL631240,,BAO_0000218,1969.0
9249,50597,,,1,,N,,Plasma,,Intermediate,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,1,,6597,CHEMBL631241,,BAO_0000218,1969.0
9250,50597,,,1,,N,,Plasma,,Intermediate,AUC value after administration of 20 mg/Kg oral dose in rat,A,1,,2959,CHEMBL631242,,BAO_0000218,1969.0
9251,50597,,,1,,N,,Plasma,,Intermediate,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,1,,17594,CHEMBL631243,,BAO_0000218,1969.0
9252,50597,,,1,,N,,Plasma,,Intermediate,AUC0-96 after administration at 50 mg/kg,A,1,,17596,CHEMBL874444,,BAO_0000218,1969.0
9253,50597,,,1,,N,,Plasma,,Intermediate,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,1,,17594,CHEMBL631244,,BAO_0000218,1969.0
9254,50597,,,1,,N,,,,Intermediate,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,1,,3293,CHEMBL631245,,BAO_0000218,
9255,50597,,,1,,N,,,,Intermediate,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,1,,6757,CHEMBL627162,,BAO_0000218,
9256,50597,,,1,,N,,,,Intermediate,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,1,,6757,CHEMBL627163,,BAO_0000218,
9257,50597,,,1,,N,,,,Intermediate,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,1,,6757,CHEMBL627164,,BAO_0000218,
9258,50597,,,1,,N,,Kidney,,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,1,,5979,CHEMBL627165,,BAO_0000218,2113.0
9259,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,1,,5979,CHEMBL627166,,BAO_0000218,
9260,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,1,,5979,CHEMBL627167,,BAO_0000218,
9261,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,1,,4026,CHEMBL627822,,BAO_0000218,
9262,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,1,,5355,CHEMBL627823,,BAO_0000218,
9263,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,1,,5355,CHEMBL627824,,BAO_0000218,
9264,50597,,,1,,N,,,,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,1,,5355,CHEMBL627825,,BAO_0000218,
9265,50597,,,1,,N,,,,Intermediate,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,1,,5633,CHEMBL627826,,BAO_0000218,
9266,50597,,,1,,N,,,,Intermediate,Area under curve (Pharmacokinetic property) was determined,A,1,,1716,CHEMBL627827,,BAO_0000218,
9267,50597,,,1,,N,,,,Intermediate,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,1,,1716,CHEMBL627828,,BAO_0000218,
9268,50597,,,1,,N,,,,Intermediate,Area under curve after intravenous administration (1 mg/kg) in rat,A,1,,4689,CHEMBL627829,,BAO_0000218,
9269,50597,,,1,,N,,,,Intermediate,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,1,,4527,CHEMBL627830,,BAO_0000218,
9270,50597,,,1,,N,,,,Intermediate,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,1,,4527,CHEMBL627831,,BAO_0000218,
9271,50597,,,1,,N,,,,Intermediate,Area under curve in male SD rats was observed after oral administration in rat,A,1,,15662,CHEMBL627832,,BAO_0000218,
9272,50597,,,1,,N,,,,Intermediate,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,1,,4413,CHEMBL627833,,BAO_0000218,
9273,50597,,,1,,N,,,,Expert,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL627834,,BAO_0000218,
9274,50597,,,1,,N,,,,Expert,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL628004,,BAO_0000218,
9275,50597,,,1,,N,,,,Intermediate,Area under curve at 5 mg/kg po was determined in rat,A,1,,5964,CHEMBL628005,,BAO_0000218,
9276,50597,,,1,,N,,,,Intermediate,Area under curve in Rat at a oral dose of 5 mg/kg,A,1,,4689,CHEMBL628006,,BAO_0000218,
9277,50597,,,1,,N,,,,Intermediate,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,1,,4186,CHEMBL628007,,BAO_0000218,
9278,50597,,,1,,N,,,,Intermediate,Area under curve was determined,A,1,,5510,CHEMBL625676,,BAO_0000218,
9279,50597,,,1,,N,,,,Intermediate,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,1,,17858,CHEMBL631309,,BAO_0000218,
9280,50597,,,1,,N,,,,Intermediate,Area under curve after intravenous administration at 3 mg/kg,A,1,,17804,CHEMBL631310,,BAO_0000218,
9281,50597,,,1,,N,,,,Intermediate,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,1,,6106,CHEMBL631311,,BAO_0000218,
9282,50597,,,1,,N,,,,Intermediate,Area under curve at 4 hr in rat,A,1,,5964,CHEMBL631312,,BAO_0000218,
9283,50597,,,1,,N,,,,Intermediate,Area under curve at a dose of 30 mg/kg,A,1,,4026,CHEMBL631313,,BAO_0000218,
9284,50597,,,1,,N,,,,Intermediate,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL631314,,BAO_0000218,
9285,50597,,,1,,N,,,,Intermediate,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL631315,,BAO_0000218,
9286,50597,,,1,,N,,,,Intermediate,Area under curve for a 2-mpk po dose in SD rats,A,1,,5862,CHEMBL631316,,BAO_0000218,
9287,50597,,,1,,N,,,,Intermediate,Area under curve in SD rats,A,1,,5862,CHEMBL631317,,BAO_0000218,
9288,50597,,,1,,N,,,,Intermediate,Area under curve in rat after oral administration at 13 mg/kg dose,A,1,,6644,CHEMBL874471,,BAO_0000218,
9289,50597,,,1,,N,,,,Intermediate,Area under curve in rat by po administration at 0-24 hr,A,1,,5871,CHEMBL631318,,BAO_0000218,
9290,50597,,,1,,N,,Plasma,,Intermediate,Area under curve in rat plasma,A,1,,5919,CHEMBL631319,,BAO_0000218,1969.0
9291,50597,,,1,,N,,,,Intermediate,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,1,,5939,CHEMBL631320,,BAO_0000218,
9292,50597,,,1,,N,,,,Intermediate,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,1,,5939,CHEMBL631321,,BAO_0000218,
9293,50597,,,1,,N,,,,Intermediate,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,1,,10,CHEMBL631322,,BAO_0000218,
9294,50597,,,1,,N,,,,Intermediate,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,1,,11149,CHEMBL631323,,BAO_0000218,
9295,50597,,,1,,N,,,,Intermediate,Area under curve value in rat at a dose of 5 mg/kg,A,1,,5302,CHEMBL631324,,BAO_0000218,
9296,50597,,,1,,N,,,,Intermediate,Area under curve was determined after oral administration in rats,A,1,,17796,CHEMBL631325,,BAO_0000218,
9297,50597,,,1,,N,,,,Intermediate,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL631326,,BAO_0000218,
9298,50597,,,1,,N,,,,Intermediate,Area under curve was determined after peroral administration in rat,A,1,,6011,CHEMBL631327,,BAO_0000218,
9299,50597,,,1,,N,,,,Intermediate,Area under curve was determined at a dose 30 mpk administered orally.,A,1,,5375,CHEMBL631328,,BAO_0000218,
9300,50597,,,1,,N,,,,Intermediate,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL631329,,BAO_0000218,
9301,50597,,,1,,N,,,,Intermediate,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,1,,4368,CHEMBL627217,,BAO_0000218,
9302,50597,,,1,,N,,,,Intermediate,Area under curve was determined in male rat,A,1,,5610,CHEMBL626352,,BAO_0000218,
9303,50597,,,1,,N,,,,Intermediate,Area under curve was determined in rat after PO administration,A,1,,5833,CHEMBL626353,,BAO_0000218,
9304,50597,,,1,,N,,,,Intermediate,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,1,,4257,CHEMBL626354,,BAO_0000218,
9305,50597,,,1,,N,,,,Intermediate,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,1,,5937,CHEMBL626355,,BAO_0000218,
9306,50597,,,1,,N,,,,Intermediate,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,1,,5932,CHEMBL626356,,BAO_0000218,
9307,50597,,,1,,N,,,,Intermediate,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,1,,5932,CHEMBL626357,,BAO_0000218,
9308,50597,,,1,,N,,,,Intermediate,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL626358,,BAO_0000218,
9309,50597,,,1,,N,,,,Intermediate,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL626359,,BAO_0000218,
9310,50597,,,1,,N,,Plasma,,Intermediate,Peak plasma concentration in rat at a dose of 3 mg/kg,A,1,,17771,CHEMBL626360,,BAO_0000218,1969.0
9311,50597,,,1,,N,,,,Intermediate,Plasma concentration at 2 hr in rats was evaluated.,A,1,,1628,CHEMBL626361,,BAO_0000218,
9312,50597,,,1,,N,,,,Intermediate,Plasma concentration at 2 hr in rats was evaluated; Not available,A,1,,1628,CHEMBL626362,,BAO_0000218,
9313,50597,,,1,,N,,,,Intermediate,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL626363,,BAO_0000218,
9314,50597,,,1,,N,,,,Intermediate,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL626970,,BAO_0000218,
9315,50597,,,1,,N,,,,Intermediate,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL626971,,BAO_0000218,
9316,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL626972,,BAO_0000218,1969.0
9317,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL626973,,BAO_0000218,1969.0
9318,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL626974,,BAO_0000218,1969.0
9319,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL874592,,BAO_0000218,1969.0
9320,50597,,,1,,N,,,,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,1,,5510,CHEMBL626975,,BAO_0000218,
9321,50597,,,1,,N,,,,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,1,,5510,CHEMBL626976,,BAO_0000218,
9322,50597,,,1,,N,,,,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,1,,5510,CHEMBL626977,,BAO_0000218,
9323,50597,,,1,,N,,,,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,1,,5510,CHEMBL626978,,BAO_0000218,
9324,50597,,,1,,N,,,,Intermediate,PK study was carried to determine the relative absorption ranking in rat.,A,1,,16427,CHEMBL626979,,BAO_0000218,
9325,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,1,,4689,CHEMBL626980,,BAO_0000218,1969.0
9326,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,1,,11450,CHEMBL626981,,BAO_0000218,178.0
9327,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,1,,11450,CHEMBL626982,,BAO_0000218,178.0
9328,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,1,,11450,CHEMBL626983,,BAO_0000218,178.0
9329,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,1,,11450,CHEMBL622522,,BAO_0000218,178.0
9330,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,1,,11450,CHEMBL622523,,BAO_0000218,178.0
9331,50597,,,1,,N,,Blood,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,1,,11450,CHEMBL622524,,BAO_0000218,178.0
9332,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,1,,11450,CHEMBL622525,,BAO_0000218,955.0
9333,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,1,,11450,CHEMBL622526,,BAO_0000218,955.0
9334,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,1,,11450,CHEMBL619849,,BAO_0000218,955.0
9335,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,1,,11450,CHEMBL619850,,BAO_0000218,955.0
9336,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,1,,11450,CHEMBL623864,,BAO_0000218,955.0
9337,50597,,,1,,N,,Brain,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,1,,11450,CHEMBL623865,,BAO_0000218,955.0
9338,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,1,,11450,CHEMBL623866,,BAO_0000218,948.0
9339,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,1,,11450,CHEMBL623867,,BAO_0000218,948.0
9340,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,1,,11450,CHEMBL877615,,BAO_0000218,948.0
9341,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,1,,11450,CHEMBL623868,,BAO_0000218,948.0
9342,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,1,,11450,CHEMBL623869,,BAO_0000218,948.0
9343,50597,,,1,,N,,Heart,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,1,,11450,CHEMBL623870,,BAO_0000218,948.0
9344,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL623871,,BAO_0000218,2048.0
9345,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL623872,,BAO_0000218,2048.0
9346,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL622129,,BAO_0000218,2048.0
9347,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL622130,,BAO_0000218,2048.0
9348,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL622131,,BAO_0000218,2048.0
9349,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL622132,,BAO_0000218,2048.0
9350,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL622133,,BAO_0000218,2048.0
9351,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL622134,,BAO_0000218,2048.0
9352,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL622135,,BAO_0000218,2048.0
9353,50597,,,1,,N,,Lung,,Intermediate,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL622136,,BAO_0000218,2048.0
9354,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL622137,,BAO_0000218,2385.0
9355,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL622138,,BAO_0000218,2385.0
9356,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL623017,,BAO_0000218,2385.0
9357,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL623018,,BAO_0000218,2385.0
9358,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL623019,,BAO_0000218,2385.0
9359,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL623020,,BAO_0000218,2385.0
9360,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL623021,,BAO_0000218,2385.0
9361,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL623022,,BAO_0000218,2385.0
9362,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL623023,,BAO_0000218,2385.0
9363,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL623024,,BAO_0000218,2385.0
9364,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL623025,,BAO_0000218,2385.0
9365,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL620545,,BAO_0000218,2385.0
9366,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL620546,,BAO_0000218,2385.0
9367,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL620547,,BAO_0000218,2385.0
9368,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL620548,,BAO_0000218,2385.0
9369,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL620549,,BAO_0000218,2385.0
9370,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL620550,,BAO_0000218,2385.0
9371,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL620551,,BAO_0000218,2385.0
9372,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL620552,,BAO_0000218,2385.0
9373,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL620553,,BAO_0000218,2385.0
9374,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL620554,,BAO_0000218,2385.0
9375,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL875845,,BAO_0000218,2385.0
9376,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL620555,,BAO_0000218,2385.0
9377,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL620556,,BAO_0000218,2385.0
9378,50597,,,1,,N,,Muscle tissue,,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL620557,,BAO_0000218,2385.0
9379,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL620558,,BAO_0000218,
9380,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL620559,,BAO_0000218,
9381,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL622939,,BAO_0000218,
9382,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL622940,,BAO_0000218,
9383,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL622941,,BAO_0000218,
9384,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL622942,,BAO_0000218,
9385,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL622943,,BAO_0000218,
9386,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL622944,,BAO_0000218,
9387,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL622945,,BAO_0000218,
9388,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL622946,,BAO_0000218,
9389,50597,,,1,,N,,,,Intermediate,Compound was evaluated for terminal half life in rat,A,1,,3341,CHEMBL622947,,BAO_0000218,
9390,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,1,,3634,CHEMBL622948,,BAO_0000218,1969.0
9391,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,1,,3634,CHEMBL622949,,BAO_0000218,1969.0
9392,50597,,,1,,N,,,,Intermediate,Compound was tested for its half life in rat,A,1,,4839,CHEMBL622950,,BAO_0000218,
9393,22224,,In vivo,0,,U,,Plasma,,Intermediate,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,1,,5005,CHEMBL622951,,BAO_0000218,1969.0
9394,22224,,,0,,U,,Plasma,,Intermediate,Compound was tested for its plasma half life in Sprague Dawley rats,A,1,,5005,CHEMBL622952,,BAO_0000366,1969.0
9395,22224,,,0,,U,,Plasma,,Intermediate,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,1,,5005,CHEMBL622953,,BAO_0000366,1969.0
9396,50597,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma half-life period in rat,A,1,,1094,CHEMBL873818,,BAO_0000218,1969.0
9397,50597,,In vivo,1,,N,,,,Intermediate,Elimination half life after i.v. administration of compound in rats,A,1,,5031,CHEMBL622954,,BAO_0000218,
9398,50597,,In vivo,1,,N,,,,Intermediate,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,1,,6518,CHEMBL622955,,BAO_0000218,
9399,50597,,In vivo,1,,N,,,,Intermediate,Elimination half-life after IV dosing at 1 mg/kg in rat,A,1,,6518,CHEMBL875229,,BAO_0000218,
9400,50597,,In vivo,1,,N,,,,Intermediate,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,1,,6518,CHEMBL622956,,BAO_0000218,
9401,50597,,In vivo,1,,N,,,,Intermediate,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,1,,6518,CHEMBL622957,,BAO_0000218,
9402,50597,,In vivo,1,,N,,Brain,,Intermediate,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,1,,5408,CHEMBL622958,,BAO_0000218,955.0
9403,50597,,In vivo,1,,N,,Plasma,,Intermediate,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,1,,5408,CHEMBL622959,,BAO_0000218,1969.0
9404,50597,,In vivo,1,,N,,Brain,,Intermediate,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,1,,5408,CHEMBL622960,,BAO_0000218,955.0
9405,50597,,In vivo,1,,N,,Plasma,,Intermediate,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,1,,5408,CHEMBL622961,,BAO_0000218,1969.0
9406,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for the half life in rat (in vivo),A,1,,4687,CHEMBL622962,,BAO_0000218,
9407,50597,,,1,,N,,,,Intermediate,Hafl life in rat,A,1,,6640,CHEMBL622963,,BAO_0000218,
9408,50597,,,1,,N,,,,Intermediate,Hafl life rat,A,1,,6640,CHEMBL622964,,BAO_0000218,
9409,50597,,,1,,N,,,,Intermediate,Hafl life rat,A,1,,6641,CHEMBL622965,,BAO_0000218,
9410,50597,,,1,,N,,,,Intermediate,Hafl life rat; Not determined,A,1,,6640,CHEMBL622966,,BAO_0000218,
9411,50597,,,1,,N,,,,Intermediate,Hafl life rat; Not determined,A,1,,6641,CHEMBL622967,,BAO_0000218,
9412,50597,,In vivo,1,,N,,Kidney,,Intermediate,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL622968,,BAO_0000218,2113.0
9413,50597,,In vivo,1,,N,,Liver,,Intermediate,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL622969,,BAO_0000218,2107.0
9414,50597,,In vivo,1,,N,,Lung,,Intermediate,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL875327,,BAO_0000218,2048.0
9415,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after 1 mg/kg i.v. administration,A,1,,6570,CHEMBL628638,,BAO_0000218,
9416,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after 2 mg/kg peroral administration,A,1,,6570,CHEMBL628639,,BAO_0000218,
9417,50597,,In vivo,1,,N,,,,Intermediate,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL625840,,BAO_0000218,
9418,50597,,In vivo,1,,N,,,,Intermediate,Half life of 10 mg/kg oral dose determined in rats,A,1,,4722,CHEMBL625841,,BAO_0000218,
9419,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL625842,,BAO_0000218,
9420,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL625843,,BAO_0000218,
9421,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL625844,,BAO_0000218,
9422,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL873822,,BAO_0000218,
9423,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL625845,,BAO_0000218,
9424,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL627059,,BAO_0000218,
9425,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL627060,,BAO_0000218,
9426,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL627061,,BAO_0000218,
9427,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound at 5 mg/kg after po administration was determined in rat,A,1,,4762,CHEMBL627709,,BAO_0000218,
9428,50597,,In vivo,1,,N,,,,Intermediate,Half life of compound determined after intravenous administration to rat,A,1,,5327,CHEMBL627710,,BAO_0000218,
9429,50597,,,1,,N,,,,Intermediate,Half life of compound was determined in rat,A,1,,4847,CHEMBL627711,,BAO_0000218,
9430,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL627712,,BAO_0000218,1969.0
9431,50597,,In vivo,1,,N,,,,Intermediate,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL627713,,BAO_0000218,
9432,50597,,In vivo,1,,N,,,,Intermediate,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL627714,,BAO_0000218,
9433,22224,,In vivo,0,,U,,,,Intermediate,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,1,,4256,CHEMBL627889,,BAO_0000218,
9434,22224,,In vivo,0,,U,,,,Intermediate,Half life determined in rat by intravenous administration,A,1,,4256,CHEMBL627890,,BAO_0000218,
9435,50597,,In vivo,1,,N,,,,Intermediate,Half life determined in rats after iv administration,A,1,,4722,CHEMBL627891,,BAO_0000218,
9436,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life in rat plasma after administration of 2 mg/kg iv,A,1,,6535,CHEMBL627892,,BAO_0000218,1969.0
9437,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life in rat plasma after administration of 2 mg/kg iv,A,1,,6535,CHEMBL627893,,BAO_0000218,1969.0
9438,50597,,,1,,N,,Plasma,,Intermediate,Half life in rat plasma was determined,A,1,,1435,CHEMBL627894,,BAO_0000218,1969.0
9439,50597,,,1,,N,,Plasma,,Intermediate,Half life in rat plasma was determined; NA means not applicable,A,1,,1435,CHEMBL627895,,BAO_0000218,1969.0
9440,50597,,,1,,N,,,,Intermediate,Half life in rat was tested,A,1,,5206,CHEMBL627896,,BAO_0000218,
9441,50597,,,1,,N,,Plasma,,Intermediate,Half life measured in rat plasma,A,1,,6080,CHEMBL627897,,BAO_0000218,1969.0
9442,50597,,,1,,N,,,,Intermediate,Half life recorded in rats,A,1,,4449,CHEMBL627898,,BAO_0000218,
9443,50597,,,1,,N,,,,Intermediate,Half life was calculated,A,1,,6057,CHEMBL627899,,BAO_0000218,
9444,50597,,,1,,N,,,,Intermediate,Half life was calculated in rat,A,1,,6057,CHEMBL873823,,BAO_0000218,
9445,50597,,,1,,N,,,,Intermediate,Half life was determined,A,1,,3747,CHEMBL627900,,BAO_0000218,
9446,50597,,In vivo,1,,N,,,,Intermediate,Half life after 10 mg/kg oral administration in rat,A,1,,17858,CHEMBL627901,,BAO_0000218,
9447,50597,,In vivo,1,,N,,,,Intermediate,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,1,,16365,CHEMBL627902,,BAO_0000218,
9448,50597,,In vivo,1,,N,,,,Intermediate,Half life after administering orally a dose of 30 mg/kg,A,1,,16365,CHEMBL627903,,BAO_0000218,
9449,50597,,,1,,N,,,,Intermediate,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,1,,5031,CHEMBL627904,,BAO_0000218,
9450,50597,,,1,,N,,,,Intermediate,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,1,,4722,CHEMBL627905,,BAO_0000218,
9451,50597,,,1,,N,,,,Intermediate,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,1,,6078,CHEMBL627906,,BAO_0000218,
9452,50597,,,1,,N,,,,Intermediate,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,1,,6078,CHEMBL627907,,BAO_0000218,
9453,50597,,,1,,N,,,,Intermediate,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,1,,6078,CHEMBL876783,,BAO_0000218,
9454,50597,,,1,,N,,,,Intermediate,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,1,,6078,CHEMBL627908,,BAO_0000218,
9455,50597,,,1,,N,,,,Intermediate,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,1,,17065,CHEMBL627909,,BAO_0000218,
9456,50597,,,1,,N,,,,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,1,,1353,CHEMBL627910,,BAO_0000218,
9457,50597,,,1,,N,,,,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,1,,1353,CHEMBL627911,,BAO_0000218,
9458,50597,,,1,,N,,,,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,1,,1353,CHEMBL627912,,BAO_0000218,
9459,50597,,,1,,N,,,,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,1,,1353,CHEMBL627913,,BAO_0000218,
9460,50597,,,1,,N,,,,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,1,,1353,CHEMBL627914,,BAO_0000218,
9461,50597,,,1,,N,,,,Intermediate,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,1,,16423,CHEMBL627915,,BAO_0000218,
9462,50597,,,1,,N,,,,Intermediate,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,1,,16423,CHEMBL627916,,BAO_0000218,
9463,50597,,,1,,N,,,,Intermediate,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL627917,,BAO_0000218,
9464,50597,,,1,,N,,,,Intermediate,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,1,,6056,CHEMBL627918,,BAO_0000218,
9465,50597,,,1,,N,,,,Intermediate,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,1,,5182,CHEMBL627919,,BAO_0000218,
9466,50597,,,1,,N,,,,Intermediate,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,1,,6410,CHEMBL627920,,BAO_0000218,
9467,50597,,,1,,N,,,,Intermediate,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL627921,,BAO_0000218,
9468,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL627922,,BAO_0000218,
9469,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL876784,,BAO_0000218,
9470,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL627923,,BAO_0000218,
9471,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL626208,,BAO_0000218,
9472,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL626209,,BAO_0000218,
9473,50597,,,1,,N,,,,Intermediate,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL626210,,BAO_0000218,
9474,50597,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,1,,2463,CHEMBL627994,,BAO_0000218,1969.0
9475,50597,,,1,,N,,,,Intermediate,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL627995,,BAO_0000218,
9476,50597,,,1,,N,,,,Intermediate,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,1,,4075,CHEMBL627996,,BAO_0000218,
9477,50597,,,1,,N,,,,Intermediate,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,1,,5394,CHEMBL627997,,BAO_0000218,
9478,50597,,,1,,N,,,,Intermediate,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,1,,2661,CHEMBL627998,,BAO_0000218,
9479,50597,,,1,,N,,,,Intermediate,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,1,,2661,CHEMBL628640,,BAO_0000218,
9480,50597,,,1,,N,,,,Intermediate,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,1,,2661,CHEMBL628641,,BAO_0000218,
9481,50597,,,1,,N,,,,Intermediate,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,1,,2661,CHEMBL628642,,BAO_0000218,
9482,50597,,,1,,N,,,,Intermediate,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,1,,17791,CHEMBL628643,,BAO_0000218,
9483,50597,,,1,,N,,,,Intermediate,Compound was tested for area under curve in rat,A,1,,2591,CHEMBL628644,,BAO_0000218,
9484,50597,,,1,,N,,,,Intermediate,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,1,,6567,CHEMBL628645,,BAO_0000218,
9485,50597,,,1,,N,,,,Intermediate,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,1,,6211,CHEMBL628646,,BAO_0000218,
9486,50597,,,1,,N,,,,Intermediate,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,1,,5529,CHEMBL628647,,BAO_0000218,
9487,50597,,,1,,N,,,,Intermediate,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,1,,5408,CHEMBL628648,,BAO_0000218,
9488,50597,,,1,,N,,,,Intermediate,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,1,,5408,CHEMBL625358,,BAO_0000218,
9489,50597,,,1,,N,,,,Intermediate,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,1,,5408,CHEMBL625359,,BAO_0000218,
9490,50597,,,1,,N,,,,Intermediate,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,1,,5408,CHEMBL625360,,BAO_0000218,
9491,50597,,,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,1,,429,CHEMBL625361,,BAO_0000218,
9492,50597,,,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,1,,429,CHEMBL625362,,BAO_0000218,
9493,50597,,,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,1,,429,CHEMBL625363,,BAO_0000218,
9494,50597,,,1,,N,,,,Intermediate,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,1,,4796,CHEMBL625364,,BAO_0000218,
9495,50597,,,1,,N,,,,Intermediate,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625365,,BAO_0000218,
9496,50597,,,1,,N,,,,Intermediate,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625366,,BAO_0000218,
9497,50597,,,1,,N,,,,Intermediate,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625367,,BAO_0000218,
9498,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,1,,11450,CHEMBL625368,,BAO_0000218,2113.0
9499,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,1,,11450,CHEMBL625369,,BAO_0000218,2113.0
9500,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,1,,11450,CHEMBL625370,,BAO_0000218,2113.0
9501,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,1,,11450,CHEMBL625371,,BAO_0000218,2113.0
9502,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,1,,11450,CHEMBL625372,,BAO_0000218,2113.0
9503,50597,,,1,,N,,Kidney,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,1,,11450,CHEMBL625373,,BAO_0000218,2113.0
9504,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,1,,11450,CHEMBL625374,,BAO_0000218,2107.0
9505,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,1,,11450,CHEMBL877593,,BAO_0000218,2107.0
9506,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,1,,11450,CHEMBL625375,,BAO_0000218,2107.0
9507,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,1,,11450,CHEMBL625376,,BAO_0000218,2107.0
9508,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,1,,11450,CHEMBL621973,,BAO_0000218,2107.0
9509,50597,,,1,,N,,Liver,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,1,,11450,CHEMBL621974,,BAO_0000218,2107.0
9510,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,1,,11450,CHEMBL621975,,BAO_0000218,2048.0
9511,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,1,,11450,CHEMBL622166,,BAO_0000218,2048.0
9512,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,1,,11450,CHEMBL622167,,BAO_0000218,2048.0
9513,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,1,,11450,CHEMBL622168,,BAO_0000218,2048.0
9514,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,1,,11450,CHEMBL622169,,BAO_0000218,2048.0
9515,50597,,,1,,N,,Lung,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,1,,11450,CHEMBL622170,,BAO_0000218,2048.0
9516,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,1,,11450,CHEMBL622171,,BAO_0000218,2046.0
9517,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,1,,11450,CHEMBL622172,,BAO_0000218,2046.0
9518,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,1,,11450,CHEMBL622173,,BAO_0000218,2046.0
9519,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,1,,11450,CHEMBL622174,,BAO_0000218,2046.0
9520,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,1,,11450,CHEMBL622175,,BAO_0000218,2046.0
9521,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,1,,11450,CHEMBL622176,,BAO_0000218,2046.0
9522,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,1,,11450,CHEMBL622177,,BAO_0000218,2046.0
9523,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,1,,11450,CHEMBL622178,,BAO_0000218,2046.0
9524,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,1,,11450,CHEMBL622179,,BAO_0000218,2046.0
9525,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,1,,11450,CHEMBL622180,,BAO_0000218,2046.0
9526,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL622181,,BAO_0000218,
9527,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL622182,,BAO_0000218,
9528,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL622183,,BAO_0000218,
9529,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL622184,,BAO_0000218,
9530,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL622185,,BAO_0000218,
9531,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL622186,,BAO_0000218,
9532,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL622187,,BAO_0000218,
9533,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL625002,,BAO_0000218,
9534,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL622090,,BAO_0000218,
9535,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL622091,,BAO_0000218,
9536,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL622092,,BAO_0000218,
9537,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL622093,,BAO_0000218,
9538,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL622094,,BAO_0000218,
9539,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL622095,,BAO_0000218,
9540,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL622264,,BAO_0000218,
9541,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL622265,,BAO_0000218,2106.0
9542,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL622266,,BAO_0000218,2106.0
9543,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL622267,,BAO_0000218,2106.0
9544,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL622268,,BAO_0000218,2106.0
9545,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL622269,,BAO_0000218,2106.0
9546,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL625071,,BAO_0000218,2106.0
9547,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL621621,,BAO_0000218,2106.0
9548,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL621622,,BAO_0000218,2106.0
9549,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL621623,,BAO_0000218,2106.0
9550,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL621624,,BAO_0000218,2106.0
9551,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL621625,,BAO_0000218,2106.0
9552,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL621626,,BAO_0000218,2106.0
9553,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL621627,,BAO_0000218,2106.0
9554,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL621628,,BAO_0000218,2106.0
9555,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL875328,,BAO_0000218,2106.0
9556,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL621629,,BAO_0000218,2106.0
9557,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL621630,,BAO_0000218,2106.0
9558,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL621631,,BAO_0000218,2106.0
9559,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL621632,,BAO_0000218,2106.0
9560,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL621633,,BAO_0000218,2106.0
9561,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL621634,,BAO_0000218,2106.0
9562,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL621635,,BAO_0000218,2106.0
9563,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL621636,,BAO_0000218,2106.0
9564,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL621637,,BAO_0000218,2106.0
9565,50597,,,1,,N,,Spleen,,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL621638,,BAO_0000218,2106.0
9566,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL618883,,BAO_0000218,
9567,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,1,,16434,CHEMBL618884,,BAO_0000218,
9568,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL628627,,BAO_0000218,
9569,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL628628,,BAO_0000218,
9570,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,1,,16434,CHEMBL628629,,BAO_0000218,
9571,50597,,In vivo,1,,N,,,,Intermediate,Half life after administering orally a dose of 3 mg/kg,A,1,,16365,CHEMBL628630,,BAO_0000218,
9572,50597,,In vivo,1,,N,,,,Intermediate,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,1,,16365,CHEMBL628631,,BAO_0000218,
9573,50597,,In vivo,1,,N,,,,Intermediate,Half life after administering intravenously a dose of 1 mg/kg,A,1,,16365,CHEMBL628632,,BAO_0000218,
9574,50597,,In vivo,1,,N,,,,Intermediate,Half life after oral dosing in rats,A,1,,526,CHEMBL628633,,BAO_0000218,
9575,50597,,In vivo,1,,N,,,,Intermediate,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,1,,16365,CHEMBL628634,,BAO_0000218,
9576,50597,,In vivo,1,,N,,,,Intermediate,Half life by intravenous administration of 3.4 mg/kg in rat,A,1,,4368,CHEMBL627789,,BAO_0000218,
9577,50597,,,1,,N,,,,Intermediate,Half life in rat,A,1,,3371,CHEMBL627790,,BAO_0000218,
9578,50597,,,1,,N,,,,Intermediate,Half life in rat,A,1,,6448,CHEMBL627791,,BAO_0000218,
9579,50597,,,1,,N,,,,Intermediate,Half life in rat,A,1,,6453,CHEMBL627792,,BAO_0000218,
9580,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after intravenous administration of the compound,A,1,,4353,CHEMBL627793,,BAO_0000218,
9581,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,1,,4353,CHEMBL627794,,BAO_0000218,1969.0
9582,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after po administration of the compound,A,1,,4353,CHEMBL627795,,BAO_0000218,
9583,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat after po administration of the compound; ND means Not determined,A,1,,4353,CHEMBL627796,,BAO_0000218,
9584,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,1,,4353,CHEMBL875335,,BAO_0000218,1969.0
9585,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,1,,4353,CHEMBL627797,,BAO_0000218,1969.0
9586,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat i.v.,A,1,,5789,CHEMBL627798,,BAO_0000218,
9587,50597,,In vivo,1,,N,,,,Intermediate,Half life in rat i.v. at 2 mg/kg concentration,A,1,,17686,CHEMBL627799,,BAO_0000218,
9588,50597,,,1,,N,,,,Intermediate,Half life in rats,A,1,,6495,CHEMBL627800,,BAO_0000218,
9589,50597,,In vivo,1,,N,,,,Intermediate,Half life in rats after intravenous administration,A,1,,484,CHEMBL627801,,BAO_0000218,
9590,50597,,In vivo,1,,N,,,,Intermediate,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,1,,6467,CHEMBL627802,,BAO_0000218,
9591,50597,,,1,,N,,,,Expert,Half life in rat,A,1,,6642,CHEMBL627803,,BAO_0000218,
9592,50597,,In vivo,1,,N,,,,Intermediate,Half life was evaluated after intravenous administration to rats,A,1,,16367,CHEMBL873820,,BAO_0000218,
9593,50597,,,1,,N,,,,Intermediate,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,1,,1369,CHEMBL627804,,BAO_0000218,
9594,50597,,,1,,N,,,,Intermediate,Half life was evaluated in rat,A,1,,5472,CHEMBL627805,,BAO_0000218,
9595,50597,,,1,,N,,,,Intermediate,Half life was evaluated in rat,A,1,,6049,CHEMBL627806,,BAO_0000218,
9596,50597,,,1,,N,,,,Intermediate,Half life was evaluated in rat; Not tested,A,1,,5472,CHEMBL627107,,BAO_0000218,
9597,50597,,In vivo,1,,N,,,,Intermediate,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,1,,16366,CHEMBL627108,,BAO_0000218,
9598,50597,,In vivo,1,,N,,,,Intermediate,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,1,,11149,CHEMBL627109,,BAO_0000218,
9599,50597,,In vivo,1,,N,,Blood,,Intermediate,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,1,,11149,CHEMBL627110,,BAO_0000218,178.0
9600,22224,,In vivo,0,,U,,,,Intermediate,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,1,,2891,CHEMBL627111,,BAO_0000218,
9601,22224,,In vivo,0,,U,,,,Intermediate,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,1,,2891,CHEMBL627112,,BAO_0000218,
9602,22224,,In vivo,0,,U,,,,Intermediate,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,1,,2891,CHEMBL627113,,BAO_0000218,
9603,22224,,In vivo,0,,U,,,,Intermediate,Half life was measured in rat at dose of 30 mg/kg by po administration,A,1,,2891,CHEMBL627114,,BAO_0000218,
9604,50597,,,1,,N,,,,Intermediate,Half life (t1/2) was determined,A,1,,4026,CHEMBL627115,,BAO_0000218,
9605,50597,,,1,,N,,,,Intermediate,Half life period at a dose of 10 uM/kg in rat was determined,A,1,,4527,CHEMBL627116,,BAO_0000218,
9606,50597,,In vivo,1,,N,,,,Intermediate,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,1,,4527,CHEMBL627117,,BAO_0000218,
9607,50597,,,1,,N,,,,Intermediate,Half life period was determined,A,1,,5503,CHEMBL627118,,BAO_0000218,
9608,50597,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration at 20 mpk in rats,A,1,,4426,CHEMBL627119,,BAO_0000218,
9609,50597,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,1,,4426,CHEMBL627120,,BAO_0000218,
9610,50597,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration in rat,A,1,,6109,CHEMBL626922,,BAO_0000218,
9611,50597,,In vivo,1,,N,,,,Intermediate,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,1,,5654,CHEMBL626923,,BAO_0000218,
9612,50597,,In vivo,1,,N,,,,Intermediate,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,1,,5654,CHEMBL626924,,BAO_0000218,
9613,50597,,,1,,N,,Plasma,,Intermediate,Half life period in 80% rat plasma at 37 degree Centigrade,A,1,,4755,CHEMBL626925,,BAO_0000218,1969.0
9614,50597,,,1,,N,,,,Intermediate,Half life period in SD rats,A,1,,5862,CHEMBL626926,,BAO_0000218,
9615,50597,,,1,,N,,Plasma,,Intermediate,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,1,,1515,CHEMBL626927,,BAO_0000218,1969.0
9616,50597,,,1,,N,,Plasma,,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,1,,1515,CHEMBL626928,,BAO_0000218,1969.0
9617,50597,,,1,,N,,Plasma,,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,1,,1515,CHEMBL626929,,BAO_0000218,1969.0
9618,50597,,,1,,N,,Plasma,,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,1,,1515,CHEMBL626930,,BAO_0000218,1969.0
9619,50597,,,1,,N,,,,Intermediate,Half life period in rat,A,1,,5960,CHEMBL626931,,BAO_0000218,
9620,50597,,,1,,N,,,,Intermediate,Half life period in rat,A,1,,6103,CHEMBL626932,,BAO_0000218,
9621,50597,,,1,,N,,,,Intermediate,Half life period in rat,A,1,,6317,CHEMBL626933,,BAO_0000218,
9622,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after oral administration at 10.5 mg/kg dose,A,1,,6644,CHEMBL873826,,BAO_0000218,
9623,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after oral administration at 11.2 mg/kg dose,A,1,,6644,CHEMBL626934,,BAO_0000218,
9624,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after oral administration at 13 mg/kg dose,A,1,,6644,CHEMBL626935,,BAO_0000218,
9625,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat after oral administration at 9.7 mg/kg dose,A,1,,6644,CHEMBL626936,,BAO_0000218,
9626,50597,,,1,,N,,,,Intermediate,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL626937,,BAO_0000218,
9627,50597,,,1,,N,,,,Intermediate,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,1,,6295,CHEMBL625906,,BAO_0000218,
9628,50597,,,1,,N,,,,Intermediate,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,1,,6296,CHEMBL625907,,BAO_0000218,
9629,50597,,,1,,N,,,,Intermediate,PK study was carried to determine AUC (area under curve) value in rat,A,1,,16427,CHEMBL625908,,BAO_0000218,
9630,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC after intravenous administration to rats,A,1,,16367,CHEMBL625909,,BAO_0000218,
9631,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC after oral administration to rats,A,1,,16367,CHEMBL625910,,BAO_0000218,
9632,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,1,,16365,CHEMBL625911,,BAO_0000218,
9633,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,1,,16365,CHEMBL625912,,BAO_0000218,
9634,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,1,,16365,CHEMBL626538,,BAO_0000218,
9635,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,1,,16365,CHEMBL876794,,BAO_0000218,
9636,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,1,,16365,CHEMBL626539,,BAO_0000218,
9637,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,1,,16365,CHEMBL626540,,BAO_0000218,
9638,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,1,,5394,CHEMBL626541,,BAO_0000218,
9639,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,1,,5394,CHEMBL626542,,BAO_0000218,
9640,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,1,,2792,CHEMBL626543,,BAO_0000218,
9641,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL626544,,BAO_0000218,
9642,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,1,,2792,CHEMBL626545,,BAO_0000218,
9643,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL626546,,BAO_0000218,
9644,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under curve was reported,A,1,,5334,CHEMBL626547,,BAO_0000218,
9645,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property (AUC) in rat,A,1,,4408,CHEMBL626548,,BAO_0000218,
9646,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,1,,5983,CHEMBL626549,,BAO_0000218,
9647,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,1,,4397,CHEMBL626550,,BAO_0000218,
9648,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,1,,4397,CHEMBL626551,,BAO_0000218,
9649,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property was determined,A,1,,5491,CHEMBL623777,,BAO_0000218,
9650,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,1,,5491,CHEMBL623778,,BAO_0000218,
9651,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,1,,5491,CHEMBL623779,,BAO_0000218,
9652,50597,,,1,,N,,Plasma,,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,1,,4199,CHEMBL623780,,BAO_0000218,1969.0
9653,50597,,,1,,N,,Plasma,,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,1,,4199,CHEMBL622015,,BAO_0000218,1969.0
9654,50597,,,1,,N,,Plasma,,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,1,,4199,CHEMBL622016,,BAO_0000218,1969.0
9655,50597,,,1,,N,,,,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,1,,5173,CHEMBL622017,,BAO_0000218,
9656,50597,,,1,,N,,,,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,1,,5173,CHEMBL622018,,BAO_0000218,
9657,50597,,,1,,N,,,,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,1,,5173,CHEMBL622019,,BAO_0000218,
9658,50597,,,1,,N,,,,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,1,,5173,CHEMBL622020,,BAO_0000218,
9659,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,1,,16366,CHEMBL622021,,BAO_0000218,
9660,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,1,,16366,CHEMBL622022,,BAO_0000218,
9661,50597,,,1,,N,,,,Intermediate,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,1,,5327,CHEMBL622023,,BAO_0000218,
9662,50597,,,1,,N,,,,Intermediate,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,1,,6681,CHEMBL622024,,BAO_0000218,
9663,50597,,,1,,N,,,,Intermediate,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,1,,12873,CHEMBL622693,,BAO_0000218,
9664,50597,,,1,,N,,,,Intermediate,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,1,,12873,CHEMBL622694,,BAO_0000218,
9665,50597,,,1,,N,,,,Intermediate,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,1,,6685,CHEMBL622695,,BAO_0000218,
9666,50597,,,1,,N,,,,Intermediate,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,1,,6685,CHEMBL622696,,BAO_0000218,
9667,50597,,,1,,N,,,,Intermediate,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,1,,6685,CHEMBL622697,,BAO_0000218,
9668,50597,,,1,,N,,,,Intermediate,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,1,,6619,CHEMBL622874,,BAO_0000218,
9669,50597,,,1,,N,,,,Intermediate,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,1,,6619,CHEMBL622875,,BAO_0000218,
9670,50597,,,1,,N,,,,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,1,,10363,CHEMBL622876,,BAO_0000218,
9671,50597,,,1,,N,,,,Intermediate,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,1,,4796,CHEMBL622877,,BAO_0000218,
9672,50597,,,1,,N,,,,Intermediate,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,1,,4910,CHEMBL622878,,BAO_0000218,
9673,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,1,,4910,CHEMBL622879,,BAO_0000218,1969.0
9674,50597,,,1,,N,,,,Intermediate,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,1,,4839,CHEMBL877602,,BAO_0000218,
9675,50597,,,1,,N,,,,Intermediate,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622880,,BAO_0000218,
9676,50597,,,1,,N,,,,Intermediate,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622881,,BAO_0000218,
9677,50597,,,1,,N,,,,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622882,,BAO_0000218,
9678,50597,,,1,,N,,,,Intermediate,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL622883,,BAO_0000218,
9679,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,1,,11450,CHEMBL622884,,BAO_0000218,2046.0
9680,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,1,,11450,CHEMBL622885,,BAO_0000218,2046.0
9681,50597,,,1,,N,,,,Intermediate,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,1,,8151,CHEMBL622886,,BAO_0000218,
9682,50597,,,1,,N,,,,Intermediate,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,1,,8151,CHEMBL622887,,BAO_0000218,
9683,50597,,,1,,N,,Urine,,Intermediate,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,1,,8151,CHEMBL622888,,BAO_0000218,1088.0
9684,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622889,,BAO_0000218,178.0
9685,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622890,,BAO_0000218,178.0
9686,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622891,,BAO_0000218,178.0
9687,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL877603,,BAO_0000218,178.0
9688,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622892,,BAO_0000218,955.0
9689,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622893,,BAO_0000218,955.0
9690,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622894,,BAO_0000218,955.0
9691,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622895,,BAO_0000218,955.0
9692,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,1,,8677,CHEMBL622896,,BAO_0000218,955.0
9693,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622897,,BAO_0000218,948.0
9694,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622898,,BAO_0000218,948.0
9695,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622899,,BAO_0000218,948.0
9696,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622900,,BAO_0000218,2113.0
9697,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624114,,BAO_0000218,2113.0
9698,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624115,,BAO_0000218,2113.0
9699,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624116,,BAO_0000218,2113.0
9700,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624117,,BAO_0000218,2107.0
9701,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624118,,BAO_0000218,2107.0
9702,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624119,,BAO_0000218,2107.0
9703,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624120,,BAO_0000218,2107.0
9704,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624121,,BAO_0000218,2048.0
9705,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624122,,BAO_0000218,2048.0
9706,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624123,,BAO_0000218,2048.0
9707,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624124,,BAO_0000218,2048.0
9708,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624125,,BAO_0000218,2385.0
9709,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624126,,BAO_0000218,2385.0
9710,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624127,,BAO_0000218,2385.0
9711,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624128,,BAO_0000218,2385.0
9712,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL624129,,BAO_0000218,14.0
9713,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL624130,,BAO_0000218,14.0
9714,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622340,,BAO_0000218,14.0
9715,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622341,,BAO_0000218,14.0
9716,50597,,In vivo,1,,N,,Intestine,,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622342,,BAO_0000218,160.0
9717,50597,,In vivo,1,,N,,Intestine,,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622343,,BAO_0000218,160.0
9718,50597,,In vivo,1,,N,,Intestine,,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622344,,BAO_0000218,160.0
9719,50597,,In vivo,1,,N,,Intestine,,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622345,,BAO_0000218,160.0
9720,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622346,,BAO_0000218,2106.0
9721,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622347,,BAO_0000218,2106.0
9722,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622348,,BAO_0000218,2106.0
9723,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622349,,BAO_0000218,2106.0
9724,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,1,,16434,CHEMBL622350,,BAO_0000218,
9725,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,1,,16434,CHEMBL622351,,BAO_0000218,
9726,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,1,,16434,CHEMBL622352,,BAO_0000218,
9727,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,1,,16435,CHEMBL622353,,BAO_0000218,
9728,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,1,,16435,CHEMBL622354,,BAO_0000218,
9729,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,1,,16435,CHEMBL622355,,BAO_0000218,
9730,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,1,,16435,CHEMBL622356,,BAO_0000218,
9731,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,1,,16435,CHEMBL622357,,BAO_0000218,
9732,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,1,,16435,CHEMBL622358,,BAO_0000218,
9733,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,1,,16435,CHEMBL622359,,BAO_0000218,
9734,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,1,,16435,CHEMBL874393,,BAO_0000218,
9735,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL622872,,BAO_0000218,
9736,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL622873,,BAO_0000218,
9737,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL623047,,BAO_0000218,
9738,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,1,,16435,CHEMBL623048,,BAO_0000218,
9739,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL623049,,BAO_0000218,
9740,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL623050,,BAO_0000218,
9741,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,1,,16435,CHEMBL623051,,BAO_0000218,
9742,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL623052,,BAO_0000218,
9743,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL626343,,BAO_0000218,
9744,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,1,,16434,CHEMBL626344,,BAO_0000218,
9745,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,1,,16434,CHEMBL626345,,BAO_0000218,
9746,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,1,,16434,CHEMBL626346,,BAO_0000218,
9747,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,1,,16434,CHEMBL626347,,BAO_0000218,
9748,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,1,,16434,CHEMBL626348,,BAO_0000218,
9749,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,1,,16434,CHEMBL626349,,BAO_0000218,
9750,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,1,,16435,CHEMBL626350,,BAO_0000218,
9751,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,1,,16435,CHEMBL626351,,BAO_0000218,
9752,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,1,,16435,CHEMBL627650,,BAO_0000218,
9753,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,1,,16435,CHEMBL627651,,BAO_0000218,
9754,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,1,,16435,CHEMBL627652,,BAO_0000218,
9755,50597,,,1,,N,,,,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,1,,16435,CHEMBL627653,,BAO_0000218,
9756,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,1,,13091,CHEMBL627654,,BAO_0000218,
9757,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,1,,13091,CHEMBL627835,,BAO_0000218,
9758,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,1,,13091,CHEMBL627836,,BAO_0000218,
9759,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,1,,13091,CHEMBL627837,,BAO_0000218,
9760,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,1,,13091,CHEMBL627838,,BAO_0000218,
9761,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,1,,13091,CHEMBL875338,,BAO_0000218,
9762,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,1,,13091,CHEMBL627839,,BAO_0000218,
9763,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,1,,13091,CHEMBL627840,,BAO_0000218,
9764,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,1,,13091,CHEMBL627841,,BAO_0000218,
9765,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,1,,13091,CHEMBL627842,,BAO_0000218,
9766,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,1,,13091,CHEMBL627843,,BAO_0000218,
9767,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,1,,13091,CHEMBL627844,,BAO_0000218,
9768,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,1,,13091,CHEMBL627845,,BAO_0000218,
9769,50597,,In vivo,1,,N,,,,Intermediate,Half life period in rat by iv administration at a dose of 3 mg/kg,A,1,,5874,CHEMBL627846,,BAO_0000218,
9770,50597,,,1,,N,,Plasma,,Intermediate,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,1,,1515,CHEMBL627847,,BAO_0000218,1969.0
9771,50597,,,1,,N,,Plasma,,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,1,,1515,CHEMBL873821,,BAO_0000218,1969.0
9772,50597,,,1,,N,,Plasma,,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,1,,1515,CHEMBL626079,,BAO_0000218,1969.0
9773,50597,,,1,,N,,Plasma,,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,1,,1515,CHEMBL626080,,BAO_0000218,1969.0
9774,50597,,,1,,N,,Plasma,,Intermediate,Half life period was evaluated in rat plasma,A,1,,5491,CHEMBL626081,,BAO_0000218,1969.0
9775,50597,,,1,,N,,Plasma,,Intermediate,Half life period was evaluated in rat plasma; Not tested,A,1,,5491,CHEMBL875344,,BAO_0000218,1969.0
9776,50597,,,1,,N,,,,Intermediate,Half life period was evaluated in rats,A,1,,1918,CHEMBL626082,,BAO_0000218,
9777,50597,,In vivo,1,,N,,,,Intermediate,"Half life period was evaluated in rats, iv",A,1,,1918,CHEMBL626250,,BAO_0000218,
9778,50597,,In vivo,1,,N,,,,Intermediate,Half life period after intravenous administration at 5 mg/kg in rat,A,1,,6113,CHEMBL626251,,BAO_0000218,
9779,50597,,In vivo,1,,N,,,,Intermediate,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,1,,5546,CHEMBL626252,,BAO_0000218,
9780,50597,,In vivo,1,,N,,,,Intermediate,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,1,,5553,CHEMBL626253,,BAO_0000218,
9781,50597,,,1,,N,,Plasma,,Intermediate,Half life stability of compound was evaluated in rat plasma,A,1,,4188,CHEMBL626254,,BAO_0000218,1969.0
9782,50597,,In vivo,1,,N,,,,Intermediate,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,1,,6215,CHEMBL626255,,BAO_0000218,
9783,50597,,In vivo,1,,N,,,,Intermediate,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,1,,6141,CHEMBL626256,,BAO_0000218,
9784,50597,,In vivo,1,,N,,,,Intermediate,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,1,,5182,CHEMBL626257,,BAO_0000218,
9785,50597,,In vivo,1,,N,,,,Intermediate,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,1,,5182,CHEMBL626258,,BAO_0000218,
9786,50597,,In vivo,1,,N,,,,Intermediate,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,1,,5710,CHEMBL626259,,BAO_0000218,
9787,50597,,In vivo,1,,N,,,,Intermediate,Half in rat i.v.,A,1,,5789,CHEMBL626260,,BAO_0000218,
9788,50597,,In vivo,1,,N,,,,Intermediate,Half period in rat after intravenous administration,A,1,,6011,CHEMBL875345,,BAO_0000218,
9789,50597,,In vivo,1,,N,,,,Intermediate,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,1,,17594,CHEMBL626261,,BAO_0000218,
9790,50597,,In vitro,1,,N,,Liver,,Intermediate,Half-life measured in in vitro Cathepsin B assay in rat liver,A,1,,12357,CHEMBL626262,,BAO_0000218,2107.0
9791,50597,,,1,,N,,,,Intermediate,Half-life of compound was determined in rats,A,1,,5210,CHEMBL626263,,BAO_0000218,
9792,50597,,In vivo,1,,N,,,,Intermediate,Half-life at 10 mg/kg in rat upon intravenous administration,A,1,,17596,CHEMBL625270,,BAO_0000218,
9793,50597,,,1,,N,,,,Intermediate,Half-life determined in rat,A,1,,6672,CHEMBL625271,,BAO_0000218,
9794,50597,,,1,,N,,,,Intermediate,Half-life determined in rat,A,1,,6673,CHEMBL625272,,BAO_0000218,
9795,50597,,In vivo,1,,N,,Brain,,Intermediate,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,1,,4910,CHEMBL625273,,BAO_0000218,955.0
9796,50597,,,1,,N,,Plasma,,Intermediate,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,1,,3741,CHEMBL625274,,BAO_0000218,1969.0
9797,50597,,In vivo,1,,N,,,,Intermediate,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,1,,17671,CHEMBL625275,,BAO_0000218,
9798,50597,,In vivo,1,,N,,Plasma,,Intermediate,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,1,,4910,CHEMBL625276,,BAO_0000218,1969.0
9799,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma,A,1,,17537,CHEMBL625277,,BAO_0000218,1969.0
9800,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma was determined,A,1,,4965,CHEMBL625278,,BAO_0000218,1969.0
9801,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma; Not tested,A,1,,17537,CHEMBL625279,,BAO_0000218,1969.0
9802,50597,,,1,,N,,Serum,,Intermediate,Half-life in rat serum,A,1,,6124,CHEMBL625280,,BAO_0000218,1977.0
9803,50597,,,1,,N,,Serum,,Intermediate,Half-life in rat serum; na is not available,A,1,,6124,CHEMBL876797,,BAO_0000218,1977.0
9804,50597,,,1,,N,,,,Intermediate,Half-life was calculated in rat,A,1,,6078,CHEMBL625281,,BAO_0000218,
9805,50597,,,1,,N,,Plasma,,Intermediate,Half-life was calculated in rat plasma,A,1,,17668,CHEMBL873827,,BAO_0000218,1969.0
9806,50597,,,1,,N,,,,Intermediate,Half-life was determined,A,1,,3185,CHEMBL625282,,BAO_0000218,
9807,50597,,,1,,N,,,,Intermediate,Half-life was determined,A,1,,4883,CHEMBL625283,,BAO_0000218,
9808,50597,,In vivo,1,,N,,,,Intermediate,Half-life after administration of 20 mg/Kg oral dose in rat,A,1,,2959,CHEMBL625284,,BAO_0000218,
9809,50597,,In vivo,1,,N,,,,Intermediate,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,1,,4029,CHEMBL625285,,BAO_0000218,
9810,50597,,In vivo,1,,N,,,,Intermediate,Half-life after intravenous administration in female rat,A,1,,4029,CHEMBL625286,,BAO_0000218,
9811,50597,,In vivo,1,,N,,,,Intermediate,Half-life after intravenous administration in male rat,A,1,,4029,CHEMBL625287,,BAO_0000218,
9812,50597,,In vivo,1,,N,,,,Intermediate,Half-life after intravenous dose in rat,A,1,,6180,CHEMBL625288,,BAO_0000218,
9813,50597,,,1,,N,,Liver,,Intermediate,Half-life in a rat liver homogenate preparation,A,1,,1557,CHEMBL625289,,BAO_0000218,2107.0
9814,50597,,,1,,N,,Plasma,,Intermediate,Half-life in plasma of rat,A,1,,12500,CHEMBL625290,,BAO_0000218,1969.0
9815,50597,,,1,,N,,Plasma,,Intermediate,Half-life in plasma of rat at dose of 3-10 mgkg,A,1,,12500,CHEMBL876798,,BAO_0000218,1969.0
9816,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,5064,CHEMBL625291,,BAO_0000218,
9817,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,5145,CHEMBL625292,,BAO_0000218,
9818,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,5147,CHEMBL625293,,BAO_0000218,
9819,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,5833,CHEMBL622832,,BAO_0000218,
9820,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,6596,CHEMBL622833,,BAO_0000218,
9821,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,17655,CHEMBL622834,,BAO_0000218,
9822,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat after oral administration at 10 mg/kg,A,1,,6495,CHEMBL622835,,BAO_0000218,
9823,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat after po administration at a dose of 10 mg/kg,A,1,,17538,CHEMBL622836,,BAO_0000218,
9824,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,1,,17538,CHEMBL622837,,BAO_0000218,
9825,50597,,In vivo,1,,N,,,,Intermediate,Half-life in rat at 3 mg/kg dose administered intravenously,A,1,,10,CHEMBL622838,,BAO_0000218,
9826,50597,,,1,,N,,Brain,,Intermediate,Half-life in rat brain homogenate,A,1,,17669,CHEMBL622839,,BAO_0000218,955.0
9827,50597,,,1,,N,,Plasma,,Intermediate,Half-life in rat plasma,A,1,,17065,CHEMBL622840,,BAO_0000218,1969.0
9828,50597,,,1,,N,,,,Intermediate,Half-life in rats,A,1,,4333,CHEMBL622841,,BAO_0000218,
9829,50597,,,1,,N,,,,Intermediate,Half-life in Dawley rats,A,1,,6827,CHEMBL622842,,BAO_0000218,
9830,50597,,In vitro,1,,N,,Plasma,,Intermediate,Half-life in vitro in rat plasma,A,1,,889,CHEMBL622843,,BAO_0000218,1969.0
9831,50597,,In vitro,1,,N,,Plasma,,Intermediate,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,1,,889,CHEMBL622844,,BAO_0000218,1969.0
9832,50597,,,1,,N,,,,Intermediate,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,1,,3747,CHEMBL622845,,BAO_0000218,
9833,50597,,,1,,N,,,,Intermediate,The area under the curve of compound was measured at the dose of 100 umol/kg,A,1,,15022,CHEMBL622846,,BAO_0000218,
9834,50597,,,1,,N,,,,Intermediate,The area under the curve of compound was measured at the dose of 300 umol/kg,A,1,,15022,CHEMBL622847,,BAO_0000218,
9835,50597,,,1,,N,,,,Intermediate,The area under the curve of compound was measured at the dose of 30 umol/kg,A,1,,15022,CHEMBL622848,,BAO_0000218,
9836,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability as oral AUC in rats,A,1,,3360,CHEMBL622849,,BAO_0000218,
9837,50597,,,1,,N,,Plasma,,Intermediate,The plasma concentration versus time curve (AUC) was determined,A,1,,5334,CHEMBL622850,,BAO_0000218,1969.0
9838,50597,,,1,,N,,,,Intermediate,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL876807,,BAO_0000218,
9839,50597,,,1,,N,,,,Intermediate,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL622851,,BAO_0000218,
9840,50597,,,1,,N,,,,Intermediate,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL622852,,BAO_0000218,
9841,50597,,,1,,N,,,,Intermediate,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,1,,6570,CHEMBL622853,,BAO_0000218,
9842,50597,,,1,,N,,,,Intermediate,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,1,,6570,CHEMBL622854,,BAO_0000218,
9843,50597,,,1,,N,,,,Intermediate,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,1,,17411,CHEMBL622855,,BAO_0000218,
9844,50597,,,1,,N,,Plasma,,Intermediate,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL622856,,BAO_0000218,1969.0
9845,50597,,,1,,N,,Plasma,,Intermediate,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL622857,,BAO_0000218,1969.0
9846,50597,,,1,,N,,Plasma,,Intermediate,AUC in rat after po administration at a dose of 10 mg/kg,A,1,,17538,CHEMBL622858,,BAO_0000218,1969.0
9847,50597,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,1,,17752,CHEMBL622859,,BAO_0000218,1969.0
9848,50597,,,1,,N,,,,Intermediate,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,1,,17509,CHEMBL622860,,BAO_0000218,
9849,50597,,,1,,N,,,,Intermediate,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,1,,17509,CHEMBL622861,,BAO_0000218,
9850,50597,,,1,,N,,,,Intermediate,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,1,,17509,CHEMBL622862,,BAO_0000218,
9851,50597,,,1,,N,,,,Intermediate,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,1,,17509,CHEMBL622863,,BAO_0000218,
9852,50597,,,1,,N,,,,Intermediate,Area under curve value 6 hr after po administration in rat,A,1,,17509,CHEMBL623817,,BAO_0000218,
9853,50597,,,1,,N,,,,Intermediate,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL623818,,BAO_0000218,
9854,50597,,,1,,N,,,,Intermediate,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,1,,17717,CHEMBL623819,,BAO_0000218,
9855,50597,,,1,,N,,,,Intermediate,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL623820,,BAO_0000218,
9856,50597,,,1,,N,,,,Intermediate,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,1,,17717,CHEMBL623821,,BAO_0000218,
9857,50597,,,1,,N,,Plasma,,Intermediate,AUC normalized for dose (AUCN) in rat,A,1,,6642,CHEMBL623822,,BAO_0000218,1969.0
9858,50597,,,1,,N,,,,Intermediate,Area under curve in rat after p.o. administration,A,1,,6640,CHEMBL623823,,BAO_0000218,
9859,50597,,,1,,N,,,,Intermediate,Area under curve in rat after p.o. administration,A,1,,6641,CHEMBL623824,,BAO_0000218,
9860,50597,,,1,,N,,,,Intermediate,Area under curve in rat after p.o. administration; Not determined,A,1,,6641,CHEMBL623825,,BAO_0000218,
9861,50597,,,1,,N,,,,Intermediate,Area under curve in rat after peroral administration,A,1,,6641,CHEMBL622070,,BAO_0000218,
9862,50597,,,1,,N,,,,Intermediate,Area under curve (carotid artery) value of the compound,A,1,,3603,CHEMBL622071,,BAO_0000218,
9863,50597,,,1,,N,,,,Intermediate,Bioavailability expressed as the area under curve of rat carotid artery,A,1,,3550,CHEMBL622072,,BAO_0000218,
9864,50597,,,1,,N,,,,Intermediate,Area under curve in male SD rats was observed after intravenous administration in rat,A,1,,15662,CHEMBL622073,,BAO_0000218,
9865,50597,,,1,,N,,,,Intermediate,Area under curve of the compound was determined,A,1,,17720,CHEMBL622074,,BAO_0000218,
9866,50597,,,1,,N,,,,Intermediate,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,1,,5407,CHEMBL622075,,BAO_0000218,
9867,50597,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,1,,17752,CHEMBL622076,,BAO_0000218,1969.0
9868,50597,,,1,,N,,Plasma,,Intermediate,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,1,,17752,CHEMBL622077,,BAO_0000218,1969.0
9869,50597,,,1,,N,,,,Intermediate,Area under curve (portal vein) value of the compound,A,1,,3603,CHEMBL622078,,BAO_0000218,
9870,50597,,,1,,N,,,,Intermediate,Bioavailability expressed as the area under curve of rat portal vein,A,1,,3550,CHEMBL622079,,BAO_0000218,
9871,50597,,,1,,N,,Plasma,,Intermediate,Area Under plasma concentration time curve in rat upon peroral administration,A,1,,17655,CHEMBL622080,,BAO_0000218,1969.0
9872,50597,,,1,,N,,,,Intermediate,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,1,,17582,CHEMBL877612,,BAO_0000218,
9873,50597,,,1,,N,,,,Intermediate,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,1,,17582,CHEMBL622081,,BAO_0000218,
9874,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats,A,1,,17791,CHEMBL622082,,BAO_0000218,
9875,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats after iv administration,A,1,,17791,CHEMBL622083,,BAO_0000218,
9876,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats; 30-80,A,1,,17791,CHEMBL622084,,BAO_0000218,
9877,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats; 50-60,A,1,,17791,CHEMBL622085,,BAO_0000218,
9878,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats; no data,A,1,,17791,CHEMBL622086,,BAO_0000218,
9879,50597,,,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats; peptide,A,1,,17791,CHEMBL622087,,BAO_0000218,
9880,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,1,,7768,CHEMBL622088,,BAO_0000218,178.0
9881,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,1,,7768,CHEMBL622089,,BAO_0000218,178.0
9882,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,1,,7768,CHEMBL623685,,BAO_0000218,178.0
9883,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,1,,7768,CHEMBL623686,,BAO_0000218,178.0
9884,50597,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL623687,,BAO_0000218,945.0
9885,50597,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL623688,,BAO_0000218,945.0
9886,50597,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL623689,,BAO_0000218,945.0
9887,50597,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622485,,BAO_0000218,945.0
9888,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622486,,BAO_0000218,2046.0
9889,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL877613,,BAO_0000218,2046.0
9890,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622487,,BAO_0000218,2046.0
9891,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622488,,BAO_0000218,2046.0
9892,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,1,,8677,CHEMBL622489,,BAO_0000218,948.0
9893,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,1,,6899,CHEMBL622490,,BAO_0000218,1088.0
9894,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,1,,6899,CHEMBL622491,,BAO_0000218,1088.0
9895,50597,,,1,,N,,Liver,,Intermediate,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,1,,6899,CHEMBL622492,,BAO_0000218,2107.0
9896,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,1,,6899,CHEMBL622493,,BAO_0000218,1088.0
9897,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,1,,6899,CHEMBL622494,,BAO_0000218,1088.0
9898,50597,,,1,,N,,Muscle tissue,,Intermediate,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,1,,8677,CHEMBL622495,,BAO_0000218,2385.0
9899,50597,,,1,,N,,,,Intermediate,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,1,,6899,CHEMBL622496,,BAO_0000218,
9900,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,1,,6899,CHEMBL622497,,BAO_0000218,1088.0
9901,50597,,,1,,N,,,,Intermediate,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,1,,2189,CHEMBL622498,,BAO_0000218,
9902,50597,,,1,,N,,Urine,,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,1,,2189,CHEMBL624918,,BAO_0000218,1088.0
9903,50597,,,1,,N,,Urine,,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,1,,2189,CHEMBL624919,,BAO_0000218,1088.0
9904,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of compound in rat blood after 5 min of administration,A,1,,10839,CHEMBL624920,,BAO_0000218,178.0
9905,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of compound in rat blood after 5 min of administration.,A,1,,10839,CHEMBL624921,,BAO_0000218,178.0
9906,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of compound in rat brain after 5 min of administration,A,1,,10839,CHEMBL624922,,BAO_0000218,955.0
9907,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of compound in rat heart after 5 min of administration,A,1,,10839,CHEMBL624923,,BAO_0000218,948.0
9908,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of compound in rat heart after 5 min of administration.,A,1,,10839,CHEMBL624924,,BAO_0000218,948.0
9909,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of compound in rat kidney after 5 min of administration,A,1,,10839,CHEMBL624925,,BAO_0000218,2113.0
9910,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of compound in rat kidney after 5 min of administration.,A,1,,10839,CHEMBL624926,,BAO_0000218,2113.0
9911,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of compound in rat liver after 5 min of administration,A,1,,10839,CHEMBL624927,,BAO_0000218,2107.0
9912,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of compound in rat liver after 5 min of administration.,A,1,,10839,CHEMBL874402,,BAO_0000218,2107.0
9913,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of compound in rat lung after 5 min of administration,A,1,,10839,CHEMBL624928,,BAO_0000218,2048.0
9914,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of compound in rat lung after 5 min of administration.,A,1,,10839,CHEMBL624929,,BAO_0000218,2048.0
9915,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of compound in rat muscle after 5 min of administration,A,1,,10839,CHEMBL624930,,BAO_0000218,2385.0
9916,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of compound in rat muscle after 5 min of administration.,A,1,,10839,CHEMBL624931,,BAO_0000218,2385.0
9917,50597,,,1,,N,,Heart,,Intermediate,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624932,,BAO_0000218,948.0
9918,50597,,,1,,N,,Heart,,Intermediate,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624933,,BAO_0000218,948.0
9919,50597,,,1,,N,,Liver,,Intermediate,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624934,,BAO_0000218,2107.0
9920,50597,,,1,,N,,Liver,,Intermediate,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624935,,BAO_0000218,2107.0
9921,50597,,,1,,N,,,,Intermediate,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624936,,BAO_0000218,
9922,50597,,,1,,N,,,,Intermediate,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624937,,BAO_0000218,
9923,50597,,,1,,N,,Spleen,,Intermediate,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624938,,BAO_0000218,2106.0
9924,50597,,,1,,N,,Spleen,,Intermediate,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624939,,BAO_0000218,2106.0
9925,50597,,,1,,N,,,,Intermediate,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL624940,,BAO_0000218,
9926,50597,,,1,,N,,,,Intermediate,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,1,,4043,CHEMBL874403,,BAO_0000218,
9927,50597,,,1,,N,,,,Intermediate,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,1,,1446,CHEMBL624941,,BAO_0000218,
9928,50597,,,1,,N,,Urine,,Intermediate,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,1,,9971,CHEMBL624942,,BAO_0000218,1088.0
9929,50597,,,1,,N,,Urine,,Intermediate,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,1,,9971,CHEMBL624943,,BAO_0000218,1088.0
9930,50597,,In vivo,1,,N,,,,Intermediate,% Bioavailability after 1 day of the drug administration in rats,A,1,,5765,CHEMBL624944,,BAO_0000218,
9931,50597,,In vivo,1,,N,,,,Intermediate,% Bioavailability after 4 day of the drug administration in rats,A,1,,5765,CHEMBL624945,,BAO_0000218,
9932,50597,,In vivo,1,,N,,,,Intermediate,Absolute bioavailability was evaluated in rat,A,1,,4257,CHEMBL624946,,BAO_0000218,
9933,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,1,,13091,CHEMBL624947,,BAO_0000218,
9934,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,1,,13091,CHEMBL624948,,BAO_0000218,
9935,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,1,,13091,CHEMBL624949,,BAO_0000218,
9936,50597,,,1,,N,,Kidney,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,1,,13091,CHEMBL622025,,BAO_0000218,2113.0
9937,50597,,,1,,N,,Kidney,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,1,,13091,CHEMBL622026,,BAO_0000218,2113.0
9938,50597,,,1,,N,,Kidney,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,1,,13091,CHEMBL622027,,BAO_0000218,2113.0
9939,50597,,,1,,N,,Kidney,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,1,,13091,CHEMBL622028,,BAO_0000218,2113.0
9940,50597,,,1,,N,,Liver,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,1,,13091,CHEMBL622029,,BAO_0000218,2107.0
9941,50597,,,1,,N,,Liver,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,1,,13091,CHEMBL622208,,BAO_0000218,2107.0
9942,50597,,,1,,N,,Liver,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,1,,13091,CHEMBL622209,,BAO_0000218,2107.0
9943,50597,,,1,,N,,Liver,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,1,,13091,CHEMBL622210,,BAO_0000218,2107.0
9944,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,1,,13091,CHEMBL622211,,BAO_0000218,
9945,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,1,,13091,CHEMBL622212,,BAO_0000218,
9946,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,1,,13091,CHEMBL622213,,BAO_0000218,
9947,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,1,,13091,CHEMBL874404,,BAO_0000218,
9948,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,1,,13091,CHEMBL620452,,BAO_0000218,2385.0
9949,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,1,,13091,CHEMBL620453,,BAO_0000218,2385.0
9950,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,1,,13091,CHEMBL620454,,BAO_0000218,2385.0
9951,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,1,,13091,CHEMBL624067,,BAO_0000218,2385.0
9952,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,1,,13091,CHEMBL624068,,BAO_0000218,
9953,50597,,,1,,N,,Female gonad,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,1,,13091,CHEMBL624069,,BAO_0000218,992.0
9954,50597,,,1,,N,,Female gonad,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,1,,13091,CHEMBL624070,,BAO_0000218,992.0
9955,50597,,,1,,N,,Female gonad,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,1,,13091,CHEMBL624071,,BAO_0000218,992.0
9956,50597,,,1,,N,,Uterus,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,1,,13091,CHEMBL624072,,BAO_0000218,995.0
9957,50597,,,1,,N,,Uterus,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,1,,13091,CHEMBL624073,,BAO_0000218,995.0
9958,50597,,,1,,N,,Uterus,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,1,,13091,CHEMBL624788,,BAO_0000218,995.0
9959,50597,,,1,,N,,Uterus,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,1,,13091,CHEMBL624789,,BAO_0000218,995.0
9960,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,1,,13091,CHEMBL624790,,BAO_0000218,
9961,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,1,,13091,CHEMBL624791,,BAO_0000218,
9962,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,1,,13091,CHEMBL624792,,BAO_0000218,
9963,50597,,,1,,N,,,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,1,,13091,CHEMBL624793,,BAO_0000218,
9964,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,1,,13091,CHEMBL877491,,BAO_0000218,2385.0
9965,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,1,,13091,CHEMBL624957,,BAO_0000218,2385.0
9966,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,1,,13091,CHEMBL624958,,BAO_0000218,2385.0
9967,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,1,,13091,CHEMBL624959,,BAO_0000218,2385.0
9968,50597,,,1,,N,,,,Intermediate,Dissociation constant was determined,A,1,,11977,CHEMBL624960,,BAO_0000218,
9969,50597,,,1,,N,,,,Intermediate,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,1,,14941,CHEMBL624961,,BAO_0000218,
9970,50597,,,1,,N,,,,Intermediate,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL624962,,BAO_0000218,
9971,50597,,,1,,N,,,,Intermediate,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL624963,,BAO_0000218,
9972,50597,,,1,,N,,,,Intermediate,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,1,,4755,CHEMBL624964,,BAO_0000218,
9973,50597,,,1,,N,,,,Intermediate,LogP value was evaluated in the in situ rat gut perfusion assay,A,1,,589,CHEMBL624965,,BAO_0000218,
9974,50597,,In vivo,1,,N,,,,Intermediate,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,1,,17582,CHEMBL624966,,BAO_0000218,
9975,50597,,In vivo,1,,N,,,,Intermediate,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,1,,5031,CHEMBL624967,,BAO_0000218,
9976,50597,,In vivo,1,,N,,,,Intermediate,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL624968,,BAO_0000218,
9977,50597,,,1,,N,,,,Intermediate,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL624969,,BAO_0000218,
9978,50597,,,1,,N,,,,Expert,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,1,,2862,CHEMBL624970,,BAO_0000218,
9979,50597,,,1,,N,,,,Intermediate,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,1,,16423,CHEMBL624971,,BAO_0000218,
9980,50597,,In vivo,1,,N,,,,Intermediate,Half-life was evaluated after 20 uM/kg of peroral administration,A,1,,16423,CHEMBL624972,,BAO_0000218,
9981,50597,,In vivo,1,,N,,,,Intermediate,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,1,,6005,CHEMBL624973,,BAO_0000218,
9982,50597,,,1,,N,,Plasma,,Intermediate,Half-life was evaluated in plasma of rat,A,1,,2938,CHEMBL624974,,BAO_0000218,1969.0
9983,50597,,In vivo,1,,N,,,,Intermediate,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,1,,6410,CHEMBL624975,,BAO_0000218,
9984,50597,,In vivo,1,,N,,,,Intermediate,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL877492,,BAO_0000218,
9985,50597,,In vivo,1,,N,,,,Intermediate,Half-life was measured in rat after an iv dose of 1 mg/kg,A,1,,6062,CHEMBL624976,,BAO_0000218,
9986,50597,,In vivo,1,,N,,,,Intermediate,Half-life period of compound in rats after peroral administration,A,1,,6571,CHEMBL624977,,BAO_0000218,
9987,50597,,,1,,N,,Plasma,,Intermediate,Half-life period of compound was measured in rat plasma.,A,1,,3136,CHEMBL626848,,BAO_0000218,1969.0
9988,50597,,,1,,N,,Plasma,,Intermediate,Half-life period of compound was measured in rat plasma; ND is not determined,A,1,,3136,CHEMBL626849,,BAO_0000218,1969.0
9989,50597,,,1,,N,,Plasma,,Intermediate,Half-life period of compound was measured in rat plasma; not determined,A,1,,3136,CHEMBL626850,,BAO_0000218,1969.0
9990,50597,,In vivo,1,,N,,,,Intermediate,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,1,,4521,CHEMBL626851,,BAO_0000218,
9991,50597,,In vivo,1,,N,,,,Intermediate,Half-life period in rat by iv administration,A,1,,5871,CHEMBL626852,,BAO_0000218,
9992,50597,,In vivo,1,,N,,,,Intermediate,Half-life period in rats following intravenous administration at 2 mg/kg,A,1,,6077,CHEMBL626853,,BAO_0000218,
9993,50597,,In vivo,1,,N,,,,Intermediate,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL626854,,BAO_0000218,
9994,50597,,,1,,N,,,,Intermediate,Half-life period was determined for the compound in rat,A,1,,5144,CHEMBL627486,,BAO_0000218,
9995,50597,,In vivo,1,,N,,,,Intermediate,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,1,,4498,CHEMBL627487,,BAO_0000218,
9996,50597,,In vivo,1,,N,,,,Intermediate,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,1,,4498,CHEMBL627488,,BAO_0000218,
9997,50597,,In vivo,1,,N,,,,Intermediate,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,1,,1908,CHEMBL627489,,BAO_0000218,
9998,50597,,In vivo,1,,N,,,,Intermediate,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,1,,6211,CHEMBL627490,,BAO_0000218,
9999,50597,,In vivo,1,,N,,,,Intermediate,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,1,,5529,CHEMBL873829,,BAO_0000218,
10000,50597,,In vivo,1,,N,,,,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.,A,1,,6444,CHEMBL627655,,BAO_0000218,
10001,50597,,In vivo,1,,N,,,,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,1,,6444,CHEMBL625994,,BAO_0000218,
10002,50597,,In vivo,1,,N,,,,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,1,,6444,CHEMBL625995,,BAO_0000218,
10003,50597,,,1,,N,,,,Intermediate,Half-life in rat,A,1,,5207,CHEMBL625996,,BAO_0000218,
10004,50597,,In vitro,1,,N,,Plasma,,Intermediate,In vitro half life in rat plasma,A,1,,530,CHEMBL625850,,BAO_0000218,1969.0
10005,50597,,In vitro,1,,N,,Plasma,,Intermediate,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,1,,1116,CHEMBL625851,,BAO_0000218,1969.0
10006,50597,,In vitro,1,,N,,,,Intermediate,In vitro half life in rat,A,1,,3219,CHEMBL625852,,BAO_0000218,
10007,50597,,In vivo,1,,N,,,,Intermediate,In vivo half life period after intravenous administration in rat,A,1,,6109,CHEMBL625853,,BAO_0000218,
10008,50597,,In vivo,1,,N,,,,Intermediate,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,1,,17582,CHEMBL625854,,BAO_0000218,
10009,50597,,In vivo,1,,N,,,,Intermediate,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,1,,17582,CHEMBL874450,,BAO_0000218,
10010,50597,,In vivo,1,,N,,,,Intermediate,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625855,,BAO_0000218,
10011,50597,,In vivo,1,,N,,,,Intermediate,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625856,,BAO_0000218,
10012,50597,,In vivo,1,,N,,,,Intermediate,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL625857,,BAO_0000218,
10013,50597,,In vivo,1,,N,,,,Intermediate,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL873831,,BAO_0000218,
10014,50597,,In vivo,1,,N,,,,Intermediate,Longer half-life in rat (i.v.) at 0.5 mpk,A,1,,17853,CHEMBL625858,,BAO_0000218,
10015,50597,,In vivo,1,,N,,,,Intermediate,Longer half-life in rat (p.o.) at 2.0 mpk,A,1,,17853,CHEMBL625859,,BAO_0000218,
10016,50597,,,1,,N,,,,Intermediate,Pharmacokinetic property (half life) in rat,A,1,,3457,CHEMBL625860,,BAO_0000218,
10017,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,1,,2792,CHEMBL625861,,BAO_0000218,
10018,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL625862,,BAO_0000218,
10019,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,1,,2792,CHEMBL625863,,BAO_0000218,
10020,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,1,,2792,CHEMBL625864,,BAO_0000218,
10021,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,1,,5739,CHEMBL625865,,BAO_0000218,
10022,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic half time was determined intravenously in rats.,A,1,,15765,CHEMBL625866,,BAO_0000218,
10023,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,1,,6567,CHEMBL625867,,BAO_0000218,1969.0
10024,50597,,,1,,N,,Plasma,,Intermediate,Plasma half life of hydrolysis of the compound,A,1,,2448,CHEMBL625868,,BAO_0000218,1969.0
10025,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,1,,5423,CHEMBL625869,,BAO_0000218,1969.0
10026,50597,,,1,,N,,Plasma,,Intermediate,Plasma half life period was calculated in rat,A,1,,4853,CHEMBL874451,,BAO_0000218,1969.0
10027,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life in Sprague-Dawley rats,A,1,,4514,CHEMBL625870,,BAO_0000218,1969.0
10028,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life in Sprague-Dawley rats; Not determined,A,1,,4514,CHEMBL625871,,BAO_0000218,1969.0
10029,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life in rats,A,1,,1500,CHEMBL625872,,BAO_0000218,1969.0
10030,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life in rats; <MQL,A,1,,1500,CHEMBL625873,,BAO_0000218,1969.0
10031,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was determined,A,1,,5334,CHEMBL625874,,BAO_0000218,1969.0
10032,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,1,,5334,CHEMBL625875,,BAO_0000218,1969.0
10033,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL625876,,BAO_0000218,1969.0
10034,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,1,,5334,CHEMBL631258,,BAO_0000218,1969.0
10035,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,1,,4956,CHEMBL631259,,BAO_0000218,1969.0
10036,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,1,,4956,CHEMBL631260,,BAO_0000218,1969.0
10037,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,1,,7768,CHEMBL631261,,BAO_0000218,178.0
10038,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,1,,7768,CHEMBL631262,,BAO_0000218,178.0
10039,50597,,,1,,N,,Blood,,Intermediate,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,1,,7768,CHEMBL631263,,BAO_0000218,178.0
10040,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,1,,7768,CHEMBL631264,,BAO_0000218,
10041,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,1,,7768,CHEMBL631265,,BAO_0000218,
10042,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,1,,7768,CHEMBL631266,,BAO_0000218,
10043,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,1,,7768,CHEMBL631267,,BAO_0000218,
10044,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,1,,7768,CHEMBL631268,,BAO_0000218,
10045,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,1,,7768,CHEMBL631269,,BAO_0000218,
10046,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,1,,7768,CHEMBL631270,,BAO_0000218,
10047,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,1,,7768,CHEMBL631271,,BAO_0000218,948.0
10048,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,1,,7768,CHEMBL631272,,BAO_0000218,948.0
10049,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,1,,7768,CHEMBL631273,,BAO_0000218,948.0
10050,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,1,,7768,CHEMBL631274,,BAO_0000218,948.0
10051,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,1,,7768,CHEMBL631275,,BAO_0000218,948.0
10052,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,1,,7768,CHEMBL626984,,BAO_0000218,948.0
10053,50597,,,1,,N,,Heart,,Intermediate,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,1,,7768,CHEMBL626985,,BAO_0000218,948.0
10054,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,1,,7768,CHEMBL626986,,BAO_0000218,2107.0
10055,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,1,,7768,CHEMBL626987,,BAO_0000218,2107.0
10056,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,1,,7768,CHEMBL626988,,BAO_0000218,2107.0
10057,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,1,,7768,CHEMBL626989,,BAO_0000218,2107.0
10058,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,1,,7768,CHEMBL626990,,BAO_0000218,2107.0
10059,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,1,,7768,CHEMBL626991,,BAO_0000218,2107.0
10060,50597,,,1,,N,,Liver,,Intermediate,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,1,,7768,CHEMBL626992,,BAO_0000218,2107.0
10061,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,1,,7768,CHEMBL626993,,BAO_0000218,2048.0
10062,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,1,,7768,CHEMBL874593,,BAO_0000218,2048.0
10063,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,1,,7768,CHEMBL626994,,BAO_0000218,2048.0
10064,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,1,,7768,CHEMBL626995,,BAO_0000218,2048.0
10065,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,1,,7768,CHEMBL626190,,BAO_0000218,2048.0
10066,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,1,,7768,CHEMBL626191,,BAO_0000218,2048.0
10067,50597,,,1,,N,,Lung,,Intermediate,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,1,,7768,CHEMBL626364,,BAO_0000218,2048.0
10068,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,1,,7768,CHEMBL626365,,BAO_0000218,2046.0
10069,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,1,,7768,CHEMBL626366,,BAO_0000218,2046.0
10070,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,1,,7768,CHEMBL626367,,BAO_0000218,2046.0
10071,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,1,,7768,CHEMBL626368,,BAO_0000218,2046.0
10072,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,1,,7768,CHEMBL626369,,BAO_0000218,2046.0
10073,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,1,,7768,CHEMBL626370,,BAO_0000218,2046.0
10074,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,1,,4498,CHEMBL626371,,BAO_0000218,
10075,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,1,,4498,CHEMBL626372,,BAO_0000218,
10076,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after a dose of 10 mg/kg p.o.,A,1,,3603,CHEMBL626373,,BAO_0000218,
10077,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,1,,6215,CHEMBL626374,,BAO_0000218,
10078,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,1,,5710,CHEMBL626375,,BAO_0000218,
10079,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,1,,5710,CHEMBL626376,,BAO_0000218,
10080,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat po was determined,A,1,,5676,CHEMBL626377,,BAO_0000218,
10081,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,1,,17667,CHEMBL626378,,BAO_0000218,
10082,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,1,,17667,CHEMBL626379,,BAO_0000218,
10083,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,1,,6848,CHEMBL626380,,BAO_0000218,
10084,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,1,,6848,CHEMBL626381,,BAO_0000218,
10085,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,17267,CHEMBL626382,,BAO_0000218,
10086,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley) (female),A,1,,6362,CHEMBL626383,,BAO_0000218,
10087,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,1,,17671,CHEMBL874652,,BAO_0000218,
10088,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,1,,17671,CHEMBL626384,,BAO_0000218,
10089,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,1,,4333,CHEMBL626385,,BAO_0000218,
10090,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at an oral dose of 2 mg/kg,A,1,,6077,CHEMBL626386,,BAO_0000218,
10091,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,3278,CHEMBL626387,,BAO_0000218,
10092,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5964,CHEMBL626388,,BAO_0000218,
10093,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,4884,CHEMBL626389,,BAO_0000218,
10094,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,4905,CHEMBL626390,,BAO_0000218,
10095,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,1,,4884,CHEMBL626391,,BAO_0000218,
10096,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6850,CHEMBL626392,,BAO_0000218,
10097,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,2864,CHEMBL626393,,BAO_0000218,
10098,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined in rat,A,1,,5780,CHEMBL623026,,BAO_0000218,
10099,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability,A,1,,1465,CHEMBL623027,,BAO_0000218,
10100,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability,A,1,,5199,CHEMBL623028,,BAO_0000218,
10101,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after 1 day dosing,A,1,,5765,CHEMBL623029,,BAO_0000218,
10102,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after 4 day dosing,A,1,,5765,CHEMBL623030,,BAO_0000218,
10103,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,1,,6518,CHEMBL623031,,BAO_0000218,
10104,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,1,,6518,CHEMBL623032,,BAO_0000218,
10105,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,1,,6518,CHEMBL623033,,BAO_0000218,
10106,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,1,,6518,CHEMBL623034,,BAO_0000218,
10107,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,1,,2083,CHEMBL623035,,BAO_0000218,
10108,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,1,,17260,CHEMBL623036,,BAO_0000218,
10109,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,1,,4956,CHEMBL623037,,BAO_0000218,
10110,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,1,,4368,CHEMBL623038,,BAO_0000218,
10111,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,1,,17752,CHEMBL874385,,BAO_0000218,1969.0
10112,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Fisher) (fasted),A,1,,1446,CHEMBL623039,,BAO_0000218,
10113,22224,,In vivo,0,,U,,,,Intermediate,Bioavailability in monkey after po administration of 10 mg/kg dose,A,1,,2891,CHEMBL623040,,BAO_0000218,
10114,22224,,In vivo,0,,U,,,,Intermediate,Oral bioavailability in monkey (dose 10 mg/kg),A,1,,2891,CHEMBL623041,,BAO_0000218,
10115,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6672,CHEMBL623741,,BAO_0000218,
10116,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6673,CHEMBL623742,,BAO_0000218,
10117,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,17655,CHEMBL623743,,BAO_0000218,
10118,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,17796,CHEMBL623744,,BAO_0000218,
10119,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,1,,17853,CHEMBL623745,,BAO_0000218,
10120,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,1,,4521,CHEMBL623746,,BAO_0000218,
10121,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,1,,4940,CHEMBL623747,,BAO_0000218,
10122,22224,,In vivo,0,,U,,,,Intermediate,Bioavailability in rat after po administration of 30 mg/kg dose,A,1,,2891,CHEMBL623748,,BAO_0000218,
10123,22224,,In vivo,0,,U,,,,Intermediate,Bioavailability in rat after po administration of 30 mg/kg dose,A,1,,2891,CHEMBL623916,,BAO_0000218,
10124,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,1,,4521,CHEMBL623917,,BAO_0000218,
10125,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 2 mg/kg i.v.),A,1,,17686,CHEMBL623918,,BAO_0000218,
10126,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,17796,CHEMBL874386,,BAO_0000218,
10127,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability in rat; Only traces detected in rat plasma,A,1,,17796,CHEMBL623919,,BAO_0000218,1969.0
10128,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5064,CHEMBL623920,,BAO_0000218,
10129,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability upon oral administration of compound,A,1,,5147,CHEMBL623148,,BAO_0000218,
10130,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,1,,1916,CHEMBL623149,,BAO_0000218,
10131,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6049,CHEMBL623150,,BAO_0000218,
10132,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,1,,1445,CHEMBL623151,,BAO_0000218,
10133,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,1,,1445,CHEMBL623152,,BAO_0000218,
10134,50597,,,1,,N,,,,Expert,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,1,,2862,CHEMBL623153,,BAO_0000218,
10135,50597,,,1,,N,,,,Expert,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,1,,2862,CHEMBL623154,,BAO_0000218,
10136,50597,,,1,,N,,,,Intermediate,In vitro and metabolic stability was determined,A,1,,4194,CHEMBL623155,,BAO_0000218,
10137,50597,,,1,,N,,,,Intermediate,In vitro metabolic stability in rat hepatocytes,A,1,,4194,CHEMBL623156,,BAO_0000218,
10138,50597,,,1,,N,,,,Intermediate,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,1,,5486,CHEMBL623157,,BAO_0000218,
10139,50597,,In vitro,1,,N,,Liver,Hepatocyte,Intermediate,Metabolic rate for compound was observed in rat hepatocytes,A,1,,17582,CHEMBL623158,401.0,BAO_0000218,2107.0
10140,50597,,,1,,N,,,,Intermediate,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,1,,5600,CHEMBL623159,,BAO_0000218,
10141,50597,,,1,,N,,,,Intermediate,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,1,,14294,CHEMBL874390,,BAO_0000218,
10142,50597,,,1,,N,,,,Intermediate,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,1,,14294,CHEMBL623160,,BAO_0000218,
10143,50597,,,1,,N,,,,Intermediate,Metabolism of compound in rat S9 microsomes; Trace,A,1,,14294,CHEMBL623161,,BAO_0000218,
10144,50597,,,1,,N,,,,Intermediate,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,1,,17847,CHEMBL623162,,BAO_0000218,
10145,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,1,,11020,CHEMBL623163,,BAO_0000218,
10146,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,1,,11020,CHEMBL623164,,BAO_0000218,
10147,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,1,,11020,CHEMBL623165,,BAO_0000218,
10148,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,1,,11020,CHEMBL623166,,BAO_0000218,
10149,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,1,,11020,CHEMBL624983,,BAO_0000218,
10150,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,1,,11020,CHEMBL624984,,BAO_0000218,
10151,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,1,,11020,CHEMBL624985,,BAO_0000218,
10152,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,1,,11020,CHEMBL622970,,BAO_0000218,
10153,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,1,,11020,CHEMBL622971,,BAO_0000218,
10154,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,1,,11020,CHEMBL622972,,BAO_0000218,
10155,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,1,,11020,CHEMBL622973,,BAO_0000218,
10156,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,1,,11020,CHEMBL622974,,BAO_0000218,
10157,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,1,,11020,CHEMBL622975,,BAO_0000218,
10158,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,1,,11020,CHEMBL622976,,BAO_0000218,
10159,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,1,,11020,CHEMBL622977,,BAO_0000218,
10160,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,1,,11020,CHEMBL624351,,BAO_0000218,
10161,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,1,,11020,CHEMBL624352,,BAO_0000218,
10162,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,1,,11020,CHEMBL624353,,BAO_0000218,
10163,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,1,,11020,CHEMBL622397,,BAO_0000218,
10164,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,1,,11020,CHEMBL622398,,BAO_0000218,
10165,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,1,,11020,CHEMBL622399,,BAO_0000218,
10166,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,1,,11020,CHEMBL622400,,BAO_0000218,
10167,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,1,,11020,CHEMBL628428,,BAO_0000218,
10168,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,1,,11020,CHEMBL628590,,BAO_0000218,
10169,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,1,,11020,CHEMBL628591,,BAO_0000218,
10170,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,1,,11020,CHEMBL628592,,BAO_0000218,
10171,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,1,,11020,CHEMBL628593,,BAO_0000218,
10172,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,1,,11020,CHEMBL875333,,BAO_0000218,
10173,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,1,,11020,CHEMBL628594,,BAO_0000218,
10174,50597,,,1,,N,,Plasma,,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,1,,4969,CHEMBL628595,,BAO_0000218,1969.0
10175,50597,,,1,,N,,Plasma,,Intermediate,Stability in rat plasma was determined,A,1,,6737,CHEMBL628596,,BAO_0000218,1969.0
10176,50597,,,1,,N,,Plasma,,Intermediate,Stability in rat plasma was determined; ND= no data,A,1,,6737,CHEMBL628597,,BAO_0000218,1969.0
10177,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma half life period in rat (0-8 hr),A,1,,5089,CHEMBL628598,,BAO_0000218,1969.0
10178,50597,,,1,,N,,Plasma,,Intermediate,Tested for plasma half life period in rat (0-8 hr); Not determined,A,1,,5089,CHEMBL628599,,BAO_0000218,1969.0
10179,50597,,In vivo,1,,N,,,,Intermediate,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,1,,1466,CHEMBL628600,,BAO_0000218,
10180,50597,,In vivo,1,,N,,,,Intermediate,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,1,,1466,CHEMBL628601,,BAO_0000218,
10181,50597,,,1,,N,,,,Intermediate,Tested for the half life in rat,A,1,,4950,CHEMBL628602,,BAO_0000218,
10182,50597,,In vitro,1,,N,,,,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,1,,2412,CHEMBL628603,,BAO_0000218,
10183,50597,,In vitro,1,,N,,,,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,1,,2412,CHEMBL628604,,BAO_0000218,
10184,50597,,In vitro,1,,N,,,,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,1,,2412,CHEMBL628605,,BAO_0000218,
10185,50597,,In vitro,1,,N,,,,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,1,,2412,CHEMBL628606,,BAO_0000218,
10186,50597,,In vitro,1,,N,,,,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,1,,2412,CHEMBL628607,,BAO_0000218,
10187,50597,,,1,,N,,,,Intermediate,The biological half life the compound was measured at the dose of 100 umol/kg,A,1,,15022,CHEMBL628608,,BAO_0000218,
10188,50597,,,1,,N,,,,Intermediate,The biological half life the compound was measured at the dose of 30 umol/kg,A,1,,15022,CHEMBL628609,,BAO_0000218,
10189,50597,,,1,,N,,Plasma,,Intermediate,The compound was evaluated for plasma half life period in rat,A,1,,406,CHEMBL628610,,BAO_0000218,1969.0
10190,50597,,In vivo,1,,N,,,,Intermediate,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL873819,,BAO_0000218,
10191,50597,,In vivo,1,,N,,,,Intermediate,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL628611,,BAO_0000218,
10192,50597,,In vivo,1,,N,,,,Intermediate,The pharmacokinetic parameter half-life period in vivo in rats,A,1,,5247,CHEMBL628612,,BAO_0000218,
10193,50597,,In vivo,1,,N,,,,Intermediate,"The pharmacokinetic property, Half-life was determined",A,1,,5041,CHEMBL628613,,BAO_0000218,
10194,50597,,In vivo,1,,N,,,,Intermediate,"The pharmacokinetic property, Half-life in rat in vivo",A,1,,5041,CHEMBL628614,,BAO_0000218,
10195,50597,,In vivo,1,,N,,,,Intermediate,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,1,,5041,CHEMBL628615,,BAO_0000218,
10196,50597,,In vivo,1,,N,,,,Intermediate,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,1,,5041,CHEMBL628616,,BAO_0000218,
10197,50597,,,1,,N,,Plasma,,Intermediate,The plasma half life period in rats,A,1,,3918,CHEMBL627924,,BAO_0000218,1969.0
10198,50597,,,1,,N,,Liver,,Intermediate,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,1,,2906,CHEMBL627925,,BAO_0000218,2107.0
10199,50597,,In vivo,1,,N,,,,Intermediate,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,1,,6467,CHEMBL627926,,BAO_0000218,
10200,50597,,,1,,N,,,,Intermediate,t1/2 (apparent elimination)of the compound was determined,A,1,,5510,CHEMBL627927,,BAO_0000218,
10201,50597,,,1,,N,,,,Intermediate,t1/2 value in rat,A,1,,3788,CHEMBL627928,,BAO_0000218,
10202,50597,,,1,,N,,,,Intermediate,Half life in rat,A,1,,17796,CHEMBL627539,,BAO_0000218,
10203,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,1,,12873,CHEMBL876790,,BAO_0000218,1969.0
10204,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,1,,5983,CHEMBL858186,,BAO_0000218,
10205,50597,,,1,,N,,,,Intermediate,Half-life period in fasted rats,A,1,,15765,CHEMBL627540,,BAO_0000218,
10206,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,1,,2661,CHEMBL627541,,BAO_0000218,
10207,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,1,,2661,CHEMBL627715,,BAO_0000218,
10208,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,1,,429,CHEMBL627716,,BAO_0000218,
10209,50597,,,1,,N,,,,Intermediate,Maximum time required to achieve Cmax was determined in rat,A,1,,17655,CHEMBL627717,,BAO_0000218,
10210,50597,,In vivo,1,,N,,,,Intermediate,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL627718,,BAO_0000218,
10211,50597,,In vivo,1,,N,,,,Intermediate,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,1,,17717,CHEMBL627719,,BAO_0000218,
10212,50597,,In vivo,1,,N,,,,Intermediate,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,1,,17717,CHEMBL627720,,BAO_0000218,
10213,50597,,In vivo,1,,N,,,,Intermediate,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,1,,6570,CHEMBL627721,,BAO_0000218,
10214,50597,,In vivo,1,,N,,,,Intermediate,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,1,,6570,CHEMBL627722,,BAO_0000218,
10215,50597,,In vivo,1,,N,,,,Intermediate,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL627723,,BAO_0000218,
10216,50597,,In vivo,1,,N,,,,Intermediate,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL626058,,BAO_0000218,
10217,50597,,In vivo,1,,N,,,,Intermediate,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL626059,,BAO_0000218,
10218,50597,,In vivo,1,,N,,,,Intermediate,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL626060,,BAO_0000218,
10219,50597,,In vivo,1,,N,,Plasma,,Intermediate,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL626061,,BAO_0000218,1969.0
10220,50597,,In vivo,1,,N,,,,Intermediate,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL876791,,BAO_0000218,
10221,50597,,In vivo,1,,N,,,,Intermediate,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,1,,4723,CHEMBL626062,,BAO_0000218,
10222,50597,,In vivo,1,,N,,,,Intermediate,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL626063,,BAO_0000218,
10223,50597,,In vivo,1,,N,,,,Intermediate,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL626064,,BAO_0000218,
10224,50597,,In vivo,1,,N,,Plasma,,Intermediate,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL626065,,BAO_0000218,1969.0
10225,50597,,In vivo,1,,N,,Plasma,,Intermediate,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,1,,17720,CHEMBL626066,,BAO_0000218,1969.0
10226,50597,,In vivo,1,,N,,,,Intermediate,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,1,,1466,CHEMBL626067,,BAO_0000218,
10227,50597,,,1,,N,,,,Intermediate,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,1,,7449,CHEMBL626068,,BAO_0000218,
10228,50597,,,1,,N,,,,Intermediate,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,1,,7449,CHEMBL626069,,BAO_0000218,
10229,50597,,,1,,N,,,,Intermediate,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,1,,7449,CHEMBL626070,,BAO_0000218,
10230,50597,,,1,,N,,,,Intermediate,Percent total excretion of N-methoxyacetaminophen glucuronide,F,1,,7449,CHEMBL626071,,BAO_0000218,
10231,50597,,,1,,N,,,,Intermediate,Percent total excretion of N-methoxyacetaminophen sulfate,F,1,,7449,CHEMBL626072,,BAO_0000218,
10232,50597,,,1,,N,,,,Intermediate,Percent total excretion of acetaminophen,F,1,,7449,CHEMBL626073,,BAO_0000218,
10233,50597,,,1,,N,,Thyroid gland,,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,1,,7768,CHEMBL626741,,BAO_0000218,2046.0
10234,50597,,,1,,N,,,,Intermediate,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,1,,17655,CHEMBL626742,,BAO_0000218,
10235,50597,,,1,,N,,,,Intermediate,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,1,,17735,CHEMBL626743,,BAO_0000218,
10236,50597,,,1,,N,,,,Intermediate,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,1,,5960,CHEMBL876792,,BAO_0000218,
10237,50597,,,1,,N,,,,Intermediate,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,1,,17735,CHEMBL626744,,BAO_0000218,
10238,50597,,,1,,N,,,,Intermediate,Compound was tested for antidiuretic activity in rats,A,1,,7116,CHEMBL626745,,BAO_0000218,
10239,50597,,In vivo,1,,N,,Plasma,,Intermediate,AUC in rat after 3mg/kg oral dose,A,1,,4878,CHEMBL626746,,BAO_0000218,1969.0
10240,50597,,,1,,N,,,,Intermediate,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,1,,5939,CHEMBL626747,,BAO_0000218,
10241,50597,,,1,,N,,,,Intermediate,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,1,,5939,CHEMBL626748,,BAO_0000218,
10242,50597,,,1,,N,,,,Intermediate,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,1,,16367,CHEMBL626749,,BAO_0000218,
10243,50597,,,1,,N,,,,Intermediate,Oral Bioavailability was determined,A,1,,16366,CHEMBL626750,,BAO_0000218,
10244,50597,,,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4426,CHEMBL626751,,BAO_0000218,
10245,50597,,,1,,N,,,,Intermediate,Oral bioavailability in rat; Not performed.,A,1,,4426,CHEMBL626913,,BAO_0000218,
10246,50597,,,1,,N,,,,Intermediate,Bioavailability,A,1,,5041,CHEMBL626914,,BAO_0000218,
10247,50597,,,1,,N,,,,Intermediate,Bioavailability was determined; ND denotes no data,A,1,,5041,CHEMBL626915,,BAO_0000218,
10248,50597,,,1,,N,,,,Intermediate,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,1,,1500,CHEMBL626916,,BAO_0000218,
10249,50597,,,1,,N,,,,Intermediate,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,1,,1500,CHEMBL626917,,BAO_0000218,
10250,50597,,,1,,N,,,,Intermediate,Binding towards rat plasma protein at 10 uM,A,1,,17409,CHEMBL626918,,BAO_0000218,
10251,50597,,,1,,N,,,,Intermediate,Binding towards rat plasma protein at 100 uM,A,1,,17409,CHEMBL626919,,BAO_0000218,
10252,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 20 mg/kg p.o.),A,1,,2959,CHEMBL626920,,BAO_0000218,
10253,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,1,,13501,CHEMBL621976,,BAO_0000218,
10254,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after 5 mg/kg oral gavage,A,1,,6567,CHEMBL877599,,BAO_0000218,
10255,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6571,CHEMBL621977,,BAO_0000218,
10256,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v.),A,1,,6715,CHEMBL621978,,BAO_0000218,
10257,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 3 mg/kg p.o.),A,1,,6715,CHEMBL621979,,BAO_0000218,
10258,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,2932,CHEMBL621980,,BAO_0000218,
10259,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability of the compound in rats after administration of 30 mg/kg,A,1,,4171,CHEMBL621981,,BAO_0000218,
10260,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after administration of 10 mg/kg in rats,A,1,,17509,CHEMBL621982,,BAO_0000218,
10261,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability after administration of 2 mg/kg in rats,A,1,,17509,CHEMBL882953,,BAO_0000218,
10262,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,1,,4527,CHEMBL621983,,BAO_0000218,
10263,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in dogs was determined; high,A,1,,4026,CHEMBL621984,,BAO_0000218,
10264,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in monkey after intravenous administration at 1 mpk,A,1,,6659,CHEMBL621985,,BAO_0000218,
10265,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in monkey after peroral administration at 10 mpk,A,1,,6659,CHEMBL621986,,BAO_0000218,
10266,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after intravenous administration at 1 mpk,A,1,,6659,CHEMBL621987,,BAO_0000218,
10267,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after intravenous administration at 2 mpk,F,1,,6659,CHEMBL877600,,BAO_0000218,
10268,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after peroral administration at 30 mpk,A,1,,6659,CHEMBL621988,,BAO_0000218,
10269,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after peroral administration at at 100 mpk,F,1,,6659,CHEMBL621989,,BAO_0000218,
10270,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rats was evaluated,A,1,,6597,CHEMBL621990,,BAO_0000218,
10271,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,1,,1202,CHEMBL621991,,BAO_0000218,
10272,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,1,,1202,CHEMBL621992,,BAO_0000218,
10273,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,1,,1202,CHEMBL621993,,BAO_0000218,
10274,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,1,,1202,CHEMBL621994,,BAO_0000218,
10275,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5207,CHEMBL621995,,BAO_0000218,
10276,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5970,CHEMBL621996,,BAO_0000218,
10277,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),A,1,,17538,CHEMBL621997,,BAO_0000218,
10278,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,1,,17538,CHEMBL621998,,BAO_0000218,
10279,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,1,,1466,CHEMBL621999,,BAO_0000218,
10280,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,2879,CHEMBL622000,,BAO_0000218,
10281,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in rat after oral administration; 2-4,A,1,,2879,CHEMBL622001,,BAO_0000218,
10282,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in rat after oral administration; 3-7,A,1,,2879,CHEMBL622002,,BAO_0000218,
10283,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (intraduodenal administration),A,1,,3777,CHEMBL622003,,BAO_0000218,
10284,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (intraduodenal administration),A,1,,3777,CHEMBL877601,,BAO_0000218,
10285,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3777,CHEMBL624871,,BAO_0000218,
10286,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3777,CHEMBL622004,,BAO_0000218,
10287,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,1,,5423,CHEMBL882954,,BAO_0000218,
10288,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,1,,16365,CHEMBL622005,,BAO_0000218,
10289,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,1,,16365,CHEMBL622006,,BAO_0000218,
10290,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in rat,A,1,,4239,CHEMBL622007,,BAO_0000218,
10291,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was reported,A,1,,5438,CHEMBL622008,,BAO_0000218,
10292,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,1,,5334,CHEMBL622009,,BAO_0000218,
10293,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,1,,5334,CHEMBL622010,,BAO_0000218,
10294,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,1,,4199,CHEMBL622011,,BAO_0000218,
10295,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,1,,4199,CHEMBL622012,,BAO_0000218,
10296,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,1,,4199,CHEMBL622013,,BAO_0000218,
10297,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,1,,4890,CHEMBL622014,,BAO_0000218,
10298,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was determined at 3 mg/kg po dose in rats,A,1,,2792,CHEMBL624749,,BAO_0000218,
10299,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 2 mg/kg),A,1,,5529,CHEMBL624750,,BAO_0000218,
10300,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,1,,6685,CHEMBL624751,,BAO_0000218,
10301,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,1,,6685,CHEMBL624752,,BAO_0000218,
10302,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,1,,6685,CHEMBL624753,,BAO_0000218,
10303,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,1,,6005,CHEMBL624754,,BAO_0000218,
10304,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,1,,6410,CHEMBL624755,,BAO_0000218,
10305,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL624756,,BAO_0000218,
10306,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6103,CHEMBL624757,,BAO_0000218,
10307,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,1,,6410,CHEMBL624758,,BAO_0000218,
10308,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,1,,6410,CHEMBL622270,,BAO_0000218,
10309,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (Sprague-Dawley),A,1,,5353,CHEMBL622271,,BAO_0000218,
10310,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at the dose of 2 mg/kg,A,1,,4727,CHEMBL622272,,BAO_0000218,
10311,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17804,CHEMBL622273,,BAO_0000218,
10312,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,1,,5809,CHEMBL622274,,BAO_0000218,
10313,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability value of compound in rats was determined after peroral administration,A,1,,17804,CHEMBL622275,,BAO_0000218,
10314,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 20 mg/kg),A,1,,3634,CHEMBL622276,,BAO_0000218,
10315,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3341,CHEMBL622277,,BAO_0000218,
10316,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 5 mg/kg),A,1,,2690,CHEMBL622278,,BAO_0000218,
10317,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3184,CHEMBL622279,,BAO_0000218,
10318,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,740,CHEMBL622280,,BAO_0000218,
10319,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,1,,1806,CHEMBL624083,,BAO_0000218,
10320,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,1,,4891,CHEMBL624084,,BAO_0000218,
10321,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,1,,3634,CHEMBL624085,,BAO_0000218,
10322,50597,,In vivo,1,,N,,,,Intermediate,Compound was tested for bioavailability in rats,A,1,,64,CHEMBL624086,,BAO_0000218,
10323,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,4839,CHEMBL624087,,BAO_0000218,
10324,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,1094,CHEMBL624088,,BAO_0000218,
10325,22224,,In vivo,0,,U,,,,Intermediate,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,1,,5005,CHEMBL624089,,BAO_0000218,
10326,22224,,In vivo,0,,U,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,1,,5005,CHEMBL624090,,BAO_0000218,
10327,50597,,In vivo,1,,N,,,,Intermediate,Evaluated for the bioavailability in rat (in vivo),A,1,,4687,CHEMBL624091,,BAO_0000218,
10328,50597,,In vivo,1,,N,,,,Intermediate,F value of compound in rats was determined after peroral administration,A,1,,17804,CHEMBL624092,,BAO_0000218,
10329,50597,,In vivo,1,,N,,,,Intermediate,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624093,,BAO_0000218,
10330,50597,,In vivo,1,,N,,,,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624094,,BAO_0000218,
10331,50597,,In vivo,1,,N,,,,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624095,,BAO_0000218,
10332,50597,,In vivo,1,,N,,,,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,1,,5974,CHEMBL624096,,BAO_0000218,
10333,50597,,In vivo,1,,N,,,,Intermediate,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,1,,1088,CHEMBL624097,,BAO_0000218,
10334,50597,,In vivo,1,,N,,,,Intermediate,Maximum fall in carotid flow in rat,A,1,,1742,CHEMBL624098,,BAO_0000218,
10335,50597,,In vivo,1,,N,,,,Intermediate,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,1,,4689,CHEMBL874392,,BAO_0000218,
10336,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 5 mg/kg),A,1,,2463,CHEMBL624099,,BAO_0000218,
10337,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,1,,5654,CHEMBL624100,,BAO_0000218,
10338,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,1,,5654,CHEMBL624101,,BAO_0000218,
10339,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (male Wistar),A,1,,6874,CHEMBL624102,,BAO_0000218,
10340,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after administration (30 mg/kg) in rat; good,A,1,,5633,CHEMBL624103,,BAO_0000218,
10341,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability at the dose of 2 mg/kg in rat,A,1,,5496,CHEMBL624104,,BAO_0000218,
10342,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability determined in rats,A,1,,2358,CHEMBL624105,,BAO_0000218,
10343,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,1,,16456,CHEMBL624106,,BAO_0000218,
10344,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose single 10 mg/kg),A,1,,5302,CHEMBL624107,,BAO_0000218,
10345,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose single 10 mg/kg),A,1,,5302,CHEMBL623943,,BAO_0000218,
10346,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 5 mg/kg,A,1,,5302,CHEMBL623944,,BAO_0000218,
10347,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,1,,11020,CHEMBL623945,,BAO_0000218,
10348,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,1,,11020,CHEMBL623946,,BAO_0000218,
10349,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,1,,11020,CHEMBL623947,,BAO_0000218,
10350,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,1,,11020,CHEMBL623948,,BAO_0000218,
10351,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,1,,11020,CHEMBL623949,,BAO_0000218,
10352,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,1,,11020,CHEMBL623950,,BAO_0000218,
10353,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,1,,11020,CHEMBL874398,,BAO_0000218,
10354,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,1,,11020,CHEMBL623951,,BAO_0000218,
10355,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,1,,11020,CHEMBL623952,,BAO_0000218,
10356,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,1,,11020,CHEMBL623953,,BAO_0000218,
10357,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,1,,11020,CHEMBL623954,,BAO_0000218,
10358,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,1,,11020,CHEMBL623955,,BAO_0000218,
10359,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,1,,11020,CHEMBL623956,,BAO_0000218,
10360,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,1,,11020,CHEMBL627807,,BAO_0000218,
10361,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,1,,11020,CHEMBL627808,,BAO_0000218,
10362,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,1,,11020,CHEMBL627809,,BAO_0000218,
10363,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,1,,11020,CHEMBL627810,,BAO_0000218,
10364,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,1,,11020,CHEMBL627811,,BAO_0000218,
10365,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,1,,11020,CHEMBL627812,,BAO_0000218,
10366,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,1,,11020,CHEMBL627813,,BAO_0000218,
10367,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,1,,11020,CHEMBL627814,,BAO_0000218,
10368,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,1,,11020,CHEMBL875336,,BAO_0000218,
10369,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,1,,11020,CHEMBL627815,,BAO_0000218,
10370,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,1,,11020,CHEMBL627816,,BAO_0000218,
10371,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,1,,11020,CHEMBL627817,,BAO_0000218,
10372,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,1,,11020,CHEMBL627818,,BAO_0000218,
10373,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,1,,11020,CHEMBL627819,,BAO_0000218,
10374,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,1,,11020,CHEMBL627820,,BAO_0000218,
10375,50597,,,1,,N,,,,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,1,,11020,CHEMBL627821,,BAO_0000218,
10376,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,1,,11020,CHEMBL628464,,BAO_0000218,
10377,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,1,,11020,CHEMBL626239,,BAO_0000218,
10378,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,1,,11020,CHEMBL626240,,BAO_0000218,
10379,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,1,,11020,CHEMBL626241,,BAO_0000218,
10380,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,1,,11020,CHEMBL626242,,BAO_0000218,
10381,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,1,,11020,CHEMBL626243,,BAO_0000218,
10382,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,1,,11020,CHEMBL626244,,BAO_0000218,
10383,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,1,,11020,CHEMBL626907,,BAO_0000218,
10384,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,1,,11020,CHEMBL626908,,BAO_0000218,
10385,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,1,,11020,CHEMBL626909,,BAO_0000218,
10386,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,1,,11020,CHEMBL626910,,BAO_0000218,
10387,50597,,,1,,N,,,,Intermediate,Percent total excretion of acetaminophen cysteine conjugate,F,1,,7449,CHEMBL875342,,BAO_0000218,
10388,50597,,,1,,N,,,,Intermediate,Percent total excretion of acetaminophen glucuronide,F,1,,7449,CHEMBL626911,,BAO_0000218,
10389,50597,,,1,,N,,,,Intermediate,Percent total excretion of acetaminophen sulfate,F,1,,7449,CHEMBL626912,,BAO_0000218,
10390,50597,,,1,,N,,,,Intermediate,Percent total excretion of acetaminophen-mercapturic acid,F,1,,7449,CHEMBL627065,,BAO_0000218,
10391,50597,,,1,,N,,Urine,,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,1,,3172,CHEMBL627066,,BAO_0000218,1088.0
10392,50597,,In vivo,1,,N,,,,Intermediate,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,1,,16456,CHEMBL627067,,BAO_0000218,
10393,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,Biodistribution of compound in rat muscle after 5 min of administration,A,1,,10839,CHEMBL627068,,BAO_0000218,2385.0
10394,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,Biodistribution of compound in rat muscle after 5 min of administration.,A,1,,10839,CHEMBL627069,,BAO_0000218,2385.0
10395,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL627070,,BAO_0000218,
10396,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL627071,,BAO_0000218,
10397,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL627072,,BAO_0000218,
10398,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL627073,,BAO_0000218,
10399,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL625387,,BAO_0000218,
10400,22224,,In vivo,0,,U,,,,Autocuration,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL625388,,BAO_0000218,
10401,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL625389,,BAO_0000218,1969.0
10402,22224,,In vivo,0,,U,,Plasma,,Autocuration,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,1,,5334,CHEMBL875343,,BAO_0000218,1969.0
10403,50497,,,1,,N,,,,Intermediate,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,1,,1735,CHEMBL876795,,BAO_0000218,
10404,50497,,,1,,N,,,,Intermediate,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,1,,1469,CHEMBL626552,,BAO_0000218,
10405,50497,,,1,,N,,,,Intermediate,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,1,,1336,CHEMBL626553,,BAO_0000218,
10406,22224,,,0,,U,,Plasma,,Autocuration,The human biological plasma half life of the compound,A,1,,12403,CHEMBL626554,,BAO_0000366,1969.0
10407,50597,,,1,,N,,Urine,,Intermediate,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,1,,8151,CHEMBL626555,,BAO_0000218,1088.0
10408,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,1,,8004,CHEMBL626556,,BAO_0000218,
10409,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,1,,8004,CHEMBL626557,,BAO_0000218,
10410,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,1,,8004,CHEMBL626558,,BAO_0000218,
10411,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,1,,8004,CHEMBL626559,,BAO_0000218,
10412,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,1,,8004,CHEMBL626560,,BAO_0000218,
10413,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,1,,8004,CHEMBL876803,,BAO_0000218,
10414,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,1,,8004,CHEMBL627964,,BAO_0000218,
10415,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,1,,8004,CHEMBL627965,,BAO_0000218,
10416,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,1,,8004,CHEMBL627966,,BAO_0000218,
10417,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,1,,8004,CHEMBL627967,,BAO_0000218,
10418,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,1,,8004,CHEMBL627968,,BAO_0000218,
10419,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,1,,8004,CHEMBL627969,,BAO_0000218,
10420,50597,,,1,,N,,,,Intermediate,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,1,,8004,CHEMBL627970,,BAO_0000218,
10421,50597,,,1,,N,,Blood,,Intermediate,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,1,,8004,CHEMBL627971,,BAO_0000218,178.0
10422,50597,,,1,,N,,Blood,,Intermediate,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,1,,8004,CHEMBL627972,,BAO_0000218,178.0
10423,180,,,9,,D,,,,Expert,Dissociation constant against binding to human cyclophilin A,B,1,,15917,CHEMBL856029,,BAO_0000357,
10424,11591,,,8,,H,,,,Expert,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,1,,12396,CHEMBL627973,,BAO_0000019,
10425,22224,,,0,,U,,,,Autocuration,-Log C was determined by performing the electroshock minimum test,A,1,,7065,CHEMBL627974,,BAO_0000019,
10426,22224,,,0,,U,,,,Autocuration,-Log C was determined by performing the foot shock test,A,1,,7065,CHEMBL627975,,BAO_0000019,
10427,22224,,,0,,U,,,,Autocuration,-Log C was determined by performing the incl screen test,A,1,,7065,CHEMBL627976,,BAO_0000019,
10428,22224,,,0,,U,,,,Autocuration,-Log C was determined by performing the maximum electroshock test,A,1,,7065,CHEMBL627977,,BAO_0000019,
10429,22224,,,0,,U,,,,Autocuration,-Log C was determined by performing the pentylenetetrazole test,A,1,,7065,CHEMBL627978,,BAO_0000019,
10430,22224,,,0,,U,,,,Autocuration,Tested for experimental arotinoid inhibitory dose,A,1,,12415,CHEMBL627979,,BAO_0000019,
10431,22224,,,0,,U,,,,Autocuration,Negative log transformed activity,A,1,,10256,CHEMBL876804,,BAO_0000019,
10432,22224,,,0,,U,,,,Autocuration,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,1,,7991,CHEMBL627980,,BAO_0000019,
10433,50512,,,1,,N,,,,Intermediate,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,1,,14342,CHEMBL627981,,BAO_0000218,
10434,50512,,,1,,N,,,,Intermediate,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,1,,14342,CHEMBL627982,,BAO_0000218,
10435,50512,,,1,,N,,,,Intermediate,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,1,,14342,CHEMBL627983,,BAO_0000218,
10436,50512,,,1,,N,,Ileum,,Intermediate,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,1,,14342,CHEMBL627984,,BAO_0000218,2116.0
10437,22229,,,0,,U,,,,Autocuration,Solubility in water was determined; values expressed as -log,P,1,,6047,CHEMBL627985,,BAO_0000100,
10438,22224,,,0,,U,,,,Autocuration,Ratio of Kcat to that of Km was determined,A,1,,17269,CHEMBL627986,,BAO_0000019,
10439,22224,,,0,,U,,,,Autocuration,Observed first order rate constant,A,1,,10026,CHEMBL627987,,BAO_0000019,
10440,22224,,,0,,U,,,,Autocuration,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,1,,14583,CHEMBL627988,,BAO_0000019,
10441,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,1,,2661,CHEMBL627989,,BAO_0000218,
10442,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,1,,2661,CHEMBL627990,,BAO_0000218,
10443,50597,,In vivo,1,,N,,,,Intermediate,Oral Bioavailability after administration of 10 mg/kg in male rat,A,1,,4029,CHEMBL876805,,BAO_0000218,
10444,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,1,,17735,CHEMBL627991,,BAO_0000218,
10445,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4576,CHEMBL627992,,BAO_0000218,
10446,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,1,,17582,CHEMBL627993,,BAO_0000218,
10447,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability at 1 mg/kg was determined in rat,A,1,,17651,CHEMBL622817,,BAO_0000218,
10448,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability at 10 mg/kg was determined in rat,A,1,,17651,CHEMBL622818,,BAO_0000218,
10449,50597,,In vivo,1,,N,,,,Intermediate,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,1,,17670,CHEMBL622819,,BAO_0000218,
10450,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5045,CHEMBL872267,,BAO_0000218,
10451,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,1696,CHEMBL622820,,BAO_0000218,
10452,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,1,,17764,CHEMBL622821,,BAO_0000218,
10453,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6448,CHEMBL622822,,BAO_0000218,
10454,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6596,CHEMBL622823,,BAO_0000218,
10455,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17547,CHEMBL622824,,BAO_0000218,
10456,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat at a dose of 3 mg/kg,A,1,,17771,CHEMBL622825,,BAO_0000218,
10457,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after oral administration at 10 mg/kg,A,1,,6495,CHEMBL622901,,BAO_0000218,
10458,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4558,CHEMBL622902,,BAO_0000218,
10459,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17596,CHEMBL621844,,BAO_0000218,
10460,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Dawley rats,A,1,,6827,CHEMBL621845,,BAO_0000218,
10461,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,4026,CHEMBL621846,,BAO_0000218,
10462,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 30 mg/kg),A,1,,10,CHEMBL621847,,BAO_0000218,
10463,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,1,,17717,CHEMBL877609,,BAO_0000218,
10464,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 3 mg/kg i.v.),A,1,,17717,CHEMBL621848,,BAO_0000218,
10465,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,1,,17717,CHEMBL621849,,BAO_0000218,
10466,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,1,,17717,CHEMBL622030,,BAO_0000218,
10467,50597,,In vivo,1,,N,,,,Intermediate,Percent oral bioavailability determined in rats,A,1,,4796,CHEMBL622031,,BAO_0000218,
10468,50597,,In vivo,1,,N,,,,Intermediate,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,1,,4883,CHEMBL622032,,BAO_0000218,
10469,50597,,In vivo,1,,N,,,,Intermediate,The compound was evaluated for bioavailability in rats; 32-51,A,1,,2137,CHEMBL622033,,BAO_0000218,
10470,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 20 mg/kg p.o.),A,1,,2959,CHEMBL622034,,BAO_0000218,
10471,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,1361,CHEMBL622035,,BAO_0000218,
10472,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability percent in rat at the dose of 2 mg/kg,A,1,,4727,CHEMBL882966,,BAO_0000218,
10473,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,1,,16423,CHEMBL622036,,BAO_0000218,
10474,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5206,CHEMBL622037,,BAO_0000218,
10475,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6448,CHEMBL622038,,BAO_0000218,
10476,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rats,A,1,,17723,CHEMBL622039,,BAO_0000218,
10477,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,1,,17738,CHEMBL622040,,BAO_0000218,178.0
10478,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622041,,BAO_0000218,178.0
10479,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622042,,BAO_0000218,178.0
10480,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622043,,BAO_0000218,178.0
10481,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622044,,BAO_0000218,178.0
10482,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622045,,BAO_0000218,10000001.0
10483,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622046,,BAO_0000218,10000001.0
10484,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622047,,BAO_0000218,10000001.0
10485,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL877610,,BAO_0000218,10000001.0
10486,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622048,,BAO_0000218,955.0
10487,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622049,,BAO_0000218,955.0
10488,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622050,,BAO_0000218,955.0
10489,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622051,,BAO_0000218,955.0
10490,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622052,,BAO_0000218,
10491,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622053,,BAO_0000218,
10492,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622054,,BAO_0000218,
10493,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622055,,BAO_0000218,
10494,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rats was determined; High,A,1,,5237,CHEMBL622056,,BAO_0000218,
10495,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in the rat was determined,A,1,,5503,CHEMBL622057,,BAO_0000218,
10496,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,1,,15765,CHEMBL628008,,BAO_0000218,
10497,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,1,,15660,CHEMBL622058,,BAO_0000218,
10498,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL622059,,BAO_0000218,
10499,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL622060,,BAO_0000218,
10500,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL622061,,BAO_0000218,
10501,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,1,,5978,CHEMBL622062,,BAO_0000218,
10502,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,1,,5656,CHEMBL622063,,BAO_0000218,
10503,50597,,In vivo,1,,N,,,,Expert,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,1,,3598,CHEMBL877611,,BAO_0000218,
10504,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound in Sprague Dawley rats,A,1,,4216,CHEMBL622064,,BAO_0000218,
10505,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound in rat,A,1,,17839,CHEMBL622065,,BAO_0000218,
10506,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 2 mg/kg),A,1,,6570,CHEMBL622066,,BAO_0000218,
10507,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound in rat was determined,A,1,,5334,CHEMBL622067,,BAO_0000218,
10508,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound in rats,A,1,,6886,CHEMBL622068,,BAO_0000218,
10509,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound was determined in rats,A,1,,5210,CHEMBL622069,,BAO_0000218,
10510,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability at a dose of 30 mg/kg in rats,A,1,,4170,CHEMBL624796,,BAO_0000218,
10511,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),A,1,,6028,CHEMBL624797,,BAO_0000218,
10512,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),A,1,,6028,CHEMBL623053,,BAO_0000218,
10513,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability evaluated in rat,A,1,,6078,CHEMBL623054,,BAO_0000218,
10514,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in fasted rat,A,1,,6168,CHEMBL623055,,BAO_0000218,
10515,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in fed rat,A,1,,6168,CHEMBL623056,,BAO_0000218,
10516,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,1,,5160,CHEMBL623057,,BAO_0000218,
10517,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6057,CHEMBL623058,,BAO_0000218,
10518,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,1,,6535,CHEMBL623059,,BAO_0000218,
10519,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after administration of 10 mg/kg po,A,1,,6535,CHEMBL623060,,BAO_0000218,
10520,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4194,CHEMBL623061,,BAO_0000218,
10521,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6230,CHEMBL623062,,BAO_0000218,
10522,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6619,CHEMBL623063,,BAO_0000218,
10523,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17607,CHEMBL623064,,BAO_0000218,
10524,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in ratrs,A,1,,4942,CHEMBL623065,,BAO_0000218,
10525,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4942,CHEMBL623066,,BAO_0000218,
10526,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6646,CHEMBL623067,,BAO_0000218,
10527,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rats was determined; High,A,1,,5237,CHEMBL623068,,BAO_0000218,
10528,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6646,CHEMBL623069,,BAO_0000218,
10529,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4449,CHEMBL623070,,BAO_0000218,
10530,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in rat,A,1,,6057,CHEMBL623071,,BAO_0000218,
10531,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,2552,CHEMBL623072,,BAO_0000218,
10532,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,5496,CHEMBL623073,,BAO_0000218,
10533,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,6484,CHEMBL623074,,BAO_0000218,
10534,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,6485,CHEMBL623075,,BAO_0000218,
10535,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after i.v. administration,A,1,,6616,CHEMBL623076,,BAO_0000218,
10536,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,1,,4969,CHEMBL623077,,BAO_0000218,
10537,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley),A,1,,5862,CHEMBL623078,,BAO_0000218,
10538,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Sprague-Dawley rats,A,1,,4514,CHEMBL623079,,BAO_0000218,
10539,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,1,,4514,CHEMBL623080,,BAO_0000218,
10540,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,1,,4514,CHEMBL623081,,BAO_0000218,
10541,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,1,,5546,CHEMBL623082,,BAO_0000218,
10542,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in fasted rat,A,1,,6168,CHEMBL874400,,BAO_0000218,
10543,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in fed rat,A,1,,6168,CHEMBL623083,,BAO_0000218,
10544,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3624,CHEMBL623084,,BAO_0000218,
10545,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5213,CHEMBL623085,,BAO_0000218,
10546,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5496,CHEMBL623086,,BAO_0000218,
10547,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5553,CHEMBL623087,,BAO_0000218,
10548,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5833,CHEMBL623088,,BAO_0000218,
10549,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5836,CHEMBL623089,,BAO_0000218,
10550,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5865,CHEMBL623090,,BAO_0000218,
10551,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5960,CHEMBL623091,,BAO_0000218,
10552,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6249,CHEMBL623092,,BAO_0000218,
10553,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6448,CHEMBL623093,,BAO_0000218,
10554,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6453,CHEMBL874401,,BAO_0000218,
10555,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6640,CHEMBL623094,,BAO_0000218,
10556,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17607,CHEMBL623095,,BAO_0000218,
10557,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,1,,5939,CHEMBL623096,,BAO_0000218,
10558,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,1,,5939,CHEMBL624913,,BAO_0000218,
10559,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,1,,6281,CHEMBL624914,,BAO_0000218,
10560,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,1,,5874,CHEMBL624915,,BAO_0000218,
10561,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat; Not measured,A,1,,5213,CHEMBL624916,,BAO_0000218,
10562,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4964,CHEMBL624917,,BAO_0000218,
10563,50597,,,1,,N,,,,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,1,,11020,CHEMBL625157,,BAO_0000218,
10564,50597,,,1,,N,,Liver,,Intermediate,In vitro metabolic potential in rat liver microsomes,A,1,,6251,CHEMBL625158,,BAO_0000218,2107.0
10565,50597,,In vivo,1,,N,,,,Intermediate,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,1,,1568,CHEMBL625159,,BAO_0000218,
10566,50597,,In vivo,1,,N,,,,Intermediate,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,1,,3032,CHEMBL625160,,BAO_0000218,
10567,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,1,,3748,CHEMBL625161,,BAO_0000218,
10568,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,401,CHEMBL625162,,BAO_0000218,
10569,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6512,CHEMBL625163,,BAO_0000218,
10570,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rats at 10 mg/kg,A,1,,17617,CHEMBL625164,,BAO_0000218,
10571,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,1,,6679,CHEMBL625165,,BAO_0000218,
10572,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6742,CHEMBL625166,,BAO_0000218,
10573,50597,,,1,,N,,,,Intermediate,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,1,,589,CHEMBL625167,,BAO_0000218,
10574,50597,,,1,,N,,,,Intermediate,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,1,,589,CHEMBL625168,,BAO_0000218,
10575,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance of the compound,A,1,,3185,CHEMBL625169,,BAO_0000218,
10576,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,1,,17596,CHEMBL626264,,BAO_0000218,
10577,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,1,,2713,CHEMBL626265,,BAO_0000218,
10578,50597,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for plasma clearance in rat,A,1,,12500,CHEMBL626266,,BAO_0000218,1969.0
10579,50597,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,1,,12500,CHEMBL626267,,BAO_0000218,1969.0
10580,50597,,,1,,N,,,,Intermediate,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,1,,2713,CHEMBL626268,,BAO_0000218,
10581,50597,,,1,,N,,,,Intermediate,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,1,,1446,CHEMBL626269,,BAO_0000218,
10582,50597,,,1,,N,,,,Intermediate,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,1,,6227,CHEMBL626270,,BAO_0000218,
10583,50597,,,1,,N,,,,Intermediate,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,1,,4709,CHEMBL626271,,BAO_0000218,
10584,50597,,,1,,N,,,,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,1,,5510,CHEMBL626272,,BAO_0000218,
10585,50597,,,1,,N,,,,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,1,,5510,CHEMBL626273,,BAO_0000218,
10586,50597,,,1,,N,,,,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,1,,5510,CHEMBL875346,,BAO_0000218,
10587,50597,,,1,,N,,,,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,1,,5510,CHEMBL626274,,BAO_0000218,
10588,50597,,,1,,N,,,,Intermediate,Compound was tested for protein binding in rat plasma,A,1,,4514,CHEMBL626275,,BAO_0000218,
10589,50597,,,1,,N,,,,Intermediate,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,1,,2713,CHEMBL624646,,BAO_0000218,
10590,50597,,,1,,N,,,,Intermediate,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,1,,2713,CHEMBL624647,,BAO_0000218,
10591,50597,,,1,,N,,Liver,,Intermediate,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,1,,5340,CHEMBL624648,,BAO_0000218,2107.0
10592,50597,,,1,,N,,,,Intermediate,Area under curve ratio was determined (po/iv) in rat,A,1,,12058,CHEMBL624649,,BAO_0000218,
10593,50597,,,1,,N,,,,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,1,,11195,CHEMBL624650,,BAO_0000218,
10594,50597,,,1,,N,,,,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,1,,11195,CHEMBL624651,,BAO_0000218,
10595,50597,,,1,,N,,,,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,1,,11195,CHEMBL624652,,BAO_0000218,
10596,50597,,,1,,N,,,,Intermediate,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,1,,6495,CHEMBL624653,,BAO_0000218,
10597,50597,,,1,,N,,,,Intermediate,Ratio of AUCbrain to AUCplasma,A,1,,6078,CHEMBL624654,,BAO_0000218,
10598,50597,,,1,,N,,,,Intermediate,Ratio of brain to plasma,A,1,,5656,CHEMBL624655,,BAO_0000218,
10599,50597,,,1,,N,,,,Intermediate,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,1,,4910,CHEMBL624656,,BAO_0000218,
10600,50597,,,1,,N,,,,Intermediate,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,1,,4910,CHEMBL624657,,BAO_0000218,
10601,50597,,,1,,N,,,,Intermediate,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,1,,4910,CHEMBL624658,,BAO_0000218,
10602,50597,,,1,,N,,,,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,1,,10130,CHEMBL624659,,BAO_0000218,
10603,50597,,,1,,N,,,,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,1,,10130,CHEMBL624660,,BAO_0000218,
10604,50597,,,1,,N,,,,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,1,,10130,CHEMBL624661,,BAO_0000218,
10605,50597,,,1,,N,,,,Intermediate,Steady state brain :blood ratio was determined,A,1,,5213,CHEMBL624662,,BAO_0000218,
10606,50597,,,1,,N,,,,Intermediate,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL625199,,BAO_0000218,
10607,50597,,,1,,N,,,,Intermediate,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,1,,4910,CHEMBL625200,,BAO_0000218,
10608,50597,,,1,,N,,,,Intermediate,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,1,,4910,CHEMBL625201,,BAO_0000218,
10609,50597,,,1,,N,,,,Intermediate,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,1,,4910,CHEMBL625202,,BAO_0000218,
10610,50597,,,1,,N,,,,Intermediate,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,1,,2083,CHEMBL625203,,BAO_0000218,
10611,50597,,,1,,N,,,,Intermediate,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,1,,2082,CHEMBL625204,,BAO_0000218,
10612,50597,,,1,,N,,,,Intermediate,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,1,,2082,CHEMBL625205,,BAO_0000218,
10613,50597,,,1,,N,,,,Intermediate,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,1,,6351,CHEMBL625206,,BAO_0000218,
10614,22224,,,0,,U,,,,Autocuration,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,1,,14583,CHEMBL625207,,BAO_0000019,
10615,22224,,,0,,U,,,,Autocuration,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,1,,14583,CHEMBL625208,,BAO_0000019,
10616,50587,,,1,,N,,,Caco-2,Intermediate,In vivo absorption in Caco-2 cell line monolayers was determined,A,1,,4608,CHEMBL625209,495.0,BAO_0000218,
10617,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13668,CHEMBL625210,,BAO_0000100,
10618,50597,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 10 mpk in Rat,A,1,,5669,CHEMBL625211,,BAO_0000218,
10619,50797,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,1,,5669,CHEMBL625212,,BAO_0000218,
10620,50597,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 160 mpk in Rat,A,1,,5669,CHEMBL625213,,BAO_0000218,
10621,50597,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 20 mpk in Rat,A,1,,5669,CHEMBL625214,,BAO_0000218,
10622,50597,,,1,,N,,,,Intermediate,Area under curve was determine after peroral administration at 50 mpk in Rat,A,1,,5669,CHEMBL874542,,BAO_0000218,
10623,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (AlogP),P,1,,6472,CHEMBL625215,,BAO_0000100,
10624,22224,,,0,,U,,,,Autocuration,Activated partial thromboplastin time measured,A,1,,15106,CHEMBL625216,,BAO_0000019,
10625,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,1,,15207,CHEMBL625217,,BAO_0000100,
10626,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,1,,15207,CHEMBL625218,,BAO_0000100,
10627,50588,,,1,,N,,Plasma,,Intermediate,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,1,,13941,CHEMBL622864,,BAO_0000218,1969.0
10628,50597,,,1,,N,,Plasma,,Intermediate,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,1,,13941,CHEMBL622865,,BAO_0000218,1969.0
10629,50597,,,1,,N,,Plasma,,Intermediate,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,1,,13941,CHEMBL622866,,BAO_0000218,1969.0
10630,50588,,,1,,N,,Plasma,,Intermediate,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,1,,13941,CHEMBL622867,,BAO_0000218,1969.0
10631,50512,,,1,,N,,Plasma,,Intermediate,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,1,,15240,CHEMBL876808,,BAO_0000218,1969.0
10632,22224,,,0,,U,,Brain,,Autocuration,AUC in brain,A,1,,10655,CHEMBL627725,,BAO_0000019,955.0
10633,22224,,,0,,U,,Serum,,Autocuration,AUC in serum,A,1,,10655,CHEMBL627726,,BAO_0000019,1977.0
10634,22224,,,0,,U,,Plasma,,Autocuration,AUC was determined,A,1,,6504,CHEMBL627727,,BAO_0000019,1969.0
10635,22224,,,0,,U,,Plasma,,Autocuration,AUC of the compound.,A,1,,10615,CHEMBL627728,,BAO_0000019,1969.0
10636,22224,,,0,,U,,Plasma,,Autocuration,AUC value (0-4 hr),A,1,,10353,CHEMBL627729,,BAO_0000019,1969.0
10637,22224,,,0,,U,,Plasma,,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,1,,14907,CHEMBL627730,,BAO_0000019,1969.0
10638,22224,,,0,,U,,Plasma,,Autocuration,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,1,,14907,CHEMBL627731,,BAO_0000019,1969.0
10639,22224,,,0,,U,,Plasma,,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,1,,14907,CHEMBL627732,,BAO_0000019,1969.0
10640,22224,,,0,,U,,Plasma,,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,1,,14907,CHEMBL627733,,BAO_0000019,1969.0
10641,50597,,,1,,N,,Plasma,,Intermediate,AUC(area under curve) was determined after intravenous administration in rats,A,1,,16359,CHEMBL627734,,BAO_0000218,1969.0
10642,50597,,,1,,N,,Plasma,,Intermediate,AUC(area under curve) was determined after oral administration in rats,A,1,,16359,CHEMBL627735,,BAO_0000218,1969.0
10643,50512,,,1,,N,,Plasma,,Intermediate,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,1,,15240,CHEMBL627736,,BAO_0000218,1969.0
10644,50597,,,1,,N,,Plasma,,Intermediate,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,1,,15240,CHEMBL876809,,BAO_0000218,1969.0
10645,22224,,,0,,U,,,,Autocuration,Area Under Curve after oral dosing of 100 uM/Kg,A,1,,15469,CHEMBL627737,,BAO_0000019,
10646,22224,,,0,,U,,,,Autocuration,Area Under Curve after oral dosing of 30 uM/Kg,A,1,,15469,CHEMBL627738,,BAO_0000019,
10647,22224,,,0,,U,,,,Autocuration,Area Under Curve was measured by ploting the graph between concentration verses time,A,1,,13520,CHEMBL627739,,BAO_0000019,
10648,50588,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,1,,17025,CHEMBL626143,,BAO_0000218,
10649,22224,,,0,,U,,,,Autocuration,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,1,,17025,CHEMBL626144,,BAO_0000218,
10650,50592,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,1,,17025,CHEMBL626145,,BAO_0000218,
10651,50597,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,1,,17025,CHEMBL626146,,BAO_0000218,
10652,50597,,,1,,N,,Blood,,Intermediate,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,1,,12032,CHEMBL626147,,BAO_0000218,178.0
10653,22224,,,0,,U,,,,Autocuration,Area under curve (AUC) was determined,A,1,,10291,CHEMBL626148,,BAO_0000019,
10654,22224,,,0,,U,,,,Autocuration,Area under curve (AUC) following ip administration at 1 mg/kg,A,1,,5767,CHEMBL626149,,BAO_0000218,
10655,22224,,,0,,U,,,,Autocuration,Area under curve (AUC) was determined; ND is Not determined,A,1,,1434,CHEMBL626150,,BAO_0000019,
10656,50588,,,1,,N,,,,Intermediate,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,1,,14925,CHEMBL626151,,BAO_0000218,
10657,50588,,,1,,N,,,,Intermediate,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,1,,14925,CHEMBL626152,,BAO_0000218,
10658,50588,,,1,,N,,,,Intermediate,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,1,,14925,CHEMBL626153,,BAO_0000218,
10659,22224,,,0,,U,,,,Autocuration,Area under curve (AUR) was determined,A,1,,1434,CHEMBL626154,,BAO_0000019,
10660,22224,,,0,,U,,,,Autocuration,Area under curve at 1 uM/dg administered intravenously,A,1,,11883,CHEMBL626155,,BAO_0000019,
10661,22224,,,0,,U,,,,Autocuration,Area under curve at 10 uM/dg administered perorally,A,1,,11883,CHEMBL626156,,BAO_0000019,
10662,22224,,,0,,U,,,,Autocuration,Area under curve at 2 uM/dg administered intravenously,A,1,,11883,CHEMBL626157,,BAO_0000019,
10663,22224,,,0,,U,,,,Autocuration,Area under curve at 20 uM/dg administered perorally,A,1,,11883,CHEMBL626158,,BAO_0000019,
10664,50588,,,1,,N,,,,Intermediate,Area under curve at a peroral dose of 3 mg/kg in dog,A,1,,15233,CHEMBL626159,,BAO_0000218,
10665,50597,,,1,,N,,,,Intermediate,Area under curve at a peroral dose of 3 mg/kg in rat,A,1,,15233,CHEMBL626160,,BAO_0000218,
10666,50588,,,1,,N,,,,Intermediate,Area under curve at an iv dose of 1 mg/kg in dog,A,1,,15233,CHEMBL626161,,BAO_0000218,
10667,50597,,,1,,N,,,,Intermediate,Area under curve at an iv dose of 1 mg/kg in rat,A,1,,15233,CHEMBL626162,,BAO_0000218,
10668,22224,,,0,,U,,,,Autocuration,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,1,,12978,CHEMBL626163,,BAO_0000019,
10669,22224,,,0,,U,,,,Autocuration,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,1,,12978,CHEMBL626164,,BAO_0000019,
10670,50594,,,1,,N,,,,Intermediate,Area under curve measured as conc vs time after intravenous administration to mice.,A,1,,11355,CHEMBL626165,,BAO_0000218,
10671,50594,,,1,,N,,,,Intermediate,Area under curve measured as conc vs time after peroral administration to mice.,A,1,,11355,CHEMBL626166,,BAO_0000218,
10672,50588,,,1,,N,,,,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,1,,12923,CHEMBL626167,,BAO_0000218,
10673,50588,,,1,,N,,,,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,1,,12923,CHEMBL626168,,BAO_0000218,
10674,50588,,,1,,N,,,,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,1,,12923,CHEMBL877463,,BAO_0000218,
10675,50588,,,1,,N,,,,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,1,,12923,CHEMBL626169,,BAO_0000218,
10676,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL626170,,BAO_0000218,948.0
10677,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL626171,,BAO_0000218,948.0
10678,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL626172,,BAO_0000218,948.0
10679,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL626173,,BAO_0000218,948.0
10680,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,1,,17738,CHEMBL626174,,BAO_0000218,2113.0
10681,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL626175,,BAO_0000218,2113.0
10682,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL626176,,BAO_0000218,2113.0
10683,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL626177,,BAO_0000218,2113.0
10684,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622499,,BAO_0000218,2113.0
10685,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,1,,17738,CHEMBL622500,,BAO_0000218,2107.0
10686,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622501,,BAO_0000218,2107.0
10687,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL622502,,BAO_0000218,2107.0
10688,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL622503,,BAO_0000218,2107.0
10689,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL877614,,BAO_0000218,2107.0
10690,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL624839,,BAO_0000218,2048.0
10691,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL624840,,BAO_0000218,2048.0
10692,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL624841,,BAO_0000218,2048.0
10693,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL624842,,BAO_0000218,2048.0
10694,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL624843,,BAO_0000218,2385.0
10695,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,1,,17738,CHEMBL624844,,BAO_0000218,2385.0
10696,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL624845,,BAO_0000218,2385.0
10697,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,1,,17738,CHEMBL621904,,BAO_0000218,2385.0
10698,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,1,,11195,CHEMBL621905,,BAO_0000218,178.0
10699,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,1,,11195,CHEMBL874382,,BAO_0000218,178.0
10700,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,1,,11195,CHEMBL621906,,BAO_0000218,178.0
10701,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,1,,11195,CHEMBL621907,,BAO_0000218,955.0
10702,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,1,,11195,CHEMBL622096,,BAO_0000218,955.0
10703,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,1,,11195,CHEMBL622097,,BAO_0000218,955.0
10704,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,1,,11195,CHEMBL622098,,BAO_0000218,948.0
10705,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,1,,11195,CHEMBL622099,,BAO_0000218,948.0
10706,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,1,,11195,CHEMBL622100,,BAO_0000218,948.0
10707,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,1,,11195,CHEMBL622101,,BAO_0000218,2113.0
10708,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,1,,11195,CHEMBL622102,,BAO_0000218,2113.0
10709,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,1,,11195,CHEMBL622103,,BAO_0000218,2113.0
10710,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,1,,11195,CHEMBL622104,,BAO_0000218,2107.0
10711,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,1,,11195,CHEMBL622105,,BAO_0000218,2107.0
10712,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,1,,11195,CHEMBL622106,,BAO_0000218,2107.0
10713,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,1,,11195,CHEMBL622107,,BAO_0000218,2048.0
10714,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,1,,11195,CHEMBL622108,,BAO_0000218,2048.0
10715,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,1,,11195,CHEMBL622109,,BAO_0000218,2048.0
10716,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,1,,11195,CHEMBL622110,,BAO_0000218,2385.0
10717,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,1,,11195,CHEMBL622111,,BAO_0000218,2385.0
10718,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,1,,11195,CHEMBL874383,,BAO_0000218,2385.0
10719,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,1,,11195,CHEMBL622112,,BAO_0000218,14.0
10720,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,1,,11195,CHEMBL622113,,BAO_0000218,14.0
10721,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,1,,11195,CHEMBL622114,,BAO_0000218,14.0
10722,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,1,,11195,CHEMBL622115,,BAO_0000218,2106.0
10723,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,1,,11195,CHEMBL622116,,BAO_0000218,2106.0
10724,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6193,CHEMBL622117,,BAO_0000218,
10725,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6803,CHEMBL622118,,BAO_0000218,
10726,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rats at 6 mg/kg,A,1,,6647,CHEMBL622119,,BAO_0000218,
10727,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 6 mg/kg),A,1,,6647,CHEMBL622120,,BAO_0000218,
10728,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,1,,6647,CHEMBL622121,,BAO_0000218,
10729,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6640,CHEMBL622122,,BAO_0000218,
10730,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6641,CHEMBL622123,,BAO_0000218,
10731,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6641,CHEMBL622124,,BAO_0000218,
10732,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,6642,CHEMBL622125,,BAO_0000218,
10733,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,5472,CHEMBL622126,,BAO_0000218,
10734,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,1,,6141,CHEMBL620455,,BAO_0000218,
10735,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,4390,CHEMBL620456,,BAO_0000218,
10736,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5472,CHEMBL620457,,BAO_0000218,
10737,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was evaluated; Not tested,A,1,,5472,CHEMBL620458,,BAO_0000218,
10738,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,5438,CHEMBL620459,,BAO_0000218,
10739,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat by oral dosing,A,1,,4883,CHEMBL620460,,BAO_0000218,
10740,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,1,,1908,CHEMBL620461,,BAO_0000218,
10741,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley),A,1,,4853,CHEMBL620462,,BAO_0000218,
10742,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,1,,4853,CHEMBL620463,,BAO_0000218,
10743,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,1,,4853,CHEMBL620464,,BAO_0000218,
10744,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,1,,4853,CHEMBL620465,,BAO_0000218,
10745,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,1,,4853,CHEMBL620466,,BAO_0000218,
10746,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,1,,4853,CHEMBL620467,,BAO_0000218,
10747,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,1,,4853,CHEMBL620468,,BAO_0000218,
10748,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,1,,12873,CHEMBL620469,,BAO_0000218,
10749,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,1,,12873,CHEMBL620470,,BAO_0000218,
10750,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3169,CHEMBL620471,,BAO_0000218,
10751,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6305,CHEMBL620472,,BAO_0000218,
10752,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,1,,4762,CHEMBL620473,,BAO_0000218,
10753,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17847,CHEMBL620474,,BAO_0000218,
10754,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,1,,6211,CHEMBL620475,,BAO_0000218,
10755,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6011,CHEMBL620476,,BAO_0000218,
10756,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,6317,CHEMBL620477,,BAO_0000218,
10757,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,1,,6644,CHEMBL620478,,BAO_0000218,
10758,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,1,,6644,CHEMBL618768,,BAO_0000218,
10759,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,1,,6644,CHEMBL618769,,BAO_0000218,
10760,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,1,,6644,CHEMBL618770,,BAO_0000218,
10761,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability (dose 20 mg/kg p.o.),A,1,,6113,CHEMBL618771,,BAO_0000218,
10762,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,1,,5937,CHEMBL618772,,BAO_0000218,
10763,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat at 10 mg/kg of the compound,A,1,,5711,CHEMBL618773,,BAO_0000218,
10764,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,1,,17717,CHEMBL875842,,BAO_0000218,
10765,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 3 mg/kg i.v.),A,1,,17717,CHEMBL618774,,BAO_0000218,
10766,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,1,,17717,CHEMBL618775,,BAO_0000218,
10767,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,1,,17717,CHEMBL618776,,BAO_0000218,
10768,50597,,In vivo,1,,N,,,,Intermediate,Percent bioavailability (F) in rats after iv administration,A,1,,4722,CHEMBL618777,,BAO_0000218,
10769,50597,,In vivo,1,,N,,,,Intermediate,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,1,,4722,CHEMBL618778,,BAO_0000218,
10770,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 5 uM/kg p.o.),A,1,,4353,CHEMBL618779,,BAO_0000218,
10771,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability,A,1,,15662,CHEMBL618780,,BAO_0000218,
10772,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat (dose 2 mg/kg p.o.),A,1,,4756,CHEMBL618781,,BAO_0000218,
10773,50597,,In vivo,1,,N,,,,Intermediate,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,1,,4756,CHEMBL618782,,BAO_0000218,
10774,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 20 mg/kg),A,1,,3436,CHEMBL618783,,BAO_0000218,
10775,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,17800,CHEMBL618784,,BAO_0000218,
10776,50597,,In vivo,1,,N,,,,Intermediate,Percent oral bioavailability evaluated in rat,A,1,,15762,CHEMBL618785,,BAO_0000218,
10777,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,5089,CHEMBL618786,,BAO_0000218,
10778,50597,,In vivo,1,,N,,,,Intermediate,Percent oral bioavailability in rat; Not determined,A,1,,5089,CHEMBL618787,,BAO_0000218,
10779,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat,A,1,,3185,CHEMBL618788,,BAO_0000218,
10780,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability in rat,A,1,,5145,CHEMBL618789,,BAO_0000218,
10781,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,1,,3457,CHEMBL618790,,BAO_0000218,
10782,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,1,,3457,CHEMBL618791,,BAO_0000218,
10783,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,1,,5983,CHEMBL875843,,BAO_0000218,
10784,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,1,,5739,CHEMBL618792,,BAO_0000218,
10785,50597,,In vivo,1,,N,,,,Intermediate,Cmax at a dose of 30 mg/kg in rat,A,1,,3579,CHEMBL623395,,BAO_0000218,
10786,22224,,In vivo,0,,U,,,,Autocuration,Cmax in monkeys at a dose of 1 mg/kg,A,1,,17788,CHEMBL623396,,BAO_0000218,
10787,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat,A,1,,14956,CHEMBL623397,,BAO_0000218,
10788,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rats at a dose of 1 mg/kg,A,1,,17788,CHEMBL623398,,BAO_0000218,
10789,50594,,In vivo,1,,N,,,,Intermediate,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,1,,9750,CHEMBL623399,,BAO_0000218,
10790,22224,,In vivo,0,,U,,,,Autocuration,"Cmax value at a dose of 12.7 uM/kg, po",A,1,,12767,CHEMBL623400,,BAO_0000218,
10791,22224,,In vivo,0,,U,,,,Autocuration,"Cmax value at a dose of 6.3 uM/kg, iv",A,1,,12767,CHEMBL623401,,BAO_0000218,
10792,22224,,In vivo,0,,U,,,,Autocuration,"Cmax value at a dose of 7.1 uM/kg, iv",A,1,,12767,CHEMBL623402,,BAO_0000218,
10793,22224,,In vivo,0,,U,,,,Autocuration,Cmax value of compound was determined after 1 hr,A,1,,12703,CHEMBL623403,,BAO_0000218,
10794,22224,,In vivo,0,,U,,,,Autocuration,Cmax value of the compound,A,1,,15778,CHEMBL623404,,BAO_0000218,
10795,50597,,In vivo,1,,N,,,,Intermediate,Cmax value administered intraintestinal in rats.,A,1,,12818,CHEMBL625997,,BAO_0000218,
10796,50597,,In vivo,1,,N,,,,Intermediate,Cmax value administered perorally was determined in rat; Not determined,A,1,,14964,CHEMBL625998,,BAO_0000218,
10797,22224,,In vivo,0,,U,,,,Autocuration,Cmax value at the dose of 2.3 mg/kg,A,1,,15808,CHEMBL625999,,BAO_0000218,
10798,22224,,In vivo,0,,U,,,,Autocuration,Cmax value at the dose of 5 mg/kg,A,1,,15808,CHEMBL626000,,BAO_0000218,
10799,22224,,In vivo,0,,U,,,,Autocuration,Cmax value in the period of 8 hr after dosing. ,A,1,,15778,CHEMBL626001,,BAO_0000218,
10800,22224,,In vivo,0,,U,,,,Autocuration,Cmax value at a oral dose of 20 mg/kg; Not tested,A,1,,3715,CHEMBL626002,,BAO_0000218,
10801,22224,,In vivo,0,,U,,,,Autocuration,Cmax value at a oral dose of 20 mg/kg,A,1,,3715,CHEMBL626003,,BAO_0000218,
10802,50597,,In vivo,1,,N,,,,Intermediate,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,1,,1446,CHEMBL626004,,BAO_0000218,
10803,50512,,In vivo,1,,N,,,,Intermediate,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,1,,15240,CHEMBL626005,,BAO_0000218,
10804,50597,,In vivo,1,,N,,,,Intermediate,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,1,,15240,CHEMBL626006,,BAO_0000218,
10805,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,1,,14810,CHEMBL626007,,BAO_0000218,1969.0
10806,50594,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,1,,14239,CHEMBL626008,,BAO_0000218,1969.0
10807,50588,,In vivo,1,,N,,Liver,,Intermediate,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,1,,12555,CHEMBL626009,,BAO_0000218,2107.0
10808,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,1,,10754,CHEMBL626010,,BAO_0000218,
10809,50594,,In vivo,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,1,,10754,CHEMBL626011,,BAO_0000218,178.0
10810,50594,,In vivo,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,1,,10754,CHEMBL626012,,BAO_0000218,178.0
10811,50594,,In vivo,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,1,,10754,CHEMBL626013,,BAO_0000218,178.0
10812,50594,,In vivo,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,1,,10754,CHEMBL626014,,BAO_0000218,178.0
10813,50594,,In vivo,1,,N,,Blood,,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,1,,10754,CHEMBL877496,,BAO_0000218,178.0
10814,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,1,,14600,CHEMBL626015,,BAO_0000218,
10815,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,1,,14600,CHEMBL626016,,BAO_0000218,
10816,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,1,,14600,CHEMBL626017,,BAO_0000218,
10817,50588,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability as maximal plasma concentration in dogs,A,1,,13543,CHEMBL626018,,BAO_0000218,1969.0
10818,50588,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability as maximal plasma concentration in dogs,A,1,,13543,CHEMBL626692,,BAO_0000218,1969.0
10819,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability as maximal plasma concentration in rats,A,1,,13543,CHEMBL626693,,BAO_0000218,1969.0
10820,22224,,In vivo,0,,U,,Plasma,,Autocuration,Bioavailability as maximal plasma concentration in rats,A,1,,13543,CHEMBL626694,,BAO_0000218,1969.0
10821,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,1,,14600,CHEMBL626695,,BAO_0000218,178.0
10822,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,1,,14600,CHEMBL626696,,BAO_0000218,178.0
10823,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,1,,14600,CHEMBL626697,,BAO_0000218,178.0
10824,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,1,,14600,CHEMBL626859,,BAO_0000218,178.0
10825,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,1,,14600,CHEMBL626860,,BAO_0000218,178.0
10826,50588,,In vivo,1,,N,,Blood,,Intermediate,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,1,,14600,CHEMBL626861,,BAO_0000218,178.0
10827,50597,,In vivo,1,,N,,,,Intermediate,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,1,,14681,CHEMBL626296,,BAO_0000218,
10828,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,1,,15905,CHEMBL626297,,BAO_0000218,
10829,22224,,In vivo,0,,U,,Plasma,,Autocuration,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,1,,15905,CHEMBL626298,,BAO_0000218,1969.0
10830,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,1,,13304,CHEMBL626299,,BAO_0000218,1969.0
10831,50597,,In vivo,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,1,,15137,CHEMBL626300,,BAO_0000218,1969.0
10832,50597,,In vivo,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,1,,15137,CHEMBL626301,,BAO_0000218,1969.0
10833,50597,,In vivo,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,1,,15137,CHEMBL626962,,BAO_0000218,1969.0
10834,50597,,In vivo,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,1,,15137,CHEMBL626963,,BAO_0000218,1969.0
10835,50597,,In vivo,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,1,,15137,CHEMBL626964,,BAO_0000218,1969.0
10836,100710,,In vivo,1,,N,,Plasma,,Intermediate,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,1,,14839,CHEMBL626965,,BAO_0000218,1969.0
10837,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL626966,,BAO_0000218,1969.0
10838,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL626967,,BAO_0000218,1969.0
10839,100710,,In vivo,1,,N,,Plasma,,Intermediate,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,1,,14839,CHEMBL626968,,BAO_0000218,1969.0
10840,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,1,,8418,CHEMBL626969,,BAO_0000218,948.0
10841,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,1,,8418,CHEMBL627126,,BAO_0000218,948.0
10842,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,1,,8418,CHEMBL631276,,BAO_0000218,948.0
10843,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,1,,8418,CHEMBL631277,,BAO_0000218,948.0
10844,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,1,,8418,CHEMBL631278,,BAO_0000218,948.0
10845,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,1,,8418,CHEMBL874457,,BAO_0000218,948.0
10846,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,1,,8418,CHEMBL631279,,BAO_0000218,948.0
10847,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,1,,8418,CHEMBL631280,,BAO_0000218,948.0
10848,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,1,,8418,CHEMBL631281,,BAO_0000218,948.0
10849,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,1,,8418,CHEMBL631968,,BAO_0000218,948.0
10850,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,1,,8418,CHEMBL631969,,BAO_0000218,948.0
10851,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,1,,8418,CHEMBL631970,,BAO_0000218,948.0
10852,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,1,,8418,CHEMBL631971,,BAO_0000218,948.0
10853,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,1,,8418,CHEMBL631972,,BAO_0000218,948.0
10854,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,1,,8418,CHEMBL630435,,BAO_0000218,948.0
10855,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,1,,8418,CHEMBL630436,,BAO_0000218,948.0
10856,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,1,,8418,CHEMBL630437,,BAO_0000218,948.0
10857,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,1,,8418,CHEMBL630438,,BAO_0000218,948.0
10858,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,1,,8418,CHEMBL630439,,BAO_0000218,948.0
10859,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,1,,8418,CHEMBL630440,,BAO_0000218,2113.0
10860,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,1,,8418,CHEMBL630441,,BAO_0000218,2113.0
10861,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,1,,8418,CHEMBL630442,,BAO_0000218,2113.0
10862,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,1,,8418,CHEMBL625234,,BAO_0000218,2113.0
10863,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,1,,8418,CHEMBL625235,,BAO_0000218,2113.0
10864,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,1,,8418,CHEMBL625236,,BAO_0000218,2113.0
10865,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,1,,8418,CHEMBL625237,,BAO_0000218,2113.0
10866,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,1,,8418,CHEMBL626125,,BAO_0000218,2113.0
10867,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,1,,8418,CHEMBL626126,,BAO_0000218,2113.0
10868,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,1,,8418,CHEMBL626127,,BAO_0000218,2113.0
10869,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,1,,8418,CHEMBL626128,,BAO_0000218,2113.0
10870,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,1,,8418,CHEMBL626129,,BAO_0000218,2113.0
10871,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,1,,8418,CHEMBL626130,,BAO_0000218,2113.0
10872,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,1,,8418,CHEMBL626131,,BAO_0000218,2113.0
10873,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,1,,8418,CHEMBL626132,,BAO_0000218,2113.0
10874,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,1,,8418,CHEMBL626752,,BAO_0000218,2113.0
10875,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,1,,8418,CHEMBL626753,,BAO_0000218,2113.0
10876,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,1,,8418,CHEMBL626754,,BAO_0000218,2113.0
10877,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,1,,8418,CHEMBL626755,,BAO_0000218,2113.0
10878,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,1,,8418,CHEMBL626756,,BAO_0000218,2107.0
10879,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,1,,8418,CHEMBL626757,,BAO_0000218,2107.0
10880,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,1,,8418,CHEMBL626758,,BAO_0000218,2107.0
10881,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,1,,8418,CHEMBL626759,,BAO_0000218,2107.0
10882,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,1,,8418,CHEMBL626760,,BAO_0000218,2107.0
10883,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL626394,,BAO_0000218,
10884,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,1,,6996,CHEMBL626395,,BAO_0000218,
10885,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL626396,,BAO_0000218,
10886,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL626397,,BAO_0000218,
10887,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL626398,,BAO_0000218,
10888,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL626399,,BAO_0000218,
10889,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,1,,6996,CHEMBL874653,,BAO_0000218,
10890,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL626400,,BAO_0000218,
10891,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL626401,,BAO_0000218,
10892,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL626402,,BAO_0000218,
10893,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL626403,,BAO_0000218,
10894,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL626404,,BAO_0000218,
10895,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,1,,6996,CHEMBL626405,,BAO_0000218,
10896,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625529,,BAO_0000218,
10897,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL625530,,BAO_0000218,
10898,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL625531,,BAO_0000218,
10899,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL625532,,BAO_0000218,
10900,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625533,,BAO_0000218,
10901,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,1,,6996,CHEMBL875474,,BAO_0000218,
10902,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625534,,BAO_0000218,
10903,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL625535,,BAO_0000218,
10904,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL625536,,BAO_0000218,
10905,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL625537,,BAO_0000218,
10906,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625538,,BAO_0000218,
10907,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,1,,6996,CHEMBL625539,,BAO_0000218,
10908,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625540,,BAO_0000218,
10909,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL625541,,BAO_0000218,
10910,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL625542,,BAO_0000218,
10911,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL625543,,BAO_0000218,
10912,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL625544,,BAO_0000218,
10913,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,1,,6996,CHEMBL625545,,BAO_0000218,
10914,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL625546,,BAO_0000218,
10915,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,1,,6996,CHEMBL625547,,BAO_0000218,
10916,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL625548,,BAO_0000218,
10917,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL625549,,BAO_0000218,
10918,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL625550,,BAO_0000218,
10919,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL625551,,BAO_0000218,
10920,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL875475,,BAO_0000218,
10921,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL625552,,BAO_0000218,
10922,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL625553,,BAO_0000218,
10923,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL625554,,BAO_0000218,
10924,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL625555,,BAO_0000218,
10925,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL625556,,BAO_0000218,
10926,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,1,,6996,CHEMBL624986,,BAO_0000218,
10927,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL624987,,BAO_0000218,
10928,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL624988,,BAO_0000218,
10929,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,1,,9025,CHEMBL624989,,BAO_0000218,1637.0
10930,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,1,,9025,CHEMBL624990,,BAO_0000218,1637.0
10931,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,1,,9025,CHEMBL874391,,BAO_0000218,1637.0
10932,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,1,,9025,CHEMBL624991,,BAO_0000218,1637.0
10933,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,1,,9025,CHEMBL624992,,BAO_0000218,1637.0
10934,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,1,,9025,CHEMBL624993,,BAO_0000218,1637.0
10935,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,1,,9025,CHEMBL624994,,BAO_0000218,1637.0
10936,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,1,,9025,CHEMBL624995,,BAO_0000218,1637.0
10937,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,1,,9025,CHEMBL624996,,BAO_0000218,1637.0
10938,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,1,,9025,CHEMBL624997,,BAO_0000218,1637.0
10939,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,1,,9025,CHEMBL624998,,BAO_0000218,1637.0
10940,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,1,,9025,CHEMBL624999,,BAO_0000218,1637.0
10941,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,1,,9025,CHEMBL882955,,BAO_0000218,1637.0
10942,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,1,,9025,CHEMBL625000,,BAO_0000218,1637.0
10943,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,1,,9025,CHEMBL625001,,BAO_0000218,1637.0
10944,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,1,,9025,CHEMBL625089,,BAO_0000218,1637.0
10945,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,1,,9025,CHEMBL625090,,BAO_0000218,1637.0
10946,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,1,,9025,CHEMBL625091,,BAO_0000218,1637.0
10947,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,1,,9025,CHEMBL625092,,BAO_0000218,1637.0
10948,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,1,,9025,CHEMBL625093,,BAO_0000218,1637.0
10949,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,1,,9025,CHEMBL625094,,BAO_0000218,1637.0
10950,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,1,,9025,CHEMBL625095,,BAO_0000218,1637.0
10951,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its bioavailability in the dogs,A,1,,2249,CHEMBL625096,,BAO_0000218,
10952,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for its bioavailability in the rats,A,1,,2249,CHEMBL625097,,BAO_0000218,
10953,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for oral bioavailability,A,1,,17515,CHEMBL882956,,BAO_0000218,
10954,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for percentage of Oral bioavailability in rats,A,1,,14541,CHEMBL625098,,BAO_0000218,
10955,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in guinea pig,A,1,,12797,CHEMBL625099,,BAO_0000218,
10956,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the oral bioavailability in rat,A,1,,12797,CHEMBL625100,,BAO_0000218,
10957,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the oral bioavailability in dog,A,1,,12797,CHEMBL625101,,BAO_0000218,
10958,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the oral bioavailability in rat,A,1,,12797,CHEMBL874396,,BAO_0000218,
10959,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog (dosed i.v.),F,1,,11727,CHEMBL625102,,BAO_0000218,
10960,50588,,In vivo,1,,N,,,,Intermediate,Compound was tested for in vivo bioavailability in dog,A,1,,13249,CHEMBL625103,,BAO_0000218,
10961,100712,,In vivo,1,,N,,,,Intermediate,Compound was tested for in vivo bioavailability in hamsters,A,1,,13249,CHEMBL625104,,BAO_0000218,
10962,22224,,In vivo,0,,U,,,,Autocuration,Compound was tested for in vivo bioavailability in monkey,A,1,,13249,CHEMBL625105,,BAO_0000218,
10963,50597,,In vivo,1,,N,,,,Intermediate,Compound was tested for in vivo bioavailability in rat,A,1,,13249,CHEMBL625106,,BAO_0000218,
10964,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in mouse,A,1,,9552,CHEMBL625107,,BAO_0000218,
10965,50594,,In vivo,1,,N,,,,Intermediate,Compound was tested for percent of oral bioavailability in mice; 56-74,A,1,,9552,CHEMBL625108,,BAO_0000218,
10966,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,1,,14839,CHEMBL625109,,BAO_0000218,
10967,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,1,,14839,CHEMBL625110,,BAO_0000218,
10968,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,1,,14839,CHEMBL625111,,BAO_0000218,
10969,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,1,,14839,CHEMBL625112,,BAO_0000218,
10970,50594,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in nude mice,A,1,,14839,CHEMBL875334,,BAO_0000218,
10971,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (i.d. dosing),A,1,,11219,CHEMBL628617,,BAO_0000218,
10972,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat,A,1,,9552,CHEMBL628618,,BAO_0000218,
10973,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,1,,11732,CHEMBL628619,,BAO_0000218,
10974,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,1,,11732,CHEMBL628620,,BAO_0000218,
10975,100710,,In vivo,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,1,,14839,CHEMBL628621,,BAO_0000218,
10976,100710,,In vivo,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,1,,14839,CHEMBL628622,,BAO_0000218,
10977,100710,,In vivo,1,,N,,,,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,1,,14839,CHEMBL628623,,BAO_0000218,
10978,100710,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,1,,14839,CHEMBL628624,,BAO_0000218,1969.0
10979,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL628625,,BAO_0000218,1969.0
10980,100710,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,1,,14839,CHEMBL628626,,BAO_0000218,1969.0
10981,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL627041,,BAO_0000218,1969.0
10982,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL627042,,BAO_0000218,1969.0
10983,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,1,,14839,CHEMBL627043,,BAO_0000218,1969.0
10984,22224,,In vivo,0,,U,,Plasma,,Autocuration,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,1,,13932,CHEMBL627044,,BAO_0000218,1969.0
10985,50594,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in mouse plasma,A,1,,11637,CHEMBL627045,,BAO_0000218,1969.0
10986,22224,,In vivo,0,,U,,Plasma,,Autocuration,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,1,,11637,CHEMBL627046,,BAO_0000218,1969.0
10987,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in rat,A,1,,13960,CHEMBL627047,,BAO_0000218,1969.0
10988,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,1,,15905,CHEMBL627048,,BAO_0000218,1969.0
10989,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,1,,14062,CHEMBL627049,,BAO_0000218,
10990,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,1,,14062,CHEMBL627050,,BAO_0000218,
10991,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,1,,14062,CHEMBL627051,,BAO_0000218,
10992,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,1,,14062,CHEMBL627052,,BAO_0000218,
10993,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,1,,14062,CHEMBL627053,,BAO_0000218,
10994,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,1,,14062,CHEMBL627054,,BAO_0000218,
10995,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627055,,BAO_0000218,
10996,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627056,,BAO_0000218,
10997,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,1,,15011,CHEMBL627057,,BAO_0000218,
10998,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL627058,,BAO_0000218,
10999,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,1,,15011,CHEMBL626211,,BAO_0000218,
11000,22224,,In vivo,0,,U,,,,Autocuration,Maximum Concentration of the compound.,A,1,,10291,CHEMBL626212,,BAO_0000218,
11001,50588,,In vivo,1,,N,,,,Intermediate,Maximum Concentration was measured after iv administration into Beagle dog,A,1,,14599,CHEMBL626213,,BAO_0000218,
11002,50588,,In vivo,1,,N,,,,Intermediate,Maximum Concentration was measured after iv administration into Beagle dog.,A,1,,14599,CHEMBL626214,,BAO_0000218,
11003,50588,,In vivo,1,,N,,,,Intermediate,Maximum Concentration was measured after po administration into Beagle dog,A,1,,14599,CHEMBL626215,,BAO_0000218,
11004,50588,,In vivo,1,,N,,,,Intermediate,Maximum Concentration was measured after po administration into Beagle dog.,A,1,,14599,CHEMBL626216,,BAO_0000218,
11005,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,1,,12767,CHEMBL626217,,BAO_0000218,178.0
11006,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,1,,12767,CHEMBL626218,,BAO_0000218,178.0
11007,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,1,,12767,CHEMBL626219,,BAO_0000218,178.0
11008,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,1,,12767,CHEMBL626220,,BAO_0000218,178.0
11009,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,1,,12767,CHEMBL626221,,BAO_0000218,178.0
11010,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum blood level reached at dose of 10.6 uM/kg orally,A,1,,12767,CHEMBL626222,,BAO_0000218,178.0
11011,50512,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,1,,14706,CHEMBL626223,,BAO_0000218,
11012,50512,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,1,,14706,CHEMBL626224,,BAO_0000218,
11013,50597,,In vivo,1,,N,,Brain,,Intermediate,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,1,,14793,CHEMBL626225,,BAO_0000218,955.0
11014,50597,,In vivo,1,,N,,Brain,,Intermediate,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,1,,14793,CHEMBL626226,,BAO_0000218,955.0
11015,50597,,In vivo,1,,N,,Brain,,Intermediate,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,1,,14793,CHEMBL626227,,BAO_0000218,955.0
11016,50597,,In vivo,1,,N,,Brain,,Intermediate,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,1,,14793,CHEMBL626228,,BAO_0000218,955.0
11017,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,1,,14793,CHEMBL626229,,BAO_0000218,
11018,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,1,,14793,CHEMBL626921,,BAO_0000218,
11019,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,1,,14793,CHEMBL876793,,BAO_0000218,
11020,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,1,,14793,CHEMBL625309,,BAO_0000218,
11021,50278,,In vivo,1,,N,,,,Intermediate,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1,,10524,CHEMBL625310,,BAO_0000218,
11022,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,1,,11871,CHEMBL625311,,BAO_0000218,
11023,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,1,,11871,CHEMBL625312,,BAO_0000218,
11024,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,1,,3437,CHEMBL625313,,BAO_0000218,
11025,50594,,In vivo,1,,N,,,,Intermediate,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,1,,12038,CHEMBL625314,,BAO_0000218,
11026,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration in male rats after iv administration of 20 mg/kg,A,1,,12038,CHEMBL625315,,BAO_0000218,
11027,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,1,,8418,CHEMBL625316,,BAO_0000218,2107.0
11028,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,1,,8418,CHEMBL625317,,BAO_0000218,2107.0
11029,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,1,,8418,CHEMBL625318,,BAO_0000218,2107.0
11030,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,1,,8418,CHEMBL625319,,BAO_0000218,2107.0
11031,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,1,,8418,CHEMBL625320,,BAO_0000218,2107.0
11032,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,1,,8418,CHEMBL625321,,BAO_0000218,2107.0
11033,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,1,,8418,CHEMBL625322,,BAO_0000218,2107.0
11034,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,1,,8418,CHEMBL876801,,BAO_0000218,2107.0
11035,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,1,,8418,CHEMBL625323,,BAO_0000218,2107.0
11036,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,1,,8418,CHEMBL625324,,BAO_0000218,2107.0
11037,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,1,,8418,CHEMBL625325,,BAO_0000218,2107.0
11038,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,1,,8418,CHEMBL625326,,BAO_0000218,2107.0
11039,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,1,,8418,CHEMBL625327,,BAO_0000218,2107.0
11040,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,1,,8418,CHEMBL625328,,BAO_0000218,2107.0
11041,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,1,,8418,CHEMBL625329,,BAO_0000218,2048.0
11042,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,1,,8418,CHEMBL625330,,BAO_0000218,2048.0
11043,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,1,,8418,CHEMBL627774,,BAO_0000218,2048.0
11044,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,1,,8418,CHEMBL627775,,BAO_0000218,2048.0
11045,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,1,,8418,CHEMBL627949,,BAO_0000218,2048.0
11046,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,1,,8418,CHEMBL627950,,BAO_0000218,2048.0
11047,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,1,,8418,CHEMBL627951,,BAO_0000218,2048.0
11048,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,1,,8418,CHEMBL627952,,BAO_0000218,2048.0
11049,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,1,,8418,CHEMBL627953,,BAO_0000218,2048.0
11050,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,1,,8418,CHEMBL627954,,BAO_0000218,2048.0
11051,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,1,,8418,CHEMBL627955,,BAO_0000218,2048.0
11052,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,1,,8418,CHEMBL627956,,BAO_0000218,2048.0
11053,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,1,,8418,CHEMBL876802,,BAO_0000218,2048.0
11054,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,1,,8418,CHEMBL627957,,BAO_0000218,2048.0
11055,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,1,,8418,CHEMBL627958,,BAO_0000218,2048.0
11056,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,1,,8418,CHEMBL627959,,BAO_0000218,2048.0
11057,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,1,,8418,CHEMBL627960,,BAO_0000218,2048.0
11058,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,1,,8418,CHEMBL627961,,BAO_0000218,2048.0
11059,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,1,,8418,CHEMBL627962,,BAO_0000218,2048.0
11060,50597,,,1,,N,,,,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,1,,9796,CHEMBL627963,,BAO_0000218,
11061,50597,,,1,,N,,,,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624759,,BAO_0000218,
11062,50597,,,1,,N,,,,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624760,,BAO_0000218,
11063,50597,,,1,,N,,,,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624761,,BAO_0000218,
11064,50597,,,1,,N,,,,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL877607,,BAO_0000218,
11065,50597,,,1,,N,,Liver,,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624762,,BAO_0000218,2107.0
11066,50597,,,1,,N,,Liver,,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624763,,BAO_0000218,2107.0
11067,50597,,,1,,N,,Liver,,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624764,,BAO_0000218,2107.0
11068,50597,,,1,,N,,Liver,,Intermediate,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624765,,BAO_0000218,2107.0
11069,50597,,,1,,N,,Liver,,Intermediate,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL624766,,BAO_0000218,2107.0
11070,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL624767,,BAO_0000218,
11071,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,1,,6996,CHEMBL624768,,BAO_0000218,
11072,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL624769,,BAO_0000218,
11073,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL624770,,BAO_0000218,
11074,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL624771,,BAO_0000218,
11075,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL624772,,BAO_0000218,
11076,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,1,,6996,CHEMBL624773,,BAO_0000218,
11077,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL624774,,BAO_0000218,
11078,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL624775,,BAO_0000218,
11079,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL624776,,BAO_0000218,
11080,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL624777,,BAO_0000218,
11081,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL624778,,BAO_0000218,
11082,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,1,,6996,CHEMBL624779,,BAO_0000218,
11083,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL624780,,BAO_0000218,
11084,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL624781,,BAO_0000218,
11085,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL877608,,BAO_0000218,
11086,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL624782,,BAO_0000218,
11087,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL624783,,BAO_0000218,
11088,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,1,,6996,CHEMBL624784,,BAO_0000218,
11089,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL624785,,BAO_0000218,
11090,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL624786,,BAO_0000218,
11091,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL624787,,BAO_0000218,
11092,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL628676,,BAO_0000218,
11093,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,1,,6996,CHEMBL621842,,BAO_0000218,
11094,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL621843,,BAO_0000218,
11095,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL623873,,BAO_0000218,
11096,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL623874,,BAO_0000218,
11097,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL623875,,BAO_0000218,
11098,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL623876,,BAO_0000218,
11099,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,1,,6996,CHEMBL623877,,BAO_0000218,
11100,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL623878,,BAO_0000218,
11101,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,1,,6996,CHEMBL623879,,BAO_0000218,
11102,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL623880,,BAO_0000218,
11103,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL623881,,BAO_0000218,
11104,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL623957,,BAO_0000218,
11105,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL623958,,BAO_0000218,
11106,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL623959,,BAO_0000218,
11107,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL623960,,BAO_0000218,
11108,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL623961,,BAO_0000218,
11109,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL623962,,BAO_0000218,
11110,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL624676,,BAO_0000218,
11111,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL624677,,BAO_0000218,
11112,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,1,,6996,CHEMBL624678,,BAO_0000218,
11113,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL624679,,BAO_0000218,
11114,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL624680,,BAO_0000218,
11115,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,1,,11732,CHEMBL624849,,BAO_0000218,
11116,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,1,,11732,CHEMBL624850,,BAO_0000218,
11117,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,1,,11732,CHEMBL874399,,BAO_0000218,
11118,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,1,,11732,CHEMBL624851,,BAO_0000218,
11119,22224,,In vivo,0,,U,,,,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,1,,11732,CHEMBL624852,,BAO_0000218,
11120,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat (dose 10 mg/kg),A,1,,13359,CHEMBL624853,,BAO_0000218,
11121,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat (Sprague-Dawley),A,1,,16618,CHEMBL624854,,BAO_0000218,
11122,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat,A,1,,13960,CHEMBL624855,,BAO_0000218,
11123,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rats was determined in vivo,A,1,,13917,CHEMBL624856,,BAO_0000218,
11124,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in dog,A,1,,14266,CHEMBL882957,,BAO_0000218,
11125,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability of compound in monkey,A,1,,12359,CHEMBL624857,,BAO_0000218,
11126,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound in rat,A,1,,12359,CHEMBL622202,,BAO_0000218,
11127,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat of PMEA prodrug,A,1,,12359,CHEMBL622203,,BAO_0000218,
11128,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,1,,12359,CHEMBL625522,,BAO_0000218,
11129,22224,,In vivo,0,,U,,,,Autocuration,Serum conc at 3 hours following 25 mg/kg dose,A,1,,10791,CHEMBL622868,,BAO_0000218,
11130,22224,,In vivo,0,,U,,Urine,,Autocuration,Urine conc 0-5 hours following 25 mg/kg dose,A,1,,10791,CHEMBL622869,,BAO_0000218,1088.0
11131,22224,,In vivo,0,,U,,Urine,,Autocuration,Urine conc 0-24 hours following 25 mg/kg dose,A,1,,10791,CHEMBL622870,,BAO_0000218,1088.0
11132,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in African green monkeys; 20-25,A,1,,138,CHEMBL622871,,BAO_0000218,
11133,100710,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in cynomolgus monkey.,A,1,,14521,CHEMBL620560,,BAO_0000218,
11134,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in dog,A,1,,13953,CHEMBL620561,,BAO_0000218,
11135,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in dog at 10 mg/kg oral dose,A,1,,12836,CHEMBL620562,,BAO_0000218,
11136,100712,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in hamster at 10 mg/kg oral dose,A,1,,12836,CHEMBL620563,,BAO_0000218,
11137,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability in rat at 10 mg/kg oral dose,A,1,,12836,CHEMBL620564,,BAO_0000218,
11138,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat,A,1,,14521,CHEMBL872265,,BAO_0000218,
11139,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat,A,1,,13953,CHEMBL620565,,BAO_0000218,
11140,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability,A,1,,6799,CHEMBL620566,,BAO_0000218,
11141,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability was determined; range 49-102%,A,1,,11311,CHEMBL620567,,BAO_0000218,
11142,50588,,In vivo,1,,N,,,,Intermediate,Oral bioavailability was determined in dogs,A,1,,4013,CHEMBL620568,,BAO_0000218,
11143,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat,A,1,,4013,CHEMBL620569,,BAO_0000218,
11144,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability,A,1,,17591,CHEMBL620570,,BAO_0000218,
11145,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability was determined; Not orally available,A,1,,17591,CHEMBL620571,,BAO_0000218,
11146,50594,,In vivo,1,,N,,,,Intermediate,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,1,,15011,CHEMBL620572,,BAO_0000218,
11147,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,1,,15011,CHEMBL620573,,BAO_0000218,
11148,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,1,,15011,CHEMBL620574,,BAO_0000218,
11149,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in Rhesus monkey,A,1,,9552,CHEMBL620575,,BAO_0000218,
11150,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in dog (female mongrel),A,1,,9552,CHEMBL620576,,BAO_0000218,
11151,22224,,In vivo,0,,U,,,,Autocuration,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,1,,3639,CHEMBL875846,,BAO_0000218,
11152,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in dog,A,1,,13397,CHEMBL620577,,BAO_0000218,
11153,22224,,In vivo,0,,U,,,,Autocuration,Percentage Bioavailability was evaluated.,A,1,,3031,CHEMBL620578,,BAO_0000218,
11154,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat administered i.d.,A,1,,12818,CHEMBL620579,,BAO_0000218,
11155,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability,A,1,,4847,CHEMBL621248,,BAO_0000218,
11156,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog (male Beagle) i.v. administration,A,1,,12421,CHEMBL625390,,BAO_0000218,
11157,22224,,In vivo,0,,U,,,,Autocuration,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,1,,11966,CHEMBL625391,,BAO_0000218,
11158,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,1,,11218,CHEMBL872266,,BAO_0000218,
11159,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in rat (Sprague-Dawley) (male),A,1,,13129,CHEMBL625392,,BAO_0000218,
11160,50597,,In vivo,1,,N,,,,Intermediate,The oral bioavailability was measured on rats after oral administration,A,1,,12350,CHEMBL625393,,BAO_0000218,
11161,50597,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,1,,2231,CHEMBL625394,,BAO_0000218,
11162,50797,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,1,,2231,CHEMBL625395,,BAO_0000218,
11163,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat (dose 10 mg/kg i.d.),A,1,,12187,CHEMBL625396,,BAO_0000218,
11164,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog (male Beagle) i.v. administration,A,1,,12421,CHEMBL625397,,BAO_0000218,
11165,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625398,,BAO_0000218,
11166,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625399,,BAO_0000218,178.0
11167,50594,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL626074,,BAO_0000218,2037.0
11168,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL626075,,BAO_0000218,
11169,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,1,,2231,CHEMBL626076,,BAO_0000218,1969.0
11170,50797,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,1,,2231,CHEMBL626077,,BAO_0000218,1969.0
11171,50597,,In vivo,1,,N,,Blood,,Intermediate,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,1,,12178,CHEMBL626078,,BAO_0000218,178.0
11172,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,1,,12178,CHEMBL625846,,BAO_0000218,178.0
11173,22224,,In vivo,0,,U,,Blood,,Autocuration,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,1,,12178,CHEMBL625847,,BAO_0000218,178.0
11174,50597,,In vivo,1,,N,,,,Expert,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,1,,15633,CHEMBL625848,,BAO_0000218,
11175,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of compound in plasma administered orally to rats,A,1,,14258,CHEMBL625849,,BAO_0000218,1969.0
11176,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,1,,14224,CHEMBL626023,,BAO_0000218,1969.0
11177,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,1,,14224,CHEMBL626024,,BAO_0000218,1969.0
11178,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,1,,14224,CHEMBL626025,,BAO_0000218,1969.0
11179,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration after 10 mg/kg by oral administration,A,1,,5566,CHEMBL626026,,BAO_0000218,
11180,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration at a dose of 1.5 mg/kg,A,1,,16935,CHEMBL626027,,BAO_0000218,
11181,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration at a dose of 2.0 mg/kg,A,1,,16935,CHEMBL626028,,BAO_0000218,
11182,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in dog plasma,A,1,,14224,CHEMBL626029,,BAO_0000218,1969.0
11183,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,1,,12536,CHEMBL626030,,BAO_0000218,1969.0
11184,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,1,,12536,CHEMBL626031,,BAO_0000218,1969.0
11185,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,1,,12536,CHEMBL626032,,BAO_0000218,1969.0
11186,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,1,,12536,CHEMBL626033,,BAO_0000218,1969.0
11187,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,1,,12536,CHEMBL626034,,BAO_0000218,1969.0
11188,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,1,,9994,CHEMBL626035,,BAO_0000218,1969.0
11189,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma at Tmax,A,1,,1434,CHEMBL626036,,BAO_0000218,1969.0
11190,50588,,In vivo,1,,N,,Plasma,,Expert,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,1,,12836,CHEMBL626037,,BAO_0000218,1969.0
11191,100712,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,1,,12836,CHEMBL626038,,BAO_0000218,1969.0
11192,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,1,,12836,CHEMBL626039,,BAO_0000218,1969.0
11193,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,1,,12545,CHEMBL626040,,BAO_0000218,1969.0
11194,50592,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,1,,13856,CHEMBL626041,,BAO_0000218,1969.0
11195,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration was calculated,A,1,,3550,CHEMBL626042,,BAO_0000218,
11196,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration was calculated.,A,1,,2632,CHEMBL626043,,BAO_0000218,
11197,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration at a peroral dose of 10 mg/kg,A,1,,5566,CHEMBL626044,,BAO_0000218,
11198,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration of the drug at 10 uM/dg administered perorally,A,1,,11883,CHEMBL626045,,BAO_0000218,
11199,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,1,,11883,CHEMBL626046,,BAO_0000218,
11200,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,1,,14122,CHEMBL626047,,BAO_0000218,1969.0
11201,100712,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,1,,14122,CHEMBL626048,,BAO_0000218,1969.0
11202,50597,,In vivo,1,,N,,Plasma,,Intermediate,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,1,,14122,CHEMBL626049,,BAO_0000218,1969.0
11203,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,1,,12542,CHEMBL626050,,BAO_0000218,1969.0
11204,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,1,,12542,CHEMBL874541,,BAO_0000218,1969.0
11205,100712,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,1,,12542,CHEMBL622826,,BAO_0000218,1969.0
11206,100712,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,1,,12542,CHEMBL622827,,BAO_0000218,1969.0
11207,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,1,,12542,CHEMBL622828,,BAO_0000218,1969.0
11208,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,1,,14080,CHEMBL622829,,BAO_0000218,1969.0
11209,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration reached following intravenous administration in male rat,A,1,,11911,CHEMBL876806,,BAO_0000218,
11210,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,1,,13204,CHEMBL622830,,BAO_0000218,
11211,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,1,,13204,CHEMBL622831,,BAO_0000218,
11212,50588,,In vivo,1,,N,,,,Intermediate,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,1,,14346,CHEMBL626794,,BAO_0000218,
11213,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL626795,,BAO_0000218,
11214,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL626796,,BAO_0000218,
11215,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL626797,,BAO_0000218,
11216,50597,,In vivo,1,,N,,,,Intermediate,Maximum drug concentration is determined after oral dosing in rats.,A,1,,14127,CHEMBL626798,,BAO_0000218,
11217,50588,,In vivo,1,,N,,,,Intermediate,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,1,,14339,CHEMBL626799,,BAO_0000218,
11218,50588,,In vivo,1,,N,,,,Intermediate,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,1,,14339,CHEMBL626800,,BAO_0000218,
11219,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration,A,1,,13494,CHEMBL626801,,BAO_0000218,1969.0
11220,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,1,,14925,CHEMBL876816,,BAO_0000218,1969.0
11221,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,1,,14474,CHEMBL626802,,BAO_0000218,1969.0
11222,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,1,,14474,CHEMBL626803,,BAO_0000218,1969.0
11223,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration following oral administration of 30 umol/kg,A,1,,13917,CHEMBL626804,,BAO_0000218,1969.0
11224,50597,,,1,,N,,Plasma,,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,1,,9796,CHEMBL626805,,BAO_0000218,1969.0
11225,50597,,,1,,N,,Plasma,,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626309,,BAO_0000218,1969.0
11226,50597,,,1,,N,,Plasma,,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626310,,BAO_0000218,1969.0
11227,50597,,,1,,N,,Plasma,,Intermediate,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626311,,BAO_0000218,1969.0
11228,50597,,,1,,N,,Plasma,,Intermediate,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626312,,BAO_0000218,1969.0
11229,50597,,,1,,N,,Uterus,,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626313,,BAO_0000218,995.0
11230,50597,,,1,,N,,Uterus,,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626314,,BAO_0000218,995.0
11231,50597,,,1,,N,,Uterus,,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626315,,BAO_0000218,995.0
11232,50597,,,1,,N,,Uterus,,Intermediate,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626316,,BAO_0000218,995.0
11233,50597,,,1,,N,,Uterus,,Intermediate,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,1,,9796,CHEMBL626317,,BAO_0000218,995.0
11234,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626318,,BAO_0000218,
11235,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL626319,,BAO_0000218,
11236,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626320,,BAO_0000218,
11237,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL875053,,BAO_0000218,
11238,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626321,,BAO_0000218,
11239,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL626322,,BAO_0000218,
11240,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626323,,BAO_0000218,
11241,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL626324,,BAO_0000218,
11242,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626325,,BAO_0000218,
11243,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL626326,,BAO_0000218,
11244,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,1,,8363,CHEMBL626327,,BAO_0000218,
11245,50597,,,1,,N,,,,Intermediate,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,1,,8363,CHEMBL626328,,BAO_0000218,
11246,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626329,,BAO_0000218,178.0
11247,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626330,,BAO_0000218,178.0
11248,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626331,,BAO_0000218,178.0
11249,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626332,,BAO_0000218,178.0
11250,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626333,,BAO_0000218,178.0
11251,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626334,,BAO_0000218,178.0
11252,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL626335,,BAO_0000218,178.0
11253,50597,,,1,,N,,Blood,,Intermediate,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624798,,BAO_0000218,178.0
11254,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624799,,BAO_0000218,955.0
11255,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624800,,BAO_0000218,955.0
11256,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624801,,BAO_0000218,955.0
11257,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624802,,BAO_0000218,955.0
11258,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624803,,BAO_0000218,955.0
11259,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624804,,BAO_0000218,955.0
11260,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624805,,BAO_0000218,955.0
11261,50597,,,1,,N,,Brain,,Intermediate,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,1,,8684,CHEMBL624806,,BAO_0000218,955.0
11262,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624807,,BAO_0000218,
11263,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624808,,BAO_0000218,
11264,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624809,,BAO_0000218,
11265,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624810,,BAO_0000218,
11266,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL877618,,BAO_0000218,
11267,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624811,,BAO_0000218,
11268,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624812,,BAO_0000218,
11269,50597,,,1,,N,,,,Intermediate,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624813,,BAO_0000218,
11270,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624814,,BAO_0000218,
11271,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624815,,BAO_0000218,
11272,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624816,,BAO_0000218,
11273,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624817,,BAO_0000218,
11274,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL624818,,BAO_0000218,
11275,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,1,,6996,CHEMBL624819,,BAO_0000218,
11276,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL624820,,BAO_0000218,
11277,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL624821,,BAO_0000218,
11278,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL624822,,BAO_0000218,
11279,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL624823,,BAO_0000218,
11280,50212,,,1,,N,,,,Intermediate,Observed diffusion coefficient in organic solvent for Escherichia coli,A,1,,15599,CHEMBL624824,,BAO_0000218,
11281,50597,,,1,,N,,Blood,,Intermediate,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624825,,BAO_0000218,178.0
11282,50597,,,1,,N,,Blood,,Intermediate,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624826,,BAO_0000218,178.0
11283,50597,,,1,,N,,Cardiac atrium,,Intermediate,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL876817,,BAO_0000218,2081.0
11284,50597,,,1,,N,,Cardiac atrium,,Intermediate,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624827,,BAO_0000218,2081.0
11285,50597,,,1,,N,,,,Intermediate,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624828,,BAO_0000218,
11286,50597,,,1,,N,,,,Intermediate,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624829,,BAO_0000218,
11287,50597,,,1,,N,,Liver,,Intermediate,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624830,,BAO_0000218,2107.0
11288,50597,,,1,,N,,Liver,,Intermediate,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624831,,BAO_0000218,2107.0
11289,50597,,,1,,N,,Cardiac atrium,,Intermediate,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624832,,BAO_0000218,2081.0
11290,50597,,,1,,N,,Cardiac atrium,,Intermediate,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624833,,BAO_0000218,2081.0
11291,50597,,,1,,N,,,,Intermediate,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624834,,BAO_0000218,
11292,50597,,,1,,N,,,,Intermediate,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624835,,BAO_0000218,
11293,50597,,,1,,N,,Spleen,,Intermediate,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,1,,9614,CHEMBL624836,,BAO_0000218,2106.0
11294,50597,,,1,,N,,Spleen,,Intermediate,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,1,,9614,CHEMBL624837,,BAO_0000218,2106.0
11295,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL624838,,BAO_0000218,178.0
11296,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,1,,9071,CHEMBL622188,,BAO_0000218,178.0
11297,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL622189,,BAO_0000218,948.0
11298,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,1,,9071,CHEMBL622190,,BAO_0000218,948.0
11299,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,1,,9071,CHEMBL625170,,BAO_0000218,948.0
11300,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL625171,,BAO_0000218,2113.0
11301,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL625172,,BAO_0000218,2113.0
11302,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,1,,9071,CHEMBL625173,,BAO_0000218,2113.0
11303,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL625174,,BAO_0000218,2107.0
11304,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,1,,9071,CHEMBL625175,,BAO_0000218,2107.0
11305,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,1,,9071,CHEMBL625176,,BAO_0000218,2107.0
11306,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL625177,,BAO_0000218,2048.0
11307,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,1,,9071,CHEMBL625178,,BAO_0000218,2048.0
11308,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,1,,9071,CHEMBL625179,,BAO_0000218,2048.0
11309,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,1,,9071,CHEMBL625180,,BAO_0000218,2048.0
11310,22224,,,0,,U,,,,Autocuration,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,1,,10677,CHEMBL625181,,BAO_0000218,
11311,50594,,,1,,N,,Urine,,Intermediate,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,1,,9750,CHEMBL625182,,BAO_0000218,1088.0
11312,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL625183,,BAO_0000218,
11313,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,1,,8319,CHEMBL875848,,BAO_0000218,
11314,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL622260,,BAO_0000218,
11315,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,1,,8319,CHEMBL622261,,BAO_0000218,
11316,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL622262,,BAO_0000218,
11317,50597,,,1,,N,,Kidney,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,1,,8319,CHEMBL622263,,BAO_0000218,2113.0
11318,50597,,,1,,N,,Kidney,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL622418,,BAO_0000218,2113.0
11319,50597,,,1,,N,,Liver,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,1,,8319,CHEMBL622419,,BAO_0000218,2107.0
11320,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623388,,BAO_0000218,
11321,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623389,,BAO_0000218,2107.0
11322,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623390,,BAO_0000218,
11323,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623391,,BAO_0000218,
11324,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623392,,BAO_0000218,178.0
11325,50594,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623393,,BAO_0000218,2037.0
11326,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL623394,,BAO_0000218,
11327,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL618885,,BAO_0000218,
11328,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL618886,,BAO_0000218,2107.0
11329,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL618887,,BAO_0000218,
11330,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619535,,BAO_0000218,
11331,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619536,,BAO_0000218,178.0
11332,50594,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619537,,BAO_0000218,2037.0
11333,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619705,,BAO_0000218,
11334,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619706,,BAO_0000218,
11335,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619707,,BAO_0000218,2107.0
11336,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL619708,,BAO_0000218,
11337,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625219,,BAO_0000218,
11338,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625220,,BAO_0000218,178.0
11339,50594,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625221,,BAO_0000218,2037.0
11340,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625222,,BAO_0000218,
11341,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625223,,BAO_0000218,
11342,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625224,,BAO_0000218,2107.0
11343,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,1,,13256,CHEMBL625225,,BAO_0000218,
11344,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 24 hours of iv administration,A,1,,8829,CHEMBL625226,,BAO_0000218,178.0
11345,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,1,,8829,CHEMBL625227,,BAO_0000218,178.0
11346,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 30 minutes of iv administration,A,1,,8829,CHEMBL625228,,BAO_0000218,178.0
11347,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL875354,,BAO_0000218,178.0
11348,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 5 minutes of iv administration,A,1,,8829,CHEMBL625229,,BAO_0000218,178.0
11349,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL625230,,BAO_0000218,178.0
11350,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 24 hours of iv administration,A,1,,8829,CHEMBL625231,,BAO_0000218,948.0
11351,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,1,,8829,CHEMBL625900,,BAO_0000218,948.0
11352,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 30 minutes of iv administration,A,1,,8829,CHEMBL625901,,BAO_0000218,948.0
11353,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL625902,,BAO_0000218,948.0
11354,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 5 minutes of iv administration,A,1,,8829,CHEMBL625903,,BAO_0000218,948.0
11355,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL625904,,BAO_0000218,948.0
11356,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 24 hours of iv administration,A,1,,8829,CHEMBL625905,,BAO_0000218,2107.0
11357,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,1,,8829,CHEMBL627861,,BAO_0000218,2107.0
11358,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration,A,1,,8829,CHEMBL627862,,BAO_0000218,2107.0
11359,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL627863,,BAO_0000218,2107.0
11360,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration,A,1,,8829,CHEMBL627769,,BAO_0000218,2107.0
11361,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,1,,13249,CHEMBL627770,,BAO_0000218,1969.0
11362,100710,,In vivo,1,,N,,,,Intermediate,Cmax in cynomolgus monkey (PO dose),A,1,,13622,CHEMBL627771,,BAO_0000218,
11363,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat (PO dose),A,1,,13622,CHEMBL627772,,BAO_0000218,
11364,50597,,In vivo,1,,N,,,,Intermediate,Cmax in rat (PO dose),A,1,,13622,CHEMBL627773,,BAO_0000218,
11365,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,1,,13494,CHEMBL621922,,BAO_0000218,1969.0
11366,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in rat plasma after oral dose (10 mg/kg),A,1,,12170,CHEMBL621923,,BAO_0000218,1969.0
11367,22224,,In vivo,0,,U,,Plasma,,Autocuration,Cmax in plasma after oral dose (10 mg/kg),A,1,,12170,CHEMBL621924,,BAO_0000218,1969.0
11368,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,1,,17025,CHEMBL621925,,BAO_0000218,1969.0
11369,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,1,,17025,CHEMBL621926,,BAO_0000218,1969.0
11370,50592,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,1,,17025,CHEMBL621927,,BAO_0000218,1969.0
11371,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,1,,17025,CHEMBL621928,,BAO_0000218,1969.0
11372,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,1,,14187,CHEMBL621929,,BAO_0000218,1969.0
11373,50594,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,1,,14816,CHEMBL621930,,BAO_0000218,1969.0
11374,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration after oral dosing in rat,A,1,,17820,CHEMBL621931,,BAO_0000218,1969.0
11375,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621932,,BAO_0000218,1969.0
11376,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621933,,BAO_0000218,1969.0
11377,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,1,,14691,CHEMBL621934,,BAO_0000218,1969.0
11378,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,1,,14691,CHEMBL621935,,BAO_0000218,1969.0
11379,50597,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,1,,13375,CHEMBL621936,,BAO_0000218,1969.0
11380,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was determined,A,1,,6236,CHEMBL621937,,BAO_0000218,1969.0
11381,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621938,,BAO_0000218,1969.0
11382,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621939,,BAO_0000218,1969.0
11383,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621940,,BAO_0000218,1969.0
11384,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621941,,BAO_0000218,1969.0
11385,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL621942,,BAO_0000218,1969.0
11386,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL626178,,BAO_0000218,1969.0
11387,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL626179,,BAO_0000218,1969.0
11388,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL626180,,BAO_0000218,1969.0
11389,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma Cmax in rat (PO dose),A,1,,13622,CHEMBL626181,,BAO_0000218,1969.0
11390,50597,,In vivo,1,,N,,,,Intermediate,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,1,,15372,CHEMBL626182,,BAO_0000218,
11391,50597,,In vivo,1,,N,,,,Intermediate,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,1,,15372,CHEMBL626183,,BAO_0000218,
11392,50597,,In vivo,1,,N,,,,Intermediate,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,1,,15372,CHEMBL626184,,BAO_0000218,
11393,50597,,In vivo,1,,N,,,,Intermediate,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,1,,15372,CHEMBL626185,,BAO_0000218,
11394,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,1,,14925,CHEMBL626186,,BAO_0000218,1969.0
11395,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,1,,14925,CHEMBL877589,,BAO_0000218,1969.0
11396,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,1,,11883,CHEMBL626187,,BAO_0000218,
11397,22224,,In vivo,0,,U,,,,Autocuration,Maximum concentration of the drug at 20 uM/dg administered perorally,A,1,,11883,CHEMBL626188,,BAO_0000218,
11398,22224,,In vivo,0,,U,,,,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,1,,13391,CHEMBL626189,,BAO_0000218,
11399,22224,,In vivo,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL626855,,BAO_0000218,178.0
11400,22224,,In vivo,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL623781,,BAO_0000218,178.0
11401,22224,,In vivo,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL623782,,BAO_0000218,178.0
11402,50597,,In vivo,1,,N,,Plasma,,Intermediate,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,1,,16360,CHEMBL623783,,BAO_0000218,1969.0
11403,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in dog plasma after 1mg/kg oral dose,A,1,,3673,CHEMBL623784,,BAO_0000218,1969.0
11404,50588,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,1,,14431,CHEMBL623785,,BAO_0000218,1969.0
11405,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,1,,14431,CHEMBL623786,,BAO_0000218,1969.0
11406,50597,,In vivo,1,,N,,,,Intermediate,Oral maximum concentration in rat,A,1,,14964,CHEMBL623787,,BAO_0000218,
11407,50597,,In vivo,1,,N,,,,Intermediate,Oral maximum concentration in rat,A,1,,14964,CHEMBL623788,,BAO_0000218,
11408,50594,,In vivo,1,,N,,Plasma,,Intermediate,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,1,,14209,CHEMBL623789,,BAO_0000218,1969.0
11409,50594,,In vivo,1,,N,,Blood,,Intermediate,Peak concentration in blood after intravenous administration to mice,A,1,,11355,CHEMBL623790,,BAO_0000218,178.0
11410,50594,,In vivo,1,,N,,Blood,,Intermediate,Peak concentration in blood after peroral administration to mice,A,1,,11355,CHEMBL623791,,BAO_0000218,178.0
11411,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak concentration in rat plasma was determined,A,1,,11966,CHEMBL623792,,BAO_0000218,1969.0
11412,22224,,In vivo,0,,U,,Plasma,,Autocuration,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL623793,,BAO_0000218,1969.0
11413,50594,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL623794,,BAO_0000218,1969.0
11414,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL623795,,BAO_0000218,1969.0
11415,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623796,,BAO_0000218,
11416,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623797,,BAO_0000218,
11417,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623798,,BAO_0000218,
11418,50597,,,1,,N,,,,Intermediate,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623799,,BAO_0000218,
11419,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624490,,BAO_0000218,160.0
11420,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624491,,BAO_0000218,160.0
11421,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624492,,BAO_0000218,160.0
11422,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624493,,BAO_0000218,160.0
11423,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL877595,,BAO_0000218,160.0
11424,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624494,,BAO_0000218,160.0
11425,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624495,,BAO_0000218,160.0
11426,50597,,,1,,N,,Intestine,,Intermediate,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624681,,BAO_0000218,160.0
11427,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624682,,BAO_0000218,
11428,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624683,,BAO_0000218,
11429,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624684,,BAO_0000218,
11430,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624685,,BAO_0000218,
11431,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624686,,BAO_0000218,
11432,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624687,,BAO_0000218,
11433,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624688,,BAO_0000218,
11434,50597,,,1,,N,,,,Intermediate,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL627161,,BAO_0000218,
11435,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL622127,,BAO_0000218,
11436,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL622128,,BAO_0000218,
11437,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL874384,,BAO_0000218,
11438,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624898,,BAO_0000218,
11439,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624899,,BAO_0000218,
11440,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624900,,BAO_0000218,
11441,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624901,,BAO_0000218,
11442,50597,,,1,,N,,,,Intermediate,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624902,,BAO_0000218,
11443,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624903,,BAO_0000218,
11444,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624904,,BAO_0000218,
11445,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624905,,BAO_0000218,
11446,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624906,,BAO_0000218,
11447,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624907,,BAO_0000218,
11448,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624908,,BAO_0000218,
11449,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624909,,BAO_0000218,
11450,50597,,,1,,N,,,,Intermediate,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624910,,BAO_0000218,
11451,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624911,,BAO_0000218,2385.0
11452,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL874388,,BAO_0000218,2385.0
11453,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL624912,,BAO_0000218,2385.0
11454,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL622930,,BAO_0000218,2385.0
11455,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623121,,BAO_0000218,2385.0
11456,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623122,,BAO_0000218,2385.0
11457,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623123,,BAO_0000218,2385.0
11458,50597,,,1,,N,,Muscle tissue,,Intermediate,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623124,,BAO_0000218,2385.0
11459,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623125,,BAO_0000218,
11460,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623126,,BAO_0000218,
11461,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623127,,BAO_0000218,
11462,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623128,,BAO_0000218,
11463,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623129,,BAO_0000218,
11464,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623130,,BAO_0000218,
11465,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623131,,BAO_0000218,
11466,50597,,,1,,N,,,,Intermediate,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL623132,,BAO_0000218,
11467,50597,,,1,,N,,Liver,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623133,,BAO_0000218,2107.0
11468,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623134,,BAO_0000218,
11469,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL874389,,BAO_0000218,
11470,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,1,,8319,CHEMBL623135,,BAO_0000218,
11471,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623136,,BAO_0000218,
11472,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,1,,8319,CHEMBL623137,,BAO_0000218,
11473,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623138,,BAO_0000218,
11474,50597,,,1,,N,,Kidney,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,1,,8319,CHEMBL623139,,BAO_0000218,2113.0
11475,50597,,,1,,N,,Kidney,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623140,,BAO_0000218,2113.0
11476,50597,,,1,,N,,Liver,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,1,,8319,CHEMBL623141,,BAO_0000218,2107.0
11477,50597,,,1,,N,,Liver,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623142,,BAO_0000218,2107.0
11478,50597,,,1,,N,,,,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL623143,,BAO_0000218,
11479,50594,,,1,,N,,Urine,,Intermediate,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,1,,14571,CHEMBL623144,,BAO_0000218,1088.0
11480,50597,,,1,,N,,Urine,,Intermediate,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,1,,14571,CHEMBL623405,,BAO_0000218,1088.0
11481,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624074,,BAO_0000218,
11482,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624075,,BAO_0000218,
11483,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624076,,BAO_0000218,
11484,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624077,,BAO_0000218,
11485,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624078,,BAO_0000218,
11486,50597,,,1,,N,,Kidney,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624079,,BAO_0000218,2113.0
11487,50597,,,1,,N,,Kidney,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624261,,BAO_0000218,2113.0
11488,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624262,,BAO_0000218,
11489,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624263,,BAO_0000218,
11490,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624264,,BAO_0000218,
11491,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624265,,BAO_0000218,
11492,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624266,,BAO_0000218,
11493,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624267,,BAO_0000218,
11494,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624268,,BAO_0000218,
11495,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL875227,,BAO_0000218,
11496,50597,,,1,,N,,Kidney,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624269,,BAO_0000218,2113.0
11497,50597,,,1,,N,,Kidney,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624270,,BAO_0000218,2113.0
11498,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,1,,8319,CHEMBL624271,,BAO_0000218,
11499,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624272,,BAO_0000218,
11500,50597,,,1,,N,,,,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,1,,8319,CHEMBL624273,,BAO_0000218,
11501,50597,,,1,,N,,Urine,,Intermediate,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,1,,12064,CHEMBL624274,,BAO_0000218,1088.0
11502,50597,,,1,,N,,Urine,,Intermediate,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,1,,12064,CHEMBL624275,,BAO_0000218,1088.0
11503,50597,,,1,,N,,Urine,,Intermediate,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,1,,12064,CHEMBL624276,,BAO_0000218,1088.0
11504,50597,,,1,,N,,Urine,,Intermediate,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,1,,12038,CHEMBL624277,,BAO_0000218,1088.0
11505,22224,,,0,,U,,,,Autocuration,% dose converted to 2-amino-5-chlorophenyl sulfate,A,1,,14314,CHEMBL624278,,BAO_0000019,
11506,22224,,,0,,U,,,,Autocuration,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,1,,14314,CHEMBL624279,,BAO_0000019,
11507,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,1,,11488,CHEMBL624280,,BAO_0000218,1988.0
11508,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,1,,11488,CHEMBL624281,,BAO_0000218,1988.0
11509,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,1,,11488,CHEMBL622933,,BAO_0000218,1988.0
11510,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,1,,11488,CHEMBL622934,,BAO_0000218,1988.0
11511,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL622935,,BAO_0000218,2107.0
11512,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 5 minutes of iv administration,A,1,,8829,CHEMBL622936,,BAO_0000218,2107.0
11513,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL875228,,BAO_0000218,2107.0
11514,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 24 hours of iv administration,A,1,,8829,CHEMBL622937,,BAO_0000218,2048.0
11515,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,1,,8829,CHEMBL622938,,BAO_0000218,2048.0
11516,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 30 minutes of iv administration,A,1,,8829,CHEMBL619736,,BAO_0000218,2048.0
11517,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL625117,,BAO_0000218,2048.0
11518,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 5 minutes of iv administration,A,1,,8829,CHEMBL625118,,BAO_0000218,2048.0
11519,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,1,,8829,CHEMBL625119,,BAO_0000218,2048.0
11520,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,1,,14972,CHEMBL625120,,BAO_0000218,2037.0
11521,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,1,,14972,CHEMBL625121,,BAO_0000218,
11522,50597,,In vivo,1,,N,,Thalamus,,Intermediate,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,1,,14972,CHEMBL625122,,BAO_0000218,10000006.0
11523,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL622204,,BAO_0000218,178.0
11524,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL877503,,BAO_0000218,178.0
11525,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL627127,,BAO_0000218,178.0
11526,22224,,In vivo,0,,U,,Hippocampus,,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL627128,,BAO_0000218,10000000.0
11527,22224,,In vivo,0,,U,,Hippocampus,,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL627129,,BAO_0000218,10000000.0
11528,22224,,In vivo,0,,U,,Hippocampus,,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL627130,,BAO_0000218,10000000.0
11529,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL627131,,BAO_0000218,955.0
11530,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL627132,,BAO_0000218,955.0
11531,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL627133,,BAO_0000218,955.0
11532,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL627134,,BAO_0000218,2037.0
11533,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL627135,,BAO_0000218,2037.0
11534,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL627136,,BAO_0000218,2037.0
11535,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL628435,,BAO_0000218,
11536,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL628436,,BAO_0000218,
11537,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL628437,,BAO_0000218,
11538,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL628438,,BAO_0000218,948.0
11539,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL628439,,BAO_0000218,948.0
11540,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL628440,,BAO_0000218,948.0
11541,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL628441,,BAO_0000218,10000000.0
11542,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL628442,,BAO_0000218,10000000.0
11543,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL628443,,BAO_0000218,10000000.0
11544,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL628444,,BAO_0000218,2113.0
11545,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL628445,,BAO_0000218,2113.0
11546,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL877504,,BAO_0000218,2113.0
11547,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL628446,,BAO_0000218,2107.0
11548,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL626874,,BAO_0000218,2107.0
11549,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL626875,,BAO_0000218,2107.0
11550,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL626876,,BAO_0000218,2048.0
11551,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL626877,,BAO_0000218,2048.0
11552,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL626878,,BAO_0000218,2048.0
11553,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL626879,,BAO_0000218,2385.0
11554,22224,,In vivo,0,,U,,Plasma,,Autocuration,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL626880,,BAO_0000218,1969.0
11555,50594,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL626881,,BAO_0000218,1969.0
11556,50597,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,1,,8918,CHEMBL626882,,BAO_0000218,1969.0
11557,50588,,In vivo,1,,N,,Plasma,,Intermediate,Peak plasma concentration was measured in dogs,A,1,,14470,CHEMBL626883,,BAO_0000218,1969.0
11558,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL626884,,BAO_0000218,
11559,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,1,,14886,CHEMBL626885,,BAO_0000218,
11560,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,1,,14886,CHEMBL626886,,BAO_0000218,
11561,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,1,,14886,CHEMBL626887,,BAO_0000218,
11562,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL626888,,BAO_0000218,
11563,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,1,,13465,CHEMBL626889,,BAO_0000218,
11564,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,1,,13465,CHEMBL626761,,BAO_0000218,
11565,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,1,,13465,CHEMBL626762,,BAO_0000218,
11566,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,1,,13465,CHEMBL626763,,BAO_0000218,
11567,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,1,,13465,CHEMBL626764,,BAO_0000218,
11568,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,1,,13465,CHEMBL626765,,BAO_0000218,
11569,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,1,,13465,CHEMBL626766,,BAO_0000218,
11570,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,1,,13465,CHEMBL626767,,BAO_0000218,
11571,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,1,,13465,CHEMBL626768,,BAO_0000218,
11572,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,1,,13465,CHEMBL626769,,BAO_0000218,
11573,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,1,,13465,CHEMBL874463,,BAO_0000218,
11574,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,1,,13465,CHEMBL626770,,BAO_0000218,
11575,22224,,In vivo,0,,U,,,,Autocuration,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,1,,13465,CHEMBL626771,,BAO_0000218,
11576,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,1,,13465,CHEMBL626772,,BAO_0000218,
11577,100710,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,1,,14731,CHEMBL626773,,BAO_0000218,
11578,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,1,,14731,CHEMBL626774,,BAO_0000218,
11579,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,1,,13376,CHEMBL626775,,BAO_0000218,
11580,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,1,,13376,CHEMBL626776,,BAO_0000218,
11581,50597,,In vivo,1,,N,,,,Intermediate,Maximum concentration (Cmax) in rat when administered orally,A,1,,14443,CHEMBL626777,,BAO_0000218,
11582,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,1,,13465,CHEMBL626778,,BAO_0000218,1969.0
11583,22224,,In vivo,0,,U,,,,Autocuration,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,1,,16359,CHEMBL626779,,BAO_0000218,
11584,22224,,In vivo,0,,U,,,,Autocuration,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,1,,16359,CHEMBL626780,,BAO_0000218,
11585,22224,,In vivo,0,,U,,Plasma,,Autocuration,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,1,,15618,CHEMBL626781,,BAO_0000218,1969.0
11586,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic profile Cmax was evaluated in rats,A,1,,14554,CHEMBL632164,,BAO_0000218,
11587,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,1,,11537,CHEMBL632165,,BAO_0000218,
11588,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,1,,11537,CHEMBL632166,,BAO_0000218,
11589,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,1,,11537,CHEMBL632167,,BAO_0000218,
11590,50594,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,1,,11537,CHEMBL632168,,BAO_0000218,
11591,22224,,In vivo,0,,U,,Plasma,,Autocuration,Cmax in rat plasma,A,1,,2021,CHEMBL632169,,BAO_0000218,1969.0
11592,50588,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in dog plasma after 30mg/kg oral dose,A,1,,5932,CHEMBL632170,,BAO_0000218,1969.0
11593,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax in rat plasma after 30mg/kg oral dose,A,1,,5932,CHEMBL632171,,BAO_0000218,1969.0
11594,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma level in rats at 30 mg/kg,A,1,,17320,CHEMBL632172,,BAO_0000218,1969.0
11595,50594,,In vivo,1,,N,,Plasma,,Intermediate,Tested for maximum plasma concentration in mice,A,1,,15831,CHEMBL632173,,BAO_0000218,1969.0
11596,50597,,In vivo,1,,N,,,,Intermediate,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL632174,,BAO_0000218,
11597,50597,,In vivo,1,,N,,,,Intermediate,The Cmax values in female wistar rats.,A,1,,14941,CHEMBL632175,,BAO_0000218,
11598,50588,,In vivo,1,,N,,Plasma,,Intermediate,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,1,,15343,CHEMBL632176,,BAO_0000218,1969.0
11599,50597,,In vivo,1,,N,,Plasma,,Intermediate,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,1,,15343,CHEMBL632177,,BAO_0000218,1969.0
11600,50597,,In vivo,1,,N,,Plasma,,Intermediate,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,1,,14856,CHEMBL632178,,BAO_0000218,1969.0
11601,50597,,In vivo,1,,N,,,,Intermediate,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,1,,13129,CHEMBL632179,,BAO_0000218,
11602,50597,,In vivo,1,,N,,Blood,,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,1,,13098,CHEMBL632180,,BAO_0000218,178.0
11603,50597,,In vivo,1,,N,,Blood,,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,1,,13098,CHEMBL632181,,BAO_0000218,178.0
11604,50597,,In vivo,1,,N,,Blood,,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,1,,13098,CHEMBL632182,,BAO_0000218,178.0
11605,22224,,In vivo,0,,U,,Blood,,Autocuration,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,1,,15478,CHEMBL632183,,BAO_0000218,178.0
11606,50588,,In vivo,1,,N,,,,Intermediate,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,1,,15341,CHEMBL632184,,BAO_0000218,
11607,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,1,,15341,CHEMBL874470,,BAO_0000218,
11608,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631302,,BAO_0000218,
11609,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631303,,BAO_0000218,
11610,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631304,,BAO_0000218,
11611,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631305,,BAO_0000218,
11612,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631306,,BAO_0000218,
11613,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631307,,BAO_0000218,
11614,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL631308,,BAO_0000218,
11615,50597,,,1,,N,,,,Intermediate,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625557,,BAO_0000218,
11616,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625558,,BAO_0000218,2106.0
11617,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625559,,BAO_0000218,2106.0
11618,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625560,,BAO_0000218,2106.0
11619,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625561,,BAO_0000218,2106.0
11620,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625562,,BAO_0000218,2106.0
11621,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL875320,,BAO_0000218,2106.0
11622,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625563,,BAO_0000218,2106.0
11623,50597,,,1,,N,,Spleen,,Intermediate,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625564,,BAO_0000218,2106.0
11624,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625565,,BAO_0000218,995.0
11625,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625566,,BAO_0000218,995.0
11626,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625567,,BAO_0000218,995.0
11627,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL625568,,BAO_0000218,995.0
11628,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL628217,,BAO_0000218,995.0
11629,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL628218,,BAO_0000218,995.0
11630,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL628219,,BAO_0000218,995.0
11631,50597,,,1,,N,,Uterus,,Intermediate,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,1,,8684,CHEMBL628220,,BAO_0000218,995.0
11632,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 120 min of intravenous administration,A,1,,8926,CHEMBL628221,,BAO_0000019,
11633,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 15 min of intravenous administration,A,1,,8926,CHEMBL628222,,BAO_0000019,
11634,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 30 min of intravenous administration,A,1,,8926,CHEMBL628223,,BAO_0000019,
11635,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 5 min of intravenous administration,A,1,,8926,CHEMBL628224,,BAO_0000019,
11636,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 60 min of intravenous administration,A,1,,8926,CHEMBL628225,,BAO_0000019,
11637,22224,,,0,,U,,,,Autocuration,Distribution in the blood after 90 min of intravenous administration,A,1,,8926,CHEMBL628226,,BAO_0000019,
11638,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 120 min of intravenous administration,A,1,,8926,CHEMBL628227,,BAO_0000019,
11639,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 15 min of intravenous administration,A,1,,8926,CHEMBL875481,,BAO_0000019,
11640,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 30 min of intravenous administration,A,1,,8926,CHEMBL628228,,BAO_0000019,
11641,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 5 min of intravenous administration,A,1,,8926,CHEMBL628229,,BAO_0000019,
11642,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 60 min of intravenous administration,A,1,,8926,CHEMBL628230,,BAO_0000019,
11643,22224,,,0,,U,,,,Autocuration,Distribution in the bone after 90 min of intravenous administration,A,1,,8926,CHEMBL628231,,BAO_0000019,
11644,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 120 min of intravenous administration,A,1,,8926,CHEMBL628232,,BAO_0000019,
11645,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 15 min of intravenous administration,A,1,,8926,CHEMBL628233,,BAO_0000019,
11646,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 30 min of intravenous administration,A,1,,8926,CHEMBL628234,,BAO_0000019,
11647,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 5 min of intravenous administration,A,1,,8926,CHEMBL628235,,BAO_0000019,
11648,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 60 min of intravenous administration,A,1,,8926,CHEMBL628236,,BAO_0000019,
11649,22224,,,0,,U,,,,Autocuration,Distribution in the heart after 90 min of intravenous administration,A,1,,8926,CHEMBL628237,,BAO_0000019,
11650,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 120 min of intravenous administration,A,1,,8926,CHEMBL628238,,BAO_0000019,
11651,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 15 min of intravenous administration,A,1,,8926,CHEMBL628239,,BAO_0000019,
11652,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 30 min of intravenous administration,A,1,,8926,CHEMBL628240,,BAO_0000019,
11653,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 5 min of intravenous administration,A,1,,8926,CHEMBL628241,,BAO_0000019,
11654,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 60 min of intravenous administration,A,1,,8926,CHEMBL628242,,BAO_0000019,
11655,22224,,,0,,U,,,,Autocuration,Distribution in the kidneys after 90 min of intravenous administration,A,1,,8926,CHEMBL875482,,BAO_0000019,
11656,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 120 min of intravenous administration,A,1,,8926,CHEMBL628243,,BAO_0000019,
11657,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 15 min of intravenous administration,A,1,,8926,CHEMBL628244,,BAO_0000019,
11658,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 30 min of intravenous administration,A,1,,8926,CHEMBL628245,,BAO_0000019,
11659,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 5 min of intravenous administration,A,1,,8926,CHEMBL628246,,BAO_0000019,
11660,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 60 min of intravenous administration,A,1,,8926,CHEMBL628247,,BAO_0000019,
11661,22224,,,0,,U,,,,Autocuration,Distribution in the liver after 90 min of intravenous administration,A,1,,8926,CHEMBL628248,,BAO_0000019,
11662,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 120 min of intravenous administration,A,1,,8926,CHEMBL628249,,BAO_0000019,
11663,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,1,,14839,CHEMBL625452,,BAO_0000218,
11664,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,1,,14839,CHEMBL625453,,BAO_0000218,
11665,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,1,,14839,CHEMBL625454,,BAO_0000218,
11666,50594,,,1,,N,,,,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,1,,14839,CHEMBL623844,,BAO_0000218,
11667,50597,,,1,,N,,,,Intermediate,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,1,,12178,CHEMBL623845,,BAO_0000218,
11668,50597,,,1,,N,,,,Intermediate,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,1,,12178,CHEMBL623846,,BAO_0000218,
11669,22224,,,0,,U,,,,Autocuration,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,1,,12178,CHEMBL623847,,BAO_0000218,
11670,100710,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,1,,12186,CHEMBL623848,,BAO_0000218,
11671,100710,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,1,,12186,CHEMBL623849,,BAO_0000218,
11672,100710,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,1,,12186,CHEMBL623850,,BAO_0000218,
11673,100710,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,1,,12186,CHEMBL623851,,BAO_0000218,
11674,22224,,,0,,U,,,,Autocuration,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,1,,12187,CHEMBL623852,,BAO_0000218,
11675,50506,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,1,,12187,CHEMBL624551,,BAO_0000218,
11676,50506,,,1,,N,,,,Intermediate,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,1,,12187,CHEMBL624552,,BAO_0000218,
11677,22224,,,0,,U,,,,Autocuration,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,1,,12187,CHEMBL624553,,BAO_0000218,
11678,22224,,,0,,U,,,,Autocuration,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,1,,12187,CHEMBL624554,,BAO_0000218,
11679,50597,,,1,,N,,,,Intermediate,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,1,,12187,CHEMBL624555,,BAO_0000218,
11680,50597,,,1,,N,,,,Intermediate,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,1,,12187,CHEMBL624741,,BAO_0000218,
11681,50588,,,1,,N,,,,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,1,,14122,CHEMBL624742,,BAO_0000218,
11682,100712,,,1,,N,,,,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,1,,14122,CHEMBL624743,,BAO_0000218,
11683,50597,,,1,,N,,,,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,1,,14122,CHEMBL877606,,BAO_0000218,
11684,22224,,,0,,U,,,,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,1,,13391,CHEMBL624744,,BAO_0000218,
11685,22224,,,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL624745,,BAO_0000218,178.0
11686,22224,,,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL624746,,BAO_0000218,178.0
11687,22224,,,0,,U,,Blood,,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,1,,13391,CHEMBL624747,,BAO_0000218,178.0
11688,22224,,,0,,U,,,,Autocuration,Oral absorption expressed as Area under curve was determined,A,1,,16360,CHEMBL624748,,BAO_0000019,
11689,50588,,,1,,N,,,,Intermediate,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,1,,3673,CHEMBL622504,,BAO_0000218,
11690,50588,,,1,,N,,,,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,1,,14122,CHEMBL622505,,BAO_0000218,
11691,100712,,,1,,N,,,,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,1,,14122,CHEMBL622506,,BAO_0000218,
11692,100712,,,1,,N,,,,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,1,,14122,CHEMBL622507,,BAO_0000218,
11693,50597,,,1,,N,,,,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,1,,14122,CHEMBL622508,,BAO_0000218,
11694,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,1,,13889,CHEMBL622509,,BAO_0000019,
11695,50597,,,1,,N,,,,Intermediate,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL622510,,BAO_0000218,
11696,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,1,,17279,CHEMBL622511,,BAO_0000218,
11697,100710,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,1,,14548,CHEMBL622512,,BAO_0000218,
11698,100710,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,1,,14548,CHEMBL622513,,BAO_0000218,
11699,100710,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,1,,14548,CHEMBL622514,,BAO_0000218,
11700,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,1,,14548,CHEMBL622515,,BAO_0000218,
11701,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,1,,14548,CHEMBL622516,,BAO_0000218,
11702,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,1,,14548,CHEMBL622517,,BAO_0000218,
11703,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,1,,14548,CHEMBL622518,,BAO_0000218,
11704,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,1,,14548,CHEMBL622519,,BAO_0000218,
11705,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL622520,,BAO_0000218,2385.0
11706,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL622521,,BAO_0000218,2385.0
11707,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL625113,,BAO_0000218,14.0
11708,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL625114,,BAO_0000218,14.0
11709,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL874397,,BAO_0000218,14.0
11710,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL625115,,BAO_0000218,2106.0
11711,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL625116,,BAO_0000218,2106.0
11712,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL623932,,BAO_0000218,2106.0
11713,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL623933,,BAO_0000218,2435.0
11714,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL623934,,BAO_0000218,2435.0
11715,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL623935,,BAO_0000218,2435.0
11716,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,1,,14608,CHEMBL623936,,BAO_0000218,2046.0
11717,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,1,,14608,CHEMBL623937,,BAO_0000218,2046.0
11718,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,1,,14608,CHEMBL623938,,BAO_0000218,2046.0
11719,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL623939,,BAO_0000218,
11720,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,1,,15383,CHEMBL623940,,BAO_0000218,
11721,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,1,,15383,CHEMBL623941,,BAO_0000218,
11722,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL627216,,BAO_0000218,
11723,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL623942,,BAO_0000218,
11724,50594,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL618793,,BAO_0000218,955.0
11725,50594,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618794,,BAO_0000218,955.0
11726,50594,,,1,,N,,Brain,,Intermediate,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618795,,BAO_0000218,955.0
11727,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618796,,BAO_0000218,
11728,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618797,,BAO_0000218,
11729,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,1,,15383,CHEMBL618798,,BAO_0000218,2113.0
11730,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL618799,,BAO_0000218,2113.0
11731,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,1,,15383,CHEMBL618800,,BAO_0000218,2113.0
11732,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,1,,15383,CHEMBL618801,,BAO_0000218,2113.0
11733,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618802,,BAO_0000218,2113.0
11734,50594,,,1,,N,,Kidney,,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618803,,BAO_0000218,2113.0
11735,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,1,,15383,CHEMBL618804,,BAO_0000218,2107.0
11736,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL618805,,BAO_0000218,2107.0
11737,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,1,,15383,CHEMBL618806,,BAO_0000218,2107.0
11738,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,1,,15383,CHEMBL618807,,BAO_0000218,2107.0
11739,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618808,,BAO_0000218,2107.0
11740,50594,,,1,,N,,Liver,,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618809,,BAO_0000218,2107.0
11741,50594,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL618810,,BAO_0000218,2385.0
11742,50594,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,1,,15383,CHEMBL618811,,BAO_0000218,2385.0
11743,50594,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,1,,15383,CHEMBL875844,,BAO_0000218,2385.0
11744,50594,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618812,,BAO_0000218,2385.0
11745,50594,,,1,,N,,Muscle tissue,,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618813,,BAO_0000218,2385.0
11746,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL618814,,BAO_0000218,
11747,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618815,,BAO_0000218,
11748,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL618816,,BAO_0000218,
11749,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL618817,,BAO_0000218,
11750,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL620544,,BAO_0000218,
11751,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,1,,15341,CHEMBL626230,,BAO_0000218,
11752,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,1,,15341,CHEMBL626231,,BAO_0000218,
11753,50597,,In vivo,1,,N,,,,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,1,,15341,CHEMBL626232,,BAO_0000218,
11754,50588,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,1,,14906,CHEMBL626233,,BAO_0000218,1969.0
11755,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,1,,14906,CHEMBL626234,,BAO_0000218,1969.0
11756,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,1,,14906,CHEMBL875341,,BAO_0000218,1969.0
11757,50587,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (100 mg/kg) administered orally in human,A,1,,14215,CHEMBL626235,,BAO_0000218,1969.0
11758,22224,,In vivo,0,,U,,Plasma,,Autocuration,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,1,,14215,CHEMBL626236,,BAO_0000218,1969.0
11759,22224,,In vivo,0,,U,,Plasma,,Autocuration,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,1,,14215,CHEMBL626237,,BAO_0000218,1969.0
11760,50588,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,1,,14215,CHEMBL626238,,BAO_0000218,1969.0
11761,50587,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (200 mg/kg) administered orally in human,A,1,,14215,CHEMBL622412,,BAO_0000218,1969.0
11762,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,1,,14215,CHEMBL623114,,BAO_0000218,1969.0
11763,22224,,In vivo,0,,U,,Plasma,,Autocuration,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,1,,14215,CHEMBL623115,,BAO_0000218,1969.0
11764,22224,,In vivo,0,,U,,Plasma,,Autocuration,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,1,,14215,CHEMBL623116,,BAO_0000218,1969.0
11765,22224,,In vivo,0,,U,,Plasma,,Autocuration,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,1,,14215,CHEMBL623117,,BAO_0000218,1969.0
11766,50587,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (400 mg/kg) administered orally in human,A,1,,14215,CHEMBL623118,,BAO_0000218,1969.0
11767,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,1,,14215,CHEMBL623119,,BAO_0000218,1969.0
11768,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,1,,14215,CHEMBL623120,,BAO_0000218,1969.0
11769,50587,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration (800 mg/kg) administered orally in human,A,1,,14215,CHEMBL623286,,BAO_0000218,1969.0
11770,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration was measured on rats,A,1,,14067,CHEMBL623287,,BAO_0000218,1969.0
11771,50597,,In vivo,1,,N,,Plasma,,Intermediate,The maximum plasma concentration was measured on rats after oral administration,A,1,,12350,CHEMBL623288,,BAO_0000218,1969.0
11772,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma drug Cmax in rat (PO dose),A,1,,14813,CHEMBL623289,,BAO_0000218,1969.0
11773,22224,,In vivo,0,,U,,,,Autocuration,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,1,,12536,CHEMBL623290,,BAO_0000218,
11774,50588,,In vivo,1,,N,,Plasma,,Intermediate,maximum Plasma concentration in Dog was determined after Peroral administration,A,1,,14169,CHEMBL623291,,BAO_0000218,1969.0
11775,50597,,In vivo,1,,N,,Plasma,,Intermediate,maximum Plasma concentration in Rats was determined after Peroral administration,A,1,,14169,CHEMBL623292,,BAO_0000218,1969.0
11776,50588,,In vivo,1,,N,,Plasma,,Intermediate,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,1,,15604,CHEMBL623293,,BAO_0000218,1969.0
11777,22224,,In vivo,0,,U,,Plasma,,Autocuration,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,1,,15604,CHEMBL623294,,BAO_0000218,1969.0
11778,50597,,In vivo,1,,N,,Plasma,,Intermediate,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,1,,15604,CHEMBL623295,,BAO_0000218,1969.0
11779,50594,,In vivo,1,,N,,,,Intermediate,maximum concentration was measured when administered through oral route in mice,A,1,,14387,CHEMBL623296,,BAO_0000218,
11780,50594,,,1,,N,,,,Intermediate,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,1,,15115,CHEMBL875349,,BAO_0000218,
11781,22224,,,0,,U,,,,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,1,,15115,CHEMBL623297,,BAO_0000019,
11782,22224,,,0,,U,,,,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,1,,15115,CHEMBL623298,,BAO_0000019,
11783,22224,,,0,,U,,,,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,1,,15115,CHEMBL623299,,BAO_0000019,
11784,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter was evaluated in rats,A,1,,16359,CHEMBL623300,,BAO_0000218,
11785,50594,,,1,,N,,,,Intermediate,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,1,,12829,CHEMBL623301,,BAO_0000218,
11786,50594,,,1,,N,,,,Intermediate,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,1,,12829,CHEMBL623302,,BAO_0000218,
11787,50594,,,1,,N,,,,Intermediate,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,1,,12829,CHEMBL623303,,BAO_0000218,
11788,50594,,,1,,N,,,,Intermediate,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,1,,12829,CHEMBL623304,,BAO_0000218,
11789,50594,,,1,,N,,,,Intermediate,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,1,,12829,CHEMBL623305,,BAO_0000218,
11790,50597,,,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,1,,15137,CHEMBL623306,,BAO_0000218,1969.0
11791,50597,,,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,1,,15137,CHEMBL623307,,BAO_0000218,1969.0
11792,50597,,,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,1,,15137,CHEMBL623308,,BAO_0000218,1969.0
11793,50594,,,1,,N,,Plasma,,Intermediate,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,1,,15137,CHEMBL623309,,BAO_0000218,1969.0
11794,50594,,,1,,N,,,,Intermediate,Plasma Concentration after 120 min of oral administration to mice,A,1,,13509,CHEMBL623310,,BAO_0000218,
11795,50594,,,1,,N,,,,Intermediate,Plasma Concentration after 30 min of oral administration to mice,A,1,,13509,CHEMBL623311,,BAO_0000218,
11796,100710,,,1,,N,,,,Intermediate,Plasma Concentration after 60 min of oral administration to mice,A,1,,13509,CHEMBL623312,,BAO_0000218,
11797,50594,,,1,,N,,,,Intermediate,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,1,,13509,CHEMBL875350,,BAO_0000218,
11798,50594,,,1,,N,,,,Intermediate,Plasma Concentration after 90 min of oral administration to mice,A,1,,13509,CHEMBL628635,,BAO_0000218,
11799,50597,,,1,,N,,,,Intermediate,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,1,,12064,CHEMBL628636,,BAO_0000218,
11800,50597,,,1,,N,,,,Intermediate,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,1,,12064,CHEMBL628637,,BAO_0000218,
11801,50597,,,1,,N,,,,Intermediate,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,1,,12064,CHEMBL628058,,BAO_0000218,
11802,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,1,,10677,CHEMBL628059,,BAO_0000218,
11803,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,1,,10677,CHEMBL628060,,BAO_0000218,
11804,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 15 min of intravenous administration,A,1,,8926,CHEMBL628061,,BAO_0000019,
11805,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 30 min of intravenous administration,A,1,,8926,CHEMBL628062,,BAO_0000019,
11806,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 5 min of intravenous administration,A,1,,8926,CHEMBL628063,,BAO_0000019,
11807,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 60 min of intravenous administration,A,1,,8926,CHEMBL628064,,BAO_0000019,
11808,22224,,,0,,U,,,,Autocuration,Distribution in the lung after 90 min of intravenous administration,A,1,,8926,CHEMBL628065,,BAO_0000019,
11809,22224,,,0,,U,,Muscle tissue,,Autocuration,Distribution in the muscle after 120 min of intravenous administration,A,1,,8926,CHEMBL628066,,BAO_0000019,2385.0
11810,22224,,,0,,U,,Muscle tissue,,Autocuration,Distribution in the muscle after 15 min of intravenous administration,A,1,,8926,CHEMBL628067,,BAO_0000019,2385.0
11811,50594,,,1,,N,,Muscle tissue,,Intermediate,Distribution in the muscle after 30 min of intravenous administration,A,1,,8926,CHEMBL874646,,BAO_0000218,2385.0
11812,22224,,,0,,U,,Muscle tissue,,Autocuration,Distribution in the muscle after 5 min of intravenous administration,A,1,,8926,CHEMBL628068,,BAO_0000019,2385.0
11813,22224,,,0,,U,,Muscle tissue,,Autocuration,Distribution in the muscle after 60 min of intravenous administration,A,1,,8926,CHEMBL628069,,BAO_0000019,2385.0
11814,22224,,,0,,U,,Muscle tissue,,Autocuration,Distribution in the muscle after 90 min of intravenous administration,A,1,,8926,CHEMBL628070,,BAO_0000019,2385.0
11815,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 120 min of intravenous administration,A,1,,8926,CHEMBL628071,,BAO_0000019,2106.0
11816,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 15 min of intravenous administration,A,1,,8926,CHEMBL628072,,BAO_0000019,2106.0
11817,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 30 min of intravenous administration,A,1,,8926,CHEMBL628073,,BAO_0000019,2106.0
11818,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 5 min of intravenous administration,A,1,,8926,CHEMBL628074,,BAO_0000019,2106.0
11819,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 60 min of intravenous administration,A,1,,8926,CHEMBL628075,,BAO_0000019,2106.0
11820,22224,,,0,,U,,Spleen,,Autocuration,Distribution in the spleen after 90 min of intravenous administration,A,1,,8926,CHEMBL628076,,BAO_0000019,2106.0
11821,50597,,,1,,N,,Adrenal cortex,,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,1,,7570,CHEMBL628077,,BAO_0000218,1235.0
11822,50597,,,1,,N,,Blood,,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,1,,7570,CHEMBL628078,,BAO_0000218,178.0
11823,50597,,,1,,N,,Liver,,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,1,,7570,CHEMBL628079,,BAO_0000218,2107.0
11824,50597,,,1,,N,,Female gonad,,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,1,,7570,CHEMBL628080,,BAO_0000218,992.0
11825,50597,,,1,,N,,Thyroid gland,,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,1,,7570,CHEMBL628081,,BAO_0000218,2046.0
11826,50597,,,1,,N,,Adrenal cortex,,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,1,,7570,CHEMBL628082,,BAO_0000218,1235.0
11827,50597,,,1,,N,,Blood,,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,1,,7570,CHEMBL874647,,BAO_0000218,178.0
11828,50597,,,1,,N,,Liver,,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,1,,7570,CHEMBL626406,,BAO_0000218,2107.0
11829,50597,,,1,,N,,Female gonad,,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,1,,7570,CHEMBL626407,,BAO_0000218,992.0
11830,50597,,,1,,N,,Thyroid gland,,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,1,,7570,CHEMBL626408,,BAO_0000218,2046.0
11831,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,1,,8608,CHEMBL626409,,BAO_0000218,178.0
11832,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,1,,8608,CHEMBL626410,,BAO_0000218,178.0
11833,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,1,,8608,CHEMBL626411,,BAO_0000218,178.0
11834,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,1,,8608,CHEMBL626412,,BAO_0000218,178.0
11835,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,1,,8608,CHEMBL626413,,BAO_0000218,178.0
11836,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,1,,8608,CHEMBL626414,,BAO_0000218,178.0
11837,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,1,,8608,CHEMBL626415,,BAO_0000218,178.0
11838,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,1,,8608,CHEMBL626416,,BAO_0000218,178.0
11839,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,1,,8608,CHEMBL627062,,BAO_0000218,178.0
11840,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,1,,8608,CHEMBL627063,,BAO_0000218,178.0
11841,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,1,,8608,CHEMBL627064,,BAO_0000218,178.0
11842,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,1,,8608,CHEMBL627227,,BAO_0000218,178.0
11843,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,1,,8608,CHEMBL627228,,BAO_0000218,178.0
11844,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,1,,8608,CHEMBL627229,,BAO_0000218,178.0
11845,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,1,,8608,CHEMBL625792,,BAO_0000218,178.0
11846,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,1,,8608,CHEMBL625793,,BAO_0000218,178.0
11847,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,1,,8608,CHEMBL625794,,BAO_0000218,178.0
11848,50597,,,1,,N,,Blood,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,1,,8608,CHEMBL625795,,BAO_0000218,178.0
11849,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,1,,13792,CHEMBL625796,,BAO_0000218,
11850,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,1,,13376,CHEMBL625797,,BAO_0000218,
11851,50588,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,1,,13376,CHEMBL625798,,BAO_0000218,
11852,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL875613,,BAO_0000218,
11853,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL625799,,BAO_0000218,
11854,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL625800,,BAO_0000218,
11855,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL625801,,BAO_0000218,
11856,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL625802,,BAO_0000218,
11857,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL625803,,BAO_0000218,
11858,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,1,,14380,CHEMBL625804,,BAO_0000019,
11859,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,1,,14380,CHEMBL622530,,BAO_0000218,
11860,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,1,,13701,CHEMBL622531,,BAO_0000218,
11861,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,1,,13701,CHEMBL622532,,BAO_0000218,
11862,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,1,,13701,CHEMBL623176,,BAO_0000218,
11863,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,1,,13701,CHEMBL623177,,BAO_0000218,
11864,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,1,,13701,CHEMBL623178,,BAO_0000218,
11865,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,1,,13701,CHEMBL623179,,BAO_0000218,
11866,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,1,,13701,CHEMBL623180,,BAO_0000218,
11867,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,1,,13701,CHEMBL623181,,BAO_0000218,
11868,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,1,,13701,CHEMBL624131,,BAO_0000218,
11869,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,1,,13701,CHEMBL624132,,BAO_0000218,
11870,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,1,,13701,CHEMBL624133,,BAO_0000218,
11871,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,1,,13701,CHEMBL624846,,BAO_0000218,
11872,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,1,,13701,CHEMBL624847,,BAO_0000218,
11873,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,1,,13701,CHEMBL624848,,BAO_0000218,
11874,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,1,,13701,CHEMBL625012,,BAO_0000218,
11875,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,1,,13701,CHEMBL625013,,BAO_0000218,
11876,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,1,,13701,CHEMBL625014,,BAO_0000218,
11877,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,1,,13701,CHEMBL625015,,BAO_0000218,
11878,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,1,,13701,CHEMBL625016,,BAO_0000218,
11879,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,1,,13701,CHEMBL625017,,BAO_0000218,
11880,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,1,,13701,CHEMBL625018,,BAO_0000218,
11881,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,1,,13701,CHEMBL625019,,BAO_0000218,
11882,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,1,,13701,CHEMBL625020,,BAO_0000218,
11883,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,1,,13701,CHEMBL625021,,BAO_0000218,
11884,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL625022,,BAO_0000218,
11885,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,1,,14731,CHEMBL625023,,BAO_0000218,
11886,100710,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,1,,14731,CHEMBL625024,,BAO_0000218,
11887,100710,,,1,,N,,,,Intermediate,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,1,,14731,CHEMBL627626,,BAO_0000218,
11888,22224,,,0,,U,,Brain,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,1,,13758,CHEMBL627627,,BAO_0000218,955.0
11889,22224,,,0,,U,,Serum,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,1,,13758,CHEMBL627628,,BAO_0000218,1977.0
11890,22224,,,0,,U,,Brain,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,1,,13758,CHEMBL627629,,BAO_0000218,955.0
11891,22224,,,0,,U,,Serum,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,1,,13758,CHEMBL627630,,BAO_0000218,1977.0
11892,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,1,,16359,CHEMBL627631,,BAO_0000019,
11893,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,1,,16359,CHEMBL629515,,BAO_0000218,
11894,50594,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL629516,,BAO_0000218,2106.0
11895,50594,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL629517,,BAO_0000218,2106.0
11896,50594,,,1,,N,,Spleen,,Intermediate,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL629518,,BAO_0000218,2106.0
11897,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,1,,15383,CHEMBL877499,,BAO_0000218,
11898,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,1,,15383,CHEMBL629519,,BAO_0000218,
11899,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,1,,15383,CHEMBL629520,,BAO_0000218,
11900,50594,,,1,,N,,,,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,1,,15383,CHEMBL629521,,BAO_0000218,
11901,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,1,,14439,CHEMBL629522,,BAO_0000218,
11902,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,1,,14439,CHEMBL629523,,BAO_0000218,
11903,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,1,,14439,CHEMBL629524,,BAO_0000218,
11904,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,1,,14439,CHEMBL629525,,BAO_0000218,
11905,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,1,,14439,CHEMBL629526,,BAO_0000218,
11906,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,1,,14439,CHEMBL629527,,BAO_0000218,
11907,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,1,,14439,CHEMBL629528,,BAO_0000218,
11908,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,1,,14439,CHEMBL629529,,BAO_0000218,
11909,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,1,,14439,CHEMBL629530,,BAO_0000218,
11910,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,1,,14439,CHEMBL629531,,BAO_0000218,
11911,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,1,,14439,CHEMBL628656,,BAO_0000218,
11912,50594,,,1,,N,,,,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,1,,14439,CHEMBL628657,,BAO_0000218,
11913,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628658,,BAO_0000218,
11914,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628659,,BAO_0000218,
11915,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL877500,,BAO_0000218,
11916,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL628660,,BAO_0000218,
11917,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL628661,,BAO_0000218,
11918,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628662,,BAO_0000218,
11919,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628663,,BAO_0000218,
11920,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628664,,BAO_0000218,
11921,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628665,,BAO_0000218,178.0
11922,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628666,,BAO_0000218,178.0
11923,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL628667,,BAO_0000218,178.0
11924,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL628668,,BAO_0000218,178.0
11925,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628669,,BAO_0000218,178.0
11926,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628670,,BAO_0000218,178.0
11927,50597,,In vivo,1,,N,,Blood,,Intermediate,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628671,,BAO_0000218,178.0
11928,50597,,In vivo,1,,N,,Bone,,Intermediate,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL628672,,BAO_0000218,10000001.0
11929,50597,,In vivo,1,,N,,Bone,,Intermediate,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL630300,,BAO_0000218,10000001.0
11930,50597,,In vivo,1,,N,,Bone,,Intermediate,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL629787,,BAO_0000218,10000001.0
11931,50597,,In vivo,1,,N,,Bone,,Intermediate,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629788,,BAO_0000218,10000001.0
11932,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629789,,BAO_0000218,955.0
11933,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629790,,BAO_0000218,955.0
11934,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL629791,,BAO_0000218,955.0
11935,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL629792,,BAO_0000218,955.0
11936,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629793,,BAO_0000218,955.0
11937,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629794,,BAO_0000218,955.0
11938,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,1,,10677,CHEMBL874459,,BAO_0000218,
11939,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,1,,10677,CHEMBL629795,,BAO_0000218,
11940,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,1,,10677,CHEMBL629796,,BAO_0000218,
11941,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,1,,10677,CHEMBL629797,,BAO_0000218,
11942,50597,,,1,,N,,,,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,1,,10677,CHEMBL629798,,BAO_0000218,
11943,50597,,In vivo,1,,N,,Adrenal gland,,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629799,,BAO_0000218,2369.0
11944,50597,,In vivo,1,,N,,Adrenal gland,,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629800,,BAO_0000218,2369.0
11945,50597,,In vivo,1,,N,,Adrenal gland,,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629801,,BAO_0000218,2369.0
11946,50597,,In vivo,1,,N,,Adrenal gland,,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,1,,10911,CHEMBL629802,,BAO_0000218,2369.0
11947,50597,,In vivo,1,,N,,Adrenal gland,,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629803,,BAO_0000218,2369.0
11948,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629804,,BAO_0000218,178.0
11949,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629805,,BAO_0000218,178.0
11950,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629806,,BAO_0000218,178.0
11951,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629807,,BAO_0000218,178.0
11952,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629808,,BAO_0000218,178.0
11953,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629809,,BAO_0000218,955.0
11954,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629810,,BAO_0000218,955.0
11955,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629811,,BAO_0000218,955.0
11956,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629812,,BAO_0000218,955.0
11957,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629813,,BAO_0000218,955.0
11958,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL874460,,BAO_0000218,955.0
11959,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629814,,BAO_0000218,
11960,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629815,,BAO_0000218,
11961,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629816,,BAO_0000218,
11962,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL629817,,BAO_0000218,
11963,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626643,,BAO_0000218,2113.0
11964,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626644,,BAO_0000218,2113.0
11965,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626806,,BAO_0000218,2113.0
11966,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626807,,BAO_0000218,2113.0
11967,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627261,,BAO_0000218,2107.0
11968,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627262,,BAO_0000218,2107.0
11969,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627263,,BAO_0000218,2107.0
11970,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627264,,BAO_0000218,2107.0
11971,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627265,,BAO_0000218,2048.0
11972,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627266,,BAO_0000218,2048.0
11973,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627267,,BAO_0000218,2048.0
11974,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627268,,BAO_0000218,2048.0
11975,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627269,,BAO_0000218,2385.0
11976,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627270,,BAO_0000218,2385.0
11977,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,1,,8608,CHEMBL627271,,BAO_0000218,
11978,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,1,,8608,CHEMBL627946,,BAO_0000218,
11979,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,1,,8608,CHEMBL875472,,BAO_0000218,
11980,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,1,,8608,CHEMBL627947,,BAO_0000218,
11981,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,1,,8608,CHEMBL627948,,BAO_0000218,
11982,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,1,,8608,CHEMBL628113,,BAO_0000218,
11983,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,1,,8608,CHEMBL628114,,BAO_0000218,
11984,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,1,,8608,CHEMBL628115,,BAO_0000218,
11985,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,1,,8608,CHEMBL628116,,BAO_0000218,
11986,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,1,,8608,CHEMBL628117,,BAO_0000218,
11987,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,1,,8608,CHEMBL628118,,BAO_0000218,
11988,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,1,,8608,CHEMBL628119,,BAO_0000218,
11989,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,1,,8608,CHEMBL628120,,BAO_0000218,
11990,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,1,,8608,CHEMBL628121,,BAO_0000218,
11991,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,1,,8608,CHEMBL628122,,BAO_0000218,
11992,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,1,,8608,CHEMBL627297,,BAO_0000218,
11993,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,1,,8608,CHEMBL627298,,BAO_0000218,
11994,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,1,,8608,CHEMBL627299,,BAO_0000218,
11995,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,1,,8608,CHEMBL627300,,BAO_0000218,
11996,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,1,,8608,CHEMBL627301,,BAO_0000218,
11997,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,1,,8608,CHEMBL627302,,BAO_0000218,
11998,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,1,,8608,CHEMBL627303,,BAO_0000218,
11999,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,1,,8608,CHEMBL627304,,BAO_0000218,
12000,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,1,,8608,CHEMBL627305,,BAO_0000218,
12001,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,1,,8608,CHEMBL627306,,BAO_0000218,
12002,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,1,,8608,CHEMBL623982,,BAO_0000218,
12003,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,1,,8608,CHEMBL623983,,BAO_0000218,
12004,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,1,,8608,CHEMBL623984,,BAO_0000218,
12005,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,1,,8608,CHEMBL623985,,BAO_0000218,
12006,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,1,,8608,CHEMBL623986,,BAO_0000218,
12007,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,1,,8608,CHEMBL623987,,BAO_0000218,
12008,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,1,,8608,CHEMBL623988,,BAO_0000218,
12009,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,1,,8608,CHEMBL623989,,BAO_0000218,
12010,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,1,,8608,CHEMBL622215,,BAO_0000218,
12011,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,1,,8608,CHEMBL622216,,BAO_0000218,
12012,50597,,,1,,N,,,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,1,,8608,CHEMBL877481,,BAO_0000218,
12013,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,1,,16359,CHEMBL622217,,BAO_0000218,
12014,50594,,,1,,N,,,,Intermediate,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,1,,13701,CHEMBL622218,,BAO_0000218,
12015,50597,,,1,,N,,,,Intermediate,Pharmacokinetic profile AUC was evaluated in rats,A,1,,14554,CHEMBL622219,,BAO_0000218,
12016,22224,,,0,,U,,,,Autocuration,Pharmacokinetic property (Area under curve),A,1,,6241,CHEMBL622220,,BAO_0000019,
12017,50588,,,1,,N,,,,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,1,,11537,CHEMBL622221,,BAO_0000218,
12018,50594,,,1,,N,,,,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,1,,11537,CHEMBL622222,,BAO_0000218,
12019,50588,,,1,,N,,,,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,1,,11537,CHEMBL622223,,BAO_0000218,
12020,50594,,,1,,N,,,,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,1,,11537,CHEMBL622224,,BAO_0000218,
12021,22224,,,0,,U,,,,Autocuration,Plasma concentration (AUC) was determined,A,1,,13118,CHEMBL622225,,BAO_0000019,
12022,22224,,,0,,U,,,,Autocuration,Plasma concentration (AUC) was determined; Not detectable,A,1,,13118,CHEMBL622226,,BAO_0000019,
12023,50512,,,1,,N,,,,Intermediate,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,1,,9562,CHEMBL624154,,BAO_0000218,
12024,50597,,,1,,N,,,,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,1,,10363,CHEMBL624155,,BAO_0000218,
12025,50597,,,1,,N,,,,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,1,,10363,CHEMBL624156,,BAO_0000218,
12026,50597,,,1,,N,,,,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,1,,10363,CHEMBL624157,,BAO_0000218,
12027,50597,,,1,,N,,,,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,1,,10363,CHEMBL624158,,BAO_0000218,
12028,50597,,,1,,N,,,,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,1,,12504,CHEMBL624159,,BAO_0000218,
12029,50597,,,1,,N,,,,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,1,,12504,CHEMBL624160,,BAO_0000218,
12030,50597,,,1,,N,,,,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,1,,12504,CHEMBL624161,,BAO_0000218,
12031,50597,,,1,,N,,,,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,1,,12504,CHEMBL624162,,BAO_0000218,
12032,50588,,,1,,N,,,,Intermediate,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,1,,13317,CHEMBL624163,,BAO_0000218,
12033,50597,,,1,,N,,,,Intermediate,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL624164,,BAO_0000218,
12034,50597,,,1,,N,,,,Intermediate,The AUC(0-infinity) values in female wistar rats.,A,1,,14941,CHEMBL624165,,BAO_0000218,
12035,50597,,,1,,N,,,,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL624166,,BAO_0000218,
12036,50597,,,1,,N,,,,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,1,,15078,CHEMBL624167,,BAO_0000218,
12037,50597,,,1,,N,,,,Intermediate,The AUC(0-t)values in female wistar rats.,A,1,,14941,CHEMBL624168,,BAO_0000218,
12038,50597,,,1,,N,,,,Intermediate,The Area under the concentration time curve of compound was measured on rats,A,1,,14067,CHEMBL624169,,BAO_0000218,
12039,50587,,,1,,N,,,,Intermediate,The area under curve (100 mg/kg) administered orally in humans,A,1,,14215,CHEMBL624170,,BAO_0000218,
12040,22224,,,0,,U,,,,Autocuration,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,1,,14215,CHEMBL624171,,BAO_0000218,
12041,22224,,,0,,U,,,,Autocuration,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,1,,14215,CHEMBL624172,,BAO_0000218,
12042,50588,,,1,,N,,,,Intermediate,The area under curve (15 mg/kg) administered intravenously in dog,A,1,,14215,CHEMBL624173,,BAO_0000218,
12043,50587,,,1,,N,,,,Intermediate,The area under curve (200 mg/kg) administered orally in humans,A,1,,14215,CHEMBL877488,,BAO_0000218,
12044,50597,,,1,,N,,,,Intermediate,The area under curve (25 mg/kg) administered intravenously in rat,A,1,,14215,CHEMBL624174,,BAO_0000218,
12045,22224,,,0,,U,,,,Autocuration,The area under curve (25 mg/kg) administered orally in marmoset,A,1,,14215,CHEMBL624175,,BAO_0000218,
12046,22224,,,0,,U,,,,Autocuration,The area under curve (25 mg/kg) administered orally in monkey,A,1,,14215,CHEMBL624176,,BAO_0000218,
12047,50588,,,1,,N,,,,Intermediate,The area under curve (30 mg/kg) administered orally in dog,A,1,,14215,CHEMBL624177,,BAO_0000218,
12048,50587,,,1,,N,,,,Intermediate,The area under curve (400 mg/kg) administered orally in humans,A,1,,14215,CHEMBL624178,,BAO_0000218,
12049,50597,,,1,,N,,,,Intermediate,The area under curve (50 mg/kg) administered orally in fasted rat,A,1,,14215,CHEMBL624179,,BAO_0000218,
12050,50597,,,1,,N,,,,Intermediate,The area under curve (50 mg/kg) administered orally in rat,A,1,,14215,CHEMBL627689,,BAO_0000218,
12051,50587,,,1,,N,,,,Intermediate,The area under curve (800 mg/kg) administered orally in humans,A,1,,14215,CHEMBL627690,,BAO_0000218,
12052,22224,,,0,,U,,,,Autocuration,The compound was evaluated for area under the curve,A,1,,11324,CHEMBL627691,,BAO_0000019,
12053,22224,,,0,,U,,,,Autocuration,The compound was evaluated for area under the curve in marmosets,A,1,,11324,CHEMBL627692,,BAO_0000019,
12054,22224,,,0,,U,,,,Autocuration,The compound was evaluated for area under the curve in marmosets,A,1,,11324,CHEMBL627693,,BAO_0000019,
12055,50597,,,1,,N,,,,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,1,,13875,CHEMBL627694,,BAO_0000218,
12056,50597,,,1,,N,,,,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,1,,13875,CHEMBL627695,,BAO_0000218,
12057,22224,,,0,,U,,,,Autocuration,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,1,,13875,CHEMBL627696,,BAO_0000218,
12058,50597,,,1,,N,,,,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,1,,13875,CHEMBL627697,,BAO_0000218,
12059,50597,,,1,,N,,,,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,1,,13875,CHEMBL627698,,BAO_0000218,
12060,50597,,,1,,N,,,,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,1,,13875,CHEMBL627699,,BAO_0000218,
12061,50597,,,1,,N,,,,Intermediate,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,1,,13807,CHEMBL627700,,BAO_0000218,
12062,50597,,,1,,N,,,,Intermediate,Total drug exposure is determined after oral dosing in rats.,A,1,,14127,CHEMBL627701,,BAO_0000218,
12063,22224,,,0,,U,,,,Autocuration,Total drug exposure (5 mg/kg) when administered intravenously,A,1,,15116,CHEMBL627702,,BAO_0000218,
12064,22224,,,0,,U,,,,Autocuration,Total drug exposure (5 mg/kg) when administered orally,A,1,,15116,CHEMBL627703,,BAO_0000218,
12065,22224,,,0,,U,,,,Autocuration,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,1,,15604,CHEMBL626873,,BAO_0000218,
12066,50597,,,1,,N,,,,Intermediate,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,1,,15604,CHEMBL629583,,BAO_0000218,
12067,50588,,,1,,N,,,,Intermediate,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,1,,15604,CHEMBL629584,,BAO_0000218,
12068,50588,,,1,,N,,,,Intermediate,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,1,,15604,CHEMBL629585,,BAO_0000218,
12069,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629586,,BAO_0000218,955.0
12070,50597,,In vivo,1,,N,,Brain,,Intermediate,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629587,,BAO_0000218,955.0
12071,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629588,,BAO_0000218,
12072,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629589,,BAO_0000218,
12073,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL629590,,BAO_0000218,
12074,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL629591,,BAO_0000218,
12075,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629592,,BAO_0000218,
12076,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629593,,BAO_0000218,
12077,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629594,,BAO_0000218,
12078,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL629595,,BAO_0000218,948.0
12079,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL630290,,BAO_0000218,948.0
12080,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627137,,BAO_0000218,948.0
12081,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627138,,BAO_0000218,948.0
12082,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627139,,BAO_0000218,948.0
12083,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627140,,BAO_0000218,948.0
12084,50597,,In vivo,1,,N,,Heart,,Intermediate,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627141,,BAO_0000218,948.0
12085,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627142,,BAO_0000218,2113.0
12086,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627143,,BAO_0000218,2113.0
12087,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL874449,,BAO_0000218,2113.0
12088,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627144,,BAO_0000218,2113.0
12089,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627145,,BAO_0000218,2113.0
12090,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627146,,BAO_0000218,2113.0
12091,50597,,In vivo,1,,N,,Kidney,,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627147,,BAO_0000218,2113.0
12092,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627148,,BAO_0000218,2107.0
12093,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627149,,BAO_0000218,2048.0
12094,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL632160,,BAO_0000218,2048.0
12095,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL632161,,BAO_0000218,2048.0
12096,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL632162,,BAO_0000218,2048.0
12097,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL632163,,BAO_0000218,2048.0
12098,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL874469,,BAO_0000218,2048.0
12099,50597,,In vivo,1,,N,,Lung,,Intermediate,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627182,,BAO_0000218,2048.0
12100,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627183,,BAO_0000218,2385.0
12101,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627184,,BAO_0000218,2385.0
12102,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627185,,BAO_0000218,2385.0
12103,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627186,,BAO_0000218,2385.0
12104,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627187,,BAO_0000218,2385.0
12105,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627188,,BAO_0000218,2385.0
12106,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627189,,BAO_0000218,2385.0
12107,50597,,In vivo,1,,N,,,,Intermediate,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627190,,BAO_0000218,
12108,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627191,,BAO_0000218,2107.0
12109,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,1,,13751,CHEMBL627192,,BAO_0000218,2107.0
12110,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,1,,13751,CHEMBL627193,,BAO_0000218,2107.0
12111,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL874590,,BAO_0000218,2385.0
12112,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627194,,BAO_0000218,2385.0
12113,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627195,,BAO_0000218,2385.0
12114,50597,,In vivo,1,,N,,Female gonad,,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627196,,BAO_0000218,992.0
12115,50597,,In vivo,1,,N,,Female gonad,,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627197,,BAO_0000218,992.0
12116,50597,,In vivo,1,,N,,Female gonad,,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627198,,BAO_0000218,992.0
12117,50597,,In vivo,1,,N,,Female gonad,,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,1,,10911,CHEMBL627199,,BAO_0000218,992.0
12118,50597,,In vivo,1,,N,,Female gonad,,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627200,,BAO_0000218,992.0
12119,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627201,,BAO_0000218,1969.0
12120,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627202,,BAO_0000218,1969.0
12121,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627203,,BAO_0000218,1969.0
12122,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627204,,BAO_0000218,1969.0
12123,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627205,,BAO_0000218,2106.0
12124,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627206,,BAO_0000218,2106.0
12125,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627207,,BAO_0000218,2106.0
12126,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627208,,BAO_0000218,2106.0
12127,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627209,,BAO_0000218,2046.0
12128,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627210,,BAO_0000218,2046.0
12129,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627211,,BAO_0000218,2046.0
12130,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627212,,BAO_0000218,2046.0
12131,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL627213,,BAO_0000218,995.0
12132,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626599,,BAO_0000218,995.0
12133,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626600,,BAO_0000218,995.0
12134,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,1,,10911,CHEMBL626601,,BAO_0000218,995.0
12135,22224,,,0,,U,,,,Autocuration,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,1,,8081,CHEMBL627484,,BAO_0000019,
12136,100710,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,1,,17248,CHEMBL627485,,BAO_0000218,1969.0
12137,100710,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,1,,17248,CHEMBL628147,,BAO_0000218,1969.0
12138,100710,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,1,,17248,CHEMBL628148,,BAO_0000218,1969.0
12139,50588,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,1,,17248,CHEMBL628149,,BAO_0000218,1969.0
12140,50588,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,1,,17248,CHEMBL628150,,BAO_0000218,1969.0
12141,50588,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,1,,17248,CHEMBL628318,,BAO_0000218,1969.0
12142,50588,,,1,,N,,Plasma,,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,1,,17248,CHEMBL628319,,BAO_0000218,1969.0
12143,50588,,,1,,N,,,,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,1,,15592,CHEMBL875609,,BAO_0000218,
12144,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,1,,7040,CHEMBL628320,,BAO_0000019,
12145,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,1,,7040,CHEMBL628321,,BAO_0000019,
12146,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,1,,7040,CHEMBL628322,,BAO_0000019,
12147,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,1,,7040,CHEMBL628323,,BAO_0000019,
12148,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,1,,7040,CHEMBL628324,,BAO_0000019,
12149,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,1,,7040,CHEMBL628325,,BAO_0000019,
12150,22224,,,0,,U,,,,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,1,,7040,CHEMBL628326,,BAO_0000019,
12151,50588,,,1,,N,,Adrenal medulla,,Intermediate,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,1,,9614,CHEMBL628327,,BAO_0000218,1236.0
12152,50588,,,1,,N,,Adrenal medulla,,Intermediate,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,1,,9614,CHEMBL628328,,BAO_0000218,1236.0
12153,50588,,,1,,N,,Blood,,Intermediate,"Concentration of compound in blood of dog 1, after administering intravenously",A,1,,9614,CHEMBL628329,,BAO_0000218,178.0
12154,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,1,,8608,CHEMBL628330,,BAO_0000218,2107.0
12155,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,1,,8608,CHEMBL628331,,BAO_0000218,2107.0
12156,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,1,,8608,CHEMBL628332,,BAO_0000218,2107.0
12157,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,1,,8608,CHEMBL628333,,BAO_0000218,2107.0
12158,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,1,,8608,CHEMBL628334,,BAO_0000218,2107.0
12159,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,1,,8608,CHEMBL628335,,BAO_0000218,2107.0
12160,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,1,,8608,CHEMBL628336,,BAO_0000218,2107.0
12161,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,1,,8608,CHEMBL628337,,BAO_0000218,2107.0
12162,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,1,,8608,CHEMBL628338,,BAO_0000218,2107.0
12163,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,1,,8608,CHEMBL875610,,BAO_0000218,2107.0
12164,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,1,,8608,CHEMBL628339,,BAO_0000218,2107.0
12165,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,1,,8608,CHEMBL628340,,BAO_0000218,2107.0
12166,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,1,,8608,CHEMBL628341,,BAO_0000218,2107.0
12167,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,1,,8608,CHEMBL622214,,BAO_0000218,2107.0
12168,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,1,,8608,CHEMBL623167,,BAO_0000218,2107.0
12169,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,1,,8608,CHEMBL623168,,BAO_0000218,2107.0
12170,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,1,,8608,CHEMBL623169,,BAO_0000218,2107.0
12171,50597,,,1,,N,,Liver,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,1,,8608,CHEMBL623170,,BAO_0000218,2107.0
12172,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,1,,8608,CHEMBL627224,,BAO_0000218,2048.0
12173,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,1,,8608,CHEMBL875634,,BAO_0000218,2048.0
12174,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,1,,8608,CHEMBL627225,,BAO_0000218,2048.0
12175,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,1,,8608,CHEMBL627226,,BAO_0000218,2048.0
12176,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,1,,8608,CHEMBL626083,,BAO_0000218,2048.0
12177,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,1,,8608,CHEMBL626084,,BAO_0000218,2048.0
12178,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,1,,8608,CHEMBL626085,,BAO_0000218,2048.0
12179,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,1,,8608,CHEMBL626086,,BAO_0000218,2048.0
12180,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,1,,8608,CHEMBL626087,,BAO_0000218,2048.0
12181,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,1,,8608,CHEMBL626088,,BAO_0000218,2048.0
12182,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,1,,8608,CHEMBL626089,,BAO_0000218,2048.0
12183,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,1,,8608,CHEMBL626090,,BAO_0000218,2048.0
12184,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,1,,8608,CHEMBL626091,,BAO_0000218,2048.0
12185,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,1,,8608,CHEMBL626092,,BAO_0000218,2048.0
12186,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,1,,8608,CHEMBL626093,,BAO_0000218,2048.0
12187,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,1,,8608,CHEMBL626094,,BAO_0000218,2048.0
12188,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,1,,8608,CHEMBL626095,,BAO_0000218,2048.0
12189,50597,,,1,,N,,Lung,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,1,,8608,CHEMBL626096,,BAO_0000218,2048.0
12190,22224,,,0,,U,,,,Autocuration,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,1,,15604,CHEMBL626097,,BAO_0000218,
12191,50597,,,1,,N,,,,Intermediate,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,1,,15604,CHEMBL626098,,BAO_0000218,
12192,22224,,,0,,U,,Plasma,,Autocuration,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,1,,1806,CHEMBL626099,,BAO_0000218,1969.0
12193,22224,,,0,,U,,Plasma,,Autocuration,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,1,,1806,CHEMBL626100,,BAO_0000218,1969.0
12194,50588,,,1,,N,,Plasma,,Intermediate,AUC 0-inf in dog,A,1,,17237,CHEMBL626101,,BAO_0000218,1969.0
12195,50512,,,1,,N,,Plasma,,Intermediate,AUC 0-inf in guinea pig,A,1,,17237,CHEMBL626102,,BAO_0000218,1969.0
12196,50588,,,1,,N,,Plasma,,Intermediate,AUC 0-t in dog,A,1,,17237,CHEMBL626103,,BAO_0000218,1969.0
12197,50512,,,1,,N,,Plasma,,Intermediate,AUC 0-t in guinea pig,A,1,,17237,CHEMBL628391,,BAO_0000218,1969.0
12198,50597,,,1,,N,,,,Intermediate,The compound was tested for brain to plasma partition in rat,A,1,,15194,CHEMBL628392,,BAO_0000218,
12199,50597,,,1,,N,,,,Intermediate,The compound was tested for brain to plasma partition in rat.,A,1,,15194,CHEMBL628393,,BAO_0000218,
12200,22224,,,0,,U,,Blood,,Autocuration,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,1,,8787,CHEMBL628394,,BAO_0000019,178.0
12201,50588,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL628395,,BAO_0000218,
12202,22224,,,0,,U,,,,Autocuration,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL628396,,BAO_0000218,
12203,50592,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL628397,,BAO_0000218,
12204,50597,,,1,,N,,,,Intermediate,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL628398,,BAO_0000218,
12205,50797,,,1,,N,,,,Intermediate,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,1,,4236,CHEMBL628399,,BAO_0000218,
12206,50588,,,1,,N,,,,Intermediate,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,1,,15343,CHEMBL628400,,BAO_0000218,
12207,50597,,,1,,N,,,,Intermediate,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,1,,15343,CHEMBL874907,,BAO_0000218,
12208,22224,,,0,,U,,,,Autocuration,Area under curve of the compound was determined,A,1,,17720,CHEMBL628401,,BAO_0000019,
12209,22224,,,0,,U,,Plasma,,Autocuration,AUC in monkeys at a dose of 1 mg/kg,A,1,,17788,CHEMBL628402,,BAO_0000218,1969.0
12210,50597,,,1,,N,,Plasma,,Intermediate,AUC in rats at a dose of 1 mg/kg,A,1,,17788,CHEMBL628403,,BAO_0000218,1969.0
12211,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 2,A,1,,8778,CHEMBL628404,,BAO_0000019,
12212,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 4,A,1,,8778,CHEMBL628405,,BAO_0000019,
12213,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 7,A,1,,8778,CHEMBL628406,,BAO_0000019,
12214,50597,,,1,,N,,,,Intermediate,Compound was evaluated for its absorption in the rats,A,1,,2249,CHEMBL628407,,BAO_0000218,
12215,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,1,,8881,CHEMBL628408,,BAO_0000218,1088.0
12216,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,1,,8881,CHEMBL629171,,BAO_0000218,1088.0
12217,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,1,,8881,CHEMBL629172,,BAO_0000218,1088.0
12218,50597,,,1,,N,,Urine,,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,1,,8881,CHEMBL629173,,BAO_0000218,1088.0
12219,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum,A,1,,15286,CHEMBL629174,,BAO_0000218,
12220,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 10-17,A,1,,15286,CHEMBL629175,,BAO_0000218,
12221,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 10-18,A,1,,15286,CHEMBL629176,,BAO_0000218,
12222,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 10-19,A,1,,15286,CHEMBL629177,,BAO_0000218,
12223,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 12-15,A,1,,15286,CHEMBL629178,,BAO_0000218,
12224,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 13-19,A,1,,15286,CHEMBL631869,,BAO_0000218,
12225,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 14-17,A,1,,15286,CHEMBL631870,,BAO_0000218,
12226,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 15-18,A,1,,15286,CHEMBL631871,,BAO_0000218,
12227,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 2-5,A,1,,15286,CHEMBL631872,,BAO_0000218,
12228,22224,,,0,,U,,Ileum,,Autocuration,In vitro percent permeability into rat ileum; Range is 23-42,A,1,,15286,CHEMBL875775,,BAO_0000221,2116.0
12229,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 28-36,A,1,,15286,CHEMBL631873,,BAO_0000218,
12230,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 29-35,A,1,,15286,CHEMBL631874,,BAO_0000218,
12231,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 46-66,A,1,,15286,CHEMBL631875,,BAO_0000218,
12232,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 50-68,A,1,,15286,CHEMBL631876,,BAO_0000218,
12233,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; Range is 78-81,A,1,,15286,CHEMBL631877,,BAO_0000218,
12234,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,1,,15286,CHEMBL631878,,BAO_0000218,
12235,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; nd indicates not detected,A,1,,15286,CHEMBL631879,,BAO_0000218,
12236,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; nt indicates not detected,A,1,,15286,CHEMBL631880,,BAO_0000218,
12237,50597,,,1,,N,,,,Intermediate,In vitro percent permeability into rat ileum; nt indicates not tested,A,1,,15286,CHEMBL631881,,BAO_0000218,
12238,50597,,,1,,N,,,,Intermediate,Compound was tested for oral absorption in bile-duct cannulated rats,A,1,,13770,CHEMBL631882,,BAO_0000218,
12239,50597,,,1,,N,,,,Intermediate,Compound was tested for oral absorption in bile-duct cannulated rats.,A,1,,13770,CHEMBL630749,,BAO_0000218,
12240,50587,,,1,,N,,,,Intermediate,Oral absorption using Caco-2 cell monolayers.,A,1,,5202,CHEMBL630750,,BAO_0000218,
12241,50587,,,1,,N,,,,Intermediate,Percent of the drug absorbed after administration to humans was determined,A,1,,14920,CHEMBL630253,,BAO_0000218,
12242,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,1,,14103,CHEMBL630254,,BAO_0000218,1969.0
12243,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,1,,14103,CHEMBL630255,,BAO_0000218,1969.0
12244,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,1,,14103,CHEMBL630256,,BAO_0000218,1969.0
12245,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,1,,13751,CHEMBL875781,,BAO_0000218,2107.0
12246,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,1,,13751,CHEMBL630257,,BAO_0000218,2107.0
12247,50597,,In vivo,1,,N,,Liver,,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,1,,13751,CHEMBL630258,,BAO_0000218,2107.0
12248,50597,,,1,,N,,,,Intermediate,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,1,,15807,CHEMBL630259,,BAO_0000218,
12249,50597,,,1,,N,,Striatum,,Intermediate,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,1,,15807,CHEMBL630260,,BAO_0000218,2435.0
12250,50597,,,1,,N,,Striatum,,Intermediate,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,1,,15807,CHEMBL630261,,BAO_0000218,2435.0
12251,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,1,,14950,CHEMBL630262,,BAO_0000218,
12252,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,1,,14950,CHEMBL630263,,BAO_0000218,
12253,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,1,,14950,CHEMBL630264,,BAO_0000218,
12254,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,1,,14950,CHEMBL630265,,BAO_0000218,
12255,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,1,,14950,CHEMBL630266,,BAO_0000218,
12256,50597,,,1,,N,,Kidney,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,1,,14950,CHEMBL630267,,BAO_0000218,2113.0
12257,50597,,,1,,N,,Kidney,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,1,,14950,CHEMBL630268,,BAO_0000218,2113.0
12258,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,1,,14950,CHEMBL630269,,BAO_0000218,
12259,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,1,,14950,CHEMBL630270,,BAO_0000218,
12260,50597,,,1,,N,,Lung,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,1,,14950,CHEMBL630141,,BAO_0000218,2048.0
12261,50597,,,1,,N,,Lung,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,1,,14950,CHEMBL630142,,BAO_0000218,2048.0
12262,50597,,,1,,N,,Muscle tissue,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,1,,14950,CHEMBL630143,,BAO_0000218,2385.0
12263,50597,,,1,,N,,Muscle tissue,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,1,,14950,CHEMBL630144,,BAO_0000218,2385.0
12264,50597,,,1,,N,,Prostate gland,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,1,,14950,CHEMBL630145,,BAO_0000218,2367.0
12265,50597,,,1,,N,,Prostate gland,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,1,,14950,CHEMBL630146,,BAO_0000218,2367.0
12266,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,1,,14950,CHEMBL630147,,BAO_0000218,
12267,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,1,,14950,CHEMBL630148,,BAO_0000218,
12268,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,1,,14950,CHEMBL630149,,BAO_0000218,
12269,50597,,,1,,N,,Spleen,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,1,,14950,CHEMBL630150,,BAO_0000218,2106.0
12270,50597,,,1,,N,,Spleen,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,1,,14950,CHEMBL630151,,BAO_0000218,2106.0
12271,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,1,,14950,CHEMBL632031,,BAO_0000218,2046.0
12272,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,1,,14950,CHEMBL632032,,BAO_0000218,2046.0
12273,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,1,,14950,CHEMBL632033,,BAO_0000218,
12274,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,1,,14950,CHEMBL632034,,BAO_0000218,
12275,50597,,,1,,N,,Muscle tissue,,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,1,,14950,CHEMBL632035,,BAO_0000218,2385.0
12276,50597,,,1,,N,,,,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,1,,14950,CHEMBL632036,,BAO_0000218,
12277,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,1,,14950,CHEMBL632037,,BAO_0000218,2046.0
12278,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,1,,8631,CHEMBL632038,,BAO_0000218,178.0
12279,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL632039,,BAO_0000218,178.0
12280,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL632040,,BAO_0000218,178.0
12281,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,1,,8631,CHEMBL632041,,BAO_0000218,178.0
12282,50588,,,1,,N,,Blood,,Intermediate,"Concentration of compound in blood of dog 2, after administering intravenously",A,1,,9614,CHEMBL632042,,BAO_0000218,178.0
12283,50588,,,1,,N,,,,Intermediate,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,1,,9614,CHEMBL632043,,BAO_0000218,
12284,50588,,,1,,N,,,,Intermediate,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,1,,9614,CHEMBL632044,,BAO_0000218,
12285,50588,,,1,,N,,Liver,,Intermediate,"Concentration of compound in liver of dog 1, after administering intravenously",A,1,,9614,CHEMBL632045,,BAO_0000218,2107.0
12286,50588,,,1,,N,,Liver,,Intermediate,"Concentration of compound in liver of dog 2, after administering intravenously",A,1,,9614,CHEMBL632046,,BAO_0000218,2107.0
12287,50588,,,1,,N,,Lung,,Intermediate,"Concentration of compound in lung of dog 1, after administering intravenously",A,1,,9614,CHEMBL632047,,BAO_0000218,2048.0
12288,50588,,,1,,N,,Lung,,Intermediate,"Concentration of compound in lung of dog 2, after administering intravenously",A,1,,9614,CHEMBL632048,,BAO_0000218,2048.0
12289,50588,,,1,,N,,Muscle tissue,,Intermediate,"Concentration of compound in muscle of dog 1, after administering intravenously",A,1,,9614,CHEMBL632049,,BAO_0000218,2385.0
12290,50588,,,1,,N,,Muscle tissue,,Intermediate,"Concentration of compound in muscle of dog 2, after administering intravenously",A,1,,9614,CHEMBL876418,,BAO_0000218,2385.0
12291,50588,,,1,,N,,Spleen,,Intermediate,"Concentration of compound in spleen of dog 1,after administering intravenously",A,1,,9614,CHEMBL632050,,BAO_0000218,2106.0
12292,50588,,,1,,N,,Spleen,,Intermediate,"Concentration of compound in spleen of dog 2, after administering intravenously",A,1,,9614,CHEMBL632051,,BAO_0000218,2106.0
12293,22224,,,0,,U,,,,Autocuration,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,1,,10353,CHEMBL632052,,BAO_0000218,
12294,22224,,,0,,U,,,,Autocuration,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,1,,10353,CHEMBL632053,,BAO_0000218,
12295,22224,,,0,,U,,,,Autocuration,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,1,,10353,CHEMBL632054,,BAO_0000218,
12296,22224,,,0,,U,,,,Autocuration,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,1,,10353,CHEMBL632055,,BAO_0000218,
12297,22224,,,0,,U,,,,Autocuration,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,1,,10353,CHEMBL631181,,BAO_0000218,
12298,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,1,,9196,CHEMBL631182,,BAO_0000218,
12299,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,1,,9196,CHEMBL631183,,BAO_0000218,
12300,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL631184,,BAO_0000218,
12301,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL629774,,BAO_0000218,
12302,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL629775,,BAO_0000218,
12303,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL876549,,BAO_0000218,
12304,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL628172,,BAO_0000218,
12305,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL628173,,BAO_0000218,
12306,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,1,,9196,CHEMBL628174,,BAO_0000218,
12307,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,1,,9196,CHEMBL628175,,BAO_0000218,
12308,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL628176,,BAO_0000218,
12309,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL628177,,BAO_0000218,
12310,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL628178,,BAO_0000218,
12311,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL628179,,BAO_0000218,
12312,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,1,,9196,CHEMBL628180,,BAO_0000218,
12313,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,1,,9196,CHEMBL628181,,BAO_0000218,
12314,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL628182,,BAO_0000218,
12315,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL628183,,BAO_0000218,
12316,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,1,,9196,CHEMBL628184,,BAO_0000218,
12317,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL628185,,BAO_0000218,
12318,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL875617,,BAO_0000218,
12319,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,1,,9196,CHEMBL628186,,BAO_0000218,
12320,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL628187,,BAO_0000218,
12321,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL628188,,BAO_0000218,
12322,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL628189,,BAO_0000218,
12323,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,1,,9196,CHEMBL628190,,BAO_0000218,
12324,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL628191,,BAO_0000218,
12325,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,1,,9196,CHEMBL626513,,BAO_0000218,
12326,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,1,,8608,CHEMBL626514,,BAO_0000218,2046.0
12327,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,1,,8608,CHEMBL626515,,BAO_0000218,2046.0
12328,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,1,,8608,CHEMBL626516,,BAO_0000218,2046.0
12329,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,1,,8608,CHEMBL626517,,BAO_0000218,2046.0
12330,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,1,,8608,CHEMBL626518,,BAO_0000218,2046.0
12331,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,1,,8608,CHEMBL626519,,BAO_0000218,2046.0
12332,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,1,,8608,CHEMBL626520,,BAO_0000218,2046.0
12333,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,1,,8608,CHEMBL626521,,BAO_0000218,2046.0
12334,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,1,,8608,CHEMBL626522,,BAO_0000218,2046.0
12335,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,1,,8608,CHEMBL626523,,BAO_0000218,2046.0
12336,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,1,,8608,CHEMBL626524,,BAO_0000218,2046.0
12337,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,1,,8608,CHEMBL626688,,BAO_0000218,2046.0
12338,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,1,,8608,CHEMBL626689,,BAO_0000218,2046.0
12339,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,1,,8608,CHEMBL626690,,BAO_0000218,2046.0
12340,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,1,,8608,CHEMBL626691,,BAO_0000218,2046.0
12341,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,1,,8608,CHEMBL627319,,BAO_0000218,2046.0
12342,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,1,,8608,CHEMBL624052,,BAO_0000218,2046.0
12343,50597,,,1,,N,,Thyroid gland,,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,1,,8608,CHEMBL624053,,BAO_0000218,2046.0
12344,50597,,,1,,N,,,,Intermediate,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL624054,,BAO_0000218,
12345,50597,,,1,,N,,,,Intermediate,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL624055,,BAO_0000218,
12346,50597,,,1,,N,,,,Intermediate,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL624056,,BAO_0000218,
12347,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL624057,,BAO_0000218,995.0
12348,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622281,,BAO_0000218,995.0
12349,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622282,,BAO_0000218,995.0
12350,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622283,,BAO_0000218,995.0
12351,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622284,,BAO_0000218,995.0
12352,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622285,,BAO_0000218,995.0
12353,50597,,,1,,N,,Uterus,,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,1,,8085,CHEMBL622286,,BAO_0000218,995.0
12354,22224,,,0,,U,,,,Autocuration,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,1,,7657,CHEMBL622287,,BAO_0000100,
12355,50594,,,1,,N,,,,Intermediate,Partition coefficient (logD7.4),A,1,,8935,CHEMBL622288,,BAO_0000218,
12356,50594,,,1,,N,,,,Intermediate,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,1,,13792,CHEMBL622289,,BAO_0000218,
12357,50594,,,1,,N,,Brain,,Intermediate,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,1,,13792,CHEMBL622290,,BAO_0000218,955.0
12358,50594,,,1,,N,,,,Intermediate,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,1,,13792,CHEMBL622291,,BAO_0000218,
12359,50594,,,1,,N,,Brain,,Intermediate,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,1,,13792,CHEMBL622292,,BAO_0000218,955.0
12360,50594,,,1,,N,,,,Intermediate,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,1,,13792,CHEMBL622293,,BAO_0000218,
12361,50594,,,1,,N,,Brain,,Intermediate,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,1,,13792,CHEMBL622294,,BAO_0000218,955.0
12362,50594,,,1,,N,,,,Intermediate,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,1,,13792,CHEMBL622295,,BAO_0000218,
12363,50597,,,1,,N,,Brain,,Intermediate,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,1,,13792,CHEMBL622296,,BAO_0000218,955.0
12364,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,1,,14103,CHEMBL874409,,BAO_0000218,1969.0
12365,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,1,,14103,CHEMBL622297,,BAO_0000218,1969.0
12366,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,1,,14103,CHEMBL622298,,BAO_0000218,1969.0
12367,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,1,,14103,CHEMBL622299,,BAO_0000218,1969.0
12368,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,1,,14103,CHEMBL622300,,BAO_0000218,1969.0
12369,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,1,,14103,CHEMBL622301,,BAO_0000218,1969.0
12370,50597,,,1,,N,,Plasma,,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,1,,14103,CHEMBL622302,,BAO_0000218,1969.0
12371,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,1,,14103,CHEMBL622303,,BAO_0000218,1969.0
12372,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,1,,14103,CHEMBL622304,,BAO_0000218,1969.0
12373,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,1,,14103,CHEMBL622305,,BAO_0000218,1969.0
12374,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,1,,14103,CHEMBL622306,,BAO_0000218,1969.0
12375,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,1,,14103,CHEMBL626864,,BAO_0000218,1969.0
12376,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,1,,14103,CHEMBL626865,,BAO_0000218,1969.0
12377,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,1,,14103,CHEMBL626866,,BAO_0000218,1969.0
12378,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,1,,14103,CHEMBL626867,,BAO_0000218,1969.0
12379,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,1,,14103,CHEMBL626868,,BAO_0000218,1969.0
12380,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,1,,14103,CHEMBL626869,,BAO_0000218,1969.0
12381,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,1,,14103,CHEMBL626870,,BAO_0000218,1969.0
12382,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,1,,14103,CHEMBL626871,,BAO_0000218,1969.0
12383,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,1,,14103,CHEMBL626872,,BAO_0000218,1969.0
12384,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,1,,14103,CHEMBL632185,,BAO_0000218,1969.0
12385,50597,,,1,,N,,Plasma,,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,1,,14103,CHEMBL632186,,BAO_0000218,1969.0
12386,22224,,,0,,U,,,,Autocuration,Amount of acetic acid produced by the compound,A,1,,12904,CHEMBL629310,,BAO_0000019,
12387,22224,,,0,,U,,,,Autocuration,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,1,,12904,CHEMBL629311,,BAO_0000019,
12388,50597,,,1,,N,,,,Intermediate,Log of (Cbrain/Cblood) in rats,A,1,,9663,CHEMBL629312,,BAO_0000218,
12389,22224,,,0,,U,,,,Autocuration,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,1,,7652,CHEMBL629313,,BAO_0000221,
12390,22224,,,0,,U,,,,Autocuration,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629314,,BAO_0000221,
12391,22224,,,0,,U,,,,Autocuration,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,1,,7652,CHEMBL629315,,BAO_0000221,
12392,22224,,,0,,U,,,,Autocuration,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,1,,7652,CHEMBL629316,,BAO_0000219,
12393,22224,,,0,,U,,,,Autocuration,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629317,,BAO_0000221,
12394,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,1,,7652,CHEMBL629318,,BAO_0000019,
12395,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL877497,,BAO_0000019,
12396,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,1,,7652,CHEMBL629319,,BAO_0000019,
12397,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629320,,BAO_0000019,
12398,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629496,,BAO_0000019,
12399,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629497,,BAO_0000019,
12400,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,1,,7652,CHEMBL629498,,BAO_0000019,
12401,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629499,,BAO_0000019,
12402,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,1,,7652,CHEMBL629500,,BAO_0000019,
12403,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,1,,7652,CHEMBL629501,,BAO_0000019,
12404,22224,,,0,,U,,,,Autocuration,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,1,,7652,CHEMBL629502,,BAO_0000019,
12405,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,1,,8267,CHEMBL629503,,BAO_0000218,
12406,50588,,,1,,N,,,,Intermediate,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,1,,8267,CHEMBL629504,,BAO_0000218,
12407,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,1,,14479,CHEMBL629505,,BAO_0000019,
12408,22224,,,0,,U,,,,Autocuration,Compound was evaluated for total body clearance,A,1,,17515,CHEMBL629506,,BAO_0000019,
12409,22224,,,0,,U,,,,Autocuration,Compound was evaluated for volume of distribution at steady state,A,1,,17515,CHEMBL629507,,BAO_0000019,
12410,22224,,,0,,U,,,,Autocuration,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,1,,8142,CHEMBL877498,,BAO_0000019,
12411,22224,,,0,,U,,,,Autocuration,Percentage of the diamine which is monoprotonated at pH 7.4,A,1,,14849,CHEMBL629508,,BAO_0000019,
12412,22224,,,0,,U,,,,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,1,,7653,CHEMBL629509,,BAO_0000019,
12413,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL629510,,BAO_0000218,178.0
12414,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,1,,8631,CHEMBL629511,,BAO_0000218,178.0
12415,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL629512,,BAO_0000218,178.0
12416,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL629513,,BAO_0000218,178.0
12417,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,1,,8631,CHEMBL629514,,BAO_0000218,178.0
12418,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL628447,,BAO_0000218,178.0
12419,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,1,,8631,CHEMBL628448,,BAO_0000218,178.0
12420,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL628449,,BAO_0000218,178.0
12421,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL631119,,BAO_0000218,178.0
12422,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,1,,8631,CHEMBL631120,,BAO_0000218,178.0
12423,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL631121,,BAO_0000218,178.0
12424,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,1,,8631,CHEMBL874458,,BAO_0000218,178.0
12425,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL631122,,BAO_0000218,178.0
12426,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL631123,,BAO_0000218,178.0
12427,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL631124,,BAO_0000218,178.0
12428,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,1,,8631,CHEMBL631125,,BAO_0000218,178.0
12429,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL631290,,BAO_0000218,178.0
12430,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL631291,,BAO_0000218,178.0
12431,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL631292,,BAO_0000218,178.0
12432,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,1,,8631,CHEMBL631293,,BAO_0000218,178.0
12433,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,1,,8631,CHEMBL631294,,BAO_0000218,178.0
12434,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,1,,8631,CHEMBL631295,,BAO_0000218,178.0
12435,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,1,,8631,CHEMBL631296,,BAO_0000218,178.0
12436,50597,,,1,,N,,Blood,,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,1,,8631,CHEMBL631297,,BAO_0000218,178.0
12437,22224,,,0,,U,,,,Autocuration,Maximum biodistribution (Bmax) was determined.,A,1,,10263,CHEMBL631298,,BAO_0000218,
12438,50594,,,1,,N,,,,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,1,,12364,CHEMBL631299,,BAO_0000218,
12439,50594,,,1,,N,,,,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,1,,12364,CHEMBL631300,,BAO_0000218,
12440,50594,,,1,,N,,,,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,1,,12364,CHEMBL631301,,BAO_0000218,
12441,50594,,,1,,N,,,,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,1,,12364,CHEMBL630291,,BAO_0000218,
12442,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,1,,14793,CHEMBL630292,,BAO_0000218,
12443,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,1,,14793,CHEMBL630293,,BAO_0000218,
12444,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,1,,14793,CHEMBL630294,,BAO_0000218,
12445,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,1,,14793,CHEMBL630295,,BAO_0000218,
12446,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,1,,14793,CHEMBL630296,,BAO_0000218,
12447,22224,,,0,,U,,,,Autocuration,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,1,,14793,CHEMBL626782,,BAO_0000218,
12448,22224,,,0,,U,,,,Autocuration,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,1,,14793,CHEMBL626783,,BAO_0000218,
12449,22224,,,0,,U,,,,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,1,,14793,CHEMBL626784,,BAO_0000218,
12450,22224,,,0,,U,,,,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,1,,14793,CHEMBL626785,,BAO_0000218,
12451,22224,,,0,,U,,,,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,1,,14793,CHEMBL626786,,BAO_0000218,
12452,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL626787,,BAO_0000218,
12453,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,1,,9196,CHEMBL626788,,BAO_0000218,
12454,22224,,,0,,U,,,,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL625927,,BAO_0000218,
12455,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL625928,,BAO_0000218,178.0
12456,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL625929,,BAO_0000218,178.0
12457,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,1,,8374,CHEMBL625930,,BAO_0000218,178.0
12458,50597,,,1,,N,,Blood,,Intermediate,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,1,,8374,CHEMBL625931,,BAO_0000218,178.0
12459,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,1,,8374,CHEMBL627230,,BAO_0000218,178.0
12460,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627231,,BAO_0000218,178.0
12461,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL627232,,BAO_0000218,178.0
12462,50597,,,1,,N,,Blood,,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,1,,8374,CHEMBL627233,,BAO_0000218,178.0
12463,50597,,,1,,N,,Blood,,Intermediate,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL875470,,BAO_0000218,178.0
12464,50597,,,1,,N,,Blood,,Intermediate,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627234,,BAO_0000218,178.0
12465,50597,,,1,,N,,Blood,,Intermediate,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627235,,BAO_0000218,178.0
12466,50597,,,1,,N,,Blood,,Intermediate,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627236,,BAO_0000218,178.0
12467,50597,,,1,,N,,Blood,,Intermediate,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627237,,BAO_0000218,178.0
12468,50597,,,1,,N,,Blood,,Intermediate,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627238,,BAO_0000218,178.0
12469,50597,,,1,,N,,Blood,,Intermediate,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627239,,BAO_0000218,178.0
12470,50597,,,1,,N,,Blood,,Intermediate,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627240,,BAO_0000218,178.0
12471,50597,,,1,,N,,Blood,,Intermediate,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627241,,BAO_0000218,178.0
12472,50597,,,1,,N,,Blood,,Intermediate,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627242,,BAO_0000218,178.0
12473,50597,,,1,,N,,Blood,,Intermediate,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,1,,8374,CHEMBL627243,,BAO_0000218,178.0
12474,50597,,,1,,N,,Blood,,Intermediate,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL627244,,BAO_0000218,178.0
12475,50597,,,1,,N,,Blood,,Intermediate,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627245,,BAO_0000218,178.0
12476,50597,,,1,,N,,Blood,,Intermediate,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627246,,BAO_0000218,178.0
12477,50597,,,1,,N,,Blood,,Intermediate,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627247,,BAO_0000218,178.0
12478,50597,,,1,,N,,Blood,,Intermediate,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627248,,BAO_0000218,178.0
12479,50597,,,1,,N,,Blood,,Intermediate,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627249,,BAO_0000218,178.0
12480,50597,,,1,,N,,Blood,,Intermediate,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL625569,,BAO_0000218,178.0
12481,50597,,,1,,N,,Blood,,Intermediate,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL625570,,BAO_0000218,178.0
12482,50597,,,1,,N,,Blood,,Intermediate,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL625571,,BAO_0000218,178.0
12483,50597,,,1,,N,,Blood,,Intermediate,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL625572,,BAO_0000218,178.0
12484,50597,,,1,,N,,Blood,,Intermediate,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL625573,,BAO_0000218,178.0
12485,50597,,,1,,N,,Blood,,Intermediate,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,1,,8374,CHEMBL625574,,BAO_0000218,178.0
12486,50597,,,1,,N,,Blood,,Intermediate,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,1,,8374,CHEMBL626245,,BAO_0000218,178.0
12487,50597,,,1,,N,,Blood,,Intermediate,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL626246,,BAO_0000218,178.0
12488,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL626247,,BAO_0000218,
12489,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL626248,,BAO_0000218,
12490,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,1,,9196,CHEMBL626249,,BAO_0000218,
12491,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL626420,,BAO_0000218,
12492,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,1,,9196,CHEMBL626421,,BAO_0000218,
12493,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL626422,,BAO_0000218,
12494,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL626423,,BAO_0000218,
12495,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL626424,,BAO_0000218,
12496,50588,,,1,,N,,,,Intermediate,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,1,,12023,CHEMBL626425,,BAO_0000218,
12497,50597,,,1,,N,,,,Intermediate,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,1,,12023,CHEMBL875476,,BAO_0000218,
12498,100710,,,1,,N,,,,Intermediate,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,1,,12023,CHEMBL626426,,BAO_0000218,
12499,22224,,,0,,U,,,,Autocuration,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,1,,10580,CHEMBL626427,,BAO_0000100,
12500,22224,,,0,,U,,,,Autocuration,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,1,,10580,CHEMBL626428,,BAO_0000100,
12501,22224,,,0,,U,,,,Autocuration,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,1,,16032,CHEMBL626429,,BAO_0000019,
12502,22224,,,0,,U,,Urine,,Autocuration,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,1,,16032,CHEMBL625025,,BAO_0000019,1088.0
12503,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL625026,,BAO_0000218,178.0
12504,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL625027,,BAO_0000218,178.0
12505,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL874410,,BAO_0000218,178.0
12506,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL625028,,BAO_0000218,178.0
12507,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL625029,,BAO_0000218,178.0
12508,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL625030,,BAO_0000218,178.0
12509,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL625031,,BAO_0000218,178.0
12510,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL625032,,BAO_0000218,178.0
12511,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL625033,,BAO_0000218,178.0
12512,50597,,,1,,N,,Blood,,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL625034,,BAO_0000218,178.0
12513,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624872,,BAO_0000218,948.0
12514,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL624873,,BAO_0000218,948.0
12515,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624874,,BAO_0000218,948.0
12516,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL624875,,BAO_0000218,948.0
12517,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL624876,,BAO_0000218,948.0
12518,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624877,,BAO_0000218,948.0
12519,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624878,,BAO_0000218,948.0
12520,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624879,,BAO_0000218,948.0
12521,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624880,,BAO_0000218,948.0
12522,50597,,,1,,N,,Heart,,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,1,,8594,CHEMBL624881,,BAO_0000218,948.0
12523,50597,,,1,,N,,Heart,,Intermediate,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,1,,8594,CHEMBL624882,,BAO_0000218,948.0
12524,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624883,,BAO_0000218,2113.0
12525,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624884,,BAO_0000218,2113.0
12526,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624885,,BAO_0000218,2113.0
12527,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL624886,,BAO_0000218,2113.0
12528,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL624887,,BAO_0000218,2113.0
12529,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624888,,BAO_0000218,2113.0
12530,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624889,,BAO_0000218,2113.0
12531,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624890,,BAO_0000218,2113.0
12532,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL621964,,BAO_0000218,2113.0
12533,50597,,,1,,N,,Kidney,,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL621965,,BAO_0000218,2113.0
12534,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL621966,,BAO_0000218,2107.0
12535,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL621967,,BAO_0000218,2107.0
12536,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL622164,,BAO_0000218,2107.0
12537,22224,,,0,,U,,,,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,1,,7653,CHEMBL623097,,BAO_0000019,
12538,22224,,,0,,U,,,,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,1,,7653,CHEMBL623098,,BAO_0000019,
12539,22224,,,0,,U,,,,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,1,,7653,CHEMBL623099,,BAO_0000019,
12540,22224,,,0,,U,,,,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,1,,7653,CHEMBL623100,,BAO_0000019,
12541,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,1,,9104,CHEMBL628673,,BAO_0000218,
12542,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,1,,9104,CHEMBL628674,,BAO_0000218,
12543,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,1,,9104,CHEMBL628675,,BAO_0000218,
12544,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,1,,9104,CHEMBL627644,,BAO_0000218,
12545,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,1,,9104,CHEMBL627645,,BAO_0000218,
12546,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,1,,9104,CHEMBL627646,,BAO_0000218,
12547,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,1,,9104,CHEMBL627647,,BAO_0000218,
12548,50597,,,1,,N,,,,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,1,,9104,CHEMBL627648,,BAO_0000218,
12549,50597,,,1,,N,,,,Intermediate,Free level in rat plasma,A,1,,12902,CHEMBL627649,,BAO_0000218,
12550,22224,,,0,,U,,,,Autocuration,Level reaching in blood plasma of rat or human was determined,A,1,,6614,CHEMBL628313,,BAO_0000019,
12551,50597,,,1,,N,,,,Intermediate,Log (Cbrain/Cblood) in rats,A,1,,9663,CHEMBL628314,,BAO_0000218,
12552,22224,,,0,,U,,,,Autocuration,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,1,,17658,CHEMBL628315,,BAO_0000019,
12553,22224,,,0,,U,,,,Autocuration,Mean percentage of compound transport through membrane; expressed as membrane transport,A,1,,17658,CHEMBL628316,,BAO_0000019,
12554,22224,,,0,,U,,,,Autocuration,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,1,,14314,CHEMBL628317,,BAO_0000218,
12555,22224,,,0,,U,,,,Autocuration,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,1,,7385,CHEMBL628473,,BAO_0000019,
12556,22224,,,0,,U,,,,Autocuration,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,1,,7385,CHEMBL628474,,BAO_0000019,
12557,22224,,,0,,U,,,,Autocuration,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,1,,7385,CHEMBL628475,,BAO_0000019,
12558,22224,,,0,,U,,,,Autocuration,Net water uptake by a carrier mediated transport (%cm) mechanism,A,1,,1329,CHEMBL628476,,BAO_0000019,
12559,22224,,,0,,U,,,,Autocuration,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,1,,12187,CHEMBL628477,,BAO_0000218,
12560,50506,,,1,,N,,,,Intermediate,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,1,,12187,CHEMBL628478,,BAO_0000218,
12561,50506,,,1,,N,,,,Intermediate,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,1,,12187,CHEMBL628479,,BAO_0000218,
12562,22224,,,0,,U,,,,Autocuration,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,1,,12187,CHEMBL628480,,BAO_0000218,
12563,22224,,,0,,U,,,,Autocuration,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,1,,12187,CHEMBL628481,,BAO_0000218,
12564,50597,,,1,,N,,,,Intermediate,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,1,,12187,CHEMBL628482,,BAO_0000218,
12565,50597,,,1,,N,,,,Intermediate,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,1,,12187,CHEMBL628483,,BAO_0000218,
12566,50597,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,1,,9278,CHEMBL628484,,BAO_0000218,1969.0
12567,50597,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,1,,9278,CHEMBL628485,,BAO_0000218,1969.0
12568,100710,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,1,,9278,CHEMBL628486,,BAO_0000218,1969.0
12569,50587,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,1,,9278,CHEMBL628487,,BAO_0000218,1969.0
12570,50597,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,1,,9278,CHEMBL628488,,BAO_0000218,1969.0
12571,50597,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,1,,9278,CHEMBL628489,,BAO_0000218,1969.0
12572,50597,,,1,,N,,Plasma,,Intermediate,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,1,,9278,CHEMBL628490,,BAO_0000218,1969.0
12573,100710,,,1,,N,,,,Intermediate,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,1,,12186,CHEMBL628491,,BAO_0000218,
12574,100710,,,1,,N,,,,Intermediate,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,1,,12186,CHEMBL877507,,BAO_0000218,
12575,22224,,,0,,U,,,,Autocuration,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,1,,12186,CHEMBL628492,,BAO_0000218,
12576,22224,,,0,,U,,,,Autocuration,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,1,,12041,CHEMBL628493,,BAO_0000019,
12577,22224,,,0,,U,,,,Autocuration,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,1,,12041,CHEMBL628494,,BAO_0000019,
12578,22224,,,0,,U,,,,Autocuration,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,1,,12041,CHEMBL628495,,BAO_0000019,
12579,50587,,,1,,N,,,,Intermediate,Permeability in Caco-2 assay at 10E-6,A,1,,6737,CHEMBL628496,,BAO_0000218,
12580,22224,,,0,,U,,Brain,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,1,,13758,CHEMBL628497,,BAO_0000218,955.0
12581,22224,,,0,,U,,Brain,,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,1,,13758,CHEMBL628498,,BAO_0000218,955.0
12582,22224,,,0,,U,,,,Autocuration,Plasma protein binding was determined,A,1,,5676,CHEMBL628499,,BAO_0000019,
12583,22224,,,0,,U,,,,Autocuration,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,1,,14793,CHEMBL627656,,BAO_0000218,
12584,22224,,,0,,U,,,,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,1,,14793,CHEMBL627657,,BAO_0000218,
12585,22224,,,0,,U,,,,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,1,,14793,CHEMBL626808,,BAO_0000218,
12586,22224,,,0,,U,,,,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,1,,14793,CHEMBL626809,,BAO_0000218,
12587,22224,,,0,,U,,,,Autocuration,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,1,,14793,CHEMBL626810,,BAO_0000218,
12588,22224,,,0,,U,,,,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,1,,14793,CHEMBL626811,,BAO_0000218,
12589,22224,,,0,,U,,,,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,1,,14793,CHEMBL874465,,BAO_0000218,
12590,22224,,,0,,U,,,,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,1,,14793,CHEMBL626812,,BAO_0000218,
12591,22224,,,0,,U,,,,Autocuration,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,1,,14793,CHEMBL626813,,BAO_0000218,
12592,22224,,,0,,U,,,,Autocuration,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,1,,14793,CHEMBL626814,,BAO_0000218,
12593,22224,,,0,,U,,,,Autocuration,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,1,,14000,CHEMBL626815,,BAO_0000019,
12594,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,5948,CHEMBL628566,,BAO_0000019,
12595,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,1,,13824,CHEMBL628567,,BAO_0000100,
12596,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,10778,CHEMBL628568,,BAO_0000100,
12597,50588,,In vivo,1,,N,,,,Intermediate,C max in dog,A,1,,17237,CHEMBL628569,,BAO_0000218,
12598,50512,,In vivo,1,,N,,,,Intermediate,C max in guinea pig,A,1,,17237,CHEMBL628570,,BAO_0000218,
12599,22224,,In vivo,0,,U,,,,Autocuration,C max value was evaluated,A,1,,2809,CHEMBL628571,,BAO_0000218,
12600,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 0.1 mg//kg,A,1,,11954,CHEMBL628572,,BAO_0000218,
12601,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 0.3 mg/kg,A,1,,11954,CHEMBL628573,,BAO_0000218,
12602,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 1 mg/kg,A,1,,11954,CHEMBL628574,,BAO_0000218,
12603,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 10 mg/kg,A,1,,11954,CHEMBL628575,,BAO_0000218,
12604,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 23.4 mg/kg,A,1,,11954,CHEMBL628576,,BAO_0000218,
12605,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 3 mg/kg,A,1,,11954,CHEMBL628577,,BAO_0000218,
12606,22224,,In vivo,0,,U,,,,Autocuration,Cmax value after oral dose of 3.87 mg/kg,A,1,,11954,CHEMBL628578,,BAO_0000218,
12607,50588,,In vivo,1,,N,,,,Intermediate,Cmax value in female Beagle dogs,A,1,,12768,CHEMBL874466,,BAO_0000218,
12608,50597,,In vivo,1,,N,,,,Intermediate,Cmax value in male rats,A,1,,12768,CHEMBL628579,,BAO_0000218,
12609,50597,,In vivo,1,,N,,Plasma,,Intermediate,Cmax value in rat plasma when administered 20 mg/kg perorally,A,1,,12780,CHEMBL628580,,BAO_0000218,1969.0
12610,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,1,,15592,CHEMBL628581,,BAO_0000218,1969.0
12611,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,1,,15592,CHEMBL628582,,BAO_0000218,1969.0
12612,50588,,,1,,N,,,,Intermediate,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL628583,,BAO_0000218,
12613,22224,,,0,,U,,,,Autocuration,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL625782,,BAO_0000218,
12614,50592,,,1,,N,,,,Intermediate,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL625783,,BAO_0000218,
12615,50597,,,1,,N,,,,Intermediate,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL625784,,BAO_0000218,
12616,50797,,,1,,N,,Plasma,,Intermediate,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,1,,4236,CHEMBL625785,,BAO_0000218,1969.0
12617,50597,,,1,,N,,,,Intermediate,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,1,,15791,CHEMBL625786,,BAO_0000218,
12618,22224,,,0,,U,,,,Autocuration,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,1,,11149,CHEMBL874467,,BAO_0000019,
12619,50588,,,1,,N,,,,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,1,,15592,CHEMBL625787,,BAO_0000218,
12620,50677,,,1,,N,,,,Intermediate,cytotoxicity against HIV protease enzyme.,A,1,,15778,CHEMBL625964,,BAO_0000218,
12621,50594,,,1,,N,,,,Intermediate,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,1,,12745,CHEMBL625965,,BAO_0000218,
12622,50594,,,1,,N,,,,Intermediate,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,1,,12745,CHEMBL625966,,BAO_0000218,
12623,50588,,In vivo,1,,N,,Plasma,,Intermediate,The plasma clearance in dog.,A,1,,13941,CHEMBL625967,,BAO_0000218,1969.0
12624,50597,,In vivo,1,,N,,Plasma,,Intermediate,The plasma clearance in rat.,A,1,,13941,CHEMBL625968,,BAO_0000218,1969.0
12625,50597,,In vivo,1,,N,,Plasma,,Intermediate,Clearance from plasma in male Sprague-Dawley rats,A,1,,16449,CHEMBL625969,,BAO_0000218,1969.0
12626,100710,,In vivo,1,,N,,Plasma,,Intermediate,Clearance from plasma in male cynomolgus monkeys,A,1,,16449,CHEMBL625970,,BAO_0000218,1969.0
12627,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,1,,14224,CHEMBL625971,,BAO_0000218,1969.0
12628,50588,,In vivo,1,,N,,Plasma,,Intermediate,Clearance of compound in dog plasma,A,1,,14224,CHEMBL625972,,BAO_0000218,1969.0
12629,50587,,In vivo,1,,N,,Plasma,,Intermediate,Clearance of compound in human plasma,A,1,,14224,CHEMBL625973,,BAO_0000218,1969.0
12630,50588,,In vivo,1,,N,,,,Intermediate,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,1,,14317,CHEMBL625974,,BAO_0000218,
12631,50588,,In vivo,1,,N,,,,Intermediate,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,1,,14317,CHEMBL625975,,BAO_0000218,
12632,50588,,In vivo,1,,N,,Plasma,,Intermediate,"Clearance (10 mg/kg, intravenously) in dog plasma",A,1,,14224,CHEMBL625976,,BAO_0000218,1969.0
12633,50588,,In vivo,1,,N,,,,Intermediate,Clearance value in dog,A,1,,17237,CHEMBL625977,,BAO_0000218,
12634,50512,,In vivo,1,,N,,,,Intermediate,Clearance value in guinea pig,A,1,,17237,CHEMBL625978,,BAO_0000218,
12635,50597,,In vivo,1,,N,,,,Intermediate,Clearance values in rats after iv administration.,A,1,,14187,CHEMBL874468,,BAO_0000218,
12636,22224,,In vivo,0,,U,,Plasma,,Autocuration,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,1,,4806,CHEMBL625421,,BAO_0000218,1969.0
12637,50592,,In vivo,1,,N,,,,Intermediate,In vivo clearance (5 mg/kg) was determined in rabbits,A,1,,15025,CHEMBL625422,,BAO_0000218,
12638,50597,,In vivo,1,,N,,,,Intermediate,Plasma Clearance rate was determined for the compound in rats,A,1,,13197,CHEMBL625423,,BAO_0000218,
12639,22224,,In vivo,0,,U,,,,Autocuration,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,1,,13197,CHEMBL625424,,BAO_0000218,
12640,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance in rat,A,1,,13960,CHEMBL625425,,BAO_0000218,
12641,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance of the compound,A,1,,17820,CHEMBL625426,,BAO_0000218,
12642,50512,,In vivo,1,,N,,,,Intermediate,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,1,,14706,CHEMBL625427,,BAO_0000218,
12643,50512,,In vivo,1,,N,,,,Intermediate,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,1,,14706,CHEMBL625428,,BAO_0000218,
12644,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance was determined,A,1,,6504,CHEMBL625429,,BAO_0000218,
12645,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,1,,14925,CHEMBL625430,,BAO_0000218,
12646,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance rate was determined for the compound in rats,A,1,,13197,CHEMBL625431,,BAO_0000218,
12647,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance rate was determined for the compound in squirrel monkeys,A,1,,13197,CHEMBL627307,,BAO_0000218,
12648,22224,,In vivo,0,,U,,,,Autocuration,Slow clearance (CL) was determined,A,1,,3437,CHEMBL627308,,BAO_0000218,
12649,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL627309,,BAO_0000218,
12650,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,1,,9196,CHEMBL627310,,BAO_0000218,
12651,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,1,,9196,CHEMBL627311,,BAO_0000218,
12652,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL627312,,BAO_0000218,
12653,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,1,,9196,CHEMBL627313,,BAO_0000218,
12654,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL627314,,BAO_0000218,
12655,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL627315,,BAO_0000218,
12656,22224,,,0,,U,,,,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL627316,,BAO_0000218,
12657,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,1,,9196,CHEMBL627317,,BAO_0000218,
12658,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL627318,,BAO_0000218,
12659,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,1,,9196,CHEMBL627999,,BAO_0000218,
12660,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,1,,9196,CHEMBL628000,,BAO_0000218,
12661,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,1,,9196,CHEMBL628001,,BAO_0000218,
12662,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL628002,,BAO_0000218,
12663,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL625610,,BAO_0000218,
12664,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL625611,,BAO_0000218,
12665,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,1,,9196,CHEMBL625612,,BAO_0000218,
12666,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,1,,9196,CHEMBL625613,,BAO_0000218,
12667,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,1,,9196,CHEMBL875479,,BAO_0000218,
12668,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,1,,9196,CHEMBL625614,,BAO_0000218,
12669,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,1,,9196,CHEMBL625615,,BAO_0000218,
12670,22224,,,0,,U,,,,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,1,,9196,CHEMBL626302,,BAO_0000218,
12671,50597,,,1,,N,,Blood,,Intermediate,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL626303,,BAO_0000218,178.0
12672,50597,,,1,,N,,Blood,,Intermediate,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,1,,8374,CHEMBL627420,,BAO_0000218,178.0
12673,50597,,,1,,N,,,,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,1,,13477,CHEMBL627421,,BAO_0000218,
12674,50597,,,1,,N,,,,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,1,,13477,CHEMBL625695,,BAO_0000218,
12675,50597,,,1,,N,,,,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,1,,13477,CHEMBL625696,,BAO_0000218,
12676,50594,,,1,,N,,Brain,,Intermediate,Distribution of compound in mice brain was measured after 1 hr,A,1,,10009,CHEMBL875606,,BAO_0000218,955.0
12677,50594,,,1,,N,,Brain,,Intermediate,Distribution of compound in mice brain was measured after 24 hr r,A,1,,10009,CHEMBL625697,,BAO_0000218,955.0
12678,50594,,,1,,N,,Brain,,Intermediate,Distribution of compound in mice brain was measured after 2 hr,A,1,,10009,CHEMBL625698,,BAO_0000218,955.0
12679,50594,,,1,,N,,Brain,,Intermediate,Distribution of compound in mice brain was measured after 3 hr,A,1,,10009,CHEMBL625699,,BAO_0000218,955.0
12680,50594,,,1,,N,,Brain,,Intermediate,Distribution of compound in mice brain was measured after 6 hr,A,1,,10009,CHEMBL625700,,BAO_0000218,955.0
12681,50594,,,1,,N,,,,Intermediate,Distribution of compound in mice liver was measured after 1 hr,A,1,,10009,CHEMBL625701,,BAO_0000218,
12682,50594,,,1,,N,,,,Intermediate,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,1,,10009,CHEMBL625702,,BAO_0000218,
12683,50594,,,1,,N,,,,Intermediate,Distribution of compound in mice liver was measured after 2 hr,A,1,,10009,CHEMBL625703,,BAO_0000218,
12684,50594,,,1,,N,,,,Intermediate,Distribution of compound in mice liver was measured after 3 hr,A,1,,10009,CHEMBL625704,,BAO_0000218,
12685,50594,,,1,,N,,,,Intermediate,Distribution of compound in mice liver was measured after 6 hr,A,1,,10009,CHEMBL625705,,BAO_0000218,
12686,50588,,,1,,N,,Adrenal medulla,,Intermediate,Distribution in dog adrenal medulla 30 min after administration.,A,1,,8170,CHEMBL625706,,BAO_0000218,1236.0
12687,50588,,,1,,N,,Adrenal medulla,,Intermediate,Distribution in dog adrenal medulla 72 hours after administration.,A,1,,8170,CHEMBL625707,,BAO_0000218,1236.0
12688,50588,,,1,,N,,,,Intermediate,Distribution in female dog Ovary 24 hours after administration.,A,1,,8170,CHEMBL625708,,BAO_0000218,
12689,50588,,,1,,N,,,,Intermediate,Distribution in female dog Ovary 72 hours after administration.,A,1,,8170,CHEMBL625709,,BAO_0000218,
12690,50588,,,1,,N,,,,Intermediate,Distribution in female dog adipose 24 hours after administration.,A,1,,8170,CHEMBL624180,,BAO_0000218,
12691,50588,,,1,,N,,,,Intermediate,Distribution in female dog adipose 72 hours after administration.,A,1,,8170,CHEMBL624181,,BAO_0000218,
12692,50588,,,1,,N,,Adrenal cortex,,Intermediate,Distribution in female dog adrenal cortex 72 hours after administration.,A,1,,8170,CHEMBL624182,,BAO_0000218,1235.0
12693,50588,,,1,,N,,Adrenal cortex,,Intermediate,Distribution in female dog adrenal cortex 72 hours after administration.,A,1,,8170,CHEMBL624183,,BAO_0000218,1235.0
12694,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL624184,,BAO_0000218,2107.0
12695,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL877489,,BAO_0000218,2107.0
12696,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624185,,BAO_0000218,2107.0
12697,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624186,,BAO_0000218,2107.0
12698,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624187,,BAO_0000218,2107.0
12699,50597,,,1,,N,,Liver,,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624188,,BAO_0000218,2107.0
12700,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624189,,BAO_0000218,2048.0
12701,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624190,,BAO_0000218,2048.0
12702,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624191,,BAO_0000218,2048.0
12703,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624192,,BAO_0000218,2048.0
12704,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL624193,,BAO_0000218,2048.0
12705,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL624194,,BAO_0000218,2048.0
12706,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624891,,BAO_0000218,2048.0
12707,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL624892,,BAO_0000218,2048.0
12708,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL624893,,BAO_0000218,2048.0
12709,50597,,,1,,N,,Lung,,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627632,,BAO_0000218,2048.0
12710,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627633,,BAO_0000218,
12711,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627634,,BAO_0000218,
12712,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL627635,,BAO_0000218,
12713,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627636,,BAO_0000218,
12714,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL626816,,BAO_0000218,
12715,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL626817,,BAO_0000218,
12716,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL626818,,BAO_0000218,
12717,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626819,,BAO_0000218,
12718,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL626820,,BAO_0000218,
12719,50597,,,1,,N,,,,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626821,,BAO_0000218,
12720,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626822,,BAO_0000218,2046.0
12721,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626823,,BAO_0000218,2046.0
12722,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL626824,,BAO_0000218,2046.0
12723,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626825,,BAO_0000218,2046.0
12724,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,1,,8594,CHEMBL626826,,BAO_0000218,2046.0
12725,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,1,,8594,CHEMBL626827,,BAO_0000218,2046.0
12726,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL626828,,BAO_0000218,2046.0
12727,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626829,,BAO_0000218,2046.0
12728,50597,,,1,,N,,Thyroid gland,,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL626830,,BAO_0000218,2046.0
12729,50597,,,1,,N,,,,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL627150,,BAO_0000218,
12730,50597,,,1,,N,,,,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627151,,BAO_0000218,
12731,50597,,,1,,N,,,,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,1,,8594,CHEMBL627152,,BAO_0000218,
12732,50597,,,1,,N,,,,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,1,,8594,CHEMBL627153,,BAO_0000218,
12733,22224,,,0,,U,,,,Autocuration,Rate of acetate production by the compound was determined,A,1,,12904,CHEMBL627154,,BAO_0000019,
12734,22224,,,0,,U,,,,Autocuration,Rate of acetate production by the compound was determined; Not determined,A,1,,12904,CHEMBL627155,,BAO_0000019,
12735,22224,,,0,,U,,,,Autocuration,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,1,,3730,CHEMBL627156,,BAO_0000019,
12736,22224,,,0,,U,,,,Autocuration,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,1,,3627,CHEMBL627157,,BAO_0000019,
12737,50592,,,1,,N,,,,Intermediate,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,1,,13799,CHEMBL627158,,BAO_0000218,
12738,50592,,,1,,N,,Plasma,,Intermediate,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,1,,13799,CHEMBL627159,,BAO_0000218,1969.0
12739,50594,,,1,,N,,,,Intermediate,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,1,,13799,CHEMBL627160,,BAO_0000218,
12740,50597,,,1,,N,,,,Intermediate,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,1,,13799,CHEMBL628540,,BAO_0000218,
12741,50597,,,1,,N,,Plasma,,Intermediate,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,1,,13799,CHEMBL628541,,BAO_0000218,1969.0
12742,50597,,,1,,N,,Plasma,,Intermediate,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,1,,13799,CHEMBL628542,,BAO_0000218,1969.0
12743,22229,,,0,,U,,,,Autocuration,Solubility after at a pH 1.2,P,1,,6629,CHEMBL628543,,BAO_0000100,
12744,22229,,,0,,U,,,,Autocuration,Solubility after at pH 1.2,P,1,,6629,CHEMBL628544,,BAO_0000100,
12745,22229,,,0,,U,,,,Autocuration,Solubility after injection of water,P,1,,6629,CHEMBL628545,,BAO_0000100,
12746,22224,,,0,,U,,,,Autocuration,Statistical significance of IC 50 values; Expressed as R value,A,1,,14000,CHEMBL628546,,BAO_0000019,
12747,22224,,,0,,U,,,,Autocuration,Systemic availability with respect to methyldopa was determined,A,1,,8267,CHEMBL874455,,BAO_0000019,
12748,50597,,,1,,N,,,,Intermediate,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,1,,13799,CHEMBL628547,,BAO_0000218,
12749,50597,,,1,,N,,Plasma,,Intermediate,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,1,,13799,CHEMBL628548,,BAO_0000218,1969.0
12750,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL628549,,BAO_0000218,1988.0
12751,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL628550,,BAO_0000218,1988.0
12752,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,1,,7132,CHEMBL628551,,BAO_0000218,1988.0
12753,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,1,,7132,CHEMBL628552,,BAO_0000218,1088.0
12754,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,1,,7132,CHEMBL628553,,BAO_0000218,1088.0
12755,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,1,,7132,CHEMBL628554,,BAO_0000218,1088.0
12756,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,1,,7132,CHEMBL628555,,BAO_0000218,1088.0
12757,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,1,,7132,CHEMBL628556,,BAO_0000218,1088.0
12758,50592,,,1,,N,,Kidney,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL628557,,BAO_0000218,2113.0
12759,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL628558,,BAO_0000218,1988.0
12760,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,1,,7132,CHEMBL628559,,BAO_0000218,1988.0
12761,50592,,,1,,N,,Feces,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL628560,,BAO_0000218,1988.0
12762,50592,,,1,,N,,Urine,,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,1,,7132,CHEMBL874456,,BAO_0000218,1088.0
12763,50592,,,1,,N,,Feces,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,1,,7132,CHEMBL628561,,BAO_0000218,1988.0
12764,50592,,,1,,N,,Feces,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,1,,7132,CHEMBL628562,,BAO_0000218,1988.0
12765,50592,,,1,,N,,Urine,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,1,,7132,CHEMBL628563,,BAO_0000218,1088.0
12766,50592,,,1,,N,,Urine,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,1,,7132,CHEMBL628564,,BAO_0000218,1088.0
12767,50592,,,1,,N,,Urine,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,1,,7132,CHEMBL628565,,BAO_0000218,1088.0
12768,50592,,,1,,N,,Urine,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,1,,7132,CHEMBL631248,,BAO_0000218,1088.0
12769,50592,,,1,,N,,Urine,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,1,,7132,CHEMBL631249,,BAO_0000218,1088.0
12770,50592,,,1,,N,,Kidney,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL627214,,BAO_0000218,2113.0
12771,50592,,,1,,N,,Feces,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL874591,,BAO_0000218,1988.0
12772,50592,,,1,,N,,Feces,,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,1,,7132,CHEMBL627215,,BAO_0000218,1988.0
12773,50592,,,1,,N,,Feces,,Intermediate,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,1,,7132,CHEMBL625471,,BAO_0000218,1988.0
12774,50592,,,1,,N,,,,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,1,,7132,CHEMBL625472,,BAO_0000218,
12775,50592,,,1,,N,,,,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,1,,7132,CHEMBL625473,,BAO_0000218,
12776,50588,,In vivo,1,,N,,,,Intermediate,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,1,,13317,CHEMBL625474,,BAO_0000218,
12777,50588,,In vivo,1,,N,,,,Intermediate,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,1,,15341,CHEMBL625475,,BAO_0000218,
12778,50597,,In vivo,1,,N,,,,Intermediate,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,1,,15341,CHEMBL625476,,BAO_0000218,
12779,50597,,In vivo,1,,N,,,,Intermediate,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,1,,15341,CHEMBL625477,,BAO_0000218,
12780,50597,,In vivo,1,,N,,,,Intermediate,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,1,,15341,CHEMBL625478,,BAO_0000218,
12781,50597,,In vitro,1,,N,,esophageal tunica muscularis mucosae,,Intermediate,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,1,,12801,CHEMBL625479,,BAO_0000218,
12782,50597,,In vitro,1,,N,,esophageal tunica muscularis mucosae,,Intermediate,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,1,,12801,CHEMBL625480,,BAO_0000218,
12783,50597,,In vivo,1,,N,,Plasma,,Intermediate,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,1,,14856,CHEMBL625481,,BAO_0000218,1969.0
12784,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,1,,14062,CHEMBL625482,,BAO_0000218,
12785,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,1,,14062,CHEMBL625483,,BAO_0000218,
12786,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,1,,14062,CHEMBL625484,,BAO_0000218,
12787,50597,,In vivo,1,,N,,,,Intermediate,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,1,,14062,CHEMBL625485,,BAO_0000218,
12788,50588,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,1,,14346,CHEMBL625486,,BAO_0000218,1969.0
12789,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL625487,,BAO_0000218,1969.0
12790,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL625488,,BAO_0000218,1969.0
12791,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL625489,,BAO_0000218,1969.0
12792,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL625490,,BAO_0000218,1969.0
12793,50588,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,1,,14346,CHEMBL625491,,BAO_0000218,1969.0
12794,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,1,,14346,CHEMBL625492,,BAO_0000218,1969.0
12795,50587,,In vivo,1,,N,,Plasma,,Intermediate,plasma clearance in human,A,1,,15711,CHEMBL625493,,BAO_0000218,1969.0
12796,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,1,,14886,CHEMBL625494,,BAO_0000218,
12797,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,1,,14886,CHEMBL625495,,BAO_0000218,
12798,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,1,,14886,CHEMBL625496,,BAO_0000218,
12799,22229,,,0,,U,,,,Autocuration,1-Octanol/water partition coefficient measured at 7.4,P,1,,4115,CHEMBL625497,,BAO_0000100,
12800,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13733,CHEMBL625498,,BAO_0000100,
12801,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,12102,CHEMBL625499,,BAO_0000019,
12802,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12676,CHEMBL625500,,BAO_0000100,
12803,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13733,CHEMBL625501,,BAO_0000100,
12804,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13740,CHEMBL625502,,BAO_0000100,
12805,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,1,,12766,CHEMBL625503,,BAO_0000100,
12806,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,2764,CHEMBL625504,,BAO_0000100,
12807,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12355,CHEMBL625505,,BAO_0000100,
12808,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient of the compound,P,1,,11314,CHEMBL625506,,BAO_0000100,
12809,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,12706,CHEMBL625507,,BAO_0000019,
12810,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12645,CHEMBL625508,,BAO_0000100,
12811,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13668,CHEMBL625509,,BAO_0000100,
12812,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12819,CHEMBL625510,,BAO_0000100,
12813,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13668,CHEMBL883125,,BAO_0000100,
12814,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13017,CHEMBL625511,,BAO_0000100,
12815,22224,,,0,,U,,,,Autocuration,Partition coefficient of the compound,A,1,,2448,CHEMBL874650,,BAO_0000019,
12816,22224,,,0,,U,,,,Autocuration,Partition coefficient of the compound,A,1,,11526,CHEMBL625512,,BAO_0000019,
12817,22224,,,0,,U,,,,Autocuration,Partition coefficient of compound was determined,A,1,,12426,CHEMBL625513,,BAO_0000019,
12818,22224,,,0,,U,,,,Autocuration,Partition coefficient was determined,A,1,,2448,CHEMBL625514,,BAO_0000019,
12819,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12001,CHEMBL625515,,BAO_0000100,
12820,22229,,,0,,U,,,,Autocuration,partition coefficient of compound was determined,P,1,,12426,CHEMBL625516,,BAO_0000100,
12821,50588,,In vivo,1,,N,,,,Intermediate,The total body administered intravenously in dog,A,1,,13204,CHEMBL625517,,BAO_0000218,
12822,50597,,In vivo,1,,N,,,,Intermediate,The total body administered intravenously in rats,A,1,,13204,CHEMBL625518,,BAO_0000218,
12823,50594,,,1,,N,,,,Intermediate,Time taken for the administration to female NIH mice weighing 25-30 g.,A,1,,13889,CHEMBL625519,,BAO_0000218,
12824,22224,,,0,,U,,,,Autocuration,Time taken for the administration,A,1,,13889,CHEMBL625520,,BAO_0000019,
12825,50588,,In vivo,1,,N,,,,Intermediate,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL874651,,BAO_0000218,
12826,22224,,In vivo,0,,U,,,,Autocuration,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL625521,,BAO_0000218,
12827,50592,,In vivo,1,,N,,,,Intermediate,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL623171,,BAO_0000218,
12828,50597,,In vivo,1,,N,,,,Intermediate,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,1,,17025,CHEMBL623853,,BAO_0000218,
12829,22224,,,0,,U,,,,Autocuration,Plasma clearance for the compound was determined.,A,1,,15067,CHEMBL623854,,BAO_0000019,
12830,22224,,,0,,U,,,,Autocuration,CLog P value of the compound,P,1,,3091,CHEMBL874405,,BAO_0000100,
12831,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,15592,CHEMBL623855,,BAO_0000100,
12832,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14738,CHEMBL623856,,BAO_0000100,
12833,22224,,,0,,U,,,,Autocuration,ClogP value of the compound; nd ='no data',P,1,,14738,CHEMBL623857,,BAO_0000100,
12834,22224,,,0,,U,,,,Autocuration,ClogP value of the compound; nd ='not determined',P,1,,14738,CHEMBL623858,,BAO_0000100,
12835,22224,,,0,,U,,,,Autocuration,CLog P was determined,P,1,,6076,CHEMBL623859,,BAO_0000100,
12836,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,17840,CHEMBL839829,,BAO_0000100,
12837,22224,,,0,,U,,,,Autocuration,CLogP was calculated,A,1,,13589,CHEMBL623860,,BAO_0000019,
12838,22224,,,0,,U,,,,Autocuration,CLogP value was determined,A,1,,17655,CHEMBL623861,,BAO_0000019,
12839,22224,,,0,,U,,,,Autocuration,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,1,,5867,CHEMBL623862,,BAO_0000019,
12840,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,5867,CHEMBL874406,,BAO_0000100,
12841,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,10783,CHEMBL623863,,BAO_0000100,
12842,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14849,CHEMBL624021,,BAO_0000100,
12843,50588,,,1,,N,,Adrenal medulla,,Intermediate,Distribution in female dog adrenal medulla 24 hours after administration.,A,1,,8170,CHEMBL624022,,BAO_0000218,1236.0
12844,50588,,,1,,N,,Adrenal medulla,,Intermediate,Distribution in female dog adrenal medulla 72 hours after administration.,A,1,,8170,CHEMBL624023,,BAO_0000218,1236.0
12845,50588,,,1,,N,,,,Intermediate,Distribution in female dog bile 24 hours after administration.,A,1,,8170,CHEMBL624024,,BAO_0000218,
12846,50588,,,1,,N,,,,Intermediate,Distribution in female dog bile 72 hr after administration.,A,1,,8170,CHEMBL624025,,BAO_0000218,
12847,50588,,,1,,N,,,,Intermediate,Distribution in female dog blood 24 hours after administration.,A,1,,8170,CHEMBL624026,,BAO_0000218,
12848,50588,,,1,,N,,,,Intermediate,Distribution in female dog blood 72 hours after administration.,A,1,,8170,CHEMBL624027,,BAO_0000218,
12849,50588,,,1,,N,,,,Intermediate,Distribution in female dog heart 24 hours after administration.,A,1,,8170,CHEMBL624028,,BAO_0000218,
12850,50588,,,1,,N,,,,Intermediate,Distribution in female dog heart 72 hours after administration.,A,1,,8170,CHEMBL624029,,BAO_0000218,
12851,50588,,,1,,N,,,,Intermediate,Distribution in female dog kidney 24 hours after administration.,A,1,,8170,CHEMBL624030,,BAO_0000218,
12852,50588,,,1,,N,,,,Intermediate,Distribution in female dog kidney 72 hours after administration.,A,1,,8170,CHEMBL624031,,BAO_0000218,
12853,50588,,,1,,N,,Intestine,,Intermediate,Distribution in female dog large intestine 24 hours after administration.,A,1,,8170,CHEMBL624032,,BAO_0000218,160.0
12854,50588,,,1,,N,,Intestine,,Intermediate,Distribution in female dog large intestine 72 hours after administration.,A,1,,8170,CHEMBL874407,,BAO_0000218,160.0
12855,50588,,,1,,N,,,,Intermediate,Distribution in female dog liver 24 hours after administration.,A,1,,8170,CHEMBL624033,,BAO_0000218,
12856,50588,,,1,,N,,,,Intermediate,Distribution in female dog liver 72 hours after administration.,A,1,,8170,CHEMBL624034,,BAO_0000218,
12857,50588,,,1,,N,,,,Intermediate,Distribution in female dog lung 24 hours after administration.,A,1,,8170,CHEMBL624035,,BAO_0000218,
12858,50588,,,1,,N,,,,Intermediate,Distribution in female dog lung 72 hours after administration.,A,1,,8170,CHEMBL624036,,BAO_0000218,
12859,50588,,,1,,N,,Muscle tissue,,Intermediate,Distribution in female dog muscle 24 hours after administration.,A,1,,8170,CHEMBL624037,,BAO_0000218,2385.0
12860,50588,,,1,,N,,Muscle tissue,,Intermediate,Distribution in female dog muscle 72 hours after administration.,A,1,,8170,CHEMBL624038,,BAO_0000218,2385.0
12861,50588,,,1,,N,,,,Intermediate,Distribution in female dog pancreas 24 hours after administration.,A,1,,8170,CHEMBL624039,,BAO_0000218,
12862,50588,,,1,,N,,,,Intermediate,Distribution in female dog pancreas 72 hours after administration.,A,1,,8170,CHEMBL624040,,BAO_0000218,
12863,50588,,,1,,N,,Intestine,,Intermediate,Distribution in female dog small intestine 24 hours after administration.,A,1,,8170,CHEMBL624041,,BAO_0000218,160.0
12864,50588,,,1,,N,,Intestine,,Intermediate,Distribution in female dog small intestine 72 hours after administration.,A,1,,8170,CHEMBL624042,,BAO_0000218,160.0
12865,50588,,,1,,N,,Spleen,,Intermediate,Distribution in female dog spleen 24 hours after administration.,A,1,,8170,CHEMBL624043,,BAO_0000218,2106.0
12866,50588,,,1,,N,,Spleen,,Intermediate,Distribution in female dog spleen 72 hours after administration.,A,1,,8170,CHEMBL624044,,BAO_0000218,2106.0
12867,50588,,,1,,N,,Stomach,,Intermediate,Distribution in female dog stomach 24 hours after administration.,A,1,,8170,CHEMBL624045,,BAO_0000218,945.0
12868,50588,,,1,,N,,Stomach,,Intermediate,Distribution in female dog stomach 72 hours after administration.,A,1,,8170,CHEMBL624046,,BAO_0000218,945.0
12869,50588,,,1,,N,,Thyroid gland,,Intermediate,Distribution in female dog thyroid 24 hours after administration.,A,1,,8170,CHEMBL624047,,BAO_0000218,2046.0
12870,50588,,,1,,N,,Thyroid gland,,Intermediate,Distribution in female dog thyroid 72 hours after administration.,A,1,,8170,CHEMBL624048,,BAO_0000218,2046.0
12871,50588,,,1,,N,,Urine,,Intermediate,Distribution in female dog urine 24 hours after administration.,A,1,,8170,CHEMBL874408,,BAO_0000218,1088.0
12872,50588,,,1,,N,,Urine,,Intermediate,Distribution in female dog urine 72 hr after administration.,A,1,,8170,CHEMBL624049,,BAO_0000218,1088.0
12873,22224,,,0,,U,,Plasma,,Autocuration,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,1,,14283,CHEMBL624050,,BAO_0000218,1969.0
12874,22224,,,0,,U,,,,Autocuration,Plasma concentration at 7 hr after intravenous dosing,A,1,,5623,CHEMBL624051,,BAO_0000019,
12875,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,1,,13477,CHEMBL623278,,BAO_0000218,
12876,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,1,,13477,CHEMBL623279,,BAO_0000218,
12877,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,1,,13477,CHEMBL623280,,BAO_0000218,
12878,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,1,,13477,CHEMBL623963,,BAO_0000218,
12879,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,1,,13477,CHEMBL623964,,BAO_0000218,
12880,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,1,,13477,CHEMBL623965,,BAO_0000218,
12881,50597,,,1,,N,,,,Intermediate,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,1,,13477,CHEMBL623966,,BAO_0000218,
12882,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,1,,13477,CHEMBL874415,,BAO_0000218,
12883,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,1,,13477,CHEMBL623967,,BAO_0000218,
12884,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,1,,13477,CHEMBL623968,,BAO_0000218,
12885,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,1,,13477,CHEMBL623969,,BAO_0000218,
12886,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,1,,13477,CHEMBL628409,,BAO_0000218,
12887,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,1,,13477,CHEMBL628410,,BAO_0000218,
12888,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,1,,13477,CHEMBL628411,,BAO_0000218,
12889,50597,,,1,,N,,,,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,1,,13477,CHEMBL628412,,BAO_0000218,
12890,22224,,,0,,U,,,,Autocuration,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,1,,12553,CHEMBL628413,,BAO_0000019,
12891,22224,,,0,,U,,Plasma,,Autocuration,The concentration in plasmat; Not determined,A,1,,14548,CHEMBL628414,,BAO_0000019,1969.0
12892,50597,,,1,,N,,,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in blood,A,1,,14393,CHEMBL628415,,BAO_0000218,
12893,50597,,,1,,N,,,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,1,,14393,CHEMBL628416,,BAO_0000218,
12894,50597,,,1,,N,,,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in heart,A,1,,14393,CHEMBL628417,,BAO_0000218,
12895,50597,,,1,,N,,Liver,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in liver,A,1,,14393,CHEMBL874908,,BAO_0000218,2107.0
12896,50597,,,1,,N,,,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,1,,14393,CHEMBL628418,,BAO_0000218,
12897,50597,,,1,,N,,Muscle tissue,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,1,,14393,CHEMBL628419,,BAO_0000218,2385.0
12898,50597,,,1,,N,,,,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,1,,14393,CHEMBL628420,,BAO_0000218,
12899,22224,,,0,,U,,,,Autocuration,Water solubility at 37 degree C.,A,1,,1629,CHEMBL628421,,BAO_0000019,
12900,22229,,,0,,U,,,,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,1,,8194,CHEMBL626726,,BAO_0000100,
12901,22229,,,0,,U,,,,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,1,,8194,CHEMBL626727,,BAO_0000100,
12902,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626728,,BAO_0000218,178.0
12903,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626729,,BAO_0000218,178.0
12904,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626730,,BAO_0000218,178.0
12905,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626731,,BAO_0000218,178.0
12906,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626732,,BAO_0000218,178.0
12907,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626733,,BAO_0000218,948.0
12908,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626734,,BAO_0000218,948.0
12909,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626735,,BAO_0000218,948.0
12910,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL874909,,BAO_0000218,948.0
12911,50597,,,1,,N,,Heart,,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626736,,BAO_0000218,948.0
12912,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL626737,,BAO_0000218,2113.0
12913,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630999,,BAO_0000218,2113.0
12914,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631000,,BAO_0000218,2113.0
12915,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631001,,BAO_0000218,2113.0
12916,50597,,,1,,N,,Kidney,,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631002,,BAO_0000218,2113.0
12917,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631003,,BAO_0000218,2107.0
12918,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631004,,BAO_0000218,2107.0
12919,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631005,,BAO_0000218,2107.0
12920,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631006,,BAO_0000218,2107.0
12921,50597,,,1,,N,,Liver,,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631007,,BAO_0000218,2107.0
12922,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631008,,BAO_0000218,2048.0
12923,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631009,,BAO_0000218,2048.0
12924,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631010,,BAO_0000218,2048.0
12925,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631011,,BAO_0000218,2048.0
12926,50597,,,1,,N,,Lung,,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL631012,,BAO_0000218,2048.0
12927,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630271,,BAO_0000218,2046.0
12928,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630272,,BAO_0000218,2046.0
12929,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630273,,BAO_0000218,2046.0
12930,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630274,,BAO_0000218,2046.0
12931,50597,,,1,,N,,Thyroid gland,,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630275,,BAO_0000218,2046.0
12932,50597,,,1,,N,,,,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL875782,,BAO_0000218,
12933,50597,,,1,,N,,,,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630276,,BAO_0000218,
12934,50597,,,1,,N,,,,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630277,,BAO_0000218,
12935,50597,,,1,,N,,,,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630278,,BAO_0000218,
12936,50597,,,1,,N,,,,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,1,,8594,CHEMBL630279,,BAO_0000218,
12937,22224,,,0,,U,,,,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,1,,8151,CHEMBL630280,,BAO_0000019,
12938,22224,,,0,,U,,,,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,1,,8151,CHEMBL630281,,BAO_0000019,
12939,50592,,,1,,N,,,,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,1,,7132,CHEMBL630282,,BAO_0000218,
12940,50592,,,1,,N,,,,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,1,,7132,CHEMBL630283,,BAO_0000218,
12941,22224,,,0,,U,,,,Autocuration,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,1,,5797,CHEMBL630284,,BAO_0000019,
12942,22224,,,0,,U,,,,Autocuration,Alkylating activity was determined,A,1,,7849,CHEMBL630285,,BAO_0000019,
12943,22224,,,0,,U,Microsomes,,,Autocuration,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,1,,14220,CHEMBL630286,,BAO_0000251,
12944,50592,,,1,,N,,,,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,1,,8650,CHEMBL630069,,BAO_0000218,
12945,50592,,,1,,N,,,,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,1,,8650,CHEMBL630070,,BAO_0000218,
12946,50592,,,1,,N,,,,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,1,,8650,CHEMBL630071,,BAO_0000218,
12947,50592,,,1,,N,,,,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,1,,8650,CHEMBL630072,,BAO_0000218,
12948,50592,,,1,,N,,,,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,1,,8650,CHEMBL875110,,BAO_0000218,
12949,50597,,,1,,N,,,,Intermediate,Compound was tested for antidiuretic activity in rats,A,1,,7116,CHEMBL630073,,BAO_0000218,
12950,22224,,,0,,U,,,,Autocuration,Compound was tested for inactivation kinetic values,A,1,,14131,CHEMBL630074,,BAO_0000019,
12951,22224,,In vivo,0,,U,,,,Autocuration,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,1,,7415,CHEMBL630075,,BAO_0000218,
12952,22224,,,0,,U,,,,Autocuration,Dissociation rate calculated from the first-order equation using the t1/2 value,A,1,,13178,CHEMBL630076,,BAO_0000019,
12953,22229,,,0,,U,,,,Autocuration,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,1,,8815,CHEMBL630077,,BAO_0000100,
12954,22229,,,0,,U,,,,Autocuration,Aqueous solubility was measured,P,1,,1450,CHEMBL630078,,BAO_0000100,
12955,22229,,,0,,U,,,,Autocuration,Aqueous solubility was measured at a pH 4,P,1,,1450,CHEMBL630079,,BAO_0000100,
12956,22229,,,0,,U,,,,Autocuration,Aqueous solubility (pH 7),P,1,,1450,CHEMBL630080,,BAO_0000100,
12957,22229,,,0,,U,,,,Autocuration,Aqueous solubility was measured at a pH 9,P,1,,1450,CHEMBL630081,,BAO_0000100,
12958,22224,,,0,,U,,,,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,1,,12711,CHEMBL630082,,BAO_0000019,
12959,22224,,,0,,U,,,,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,1,,12711,CHEMBL630083,,BAO_0000019,
12960,22224,,,0,,U,,,,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,1,,12711,CHEMBL630084,,BAO_0000019,
12961,22229,,,0,,U,,,,Autocuration,Aqueous solubility of the compound,P,1,,15032,CHEMBL629198,,BAO_0000100,
12962,22229,,,0,,U,,,,Autocuration,Aqueous solubility at 37 degree Celsius at pH 7.38,P,1,,9964,CHEMBL629199,,BAO_0000100,
12963,22229,,,0,,U,,,,Autocuration,Aqueous solubility in pH 7.4 phosphate buffer,P,1,,14962,CHEMBL629200,,BAO_0000100,
12964,50588,,,1,,N,,,,Intermediate,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,1,,12487,CHEMBL629201,,BAO_0000218,
12965,50588,,,1,,N,,,,Intermediate,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,1,,12487,CHEMBL629202,,BAO_0000218,
12966,50587,,,1,,N,,,,Intermediate,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL875111,,BAO_0000218,
12967,50587,,,1,,N,,,,Intermediate,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL629203,,BAO_0000218,
12968,50587,,,1,,N,,,,Intermediate,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL629204,,BAO_0000218,
12969,50587,,,1,,N,,,,Intermediate,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL629205,,BAO_0000218,
12970,50587,,,1,,N,,,,Intermediate,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL629206,,BAO_0000218,
12971,22224,,,0,,U,,,,Autocuration,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,1,,10026,CHEMBL631185,,BAO_0000019,
12972,50597,,,1,,N,,,,Intermediate,Compound was evaluated for the average bile flow rat in rats,A,1,,7415,CHEMBL631186,,BAO_0000218,
12973,50592,,,1,,N,,,,Intermediate,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,1,,17025,CHEMBL631187,,BAO_0000218,
12974,50592,,,1,,N,,,,Intermediate,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,1,,17025,CHEMBL631188,,BAO_0000218,
12975,22224,,,0,,U,,,,Autocuration,Average half life period was determined,A,1,,10184,CHEMBL876419,,BAO_0000019,
12976,22224,,,0,,U,,,,Autocuration,Average half life period was determined,A,1,,10184,CHEMBL631189,,BAO_0000019,
12977,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,1,,8613,CHEMBL631190,,BAO_0000218,
12978,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,1,,8613,CHEMBL631191,,BAO_0000218,
12979,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,1,,8613,CHEMBL631192,,BAO_0000218,
12980,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,1,,8613,CHEMBL632400,,BAO_0000218,
12981,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,1,,8613,CHEMBL630564,,BAO_0000218,
12982,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,1,,8613,CHEMBL630565,,BAO_0000218,
12983,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,1,,8613,CHEMBL630566,,BAO_0000218,
12984,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,1,,8613,CHEMBL631229,,BAO_0000218,
12985,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,1,,8613,CHEMBL631230,,BAO_0000218,
12986,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6030,CHEMBL876428,,BAO_0000100,
12987,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6147,CHEMBL631231,,BAO_0000100,
12988,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (MacLogP),P,1,,14556,CHEMBL631232,,BAO_0000100,
12989,22224,,,0,,U,,,,Autocuration,Hydrophilicity was determined,A,1,,768,CHEMBL631233,,BAO_0000019,
12990,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14452,CHEMBL631234,,BAO_0000100,
12991,22224,,,0,,U,,,,Autocuration,Increased absorption was determined,A,1,,5237,CHEMBL883126,,BAO_0000019,
12992,22224,,,0,,U,,,,Autocuration,Lipophilicity value was evaluated,P,1,,14378,CHEMBL631235,,BAO_0000100,
12993,22224,,,0,,U,,,,Autocuration,Log P value of the compound.,P,1,,14418,CHEMBL631236,,BAO_0000100,
12994,22224,,,0,,U,,,,Autocuration,Partition coefficient of compound was determined,A,1,,5249,CHEMBL631237,,BAO_0000019,
12995,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14621,CHEMBL631238,,BAO_0000100,
12996,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12542,CHEMBL876429,,BAO_0000100,
12997,22224,,,0,,U,,,,Autocuration,Partition coefficient was measured by medchem software; Not calculated,A,1,,12542,CHEMBL631414,,BAO_0000019,
12998,22224,,,0,,U,,,,Autocuration,Partition coefficient was measured by octanol-water using standard shake-flask method,P,1,,12542,CHEMBL631415,,BAO_0000100,
12999,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,15462,CHEMBL631416,,BAO_0000100,
13000,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,14884,CHEMBL631417,,BAO_0000019,
13001,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,16526,CHEMBL631418,,BAO_0000100,
13002,22229,,,0,,U,,,,Autocuration,The Octanol/Water partition coefficient CLogP,P,1,,13693,CHEMBL631419,,BAO_0000100,
13003,22224,,,0,,U,,,,Autocuration,The pharmacokinetic parameter C Log p was reported,A,1,,13693,CHEMBL631420,,BAO_0000019,
13004,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13779,CHEMBL631421,,BAO_0000100,
13005,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14772,CHEMBL631422,,BAO_0000100,
13006,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,14393,CHEMBL631423,,BAO_0000100,
13007,50597,,In vivo,1,,N,,Plasma,,Intermediate,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,1,,14793,CHEMBL876430,,BAO_0000218,1969.0
13008,50597,,In vivo,1,,N,,Plasma,,Intermediate,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,1,,14793,CHEMBL631424,,BAO_0000218,1969.0
13009,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was administered intravenously in dog to evaluate plasma clearance values,A,1,,13744,CHEMBL631425,,BAO_0000218,1969.0
13010,22224,,In vivo,0,,U,,Plasma,,Autocuration,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,1,,13744,CHEMBL631426,,BAO_0000218,1969.0
13011,50594,,In vivo,1,,N,,Plasma,,Intermediate,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,1,,13744,CHEMBL631427,,BAO_0000218,1969.0
13012,50588,,In vivo,1,,N,,Plasma,,Intermediate,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,1,,13207,CHEMBL631428,,BAO_0000218,1969.0
13013,50797,,In vitro,1,,N,Microsomes,Liver,,Intermediate,Intrinsic clearance in Rhesus liver microsome,A,1,,5669,CHEMBL631429,,BAO_0000218,2107.0
13014,50588,,In vitro,1,,N,Microsomes,Liver,,Intermediate,Intrinsic clearance in dog liver microsome,A,1,,5669,CHEMBL631430,,BAO_0000218,2107.0
13015,50597,,In vitro,1,,N,Microsomes,Liver,,Intermediate,Intrinsic clearance in rat liver microsome,A,1,,5669,CHEMBL631431,,BAO_0000218,2107.0
13016,50797,,In vivo,1,,N,,Plasma,,Intermediate,Low plasma clearance was calculated in rhesus monkey,A,1,,4853,CHEMBL631432,,BAO_0000218,1969.0
13017,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,1,,16452,CHEMBL631433,,BAO_0000218,
13018,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after intravenous dose of 0.3 mg/kg,A,1,,11954,CHEMBL631434,,BAO_0000218,
13019,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after intravenous dose of 1 mg/kg,A,1,,11954,CHEMBL631435,,BAO_0000218,
13020,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after intravenous dose of 3 mg/kg,A,1,,11954,CHEMBL631436,,BAO_0000218,
13021,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance after intravenous dose of 3.87 mg/kg,A,1,,11954,CHEMBL631437,,BAO_0000218,
13022,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 10 mpk in Rat,A,1,,5669,CHEMBL631438,,BAO_0000218,
13023,50797,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,1,,5669,CHEMBL876431,,BAO_0000218,
13024,50588,,In vivo,1,,N,,,,Intermediate,Plasma clearance after peroral administration at 10 mpk in dog,A,1,,5669,CHEMBL631439,,BAO_0000218,
13025,50597,,In vivo,1,,N,,,,Intermediate,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,1,,13662,CHEMBL631440,,BAO_0000218,
13026,22224,,,0,,U,,,,Autocuration,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,1,,8272,CHEMBL631441,,BAO_0000019,
13027,22224,,,0,,U,,,,Autocuration,Critical Micellar concentration was determined,A,1,,13410,CHEMBL631442,,BAO_0000019,
13028,22224,,,0,,U,,,,Autocuration,Critical Micellar concentration of the compound. was determined,A,1,,13410,CHEMBL626525,,BAO_0000019,
13029,22224,,,0,,U,,,,Autocuration,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,1,,12628,CHEMBL627168,,BAO_0000019,
13030,22224,,,0,,U,,,,Autocuration,Critical micellar concentration was measured in water by the dye solubilization method,A,1,,9675,CHEMBL875618,,BAO_0000019,
13031,22224,,,0,,U,,,,Autocuration,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,1,,12628,CHEMBL626612,,BAO_0000019,
13032,22224,,,0,,U,,,,Autocuration,CMR value (relative to BAY K 8644),A,1,,12766,CHEMBL626613,,BAO_0000019,
13033,22224,,,0,,U,,,,Autocuration,Carbamoylating activity was determined,A,1,,7849,CHEMBL626614,,BAO_0000019,
13034,22224,,,0,,U,,,,Autocuration,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,1,,12187,CHEMBL626615,,BAO_0000218,
13035,22224,,,0,,U,,,,Autocuration,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,1,,2040,CHEMBL626616,,BAO_0000019,
13036,22224,,,0,,U,,,,Autocuration,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,1,,2040,CHEMBL626617,,BAO_0000019,
13037,50588,,In vivo,1,,N,,Plasma,,Intermediate,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,1,,14180,CHEMBL626618,,BAO_0000218,1969.0
13038,50597,,In vivo,1,,N,,Plasma,,Intermediate,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,1,,14180,CHEMBL626619,,BAO_0000218,1969.0
13039,50588,,In vivo,1,,N,,,,Intermediate,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,1,,14474,CHEMBL626620,,BAO_0000218,
13040,50597,,In vivo,1,,N,,,,Intermediate,"Clearance rate at 5.5 mg/kg, iv, in rat",A,1,,14474,CHEMBL626621,,BAO_0000218,
13041,100710,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,1,,14548,CHEMBL626622,,BAO_0000218,
13042,100710,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,1,,14548,CHEMBL626623,,BAO_0000218,
13043,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,1,,14548,CHEMBL626624,,BAO_0000218,
13044,50597,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,1,,14548,CHEMBL626625,,BAO_0000218,
13045,50597,,Ex vivo,1,,N,,Liver,,Intermediate,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,1,,6125,CHEMBL626626,,BAO_0000218,2107.0
13046,22224,,In vivo,0,,U,,,,Autocuration,Tested for the total clearance of the compound,A,1,,6874,CHEMBL626627,,BAO_0000218,
13047,50588,,In vivo,1,,N,,,,Intermediate,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,1,,15343,CHEMBL626628,,BAO_0000218,
13048,22224,,In vivo,0,,U,,,,Autocuration,Total body clearance was determined,A,1,,6236,CHEMBL626629,,BAO_0000218,
13049,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,1,,11510,CHEMBL626630,,BAO_0000218,
13050,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,1,,11510,CHEMBL626631,,BAO_0000218,
13051,22229,,,0,,U,,,,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,1,,8194,CHEMBL626632,,BAO_0000100,
13052,22229,,,0,,U,,,,Autocuration,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,1,,8194,CHEMBL626633,,BAO_0000100,
13053,22229,,,0,,U,,,,Autocuration,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,1,,8194,CHEMBL626634,,BAO_0000100,
13054,22229,,,0,,U,,,,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,1,,8194,CHEMBL626635,,BAO_0000100,
13055,22229,,,0,,U,,,,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,1,,8194,CHEMBL626636,,BAO_0000100,
13056,22229,,,0,,U,,,,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,1,,8194,CHEMBL626637,,BAO_0000100,
13057,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,1,,13273,CHEMBL626638,,BAO_0000218,
13058,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,1,,13273,CHEMBL626639,,BAO_0000218,
13059,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,1,,13273,CHEMBL626640,,BAO_0000218,
13060,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,1,,13273,CHEMBL626641,,BAO_0000218,
13061,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,1,,13273,CHEMBL627272,,BAO_0000218,
13062,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,1,,13273,CHEMBL627273,,BAO_0000218,
13063,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,1,,13273,CHEMBL627441,,BAO_0000218,
13064,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,1,,13273,CHEMBL628355,,BAO_0000218,
13065,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,1,,13273,CHEMBL628356,,BAO_0000218,
13066,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,1,,13273,CHEMBL628357,,BAO_0000218,
13067,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,1,,13273,CHEMBL628358,,BAO_0000218,
13068,50339,,,1,,N,,,,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,1,,13273,CHEMBL622307,,BAO_0000218,
13069,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,1,,13118,CHEMBL622527,,BAO_0000019,
13070,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,1,,13118,CHEMBL622528,,BAO_0000019,
13071,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,1,,13118,CHEMBL622529,,BAO_0000019,
13072,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,1,,13118,CHEMBL622992,,BAO_0000019,
13073,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,1,,13118,CHEMBL622993,,BAO_0000019,
13074,22224,,,0,,U,,,,Autocuration,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,1,,13118,CHEMBL622994,,BAO_0000019,
13075,50597,,,1,,N,,,,Intermediate,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,1,,10633,CHEMBL622995,,BAO_0000218,
13076,50597,,,1,,N,,,,Intermediate,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,1,,10633,CHEMBL622996,,BAO_0000218,
13077,50597,,,1,,N,,,,Intermediate,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,1,,10633,CHEMBL622997,,BAO_0000218,
13078,50597,,,1,,N,,,,Intermediate,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,1,,10633,CHEMBL622998,,BAO_0000218,
13079,22224,,,0,,U,,,,Autocuration,Cp max following ip administration at 1 mg/kg,A,1,,5767,CHEMBL622999,,BAO_0000218,
13080,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma was reported at 0.5 hour,A,1,,3302,CHEMBL623000,,BAO_0000218,1969.0
13081,22224,,In vivo,0,,U,,Plasma,,Autocuration,Maximum concentration in plasma was reported at 2 hour,A,1,,3302,CHEMBL623001,,BAO_0000218,1969.0
13082,50594,,,1,,N,,,,Intermediate,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,1,,12467,CHEMBL623002,,BAO_0000218,
13083,22229,,,0,,U,,,,Autocuration,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,1,,11778,CHEMBL623003,,BAO_0000100,
13084,22224,,,0,,U,,,,Autocuration,Steady state concentration was evaluated,A,1,,4321,CHEMBL623004,,BAO_0000019,
13085,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,14884,CHEMBL623005,,BAO_0000019,
13086,22224,,,0,,U,,,,Autocuration,Partition coefficient (logD7.4),A,1,,15234,CHEMBL623006,,BAO_0000019,
13087,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,1,,14198,CHEMBL623007,,BAO_0000218,2107.0
13088,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,1,,14198,CHEMBL623008,,BAO_0000218,10000001.0
13089,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,1,,14198,CHEMBL876654,,BAO_0000218,2037.0
13090,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,1,,14198,CHEMBL623009,,BAO_0000218,
13091,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,1,,14198,CHEMBL623010,,BAO_0000218,
13092,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,1,,14198,CHEMBL623011,,BAO_0000218,948.0
13093,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,1,,14198,CHEMBL623012,,BAO_0000218,160.0
13094,22224,,,0,,U,,,,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,1,,8151,CHEMBL623013,,BAO_0000019,
13095,22224,,,0,,U,,,,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,1,,8151,CHEMBL623014,,BAO_0000019,
13096,22224,,,0,,U,,Urine,,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,1,,8151,CHEMBL623015,,BAO_0000019,1088.0
13097,22224,,,0,,U,,Urine,,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,1,,8151,CHEMBL623016,,BAO_0000019,1088.0
13098,22224,,,0,,U,,Urine,,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,1,,8151,CHEMBL624858,,BAO_0000019,1088.0
13099,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,1,,8151,CHEMBL624859,,BAO_0000218,
13100,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,1,,8151,CHEMBL624860,,BAO_0000218,
13101,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,1,,8151,CHEMBL624861,,BAO_0000218,
13102,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,1,,8151,CHEMBL624862,,BAO_0000218,
13103,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,1,,8151,CHEMBL624863,,BAO_0000218,
13104,50597,,,1,,N,,,,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,1,,8151,CHEMBL876655,,BAO_0000218,
13105,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,1,,6996,CHEMBL624864,,BAO_0000218,
13106,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,1,,6996,CHEMBL624865,,BAO_0000218,
13107,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,1,,6996,CHEMBL624866,,BAO_0000218,
13108,50588,,,1,,N,,,,Expert,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,1,,6996,CHEMBL624867,,BAO_0000218,
13109,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,1,,6996,CHEMBL624868,,BAO_0000218,
13110,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,1,,6996,CHEMBL628450,,BAO_0000218,
13111,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,1,,6996,CHEMBL628451,,BAO_0000218,
13112,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,1,,6996,CHEMBL628452,,BAO_0000218,
13113,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,1,,6996,CHEMBL628453,,BAO_0000218,
13114,50588,,,1,,N,,,,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,1,,6996,CHEMBL628454,,BAO_0000218,
13115,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,1,,6996,CHEMBL628455,,BAO_0000218,
13116,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,1,,6996,CHEMBL628456,,BAO_0000218,
13117,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,1,,6996,CHEMBL628457,,BAO_0000218,
13118,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,1,,6996,CHEMBL877505,,BAO_0000218,
13119,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,1,,6996,CHEMBL628458,,BAO_0000218,
13120,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,1,,6996,CHEMBL628459,,BAO_0000218,
13121,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,1,,6996,CHEMBL628460,,BAO_0000218,
13122,50588,,,1,,N,,,,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,1,,6996,CHEMBL628461,,BAO_0000218,
13123,22224,,,0,,U,,,,Autocuration,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,1,,6996,CHEMBL628462,,BAO_0000218,
13124,50588,,,1,,N,,,,Intermediate,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,1,,6996,CHEMBL628463,,BAO_0000218,
13125,50597,,,1,,N,,,,Expert,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,1,,6996,CHEMBL625666,,BAO_0000218,
13126,22224,,,0,,U,,,,Autocuration,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,1,,6996,CHEMBL625667,,BAO_0000218,
13127,50597,,,1,,N,,,,Expert,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,1,,6996,CHEMBL625668,,BAO_0000218,
13128,50597,,,1,,N,,,,Intermediate,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,1,,6996,CHEMBL625669,,BAO_0000218,
13129,22224,,,0,,U,,,,Autocuration,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,1,,7114,CHEMBL625670,,BAO_0000019,
13130,50597,,,1,,N,,,,Intermediate,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,1,,7114,CHEMBL625671,,BAO_0000218,
13131,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,1,,8613,CHEMBL625672,,BAO_0000218,
13132,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,1,,8613,CHEMBL625673,,BAO_0000218,
13133,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,1,,8613,CHEMBL625674,,BAO_0000218,
13134,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,1,,8613,CHEMBL625675,,BAO_0000218,
13135,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,1,,8613,CHEMBL627637,,BAO_0000218,
13136,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,1,,8613,CHEMBL627638,,BAO_0000218,
13137,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,1,,8613,CHEMBL627639,,BAO_0000218,
13138,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,1,,8613,CHEMBL627640,,BAO_0000218,
13139,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,1,,8613,CHEMBL627641,,BAO_0000218,
13140,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,1,,8613,CHEMBL627642,,BAO_0000218,
13141,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,1,,8613,CHEMBL877506,,BAO_0000218,
13142,50594,,,1,,N,,,,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,1,,8613,CHEMBL627275,,BAO_0000218,
13143,50506,,,1,,N,,,,Intermediate,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,1,,11219,CHEMBL627643,,BAO_0000218,
13144,50506,,,1,,N,,,,Intermediate,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,1,,11219,CHEMBL631246,,BAO_0000218,
13145,50506,,,1,,N,,,,Intermediate,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,1,,11219,CHEMBL631247,,BAO_0000218,
13146,50506,,,1,,N,,,,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,1,,11219,CHEMBL629532,,BAO_0000218,
13147,50506,,,1,,N,,,,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,1,,11219,CHEMBL629533,,BAO_0000218,
13148,50506,,,1,,N,,,,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,1,,11219,CHEMBL629534,,BAO_0000218,
13149,50506,,,1,,N,,,,Intermediate,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,1,,11219,CHEMBL629535,,BAO_0000218,
13150,22224,,,0,,U,,,,Autocuration,Pharmacokinetic parameter :drug bound to plasma was reported,A,1,,14837,CHEMBL625932,,BAO_0000019,
13151,22224,,,0,,U,,,,Autocuration,compound was evaluated for drug bound in plasma,A,1,,14837,CHEMBL625933,,BAO_0000019,
13152,50597,,,1,,N,,,,Intermediate,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,1,,15343,CHEMBL625934,,BAO_0000218,
13153,22224,,,0,,U,,,,Autocuration,Bioavailability,A,1,,13761,CHEMBL625935,,BAO_0000218,
13154,50597,,,1,,N,,,,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,1,,14810,CHEMBL625936,,BAO_0000218,
13155,50597,,,1,,N,,,,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,1,,14810,CHEMBL625937,,BAO_0000218,
13156,50588,,,1,,N,,,,Intermediate,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,1,,13249,CHEMBL625938,,BAO_0000218,
13157,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,1,,9267,CHEMBL625939,,BAO_0000218,1970.0
13158,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,1,,9267,CHEMBL625940,,BAO_0000218,1970.0
13159,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,1,,9267,CHEMBL874464,,BAO_0000218,1970.0
13160,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,1,,9267,CHEMBL625941,,BAO_0000218,1970.0
13161,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,1,,9267,CHEMBL625942,,BAO_0000218,1970.0
13162,50597,,,1,,N,,Bile,,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,1,,9267,CHEMBL625943,,BAO_0000218,1970.0
13163,50587,,,1,,N,,Serum,,Intermediate,In vitro protein binding in human serum at 5 ug/ml,A,1,,15549,CHEMBL625944,,BAO_0000218,1977.0
13164,22224,,,0,,U,,,,Autocuration,Serum protein binding ability was measured,A,1,,10929,CHEMBL625945,,BAO_0000019,
13165,22224,,,0,,U,,,,Autocuration,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,1,,15444,CHEMBL625946,,BAO_0000019,
13166,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability in dog,A,1,,12860,CHEMBL625947,,BAO_0000218,
13167,50597,,In vivo,1,,N,,,,Intermediate,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,1,,12170,CHEMBL625948,,BAO_0000218,
13168,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,1,,15173,CHEMBL625949,,BAO_0000218,
13169,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,1,,15173,CHEMBL625950,,BAO_0000218,
13170,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability (dose 15 mg/kg i.v.),A,1,,15173,CHEMBL625951,,BAO_0000218,
13171,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,1,,15173,CHEMBL625952,,BAO_0000218,
13172,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,1,,15173,CHEMBL625953,,BAO_0000218,
13173,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,1,,15173,CHEMBL625954,,BAO_0000218,
13174,22224,,In vivo,0,,U,,,,Autocuration,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,1,,15173,CHEMBL882959,,BAO_0000218,
13175,50588,,In vivo,1,,N,,,,Intermediate,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,1,,11767,CHEMBL625955,,BAO_0000218,
13176,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in ferret,A,1,,11219,CHEMBL625956,,BAO_0000218,
13177,100710,,In vivo,1,,N,,,,Intermediate,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,1,,12186,CHEMBL625957,,BAO_0000218,
13178,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,1,,11510,CHEMBL625958,,BAO_0000218,
13179,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,1,,11510,CHEMBL625959,,BAO_0000218,
13180,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,1,,11510,CHEMBL626642,,BAO_0000218,
13181,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,1,,11510,CHEMBL631330,,BAO_0000218,
13182,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,1,,11510,CHEMBL631331,,BAO_0000218,
13183,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,1,,11510,CHEMBL631332,,BAO_0000218,
13184,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,1,,11510,CHEMBL631333,,BAO_0000218,
13185,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,1,,11510,CHEMBL632018,,BAO_0000218,
13186,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,1,,11510,CHEMBL632019,,BAO_0000218,
13187,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,1,,11510,CHEMBL632020,,BAO_0000218,
13188,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,1,,11510,CHEMBL632021,,BAO_0000218,
13189,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,1,,11510,CHEMBL632022,,BAO_0000218,
13190,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,1,,11510,CHEMBL632023,,BAO_0000218,
13191,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,1,,11510,CHEMBL632024,,BAO_0000218,
13192,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,1,,11510,CHEMBL874472,,BAO_0000218,
13193,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,1,,11510,CHEMBL632025,,BAO_0000218,
13194,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,1,,11510,CHEMBL632026,,BAO_0000218,
13195,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,1,,11510,CHEMBL632027,,BAO_0000218,
13196,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,1,,11510,CHEMBL632028,,BAO_0000218,
13197,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,1,,11510,CHEMBL626430,,BAO_0000218,
13198,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,1,,11510,CHEMBL626431,,BAO_0000218,
13199,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,1,,11510,CHEMBL626432,,BAO_0000218,
13200,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,1,,11510,CHEMBL626433,,BAO_0000218,
13201,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,1,,11510,CHEMBL626434,,BAO_0000218,
13202,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,1,,11510,CHEMBL627280,,BAO_0000218,
13203,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,1,,11510,CHEMBL627281,,BAO_0000218,
13204,50597,,,1,,N,,,,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,1,,11510,CHEMBL627282,,BAO_0000218,
13205,22224,,,0,,U,,,,Autocuration,Total body clearance was measured at given dose,A,1,,7199,CHEMBL627283,,BAO_0000019,
13206,22224,,,0,,U,,,,Autocuration,Total body clearance was measured at given dose.,A,1,,7199,CHEMBL627284,,BAO_0000218,
13207,50597,,,1,,N,,,,Intermediate,Metabolic clearance from the body in rat,A,1,,7095,CHEMBL627285,,BAO_0000218,
13208,22224,,In vivo,0,,U,,,,Autocuration,Renal clearance from the body,A,1,,7095,CHEMBL627286,,BAO_0000218,
13209,50597,,In vivo,1,,N,,,,Intermediate,Renal clearance from the body in rat,A,1,,7095,CHEMBL875477,,BAO_0000218,
13210,50597,,In vivo,1,,N,,,,Intermediate,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,1,,12528,CHEMBL627287,,BAO_0000218,
13211,50588,,In vivo,1,,N,,,,Intermediate,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,1,,12528,CHEMBL627288,,BAO_0000218,
13212,50597,,,1,,N,,,,Intermediate,Total clearance from the body in rat,A,1,,7095,CHEMBL627289,,BAO_0000218,
13213,50597,,In vivo,1,,N,,Plasma,,Intermediate,Clearance into cortex from rat plasma or PBS,A,1,,14223,CHEMBL627290,,BAO_0000218,1969.0
13214,22224,,In vivo,0,,U,,,,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,1,,13569,CHEMBL627291,,BAO_0000218,
13215,22224,,In vivo,0,,U,,,,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,1,,13569,CHEMBL627292,,BAO_0000218,
13216,22224,,In vivo,0,,U,,,,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,1,,13569,CHEMBL627293,,BAO_0000218,
13217,22224,,In vivo,0,,U,,,,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,1,,13569,CHEMBL627294,,BAO_0000218,
13218,22224,,In vivo,0,,U,,,,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,1,,13569,CHEMBL875478,,BAO_0000218,
13219,22224,,In vivo,0,,U,,,,Autocuration,Clearance was determined,A,1,,13979,CHEMBL627295,,BAO_0000218,
13220,50594,,In vivo,1,,N,,,,Intermediate,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,1,,14315,CHEMBL627296,,BAO_0000218,
13221,50592,,In vivo,1,,N,,,,Intermediate,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,1,,14315,CHEMBL626119,,BAO_0000218,
13222,50597,,In vivo,1,,N,,,,Intermediate,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,1,,14315,CHEMBL626120,,BAO_0000218,
13223,50597,,In vivo,1,,N,,,,Intermediate,Clearance in rat after iv dose (100 ug/kg),A,1,,12174,CHEMBL626121,,BAO_0000218,
13224,22224,,In vivo,0,,U,,,,Autocuration,Clearance in guinea pig,A,1,,12797,CHEMBL626122,,BAO_0000218,
13225,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for clearance in rat,A,1,,12797,CHEMBL626123,,BAO_0000218,
13226,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the clearance in dog,A,1,,12797,CHEMBL623456,,BAO_0000218,
13227,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for the clearance in rat,A,1,,12797,CHEMBL623457,,BAO_0000218,
13228,50597,,In vivo,1,,N,,,,Intermediate,Compound was tested in vivo for clearance after iv administration in the rat,A,1,,11500,CHEMBL623458,,BAO_0000218,
13229,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an iv dose of 14 mg/kg,A,1,,15173,CHEMBL623459,,BAO_0000218,
13230,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an iv dose of 15.2 mg/kg,A,1,,15173,CHEMBL875484,,BAO_0000218,
13231,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an iv dose of 15 mg/kg,A,1,,15173,CHEMBL623460,,BAO_0000218,
13232,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an peroral dose of 30 mg/kg.,A,1,,15173,CHEMBL623461,,BAO_0000218,
13233,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,1,,15173,CHEMBL623462,,BAO_0000218,
13234,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,1,,15173,CHEMBL627386,,BAO_0000218,
13235,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,1,,14198,CHEMBL627387,,BAO_0000218,2113.0
13236,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,1,,14198,CHEMBL627388,,BAO_0000218,2107.0
13237,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,1,,14198,CHEMBL627389,,BAO_0000218,2048.0
13238,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,1,,14198,CHEMBL627390,,BAO_0000218,2385.0
13239,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,1,,14198,CHEMBL627391,,BAO_0000218,1969.0
13240,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,1,,14198,CHEMBL627392,,BAO_0000218,
13241,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,1,,14198,CHEMBL627393,,BAO_0000218,2106.0
13242,50597,,In vivo,1,,N,,Trachea,,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,1,,14198,CHEMBL627394,,BAO_0000218,3126.0
13243,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,1,,14198,CHEMBL627395,,BAO_0000218,10000001.0
13244,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,1,,14198,CHEMBL875485,,BAO_0000218,2037.0
13245,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,1,,14198,CHEMBL627396,,BAO_0000218,
13246,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,1,,14198,CHEMBL627397,,BAO_0000218,
13247,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,1,,14198,CHEMBL627398,,BAO_0000218,948.0
13248,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,1,,14198,CHEMBL627399,,BAO_0000218,10000001.0
13249,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,1,,14198,CHEMBL627400,,BAO_0000218,2113.0
13250,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,1,,14198,CHEMBL627401,,BAO_0000218,2107.0
13251,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,1,,14198,CHEMBL627402,,BAO_0000218,2048.0
13252,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,1,,14198,CHEMBL627403,,BAO_0000218,2385.0
13253,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,1,,14198,CHEMBL627404,,BAO_0000218,1969.0
13254,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,1,,14198,CHEMBL623101,,BAO_0000218,
13255,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,1,,14198,CHEMBL877480,,BAO_0000218,2106.0
13256,50597,,In vivo,1,,N,,Trachea,,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,1,,14198,CHEMBL623102,,BAO_0000218,3126.0
13257,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,1,,14198,CHEMBL623103,,BAO_0000218,10000001.0
13258,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,1,,14198,CHEMBL623104,,BAO_0000218,2037.0
13259,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,1,,14198,CHEMBL623105,,BAO_0000218,
13260,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,1,,14198,CHEMBL623106,,BAO_0000218,
13261,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,1,,14198,CHEMBL623107,,BAO_0000218,948.0
13262,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,1,,14198,CHEMBL623108,,BAO_0000218,160.0
13263,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,1,,14198,CHEMBL623109,,BAO_0000218,2113.0
13264,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,1,,14198,CHEMBL623110,,BAO_0000218,2107.0
13265,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,1,,14198,CHEMBL623111,,BAO_0000218,2048.0
13266,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,1,,14198,CHEMBL625060,,BAO_0000218,2385.0
13267,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,1,,14198,CHEMBL625061,,BAO_0000218,1969.0
13268,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,1,,14198,CHEMBL625062,,BAO_0000218,
13269,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,1,,14198,CHEMBL625063,,BAO_0000218,2106.0
13270,50597,,In vivo,1,,N,,Trachea,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,1,,14198,CHEMBL625064,,BAO_0000218,3126.0
13271,50597,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,1,,14198,CHEMBL625065,,BAO_0000218,10000001.0
13272,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,1,,14198,CHEMBL625066,,BAO_0000218,2037.0
13273,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,1,,14198,CHEMBL625067,,BAO_0000218,
13274,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,1,,14198,CHEMBL625068,,BAO_0000218,
13275,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,1,,14198,CHEMBL622159,,BAO_0000218,948.0
13276,50597,,In vivo,1,,N,,Intestine,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,1,,14198,CHEMBL622160,,BAO_0000218,160.0
13277,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,1,,14198,CHEMBL622161,,BAO_0000218,2113.0
13278,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,1,,14198,CHEMBL622162,,BAO_0000218,2048.0
13279,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,1,,14198,CHEMBL622163,,BAO_0000218,2385.0
13280,50597,,In vivo,1,,N,,Plasma,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,1,,14198,CHEMBL622313,,BAO_0000218,1969.0
13281,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,1,,14198,CHEMBL622314,,BAO_0000218,
13282,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,1,,14198,CHEMBL622315,,BAO_0000218,2106.0
13283,50597,,In vivo,1,,N,,Trachea,,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,1,,14198,CHEMBL622316,,BAO_0000218,3126.0
13284,50212,,,1,,N,,,,Intermediate,Normal diffusion coefficient in water for Escherichia coli,A,1,,15599,CHEMBL877486,,BAO_0000218,
13285,22224,,,0,,U,,,,Autocuration,Average max percent decrease in RVR (renal vascular resistance) was determined,A,1,,8204,CHEMBL622317,,BAO_0000019,
13286,22224,,,0,,U,,,,Autocuration,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,1,,8204,CHEMBL622318,,BAO_0000019,
13287,22224,,,0,,U,,,,Autocuration,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,1,,6154,CHEMBL622319,,BAO_0000019,
13288,22224,,,0,,U,,,,Autocuration,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,1,,6154,CHEMBL622320,,BAO_0000019,
13289,22224,,,0,,U,,,,Autocuration,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,1,,6154,CHEMBL622321,,BAO_0000019,
13290,22224,,,0,,U,,,,Autocuration,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,1,,6154,CHEMBL622322,,BAO_0000019,
13291,22224,,,0,,U,,,,Autocuration,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,1,,7114,CHEMBL622323,,BAO_0000019,
13292,50597,,,1,,N,,,,Intermediate,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,1,,7114,CHEMBL622324,,BAO_0000218,
13293,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,1,,8133,CHEMBL622325,,BAO_0000218,1088.0
13294,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,1,,8133,CHEMBL622326,,BAO_0000218,1088.0
13295,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,1,,8133,CHEMBL877487,,BAO_0000218,1088.0
13296,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,1,,8133,CHEMBL622327,,BAO_0000218,1088.0
13297,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,1,,8133,CHEMBL622328,,BAO_0000218,1088.0
13298,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,1,,8133,CHEMBL622329,,BAO_0000218,1088.0
13299,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,1,,8133,CHEMBL622330,,BAO_0000218,1088.0
13300,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,1,,8133,CHEMBL622331,,BAO_0000218,1088.0
13301,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,1,,8133,CHEMBL622332,,BAO_0000218,1088.0
13302,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,1,,8133,CHEMBL622333,,BAO_0000218,1088.0
13303,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,1,,8133,CHEMBL627658,,BAO_0000218,1088.0
13304,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,1,,8133,CHEMBL630428,,BAO_0000218,1088.0
13305,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,1,,8133,CHEMBL630429,,BAO_0000218,1088.0
13306,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,1,,8133,CHEMBL630430,,BAO_0000218,1088.0
13307,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,1,,8133,CHEMBL630431,,BAO_0000218,1088.0
13308,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,1,,8133,CHEMBL630432,,BAO_0000218,1088.0
13309,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,1,,8133,CHEMBL630433,,BAO_0000218,1088.0
13310,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,1,,8133,CHEMBL630434,,BAO_0000218,1088.0
13311,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,1,,8133,CHEMBL629372,,BAO_0000218,1088.0
13312,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,1,,8133,CHEMBL629553,,BAO_0000218,1088.0
13313,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,1,,8133,CHEMBL629554,,BAO_0000218,1088.0
13314,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,1,,8133,CHEMBL874447,,BAO_0000218,1088.0
13315,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,1,,8133,CHEMBL629555,,BAO_0000218,1088.0
13316,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,1,,8133,CHEMBL629556,,BAO_0000218,1088.0
13317,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,1,,8133,CHEMBL629557,,BAO_0000218,1088.0
13318,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,1,,8133,CHEMBL629558,,BAO_0000218,1088.0
13319,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,1,,8133,CHEMBL629559,,BAO_0000218,1088.0
13320,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,1,,8133,CHEMBL629560,,BAO_0000218,1088.0
13321,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,1,,8133,CHEMBL629561,,BAO_0000218,1088.0
13322,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,1,,8133,CHEMBL629562,,BAO_0000218,1088.0
13323,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,1,,8133,CHEMBL629563,,BAO_0000218,1088.0
13324,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,1,,8133,CHEMBL629564,,BAO_0000218,1088.0
13325,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,1,,8133,CHEMBL629565,,BAO_0000218,1088.0
13326,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,1,,8133,CHEMBL629566,,BAO_0000218,1088.0
13327,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,1,,8133,CHEMBL629567,,BAO_0000218,1088.0
13328,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,1,,8133,CHEMBL629568,,BAO_0000218,1088.0
13329,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,1,,8133,CHEMBL629569,,BAO_0000218,1088.0
13330,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,1,,8133,CHEMBL629570,,BAO_0000218,1088.0
13331,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,1,,8133,CHEMBL629571,,BAO_0000218,1088.0
13332,22224,,In vivo,0,,U,,,,Autocuration,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,1,,12170,CHEMBL629572,,BAO_0000218,
13333,22224,,In vivo,0,,U,,,,Autocuration,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,1,,12170,CHEMBL629573,,BAO_0000218,
13334,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability (dose 20 mg/kg),A,1,,4985,CHEMBL629574,,BAO_0000218,
13335,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog,A,1,,15145,CHEMBL629575,,BAO_0000218,
13336,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat (Sprague-Dawley) (male),A,1,,14080,CHEMBL874448,,BAO_0000218,
13337,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in monkey (dose 10 mg/kg i.d.),A,1,,11219,CHEMBL629576,,BAO_0000218,
13338,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat,A,1,,15145,CHEMBL629577,,BAO_0000218,
13339,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat,A,1,,15145,CHEMBL629578,,BAO_0000218,
13340,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,1,,1202,CHEMBL629579,,BAO_0000218,
13341,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,1,,1202,CHEMBL882958,,BAO_0000218,
13342,50505,,In vivo,1,,N,,,,Intermediate,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,1,,1202,CHEMBL629580,,BAO_0000218,
13343,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability,A,1,,4026,CHEMBL629581,,BAO_0000218,
13344,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in squirrel monkey,A,1,,1492,CHEMBL629582,,BAO_0000218,
13345,50588,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in dog,A,1,,12793,CHEMBL628522,,BAO_0000218,
13346,100712,,In vivo,1,,N,,,,Intermediate,Bioavailability was evaluated in hamster,A,1,,12793,CHEMBL625432,,BAO_0000218,
13347,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat,A,1,,12793,CHEMBL625433,,BAO_0000218,
13348,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,1,,14793,CHEMBL625434,,BAO_0000218,1969.0
13349,50597,,In vivo,1,,N,,Plasma,,Intermediate,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,1,,14793,CHEMBL625435,,BAO_0000218,1969.0
13350,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat (dose 10 mg/kg p.o.),A,1,,14793,CHEMBL625436,,BAO_0000218,
13351,100710,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in cynomolgus monkeys.,A,1,,14731,CHEMBL874588,,BAO_0000218,
13352,50594,,In vivo,1,,N,,,,Intermediate,Bioavailability was measured in nude mice.,A,1,,14731,CHEMBL625437,,BAO_0000218,
13353,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in ferret (dose 10 mg/kg i.d.),A,1,,12187,CHEMBL625438,,BAO_0000218,
13354,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,1,,12187,CHEMBL625439,,BAO_0000218,
13355,22224,,In vivo,0,,U,,,,Autocuration,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,1,,12187,CHEMBL625440,,BAO_0000218,
13356,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,1,,12187,CHEMBL625441,,BAO_0000218,
13357,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability in rat (dose 10 mg/kg i.d.),A,1,,12187,CHEMBL625442,,BAO_0000218,
13358,50597,,In vivo,1,,N,,,,Intermediate,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,1,,12187,CHEMBL625443,,BAO_0000218,
13359,22224,,In vivo,0,,U,,,,Autocuration,Bioavailability was determined; extremely poor,A,1,,17431,CHEMBL625444,,BAO_0000218,
13360,50594,,In vivo,1,,N,,,,Intermediate,% bioavailability in mice after oral administration of prodrug,A,1,,13318,CHEMBL625445,,BAO_0000218,
13361,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,1,,9025,CHEMBL625446,,BAO_0000218,
13362,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,1,,9025,CHEMBL882960,,BAO_0000218,
13363,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,1,,9025,CHEMBL625447,,BAO_0000218,
13364,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,1,,9025,CHEMBL625448,,BAO_0000218,
13365,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,1,,9025,CHEMBL625449,,BAO_0000218,
13366,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,1,,9025,CHEMBL874589,,BAO_0000218,
13367,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,1,,9025,CHEMBL625450,,BAO_0000218,
13368,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,1,,9025,CHEMBL625451,,BAO_0000218,
13369,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,1,,9025,CHEMBL626584,,BAO_0000218,
13370,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,1,,9025,CHEMBL626585,,BAO_0000218,
13371,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,1,,9025,CHEMBL626586,,BAO_0000218,
13372,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,1,,9025,CHEMBL626587,,BAO_0000218,
13373,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,1,,9025,CHEMBL626588,,BAO_0000218,
13374,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,1,,9025,CHEMBL626589,,BAO_0000218,
13375,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,1,,9025,CHEMBL626590,,BAO_0000218,
13376,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,1,,9025,CHEMBL626591,,BAO_0000218,
13377,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,1,,9025,CHEMBL627181,,BAO_0000218,
13378,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,1,,9025,CHEMBL628083,,BAO_0000218,
13379,22224,,In vivo,0,,U,,,,Autocuration,IV clearance determined at an peroral dose of 15 mg/kg.,A,1,,15173,CHEMBL628084,,BAO_0000218,
13380,50064,,In vivo,1,,N,,,,Expert,Mouse oral clearance was measured against Hymenolepiasis nana.,F,1,,7732,CHEMBL628085,,BAO_0000218,
13381,50545,,In vivo,1,,N,,,,Expert,Mouse oral clearance was measured against Nematospiroides dubius,F,1,,7732,CHEMBL628086,,BAO_0000218,
13382,22224,,In vivo,0,,U,,,,Autocuration,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,1,,7732,CHEMBL628087,,BAO_0000218,
13383,50594,,In vivo,1,,N,,,,Intermediate,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,1,,7732,CHEMBL628088,,BAO_0000218,
13384,22224,,In vivo,0,,U,,,,Autocuration,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,1,,7732,CHEMBL628089,,BAO_0000218,
13385,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL628090,,BAO_0000218,
13386,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL628091,,BAO_0000218,
13387,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL628092,,BAO_0000218,
13388,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL628093,,BAO_0000218,
13389,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL875607,,BAO_0000218,
13390,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL625710,,BAO_0000218,
13391,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL625711,,BAO_0000218,
13392,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL625712,,BAO_0000218,
13393,22224,,In vivo,0,,U,,,,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,1,,8328,CHEMBL625713,,BAO_0000218,
13394,50588,,In vivo,1,,N,,,,Intermediate,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,1,,13376,CHEMBL625714,,BAO_0000218,
13395,50797,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,1,,13477,CHEMBL625715,,BAO_0000218,
13396,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,1,,13477,CHEMBL625716,,BAO_0000218,
13397,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,1,,13477,CHEMBL625717,,BAO_0000218,
13398,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance was determined for the compound in rats,A,1,,13313,CHEMBL625718,,BAO_0000218,
13399,50597,,In vivo,1,,N,,,,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,1,,12504,CHEMBL625719,,BAO_0000218,
13400,50597,,In vivo,1,,N,,,,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,1,,12504,CHEMBL625720,,BAO_0000218,
13401,50597,,In vivo,1,,N,,,,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,1,,12504,CHEMBL625721,,BAO_0000218,
13402,50597,,In vivo,1,,N,,,,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,1,,12504,CHEMBL625722,,BAO_0000218,
13403,50597,,In vivo,1,,N,,,,Intermediate,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,1,,13129,CHEMBL625723,,BAO_0000218,
13404,50545,,In vivo,1,,N,,,,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,1,,7732,CHEMBL625724,,BAO_0000218,
13405,50545,,In vivo,1,,N,,,,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,1,,7732,CHEMBL625725,,BAO_0000218,
13406,50545,,In vivo,1,,N,,,,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,1,,7732,CHEMBL625726,,BAO_0000218,
13407,50545,,In vivo,1,,N,,,,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,1,,7732,CHEMBL875608,,BAO_0000218,
13408,50545,,In vivo,1,,N,,,,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,1,,7732,CHEMBL625727,,BAO_0000218,
13409,22224,,In vivo,0,,U,,Urine,,Autocuration,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,1,,9278,CHEMBL625728,,BAO_0000218,1088.0
13410,22224,,In vivo,0,,U,,,,Autocuration,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,1,,9278,CHEMBL625729,,BAO_0000218,
13411,22224,,In vivo,0,,U,,,,Autocuration,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,1,,9278,CHEMBL625730,,BAO_0000218,
13412,22224,,In vivo,0,,U,,Urine,,Autocuration,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,1,,9278,CHEMBL625731,,BAO_0000218,1088.0
13413,22224,,In vivo,0,,U,,Urine,,Autocuration,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,1,,9278,CHEMBL626417,,BAO_0000218,1088.0
13414,50587,,In vivo,1,,N,,Urine,,Intermediate,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,1,,9278,CHEMBL626418,,BAO_0000218,1088.0
13415,50588,,In vivo,1,,N,,Urine,,Intermediate,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,1,,9278,CHEMBL626419,,BAO_0000218,1088.0
13416,50588,,In vivo,1,,N,,Plasma,,Intermediate,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,1,,5932,CHEMBL626592,,BAO_0000218,1969.0
13417,50597,,In vivo,1,,N,,Plasma,,Intermediate,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,1,,5932,CHEMBL626593,,BAO_0000218,1969.0
13418,50597,,In vivo,1,,N,,,,Intermediate,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,1,,5182,CHEMBL626594,,BAO_0000218,
13419,50588,,In vivo,1,,N,,,,Intermediate,Clearance rate in dogs,A,1,,10499,CHEMBL625035,,BAO_0000218,
13420,22224,,In vitro,0,,U,,,,Autocuration,Compound was measured for intrinsic clearance,A,1,,6051,CHEMBL625036,,BAO_0000019,
13421,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,17508,CHEMBL625037,,BAO_0000100,
13422,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6228,CHEMBL625038,,BAO_0000100,
13423,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6231,CHEMBL625039,,BAO_0000100,
13424,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,17740,CHEMBL625040,,BAO_0000100,
13425,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6495,CHEMBL625041,,BAO_0000100,
13426,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,2171,CHEMBL625042,,BAO_0000100,
13427,22224,,,0,,U,,,,Autocuration,Partition coefficient of the compound,A,1,,3255,CHEMBL874411,,BAO_0000019,
13428,22224,,,0,,U,,,,Autocuration,Permeability,A,1,,6821,CHEMBL625043,,BAO_0000019,
13429,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,2685,CHEMBL625044,,BAO_0000100,
13430,22224,,,0,,U,,,,Autocuration,Partition coefficient (logD),A,1,,17584,CHEMBL625045,,BAO_0000019,
13431,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,1,,13824,CHEMBL625046,,BAO_0000100,
13432,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,1,,13824,CHEMBL625047,,BAO_0000100,
13433,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,16479,CHEMBL625048,,BAO_0000100,
13434,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,11997,CHEMBL625049,,BAO_0000100,
13435,22229,,,0,,U,,,,Autocuration,Calculated logarithm of partition coefficient (P) was determined,P,1,,2988,CHEMBL625050,,BAO_0000100,
13436,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,931,CHEMBL625051,,BAO_0000100,
13437,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,4381,CHEMBL874412,,BAO_0000100,
13438,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,4397,CHEMBL625052,,BAO_0000100,
13439,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,5889,CHEMBL625053,,BAO_0000100,
13440,22224,,,0,,U,,,,Autocuration,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,1,,6154,CHEMBL623250,,BAO_0000019,
13441,22224,,,0,,U,,,,Autocuration,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,1,,6154,CHEMBL623251,,BAO_0000019,
13442,22224,,,0,,U,,,,Autocuration,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,1,,6154,CHEMBL623252,,BAO_0000019,
13443,22224,,,0,,U,,,,Autocuration,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,1,,6154,CHEMBL623253,,BAO_0000019,
13444,22224,,,0,,U,,,,Autocuration,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,1,,6154,CHEMBL623254,,BAO_0000019,
13445,22224,,,0,,U,,,,Autocuration,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,1,,6154,CHEMBL623255,,BAO_0000019,
13446,22224,,,0,,U,,,,Autocuration,Percent degradation of compound at a pH of 1 over a 18 hr period,A,1,,6887,CHEMBL626831,,BAO_0000019,
13447,22224,,,0,,U,,,,Autocuration,Percent degradation of compound at pH of 1 over an 18 hr period,A,1,,6887,CHEMBL877494,,BAO_0000019,
13448,22224,,,0,,U,,,,Autocuration,Delta Logarithm of Partition Coefficient value was determined.,A,1,,14116,CHEMBL626832,,BAO_0000019,
13449,22224,,,0,,U,,,,Autocuration,Delta logPoct-cyc,A,1,,11137,CHEMBL626833,,BAO_0000019,
13450,22224,,,0,,U,,,,Autocuration,Lipophilicity estimated on reversed phase TLC,P,1,,7230,CHEMBL626834,,BAO_0000100,
13451,22224,,,0,,U,,,,Autocuration,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,1,,15741,CHEMBL626835,,BAO_0000019,
13452,22224,,,0,,U,,,,Autocuration,Delta logPoct-cyc,A,1,,9663,CHEMBL626836,,BAO_0000019,
13453,22229,,,0,,U,,,,Autocuration,Change in logarithm of partition coefficient of the compound,P,1,,9663,CHEMBL626837,,BAO_0000100,
13454,22224,,,0,,U,,,,Autocuration,Delta logD (pH 6.5),A,1,,13807,CHEMBL626838,,BAO_0000019,
13455,22224,,,0,,U,,,,Autocuration,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,1,,13807,CHEMBL626839,,BAO_0000100,
13456,22224,,,0,,U,,,,Autocuration,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,1,,17425,CHEMBL626840,,BAO_0000019,
13457,22224,,,0,,U,,,,Autocuration,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,1,,12143,CHEMBL626841,,BAO_0000019,
13458,22224,,,0,,U,,,,Autocuration,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,1,,12608,CHEMBL626842,,BAO_0000219,
13459,22224,,,0,,U,,,,Autocuration,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,1,,12608,CHEMBL626843,,BAO_0000219,
13460,50597,,,1,,N,,,,Intermediate,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,1,,8649,CHEMBL626844,,BAO_0000218,
13461,50597,,,1,,N,,,,Intermediate,Amount of deuterium retained was reported after normal workup in rats,A,1,,8649,CHEMBL877495,,BAO_0000218,
13462,50597,,,1,,N,,,,Intermediate,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,1,,8649,CHEMBL626845,,BAO_0000218,
13463,50597,,,1,,N,,,,Intermediate,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,1,,8649,CHEMBL626846,,BAO_0000218,
13464,50597,,,1,,N,,,,Intermediate,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,1,,8649,CHEMBL626847,,BAO_0000218,
13465,50597,,,1,,N,,,,Intermediate,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,1,,8649,CHEMBL628677,,BAO_0000218,
13466,50597,,,1,,N,,,,Intermediate,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,1,,8649,CHEMBL628678,,BAO_0000218,
13467,22224,,,0,,U,,,,Autocuration,Compound was subjected to electrochemical oxidation,A,1,,9659,CHEMBL628679,,BAO_0000019,
13468,22224,,,0,,U,,,,Autocuration,Compound was subjected to photochemical oxidation,A,1,,9659,CHEMBL628680,,BAO_0000019,
13469,22224,,,0,,U,,,,Autocuration,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,1,,9659,CHEMBL628681,,BAO_0000019,
13470,22224,,,0,,U,,,,Autocuration,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,1,,9659,CHEMBL628682,,BAO_0000019,
13471,22224,,,0,,U,,,,Autocuration,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,1,,9659,CHEMBL628683,,BAO_0000019,
13472,50597,,,1,,N,,,,Intermediate,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,1,,9607,CHEMBL628684,,BAO_0000218,
13473,22229,,,0,,U,,,,Autocuration,Dissociation constant (pKa),P,1,,7057,CHEMBL877501,,BAO_0000100,
13474,22224,,,0,,U,,,,Autocuration,Dissociation constant value of the compound; ND means not determined.,P,1,,7057,CHEMBL628685,,BAO_0000100,
13475,50597,,,1,,N,,Blood,,Intermediate,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL628686,,BAO_0000218,178.0
13476,50597,,,1,,N,,Blood,,Intermediate,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,1,,7911,CHEMBL628687,,BAO_0000218,178.0
13477,50597,,,1,,N,,,,Intermediate,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL628688,,BAO_0000218,
13478,50597,,,1,,N,,,,Intermediate,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,1,,7911,CHEMBL628689,,BAO_0000218,
13479,50597,,,1,,N,,Liver,,Intermediate,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL628690,,BAO_0000218,2107.0
13480,50597,,,1,,N,,Liver,,Intermediate,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,1,,7911,CHEMBL629363,,BAO_0000218,2107.0
13481,50597,,,1,,N,,Spleen,,Intermediate,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL629364,,BAO_0000218,2106.0
13482,50597,,,1,,N,,Spleen,,Intermediate,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,1,,7911,CHEMBL629365,,BAO_0000218,2106.0
13483,50597,,,1,,N,,,,Intermediate,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL629366,,BAO_0000218,
13484,50597,,,1,,N,,Urine,,Intermediate,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,1,,7911,CHEMBL629367,,BAO_0000218,1088.0
13485,50597,,,1,,N,,Feces,,Intermediate,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,1,,7911,CHEMBL629368,,BAO_0000218,1988.0
13486,50597,,,1,,N,,Urine,,Intermediate,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,1,,7911,CHEMBL877502,,BAO_0000218,1088.0
13487,50594,,,1,,N,,Cerebellum,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,1,,13792,CHEMBL629369,,BAO_0000218,2037.0
13488,50594,,,1,,N,,Brain,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,1,,13792,CHEMBL629370,,BAO_0000218,955.0
13489,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,1,,8133,CHEMBL629371,,BAO_0000218,1088.0
13490,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,1,,8133,CHEMBL626276,,BAO_0000218,1088.0
13491,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,1,,8133,CHEMBL626277,,BAO_0000218,1088.0
13492,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,1,,8133,CHEMBL631250,,BAO_0000218,1088.0
13493,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,1,,8133,CHEMBL631251,,BAO_0000218,1088.0
13494,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,1,,8133,CHEMBL631252,,BAO_0000218,1088.0
13495,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,1,,8133,CHEMBL631253,,BAO_0000218,1088.0
13496,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,1,,8133,CHEMBL631254,,BAO_0000218,1088.0
13497,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,1,,8133,CHEMBL631255,,BAO_0000218,1088.0
13498,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,1,,8133,CHEMBL631256,,BAO_0000218,1088.0
13499,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,1,,8133,CHEMBL631257,,BAO_0000218,1088.0
13500,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,1,,8133,CHEMBL628009,,BAO_0000218,1088.0
13501,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,1,,8133,CHEMBL628010,,BAO_0000218,1088.0
13502,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,1,,8133,CHEMBL628011,,BAO_0000218,1088.0
13503,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,1,,8133,CHEMBL628012,,BAO_0000218,1088.0
13504,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,1,,8133,CHEMBL628013,,BAO_0000218,1088.0
13505,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,1,,8133,CHEMBL628014,,BAO_0000218,1088.0
13506,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,1,,8133,CHEMBL628015,,BAO_0000218,1088.0
13507,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,1,,8133,CHEMBL628016,,BAO_0000218,1088.0
13508,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,1,,8133,CHEMBL874461,,BAO_0000218,1088.0
13509,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,1,,8133,CHEMBL628017,,BAO_0000218,1088.0
13510,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,1,,8133,CHEMBL628018,,BAO_0000218,1088.0
13511,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,1,,8133,CHEMBL628019,,BAO_0000218,1088.0
13512,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,1,,8133,CHEMBL628020,,BAO_0000218,1088.0
13513,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,1,,8133,CHEMBL628021,,BAO_0000218,1088.0
13514,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,1,,8133,CHEMBL628022,,BAO_0000218,1088.0
13515,50588,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,1,,8133,CHEMBL628023,,BAO_0000218,1088.0
13516,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,1,,8133,CHEMBL628024,,BAO_0000218,1088.0
13517,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,1,,8133,CHEMBL628025,,BAO_0000218,1088.0
13518,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,1,,8133,CHEMBL628026,,BAO_0000218,1088.0
13519,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,1,,8133,CHEMBL628027,,BAO_0000218,1088.0
13520,22224,,,0,,U,,Urine,,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,1,,8133,CHEMBL628028,,BAO_0000218,1088.0
13521,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,1,,8133,CHEMBL628029,,BAO_0000218,1088.0
13522,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,1,,8133,CHEMBL628030,,BAO_0000218,1088.0
13523,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,1,,8133,CHEMBL628031,,BAO_0000218,1088.0
13524,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,1,,8133,CHEMBL628032,,BAO_0000218,1088.0
13525,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,1,,8133,CHEMBL628033,,BAO_0000218,1088.0
13526,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,1,,8133,CHEMBL628034,,BAO_0000218,1088.0
13527,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,1,,8133,CHEMBL628035,,BAO_0000218,1088.0
13528,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,1,,8133,CHEMBL628036,,BAO_0000218,1088.0
13529,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,1,,8133,CHEMBL874462,,BAO_0000218,1088.0
13530,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,1,,9025,CHEMBL628037,,BAO_0000218,
13531,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,1,,9025,CHEMBL628123,,BAO_0000218,
13532,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,1,,9025,CHEMBL628124,,BAO_0000218,
13533,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,1,,9025,CHEMBL628125,,BAO_0000218,
13534,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,1,,9025,CHEMBL628126,,BAO_0000218,
13535,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,1,,9025,CHEMBL628127,,BAO_0000218,
13536,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,1,,9025,CHEMBL628128,,BAO_0000218,
13537,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,1,,9025,CHEMBL628129,,BAO_0000218,
13538,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,1,,9025,CHEMBL628130,,BAO_0000218,
13539,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,1,,9025,CHEMBL628131,,BAO_0000218,
13540,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,1,,9025,CHEMBL628132,,BAO_0000218,
13541,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,1,,9025,CHEMBL628133,,BAO_0000218,
13542,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,1,,9025,CHEMBL628134,,BAO_0000218,
13543,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,1,,9025,CHEMBL628135,,BAO_0000218,
13544,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,1,,9025,CHEMBL628136,,BAO_0000218,
13545,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,1,,9025,CHEMBL628137,,BAO_0000218,
13546,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,1,,9025,CHEMBL628138,,BAO_0000218,
13547,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,1,,9025,CHEMBL628139,,BAO_0000218,
13548,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,1,,9025,CHEMBL628140,,BAO_0000218,
13549,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,1,,9025,CHEMBL628141,,BAO_0000218,
13550,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,1,,9025,CHEMBL628142,,BAO_0000218,
13551,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,1,,9025,CHEMBL628143,,BAO_0000218,
13552,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,1,,9025,CHEMBL628144,,BAO_0000218,
13553,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,1,,9025,CHEMBL628145,,BAO_0000218,
13554,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,1,,9025,CHEMBL628146,,BAO_0000218,
13555,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,1,,9025,CHEMBL625355,,BAO_0000218,
13556,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,1,,9025,CHEMBL625356,,BAO_0000218,
13557,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,1,,9025,CHEMBL625357,,BAO_0000218,
13558,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,1,,9025,CHEMBL625527,,BAO_0000218,
13559,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,1,,9025,CHEMBL875473,,BAO_0000218,
13560,50588,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,1,,9025,CHEMBL625528,,BAO_0000218,
13561,50597,,In vivo,1,,N,,,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,1,,9025,CHEMBL626304,,BAO_0000218,
13562,50588,,In vivo,1,,N,,Artery,,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,1,,9025,CHEMBL624138,,BAO_0000218,1637.0
13563,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6448,CHEMBL624139,,BAO_0000100,
13564,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,17221,CHEMBL624140,,BAO_0000100,
13565,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6545,CHEMBL624141,,BAO_0000100,
13566,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,577,CHEMBL624142,,BAO_0000100,
13567,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6285,CHEMBL624143,,BAO_0000100,
13568,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6500,CHEMBL624144,,BAO_0000100,
13569,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6716,CHEMBL624145,,BAO_0000100,
13570,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,13658,CHEMBL624146,,BAO_0000100,
13571,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6549,CHEMBL624147,,BAO_0000100,
13572,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (MacLogP),P,1,,14685,CHEMBL883123,,BAO_0000100,
13573,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,6893,CHEMBL624148,,BAO_0000019,
13574,22224,,,0,,U,,,,Autocuration,Kinetic parameter was determined,A,1,,3687,CHEMBL874416,,BAO_0000019,
13575,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,4207,CHEMBL624149,,BAO_0000100,
13576,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,4626,CHEMBL624150,,BAO_0000100,
13577,22224,,,0,,U,,,,Autocuration,Lipophilicity was determined,P,1,,1021,CHEMBL624151,,BAO_0000100,
13578,22224,,,0,,U,,,,Autocuration,Lipophilicity was determined,P,1,,3777,CHEMBL624152,,BAO_0000100,
13579,22224,,,0,,U,,,,Autocuration,Lipophilicity was determined,P,1,,17533,CHEMBL622139,,BAO_0000100,
13580,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,6524,CHEMBL622140,,BAO_0000100,
13581,22224,,,0,,U,,,,Autocuration,Lipophilicity was determined,P,1,,17533,CHEMBL622141,,BAO_0000100,
13582,22224,,,0,,U,,,,Autocuration,Lipophilicity in octanol-water,P,1,,6480,CHEMBL622142,,BAO_0000100,
13583,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,17606,CHEMBL622143,,BAO_0000100,
13584,22229,,,0,,U,,,,Autocuration,Octanol-water partition coefficient was determined,P,1,,6863,CHEMBL622144,,BAO_0000100,
13585,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,1356,CHEMBL877473,,BAO_0000019,
13586,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,3326,CHEMBL622145,,BAO_0000100,
13587,22224,,,0,,U,,,,Autocuration,Partition coefficient was determined; ND means not determined,A,1,,1356,CHEMBL622146,,BAO_0000019,
13588,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP),P,1,,12984,CHEMBL622147,,BAO_0000100,
13589,22224,,,0,,U,,,,Autocuration,Partition coefficient of the compound,A,1,,17363,CHEMBL622148,,BAO_0000019,
13590,22224,,,0,,U,,,,Autocuration,Permeability was determined,A,1,,6827,CHEMBL883124,,BAO_0000019,
13591,22229,,,0,,U,,,,Autocuration,The compound was evaluated for the partition coefficient,P,1,,261,CHEMBL622149,,BAO_0000100,
13592,22224,,,0,,U,,,,Autocuration,Partition coefficient (logP),A,1,,2685,CHEMBL622150,,BAO_0000019,
13593,22224,,,0,,U,,,,Autocuration,The lipophilicity was reported,P,1,,414,CHEMBL622151,,BAO_0000100,
13594,22229,,,0,,U,,,,Autocuration,logarithm of the octanol-water partition coefficient for the compound,P,1,,15769,CHEMBL622152,,BAO_0000100,
13595,22224,,,0,,U,,,,Autocuration,Clogp value was determined,A,1,,17248,CHEMBL622153,,BAO_0000019,
13596,22224,,In vivo,0,,U,,,,Autocuration,Clp at a dose of 1.5 mg/kg,A,1,,16935,CHEMBL877474,,BAO_0000218,
13597,22224,,In vivo,0,,U,,,,Autocuration,Clp at a dose of 2.0 mg/kg,A,1,,16935,CHEMBL622154,,BAO_0000218,
13598,22224,,In vivo,0,,U,,Plasma,,Autocuration,"Clp, plasma clearance at a dose of 10 mg/kg",A,1,,14832,CHEMBL622155,,BAO_0000218,1969.0
13599,22224,,In vivo,0,,U,,Plasma,,Autocuration,"Clp, plasma clearance at a dose of 50 mg/kg",A,1,,14832,CHEMBL622156,,BAO_0000218,1969.0
13600,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in rat,A,1,,2399,CHEMBL622157,,BAO_0000218,1969.0
13601,50597,,In vivo,1,,N,,Plasma,,Intermediate,Compound was tested for plasma clearance in rat; Not determined,A,1,,2399,CHEMBL622158,,BAO_0000218,1969.0
13602,50597,,In vivo,1,,N,,,,Intermediate,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,1,,6227,CHEMBL622807,,BAO_0000218,
13603,50797,,In vivo,1,,N,,,,Intermediate,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,1,,6227,CHEMBL622808,,BAO_0000218,
13604,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,1,,5623,CHEMBL622809,,BAO_0000218,
13605,22224,,In vivo,0,,U,,,,Autocuration,Plasma clearance determined,A,1,,4854,CHEMBL622810,,BAO_0000218,
13606,100712,,In vivo,1,,N,,,,Intermediate,Plasma clearance after iv administration at 3 mg/kg in hamster,A,1,,4493,CHEMBL876653,,BAO_0000218,
13607,100712,,In vivo,1,,N,,,,Intermediate,Plasma clearance after iv administration at 4 mg/kg in hamster,A,1,,4493,CHEMBL622811,,BAO_0000218,
13608,50597,,In vivo,1,,N,,,,Intermediate,Rate of clearance in rat was determined,A,1,,14956,CHEMBL622986,,BAO_0000218,
13609,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,1,,15372,CHEMBL622987,,BAO_0000218,1969.0
13610,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,1,,15372,CHEMBL622988,,BAO_0000218,1969.0
13611,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,1,,15372,CHEMBL622989,,BAO_0000218,1969.0
13612,50597,,In vivo,1,,N,,Plasma,,Intermediate,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,1,,15372,CHEMBL622990,,BAO_0000218,1969.0
13613,22224,,In vivo,0,,U,,Plasma,,Autocuration,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,1,,15604,CHEMBL622991,,BAO_0000218,1969.0
13614,50597,,In vivo,1,,N,,Plasma,,Intermediate,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,1,,15604,CHEMBL622227,,BAO_0000218,1969.0
13615,50588,,In vivo,1,,N,,Plasma,,Intermediate,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,1,,15604,CHEMBL622228,,BAO_0000218,1969.0
13616,50597,,In vivo,1,,N,,,,Intermediate,Clpl value in rat,A,1,,14964,CHEMBL622229,,BAO_0000218,
13617,50512,,In vivo,1,,N,,,,Intermediate,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,1,,15240,CHEMBL622230,,BAO_0000218,
13618,50597,,In vivo,1,,N,,,,Intermediate,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,1,,16449,CHEMBL622231,,BAO_0000218,
13619,100710,,In vivo,1,,N,,,,Intermediate,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,1,,16449,CHEMBL622232,,BAO_0000218,
13620,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,1,,12902,CHEMBL622233,,BAO_0000218,
13621,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,1,,12902,CHEMBL622234,,BAO_0000218,
13622,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,1,,12902,CHEMBL622235,,BAO_0000218,
13623,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,1,,12902,CHEMBL622236,,BAO_0000218,
13624,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,1,,12902,CHEMBL622237,,BAO_0000218,
13625,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,1,,12902,CHEMBL877482,,BAO_0000218,
13626,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,1,,12902,CHEMBL622238,,BAO_0000218,
13627,22224,,In vivo,0,,U,,,,Autocuration,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,1,,12902,CHEMBL622239,,BAO_0000218,
13628,22224,,In vivo,0,,U,,Blood,,Autocuration,Cmax was calculated as maximum concentration reached in the blood,A,1,,11149,CHEMBL622240,,BAO_0000218,178.0
13629,22224,,In vivo,0,,U,,Blood,,Autocuration,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,1,,11149,CHEMBL622241,,BAO_0000218,178.0
13630,50597,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 10 mpk in Rat,A,1,,5669,CHEMBL631013,,BAO_0000218,
13631,50797,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,1,,5669,CHEMBL631014,,BAO_0000218,
13632,50588,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 10 mpk in dog,A,1,,5669,CHEMBL631015,,BAO_0000218,
13633,50597,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 160 mpk in Rat,A,1,,5669,CHEMBL631016,,BAO_0000218,
13634,50597,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 20 mpk in Rat,A,1,,5669,CHEMBL631017,,BAO_0000218,
13635,50597,,In vivo,1,,N,,,,Intermediate,Cmax was determine after peroral administration at 50 mpk in Rat,A,1,,5669,CHEMBL631018,,BAO_0000218,
13636,22224,,In vivo,0,,U,,,,Autocuration,Cmax was determined,A,1,,4236,CHEMBL631019,,BAO_0000218,
13637,50594,,,1,,N,,Brain,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,1,,13792,CHEMBL875761,,BAO_0000218,955.0
13638,50594,,,1,,N,,Brain,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,1,,13792,CHEMBL631020,,BAO_0000218,955.0
13639,50594,,,1,,N,,Brain,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,1,,13792,CHEMBL631669,,BAO_0000218,955.0
13640,50594,,,1,,N,,Brain,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,1,,13792,CHEMBL631670,,BAO_0000218,955.0
13641,50594,,,1,,N,,Striatum,,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,1,,13792,CHEMBL631671,,BAO_0000218,2435.0
13642,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,1,,8418,CHEMBL631672,,BAO_0000218,178.0
13643,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,1,,8418,CHEMBL631673,,BAO_0000218,178.0
13644,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,1,,8418,CHEMBL631856,,BAO_0000218,178.0
13645,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,1,,8418,CHEMBL631857,,BAO_0000218,178.0
13646,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,1,,8418,CHEMBL631858,,BAO_0000218,178.0
13647,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,1,,8418,CHEMBL631859,,BAO_0000218,178.0
13648,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,1,,8418,CHEMBL631860,,BAO_0000218,178.0
13649,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,1,,8418,CHEMBL631861,,BAO_0000218,178.0
13650,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,1,,8418,CHEMBL631862,,BAO_0000218,178.0
13651,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,1,,8418,CHEMBL631863,,BAO_0000218,178.0
13652,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,1,,8418,CHEMBL631864,,BAO_0000218,178.0
13653,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,1,,8418,CHEMBL631865,,BAO_0000218,178.0
13654,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,1,,8418,CHEMBL631866,,BAO_0000218,178.0
13655,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,1,,8418,CHEMBL629360,,BAO_0000218,178.0
13656,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,1,,8418,CHEMBL629361,,BAO_0000218,178.0
13657,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,1,,8418,CHEMBL629362,,BAO_0000218,178.0
13658,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,1,,8418,CHEMBL630740,,BAO_0000218,178.0
13659,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,1,,8418,CHEMBL630741,,BAO_0000218,178.0
13660,50597,,,1,,N,,Blood,,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,1,,8418,CHEMBL630742,,BAO_0000218,178.0
13661,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,1,,8418,CHEMBL630743,,BAO_0000218,
13662,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,1,,8418,CHEMBL630744,,BAO_0000218,
13663,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,1,,8418,CHEMBL630745,,BAO_0000218,
13664,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,1,,8418,CHEMBL630746,,BAO_0000218,
13665,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,1,,8418,CHEMBL630747,,BAO_0000218,
13666,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,1,,8418,CHEMBL630748,,BAO_0000218,
13667,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,1,,8418,CHEMBL632056,,BAO_0000218,
13668,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,1,,8418,CHEMBL632057,,BAO_0000218,
13669,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,1,,8418,CHEMBL632058,,BAO_0000218,
13670,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,1,,8418,CHEMBL632059,,BAO_0000218,
13671,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,1,,8418,CHEMBL632060,,BAO_0000218,
13672,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,1,,8418,CHEMBL632061,,BAO_0000218,
13673,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,1,,8418,CHEMBL629207,,BAO_0000218,
13674,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,1,,8418,CHEMBL629208,,BAO_0000218,
13675,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,1,,8418,CHEMBL629209,,BAO_0000218,
13676,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,1,,8418,CHEMBL629210,,BAO_0000218,
13677,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,1,,8418,CHEMBL629211,,BAO_0000218,
13678,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,1,,8418,CHEMBL629212,,BAO_0000218,
13679,50597,,,1,,N,,,,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,1,,8418,CHEMBL629213,,BAO_0000218,
13680,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,1,,8133,CHEMBL629214,,BAO_0000218,1088.0
13681,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,1,,8133,CHEMBL629215,,BAO_0000218,1088.0
13682,50597,,,1,,N,,Urine,,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,1,,8133,CHEMBL635154,,BAO_0000218,1088.0
13683,50597,,,1,,N,,,,Intermediate,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL629216,,BAO_0000218,
13684,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,1,,6996,CHEMBL629217,,BAO_0000218,
13685,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL629218,,BAO_0000218,
13686,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL629219,,BAO_0000218,
13687,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL629220,,BAO_0000218,
13688,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL629221,,BAO_0000218,
13689,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631127,,BAO_0000218,
13690,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,1,,6996,CHEMBL631128,,BAO_0000218,
13691,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631129,,BAO_0000218,
13692,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL631130,,BAO_0000218,
13693,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL631131,,BAO_0000218,
13694,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL631132,,BAO_0000218,
13695,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631133,,BAO_0000218,
13696,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,1,,6996,CHEMBL631134,,BAO_0000218,
13697,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL875120,,BAO_0000218,
13698,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL631135,,BAO_0000218,
13699,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL631136,,BAO_0000218,
13700,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL631137,,BAO_0000218,
13701,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631138,,BAO_0000218,
13702,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,1,,6996,CHEMBL631139,,BAO_0000218,
13703,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631140,,BAO_0000218,
13704,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,1,,6996,CHEMBL631141,,BAO_0000218,
13705,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,1,,6996,CHEMBL631142,,BAO_0000218,
13706,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,1,,6996,CHEMBL631143,,BAO_0000218,
13707,50597,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,1,,6996,CHEMBL631144,,BAO_0000218,
13708,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,1,,6996,CHEMBL631145,,BAO_0000218,
13709,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL631146,,BAO_0000218,
13710,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,1,,6996,CHEMBL631147,,BAO_0000218,
13711,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631148,,BAO_0000218,
13712,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631149,,BAO_0000218,
13713,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL631150,,BAO_0000218,
13714,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631151,,BAO_0000218,
13715,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631152,,BAO_0000218,
13716,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631443,,BAO_0000218,
13717,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL631444,,BAO_0000218,
13718,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL631445,,BAO_0000218,
13719,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,1,,6996,CHEMBL631446,,BAO_0000218,
13720,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,1,,6996,CHEMBL631447,,BAO_0000218,
13721,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,1,,6996,CHEMBL631448,,BAO_0000218,
13722,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,1,,6996,CHEMBL631449,,BAO_0000218,
13723,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,1,,6996,CHEMBL631450,,BAO_0000218,
13724,50588,,,1,,N,,,,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,1,,6996,CHEMBL629724,,BAO_0000218,
13725,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL629725,,BAO_0000218,14.0
13726,50594,,In vivo,1,,N,,Zone of skin,,Intermediate,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL629726,,BAO_0000218,14.0
13727,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL629727,,BAO_0000218,2106.0
13728,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630404,,BAO_0000218,2106.0
13729,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630405,,BAO_0000218,2106.0
13730,50594,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630406,,BAO_0000218,2106.0
13731,50594,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630407,,BAO_0000218,945.0
13732,50594,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630573,,BAO_0000218,945.0
13733,50594,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630574,,BAO_0000218,945.0
13734,50594,,In vivo,1,,N,,Stomach,,Intermediate,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630575,,BAO_0000218,945.0
13735,50594,,In vivo,1,,N,,,,Intermediate,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630576,,BAO_0000218,
13736,50594,,In vivo,1,,N,,,,Intermediate,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630577,,BAO_0000218,
13737,50594,,In vivo,1,,N,,,,Intermediate,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630578,,BAO_0000218,
13738,50594,,In vivo,1,,N,,,,Intermediate,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,1,,9716,CHEMBL630579,,BAO_0000218,
13739,50594,,,1,,N,,Kidney,,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,1,,12192,CHEMBL630580,,BAO_0000218,2113.0
13740,50594,,,1,,N,,Kidney,,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,1,,12192,CHEMBL630581,,BAO_0000218,2113.0
13741,50594,,,1,,N,,Kidney,,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,1,,12192,CHEMBL630582,,BAO_0000218,2113.0
13742,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,1,,12192,CHEMBL630583,,BAO_0000218,
13743,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,1,,12192,CHEMBL630584,,BAO_0000218,
13744,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,1,,12192,CHEMBL630585,,BAO_0000218,
13745,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,1,,12192,CHEMBL630586,,BAO_0000218,
13746,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,1,,12192,CHEMBL630587,,BAO_0000218,
13747,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,1,,12192,CHEMBL630588,,BAO_0000218,
13748,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,1,,12192,CHEMBL630589,,BAO_0000218,
13749,50594,,,1,,N,,,,Intermediate,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,1,,12192,CHEMBL630590,,BAO_0000218,
13750,22224,,,0,,U,,Feces,,Autocuration,Removal of 238-Plutonium(IV) in feces at 24 h,A,1,,12192,CHEMBL630591,,BAO_0000019,1988.0
13751,22224,,,0,,U,,Feces,,Autocuration,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,1,,12192,CHEMBL630592,,BAO_0000019,1988.0
13752,22224,,,0,,U,,,,Autocuration,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,1,,12192,CHEMBL630593,,BAO_0000019,
13753,22224,,,0,,U,,,,Autocuration,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,1,,12192,CHEMBL630594,,BAO_0000019,
13754,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,1,,12192,CHEMBL630595,,BAO_0000019,1088.0
13755,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,1,,12192,CHEMBL630596,,BAO_0000019,1088.0
13756,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,1,,12192,CHEMBL630597,,BAO_0000019,1088.0
13757,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,1,,12192,CHEMBL630598,,BAO_0000019,1088.0
13758,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,1,,12192,CHEMBL630599,,BAO_0000019,1088.0
13759,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,1,,12192,CHEMBL630600,,BAO_0000019,1088.0
13760,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,1,,12192,CHEMBL630601,,BAO_0000019,1088.0
13761,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,1,,12192,CHEMBL630602,,BAO_0000019,1088.0
13762,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,1,,12192,CHEMBL630603,,BAO_0000019,1088.0
13763,22224,,,0,,U,,Urine,,Autocuration,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,1,,12192,CHEMBL630604,,BAO_0000019,1088.0
13764,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL624869,,BAO_0000218,178.0
13765,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL624870,,BAO_0000218,178.0
13766,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL623189,,BAO_0000218,178.0
13767,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623190,,BAO_0000218,178.0
13768,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623191,,BAO_0000218,178.0
13769,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623192,,BAO_0000218,
13770,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623193,,BAO_0000218,
13771,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL623194,,BAO_0000218,
13772,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623195,,BAO_0000218,
13773,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623196,,BAO_0000218,
13774,50597,,,1,,N,,,,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,1,,11836,CHEMBL623197,,BAO_0000218,
13775,50597,,,1,,N,,,,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623198,,BAO_0000218,
13776,50597,,,1,,N,,,,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,1,,11836,CHEMBL623199,,BAO_0000218,
13777,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623200,,BAO_0000218,2385.0
13778,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623201,,BAO_0000218,2385.0
13779,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623202,,BAO_0000218,2385.0
13780,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623203,,BAO_0000218,2385.0
13781,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623204,,BAO_0000218,2385.0
13782,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,1,,11836,CHEMBL623205,,BAO_0000218,2385.0
13783,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623206,,BAO_0000218,2385.0
13784,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,1,,11836,CHEMBL623207,,BAO_0000218,2385.0
13785,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,1,,11836,CHEMBL623208,,BAO_0000218,2385.0
13786,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623209,,BAO_0000218,2385.0
13787,50597,,,1,,N,,Muscle tissue,,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,1,,11836,CHEMBL623210,,BAO_0000218,2385.0
13788,50597,,,1,,N,,,,Intermediate,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623211,,BAO_0000218,
13789,50597,,,1,,N,,Uterus,,Intermediate,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,1,,11836,CHEMBL623212,,BAO_0000218,995.0
13790,22224,,,0,,U,,,,Autocuration,Tested in vitro for intrinsic activity relative to quinpirole,A,1,,12640,CHEMBL623213,,BAO_0000019,
13791,22224,,,0,,U,,,,Autocuration,"Relative ion enhancement, determined in pulsed ultrafiltration",A,1,,14218,CHEMBL623214,,BAO_0000019,
13792,22224,,,0,,U,,,,Autocuration,% ionization at the pH 7.4 at 37 degree Centigrade,A,1,,11296,CHEMBL623215,,BAO_0000019,
13793,22224,,,0,,U,,,,Autocuration,Percentage ionization was measured,A,1,,10929,CHEMBL623216,,BAO_0000019,
13794,50591,,,1,,N,,,,Intermediate,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,1,,13841,CHEMBL623217,,BAO_0000218,
13795,22224,,,0,,U,,,,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,1,,10431,CHEMBL623218,,BAO_0000019,
13796,22224,,,0,,U,,,,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,1,,10431,CHEMBL623913,,BAO_0000019,
13797,22224,,,0,,U,,,,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,1,,10431,CHEMBL623914,,BAO_0000019,
13798,22229,,,0,,U,,,,Autocuration,Compound was evaluated for the partition coefficient in octanol/water,P,1,,8826,CHEMBL623915,,BAO_0000100,
13799,22229,,,0,,U,,,,Autocuration,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,1,,8826,CHEMBL624080,,BAO_0000100,
13800,22224,,,0,,U,,,,Autocuration,Equilibrium constant measured by the pulse radiolysis at pH 7,A,1,,9884,CHEMBL624081,,BAO_0000019,
13801,50587,,,1,,N,,,,Intermediate,In vitro hydrolytic rate constant determined in human blood,A,1,,9827,CHEMBL624082,,BAO_0000218,
13802,50587,,,1,,N,,,,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,1,,10009,CHEMBL625054,,BAO_0000218,
13803,22224,,,0,,U,,,,Autocuration,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,1,,10009,CHEMBL877485,,BAO_0000019,
13804,50594,,,1,,N,,,,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,1,,10009,CHEMBL625055,,BAO_0000218,
13805,50594,,,1,,N,,,,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,1,,10009,CHEMBL625056,,BAO_0000218,
13806,50587,,,1,,N,,,,Intermediate,In vitro oxidation of compound in presence of human plasma,A,1,,10009,CHEMBL625057,,BAO_0000218,
13807,22224,,,0,,U,,,,Autocuration,In vitro oxidation of compound in presence of hydrogen peroxide,A,1,,10009,CHEMBL625058,,BAO_0000019,
13808,50594,,,1,,N,,,,Intermediate,In vitro oxidation of compound in presence of mouse brain homogenate,A,1,,10009,CHEMBL625059,,BAO_0000218,
13809,50594,,,1,,N,,,,Intermediate,In vitro oxidation of compound in presence of mouse liver homogenate,A,1,,10009,CHEMBL629536,,BAO_0000218,
13810,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,1,,11510,CHEMBL629537,,BAO_0000218,
13811,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,1,,11510,CHEMBL629538,,BAO_0000218,
13812,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,1,,11510,CHEMBL629539,,BAO_0000218,
13813,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,1,,11510,CHEMBL874445,,BAO_0000218,
13814,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,1,,11510,CHEMBL629540,,BAO_0000218,
13815,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,1,,11510,CHEMBL629541,,BAO_0000218,
13816,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,1,,11510,CHEMBL629542,,BAO_0000218,
13817,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,1,,11510,CHEMBL630243,,BAO_0000218,
13818,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,1,,11510,CHEMBL630244,,BAO_0000218,
13819,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,1,,11510,CHEMBL630245,,BAO_0000218,
13820,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,1,,11510,CHEMBL630246,,BAO_0000218,
13821,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,1,,11510,CHEMBL630247,,BAO_0000218,
13822,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,1,,11510,CHEMBL630248,,BAO_0000218,
13823,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood at 240 minutes after dose administration.,A,1,,13100,CHEMBL630249,,BAO_0000218,178.0
13824,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood at 30 minutes after dose administration.,A,1,,13100,CHEMBL630250,,BAO_0000218,178.0
13825,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood at 360 minutes after dose administration.,A,1,,13100,CHEMBL630251,,BAO_0000218,178.0
13826,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood at 3 hr after dose administration.,A,1,,13100,CHEMBL630252,,BAO_0000218,178.0
13827,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood at 60 minutes after dose administration.,A,1,,13100,CHEMBL630408,,BAO_0000218,178.0
13828,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,1,,13100,CHEMBL630409,,BAO_0000218,2037.0
13829,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,1,,13100,CHEMBL874446,,BAO_0000218,2037.0
13830,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,1,,13100,CHEMBL630410,,BAO_0000218,2037.0
13831,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,1,,13100,CHEMBL630411,,BAO_0000218,2037.0
13832,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,1,,13100,CHEMBL630412,,BAO_0000218,2037.0
13833,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,1,,13100,CHEMBL630413,,BAO_0000218,2037.0
13834,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,1,,13100,CHEMBL630414,,BAO_0000218,2037.0
13835,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,1,,13100,CHEMBL630415,,BAO_0000218,2037.0
13836,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 120 minutes after dose administration.,A,1,,13100,CHEMBL630416,,BAO_0000218,
13837,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,1,,13100,CHEMBL630417,,BAO_0000218,
13838,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 15 minutes after dose administration.,A,1,,13100,CHEMBL630418,,BAO_0000218,
13839,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 240 minutes after dose administration.,A,1,,13100,CHEMBL630419,,BAO_0000218,
13840,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 30 minutes after dose administration.,A,1,,13100,CHEMBL630420,,BAO_0000218,
13841,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 360 minutes after dose administration.,A,1,,13100,CHEMBL630421,,BAO_0000218,
13842,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 3 hr after dose administration.,A,1,,13100,CHEMBL630422,,BAO_0000218,
13843,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat cortex at 60 minutes after dose administration.,A,1,,13100,CHEMBL630423,,BAO_0000218,
13844,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 120 minutes after dose administration.,A,1,,13100,CHEMBL630424,,BAO_0000218,948.0
13845,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 15 minutes after dose administration.,A,1,,13100,CHEMBL630425,,BAO_0000218,948.0
13846,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 240 minutes after dose administration.,A,1,,13100,CHEMBL629462,,BAO_0000218,948.0
13847,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 30 minutes after dose administration.,A,1,,13100,CHEMBL630426,,BAO_0000218,948.0
13848,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 360 minutes after dose administration.,A,1,,13100,CHEMBL630427,,BAO_0000218,948.0
13849,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 3 hr after dose administration.,A,1,,13100,CHEMBL625877,,BAO_0000218,948.0
13850,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart at 60 minutes after dose administration.,A,1,,13100,CHEMBL625878,,BAO_0000218,948.0
13851,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,1,,13100,CHEMBL625879,,BAO_0000218,10000000.0
13852,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,1,,13100,CHEMBL625880,,BAO_0000218,10000000.0
13853,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,1,,13100,CHEMBL625881,,BAO_0000218,10000000.0
13854,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,1,,13100,CHEMBL625882,,BAO_0000218,10000000.0
13855,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,1,,13100,CHEMBL625883,,BAO_0000218,10000000.0
13856,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 120 minutes after dose administration.,A,1,,13100,CHEMBL625884,,BAO_0000218,2113.0
13857,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,1,,13100,CHEMBL625885,,BAO_0000218,2113.0
13858,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 15 minutes after dose administration.,A,1,,13100,CHEMBL628649,,BAO_0000218,2113.0
13859,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 240 minutes after dose administration.,A,1,,13100,CHEMBL628650,,BAO_0000218,2113.0
13860,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 30 minutes after dose administration.,A,1,,13100,CHEMBL628651,,BAO_0000218,2113.0
13861,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 360 minutes after dose administration.,A,1,,13100,CHEMBL628652,,BAO_0000218,2113.0
13862,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney at 60 minutes after dose administration.,A,1,,13100,CHEMBL628653,,BAO_0000218,2113.0
13863,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 120 minutes after dose administration.,A,1,,13100,CHEMBL628654,,BAO_0000218,2107.0
13864,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 1440 minutes after dose administration.,A,1,,13100,CHEMBL628655,,BAO_0000218,2107.0
13865,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 15 minutes after dose administration.,A,1,,13100,CHEMBL625238,,BAO_0000218,2107.0
13866,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 240 minutes after dose administration.,A,1,,13100,CHEMBL625239,,BAO_0000218,2107.0
13867,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 30 minutes after dose administration.,A,1,,13100,CHEMBL625240,,BAO_0000218,2107.0
13868,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 360 minutes after dose administration.,A,1,,13100,CHEMBL625241,,BAO_0000218,2107.0
13869,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver at 60 minutes after dose administration.,A,1,,13100,CHEMBL625242,,BAO_0000218,2107.0
13870,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 120 minutes after dose administration.,A,1,,13100,CHEMBL874587,,BAO_0000218,2048.0
13871,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 1440 minutes after dose administration.,A,1,,13100,CHEMBL625405,,BAO_0000218,2048.0
13872,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 15 minutes after dose administration.,A,1,,13100,CHEMBL625406,,BAO_0000218,2048.0
13873,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 240 minutes after dose administration.,A,1,,13100,CHEMBL625407,,BAO_0000218,2048.0
13874,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 30 minutes after dose administration.,A,1,,13100,CHEMBL625408,,BAO_0000218,2048.0
13875,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 360 minutes after dose administration.,A,1,,13100,CHEMBL625409,,BAO_0000218,2048.0
13876,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,1,,12361,CHEMBL625410,,BAO_0000218,1515.0
13877,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,1,,12361,CHEMBL625411,,BAO_0000218,1515.0
13878,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,1,,12361,CHEMBL625412,,BAO_0000218,1515.0
13879,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,1,,12361,CHEMBL625413,,BAO_0000218,1515.0
13880,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,1,,12361,CHEMBL625414,,BAO_0000218,1515.0
13881,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,1,,12361,CHEMBL625415,,BAO_0000218,1515.0
13882,50597,,,1,,N,,Thoracic aorta,,Intermediate,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,1,,12361,CHEMBL625416,,BAO_0000218,1515.0
13883,50597,,,1,,N,,Urine,,Intermediate,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,1,,12712,CHEMBL625417,,BAO_0000218,1088.0
13884,50597,,,1,,N,,Feces,,Intermediate,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,1,,7415,CHEMBL625418,,BAO_0000218,1988.0
13885,50597,,,1,,N,,Urine,,Intermediate,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,1,,7415,CHEMBL625419,,BAO_0000218,1088.0
13886,50597,,,1,,N,,,,Intermediate,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,1,,7415,CHEMBL625420,,BAO_0000218,
13887,50597,,,1,,N,,,,Intermediate,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,1,,7415,CHEMBL626996,,BAO_0000218,
13888,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,1,,7415,CHEMBL626997,,BAO_0000218,1988.0
13889,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,1,,7415,CHEMBL626998,,BAO_0000218,1088.0
13890,50597,,,1,,N,,,,Intermediate,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,1,,7415,CHEMBL626999,,BAO_0000218,
13891,50594,,,1,,N,,,,Intermediate,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,1,,8050,CHEMBL627000,,BAO_0000218,
13892,50594,,,1,,N,,,,Intermediate,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,1,,8050,CHEMBL627001,,BAO_0000218,
13893,50594,,,1,,N,,,,Intermediate,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,1,,8050,CHEMBL627002,,BAO_0000218,
13894,50594,,,1,,N,,,,Intermediate,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,1,,8050,CHEMBL627003,,BAO_0000218,
13895,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,1,,8050,CHEMBL627004,,BAO_0000218,1088.0
13896,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,1,,8050,CHEMBL627005,,BAO_0000218,1088.0
13897,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,1,,8050,CHEMBL874594,,BAO_0000218,1088.0
13898,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,1,,8050,CHEMBL627006,,BAO_0000218,1088.0
13899,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,1,,8050,CHEMBL627007,,BAO_0000218,1088.0
13900,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,1,,8050,CHEMBL627884,,BAO_0000218,1088.0
13901,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,1,,8050,CHEMBL627885,,BAO_0000218,1088.0
13902,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,1,,8050,CHEMBL627886,,BAO_0000218,1088.0
13903,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,1,,8050,CHEMBL627887,,BAO_0000218,1088.0
13904,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,1,,8050,CHEMBL627888,,BAO_0000218,1088.0
13905,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,1,,8050,CHEMBL628057,,BAO_0000218,1088.0
13906,50594,,,1,,N,,Urine,,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,1,,8050,CHEMBL627405,,BAO_0000218,1088.0
13907,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,1,,12582,CHEMBL627406,,BAO_0000218,1088.0
13908,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,1,,12582,CHEMBL627407,,BAO_0000218,1088.0
13909,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,1,,12582,CHEMBL627408,,BAO_0000218,1088.0
13910,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,1,,12582,CHEMBL627409,,BAO_0000218,1088.0
13911,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,1,,12582,CHEMBL875486,,BAO_0000218,1088.0
13912,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL627410,,BAO_0000218,1088.0
13913,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,1,,12582,CHEMBL627411,,BAO_0000218,1088.0
13914,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,1,,12582,CHEMBL627412,,BAO_0000218,1088.0
13915,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,1,,12582,CHEMBL627413,,BAO_0000218,1088.0
13916,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,1,,12582,CHEMBL627414,,BAO_0000218,1088.0
13917,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL627415,,BAO_0000218,1088.0
13918,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,1,,12582,CHEMBL627416,,BAO_0000218,1088.0
13919,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL627417,,BAO_0000218,1088.0
13920,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL627418,,BAO_0000218,1088.0
13921,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL627419,,BAO_0000218,1088.0
13922,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,1,,12582,CHEMBL627320,,BAO_0000218,1088.0
13923,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,1,,12582,CHEMBL627321,,BAO_0000218,1088.0
13924,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627322,,BAO_0000218,2113.0
13925,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627323,,BAO_0000218,2113.0
13926,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL627491,,BAO_0000218,2113.0
13927,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627492,,BAO_0000218,2113.0
13928,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627493,,BAO_0000218,2113.0
13929,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627494,,BAO_0000218,2107.0
13930,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627495,,BAO_0000218,2107.0
13931,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL627496,,BAO_0000218,2107.0
13932,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627497,,BAO_0000218,2107.0
13933,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627498,,BAO_0000218,2107.0
13934,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627499,,BAO_0000218,2048.0
13935,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL627500,,BAO_0000218,2048.0
13936,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL627501,,BAO_0000218,2048.0
13937,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625616,,BAO_0000218,2048.0
13938,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625617,,BAO_0000218,2048.0
13939,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625618,,BAO_0000218,2385.0
13940,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625619,,BAO_0000218,2385.0
13941,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL625620,,BAO_0000218,2385.0
13942,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625621,,BAO_0000218,2385.0
13943,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625622,,BAO_0000218,2385.0
13944,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625788,,BAO_0000218,2106.0
13945,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625789,,BAO_0000218,2106.0
13946,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL625790,,BAO_0000218,2106.0
13947,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL625791,,BAO_0000218,2106.0
13948,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL622334,,BAO_0000218,2106.0
13949,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL622335,,BAO_0000218,2046.0
13950,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL622336,,BAO_0000218,2046.0
13951,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL622337,,BAO_0000218,2046.0
13952,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL622338,,BAO_0000218,2046.0
13953,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL622339,,BAO_0000218,2046.0
13954,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL624153,,BAO_0000218,
13955,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL628430,,BAO_0000218,
13956,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL628431,,BAO_0000218,
13957,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL628432,,BAO_0000218,
13958,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL628433,,BAO_0000218,
13959,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL628434,,BAO_0000218,2106.0
13960,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL626789,,BAO_0000218,2106.0
13961,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,1,,12017,CHEMBL626790,,BAO_0000218,2106.0
13962,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL626791,,BAO_0000218,2106.0
13963,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL626792,,BAO_0000218,2106.0
13964,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL626793,,BAO_0000218,2106.0
13965,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,1,,11510,CHEMBL627436,,BAO_0000218,
13966,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,1,,11510,CHEMBL627437,,BAO_0000218,
13967,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,1,,11510,CHEMBL627438,,BAO_0000218,
13968,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,1,,11510,CHEMBL627439,,BAO_0000218,
13969,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,1,,11510,CHEMBL627440,,BAO_0000218,
13970,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,1,,11510,CHEMBL627602,,BAO_0000218,
13971,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,1,,11510,CHEMBL627603,,BAO_0000218,
13972,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,1,,11510,CHEMBL627604,,BAO_0000218,
13973,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,1,,11510,CHEMBL627605,,BAO_0000218,
13974,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,1,,11510,CHEMBL627606,,BAO_0000218,
13975,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,1,,11510,CHEMBL627607,,BAO_0000218,
13976,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,1,,11510,CHEMBL627608,,BAO_0000218,
13977,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,1,,11510,CHEMBL627609,,BAO_0000218,
13978,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,1,,11510,CHEMBL627610,,BAO_0000218,
13979,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,1,,11510,CHEMBL627611,,BAO_0000218,
13980,50597,,,1,,N,,,,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,1,,11510,CHEMBL627612,,BAO_0000218,
13981,22229,,,0,,U,,,,Autocuration,Octanol:water partition coefficient is evaluated,P,1,,8362,CHEMBL627613,,BAO_0000100,
13982,22224,,,0,,U,,,,Autocuration,Partition coefficient in 1-octanol/water system,P,1,,8257,CHEMBL627614,,BAO_0000100,
13983,22224,,,0,,U,,,,Autocuration,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,1,,8257,CHEMBL627615,,BAO_0000100,
13984,22224,,,0,,U,,,,Autocuration,Partition coefficient in octanol/water system was determined,P,1,,9468,CHEMBL627616,,BAO_0000100,
13985,22224,,,0,,U,,,,Autocuration,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,1,,9468,CHEMBL627617,,BAO_0000100,
13986,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,1,,10568,CHEMBL627618,,BAO_0000019,
13987,22224,,,0,,U,,,,Autocuration,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,1,,10568,CHEMBL627619,,BAO_0000019,
13988,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant of the compound,A,1,,15359,CHEMBL627620,,BAO_0000019,
13989,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant with 1-min time point,A,1,,15359,CHEMBL627621,,BAO_0000019,
13990,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant without 1-min time point,A,1,,15359,CHEMBL627622,,BAO_0000019,
13991,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,1,,10431,CHEMBL627623,,BAO_0000019,
13992,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,1,,10431,CHEMBL627624,,BAO_0000019,
13993,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,1,,10431,CHEMBL627625,,BAO_0000019,
13994,22224,,,0,,U,,,,Autocuration,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,1,,15704,CHEMBL628523,,BAO_0000019,
13995,22224,,,0,,U,,,,Autocuration,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,1,,15287,CHEMBL628524,,BAO_0000019,
13996,22224,,,0,,U,,,,Autocuration,The efflux rate constant of the compound,A,1,,7516,CHEMBL628525,,BAO_0000019,
13997,22224,,,0,,U,,,,Autocuration,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,1,,12973,CHEMBL625732,,BAO_0000019,
13998,22224,,,0,,U,,,,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,1,,12973,CHEMBL625733,,BAO_0000019,
13999,22224,,,0,,U,,,,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,1,,12973,CHEMBL625734,,BAO_0000019,
14000,22224,,,0,,U,,,,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,1,,12973,CHEMBL625913,,BAO_0000019,
14001,22224,,,0,,U,,,,Autocuration,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,1,,8696,CHEMBL625914,,BAO_0000019,
14002,22224,,,0,,U,,,,Autocuration,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,1,,15052,CHEMBL625915,,BAO_0000019,
14003,22224,,,0,,U,,,,Autocuration,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,1,,15052,CHEMBL625916,,BAO_0000019,
14004,22224,,,0,,U,,,,Autocuration,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,1,,10503,CHEMBL625917,,BAO_0000019,
14005,22224,,,0,,U,,,,Autocuration,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625918,,BAO_0000019,
14006,22224,,,0,,U,,,,Autocuration,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625919,,BAO_0000019,
14007,22224,,,0,,U,,,,Autocuration,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625920,,BAO_0000019,
14008,22224,,,0,,U,,,,Autocuration,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL874453,,BAO_0000019,
14009,22224,,,0,,U,,,,Autocuration,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625921,,BAO_0000019,
14010,22224,,,0,,U,,,,Autocuration,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,1,,10503,CHEMBL625922,,BAO_0000019,
14011,22224,,,0,,U,,,,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625923,,BAO_0000019,
14012,22224,,,0,,U,,,,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625924,,BAO_0000019,
14013,22224,,,0,,U,,,,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625925,,BAO_0000019,
14014,22224,,,0,,U,,,,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL625926,,BAO_0000019,
14015,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung at 60 minutes after dose administration.,A,1,,13100,CHEMBL627704,,BAO_0000218,2048.0
14016,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,1,,13100,CHEMBL627705,,BAO_0000218,
14017,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,1,,13100,CHEMBL627706,,BAO_0000218,
14018,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,1,,13100,CHEMBL627707,,BAO_0000218,
14019,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,1,,13100,CHEMBL627708,,BAO_0000218,
14020,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,1,,13100,CHEMBL628361,,BAO_0000218,
14021,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,1,,13100,CHEMBL628362,,BAO_0000218,
14022,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 120 minutes after dose administration.,A,1,,13100,CHEMBL628363,,BAO_0000218,2435.0
14023,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,1,,13100,CHEMBL628364,,BAO_0000218,2435.0
14024,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 15 minutes after dose administration.,A,1,,13100,CHEMBL628365,,BAO_0000218,2435.0
14025,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 240 minutes after dose administration.,A,1,,13100,CHEMBL874454,,BAO_0000218,2435.0
14026,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 30 minutes after dose administration.,A,1,,13100,CHEMBL628531,,BAO_0000218,2435.0
14027,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 360 minutes after dose administration.,A,1,,13100,CHEMBL628532,,BAO_0000218,2435.0
14028,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 3 hr after dose administration.,A,1,,13100,CHEMBL628533,,BAO_0000218,2435.0
14029,50597,,In vivo,1,,N,,Striatum,,Intermediate,Biodistribution in rat striatum at 60 minutes after dose administration.,A,1,,13100,CHEMBL628534,,BAO_0000218,2435.0
14030,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,1,,13100,CHEMBL628535,,BAO_0000218,2046.0
14031,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,1,,13100,CHEMBL628536,,BAO_0000218,2046.0
14032,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,1,,13100,CHEMBL628537,,BAO_0000218,2046.0
14033,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,1,,13100,CHEMBL628538,,BAO_0000218,2046.0
14034,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,1,,13100,CHEMBL628539,,BAO_0000218,2046.0
14035,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,1,,13100,CHEMBL630297,,BAO_0000218,2046.0
14036,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,1,,13100,CHEMBL630298,,BAO_0000218,2046.0
14037,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,1,,13100,CHEMBL630299,,BAO_0000218,955.0
14038,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,1,,13100,CHEMBL628094,,BAO_0000218,955.0
14039,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,1,,13100,CHEMBL628095,,BAO_0000218,955.0
14040,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,1,,13100,CHEMBL874648,,BAO_0000218,955.0
14041,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,1,,13100,CHEMBL628096,,BAO_0000218,955.0
14042,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,1,,13100,CHEMBL628097,,BAO_0000218,955.0
14043,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,1,,13100,CHEMBL628098,,BAO_0000218,955.0
14044,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,1,,13331,CHEMBL628099,,BAO_0000019,
14045,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,1,,13331,CHEMBL628100,,BAO_0000019,
14046,22224,,,0,,U,,,,Autocuration,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,1,,13331,CHEMBL628101,,BAO_0000019,
14047,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,1,,13331,CHEMBL628102,,BAO_0000019,
14048,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,1,,13331,CHEMBL628103,,BAO_0000019,
14049,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,1,,13331,CHEMBL628104,,BAO_0000019,
14050,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,1,,13331,CHEMBL628105,,BAO_0000019,
14051,22224,,,0,,U,,,,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,1,,13331,CHEMBL628106,,BAO_0000019,
14052,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,1,,10086,CHEMBL628107,,BAO_0000218,1088.0
14053,22224,,,0,,U,,Urine,,Autocuration,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,1,,10086,CHEMBL628108,,BAO_0000218,1088.0
14054,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,1,,10086,CHEMBL628109,,BAO_0000218,1088.0
14055,22224,,,0,,U,,Urine,,Autocuration,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,1,,10086,CHEMBL625299,,BAO_0000218,1088.0
14056,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,1,,10086,CHEMBL625300,,BAO_0000218,1088.0
14057,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,1,,10086,CHEMBL625301,,BAO_0000218,1088.0
14058,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,1,,10086,CHEMBL625302,,BAO_0000218,1088.0
14059,50597,,,1,,N,,Urine,,Intermediate,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,1,,10086,CHEMBL874649,,BAO_0000218,1088.0
14060,50597,,,1,,N,,,,Intermediate,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,1,,13248,CHEMBL625303,,BAO_0000218,
14061,50597,,,1,,N,,,,Intermediate,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,1,,13248,CHEMBL625463,,BAO_0000218,
14062,50587,,,1,,N,,Liver,,Intermediate,In vitro metabolism in human liver microsomes,A,1,,14527,CHEMBL625464,,BAO_0000218,2107.0
14063,50587,,,1,,N,,,,Intermediate,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,1,,3008,CHEMBL625465,,BAO_0000218,
14064,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,1,,12582,CHEMBL625466,,BAO_0000218,1088.0
14065,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,1,,12582,CHEMBL625467,,BAO_0000218,1088.0
14066,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,1,,12582,CHEMBL625468,,BAO_0000218,1088.0
14067,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,1,,12582,CHEMBL625469,,BAO_0000218,1088.0
14068,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,1,,12582,CHEMBL625470,,BAO_0000218,1088.0
14069,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,1,,12582,CHEMBL632418,,BAO_0000218,1088.0
14070,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL627250,,BAO_0000218,1088.0
14071,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,1,,12582,CHEMBL627251,,BAO_0000218,1088.0
14072,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,1,,12582,CHEMBL627252,,BAO_0000218,1088.0
14073,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,1,,12582,CHEMBL627253,,BAO_0000218,1088.0
14074,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,1,,12582,CHEMBL627254,,BAO_0000218,1088.0
14075,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,1,,12582,CHEMBL875471,,BAO_0000218,1088.0
14076,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,1,,12582,CHEMBL627255,,BAO_0000218,1088.0
14077,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,1,,12582,CHEMBL627256,,BAO_0000218,1088.0
14078,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,1,,12582,CHEMBL627257,,BAO_0000218,1088.0
14079,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,1,,12582,CHEMBL627258,,BAO_0000218,1088.0
14080,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,1,,12582,CHEMBL627259,,BAO_0000218,1088.0
14081,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,1,,12582,CHEMBL627260,,BAO_0000218,1088.0
14082,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,1,,12582,CHEMBL623256,,BAO_0000218,1088.0
14083,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,1,,12582,CHEMBL874413,,BAO_0000218,1088.0
14084,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,1,,12582,CHEMBL623257,,BAO_0000218,1088.0
14085,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,1,,12582,CHEMBL623258,,BAO_0000218,1088.0
14086,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,1,,12582,CHEMBL623259,,BAO_0000218,1088.0
14087,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,1,,12582,CHEMBL623260,,BAO_0000218,1088.0
14088,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,1,,12582,CHEMBL623261,,BAO_0000218,1088.0
14089,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,1,,12582,CHEMBL623262,,BAO_0000218,1088.0
14090,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,1,,12582,CHEMBL623263,,BAO_0000218,1088.0
14091,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,1,,12582,CHEMBL623264,,BAO_0000218,1088.0
14092,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,1,,12582,CHEMBL623265,,BAO_0000218,1088.0
14093,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,1,,12582,CHEMBL623266,,BAO_0000218,1088.0
14094,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,1,,12582,CHEMBL623267,,BAO_0000218,1088.0
14095,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,1,,12582,CHEMBL623268,,BAO_0000218,1088.0
14096,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL623269,,BAO_0000218,1088.0
14097,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL623270,,BAO_0000218,1088.0
14098,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,1,,12582,CHEMBL623271,,BAO_0000218,1088.0
14099,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,1,,12582,CHEMBL623272,,BAO_0000218,1088.0
14100,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,1,,12582,CHEMBL623273,,BAO_0000218,1088.0
14101,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,1,,12582,CHEMBL623274,,BAO_0000218,1088.0
14102,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,1,,12582,CHEMBL874414,,BAO_0000218,1088.0
14103,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,1,,12582,CHEMBL623275,,BAO_0000218,1088.0
14104,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,1,,12582,CHEMBL629150,,BAO_0000218,1088.0
14105,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL623276,,BAO_0000218,1088.0
14106,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,1,,12582,CHEMBL623277,,BAO_0000218,1088.0
14107,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,1,,12582,CHEMBL623112,,BAO_0000218,1088.0
14108,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,1,,12582,CHEMBL623113,,BAO_0000218,1088.0
14109,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,1,,12582,CHEMBL623800,,BAO_0000218,1088.0
14110,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,1,,12582,CHEMBL623801,,BAO_0000218,1088.0
14111,50597,,In vivo,1,,N,,Spleen,,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,1,,12017,CHEMBL623802,,BAO_0000218,2106.0
14112,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623803,,BAO_0000218,995.0
14113,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623970,,BAO_0000218,995.0
14114,50597,,In vivo,1,,N,,Uterus,,Intermediate,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL623971,,BAO_0000218,995.0
14115,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623972,,BAO_0000218,178.0
14116,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623973,,BAO_0000218,178.0
14117,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623974,,BAO_0000218,178.0
14118,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623975,,BAO_0000218,178.0
14119,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623976,,BAO_0000218,955.0
14120,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623977,,BAO_0000218,955.0
14121,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623978,,BAO_0000218,955.0
14122,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623979,,BAO_0000218,955.0
14123,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623980,,BAO_0000218,
14124,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,1,,14045,CHEMBL623981,,BAO_0000218,
14125,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,1,,14045,CHEMBL626278,,BAO_0000218,
14126,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,1,,14045,CHEMBL626279,,BAO_0000218,
14127,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in mice bladder plus excreted urine was determined,A,1,,14045,CHEMBL626280,,BAO_0000218,
14128,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,1,,14045,CHEMBL626281,,BAO_0000218,
14129,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,1,,14045,CHEMBL626282,,BAO_0000218,
14130,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,1,,14045,CHEMBL626283,,BAO_0000218,
14131,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,1,,14045,CHEMBL626284,,BAO_0000218,
14132,50594,,,1,,N,,Brain,,Intermediate,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,1,,14045,CHEMBL626285,,BAO_0000218,955.0
14133,50594,,,1,,N,,Brain,,Intermediate,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,1,,14045,CHEMBL626286,,BAO_0000218,955.0
14134,50594,,,1,,N,,Brain,,Intermediate,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,1,,14045,CHEMBL626287,,BAO_0000218,955.0
14135,50594,,,1,,N,,Brain,,Intermediate,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,1,,14045,CHEMBL626288,,BAO_0000218,955.0
14136,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,1,,14045,CHEMBL626289,,BAO_0000218,
14137,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,1,,14045,CHEMBL626290,,BAO_0000218,
14138,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,1,,14045,CHEMBL626291,,BAO_0000218,
14139,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,1,,14045,CHEMBL839888,,BAO_0000218,
14140,50594,,,1,,N,,Intestine,,Intermediate,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,1,,14045,CHEMBL626292,,BAO_0000218,160.0
14141,50594,,,1,,N,,Intestine,,Intermediate,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,1,,14045,CHEMBL626293,,BAO_0000218,160.0
14142,50594,,,1,,N,,Intestine,,Intermediate,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,1,,14045,CHEMBL626294,,BAO_0000218,160.0
14143,50594,,,1,,N,,Intestine,,Intermediate,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,1,,14045,CHEMBL626295,,BAO_0000218,160.0
14144,50594,,,1,,N,,Liver,,Intermediate,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,1,,14045,CHEMBL627659,,BAO_0000218,2107.0
14145,50594,,,1,,N,,Liver,,Intermediate,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,1,,14045,CHEMBL627660,,BAO_0000218,2107.0
14146,50594,,,1,,N,,Liver,,Intermediate,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,1,,14045,CHEMBL627661,,BAO_0000218,2107.0
14147,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in mice liver at 60 minutes of post injection,A,1,,14045,CHEMBL627662,,BAO_0000218,2107.0
14148,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in mice lungs at 10 min of post injection,A,1,,14045,CHEMBL627663,,BAO_0000218,2048.0
14149,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,1,,14045,CHEMBL627664,,BAO_0000218,
14150,50594,,,1,,N,,,,Intermediate,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,1,,14045,CHEMBL627665,,BAO_0000218,
14151,50594,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in mice lungs at 60 min of post injection,A,1,,14045,CHEMBL627666,,BAO_0000218,2048.0
14152,50594,,,1,,N,,Spleen,,Intermediate,Percentage biodistribution in mouse spleen,A,1,,14045,CHEMBL627667,,BAO_0000218,2106.0
14153,50594,,,1,,N,,Stomach,,Intermediate,Percentage biodistribution in mouse stomach,A,1,,14045,CHEMBL627668,,BAO_0000218,945.0
14154,50594,,,1,,N,,Urine,,Intermediate,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,1,,11745,CHEMBL627669,,BAO_0000218,1088.0
14155,22224,,In vivo,0,,U,,Urinary bladder,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,1,,13257,CHEMBL627670,,BAO_0000218,1255.0
14156,22224,,In vivo,0,,U,,Blood,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,1,,13257,CHEMBL627671,,BAO_0000218,178.0
14157,22224,,In vivo,0,,U,,Bone element,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,1,,13257,CHEMBL627672,,BAO_0000218,1474.0
14158,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,1,,13257,CHEMBL627673,,BAO_0000218,
14159,22224,,In vivo,0,,U,,Kidney,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,1,,13257,CHEMBL627674,,BAO_0000218,2113.0
14160,22224,,In vivo,0,,U,,Liver,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,1,,13257,CHEMBL627675,,BAO_0000218,2107.0
14161,22224,,In vivo,0,,U,,Lung,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,1,,13257,CHEMBL627676,,BAO_0000218,2048.0
14162,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,1,,13257,CHEMBL627677,,BAO_0000218,2385.0
14163,22224,,,0,,U,,,,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL627678,,BAO_0000019,
14164,50597,,,1,,N,,Serum,,Intermediate,Affinity for protein binding expressed as association constant in fresh rat serum,A,1,,7095,CHEMBL627679,,BAO_0000218,1977.0
14165,22224,,,0,,U,,,,Autocuration,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,1,,12185,CHEMBL627680,,BAO_0000019,
14166,22224,,,0,,U,,,,Autocuration,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,1,,12185,CHEMBL627681,,BAO_0000019,
14167,22224,,,0,,U,,,,Autocuration,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,1,,12185,CHEMBL627682,,BAO_0000019,
14168,22224,,,0,,U,,,,Autocuration,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,1,,12185,CHEMBL627683,,BAO_0000019,
14169,22224,,,0,,U,,,,Autocuration,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,1,,12686,CHEMBL627684,,BAO_0000019,
14170,22224,,,0,,U,,,,Autocuration,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,1,,12686,CHEMBL874441,,BAO_0000019,
14171,22224,,,0,,U,,,,Autocuration,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,1,,12686,CHEMBL627685,,BAO_0000019,
14172,22224,,,0,,U,,,,Autocuration,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,1,,12686,CHEMBL627686,,BAO_0000019,
14173,22224,,,0,,U,,,,Autocuration,Apparent rate constant Koff for inactivation of dTMP synthase.,A,1,,8057,CHEMBL627687,,BAO_0000019,
14174,22224,,,0,,U,,,,Autocuration,The irreversible inhibitor activity by second order rate equation.,A,1,,15778,CHEMBL627688,,BAO_0000019,
14175,50597,,,1,,N,,,,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,1,,12375,CHEMBL628038,,BAO_0000218,
14176,50597,,,1,,N,,,,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,1,,12375,CHEMBL628039,,BAO_0000218,
14177,50597,,,1,,N,,,,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,1,,12375,CHEMBL628040,,BAO_0000218,
14178,22224,,,0,,U,,,,Autocuration,Dissociation rate calculated from the first-order equation using t1/2 value,A,1,,13588,CHEMBL628041,,BAO_0000019,
14179,22224,,,0,,U,,,,Autocuration,The compound was tested for Binding constant against DNA,A,1,,15039,CHEMBL630226,,BAO_0000019,
14180,22224,,,0,,U,,,,Autocuration,First order rate constant for cyclization of the compound,A,1,,9500,CHEMBL628042,,BAO_0000019,
14181,22224,,,0,,U,,,,Autocuration,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,1,,10014,CHEMBL625232,,BAO_0000019,
14182,22224,,,0,,U,,,,Autocuration,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,1,,10014,CHEMBL625233,,BAO_0000019,
14183,22224,,,0,,U,,,,Autocuration,Hydrolysis rate constant was determined,A,1,,568,CHEMBL625979,,BAO_0000019,
14184,22224,,,0,,U,,,,Autocuration,Observed first order rate constant,A,1,,10026,CHEMBL625980,,BAO_0000019,
14185,22224,,,0,,U,,,,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,1,,10281,CHEMBL625981,,BAO_0000019,
14186,22224,,,0,,U,,,,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,1,,10281,CHEMBL625982,,BAO_0000019,
14187,22224,,,0,,U,,,,Autocuration,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,1,,9680,CHEMBL625983,,BAO_0000019,
14188,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625984,,BAO_0000019,
14189,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625985,,BAO_0000019,
14190,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625986,,BAO_0000019,
14191,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625987,,BAO_0000019,
14192,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625988,,BAO_0000019,
14193,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625989,,BAO_0000019,
14194,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625990,,BAO_0000019,
14195,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625991,,BAO_0000019,
14196,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625992,,BAO_0000019,
14197,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL625993,,BAO_0000019,
14198,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL631973,,BAO_0000019,
14199,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632143,,BAO_0000019,
14200,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632144,,BAO_0000019,
14201,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632145,,BAO_0000019,
14202,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632146,,BAO_0000019,
14203,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632147,,BAO_0000019,
14204,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632148,,BAO_0000019,
14205,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632149,,BAO_0000019,
14206,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632150,,BAO_0000019,
14207,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL632151,,BAO_0000019,
14208,50587,,,1,,N,,,,Intermediate,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,1,,3008,CHEMBL632152,,BAO_0000218,
14209,50587,,,1,,N,,,,Intermediate,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,1,,4509,CHEMBL632153,,BAO_0000218,
14210,50587,,,1,,N,,,,Intermediate,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,1,,4509,CHEMBL632154,,BAO_0000218,
14211,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL632155,,BAO_0000218,
14212,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,1,,8613,CHEMBL632156,,BAO_0000218,
14213,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL632157,,BAO_0000218,
14214,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL632158,,BAO_0000218,
14215,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,1,,8613,CHEMBL632159,,BAO_0000218,
14216,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL626305,,BAO_0000218,
14217,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,1,,8613,CHEMBL626306,,BAO_0000218,
14218,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL626307,,BAO_0000218,
14219,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL626308,,BAO_0000218,
14220,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL626479,,BAO_0000218,
14221,50602,,,1,,N,,,,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,1,,8613,CHEMBL626480,,BAO_0000218,
14222,22229,,,0,,U,,,,Autocuration,Calculated partition coefficient (clogP) (MlogP),P,1,,6021,CHEMBL626481,,BAO_0000100,
14223,22224,,,0,,U,,,,Autocuration,Equipotent potent ratio relative to carbachol (nicotinic activity),A,1,,9348,CHEMBL626482,,BAO_0000019,
14224,50588,,,1,,N,,,,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,1,,15592,CHEMBL626483,,BAO_0000218,
14225,50588,,,1,,N,,,,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,1,,15592,CHEMBL626484,,BAO_0000218,
14226,22229,,,0,,U,,,,Autocuration,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,1,,15592,CHEMBL626485,,BAO_0000100,
14227,22229,,,0,,U,,,,Autocuration,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,1,,15592,CHEMBL626486,,BAO_0000100,
14228,22229,,,0,,U,,,,Autocuration,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,1,,15592,CHEMBL626487,,BAO_0000100,
14229,50588,,In vivo,1,,N,,Plasma,,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,1,,15592,CHEMBL626488,,BAO_0000218,1969.0
14230,50597,,,1,,N,,Serum,,Intermediate,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,1,,7095,CHEMBL626489,,BAO_0000218,1977.0
14231,22224,,,0,,U,,,,Autocuration,Area under the MAP curve measured over 5 min; ND means Not determined,A,1,,16618,CHEMBL626490,,BAO_0000019,
14232,22224,,,0,,U,,,,Autocuration,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,1,,16835,CHEMBL626491,,BAO_0000100,
14233,22229,,,0,,U,,,,Autocuration,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,1,,15284,CHEMBL626492,,BAO_0000100,
14234,22224,,,0,,U,,,,Autocuration,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,1,,15750,CHEMBL626493,,BAO_0000019,
14235,50597,,In vivo,1,,N,,,,Intermediate,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,1,,16618,CHEMBL626494,,BAO_0000218,
14236,22224,,In vivo,0,,U,,,,Autocuration,Half life after oral tested,A,1,,16618,CHEMBL626495,,BAO_0000218,
14237,50597,,,1,,N,,Plasma,,Intermediate,Half life was determined in plasma of rat; NT indicates not tested,A,1,,15812,CHEMBL626496,,BAO_0000218,1969.0
14238,50597,,In vivo,1,,N,,,,Intermediate,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,1,,16618,CHEMBL626497,,BAO_0000218,
14239,22224,,In vivo,0,,U,,,,Autocuration,Oral bioavailability after oral tested,A,1,,16618,CHEMBL626498,,BAO_0000218,
14240,50597,,,1,,N,,,,Intermediate,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,1,,13098,CHEMBL626499,,BAO_0000218,
14241,50597,,,1,,N,,,,Intermediate,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,1,,13098,CHEMBL626500,,BAO_0000218,
14242,50597,,,1,,N,,Plasma,,Intermediate,half life was determined in plasma of rat; NT indicates not tested,A,1,,15812,CHEMBL626501,,BAO_0000218,1969.0
14243,50597,,,1,,N,,Plasma,,Intermediate,half life was determined in plasma of rat; NT means not tested,A,1,,15812,CHEMBL626502,,BAO_0000218,1969.0
14244,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,1,,11510,CHEMBL626503,,BAO_0000218,
14245,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,1,,11510,CHEMBL626504,,BAO_0000218,
14246,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,1,,11510,CHEMBL626505,,BAO_0000218,
14247,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,1,,11510,CHEMBL626506,,BAO_0000218,
14248,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,1,,11510,CHEMBL626507,,BAO_0000218,
14249,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,1,,11510,CHEMBL626508,,BAO_0000218,
14250,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,1,,11510,CHEMBL626509,,BAO_0000218,
14251,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,1,,11510,CHEMBL875480,,BAO_0000218,
14252,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,1,,11510,CHEMBL626510,,BAO_0000218,
14253,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,1,,11510,CHEMBL626511,,BAO_0000218,
14254,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,1,,11510,CHEMBL626512,,BAO_0000218,
14255,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,1,,11510,CHEMBL628208,,BAO_0000218,
14256,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,1,,11510,CHEMBL628209,,BAO_0000218,
14257,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,1,,11510,CHEMBL628210,,BAO_0000218,
14258,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,1,,11510,CHEMBL628211,,BAO_0000218,
14259,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,1,,11510,CHEMBL628212,,BAO_0000218,
14260,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,1,,11510,CHEMBL628213,,BAO_0000218,
14261,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,1,,12582,CHEMBL628214,,BAO_0000218,1088.0
14262,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,1,,12582,CHEMBL628215,,BAO_0000218,1088.0
14263,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,1,,12582,CHEMBL628216,,BAO_0000218,1088.0
14264,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,1,,12582,CHEMBL626595,,BAO_0000218,1088.0
14265,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,1,,12582,CHEMBL626596,,BAO_0000218,1088.0
14266,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,1,,12582,CHEMBL626597,,BAO_0000218,1088.0
14267,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,1,,12582,CHEMBL626598,,BAO_0000218,1088.0
14268,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,1,,12582,CHEMBL622242,,BAO_0000218,1088.0
14269,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,1,,12582,CHEMBL622243,,BAO_0000218,1088.0
14270,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,1,,12582,CHEMBL622244,,BAO_0000218,1088.0
14271,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,1,,12582,CHEMBL622245,,BAO_0000218,1088.0
14272,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,1,,12582,CHEMBL622246,,BAO_0000218,1088.0
14273,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,1,,12582,CHEMBL622247,,BAO_0000218,1088.0
14274,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,1,,12582,CHEMBL622248,,BAO_0000218,1088.0
14275,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,1,,12582,CHEMBL877483,,BAO_0000218,1088.0
14276,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,1,,12582,CHEMBL622249,,BAO_0000218,1088.0
14277,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,1,,12582,CHEMBL622250,,BAO_0000218,1088.0
14278,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,1,,12582,CHEMBL622251,,BAO_0000218,1088.0
14279,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,1,,12582,CHEMBL622252,,BAO_0000218,1088.0
14280,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,1,,12582,CHEMBL622253,,BAO_0000218,1088.0
14281,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,1,,12582,CHEMBL622254,,BAO_0000218,1088.0
14282,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL622255,,BAO_0000218,1088.0
14283,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,1,,12582,CHEMBL622256,,BAO_0000218,1088.0
14284,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,1,,12582,CHEMBL622257,,BAO_0000218,1088.0
14285,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,1,,12582,CHEMBL622258,,BAO_0000218,1088.0
14286,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,1,,12582,CHEMBL622259,,BAO_0000218,1088.0
14287,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL622927,,BAO_0000218,1088.0
14288,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL622928,,BAO_0000218,1088.0
14289,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL622929,,BAO_0000218,1088.0
14290,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,1,,12582,CHEMBL623182,,BAO_0000218,1088.0
14291,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,1,,12582,CHEMBL623183,,BAO_0000218,1088.0
14292,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,1,,12582,CHEMBL623184,,BAO_0000218,1088.0
14293,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,1,,12582,CHEMBL623185,,BAO_0000218,1088.0
14294,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,1,,12582,CHEMBL877484,,BAO_0000218,1088.0
14295,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL627274,,BAO_0000218,1088.0
14296,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,1,,12582,CHEMBL623186,,BAO_0000218,1088.0
14297,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,1,,12582,CHEMBL623187,,BAO_0000218,1088.0
14298,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,1,,12582,CHEMBL623188,,BAO_0000218,1088.0
14299,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,1,,12582,CHEMBL628055,,BAO_0000218,1088.0
14300,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,1,,12582,CHEMBL628056,,BAO_0000218,1088.0
14301,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,1,,12582,CHEMBL628200,,BAO_0000218,1088.0
14302,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,1,,12582,CHEMBL628201,,BAO_0000218,1088.0
14303,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,1,,12582,CHEMBL628202,,BAO_0000218,1088.0
14304,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,1,,12582,CHEMBL628203,,BAO_0000218,1088.0
14305,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,1,,12582,CHEMBL628204,,BAO_0000218,1088.0
14306,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,1,,12582,CHEMBL628205,,BAO_0000218,1088.0
14307,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,1,,12582,CHEMBL628206,,BAO_0000218,1088.0
14308,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,1,,13257,CHEMBL628207,,BAO_0000218,2367.0
14309,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,1,,13257,CHEMBL627220,,BAO_0000218,2367.0
14310,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,1,,13257,CHEMBL627221,,BAO_0000218,2385.0
14311,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,1,,13257,CHEMBL627222,,BAO_0000218,2367.0
14312,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,1,,13257,CHEMBL627223,,BAO_0000218,
14313,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,1,,13257,CHEMBL632062,,BAO_0000218,2385.0
14314,22224,,In vivo,0,,U,,Spleen,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,1,,13257,CHEMBL632063,,BAO_0000218,2106.0
14315,22224,,In vivo,0,,U,,Urinary bladder,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,1,,13257,CHEMBL632064,,BAO_0000218,1255.0
14316,22224,,In vivo,0,,U,,Blood,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,1,,13257,CHEMBL632065,,BAO_0000218,178.0
14317,22224,,In vivo,0,,U,,Bone element,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,1,,13257,CHEMBL632066,,BAO_0000218,1474.0
14318,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,1,,13257,CHEMBL632067,,BAO_0000218,
14319,22224,,In vivo,0,,U,,Kidney,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,1,,13257,CHEMBL629188,,BAO_0000218,2113.0
14320,22224,,In vivo,0,,U,,Liver,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,1,,13257,CHEMBL629189,,BAO_0000218,2107.0
14321,22224,,In vivo,0,,U,,Lung,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,1,,13257,CHEMBL629190,,BAO_0000218,2048.0
14322,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,1,,13257,CHEMBL629191,,BAO_0000218,2385.0
14323,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,1,,13257,CHEMBL629192,,BAO_0000218,2367.0
14324,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,1,,13257,CHEMBL629193,,BAO_0000218,2385.0
14325,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,1,,13257,CHEMBL629194,,BAO_0000218,2367.0
14326,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,1,,13257,CHEMBL629195,,BAO_0000218,
14327,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,1,,13257,CHEMBL629373,,BAO_0000218,2385.0
14328,22224,,In vivo,0,,U,,Spleen,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,1,,13257,CHEMBL629374,,BAO_0000218,2106.0
14329,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,1,,13257,CHEMBL629375,,BAO_0000218,2367.0
14330,22224,,In vivo,0,,U,,Urinary bladder,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,1,,13257,CHEMBL629376,,BAO_0000218,1255.0
14331,22224,,In vivo,0,,U,,Blood,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,1,,13257,CHEMBL629377,,BAO_0000218,178.0
14332,22224,,In vivo,0,,U,,Bone element,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,1,,13257,CHEMBL629378,,BAO_0000218,1474.0
14333,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,1,,13257,CHEMBL629379,,BAO_0000218,
14334,22224,,In vivo,0,,U,,Kidney,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,1,,13257,CHEMBL629151,,BAO_0000218,2113.0
14335,22224,,In vivo,0,,U,,Liver,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,1,,13257,CHEMBL629152,,BAO_0000218,2107.0
14336,22224,,In vivo,0,,U,,Lung,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,1,,13257,CHEMBL629153,,BAO_0000218,2048.0
14337,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,1,,13257,CHEMBL629154,,BAO_0000218,2385.0
14338,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,1,,13257,CHEMBL629155,,BAO_0000218,2367.0
14339,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,1,,13257,CHEMBL629156,,BAO_0000218,2367.0
14340,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,1,,13257,CHEMBL629157,,BAO_0000218,2385.0
14341,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,1,,13257,CHEMBL629158,,BAO_0000218,2367.0
14342,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,1,,13257,CHEMBL629159,,BAO_0000218,
14343,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,1,,13257,CHEMBL629160,,BAO_0000218,2385.0
14344,22224,,In vivo,0,,U,,Spleen,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,1,,13257,CHEMBL629161,,BAO_0000218,2106.0
14345,22224,,In vivo,0,,U,,Urinary bladder,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,1,,13257,CHEMBL629162,,BAO_0000218,1255.0
14346,22224,,In vivo,0,,U,,Blood,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,1,,13257,CHEMBL629163,,BAO_0000218,178.0
14347,22224,,In vivo,0,,U,,Bone element,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,1,,13257,CHEMBL629164,,BAO_0000218,1474.0
14348,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,1,,13257,CHEMBL629165,,BAO_0000218,
14349,22224,,In vivo,0,,U,,Liver,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,1,,13257,CHEMBL629166,,BAO_0000218,2107.0
14350,22224,,In vivo,0,,U,,Lung,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,1,,13257,CHEMBL629167,,BAO_0000218,2048.0
14351,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,1,,13257,CHEMBL629168,,BAO_0000218,2385.0
14352,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,1,,2193,CHEMBL629169,,BAO_0000019,
14353,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,1,,2193,CHEMBL629170,,BAO_0000019,
14354,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,1,,2193,CHEMBL631153,,BAO_0000019,
14355,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,1,,2193,CHEMBL875121,,BAO_0000019,
14356,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,1,,2193,CHEMBL631154,,BAO_0000019,
14357,22224,,,0,,U,,,,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,1,,2193,CHEMBL631155,,BAO_0000019,
14358,22224,,,0,,U,,,,Autocuration,Hydrolysis rate constant was determined,A,1,,568,CHEMBL631156,,BAO_0000019,
14359,22224,,,0,,U,,,,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,1,,9680,CHEMBL631157,,BAO_0000019,
14360,22224,,,0,,U,,,,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,1,,9680,CHEMBL631158,,BAO_0000019,
14361,22224,,,0,,U,,,,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,1,,9680,CHEMBL631159,,BAO_0000019,
14362,22224,,,0,,U,,,,Autocuration,Observed second order rate constant,A,1,,10026,CHEMBL631160,,BAO_0000019,
14363,22224,,,0,,U,,,,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,1,,10281,CHEMBL631161,,BAO_0000019,
14364,22224,,,0,,U,,,,Autocuration,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,1,,10014,CHEMBL631162,,BAO_0000019,
14365,22224,,,0,,U,,,,Autocuration,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,1,,10014,CHEMBL630313,,BAO_0000019,
14366,22224,,,0,,U,,,,Autocuration,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,1,,9680,CHEMBL630314,,BAO_0000019,
14367,22224,,,0,,U,,,,Autocuration,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,1,,9680,CHEMBL630315,,BAO_0000019,
14368,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630316,,BAO_0000019,
14369,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630986,,BAO_0000019,
14370,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630987,,BAO_0000019,
14371,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630988,,BAO_0000019,
14372,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630989,,BAO_0000019,
14373,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630990,,BAO_0000019,
14374,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630991,,BAO_0000019,
14375,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630992,,BAO_0000019,
14376,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630993,,BAO_0000019,
14377,22224,,,0,,U,,,,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,1,,13028,CHEMBL630994,,BAO_0000019,
14378,50597,,,1,,N,,,,Intermediate,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,1,,10014,CHEMBL630995,,BAO_0000218,
14379,22224,,,0,,U,,,,Autocuration,Association constant for compound at 31 degree C was determined,A,1,,9962,CHEMBL629252,,BAO_0000019,
14380,22224,,,0,,U,,,,Autocuration,Calculated antagonist equilibrium dissociation constant of the compound,A,1,,12029,CHEMBL629253,,BAO_0000019,
14381,22224,,,0,,U,,,,Autocuration,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,1,,12029,CHEMBL629944,,BAO_0000019,
14382,50512,,,1,,N,,Trachea,,Intermediate,Dissociation constants vs LTE4 on guinea pig trachea,A,1,,10583,CHEMBL629945,,BAO_0000218,3126.0
14383,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,1,,568,CHEMBL629946,,BAO_0000019,
14384,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,1,,568,CHEMBL629947,,BAO_0000019,
14385,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,1,,568,CHEMBL629948,,BAO_0000019,
14386,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,1,,568,CHEMBL856024,,BAO_0000019,
14387,22224,,,0,,U,,,,Autocuration,Affinity constant KD value was derived from TMP,A,1,,7493,CHEMBL629949,,BAO_0000019,
14388,22224,,,0,,U,,,,Autocuration,Apparent dissociation (binding) rate constant was evaluated,A,1,,8371,CHEMBL629950,,BAO_0000019,
14389,22224,,,0,,U,,,,Autocuration,Dissociation constant (KD) of the compound,P,1,,13114,CHEMBL630127,,BAO_0000100,
14390,22224,,,0,,U,,,,Autocuration,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,1,,15515,CHEMBL630128,,BAO_0000100,
14391,22224,,,0,,U,,,,Autocuration,Dissociation constant from ESR titration experiments,P,1,,522,CHEMBL630129,,BAO_0000100,
14392,22224,,,0,,U,,,,Autocuration,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,1,,13888,CHEMBL630130,,BAO_0000019,
14393,22224,,,0,,U,,,,Autocuration,Dissociation constant was evaluated.,P,1,,2616,CHEMBL875234,,BAO_0000100,
14394,22224,,,0,,U,,,,Autocuration,Dissociation constant was reported,P,1,,3798,CHEMBL630131,,BAO_0000100,
14395,50597,,,1,,N,,,,Intermediate,Dissociation constant was determined in rat pituitary cells.,A,1,,8731,CHEMBL630132,,BAO_0000218,
14396,22224,,,0,,U,,,,Autocuration,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,1,,11892,CHEMBL630133,,BAO_0000019,
14397,22224,,,0,,U,,,,Autocuration,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,1,,11892,CHEMBL630134,,BAO_0000019,
14398,22224,,,0,,U,,,,Autocuration,Equilibrium dissociation constant of the compound,A,1,,2582,CHEMBL630135,,BAO_0000019,
14399,22224,,,0,,U,,,,Autocuration,Equilibrium dissociation constant was determined,A,1,,11892,CHEMBL630136,,BAO_0000019,
14400,22224,,,0,,U,,,,Autocuration,Kinetic constant KD was evaluated,A,1,,13396,CHEMBL630137,,BAO_0000019,
14401,22224,,,0,,U,,,,Autocuration,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,1,,603,CHEMBL630138,,BAO_0000019,
14402,22224,,,0,,U,,,,Autocuration,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,1,,15673,CHEMBL630139,,BAO_0000019,
14403,22224,,,0,,U,,,,Autocuration,Rate constant for hydrolysis in aqueous acetone.,A,1,,10368,CHEMBL630140,,BAO_0000019,
14404,22224,,,0,,U,,,,Autocuration,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,1,,14228,CHEMBL875235,,BAO_0000019,
14405,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,1,,11510,CHEMBL876439,,BAO_0000218,
14406,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,1,,11510,CHEMBL630605,,BAO_0000218,
14407,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,1,,11510,CHEMBL630606,,BAO_0000218,
14408,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,1,,11510,CHEMBL630607,,BAO_0000218,
14409,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,1,,11510,CHEMBL630608,,BAO_0000218,
14410,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,1,,11510,CHEMBL630609,,BAO_0000218,
14411,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,1,,11510,CHEMBL630610,,BAO_0000218,
14412,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,1,,11510,CHEMBL630611,,BAO_0000218,
14413,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,1,,11510,CHEMBL629552,,BAO_0000218,
14414,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,1,,11510,CHEMBL629733,,BAO_0000218,
14415,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,1,,11510,CHEMBL629734,,BAO_0000218,
14416,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,1,,11510,CHEMBL629735,,BAO_0000218,
14417,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,1,,11510,CHEMBL629736,,BAO_0000218,
14418,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,1,,11510,CHEMBL629737,,BAO_0000218,
14419,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,1,,11510,CHEMBL629738,,BAO_0000218,
14420,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,1,,11510,CHEMBL629739,,BAO_0000218,
14421,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,1,,11510,CHEMBL629740,,BAO_0000218,
14422,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,1,,11510,CHEMBL629741,,BAO_0000218,
14423,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,1,,11510,CHEMBL629742,,BAO_0000218,
14424,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,1,,11510,CHEMBL629743,,BAO_0000218,
14425,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,1,,11510,CHEMBL629744,,BAO_0000218,
14426,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,1,,11510,CHEMBL629745,,BAO_0000218,
14427,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,1,,11510,CHEMBL629746,,BAO_0000218,
14428,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,1,,11510,CHEMBL629747,,BAO_0000218,
14429,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,1,,11510,CHEMBL629748,,BAO_0000218,
14430,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,1,,11510,CHEMBL629749,,BAO_0000218,
14431,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,1,,11510,CHEMBL629750,,BAO_0000218,
14432,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,1,,11510,CHEMBL629751,,BAO_0000218,
14433,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,1,,11510,CHEMBL629752,,BAO_0000218,
14434,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,1,,11510,CHEMBL629753,,BAO_0000218,
14435,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,1,,11510,CHEMBL629754,,BAO_0000218,
14436,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,1,,11510,CHEMBL629755,,BAO_0000218,
14437,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,1,,11510,CHEMBL629756,,BAO_0000218,
14438,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,1,,11510,CHEMBL629757,,BAO_0000218,
14439,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,1,,11510,CHEMBL629758,,BAO_0000218,
14440,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,1,,11510,CHEMBL629759,,BAO_0000218,
14441,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,1,,11510,CHEMBL629760,,BAO_0000218,
14442,50597,,,1,,N,,,,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,1,,11510,CHEMBL876443,,BAO_0000218,
14443,50588,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,1,,8310,CHEMBL629761,,BAO_0000218,
14444,50588,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,1,,8310,CHEMBL629762,,BAO_0000218,
14445,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,1,,8310,CHEMBL629763,,BAO_0000218,
14446,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,1,,8310,CHEMBL629764,,BAO_0000218,
14447,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,1,,8310,CHEMBL629765,,BAO_0000218,
14448,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,1,,8310,CHEMBL629766,,BAO_0000218,
14449,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,1,,8310,CHEMBL629767,,BAO_0000218,
14450,50588,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,1,,8310,CHEMBL629768,,BAO_0000218,
14451,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,1,,8310,CHEMBL629769,,BAO_0000218,
14452,50588,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,1,,8310,CHEMBL629770,,BAO_0000218,
14453,50588,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,1,,8310,CHEMBL629771,,BAO_0000218,
14454,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,1,,8310,CHEMBL629772,,BAO_0000218,
14455,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,1,,8310,CHEMBL629773,,BAO_0000218,
14456,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,1,,8310,CHEMBL625455,,BAO_0000218,
14457,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,1,,8310,CHEMBL625456,,BAO_0000218,
14458,50594,,,1,,N,,,,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,1,,8310,CHEMBL625457,,BAO_0000218,
14459,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,1,,12582,CHEMBL625458,,BAO_0000218,1088.0
14460,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,1,,12582,CHEMBL625459,,BAO_0000218,1088.0
14461,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,1,,12582,CHEMBL875483,,BAO_0000218,1088.0
14462,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,1,,12582,CHEMBL634779,,BAO_0000218,1088.0
14463,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,1,,12582,CHEMBL625460,,BAO_0000218,1088.0
14464,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,1,,12582,CHEMBL626117,,BAO_0000218,1088.0
14465,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,1,,12582,CHEMBL626118,,BAO_0000218,1088.0
14466,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,1,,12582,CHEMBL628342,,BAO_0000218,1088.0
14467,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,1,,12582,CHEMBL628343,,BAO_0000218,1088.0
14468,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,1,,12582,CHEMBL628344,,BAO_0000218,1088.0
14469,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,1,,12582,CHEMBL628345,,BAO_0000218,1088.0
14470,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,1,,12582,CHEMBL628346,,BAO_0000218,1088.0
14471,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,1,,12582,CHEMBL628347,,BAO_0000218,1088.0
14472,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL628348,,BAO_0000218,1088.0
14473,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL628349,,BAO_0000218,1088.0
14474,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,1,,12582,CHEMBL875611,,BAO_0000218,1088.0
14475,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,1,,12582,CHEMBL628350,,BAO_0000218,1088.0
14476,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,1,,12582,CHEMBL628351,,BAO_0000218,1088.0
14477,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,1,,12582,CHEMBL628352,,BAO_0000218,1088.0
14478,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,1,,12582,CHEMBL628353,,BAO_0000218,1088.0
14479,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,1,,12582,CHEMBL628354,,BAO_0000218,1088.0
14480,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,1,,12582,CHEMBL626667,,BAO_0000218,1088.0
14481,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL626668,,BAO_0000218,1088.0
14482,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,1,,12582,CHEMBL626669,,BAO_0000218,1088.0
14483,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,1,,12582,CHEMBL626670,,BAO_0000218,1088.0
14484,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,1,,12582,CHEMBL626671,,BAO_0000218,1088.0
14485,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,1,,12582,CHEMBL626672,,BAO_0000218,1088.0
14486,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,1,,12582,CHEMBL626673,,BAO_0000218,1088.0
14487,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,1,,12582,CHEMBL626674,,BAO_0000218,1088.0
14488,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,1,,12582,CHEMBL626675,,BAO_0000218,1088.0
14489,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,1,,12582,CHEMBL626676,,BAO_0000218,1088.0
14490,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,1,,12582,CHEMBL626677,,BAO_0000218,1088.0
14491,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,1,,12582,CHEMBL626678,,BAO_0000218,1088.0
14492,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,1,,12582,CHEMBL626679,,BAO_0000218,1088.0
14493,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,1,,12582,CHEMBL875612,,BAO_0000218,1088.0
14494,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,1,,12582,CHEMBL626680,,BAO_0000218,1088.0
14495,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,1,,12582,CHEMBL626681,,BAO_0000218,1088.0
14496,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,1,,12582,CHEMBL626682,,BAO_0000218,1088.0
14497,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,1,,12582,CHEMBL626683,,BAO_0000218,1088.0
14498,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,1,,12582,CHEMBL626684,,BAO_0000218,1088.0
14499,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,1,,12582,CHEMBL626685,,BAO_0000218,1088.0
14500,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,1,,12582,CHEMBL626686,,BAO_0000218,1088.0
14501,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,1,,12582,CHEMBL626687,,BAO_0000218,1088.0
14502,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,1,,12582,CHEMBL624978,,BAO_0000218,1088.0
14503,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,1,,12582,CHEMBL624979,,BAO_0000218,1088.0
14504,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,1,,12582,CHEMBL624980,,BAO_0000218,1088.0
14505,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,1,,12582,CHEMBL624981,,BAO_0000218,1088.0
14506,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,1,,12582,CHEMBL624982,,BAO_0000218,1088.0
14507,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,1,,13257,CHEMBL627564,,BAO_0000218,2367.0
14508,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,1,,13257,CHEMBL627565,,BAO_0000218,2367.0
14509,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,1,,13257,CHEMBL627566,,BAO_0000218,
14510,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,1,,13257,CHEMBL627567,,BAO_0000218,2385.0
14511,22224,,In vivo,0,,U,,Spleen,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,1,,13257,CHEMBL627568,,BAO_0000218,2106.0
14512,22224,,In vivo,0,,U,,Kidney,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,1,,13257,CHEMBL627569,,BAO_0000218,2113.0
14513,22224,,In vivo,0,,U,,Urinary bladder,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,1,,13257,CHEMBL627570,,BAO_0000218,1255.0
14514,22224,,In vivo,0,,U,,Blood,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,1,,13257,CHEMBL627571,,BAO_0000218,178.0
14515,22224,,In vivo,0,,U,,Bone element,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,1,,13257,CHEMBL627572,,BAO_0000218,1474.0
14516,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,1,,13257,CHEMBL627573,,BAO_0000218,
14517,22224,,In vivo,0,,U,,Kidney,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,1,,13257,CHEMBL627574,,BAO_0000218,2113.0
14518,22224,,In vivo,0,,U,,Liver,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,1,,13257,CHEMBL627575,,BAO_0000218,2107.0
14519,22224,,In vivo,0,,U,,Lung,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,1,,13257,CHEMBL627576,,BAO_0000218,2048.0
14520,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,1,,13257,CHEMBL627577,,BAO_0000218,2385.0
14521,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,1,,13257,CHEMBL627578,,BAO_0000218,2367.0
14522,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,1,,13257,CHEMBL627579,,BAO_0000218,2367.0
14523,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,1,,13257,CHEMBL627580,,BAO_0000218,2385.0
14524,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,1,,13257,CHEMBL627581,,BAO_0000218,2367.0
14525,22224,,In vivo,0,,U,,,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,1,,13257,CHEMBL627582,,BAO_0000218,
14526,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,1,,13257,CHEMBL627583,,BAO_0000218,2385.0
14527,22224,,In vivo,0,,U,,Spleen,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,1,,13257,CHEMBL627584,,BAO_0000218,2106.0
14528,22224,,In vivo,0,,U,,Prostate gland,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,1,,13257,CHEMBL627585,,BAO_0000218,2367.0
14529,22224,,In vivo,0,,U,,Muscle tissue,,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,1,,13257,CHEMBL627586,,BAO_0000218,2385.0
14530,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,1,,15413,CHEMBL627587,,BAO_0000218,
14531,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL627588,,BAO_0000218,
14532,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,1,,15413,CHEMBL628250,,BAO_0000218,
14533,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628251,,BAO_0000218,
14534,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,1,,15413,CHEMBL628252,,BAO_0000218,10000000.0
14535,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628253,,BAO_0000218,10000000.0
14536,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,1,,15413,CHEMBL628254,,BAO_0000218,1898.0
14537,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL877493,,BAO_0000218,1898.0
14538,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628255,,BAO_0000218,
14539,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628256,,BAO_0000218,
14540,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628257,,BAO_0000218,10000000.0
14541,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628258,,BAO_0000218,1898.0
14542,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628259,,BAO_0000218,
14543,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL628429,,BAO_0000218,
14544,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,1,,15413,CHEMBL626862,,BAO_0000218,10000000.0
14545,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,1,,15413,CHEMBL626863,,BAO_0000218,1898.0
14546,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,1,,15413,CHEMBL625886,,BAO_0000218,2037.0
14547,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,1,,15413,CHEMBL625887,,BAO_0000218,2037.0
14548,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,1,,15413,CHEMBL625888,,BAO_0000218,
14549,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,1,,15413,CHEMBL625889,,BAO_0000218,
14550,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,1,,15413,CHEMBL625890,,BAO_0000218,10000000.0
14551,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,1,,15413,CHEMBL625891,,BAO_0000218,10000000.0
14552,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,1,,15413,CHEMBL625892,,BAO_0000218,1898.0
14553,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,1,,15413,CHEMBL625893,,BAO_0000218,1898.0
14554,50597,,In vivo,1,,N,,Cerebellum,,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,1,,15413,CHEMBL625894,,BAO_0000218,2037.0
14555,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,1,,15413,CHEMBL625895,,BAO_0000218,
14556,22224,,,0,,U,,,,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,1,,12404,CHEMBL625896,,BAO_0000019,
14557,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,1,,568,CHEMBL625897,,BAO_0000019,
14558,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,1,,568,CHEMBL625898,,BAO_0000019,
14559,22224,,,0,,U,,,,Autocuration,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,1,,568,CHEMBL625899,,BAO_0000019,
14560,22224,,,0,,U,,,,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,1,,12404,CHEMBL626124,,BAO_0000019,
14561,50212,,,1,,N,,,,Intermediate,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,1,,7624,CHEMBL628500,,BAO_0000218,
14562,50597,,,1,,N,,,,Intermediate,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,1,,7624,CHEMBL857856,,BAO_0000218,
14563,50597,,,1,,N,,,,Intermediate,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,1,,7624,CHEMBL628501,,BAO_0000218,
14564,22224,,,0,,U,,,,Autocuration,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,1,,4643,CHEMBL628502,,BAO_0000019,
14565,22224,,,0,,U,,,,Autocuration,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,1,,11532,CHEMBL628503,,BAO_0000019,
14566,22224,,,0,,U,,,,Autocuration,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,1,,11018,CHEMBL628504,,BAO_0000019,
14567,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,1,,2276,CHEMBL628505,,BAO_0000019,
14568,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,1,,2276,CHEMBL874452,,BAO_0000019,
14569,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,1,,2276,CHEMBL628506,,BAO_0000019,
14570,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,1,,2276,CHEMBL628507,,BAO_0000019,
14571,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,1,,2276,CHEMBL628508,,BAO_0000019,
14572,22224,,,0,,U,,,,Autocuration,Michaelis constant (KM) was evaluated,A,1,,8949,CHEMBL628509,,BAO_0000019,
14573,22224,,,0,,U,,,,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,1,,12404,CHEMBL628510,,BAO_0000019,
14574,22224,,,0,,U,,,,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,1,,7625,CHEMBL628511,,BAO_0000019,
14575,22224,,,0,,U,,,,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,1,,7625,CHEMBL628512,,BAO_0000019,
14576,22224,,,0,,U,,,,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,1,,7625,CHEMBL628513,,BAO_0000019,
14577,22224,,,0,,U,,,,Autocuration,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,1,,7625,CHEMBL628514,,BAO_0000019,
14578,22224,,,0,,U,,,,Autocuration,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,1,,12908,CHEMBL628515,,BAO_0000019,
14579,22224,,,0,,U,,,,Autocuration,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,1,,10368,CHEMBL628516,,BAO_0000019,
14580,22224,,,0,,U,,,,Autocuration,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,1,,13108,CHEMBL628517,,BAO_0000019,
14581,22224,,,0,,U,,,,Autocuration,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,1,,13108,CHEMBL628518,,BAO_0000019,
14582,22224,,,0,,U,,,,Autocuration,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,1,,15217,CHEMBL628519,,BAO_0000019,
14583,22224,,,0,,U,,,,Autocuration,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,1,,15217,CHEMBL628520,,BAO_0000019,
14584,22224,,,0,,U,,,,Autocuration,Binding constant was determined,A,1,,10933,CHEMBL628521,,BAO_0000019,
14585,22224,,,0,,U,,,,Autocuration,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,1,,2363,CHEMBL630443,,BAO_0000019,
14586,22224,,,0,,U,,,,Autocuration,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,1,,2363,CHEMBL630444,,BAO_0000019,
14587,22224,,,0,,U,,,,Autocuration,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,1,,2276,CHEMBL857732,,BAO_0000019,
14588,22224,,,0,,U,,,,Autocuration,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,1,,14915,CHEMBL630445,,BAO_0000100,
14589,22224,,,0,,U,,,,Autocuration,Catalytic rate constant of the compound,A,1,,8847,CHEMBL630446,,BAO_0000019,
14590,22224,,,0,,U,,,,Autocuration,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,1,,15357,CHEMBL630447,,BAO_0000019,
14591,22224,,,0,,U,,,,Autocuration,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,1,,2869,CHEMBL630448,,BAO_0000019,
14592,22224,,,0,,U,,,,Autocuration,Catalytic rate constant against phospholipase A2 was determined,A,1,,3484,CHEMBL630449,,BAO_0000019,
14593,22224,,,0,,U,,,,Autocuration,"Compound was evaluated for catalytic constant, Kcat",A,1,,1373,CHEMBL630450,,BAO_0000019,
14594,22224,,,0,,U,,,,Autocuration,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,1,,8142,CHEMBL630451,,BAO_0000019,
14595,22224,,,0,,U,,,,Autocuration,Kcat calculated from 0.693/T1/2,A,1,,14131,CHEMBL630452,,BAO_0000019,
14596,22224,,,0,,U,,,,Autocuration,Kcat was determined,A,1,,17269,CHEMBL630453,,BAO_0000019,
14597,22224,,,0,,U,,,,Autocuration,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,1,,3485,CHEMBL630454,,BAO_0000019,
14598,22224,,,0,,U,,,,Autocuration,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,1,,3485,CHEMBL630455,,BAO_0000019,
14599,22224,,,0,,U,,,,Autocuration,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,1,,3485,CHEMBL631487,,BAO_0000019,
14600,22224,,,0,,U,,,,Autocuration,Kcat value was determined,A,1,,5962,CHEMBL631488,,BAO_0000019,
14601,22224,,,0,,U,,,,Autocuration,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,1,,3133,CHEMBL876440,,BAO_0000019,
14602,22224,,,0,,U,,,,Autocuration,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,1,,3133,CHEMBL631489,,BAO_0000019,
14603,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,1,,2276,CHEMBL857742,,BAO_0000019,
14604,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,1,,2276,CHEMBL631490,,BAO_0000019,
14605,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,1,,2276,CHEMBL631491,,BAO_0000019,
14606,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,1,,2276,CHEMBL631492,,BAO_0000019,
14607,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,1,,2276,CHEMBL631493,,BAO_0000019,
14608,22224,,,0,,U,,,,Autocuration,Kinetic parameter for rate of conversion to PABA was determined,A,1,,4892,CHEMBL631494,,BAO_0000019,
14609,22224,,,0,,U,,,,Autocuration,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,1,,3133,CHEMBL631495,,BAO_0000019,
14610,50597,,,1,,N,,Feces,,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,1,,11488,CHEMBL631496,,BAO_0000218,1988.0
14611,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,1,,11488,CHEMBL631497,,BAO_0000218,1088.0
14612,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,1,,11488,CHEMBL631498,,BAO_0000218,1088.0
14613,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,1,,11488,CHEMBL629776,,BAO_0000218,1088.0
14614,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,1,,11488,CHEMBL629777,,BAO_0000218,1088.0
14615,50597,,,1,,N,,Urine,,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,1,,11488,CHEMBL629778,,BAO_0000218,1088.0
14616,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,1,,11488,CHEMBL630456,,BAO_0000218,
14617,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,1,,11488,CHEMBL630457,,BAO_0000218,
14618,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,1,,11488,CHEMBL630458,,BAO_0000218,
14619,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,1,,11488,CHEMBL630459,,BAO_0000218,
14620,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,1,,11488,CHEMBL630460,,BAO_0000218,
14621,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,1,,11488,CHEMBL876550,,BAO_0000218,
14622,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,1,,11488,CHEMBL630461,,BAO_0000218,
14623,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,1,,11488,CHEMBL630462,,BAO_0000218,
14624,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,1,,11488,CHEMBL630463,,BAO_0000218,
14625,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,1,,11488,CHEMBL630464,,BAO_0000218,
14626,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,1,,11488,CHEMBL630465,,BAO_0000218,
14627,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,1,,11488,CHEMBL630466,,BAO_0000218,
14628,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,1,,11488,CHEMBL630467,,BAO_0000218,
14629,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,1,,11488,CHEMBL630633,,BAO_0000218,
14630,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,1,,11488,CHEMBL630634,,BAO_0000218,
14631,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,1,,11488,CHEMBL630635,,BAO_0000218,
14632,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,1,,11488,CHEMBL630636,,BAO_0000218,
14633,50597,,,1,,N,,,,Intermediate,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,1,,11488,CHEMBL630637,,BAO_0000218,
14634,50592,,,1,,N,,Feces,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,1,,7132,CHEMBL630638,,BAO_0000218,1988.0
14635,50592,,,1,,N,,Feces,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,1,,7132,CHEMBL630639,,BAO_0000218,1988.0
14636,50592,,,1,,N,,Feces,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,1,,7132,CHEMBL630640,,BAO_0000218,1988.0
14637,50592,,,1,,N,,Feces,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,1,,7132,CHEMBL876551,,BAO_0000218,1988.0
14638,50592,,,1,,N,,Urine,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,1,,7132,CHEMBL630641,,BAO_0000218,1088.0
14639,50592,,,1,,N,,Urine,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,1,,7132,CHEMBL630642,,BAO_0000218,1088.0
14640,50592,,,1,,N,,Urine,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,1,,7132,CHEMBL630643,,BAO_0000218,1088.0
14641,50592,,,1,,N,,Urine,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,1,,7132,CHEMBL630644,,BAO_0000218,1088.0
14642,50592,,,1,,N,,Urine,,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,1,,7132,CHEMBL630645,,BAO_0000218,1088.0
14643,50592,,,1,,N,,Feces,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,1,,7132,CHEMBL625599,,BAO_0000218,1988.0
14644,50592,,,1,,N,,Feces,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,1,,7132,CHEMBL625600,,BAO_0000218,1988.0
14645,50592,,,1,,N,,Feces,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,1,,7132,CHEMBL625601,,BAO_0000218,1988.0
14646,50592,,,1,,N,,Feces,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,1,,7132,CHEMBL625602,,BAO_0000218,1988.0
14647,50592,,,1,,N,,Urine,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,1,,7132,CHEMBL627470,,BAO_0000218,1088.0
14648,50592,,,1,,N,,Urine,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,1,,7132,CHEMBL627471,,BAO_0000218,1088.0
14649,50592,,,1,,N,,Urine,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,1,,7132,CHEMBL627472,,BAO_0000218,1088.0
14650,50592,,,1,,N,,Urine,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,1,,7132,CHEMBL627473,,BAO_0000218,1088.0
14651,50592,,,1,,N,,Urine,,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,1,,7132,CHEMBL627474,,BAO_0000218,1088.0
14652,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL627475,,BAO_0000218,178.0
14653,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL627476,,BAO_0000218,178.0
14654,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,1,,12582,CHEMBL627477,,BAO_0000218,1088.0
14655,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,1,,12582,CHEMBL627478,,BAO_0000218,1088.0
14656,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,1,,12582,CHEMBL627479,,BAO_0000218,1088.0
14657,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,1,,12582,CHEMBL627480,,BAO_0000218,1088.0
14658,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,1,,12582,CHEMBL627481,,BAO_0000218,1088.0
14659,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL627482,,BAO_0000218,1088.0
14660,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,1,,12582,CHEMBL627483,,BAO_0000218,1088.0
14661,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,1,,12582,CHEMBL875636,,BAO_0000218,1088.0
14662,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,1,,12582,CHEMBL625764,,BAO_0000218,1088.0
14663,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL625765,,BAO_0000218,1088.0
14664,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,1,,12582,CHEMBL625766,,BAO_0000218,1088.0
14665,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL625767,,BAO_0000218,1088.0
14666,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL625768,,BAO_0000218,1088.0
14667,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL625769,,BAO_0000218,1088.0
14668,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,1,,12582,CHEMBL625770,,BAO_0000218,1088.0
14669,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,1,,12582,CHEMBL625771,,BAO_0000218,1088.0
14670,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,1,,12582,CHEMBL625772,,BAO_0000218,1088.0
14671,50588,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,1,,12582,CHEMBL625773,,BAO_0000218,1088.0
14672,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,1,,12582,CHEMBL625774,,BAO_0000218,1088.0
14673,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,1,,12582,CHEMBL625775,,BAO_0000218,1088.0
14674,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,1,,12582,CHEMBL625776,,BAO_0000218,1088.0
14675,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,1,,12582,CHEMBL625777,,BAO_0000218,1088.0
14676,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,1,,12582,CHEMBL625778,,BAO_0000218,1088.0
14677,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,1,,12582,CHEMBL625779,,BAO_0000218,1088.0
14678,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,1,,12582,CHEMBL625780,,BAO_0000218,1088.0
14679,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,1,,12582,CHEMBL625781,,BAO_0000218,1088.0
14680,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,1,,12582,CHEMBL875637,,BAO_0000218,1088.0
14681,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,1,,12582,CHEMBL626473,,BAO_0000218,1088.0
14682,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,1,,12582,CHEMBL626474,,BAO_0000218,1088.0
14683,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,1,,12582,CHEMBL626475,,BAO_0000218,1088.0
14684,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,1,,12582,CHEMBL626476,,BAO_0000218,1088.0
14685,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,1,,12582,CHEMBL634397,,BAO_0000218,1088.0
14686,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,1,,12582,CHEMBL626477,,BAO_0000218,1088.0
14687,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,1,,12582,CHEMBL631069,,BAO_0000218,1088.0
14688,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,1,,12582,CHEMBL631070,,BAO_0000218,1088.0
14689,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,1,,12582,CHEMBL631071,,BAO_0000218,1088.0
14690,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,1,,12582,CHEMBL631072,,BAO_0000218,1088.0
14691,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,1,,12582,CHEMBL631073,,BAO_0000218,1088.0
14692,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,1,,12582,CHEMBL631074,,BAO_0000218,1088.0
14693,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,1,,12582,CHEMBL631075,,BAO_0000218,1088.0
14694,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,1,,12582,CHEMBL631725,,BAO_0000218,1088.0
14695,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,1,,12582,CHEMBL631726,,BAO_0000218,1088.0
14696,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,1,,12582,CHEMBL631727,,BAO_0000218,1088.0
14697,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,1,,12582,CHEMBL631728,,BAO_0000218,1088.0
14698,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,1,,12582,CHEMBL631729,,BAO_0000218,1088.0
14699,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,1,,12582,CHEMBL631730,,BAO_0000218,1088.0
14700,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,1,,12582,CHEMBL631731,,BAO_0000218,1088.0
14701,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,1,,12582,CHEMBL631910,,BAO_0000218,1088.0
14702,50597,,In vivo,1,,N,,Hippocampus,,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,1,,15413,CHEMBL631911,,BAO_0000218,10000000.0
14703,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,1,,15413,CHEMBL631912,,BAO_0000218,1898.0
14704,50597,,In vivo,1,,N,,Hypothalamus,,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,1,,15413,CHEMBL631913,,BAO_0000218,1898.0
14705,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631914,,BAO_0000218,178.0
14706,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631915,,BAO_0000218,178.0
14707,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL875778,,BAO_0000218,178.0
14708,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631916,,BAO_0000218,178.0
14709,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631917,,BAO_0000218,178.0
14710,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631918,,BAO_0000218,178.0
14711,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631919,,BAO_0000218,178.0
14712,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL631920,,BAO_0000218,178.0
14713,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631921,,BAO_0000218,178.0
14714,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631922,,BAO_0000218,178.0
14715,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL631923,,BAO_0000218,178.0
14716,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631924,,BAO_0000218,
14717,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630234,,BAO_0000218,
14718,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630235,,BAO_0000218,
14719,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630236,,BAO_0000218,
14720,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630237,,BAO_0000218,
14721,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630238,,BAO_0000218,
14722,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630239,,BAO_0000218,
14723,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630303,,BAO_0000218,
14724,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630304,,BAO_0000218,
14725,50597,,In vivo,1,,N,,,,Intermediate,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630305,,BAO_0000218,
14726,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630306,,BAO_0000218,2113.0
14727,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630307,,BAO_0000218,2113.0
14728,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630308,,BAO_0000218,2113.0
14729,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630309,,BAO_0000218,2113.0
14730,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL629309,,BAO_0000218,2113.0
14731,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL629993,,BAO_0000218,2113.0
14732,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL629994,,BAO_0000218,2113.0
14733,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL629995,,BAO_0000218,2113.0
14734,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631993,,BAO_0000218,2113.0
14735,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631994,,BAO_0000218,2113.0
14736,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631995,,BAO_0000218,2113.0
14737,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL631996,,BAO_0000218,2107.0
14738,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631997,,BAO_0000218,2107.0
14739,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631998,,BAO_0000218,2107.0
14740,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631999,,BAO_0000218,2107.0
14741,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL632000,,BAO_0000218,2107.0
14742,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL632001,,BAO_0000218,2107.0
14743,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL874424,,BAO_0000218,2107.0
14744,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL632002,,BAO_0000218,2107.0
14745,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL632003,,BAO_0000218,2107.0
14746,22224,,,0,,U,,,,Autocuration,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,1,,3133,CHEMBL632004,,BAO_0000019,
14747,22224,,,0,,U,,,,Autocuration,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,1,,2742,CHEMBL632005,,BAO_0000019,
14748,22224,,,0,,U,,,,Autocuration,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,1,,2742,CHEMBL632006,,BAO_0000019,
14749,22224,,,0,,U,,,,Autocuration,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,1,,2742,CHEMBL632007,,BAO_0000019,
14750,22224,,,0,,U,,,,Autocuration,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,1,,2742,CHEMBL632008,,BAO_0000019,
14751,22224,,,0,,U,,,,Autocuration,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,1,,2742,CHEMBL632009,,BAO_0000019,
14752,22224,,,0,,U,,,,Autocuration,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,1,,2742,CHEMBL632010,,BAO_0000019,
14753,22224,,,0,,U,,,,Autocuration,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,1,,2742,CHEMBL857750,,BAO_0000019,
14754,22224,,,0,,U,,,,Autocuration,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,1,,2742,CHEMBL632011,,BAO_0000019,
14755,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,1,,2276,CHEMBL632012,,BAO_0000019,
14756,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,1,,2276,CHEMBL632013,,BAO_0000019,
14757,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,1,,2276,CHEMBL632014,,BAO_0000019,
14758,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,1,,2276,CHEMBL629622,,BAO_0000019,
14759,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,1,,2276,CHEMBL629623,,BAO_0000019,
14760,22224,,,0,,U,,,,Autocuration,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,1,,2276,CHEMBL629624,,BAO_0000019,
14761,22224,,,0,,U,,,,Autocuration,Ratio of Kcat to that of Km was determined,A,1,,17269,CHEMBL629625,,BAO_0000019,
14762,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,1,,2276,CHEMBL629626,,BAO_0000019,
14763,22224,,,0,,U,,,,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,1,,2276,CHEMBL629627,,BAO_0000019,
14764,22224,,,0,,U,,,,Autocuration,"Compound was evaluated for constant, Kd",A,1,,15917,CHEMBL629628,,BAO_0000019,
14765,22224,,,0,,U,,,,Autocuration,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,1,,10933,CHEMBL629629,,BAO_0000019,
14766,22224,,,0,,U,,,,Autocuration,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,1,,10933,CHEMBL629630,,BAO_0000019,
14767,22224,,,0,,U,,,,Autocuration,Dissociation Constant of compound determined,A,1,,14293,CHEMBL856030,,BAO_0000019,
14768,22224,,,0,,U,,,,Autocuration,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,1,,6698,CHEMBL629631,,BAO_0000019,
14769,22224,,,0,,U,,,,Autocuration,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,1,,6698,CHEMBL629632,,BAO_0000019,
14770,22224,,,0,,U,,,,Autocuration,Dissociation constant of compound with Fructose was determined,P,1,,4318,CHEMBL629633,,BAO_0000100,
14771,22224,,,0,,U,,,,Autocuration,Dissociation constant of compound with Fructose was determined; Not determined,P,1,,4318,CHEMBL629634,,BAO_0000100,
14772,22224,,,0,,U,,,,Autocuration,Dissociation constant of compound with Lactulose was determined,P,1,,4318,CHEMBL629635,,BAO_0000100,
14773,22224,,,0,,U,,,,Autocuration,Dissociation constant of compound with Lactulose was determined; Not determined,P,1,,4318,CHEMBL629636,,BAO_0000100,
14774,22224,,,0,,U,,,,Autocuration,Dissociation constant of the Compound,P,1,,14959,CHEMBL629637,,BAO_0000100,
14775,22224,,,0,,U,,,,Autocuration,Dissociation constant by non-linear regression analysis,P,1,,5913,CHEMBL629638,,BAO_0000100,
14776,22224,,,0,,U,,,,Autocuration,Dissociation constant was determined,P,1,,14218,CHEMBL629639,,BAO_0000100,
14777,22224,,,0,,U,,,,Autocuration,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,1,,10689,CHEMBL629640,,BAO_0000100,
14778,22224,,,0,,U,,,,Autocuration,Dissociation constant was determined,P,1,,13925,CHEMBL629641,,BAO_0000100,
14779,22224,,,0,,U,,,,Autocuration,Dissociation constant was determined,P,1,,16359,CHEMBL631344,,BAO_0000100,
14780,50597,,,1,,N,,Muscle tissue,,Intermediate,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,1,,10944,CHEMBL631345,,BAO_0000218,2385.0
14781,22224,,,0,,U,,,,Autocuration,The dissociation constant determined by fluorescence displacement assay,A,1,,11080,CHEMBL631346,,BAO_0000019,
14782,22224,,,0,,U,,,,Autocuration,kd value surface plasmon resonance (SPR) method,A,1,,17805,CHEMBL631524,,BAO_0000019,
14783,50597,,,1,,N,,Muscle tissue,,Intermediate,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,1,,10944,CHEMBL631525,,BAO_0000218,2385.0
14784,22224,,,0,,U,,,,Autocuration,First dissociation constant of the binding of compound to V30M TTR,F,1,,16645,CHEMBL631526,,BAO_0000019,
14785,22224,,,0,,U,,,,Autocuration,Second dissociation constant of the binding of compound to V30M TTR,F,1,,16645,CHEMBL631527,,BAO_0000019,
14786,22224,,,0,,U,,,,Autocuration,"Compound was evaluated for equilibrium constant, Ke",A,1,,7793,CHEMBL631528,,BAO_0000019,
14787,22224,,,0,,U,,Hypothalamus,,Autocuration,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,1,,12199,CHEMBL631529,,BAO_0000019,1898.0
14788,22224,,,0,,U,,Hypothalamus,,Autocuration,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,1,,12199,CHEMBL631530,,BAO_0000019,1898.0
14789,22224,,,0,,U,,,,Autocuration,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,1,,9680,CHEMBL631531,,BAO_0000019,
14790,22224,,,0,,U,,,,Autocuration,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,1,,9680,CHEMBL631532,,BAO_0000019,
14791,22224,,,0,,U,,,,Autocuration,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,1,,9680,CHEMBL631533,,BAO_0000019,
14792,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,1,,13758,CHEMBL876552,,BAO_0000218,
14793,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,1,,13758,CHEMBL631534,,BAO_0000218,
14794,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,1,,13758,CHEMBL631535,,BAO_0000218,
14795,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,1,,13758,CHEMBL631536,,BAO_0000218,
14796,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,1,,13758,CHEMBL631537,,BAO_0000218,
14797,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,1,,13758,CHEMBL631538,,BAO_0000218,
14798,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,1,,13758,CHEMBL631539,,BAO_0000218,
14799,50594,,,1,,N,,,,Intermediate,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,1,,13758,CHEMBL631540,,BAO_0000218,
14800,50597,,,1,,N,,,,Intermediate,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL625637,,BAO_0000218,
14801,50597,,,1,,N,,,,Intermediate,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,1,,14393,CHEMBL625638,,BAO_0000218,
14802,50597,,,1,,N,,,,Intermediate,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,1,,15078,CHEMBL625639,,BAO_0000218,
14803,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625640,,BAO_0000218,955.0
14804,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625641,,BAO_0000218,955.0
14805,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625642,,BAO_0000218,948.0
14806,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625643,,BAO_0000218,948.0
14807,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625644,,BAO_0000218,2113.0
14808,50597,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625645,,BAO_0000218,2113.0
14809,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625646,,BAO_0000218,2107.0
14810,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625647,,BAO_0000218,2107.0
14811,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625648,,BAO_0000218,2048.0
14812,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625649,,BAO_0000218,2048.0
14813,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625650,,BAO_0000218,2385.0
14814,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625651,,BAO_0000218,2385.0
14815,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625652,,BAO_0000218,14.0
14816,50597,,In vivo,1,,N,,Zone of skin,,Intermediate,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625653,,BAO_0000218,14.0
14817,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625654,,BAO_0000218,2106.0
14818,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,1,,13925,CHEMBL625655,,BAO_0000218,2106.0
14819,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of Compound in rat blood after 15 minutes of administration,A,1,,9712,CHEMBL625656,,BAO_0000218,178.0
14820,50597,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution of Compound in rat blood after 2 minutes of administration,A,1,,9712,CHEMBL625657,,BAO_0000218,178.0
14821,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of Compound in rat brain after 15 minutes of administration,A,1,,9712,CHEMBL625658,,BAO_0000218,955.0
14822,50597,,In vivo,1,,N,,Brain,,Intermediate,Biodistribution of Compound in rat brain after 2 minutes of administration,A,1,,9712,CHEMBL625659,,BAO_0000218,955.0
14823,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of Compound in rat heart after 15 minutes of administration,A,1,,9712,CHEMBL625660,,BAO_0000218,948.0
14824,50597,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution of Compound in rat heart after 2 minutes of administration,A,1,,9712,CHEMBL625661,,BAO_0000218,948.0
14825,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of Compound in rat liver after 15 minutes of administration,A,1,,9712,CHEMBL625662,,BAO_0000218,2107.0
14826,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution of Compound in rat liver after 2 minutes of administration,A,1,,9712,CHEMBL625663,,BAO_0000218,2107.0
14827,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of Compound in rat lung after 15 minutes of administration,A,1,,9712,CHEMBL875621,,BAO_0000218,2048.0
14828,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution of Compound in rat lung after 2 minutes of administration,A,1,,9712,CHEMBL628382,,BAO_0000218,2048.0
14829,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,1,,9712,CHEMBL628383,,BAO_0000218,2385.0
14830,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,1,,9712,CHEMBL628384,,BAO_0000218,2385.0
14831,50597,,,1,,N,,,,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,1,,13925,CHEMBL628385,,BAO_0000218,
14832,50597,,,1,,N,,,,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,1,,13925,CHEMBL875753,,BAO_0000218,
14833,50597,,,1,,N,,,,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,1,,13925,CHEMBL628386,,BAO_0000218,
14834,50597,,,1,,N,,,,Intermediate,Organ distribution in rat blood 2 minutes after intravenous injection,A,1,,6941,CHEMBL628387,,BAO_0000218,
14835,50597,,,1,,N,,,,Intermediate,Organ distribution in rat blood 2 hr after intravenous injection,A,1,,6941,CHEMBL628388,,BAO_0000218,
14836,50597,,,1,,N,,,,Intermediate,Organ distribution in rat blood 30 minutes after intravenous injection,A,1,,6941,CHEMBL628389,,BAO_0000218,
14837,50597,,,1,,N,,,,Intermediate,Organ distribution in rat blood 30 min after intravenous injection,A,1,,6941,CHEMBL632756,,BAO_0000218,
14838,50597,,,1,,N,,,,Intermediate,Organ distribution in rat brain 2 minutes after intravenous injection,A,1,,6941,CHEMBL628390,,BAO_0000218,
14839,50597,,,1,,N,,,,Intermediate,Organ distribution in rat brain 2 hr after intravenous injection,A,1,,6941,CHEMBL631811,,BAO_0000218,
14840,50597,,,1,,N,,,,Intermediate,Organ distribution in rat brain 30 minutes after intravenous injection,A,1,,6941,CHEMBL631812,,BAO_0000218,
14841,50597,,,1,,N,,,,Intermediate,Organ distribution in rat heart 2 minutes after intravenous injection,A,1,,6941,CHEMBL631813,,BAO_0000218,
14842,50597,,,1,,N,,,,Intermediate,Organ distribution in rat heart 2 hr after intravenous injection,A,1,,6941,CHEMBL631814,,BAO_0000218,
14843,50597,,,1,,N,,,,Intermediate,Organ distribution in rat heart 30 minutes after intravenous injection,A,1,,6941,CHEMBL631815,,BAO_0000218,
14844,50597,,,1,,N,,,,Intermediate,Organ distribution in rat kidney 2 minutes after intravenous injection,A,1,,6941,CHEMBL631816,,BAO_0000218,
14845,50597,,,1,,N,,,,Intermediate,Organ distribution in rat kidney 2 hr after intravenous injection,A,1,,6941,CHEMBL875758,,BAO_0000218,
14846,50597,,,1,,N,,,,Intermediate,Organ distribution in rat kidney 30 minutes after intravenous injection,A,1,,6941,CHEMBL631817,,BAO_0000218,
14847,50597,,,1,,N,,Liver,,Intermediate,Organ distribution in rat liver 2 minutes after intravenous injection,A,1,,6941,CHEMBL631818,,BAO_0000218,2107.0
14848,50597,,,1,,N,,Liver,,Intermediate,Organ distribution in rat liver 2 hr after intravenous injection,A,1,,6941,CHEMBL631819,,BAO_0000218,2107.0
14849,50597,,,1,,N,,Liver,,Intermediate,Organ distribution in rat liver 30 minutes after intravenous injection,A,1,,6941,CHEMBL631820,,BAO_0000218,2107.0
14850,50597,,,1,,N,,,,Intermediate,Organ distribution in rat lung 2 minutes after intravenous injection,A,1,,6941,CHEMBL631821,,BAO_0000218,
14851,50597,,,1,,N,,,,Intermediate,Organ distribution in rat lung 2 hr after intravenous injection,A,1,,6941,CHEMBL631822,,BAO_0000218,
14852,50597,,,1,,N,,,,Intermediate,Organ distribution in rat lung 30 minutes after intravenous injection,A,1,,6941,CHEMBL631823,,BAO_0000218,
14853,50597,,,1,,N,,Muscle tissue,,Intermediate,Organ distribution in rat muscle 2 minutes after intravenous injection,A,1,,6941,CHEMBL631824,,BAO_0000218,2385.0
14854,50597,,,1,,N,,Muscle tissue,,Intermediate,Organ distribution in rat muscle 2 hr after intravenous injection,A,1,,6941,CHEMBL631825,,BAO_0000218,2385.0
14855,50597,,,1,,N,,Muscle tissue,,Intermediate,Organ distribution in rat muscle 30 minutes after intravenous injection,A,1,,6941,CHEMBL631826,,BAO_0000218,2385.0
14856,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,1,,14439,CHEMBL631827,,BAO_0000218,
14857,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,1,,14439,CHEMBL631828,,BAO_0000218,
14858,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,1,,14439,CHEMBL631829,,BAO_0000218,
14859,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,1,,12582,CHEMBL875759,,BAO_0000218,1088.0
14860,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,1,,12582,CHEMBL631830,,BAO_0000218,1088.0
14861,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,1,,12582,CHEMBL631831,,BAO_0000218,1088.0
14862,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,1,,12582,CHEMBL631832,,BAO_0000218,1088.0
14863,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,1,,12582,CHEMBL631833,,BAO_0000218,1088.0
14864,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,1,,12582,CHEMBL631834,,BAO_0000218,1088.0
14865,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,1,,12582,CHEMBL631835,,BAO_0000218,1088.0
14866,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,1,,12582,CHEMBL631836,,BAO_0000218,1088.0
14867,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,1,,12582,CHEMBL631837,,BAO_0000218,1088.0
14868,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,1,,12582,CHEMBL631838,,BAO_0000218,1088.0
14869,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,1,,12582,CHEMBL631839,,BAO_0000218,1088.0
14870,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,1,,12582,CHEMBL631840,,BAO_0000218,1088.0
14871,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,1,,12582,CHEMBL631841,,BAO_0000218,1088.0
14872,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,1,,12582,CHEMBL631842,,BAO_0000218,1088.0
14873,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,1,,12582,CHEMBL631843,,BAO_0000218,1088.0
14874,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,1,,12582,CHEMBL631844,,BAO_0000218,1088.0
14875,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,1,,12582,CHEMBL631845,,BAO_0000218,1088.0
14876,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,1,,12582,CHEMBL631846,,BAO_0000218,1088.0
14877,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,1,,12582,CHEMBL875760,,BAO_0000218,1088.0
14878,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,1,,12582,CHEMBL632199,,BAO_0000218,1088.0
14879,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,1,,12582,CHEMBL631847,,BAO_0000218,1088.0
14880,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,1,,12582,CHEMBL631848,,BAO_0000218,1088.0
14881,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,1,,12582,CHEMBL628707,,BAO_0000218,1088.0
14882,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,1,,12582,CHEMBL628708,,BAO_0000218,1088.0
14883,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,1,,12582,CHEMBL628709,,BAO_0000218,1088.0
14884,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,1,,12582,CHEMBL628710,,BAO_0000218,1088.0
14885,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,1,,12582,CHEMBL628711,,BAO_0000218,1088.0
14886,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,1,,12582,CHEMBL628712,,BAO_0000218,1088.0
14887,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,1,,12582,CHEMBL628713,,BAO_0000218,1088.0
14888,50597,,,1,,N,,Urine,,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,1,,12582,CHEMBL628714,,BAO_0000218,1088.0
14889,50597,,,1,,N,,,,Intermediate,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,1,,7415,CHEMBL628715,,BAO_0000218,
14890,22224,,,0,,U,,,,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,1,,7313,CHEMBL629179,,BAO_0000019,
14891,22224,,,0,,U,,,,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,1,,7313,CHEMBL629180,,BAO_0000019,
14892,22224,,,0,,U,,,,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,1,,7313,CHEMBL875108,,BAO_0000019,
14893,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629181,,BAO_0000019,1235.0
14894,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629182,,BAO_0000019,1235.0
14895,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,1,,7570,CHEMBL629183,,BAO_0000019,
14896,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629184,,BAO_0000019,
14897,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,1,,7570,CHEMBL629185,,BAO_0000019,1235.0
14898,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629186,,BAO_0000019,1235.0
14899,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629187,,BAO_0000019,
14900,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,1,,7570,CHEMBL629887,,BAO_0000019,
14901,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629888,,BAO_0000019,
14902,22224,,,0,,U,,,,Autocuration,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629889,,BAO_0000019,
14903,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,1,,7570,CHEMBL629890,,BAO_0000019,1235.0
14904,22224,,,0,,U,,,,Autocuration,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629891,,BAO_0000019,
14905,22224,,,0,,U,,,,Autocuration,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,1,,7570,CHEMBL629892,,BAO_0000019,
14906,22224,,,0,,U,,Adrenal cortex,,Autocuration,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,1,,7570,CHEMBL629893,,BAO_0000019,1235.0
14907,22224,,,0,,U,,,,Autocuration,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,1,,7570,CHEMBL629894,,BAO_0000019,
14908,22224,,,0,,U,,,,Autocuration,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,1,,7570,CHEMBL629895,,BAO_0000019,
14909,22224,,In vivo,0,,U,,,,Autocuration,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,1,,14122,CHEMBL875109,,BAO_0000218,
14910,22224,,In vivo,0,,U,,,,Autocuration,Absolute bioavailability in male cynomolgus monkeys,A,1,,16449,CHEMBL629896,,BAO_0000218,
14911,22224,,In vivo,0,,U,,,,Autocuration,Absolute bioavailability in maleSprague-Dawley rats,A,1,,16449,CHEMBL629897,,BAO_0000218,
14912,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL629898,,BAO_0000218,2107.0
14913,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630057,,BAO_0000218,2107.0
14914,50597,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630058,,BAO_0000218,2107.0
14915,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630059,,BAO_0000218,2048.0
14916,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630060,,BAO_0000218,2048.0
14917,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630061,,BAO_0000218,2048.0
14918,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630062,,BAO_0000218,2048.0
14919,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630063,,BAO_0000218,2048.0
14920,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630064,,BAO_0000218,2048.0
14921,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630065,,BAO_0000218,2048.0
14922,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630066,,BAO_0000218,2048.0
14923,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630067,,BAO_0000218,2048.0
14924,50597,,In vivo,1,,N,,Lung,,Intermediate,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630068,,BAO_0000218,2048.0
14925,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631113,,BAO_0000218,2385.0
14926,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631114,,BAO_0000218,2385.0
14927,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL631115,,BAO_0000218,2385.0
14928,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL631116,,BAO_0000218,2385.0
14929,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630528,,BAO_0000218,2385.0
14930,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630529,,BAO_0000218,2385.0
14931,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630530,,BAO_0000218,2385.0
14932,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630531,,BAO_0000218,2385.0
14933,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630532,,BAO_0000218,2385.0
14934,50597,,In vivo,1,,N,,Muscle tissue,,Intermediate,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630533,,BAO_0000218,2385.0
14935,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal mice blood after 120 hr,A,1,,15045,CHEMBL630534,,BAO_0000218,178.0
14936,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal mice blood after 24 hr,A,1,,15045,CHEMBL630535,,BAO_0000218,178.0
14937,50594,,In vivo,1,,N,,Blood,,Intermediate,Biodistribution in normal mice blood after 4 hr,A,1,,15045,CHEMBL630536,,BAO_0000218,178.0
14938,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal mice bone after 120 hr,A,1,,15045,CHEMBL630537,,BAO_0000218,10000001.0
14939,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal mice bone after 24 hr,A,1,,15045,CHEMBL630538,,BAO_0000218,10000001.0
14940,50594,,In vivo,1,,N,,Bone,,Intermediate,Biodistribution in normal mice bone after 4 hr,A,1,,15045,CHEMBL630539,,BAO_0000218,10000001.0
14941,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal mice heart after 120 hr,A,1,,15045,CHEMBL630540,,BAO_0000218,948.0
14942,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal mice heart after 24 hr,A,1,,15045,CHEMBL630541,,BAO_0000218,948.0
14943,50594,,In vivo,1,,N,,Heart,,Intermediate,Biodistribution in normal mice heart after 4 hr,A,1,,15045,CHEMBL630542,,BAO_0000218,948.0
14944,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal mice kidney after 120 hr,A,1,,15045,CHEMBL630543,,BAO_0000218,2113.0
14945,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal mice kidney after 24 hr,A,1,,15045,CHEMBL630544,,BAO_0000218,2113.0
14946,50594,,In vivo,1,,N,,Kidney,,Intermediate,Biodistribution in normal mice kidney after 4 hr,A,1,,15045,CHEMBL630545,,BAO_0000218,2113.0
14947,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal mice liver after 120 hr,A,1,,15045,CHEMBL630546,,BAO_0000218,2107.0
14948,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal mice liver after 24 hr,A,1,,15045,CHEMBL630547,,BAO_0000218,2107.0
14949,50594,,In vivo,1,,N,,Liver,,Intermediate,Biodistribution in normal mice liver after 4 hr,A,1,,15045,CHEMBL630548,,BAO_0000218,2107.0
14950,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal mice spleen after 120 hr,A,1,,15045,CHEMBL630549,,BAO_0000218,2106.0
14951,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal mice spleen after 24 hr,A,1,,15045,CHEMBL630550,,BAO_0000218,2106.0
14952,50594,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in normal mice spleen after 4 hr,A,1,,15045,CHEMBL876426,,BAO_0000218,2106.0
14953,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630551,,BAO_0000218,2106.0
14954,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630552,,BAO_0000218,2106.0
14955,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630553,,BAO_0000218,2106.0
14956,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630554,,BAO_0000218,2106.0
14957,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630555,,BAO_0000218,2106.0
14958,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630556,,BAO_0000218,2106.0
14959,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630557,,BAO_0000218,2106.0
14960,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,1,,12017,CHEMBL630558,,BAO_0000218,2106.0
14961,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630559,,BAO_0000218,2106.0
14962,50597,,In vivo,1,,N,,Spleen,,Intermediate,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL630560,,BAO_0000218,2106.0
14963,50597,,In vivo,1,,N,,Thyroid gland,,Intermediate,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,1,,12017,CHEMBL876427,,BAO_0000218,2046.0
14964,50597,,,1,,N,,,,Intermediate,The Kel values in female wistar rats.,A,1,,14941,CHEMBL630561,,BAO_0000218,
14965,22224,,,0,,U,,,,Autocuration,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,1,,4646,CHEMBL630562,,BAO_0000019,
14966,22224,,,0,,U,,,,Autocuration,Hydrolysis rate constant of the compound,A,1,,8847,CHEMBL630563,,BAO_0000019,
14967,22229,,,0,,U,,,,Autocuration,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,1,,11778,CHEMBL629673,,BAO_0000100,
14968,22224,,,0,,U,,,,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,1,,2363,CHEMBL629674,,BAO_0000019,
14969,22224,,,0,,U,,,,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,1,,2363,CHEMBL629675,,BAO_0000019,
14970,22224,,,0,,U,,,,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,1,,2363,CHEMBL629676,,BAO_0000019,
14971,22224,,,0,,U,,,,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,1,,2363,CHEMBL629677,,BAO_0000019,
14972,22224,,,0,,U,,,,Autocuration,Apparent inactivation rate constant was evaluated,A,1,,8371,CHEMBL629678,,BAO_0000019,
14973,22224,,,0,,U,,,,Autocuration,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,1,,14883,CHEMBL629679,,BAO_0000019,
14974,22224,,,0,,U,,,,Autocuration,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,1,,14883,CHEMBL629680,,BAO_0000019,
14975,22224,,,0,,U,,,,Autocuration,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,1,,4643,CHEMBL629681,,BAO_0000019,
14976,22224,,,0,,U,,,,Autocuration,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,1,,3519,CHEMBL629682,,BAO_0000019,
14977,22224,,,0,,U,,,,Autocuration,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,1,,10600,CHEMBL629683,,BAO_0000019,
14978,22224,,,0,,U,,,,Autocuration,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,1,,8501,CHEMBL629684,,BAO_0000019,
14979,22224,,,0,,U,,,,Autocuration,Dissociation constant was determined,P,1,,8505,CHEMBL629685,,BAO_0000100,
14980,22224,,,0,,U,,,,Autocuration,Dissociation constant was determined,P,1,,9778,CHEMBL629686,,BAO_0000100,
14981,22224,,,0,,U,,,,Autocuration,Dissociation constant at pH 7.4,P,1,,9778,CHEMBL872932,,BAO_0000100,
14982,22224,,,0,,U,,,,Autocuration,Dissociation constant in presence of 1 mM dithiothreitol,P,1,,9778,CHEMBL629687,,BAO_0000100,
14983,22224,,,0,,U,,,,Autocuration,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,1,,13007,CHEMBL872931,,BAO_0000019,
14984,22224,,,0,,U,,,,Autocuration,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,1,,13007,CHEMBL628151,,BAO_0000019,
14985,22224,,,0,,U,,,,Autocuration,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,1,,13007,CHEMBL628152,,BAO_0000019,
14986,22224,,,0,,U,,,,Autocuration,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,1,,13007,CHEMBL628153,,BAO_0000019,
14987,22224,,,0,,U,,,,Autocuration,Kinetic constant for aromatization of androstenedione,A,1,,11482,CHEMBL628154,,BAO_0000019,
14988,22224,,,0,,U,,,,Autocuration,Kinetic constant for aromatization of testosterone,A,1,,11482,CHEMBL628155,,BAO_0000019,
14989,22224,,,0,,U,,,,Autocuration,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,1,,2303,CHEMBL628156,,BAO_0000019,
14990,22224,,,0,,U,,,,Autocuration,Local inhibition constant was determined,A,1,,11964,CHEMBL628157,,BAO_0000019,
14991,50347,,,1,,N,,,,Intermediate,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,1,,3140,CHEMBL857533,,BAO_0000218,
14992,22224,,,0,,U,,,,Autocuration,Dissociation constant value of the compound,P,1,,10650,CHEMBL628158,,BAO_0000100,
14993,22224,,,0,,U,,Cornea,,Autocuration,In vitro permeability through cornea without epithelium,A,1,,4667,CHEMBL628159,,BAO_0000019,964.0
14994,22224,,,0,,U,,Cornea,,Autocuration,In vitro permeability through intact cornea,A,1,,4667,CHEMBL875616,,BAO_0000019,964.0
14995,50592,,,1,,N,,Cornea,,Intermediate,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,1,,9199,CHEMBL628160,,BAO_0000218,964.0
14996,22224,,,0,,U,,,,Autocuration,Rate of enzyme inactivation for the compound was determined,A,1,,11966,CHEMBL628161,,BAO_0000019,
14997,22224,,,0,,U,,Cornea,,Autocuration,In vitro permeability through cornea without epithelium,A,1,,4667,CHEMBL628162,,BAO_0000019,964.0
14998,22224,,,0,,U,,Cornea,,Autocuration,In vitro permeability through intact cornea,A,1,,4667,CHEMBL628163,,BAO_0000019,964.0
14999,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628164,,BAO_0000019,
15000,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628165,,BAO_0000019,
15001,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628166,,BAO_0000019,
15002,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628167,,BAO_0000019,
15003,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628168,,BAO_0000019,
15004,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628169,,BAO_0000019,
15005,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628170,,BAO_0000019,
15006,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628171,,BAO_0000019,
15007,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL627434,,BAO_0000019,
15008,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL627435,,BAO_0000019,
15009,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628110,,BAO_0000019,
15010,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628111,,BAO_0000019,
15011,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628112,,BAO_0000019,
15012,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628260,,BAO_0000019,
15013,22224,,,0,,U,,,,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,1,,8354,CHEMBL628261,,BAO_0000019,
15014,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,1,,14439,CHEMBL628262,,BAO_0000218,
15015,50587,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,1,,14439,CHEMBL628263,,BAO_0000218,
15016,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,1,,14439,CHEMBL628264,,BAO_0000218,
15017,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,1,,14439,CHEMBL628265,,BAO_0000218,
15018,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,1,,14439,CHEMBL628266,,BAO_0000218,
15019,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,1,,14439,CHEMBL628267,,BAO_0000218,
15020,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,1,,14439,CHEMBL628268,,BAO_0000218,
15021,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,1,,14439,CHEMBL628269,,BAO_0000218,
15022,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,1,,14439,CHEMBL628270,,BAO_0000218,
15023,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,1,,14439,CHEMBL628271,,BAO_0000218,
15024,50594,,In vivo,1,,N,,,,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,1,,14439,CHEMBL628272,,BAO_0000218,
